[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fyk10ZMCoDFCbDQ1538i--PEy7Jx8rE5FWbvNdLBE3Uo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Washington University School of Medicine",[4],1761,false,357,64,2179900,252,981,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Obesity",65,{"name":18,"count":19},"Breast Cancer",49,{"name":21,"count":22},"Depression",36,{"name":24,"count":22},"Multiple Myeloma",{"name":26,"count":27},"Myelodysplastic Syndromes",27,{"name":29,"count":30},"Pancreatic Cancer",24,{"name":32,"count":33},"Parkinson Disease",22,{"name":35,"count":36},"Cancer",21,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02253316","Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma","2020-02-05","Ixazomib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT01723774","PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","2021-04-13","PD0332991",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03572764","CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome","2021-11-27","CPX-351",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03389477","Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma","2022-02-15","Palbociclib",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT02204098","Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy","2022-04-06","Mammaglobin-A DNA Vaccine",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04015700","Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma","2022-05-13","Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT03030261","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma","2022-09-29","Elotuzumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03687957","rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide","2023-02-13","rhIL-7-hyFc",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04331067","Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer","2023-03-20","Paclitaxel",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT03955978","TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer","2024-03-22","TSR-042",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,187,218,236,254,272,302,320,338,472,524,598,647,680,702,771,808,830,865,890,919,958,1168,1339,1514,1663,1773,1817,1978,2080,2144,2182,2248,2308,2361,2484,2543,2620,2689,2736,2773,2803,2843,2880,2921,2952,2974,3001,3123,3158,3269,3367,3441,3531,3590,3643,3694,3740,3786,3830,3882,3919,3953,3984,4033,4070,4102,4134,4156,4178,4205,4227,4256,4278,4300,4326,4344,4369,4387,4405,4427,4453,4477,4495,4517,4542,4572,4590,4614,4632,4650,4688,4714,4732,4750,4774,4792,4810,4828,4852,4870,4891,4909,4927,4951,4969,4987,5005,5023,5048,5071,5089,5107,5125,5157,5175,5193,5211,5229,5247,5265,5292,5310,5335,5353,5380,5398,5416,5434,5459,5483,5501,5519,5537,5555,5578,5602,5627,5645,5663,5688,5706,5724,5742,5760,5784,5809,5827,5845,5863,5881,5905,5928,5946,5964,5989,6007,6045,6093,6125,6212,6264,6304,6347,6380,6469,6515,6562,6632,6676,6721,6749,6792,6831,6853,6875,6897,6957,6988,7016,7038,7066,7092,7110,7134,7152,7175,7199,7223,7241,7259,7277,7295,7313,7331,7349,7372,7392,7412,7430,7465,7483,7501,7519,7537,7555,7578,7596,7614,7632,7650,7671,7689,7707,7732,7750,7768,7821,7851,7886,7904,7927,7945,7968,7991,8009,8027,8114,8144,8173,8272,8323,8368,8397,8429,8452,8475,8498,8523,8548,8573,8591,8609,8633,8657,8680,8708,8726,8750,8774,8798,8822,8844,8882,8923,8959,9003,9041,9071,9107,9143,9182,9211,9238,9268,9300,9325,9343,9361,9379,9397,9415,9433,9459,9484,9505,9528,9559,9577,9595,9613,9631,9655,9681,9707,9725,9748,9772,9790,9812,9836,9860,9878,9902,9920,9945,9963,9990,10008,10035,10053,10075,10097,10120,10138,10163,10181,10207,10234,10252,10278,10296,10322,10340,10364,10387,10415,10433,10458,10476,10494,10521,10539,10562,10580,10603,10621,10645,10679,10713,10748,10783,10806,10830,10855,10873,10896,10914,10941,10964,10982,11006,11029,11054,11072,11095,11113,11131,11149,11174,11199,11223,11241,11263,11290,11308,11332,11350,11368,11386,11411,11438,11505,11555,11627,11669,11711,11753,11799,11843,11877,11907,11937,11976,12006,12041,12067,12099,12138,12169,12201,12241,12267,12296,12326,12348,12370,12392,12414,12447,12473,12500,12522,12550,12575,12597,12626,12653,12691,12724,12746,12783,12823,12841,12859,12887,12905,12923,12945,12963,12981,12999,13022,13046,13069,13094,13112,13130,13148,13170,13188,13212,13230,13248,13271,13294,13326,13353,13371,13397,13415,13439,13457,13480,13504,13522,13540,13558,13581,13599,13617,13641,13659,13681,13704,13728,13746,13770,13788,13806,13824,13842,13866,13884,13902,13924,13948,13966,13991,14009,14037,14055,14073,14091,14116,14134,14152,14178,14196,14214,14238,14256,14279,14297,14315,14333,14357,14375,14393,14411,14437,14455,14473,14491,14514,14532,14550,14575,14598,14616,14634,14652,14677,14695,14717,14735,14759,14780,14803,14826,14844,14869,14893,14916,14934,14952,14976,14999,15017,15038,15056,15074,15092,15117,15138,15156,15183,15201,15219,15243,15261,15279,15297,15322,15340,15358,15376,15399,15421,15447,15465,15483,15506,15524,15542,15569,15587,15610,15628,15652,15677,15695,15720,15742,15765,15783,15801,15819,15841,15859,15881,15899,15921,15942,15978,16007,16037,16059,16081,16110,16139,16161,16183,16205,16223,16246,16264,16282,16300,16321,16349,16367,16385,16403,16421,16439,16464,16482,16500,16522,16546,16571,16596,16619,16644,16662,16685,16703,16732,16750,16768,16786,16804,16825,16843,16866,16889,16907,16925,16943,16961,16979,17003,17021,17044,17062,17084,17107,17128,17149,17170,17188,17206,17224,17242,17264,17288,17306,17324,17342,17360,17378,17396,17414,17432,17455,17473,17496,17514,17537,17555,17580,17598,17616,17644,17662,17680,17698,17716,17734,17752,17776,17798,17816,17838,17862,17880,17898,17916,17938,17962,17980,18001,18019,18037,18061,18079,18097,18115,18139,18157,18180,18202,18227,18248,18266,18284,18316,18340,18358,18381,18403,18421,18439,18461,18487,18510,18528,18552,18575,18599,18617,18640,18665,18683,18705,18723,18745,18763,18785,18808,18833,18851,18869,18894,18912,18930,18953,18974,19004,19022,19040,19058,19076,19099,19117,19141,19159,19177,19195,19217,19241,19259,19287,19305,19323,19341,19364,19386,19479,19518,19562,19611,19645,19676,19702,19733,19781,19807,19836,19869,19895,19917,19949,19979,20008,20030,20065,20091,20115,20149,20188,20215,20241,20265,20287,20317,20343,20371,20398,20420,20445,20463,20481,20499,20523,20545,20567,20585,20603,20626,20649,20673,20691,20715,20736,20754,20775,20798,20816,20840,20864,20891,20909,20927,20952,20970,20991,21014,21032,21050,21073,21091,21109,21131,21149,21173,21191,21209,21227,21245,21270,21288,21311,21329,21347,21369,21393,21411,21429,21451,21469,21487,21509,21532,21555,21573,21591,21612,21633,21656,21674,21692,21717,21739,21762,21786,21804,21827,21848,21866,21890,21913,21937,21962,21980,22004,22022,22044,22068,22086,22104,22122,22147,22170,22188,22210,22228,22251,22269,22290,22312,22333,22355,22373,22396,22418,22442,22460,22482,22505,22523,22541,22559,22582,22605,22626,22649,22675,22693],{"intervention":97,"totalTrials":98,"cells":99},"Bupivacaine",5,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":132,"PHASE3":166,"PHASE4":168,"NA":185},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105,119],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":118},"NCT02681796","Epidural Analgesia Use in Pancreatic Resections","COMPLETED",[90],"2020-02-07","2016-06-07",23,[114,115,116,117,29],"Cancer of Pancreas","Cancer of the Pancreas","Pancreas Cancer","Pancreas Neoplasms",[97],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":102,"conditions":126,"interventions":129},"NCT03177252","Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients","WITHDRAWN",[90],"2021-09-30","2020-10-01",[127,128],"Tumor, Brain","Anesthesia, Local",[130,131,97],"Lidocaine","Sodium chloride",{"trials":133,"activeCount":102},[134,150],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":148},"NCT05017246","Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy","TERMINATED",[91],"2024-07-17","2024-08-29","2022-01-18",110,[144,145,146,147],"Cancer Debulking","Enlarged Uterus","Fibroid Uterus","Adnexal Mass",[97,149,130],"Morphine",{"nctId":151,"briefTitle":152,"status":108,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":160},"NCT03084536","PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery",[91],"2021-02-25","2017-06-07",134,[18,158,159],"Breast Cancer Female","Cancer of Breast",[97,161,162,163,164,165],"Gabapentin","Celecoxib","Acetaminophen","Midazolam","Fentanyl",{"trials":167,"activeCount":102},[],{"trials":169,"activeCount":184,"soonestReadout":175},[170],{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":182},"NCT07280195","ZYNRELEF vs Continuous Catheter for Pain Management Following Shoulder Arthroplasty","ENROLLING_BY_INVITATION",[93],"2026-12","2027-12","2026-02-14",86,[180,181],"Total Shoulder Arthroplasty","Pain Management",[183,97],"Zynrelef",1,{"trials":186,"activeCount":102},[],{"intervention":188,"totalTrials":184,"cells":189},"trivalent inactivated influenza vaccine",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":216},{"trials":191,"activeCount":102},[],{"trials":193,"activeCount":102},[],{"trials":195,"activeCount":102},[],{"trials":197,"activeCount":102},[],{"trials":199,"activeCount":184,"soonestReadout":205},[200],{"nctId":201,"briefTitle":202,"status":203,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":212},"NCT07493460","Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","ACTIVE_NOT_RECRUITING",[93],"2026-08","2027-08","2025-08-26",25,[210,211],"Immunology","Healthy Adults",[188,213,214,215],"nonavalent HPV vaccine","hepatitis A (HAV) vaccines","tetanus, diphtheria and acellular pertussis vaccine",{"trials":217,"activeCount":102},[],{"intervention":213,"totalTrials":184,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":234},{"trials":221,"activeCount":102},[],{"trials":223,"activeCount":102},[],{"trials":225,"activeCount":102},[],{"trials":227,"activeCount":102},[],{"trials":229,"activeCount":184,"soonestReadout":205},[230],{"nctId":201,"briefTitle":202,"status":203,"phases":231,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":232,"interventions":233},[93],[210,211],[188,213,214,215],{"trials":235,"activeCount":102},[],{"intervention":214,"totalTrials":184,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":252},{"trials":239,"activeCount":102},[],{"trials":241,"activeCount":102},[],{"trials":243,"activeCount":102},[],{"trials":245,"activeCount":102},[],{"trials":247,"activeCount":184,"soonestReadout":205},[248],{"nctId":201,"briefTitle":202,"status":203,"phases":249,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":250,"interventions":251},[93],[210,211],[188,213,214,215],{"trials":253,"activeCount":102},[],{"intervention":215,"totalTrials":184,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":270},{"trials":257,"activeCount":102},[],{"trials":259,"activeCount":102},[],{"trials":261,"activeCount":102},[],{"trials":263,"activeCount":102},[],{"trials":265,"activeCount":184,"soonestReadout":205},[266],{"nctId":201,"briefTitle":202,"status":203,"phases":267,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":268,"interventions":269},[93],[210,211],[188,213,214,215],{"trials":271,"activeCount":102},[],{"intervention":273,"totalTrials":184,"cells":274},"FluMist",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":300},{"trials":276,"activeCount":102},[],{"trials":278,"activeCount":102},[],{"trials":280,"activeCount":102},[],{"trials":282,"activeCount":102},[],{"trials":284,"activeCount":184,"soonestReadout":290},[285],{"nctId":286,"briefTitle":287,"status":288,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":298},"NCT07177417","Characterizing the Human Airway Immune Response to FluMist Vaccination","RECRUITING",[93],"2026-09","2028-11","2025-09-09",30,[295,296,297],"Healthy Young Adults","Influenza Vaccines","Influenza Vaccine Response",[273,299],"inactivated influenza vaccine",{"trials":301,"activeCount":102},[],{"intervention":299,"totalTrials":184,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":318},{"trials":305,"activeCount":102},[],{"trials":307,"activeCount":102},[],{"trials":309,"activeCount":102},[],{"trials":311,"activeCount":102},[],{"trials":313,"activeCount":184,"soonestReadout":290},[314],{"nctId":286,"briefTitle":287,"status":288,"phases":315,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":316,"interventions":317},[93],[295,296,297],[273,299],{"trials":319,"activeCount":102},[],{"intervention":183,"totalTrials":184,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":336},{"trials":323,"activeCount":102},[],{"trials":325,"activeCount":102},[],{"trials":327,"activeCount":102},[],{"trials":329,"activeCount":102},[],{"trials":331,"activeCount":184,"soonestReadout":175},[332],{"nctId":171,"briefTitle":172,"status":173,"phases":333,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":334,"interventions":335},[93],[180,181],[183,97],{"trials":337,"activeCount":102},[],{"intervention":339,"totalTrials":340,"cells":341},"Cetuximab",10,{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":358,"PHASE3":457,"PHASE4":468,"NA":470},{"trials":343,"activeCount":102},[],{"trials":345,"activeCount":102},[346],{"nctId":347,"briefTitle":348,"status":108,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT01716416","Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)",[90],"2015-07-31","2017-08-31","2013-05-31",32,[355],"Squamous Cell Carcinoma of the Head and Neck",[357,339],"Pazopanib",{"trials":359,"activeCount":456,"soonestReadout":56},[360,376,387,404,415,427,438,445],{"nctId":361,"briefTitle":362,"status":137,"phases":363,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":371},"NCT00537823","Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement",[91],"2009-12","2011-07","2007-06",9,[369,370],"Colorectal Cancer","Metastases",[339,372,373,374,375],"Bevacizumab","Leucovorin","Oxaliplatin","Fluorouracil",{"nctId":377,"briefTitle":378,"status":108,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},"NCT00671437","Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)\u002FComputed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer",[91],"2011-12","2015-08","2008-06",42,[385],"Carcinoma, Squamous Cell",[339],{"nctId":388,"briefTitle":389,"status":108,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":401},"NCT02573493","Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)",[91],"2019-12-12","2024-07-01","2016-04-13",96,[355,396,397,398,399,400],"Carcinoma, Squamous Cell of the Head and Neck","Cancer of Head and Neck","Cancer of the Head and Neck","Head and Neck Cancer","Neoplasms, Head and Neck",[402,403,339],"nab-Paclitaxel","Cisplatin",{"nctId":405,"briefTitle":406,"status":108,"phases":407,"primaryCompletion":408,"completion":409,"start":410,"enrollment":293,"conditions":411,"interventions":412},"NCT00736944","Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer",[91],"2010-08-31","2020-07-06","2008-12-19",[355],[413,339,339,403,414,403,339],"Abraxane","5-FU",{"nctId":416,"briefTitle":417,"status":203,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT02270814","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",[91],"2026-05-15","2015-02-02",74,[399,423,398],"Head and Neck Squamous Cell Carcinoma",[425,403,426,339],"nab-paclitaxel","Carboplatin",{"nctId":428,"briefTitle":429,"status":108,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":293,"conditions":434,"interventions":436},"NCT01566435","Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer",[91],"2013-10-31","2019-10-31","2012-08-09",[435],"Head and Neck Neoplasms",[437,403,375,339],"paclitaxel albumin-stabilized nanoparticle formulation",{"nctId":54,"briefTitle":55,"status":203,"phases":439,"primaryCompletion":56,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":444},[91],"2027-04-06","2018-04-27",26,[423],[57,339,403],{"nctId":446,"briefTitle":447,"status":108,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":394,"conditions":452,"interventions":454},"NCT02101034","PD 0332991 and Cetuximab in Patients With Incurable SCCHN",[90,91],"2020-06-08","2023-11-10","2014-06-17",[453],"Carcinoma, Squamous Cell of Head and Neck",[339,455],"PD 0332991",2,{"trials":458,"activeCount":184,"soonestReadout":463},[459],{"nctId":460,"briefTitle":461,"status":288,"phases":462,"primaryCompletion":463,"completion":463,"start":61,"enrollment":464,"conditions":465,"interventions":467},"NCT04966481","Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1\u002FL1 Inhibitor",[92],"2028-02-28",81,[466],"HPV-unrelated Head and Neck Squamous Cell Carcinoma",[57,339],{"trials":469,"activeCount":102},[],{"trials":471,"activeCount":102},[],{"intervention":473,"totalTrials":474,"cells":475},"Lecanemab",3,{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":520,"NA":522},{"trials":477,"activeCount":102},[],{"trials":479,"activeCount":102},[],{"trials":481,"activeCount":102},[],{"trials":483,"activeCount":474,"soonestReadout":488},[484,500,512],{"nctId":485,"briefTitle":486,"status":203,"phases":487,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":496},"NCT01760005","Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001",[91,92],"2028-04","2028-07","2012-12",490,[493,494,495],"Alzheimers Disease","Dementia","Alzheimers Disease, Familial",[497,498,497,499,473],"Gantenerumab","Solanezumab","E2814",{"nctId":501,"briefTitle":502,"status":203,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":510},"NCT06384573","DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease",[92],"2030-06","2024-06-10",40,[508,494,509],"Alzheimer's Disease","Alzheimer's Disease, Familial",[511],"lecanemab",{"nctId":513,"briefTitle":514,"status":203,"phases":515,"primaryCompletion":488,"completion":489,"start":516,"enrollment":517,"conditions":518,"interventions":519},"NCT05269394","Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)",[91,92],"2021-12-22",197,[493,494,495],[499,473],{"trials":521,"activeCount":102},[],{"trials":523,"activeCount":102},[],{"intervention":525,"totalTrials":98,"cells":526},"Normal saline",{"EARLY_PHASE1":527,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":594,"NA":596},{"trials":528,"activeCount":184,"soonestReadout":533},[529],{"nctId":530,"briefTitle":531,"status":288,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":22,"conditions":536,"interventions":539},"NCT03638999","NSAIDs Stent Study",[89],"2026-10","2027-10","2018-07-31",[537,538],"Ureteral Stent Placement","Kidney Stone",[540,525],"Ketorolac Trometamol 30Mg\u002F1mL",{"trials":542,"activeCount":102},[],{"trials":544,"activeCount":102},[],{"trials":546,"activeCount":184,"soonestReadout":564},[547,560,571,585],{"nctId":548,"briefTitle":549,"status":108,"phases":550,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":557},"NCT01690988","The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial",[92],"2016-06-26","2017-07","2014-02-01",746,[556],"Delirium",[558,559,558],"Ketamine","Normal Saline",{"nctId":561,"briefTitle":562,"status":288,"phases":563,"primaryCompletion":564,"completion":564,"start":392,"enrollment":565,"conditions":566,"interventions":569},"NCT06391125","LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment",[92],"2025-12",48,[567,568],"Syphilis Infection","Benzathine Penicillin Adverse Reaction",[570,130],"normal Saline",{"nctId":572,"briefTitle":573,"status":108,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":583},"NCT02581111","Naloxone for Optimizing Hypoxemia Of Lung Donors",[91,92],"2017-09-22","2017-09-25","2015-09",199,[580,581,582],"Brain Death","Organ Donors","Lung Transplantation",[584,525],"Naloxone",{"nctId":586,"briefTitle":587,"status":108,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":353,"conditions":591,"interventions":593},"NCT05233566","Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial",[92],"2023-03-08","2022-04-25",[592],"Postoperative Depression",[558,525],{"trials":595,"activeCount":102},[],{"trials":597,"activeCount":102},[],{"intervention":57,"totalTrials":599,"cells":600},4,{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":637,"PHASE4":643,"NA":645},{"trials":602,"activeCount":102},[],{"trials":604,"activeCount":102},[],{"trials":606,"activeCount":184,"soonestReadout":56},[607,622,633],{"nctId":608,"briefTitle":609,"status":108,"phases":610,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":618},"NCT03007979","Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer",[91],"2020-03-13","2023-03-31","2017-06-15",55,[18,616,159,617],"Breast Carcinoma","Malignant Tumor of Breast",[57,619,620,621],"Letrozole","Fulvestrant","Goserelin",{"nctId":623,"briefTitle":624,"status":137,"phases":625,"primaryCompletion":626,"completion":627,"start":628,"enrollment":442,"conditions":629,"interventions":630},"NCT02907918","Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer",[91],"2020-08-24","2020-09-23","2017-06-30",[18,159,616],[57,619,631,621,632],"Trastuzumab","Research blood for germline DNA",{"nctId":54,"briefTitle":55,"status":203,"phases":634,"primaryCompletion":56,"completion":440,"start":441,"enrollment":442,"conditions":635,"interventions":636},[91],[423],[57,339,403],{"trials":638,"activeCount":184,"soonestReadout":463},[639],{"nctId":460,"briefTitle":461,"status":288,"phases":640,"primaryCompletion":463,"completion":463,"start":61,"enrollment":464,"conditions":641,"interventions":642},[92],[466],[57,339],{"trials":644,"activeCount":102},[],{"trials":646,"activeCount":102},[],{"intervention":648,"totalTrials":456,"cells":649},"Remternetug",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":676,"NA":678},{"trials":651,"activeCount":102},[],{"trials":653,"activeCount":102},[],{"trials":655,"activeCount":102},[],{"trials":657,"activeCount":456,"soonestReadout":662},[658,668],{"nctId":659,"briefTitle":660,"status":288,"phases":661,"primaryCompletion":662,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":667},"NCT06647498","A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation",[91,92],"2034-03","2034-08","2024-11-22",280,[493,494,495],[648],{"nctId":669,"briefTitle":670,"status":288,"phases":671,"primaryCompletion":672,"completion":673,"start":664,"enrollment":665,"conditions":674,"interventions":675},"NCT05552157","A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation",[91,92],"2034-03-30","2034-08-30",[493,494,495],[648],{"trials":677,"activeCount":102},[],{"trials":679,"activeCount":102},[],{"intervention":499,"totalTrials":456,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":698,"NA":700},{"trials":683,"activeCount":102},[],{"trials":685,"activeCount":102},[],{"trials":687,"activeCount":102},[],{"trials":689,"activeCount":456,"soonestReadout":488},[690,694],{"nctId":485,"briefTitle":486,"status":203,"phases":691,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":692,"interventions":693},[91,92],[493,494,495],[497,498,497,499,473],{"nctId":513,"briefTitle":514,"status":203,"phases":695,"primaryCompletion":488,"completion":489,"start":516,"enrollment":517,"conditions":696,"interventions":697},[91,92],[493,494,495],[499,473],{"trials":699,"activeCount":102},[],{"trials":701,"activeCount":102},[],{"intervention":703,"totalTrials":98,"cells":704},"Fluvoxamine",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":734,"PHASE4":767,"NA":769},{"trials":706,"activeCount":102},[],{"trials":708,"activeCount":102},[],{"trials":710,"activeCount":102},[711,722],{"nctId":712,"briefTitle":713,"status":122,"phases":714,"primaryCompletion":715,"completion":715,"start":716,"enrollment":102,"conditions":717,"interventions":721},"NCT05216614","Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia",[91],"2022-02-22","2021-12-14",[718,719,720],"COVID-19","Olfactory Disorder","Parosmia",[703],{"nctId":723,"briefTitle":724,"status":108,"phases":725,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":733},"NCT04342663","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",[91],"2020-08-20","2020-12-12","2020-04-10",152,[731,732],"COVID 19","Coronavirus",[703],{"trials":735,"activeCount":184,"soonestReadout":740},[736,747,757],{"nctId":737,"briefTitle":738,"status":288,"phases":739,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":746},"NCT06969287","Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery",[92],"2027-04-01","2028-04-01","2026-04-06",46,[556,745],"Surgery-Complications",[703],{"nctId":748,"briefTitle":749,"status":108,"phases":750,"primaryCompletion":751,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":756},"NCT05874037","Fluvoxamine for Long COVID-19",[91,92],"2025-03-15","2023-05-15",191,[755],"Long COVID",[703],{"nctId":758,"briefTitle":759,"status":108,"phases":760,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":766},"NCT04668950","Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)",[92],"2021-09-28","2020-12-22",670,[765,732],"Covid19",[703],{"trials":768,"activeCount":102},[],{"trials":770,"activeCount":102},[],{"intervention":497,"totalTrials":474,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":804,"NA":806},{"trials":774,"activeCount":102},[],{"trials":776,"activeCount":102},[],{"trials":778,"activeCount":102},[],{"trials":780,"activeCount":184,"soonestReadout":488},[781,785,795],{"nctId":485,"briefTitle":486,"status":203,"phases":782,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":783,"interventions":784},[91,92],[493,494,495],[497,498,497,499,473],{"nctId":786,"briefTitle":787,"status":137,"phases":788,"primaryCompletion":789,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":794},"NCT06424236","Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation",[91,92],"2023-10-06","2023-11-13","2020-06-03",73,[493,494,495],[497],{"nctId":796,"briefTitle":797,"status":108,"phases":798,"primaryCompletion":799,"completion":800,"start":490,"enrollment":801,"conditions":802,"interventions":803},"NCT04623242","Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.",[91,92],"2019-11-22","2020-03-06",194,[493,494,495],[497,498],{"trials":805,"activeCount":102},[],{"trials":807,"activeCount":102},[],{"intervention":498,"totalTrials":456,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":826,"NA":828},{"trials":811,"activeCount":102},[],{"trials":813,"activeCount":102},[],{"trials":815,"activeCount":102},[],{"trials":817,"activeCount":184,"soonestReadout":488},[818,822],{"nctId":485,"briefTitle":486,"status":203,"phases":819,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":820,"interventions":821},[91,92],[493,494,495],[497,498,497,499,473],{"nctId":796,"briefTitle":797,"status":108,"phases":823,"primaryCompletion":799,"completion":800,"start":490,"enrollment":801,"conditions":824,"interventions":825},[91,92],[493,494,495],[497,498],{"trials":827,"activeCount":102},[],{"trials":829,"activeCount":102},[],{"intervention":831,"totalTrials":456,"cells":832},"HFrEF Polypill",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":846,"PHASE3":848,"PHASE4":861,"NA":863},{"trials":834,"activeCount":102},[],{"trials":836,"activeCount":102},[837],{"nctId":838,"briefTitle":839,"status":108,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":506,"conditions":843,"interventions":845},"NCT06831864","Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka",[90],"2025-05-05","2025-02-15",[844],"Heart Failure With Reduced Ejection Fraction",[831],{"trials":847,"activeCount":102},[],{"trials":849,"activeCount":184,"soonestReadout":855},[850],{"nctId":851,"briefTitle":852,"status":853,"phases":854,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":860},"NCT07569640","HFrEF Polypill in Sri Lanka RCT","NOT_YET_RECRUITING",[92],"2028-12-01","2029-03-01","2026-06-01",1656,[844],[831],{"trials":862,"activeCount":102},[],{"trials":864,"activeCount":102},[],{"intervention":866,"totalTrials":184,"cells":867},"Extracorporeal Photopheresis",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":886,"NA":888},{"trials":869,"activeCount":102},[],{"trials":871,"activeCount":102},[],{"trials":873,"activeCount":102},[],{"trials":875,"activeCount":184,"soonestReadout":880},[876],{"nctId":877,"briefTitle":878,"status":203,"phases":879,"primaryCompletion":880,"completion":881,"start":882,"enrollment":665,"conditions":883,"interventions":885},"NCT02181257","Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts",[92],"2027-04","2028-12","2015-01",[884],"Bronchiolitis Obliterans Syndrome (BOS)",[866],{"trials":887,"activeCount":102},[],{"trials":889,"activeCount":102},[],{"intervention":891,"totalTrials":184,"cells":892},"Buprenorphine Transdermal Matrix Patch",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":915,"NA":917},{"trials":894,"activeCount":102},[],{"trials":896,"activeCount":102},[],{"trials":898,"activeCount":102},[],{"trials":900,"activeCount":184,"soonestReadout":905},[901],{"nctId":902,"briefTitle":903,"status":288,"phases":904,"primaryCompletion":905,"completion":906,"start":907,"enrollment":506,"conditions":908,"interventions":914},"NCT05790252","Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)",[92],"2026-07-01","2026-12-01","2023-11-27",[909,910,911,912,913],"Opioid Use Disorder","Pregnancy Related","Pregnancy, High Risk","Pregnancy Complications","Buprenorphine Withdrawal",[891],{"trials":916,"activeCount":102},[],{"trials":918,"activeCount":102},[],{"intervention":130,"totalTrials":599,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":929,"PHASE3":935,"PHASE4":941,"NA":943},{"trials":922,"activeCount":102},[],{"trials":924,"activeCount":102},[925],{"nctId":120,"briefTitle":121,"status":122,"phases":926,"primaryCompletion":124,"completion":124,"start":125,"enrollment":102,"conditions":927,"interventions":928},[90],[127,128],[130,131,97],{"trials":930,"activeCount":102},[931],{"nctId":135,"briefTitle":136,"status":137,"phases":932,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":933,"interventions":934},[91],[144,145,146,147],[97,149,130],{"trials":936,"activeCount":184,"soonestReadout":564},[937],{"nctId":561,"briefTitle":562,"status":288,"phases":938,"primaryCompletion":564,"completion":564,"start":392,"enrollment":565,"conditions":939,"interventions":940},[92],[567,568],[570,130],{"trials":942,"activeCount":102},[],{"trials":944,"activeCount":102},[945],{"nctId":946,"briefTitle":947,"status":108,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":956},"NCT02363803","Lidocaine for Diabetic Peripheral Neuropathy",[94],"2018-10-17","2015-02",34,[953,954,955],"Diabetes","Peripheral Neuropathy","Pain",[957],"lidocaine",{"intervention":959,"totalTrials":960,"cells":961},"Nivolumab",16,{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":1074,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":963,"activeCount":102},[],{"trials":965,"activeCount":474,"soonestReadout":1053},[966,979,996,1008,1022,1035,1049,1061],{"nctId":967,"briefTitle":968,"status":137,"phases":969,"primaryCompletion":970,"completion":971,"start":972,"enrollment":599,"conditions":973,"interventions":975},"NCT03121677","Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma",[90],"2020-09-24","2023-08-07","2018-10-16",[974],"Follicular Lymphoma",[976,977,959,978],"Personalized tumor vaccine","Poly ICLC","Rituximab",{"nctId":980,"briefTitle":981,"status":288,"phases":982,"primaryCompletion":983,"completion":984,"start":985,"enrollment":383,"conditions":986,"interventions":992},"NCT05187182","CA-4948 in Combination With FOLFOX\u002FPD-1 Inhibitor +\u002F- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer",[90],"2028-07-31","2029-04-30","2023-06-02",[987,988,989,990,991],"Gastric Cancer","Esophageal Cancer","Stomach Cancer","Esophagus Cancer","Gastroesophageal Junction Cancer",[993,959,994,631,995],"CA-4948","Pembrolizumab","mFOLFOX7",{"nctId":997,"briefTitle":998,"status":137,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":474,"conditions":1003,"interventions":1005},"NCT03422094","Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",[90],"2020-04-26","2020-12-31","2018-10-31",[1004],"Glioblastoma",[1006,959,1007],"NeoVax","Ipilimumab",{"nctId":1009,"briefTitle":1010,"status":288,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1019},"NCT05629546","Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors",[90],"2029-02-28","2030-11-30","2024-11-06",33,[1017,1018],"Advanced Melanoma","Metastatic Melanoma",[1020,1021,959],"Cytokine-induced memory-like natural killer cells","Relatilmab",{"nctId":1023,"briefTitle":1024,"status":137,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":960,"conditions":1029,"interventions":1033},"NCT03511222","Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors",[90],"2019-08-15","2020-05-28","2018-09-11",[1030,1031,987,1032],"Solid Tumor","Hepatocellular Carcinoma","Gastroesophageal Junction Adenocarcinoma",[1034,959,994],"Vorolanib",{"nctId":1036,"briefTitle":1037,"status":108,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1045},"NCT03532217","Neoantigen DNA Vaccine in Combination With Nivolumab\u002FIpilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer",[90],"2022-04-01","2022-07-25","2018-09-14",19,[1044],"Metastatic Hormone-Sensitive Prostate Cancer",[1046,1047,959,1007,1048],"PROSTVAC-V","PROSTVAC-F","Neoantigen DNA vaccine",{"nctId":1050,"briefTitle":1051,"status":288,"phases":1052,"primaryCompletion":1053,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},"NCT06968988","Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma",[90],"2026-08-12","2031-07-31","2026-01-05",18,[1058],"Metastatic Soft-tissue Sarcoma",[1060,1007,959],"Zanzalintinib",{"nctId":1062,"briefTitle":1063,"status":108,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1056,"conditions":1068,"interventions":1070},"NCT04477512","Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)",[90],"2021-09-09","2025-09-10","2021-02-19",[1069],"Metastatic Hormone Refractory Prostate Cancer",[1071,959,1072,1073],"Cabozantinib","Abiraterone acetate","Prednisone",{"trials":1075,"activeCount":98,"soonestReadout":81},[1076,1085,1094,1103,1113,1126,1135,1152],{"nctId":79,"briefTitle":80,"status":203,"phases":1077,"primaryCompletion":81,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},[90,91],"2026-07-11","2020-11-19",15,[1082],"Triple Negative Breast Cancer",[82,426,959,1084],"Cabiralizumab",{"nctId":1086,"briefTitle":1087,"status":203,"phases":1088,"primaryCompletion":1089,"completion":1090,"start":761,"enrollment":743,"conditions":1091,"interventions":1093},"NCT04831320","Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor",[91],"2026-06-30","2027-01-31",[1092],"Metastatic Head-and-neck Squamous-cell Carcinoma",[425,959],{"nctId":1095,"briefTitle":1096,"status":137,"phases":1097,"primaryCompletion":449,"completion":1098,"start":1099,"enrollment":456,"conditions":1100,"interventions":1102},"NCT03903640","Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis",[91],"2021-11-03","2019-10-14",[1101],"Melanoma With Brain Metastasis",[959,1007],{"nctId":1104,"briefTitle":1105,"status":203,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1112},"NCT04551430","Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma",[91],"2027-02-01","2029-02-01","2021-01-05",105,[1058],[1071,959,1007],{"nctId":1114,"briefTitle":1115,"status":108,"phases":1116,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":506,"conditions":1120,"interventions":1122},"NCT03496662","BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)",[90,91],"2021-10-28","2024-07-25","2018-08-31",[1121],"Pancreatic Ductal Adenocarcinoma",[1123,959,1124,1125],"BMS-813160","Gemcitabine","Nab-paclitaxel",{"nctId":1127,"briefTitle":1128,"status":137,"phases":1129,"primaryCompletion":626,"completion":626,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1133},"NCT03655444","Abemaciclib + Nivolumab in Patients With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy",[90,91],"2019-05-29",6,[423],[1134,959],"Abemaciclib",{"nctId":1136,"briefTitle":1137,"status":853,"phases":1138,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1148},"NCT06639607","PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma\u002FHigh-grade Glioma and Recurrent Diffuse Midline Glioma\u002FHigh-grade Glioma, Medulloblastoma, and Ependymoma",[90,91],"2031-06-30","2043-04-30","2026-04-30",68,[1144,1145,1146,1147],"Diffuse Midline Glioma","Diffuse Midline High-grade Glioma","Medulloblastoma","Ependymoma",[1149,1150,959,1151],"PEP-CMV vaccine","Tetanus booster","Temozolomide",{"nctId":1153,"briefTitle":1154,"status":853,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1089,"enrollment":442,"conditions":1157,"interventions":1160},"NCT07355205","First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer",[91],"2032-06-30",[1158,1159],"Non-small Cell Lung Cancer Stage IV","Non-small Cell Lung Cancer Recurrent",[1007,959,1161],"Nogapendekin alfa inbakicept",{"trials":1163,"activeCount":102},[],{"trials":1165,"activeCount":102},[],{"trials":1167,"activeCount":102},[],{"intervention":994,"totalTrials":1080,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1253,"PHASE3":1333,"PHASE4":1335,"NA":1337},{"trials":1171,"activeCount":102},[],{"trials":1173,"activeCount":456,"soonestReadout":983},[1174,1187,1191,1205,1209,1220,1233,1242],{"nctId":1175,"briefTitle":1176,"status":108,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1185},"NCT02546531","Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer",[90],"2017-11-17","2021-01-11","2016-02-03",43,[1183,1184,29],"Advanced Solid Tumors","Solid Tumors",[1186,994,1124],"Defactinib",{"nctId":980,"briefTitle":981,"status":288,"phases":1188,"primaryCompletion":983,"completion":984,"start":985,"enrollment":383,"conditions":1189,"interventions":1190},[90],[987,988,989,990,991],[993,959,994,631,995],{"nctId":1192,"briefTitle":1193,"status":122,"phases":1194,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":102,"conditions":1198,"interventions":1203},"NCT03166254","Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer",[90],"2022-06-30","2027-05-31","2019-04-30",[1199,1200,1201,1202],"Non Small Cell Lung Cancer","NSCLC","Non-small Cell Lung Cancer","Small Cell Lung Extensive Stage",[994,1204,977],"NEO-PV-01 vaccine",{"nctId":1023,"briefTitle":1024,"status":137,"phases":1206,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":960,"conditions":1207,"interventions":1208},[90],[1030,1031,987,1032],[1034,959,994],{"nctId":1210,"briefTitle":1211,"status":137,"phases":1212,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":184,"conditions":1215,"interventions":1217},"NCT03982004","Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer",[90],"2021-03-03","2020-09-14",[1216],"Metastatic Breast Cancer",[1218,994,1219],"Topical imiquimod","Intra-lesional GM-CSF",{"nctId":1221,"briefTitle":1222,"status":853,"phases":1223,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":1226,"interventions":1227},"NCT07300475","Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients",[90],"2030-04-08","2035-03-09",[1082],[82,426,994,1228,1229,1230,1231,1232],"Doxorubicin","Cyclophosphamide","Personalized cancer immunotherapeutic","AB248","poly-ICLC",{"nctId":1234,"briefTitle":1235,"status":108,"phases":1236,"primaryCompletion":970,"completion":1237,"start":1238,"enrollment":960,"conditions":1239,"interventions":1241},"NCT02642809","Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers",[90],"2021-08-03","2016-06-08",[988,1240],"Cancer of the Esophagus",[994],{"nctId":1243,"briefTitle":1244,"status":137,"phases":1245,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1251},"NCT04624113","Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma",[90],"2022-08-09","2024-02-17","2021-04-14",13,[423],[1252,994],"Tazemetostat",{"trials":1254,"activeCount":599,"soonestReadout":1326},[1255,1265,1276,1292,1303,1315,1322],{"nctId":1256,"briefTitle":1257,"status":122,"phases":1258,"primaryCompletion":1090,"completion":1259,"start":1260,"enrollment":102,"conditions":1261,"interventions":1263},"NCT05255666","Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)",[91],"2030-01-31","2023-07-31",[1082,1262],"Brain Metastases",[994,1264],"Liposomal Irinotecan",{"nctId":1266,"briefTitle":1267,"status":853,"phases":1268,"primaryCompletion":1269,"completion":1270,"start":1089,"enrollment":1271,"conditions":1272,"interventions":1274},"NCT07552558","Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)",[90,91],"2028-08-31","2033-08-31",45,[423,1273],"HPV-Negative Squamous Cell Carcinoma",[994,1275],"Ficerafusp alfa",{"nctId":1277,"briefTitle":1278,"status":203,"phases":1279,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1290},"NCT05980000","Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma",[91],"2027-06-30","2030-06-30","2023-10-27",37,[1285,1286,1287,1092,1288,1289],"Recurrent Head and Neck Cancer","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Carcinoma","Metastatic Head and Neck Cancer","HNSCC",[1291,994],"Ramucirumab",{"nctId":1293,"briefTitle":1294,"status":288,"phases":1295,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1302},"NCT04318717","Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma",[91],"2030-07-31","2032-07-31","2020-05-29",20,[1301],"Mucosal Melanoma of the Head and Neck",[994],{"nctId":1304,"briefTitle":1305,"status":137,"phases":1306,"primaryCompletion":1307,"completion":1308,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1313},"NCT04267120","Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)",[91],"2024-05-09","2024-09-01","2020-07-29",11,[1312],"Renal Cell Carcinoma",[1314,994],"Lenvatinib",{"nctId":1316,"briefTitle":1317,"status":108,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":1130,"enrollment":1181,"conditions":1320,"interventions":1321},"NCT03650764","Ramucirumab + Pembrolizumab in Patients With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[90,91],"2026-05-11",[423],[1291,994],{"nctId":1323,"briefTitle":1324,"status":203,"phases":1325,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":293,"conditions":1329,"interventions":1331},"NCT04643379","Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma",[91],"2025-10-16","2028-10-31","2021-08-07",[1286,1330],"Metastatic Head and Neck Squamous Cell Carcinoma",[1332,994,426],"Olaparib",{"trials":1334,"activeCount":102},[],{"trials":1336,"activeCount":102},[],{"trials":1338,"activeCount":102},[],{"intervention":403,"totalTrials":1056,"cells":1340},{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1371,"PHASE3":1499,"PHASE4":1510,"NA":1512},{"trials":1342,"activeCount":102},[],{"trials":1344,"activeCount":184,"soonestReadout":1281},[1345,1359],{"nctId":1346,"briefTitle":1347,"status":122,"phases":1348,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":102,"conditions":1352,"interventions":1357},"NCT02537561","Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors",[90],"2018-06","2018-12","2015-12",[1184,1353,1354,1355,1356],"Carcinoma, Non-Small Cell Lung","Non-Small Cell Lung Cancer","Non-Small-Cell Lung Carcinoma","Nonsmall Cell Lung Cancer",[403,1124,1358],"Talazoparib",{"nctId":1360,"briefTitle":1361,"status":288,"phases":1362,"primaryCompletion":1281,"completion":1363,"start":1364,"enrollment":565,"conditions":1365,"interventions":1368},"NCT07107750","Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer",[90],"2032-05-31","2026-03-27",[1366,1367],"Metastatic Biliary Tract Cancer","Metastatic Biliary Tract Carcinoma",[1369,1124,403,1370],"Emavusertib","Durvalumab",{"trials":1372,"activeCount":599,"soonestReadout":56},[1373,1384,1396,1403,1407,1411,1415,1426,1437,1447,1456,1460,1469,1473,1487],{"nctId":1374,"briefTitle":1375,"status":108,"phases":1376,"primaryCompletion":1377,"completion":1378,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1383},"NCT03621696","Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: \"The Minimalist Trial (MINT)\"",[91],"2021-03-10","2026-03-17","2018-10-23",63,[1382],"HPV Related Oropharyngeal Squamous Cell Carcinoma",[403],{"nctId":1385,"briefTitle":1386,"status":108,"phases":1387,"primaryCompletion":1388,"completion":1389,"start":1390,"enrollment":1391,"conditions":1392,"interventions":1394},"NCT02296684","Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma",[91],"2022-04-05","2025-07-21","2015-03-25",67,[397,399,400,453,355,1393],"Squamous Cell Carcinoma, Head and Neck",[1395,403,1395],"MK-3475",{"nctId":1397,"briefTitle":1398,"status":137,"phases":1399,"primaryCompletion":364,"completion":364,"start":1400,"enrollment":98,"conditions":1401,"interventions":1402},"NCT00603408","Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer",[91],"2007-12",[18],[403],{"nctId":388,"briefTitle":389,"status":108,"phases":1404,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":1405,"interventions":1406},[91],[355,396,397,398,399,400],[402,403,339],{"nctId":405,"briefTitle":406,"status":108,"phases":1408,"primaryCompletion":408,"completion":409,"start":410,"enrollment":293,"conditions":1409,"interventions":1410},[91],[355],[413,339,339,403,414,403,339],{"nctId":416,"briefTitle":417,"status":203,"phases":1412,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":1413,"interventions":1414},[91],[399,423,398],[425,403,426,339],{"nctId":1416,"briefTitle":1417,"status":288,"phases":1418,"primaryCompletion":1419,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT06702033","The Minimalist Trial-2",[91],"2030-04-30","2033-07-15","2025-04-10",142,[1424],"HPV-Related Oropharynx Squamous Cell Carcinoma",[403],{"nctId":1427,"briefTitle":1428,"status":108,"phases":1429,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":1434,"interventions":1435},"NCT00660270","Chemotherapy and Radiation Following Pancreatic Surgery",[91],"2006-11","2009-02","2002-05",53,[29],[403,414,1436,1124],"Alpha-interferon",{"nctId":1438,"briefTitle":1439,"status":137,"phases":1440,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":340,"conditions":1444,"interventions":1446},"NCT01167192","Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer",[91],"2012-08","2016-09","2011-02",[1445],"Breast Neoplasms",[403,426],{"nctId":1448,"briefTitle":1449,"status":108,"phases":1450,"primaryCompletion":490,"completion":490,"start":1451,"enrollment":27,"conditions":1452,"interventions":1454},"NCT00548418","Topotecan, Cisplatin and Bevacizumab for Recurrent\u002FPersistent Cervical Cancer",[91],"2007-02",[1453],"Cervical Cancer",[1455,403,372],"Topotecan",{"nctId":428,"briefTitle":429,"status":108,"phases":1457,"primaryCompletion":431,"completion":432,"start":433,"enrollment":293,"conditions":1458,"interventions":1459},[91],[435],[437,403,375,339],{"nctId":1461,"briefTitle":1462,"status":137,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1468},"NCT00590967","A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy",[91],"2013-01","2003-05",69,[1453],[403],{"nctId":54,"briefTitle":55,"status":203,"phases":1470,"primaryCompletion":56,"completion":440,"start":441,"enrollment":442,"conditions":1471,"interventions":1472},[91],[423],[57,339,403],{"nctId":1474,"briefTitle":1475,"status":108,"phases":1476,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":951,"conditions":1479,"interventions":1483},"NCT00004176","Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",[91],"2001-02","1998-10",[1480,1481,1482],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Lung Cancer","Radiation Toxicity",[1484,1485,1486],"amifostine trihydrate","cisplatin","etoposide",{"nctId":1488,"briefTitle":1489,"status":853,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":383,"conditions":1493,"interventions":1497},"NCT05521997","Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer",[91],"2032-10-07","2026-07-31",[1494,1453,1495,1496],"Advanced Cervical Carcinoma","Cervix Cancer","Cancer of the Cervix",[1498,403],"Telaglenastat",{"trials":1500,"activeCount":102},[1501],{"nctId":1502,"briefTitle":1503,"status":137,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":383,"conditions":1507,"interventions":1509},"NCT01687413","Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer",[92],"2019-10-18","2013-01-10",[1508],"Oropharyngeal Neoplasms",[403],{"trials":1511,"activeCount":102},[],{"trials":1513,"activeCount":102},[],{"intervention":426,"totalTrials":960,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1577,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1517,"activeCount":102},[],{"trials":1519,"activeCount":456,"soonestReadout":1563},[1520,1532,1545,1555,1559,1569],{"nctId":1521,"briefTitle":1522,"status":108,"phases":1523,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":340,"conditions":1527,"interventions":1531},"NCT02630823","MK-3475 Immunotherapy in Endometrial Carcinoma",[90],"2019-01-01","2020-10-03","2016-02-05",[1528,1529,1530],"Endometrial Cancer","Endometrial Carcinoma","Neoplasms, Endometrial",[1395,82,426],{"nctId":1533,"briefTitle":1534,"status":122,"phases":1535,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":102,"conditions":1539,"interventions":1543},"NCT03607955","Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy",[90],"2024-08-31","2029-08-31","2021-06-30",[1540,1541,1542],"Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer",[1544,82,426],"AVB-S6-500",{"nctId":1546,"briefTitle":1547,"status":108,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":112,"conditions":1552,"interventions":1554},"NCT02172846","Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer",[90],"2016-08-23","2017-10-02","2014-05-22",[1553],"Carcinoma, Non-Small-Cell Lung",[82,426],{"nctId":1221,"briefTitle":1222,"status":853,"phases":1556,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":1557,"interventions":1558},[90],[1082],[82,426,994,1228,1229,1230,1231,1232],{"nctId":1560,"briefTitle":1561,"status":203,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":1567,"interventions":1568},"NCT04046575","Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer",[90],"2025-06-02","2029-11-20","2019-11-07",12,[990,988,1240],[426,82],{"nctId":1570,"briefTitle":1571,"status":108,"phases":1572,"primaryCompletion":1573,"completion":577,"start":1574,"enrollment":16,"conditions":1575,"interventions":1576},"NCT00334321","Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients",[90],"2011-04","2006-04",[1528],[82,426],{"trials":1578,"activeCount":474,"soonestReadout":81},[1579,1583,1595,1599,1610,1617,1627,1638,1642,1653],{"nctId":79,"briefTitle":80,"status":203,"phases":1580,"primaryCompletion":81,"completion":1078,"start":1079,"enrollment":1080,"conditions":1581,"interventions":1582},[90,91],[1082],[82,426,959,1084],{"nctId":1584,"briefTitle":1585,"status":137,"phases":1586,"primaryCompletion":1587,"completion":1588,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1593},"NCT02124902","Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity",[91],"2021-11-10","2021-12-31","2014-07-07",148,[1592],"Triple Negative Breast Neoplasms",[1594,426],"Docetaxel",{"nctId":416,"briefTitle":417,"status":203,"phases":1596,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":1597,"interventions":1598},[91],[399,423,398],[425,403,426,339],{"nctId":1600,"briefTitle":1601,"status":137,"phases":1602,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1056,"conditions":1606,"interventions":1608},"NCT02469116","Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma",[91],"2009-08","2010-03","2006-01",[1607],"Ovarian Cancer",[1594,426,1609],"Pegylated G-CSF",{"nctId":1611,"briefTitle":1612,"status":137,"phases":1613,"primaryCompletion":382,"completion":382,"start":1574,"enrollment":340,"conditions":1614,"interventions":1615},"NCT00352690","A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer",[91],[1553],[1616,426],"Paclitaxel poliglumex",{"nctId":1618,"briefTitle":1619,"status":137,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1625},"NCT01779050","Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells",[91],"2021-09-01","2013-12-19",7,[1445],[1228,631,1229,82,1626,1594,426,375],"Epirubicin",{"nctId":1628,"briefTitle":1629,"status":108,"phases":1630,"primaryCompletion":1631,"completion":1632,"start":1633,"enrollment":19,"conditions":1634,"interventions":1637},"NCT00660140","Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma\u002FGallbladder Cancer",[91],"2007-01","2009-04","2002-03",[1635,1636],"Cholangiocarcinoma","Gallbladder Cancer",[1124,426],{"nctId":1438,"briefTitle":1439,"status":137,"phases":1639,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":340,"conditions":1640,"interventions":1641},[91],[1445],[403,426],{"nctId":1643,"briefTitle":1644,"status":137,"phases":1645,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":367,"conditions":1649,"interventions":1651},"NCT00383266","A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer",[91],"2009-11","2010-06","2006-10",[1650],"Esophageal Neoplasms",[1652,426],"Pemetrexed",{"nctId":1323,"briefTitle":1324,"status":203,"phases":1654,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":293,"conditions":1655,"interventions":1656},[91],[1286,1330],[1332,994,426],{"trials":1658,"activeCount":102},[],{"trials":1660,"activeCount":102},[],{"trials":1662,"activeCount":102},[],{"intervention":82,"totalTrials":1664,"cells":1665},14,{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1724,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1667,"activeCount":102},[],{"trials":1669,"activeCount":474,"soonestReadout":1563},[1670,1680,1691,1695,1699,1703,1712,1716,1720],{"nctId":1671,"briefTitle":1672,"status":288,"phases":1673,"primaryCompletion":1674,"completion":1675,"start":1676,"enrollment":22,"conditions":1677,"interventions":1679},"NCT06795009","Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer",[90],"2029-11-30","2035-04-30","2025-10-17",[1678,1528],"Uterine Cancer",[1060,82],{"nctId":1681,"briefTitle":1682,"status":122,"phases":1683,"primaryCompletion":1684,"completion":1685,"start":1686,"enrollment":102,"conditions":1687,"interventions":1689},"NCT05826015","AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer",[90],"2029-06-03","2034-06-04","2024-10-31",[1688],"Recurrent High Grade Uterine Cancer",[82,1690],"Batiraxcept",{"nctId":1521,"briefTitle":1522,"status":108,"phases":1692,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":340,"conditions":1693,"interventions":1694},[90],[1528,1529,1530],[1395,82,426],{"nctId":1533,"briefTitle":1534,"status":122,"phases":1696,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":102,"conditions":1697,"interventions":1698},[90],[1540,1541,1542],[1544,82,426],{"nctId":1546,"briefTitle":1547,"status":108,"phases":1700,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":112,"conditions":1701,"interventions":1702},[90],[1553],[82,426],{"nctId":1704,"briefTitle":1705,"status":122,"phases":1706,"primaryCompletion":432,"completion":1707,"start":1708,"enrollment":102,"conditions":1709,"interventions":1710},"NCT03285607","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",[90],"2021-02-28","2018-09-30",[18,159],[1711,1228,1229,82],"MCS110",{"nctId":1221,"briefTitle":1222,"status":853,"phases":1713,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":1714,"interventions":1715},[90],[1082],[82,426,994,1228,1229,1230,1231,1232],{"nctId":1560,"briefTitle":1561,"status":203,"phases":1717,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":1718,"interventions":1719},[90],[990,988,1240],[426,82],{"nctId":1570,"briefTitle":1571,"status":108,"phases":1721,"primaryCompletion":1573,"completion":577,"start":1574,"enrollment":16,"conditions":1722,"interventions":1723},[90],[1528],[82,426],{"trials":1725,"activeCount":456,"soonestReadout":81},[1726,1730,1741,1745,1754],{"nctId":79,"briefTitle":80,"status":203,"phases":1727,"primaryCompletion":81,"completion":1078,"start":1079,"enrollment":1080,"conditions":1728,"interventions":1729},[90,91],[1082],[82,426,959,1084],{"nctId":1731,"briefTitle":1732,"status":122,"phases":1733,"primaryCompletion":1734,"completion":1735,"start":1736,"enrollment":102,"conditions":1737,"interventions":1738},"NCT01953445","Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer",[91],"2015-06","2015-07","2014-08",[1445],[1739,1740],"paclitaxel","BKM120",{"nctId":1618,"briefTitle":1619,"status":137,"phases":1742,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1743,"interventions":1744},[91],[1445],[1228,631,1229,82,1626,1594,426,375],{"nctId":1746,"briefTitle":1747,"status":203,"phases":1748,"primaryCompletion":1749,"completion":1749,"start":1750,"enrollment":1299,"conditions":1751,"interventions":1753},"NCT03921008","Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma",[90,91],"2028-01-16","2019-05-21",[1752],"Cutaneous Angiosarcoma",[82],{"nctId":1755,"briefTitle":1756,"status":108,"phases":1757,"primaryCompletion":1758,"completion":1758,"start":1759,"enrollment":442,"conditions":1760,"interventions":1765},"NCT03916419","Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer",[91],"2025-09-28","2019-06-20",[1761,1762,1763,1764],"Stage IIB Non-Small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IIIC Non-Small Cell Lung Cancer",[82,1766,1370],"Carboplatin AUC",{"trials":1768,"activeCount":102},[],{"trials":1770,"activeCount":102},[],{"trials":1772,"activeCount":102},[],{"intervention":1060,"totalTrials":599,"cells":1774},{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1800,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1776,"activeCount":102},[],{"trials":1778,"activeCount":474,"soonestReadout":1053},[1779,1783,1796],{"nctId":1671,"briefTitle":1672,"status":288,"phases":1780,"primaryCompletion":1674,"completion":1675,"start":1676,"enrollment":22,"conditions":1781,"interventions":1782},[90],[1678,1528],[1060,82],{"nctId":1784,"briefTitle":1785,"status":288,"phases":1786,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1056,"conditions":1790,"interventions":1794},"NCT06957431","Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma",[90],"2028-11-30","2033-10-31","2025-10-22",[1791,1792,1793],"Advanced Leiomyosarcoma","Adipocytic Sarcoma","Advanced Liposarcoma",[1060,1795],"Eribulin",{"nctId":1050,"briefTitle":1051,"status":288,"phases":1797,"primaryCompletion":1053,"completion":1054,"start":1055,"enrollment":1056,"conditions":1798,"interventions":1799},[90],[1058],[1060,1007,959],{"trials":1801,"activeCount":184,"soonestReadout":1806},[1802],{"nctId":1803,"briefTitle":1804,"status":288,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":353,"conditions":1808,"interventions":1810},"NCT06926634","Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)",[91],"2034-12-31","2025-12-09",[1809],"High Grade Neuroendocrine Neoplasms",[1060],{"trials":1812,"activeCount":102},[],{"trials":1814,"activeCount":102},[],{"trials":1816,"activeCount":102},[],{"intervention":1124,"totalTrials":1818,"cells":1819},17,{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1902,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1821,"activeCount":102},[],{"trials":1823,"activeCount":184,"soonestReadout":1281},[1824,1828,1838,1850,1854,1858,1868,1878,1893],{"nctId":1175,"briefTitle":1176,"status":108,"phases":1825,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1826,"interventions":1827},[90],[1183,1184,29],[1186,994,1124],{"nctId":1829,"briefTitle":1830,"status":137,"phases":1831,"primaryCompletion":1832,"completion":1833,"start":1834,"enrollment":1056,"conditions":1835,"interventions":1836},"NCT02608229","BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer",[90],"2019-03-27","2020-05-21","2016-06-06",[29,114,115,116],[1837,1125,1124],"BVD-523",{"nctId":1839,"briefTitle":1840,"status":137,"phases":1841,"primaryCompletion":1842,"completion":1843,"start":1844,"enrollment":27,"conditions":1845,"interventions":1847},"NCT01525069","Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma",[90],"2018-08-08","2022-08-02","2012-04-03",[1635,1846],"Liver Neoplasms",[1848,1849,1124,374],"Floxuridine","Dexamethasone",{"nctId":1346,"briefTitle":1347,"status":122,"phases":1851,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":102,"conditions":1852,"interventions":1853},[90],[1184,1353,1354,1355,1356],[403,1124,1358],{"nctId":1360,"briefTitle":1361,"status":288,"phases":1855,"primaryCompletion":1281,"completion":1363,"start":1364,"enrollment":565,"conditions":1856,"interventions":1857},[90],[1366,1367],[1369,1124,403,1370],{"nctId":1859,"briefTitle":1860,"status":108,"phases":1861,"primaryCompletion":1648,"completion":1862,"start":1863,"enrollment":293,"conditions":1864,"interventions":1866},"NCT00660426","Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors",[90],"2008-04","2005-03",[1865,1184],"Advanced Gastrointestinal Malignancies",[374,1124,1867],"Capecitabine",{"nctId":1869,"briefTitle":1870,"status":137,"phases":1871,"primaryCompletion":1872,"completion":1873,"start":1431,"enrollment":1056,"conditions":1874,"interventions":1876},"NCT00732082","Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer",[90],"2010-02","2012-09",[1875],"Pancreatic Neoplasms",[1124,1877],"LAG-3",{"nctId":1879,"briefTitle":1880,"status":108,"phases":1881,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":30,"conditions":1885,"interventions":1890},"NCT02181218","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed\u002FRefractory Aggressive Lymphomas",[90],"2019-03-28","2020-06-26","2015-02-04",[1886,1887,1888,1889],"Lymphoma, T-Cell, Cutaneous","Lymphoma, T-Cell, Peripheral","Hodgkin Disease","Lymphoma, Large B-Cell, Diffuse",[1891,1124,374,1849,1892],"Romidepsin","Pegfilgrastim",{"nctId":1894,"briefTitle":1895,"status":108,"phases":1896,"primaryCompletion":1897,"completion":1898,"start":1899,"enrollment":293,"conditions":1900,"interventions":1901},"NCT02283372","Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer",[90],"2018-05-14","2019-04-18","2015-01-21",[29],[402,1124],{"trials":1903,"activeCount":456,"soonestReadout":1936},[1904,1917,1928,1932,1944,1948,1959,1968],{"nctId":1905,"briefTitle":1906,"status":288,"phases":1907,"primaryCompletion":1908,"completion":1909,"start":1910,"enrollment":1911,"conditions":1912,"interventions":1914},"NCT06904378","ONT01 and Gemcitabine\u002FNab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma",[90,91],"2028-09-30","2029-09-30","2026-03-25",61,[1913],"Metastatic Pancreatic Ductal Adenocarcinoma",[1915,1124,1916],"ONT01","Nab paclitaxel",{"nctId":1918,"briefTitle":1919,"status":108,"phases":1920,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":1923,"conditions":1924,"interventions":1926},"NCT03449901","ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer",[91],"2022-07-08","2018-05-09",98,[1925],"Soft Tissue Sarcoma",[1927,1124,1594],"pegylated arginine deiminase",{"nctId":1628,"briefTitle":1629,"status":108,"phases":1929,"primaryCompletion":1631,"completion":1632,"start":1633,"enrollment":19,"conditions":1930,"interventions":1931},[91],[1635,1636],[1124,426],{"nctId":1933,"briefTitle":1934,"status":203,"phases":1935,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":1938,"conditions":1939,"interventions":1942},"NCT05616624","ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers",[90,91],"2026-07-22","2023-04-05",31,[1199,1201,1940,1941],"Small-cell Lung Cancer","Small Cell Lung Carcinoma",[1943,1124,1594],"ADI-PEG 20",{"nctId":1427,"briefTitle":1428,"status":108,"phases":1945,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":1946,"interventions":1947},[91],[29],[403,414,1436,1124],{"nctId":1949,"briefTitle":1950,"status":108,"phases":1951,"primaryCompletion":1952,"completion":1873,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1958},"NCT00660699","A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers",[91],"2010-09","2002-09",50,[1956,1636,29,1957],"Cholangiocarcinoma Cancer","Ampullary Cancer",[1124,1594],{"nctId":1960,"briefTitle":1961,"status":137,"phases":1962,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":456,"conditions":1966,"interventions":1967},"NCT01080248","Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer",[91],"2010-12","2011-10","2010-08",[29],[1124,357],{"nctId":1114,"briefTitle":1115,"status":108,"phases":1969,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":506,"conditions":1970,"interventions":1971},[90,91],[1121],[1123,959,1124,1125],{"trials":1973,"activeCount":102},[],{"trials":1975,"activeCount":102},[],{"trials":1977,"activeCount":102},[],{"intervention":1151,"totalTrials":367,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":2014,"PHASE2":2028,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":1981,"activeCount":184,"soonestReadout":1012},[1982,1991,2004],{"nctId":1983,"briefTitle":1984,"status":288,"phases":1985,"primaryCompletion":1012,"completion":1986,"start":1987,"enrollment":1566,"conditions":1988,"interventions":1989},"NCT06831526","Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma",[89],"2030-08-31","2025-11-06",[1004],[1990,1151],"Azeliragon",{"nctId":1992,"briefTitle":1993,"status":122,"phases":1994,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":102,"conditions":1997,"interventions":2003},"NCT02976441","Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas",[89],"2018-02","2017-01",[1998,1999,1147,2000,2001,2002],"Astrocytoma","Brainstem Glioma","Mixed Glioma","Oligodendroglioma","Optic Nerve Glioma",[1151],{"nctId":2005,"briefTitle":2006,"status":108,"phases":2007,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":36,"conditions":2011,"interventions":2012},"NCT01907165","Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide",[89],"2016-11-10","2018-02-09","2013-10-10",[1004],[1151,2013],"Disulfiram",{"trials":2015,"activeCount":102},[2016],{"nctId":2017,"briefTitle":2018,"status":137,"phases":2019,"primaryCompletion":2020,"completion":2020,"start":2021,"enrollment":184,"conditions":2022,"interventions":2025},"NCT02510950","Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma",[90],"2017-02-14","2015-12-03",[2023,2024],"Glioblastoma Multiforme","Astrocytoma, Grade IV",[2026,2027,1151],"Personalized peptide vaccine","Poly-ICLC",{"trials":2029,"activeCount":456,"soonestReadout":76},[2030,2046,2054,2060,2064],{"nctId":2031,"briefTitle":2032,"status":122,"phases":2033,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":102,"conditions":2037,"interventions":2044},"NCT02689336","Erlotinib in Combination With Temozolomide in Treating Relapsed\u002FRecurrent\u002FRefractory Pediatric Solid Tumors",[91],"2019-11-30","2020-05-31","2016-08-06",[2038,2039,2040,1146,2041,1147,2042,2043],"Glioma","Rhabdomyosarcoma","Osteosarcoma","Neuroectodermal Tumor","Ewing's Sarcoma","Wilms Tumor",[2045,1151],"Erlotinib",{"nctId":2047,"briefTitle":2048,"status":108,"phases":2049,"primaryCompletion":2050,"completion":2050,"start":2051,"enrollment":383,"conditions":2052,"interventions":2053},"NCT02781792","Temozolomide Chronotherapy for High Grade Glioma",[91],"2024-07-18","2016-08-11",[2038,2023],[1151],{"nctId":74,"briefTitle":75,"status":203,"phases":2055,"primaryCompletion":76,"completion":2056,"start":2057,"enrollment":383,"conditions":2058,"interventions":2059},[90,91],"2028-04-13","2019-01-04",[2038],[77,1151],{"nctId":1136,"briefTitle":1137,"status":853,"phases":2061,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":1142,"conditions":2062,"interventions":2063},[90,91],[1144,1145,1146,1147],[1149,1150,959,1151],{"nctId":2065,"briefTitle":2066,"status":108,"phases":2067,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":2070,"conditions":2071,"interventions":2072},"NCT02715609","Disulfiram\u002FCopper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma",[90,91],"2024-05-12","2016-06-15",35,[2023],[2013,2073,1151],"Copper Gluconate",{"trials":2075,"activeCount":102},[],{"trials":2077,"activeCount":102},[],{"trials":2079,"activeCount":102},[],{"intervention":1370,"totalTrials":1131,"cells":2081},{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2112,"PHASE3":2138,"PHASE4":2140,"NA":2142},{"trials":2083,"activeCount":102},[],{"trials":2085,"activeCount":456,"soonestReadout":2090},[2086,2097,2101],{"nctId":2087,"briefTitle":2088,"status":203,"phases":2089,"primaryCompletion":2090,"completion":2091,"start":2092,"enrollment":208,"conditions":2093,"interventions":2095},"NCT04462328","Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma",[90],"2026-08-31","2028-05-31","2021-04-29",[2094],"Primary Central Nervous System Lymphoma",[1370,2096],"Acalabrutinib",{"nctId":1360,"briefTitle":1361,"status":288,"phases":2098,"primaryCompletion":1281,"completion":1363,"start":1364,"enrollment":565,"conditions":2099,"interventions":2100},[90],[1366,1367],[1369,1124,403,1370],{"nctId":2102,"briefTitle":2103,"status":137,"phases":2104,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":1056,"conditions":2108,"interventions":2111},"NCT03199040","Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy",[90],"2022-11-21","2023-05-01","2019-07-23",[1082,1592,2109,2110],"TNBC - Triple-Negative Breast Cancer","Triple-negative Breast Carcinoma",[1370,1048],{"trials":2113,"activeCount":184,"soonestReadout":2118},[2114,2123,2134],{"nctId":2115,"briefTitle":2116,"status":203,"phases":2117,"primaryCompletion":2118,"completion":1909,"start":2119,"enrollment":1131,"conditions":2120,"interventions":2122},"NCT04397003","Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer",[91],"2027-09-30","2022-03-30",[2121],"Extensive-stage Small Cell Lung Cancer",[1048,1370],{"nctId":2124,"briefTitle":2125,"status":122,"phases":2126,"primaryCompletion":2127,"completion":2128,"start":2129,"enrollment":102,"conditions":2130,"interventions":2131},"NCT03598816","PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced\u002FMetastatic Renal Cell Carcinoma",[91],"2022-12-31","2024-05-31","2020-08-31",[1312],[1370,2132,2133],"Tremelimumab","Neoantigen DNA Vaccine",{"nctId":1755,"briefTitle":1756,"status":108,"phases":2135,"primaryCompletion":1758,"completion":1758,"start":1759,"enrollment":442,"conditions":2136,"interventions":2137},[91],[1761,1762,1763,1764],[82,1766,1370],{"trials":2139,"activeCount":102},[],{"trials":2141,"activeCount":102},[],{"trials":2143,"activeCount":102},[],{"intervention":1007,"totalTrials":1131,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2162,"PHASE3":2176,"PHASE4":2178,"NA":2180},{"trials":2147,"activeCount":102},[],{"trials":2149,"activeCount":184,"soonestReadout":1053},[2150,2154,2158],{"nctId":997,"briefTitle":998,"status":137,"phases":2151,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":474,"conditions":2152,"interventions":2153},[90],[1004],[1006,959,1007],{"nctId":1036,"briefTitle":1037,"status":108,"phases":2155,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":2156,"interventions":2157},[90],[1044],[1046,1047,959,1007,1048],{"nctId":1050,"briefTitle":1051,"status":288,"phases":2159,"primaryCompletion":1053,"completion":1054,"start":1055,"enrollment":1056,"conditions":2160,"interventions":2161},[90],[1058],[1060,1007,959],{"trials":2163,"activeCount":456,"soonestReadout":1107},[2164,2168,2172],{"nctId":1095,"briefTitle":1096,"status":137,"phases":2165,"primaryCompletion":449,"completion":1098,"start":1099,"enrollment":456,"conditions":2166,"interventions":2167},[91],[1101],[959,1007],{"nctId":1104,"briefTitle":1105,"status":203,"phases":2169,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":1110,"conditions":2170,"interventions":2171},[91],[1058],[1071,959,1007],{"nctId":1153,"briefTitle":1154,"status":853,"phases":2173,"primaryCompletion":1156,"completion":1156,"start":1089,"enrollment":442,"conditions":2174,"interventions":2175},[91],[1158,1159],[1007,959,1161],{"trials":2177,"activeCount":102},[],{"trials":2179,"activeCount":102},[],{"trials":2181,"activeCount":102},[],{"intervention":2183,"totalTrials":98,"cells":2184},"Dapagliflozin",{"EARLY_PHASE1":2185,"PHASE1":2196,"PHASE2":2226,"PHASE3":2242,"PHASE4":2244,"NA":2246},{"trials":2186,"activeCount":102},[2187],{"nctId":2188,"briefTitle":2189,"status":108,"phases":2190,"primaryCompletion":2191,"completion":2191,"start":2192,"enrollment":1131,"conditions":2193,"interventions":2195},"NCT06812429","Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation",[89],"2025-04-05","2024-05-08",[2194],"Inflammation",[2183],{"trials":2197,"activeCount":456,"soonestReadout":2090},[2198,2207,2215],{"nctId":2199,"briefTitle":2200,"status":288,"phases":2201,"primaryCompletion":2090,"completion":2090,"start":2202,"enrollment":30,"conditions":2203,"interventions":2206},"NCT04887935","Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer",[90],"2024-06-04",[2204,2205],"Prostate Cancer","Cancer of Prostate",[2183],{"nctId":2208,"briefTitle":2209,"status":108,"phases":2210,"primaryCompletion":2211,"completion":2212,"start":154,"enrollment":1080,"conditions":2213,"interventions":2214},"NCT04542291","Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition",[90],"2021-12-24","2022-01-19",[116,29,115],[2183],{"nctId":2216,"briefTitle":2217,"status":288,"phases":2218,"primaryCompletion":2219,"completion":1139,"start":2220,"enrollment":1299,"conditions":2221,"interventions":2224},"NCT05521984","Targeting Pediatric Brain Tumors and Relapsed\u002FRefractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)",[90],"2031-03-31","2023-04-03",[2222,2223],"Pediatric Brain Tumor","Pediatric Solid Tumor",[2183,2225,1455,1229],"Carmustine",{"trials":2227,"activeCount":184,"soonestReadout":176},[2228],{"nctId":2229,"briefTitle":2230,"status":288,"phases":2231,"primaryCompletion":176,"completion":2232,"start":2233,"enrollment":2234,"conditions":2235,"interventions":2241},"NCT07174687","SGLT2 Inhibitors in Geographic Atrophy",[91],"2028-06","2025-12-02",70,[2236,2237,2238,2239,2240],"Retinal Degeneration","Retinal Diseases","Eye Diseases","Geographic Atrophy","Pathological Conditions, Anatomical",[2183],{"trials":2243,"activeCount":102},[],{"trials":2245,"activeCount":102},[],{"trials":2247,"activeCount":102},[],{"intervention":2249,"totalTrials":599,"cells":2250},"Anastrozole",{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2252,"activeCount":102},[],{"trials":2254,"activeCount":102},[],{"trials":2256,"activeCount":474,"soonestReadout":46},[2257,2264,2274,2283],{"nctId":44,"briefTitle":45,"status":203,"phases":2258,"primaryCompletion":46,"completion":2259,"start":2260,"enrollment":2261,"conditions":2262,"interventions":2263},[91],"2026-08-24","2013-04-10",84,[1445],[47,2249,621],{"nctId":2265,"briefTitle":2266,"status":288,"phases":2267,"primaryCompletion":2268,"completion":2268,"start":2269,"enrollment":464,"conditions":2270,"interventions":2272},"NCT05837455","NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II\u002FIII ER-positive, HER2-negative Breast Cancer",[91],"2027-11-30","2024-05-30",[18,2271],"Cancer of the Breast",[2249,2273],"Combination anthracycline and\u002For taxane based treatment",{"nctId":2275,"briefTitle":2276,"status":288,"phases":2277,"primaryCompletion":1090,"completion":1297,"start":2278,"enrollment":1954,"conditions":2279,"interventions":2280},"NCT02476786","Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score",[91],"2017-01-17",[18,159,1445,2271],[621,2249,2281,620,2282],"Exemestane","Tamoxifen",{"nctId":2284,"briefTitle":2285,"status":137,"phases":2286,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":2289,"conditions":2290,"interventions":2297},"NCT01368263","Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer",[91],"2013-05","2011-09",8,[2291,2292,2293,2294,2295,2296],"Estrogen Receptor-positive Breast Cancer","HER2-negative Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[2298,2299,2300,2301],"goserelin acetate","letrozole","anastrozole","chemotherapy",{"trials":2303,"activeCount":102},[],{"trials":2305,"activeCount":102},[],{"trials":2307,"activeCount":102},[],{"intervention":2309,"totalTrials":474,"cells":2310},"Mosunetuzumab",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2342,"PHASE3":2355,"PHASE4":2357,"NA":2359},{"trials":2312,"activeCount":102},[],{"trials":2314,"activeCount":456,"soonestReadout":2332},[2315,2328],{"nctId":2316,"briefTitle":2317,"status":203,"phases":2318,"primaryCompletion":1090,"completion":1269,"start":2319,"enrollment":367,"conditions":2320,"interventions":2327},"NCT05412290","Mosunetuzumab Consolidation Therapy After autoSCT in r\u002Fr Aggressive B Cell Lymphoma",[90],"2022-12-22",[2321,2322,2323,2324,2325,2326],"B Cell Lymphoma","Aggressive Lymphoma","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Transformed Lymphoma","Follicular Lymphoma Grade 3",[2309],{"nctId":2329,"briefTitle":2330,"status":203,"phases":2331,"primaryCompletion":2332,"completion":2333,"start":2334,"enrollment":30,"conditions":2335,"interventions":2339},"NCT05464329","Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed\u002FRefractory Aggressive B Cell Lymphoma",[90],"2026-01-02","2029-10-16","2023-01-03",[2336,2324,2337,2338],"Large B-cell Lymphoma","Transformed B-Cell Lymphoma","Follicular Lymphoma Grade 3B",[2309,2340,2341],"DHAX","ICE",{"trials":2343,"activeCount":184,"soonestReadout":2348},[2344],{"nctId":2345,"briefTitle":2346,"status":203,"phases":2347,"primaryCompletion":2348,"completion":2349,"start":2350,"enrollment":951,"conditions":2351,"interventions":2353},"NCT05410418","Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma",[91],"2025-09-18","2029-04-24","2022-10-24",[2352,974],"Lymphoma, Follicular",[2309,2354],"Polatuzumab vedotin",{"trials":2356,"activeCount":102},[],{"trials":2358,"activeCount":102},[],{"trials":2360,"activeCount":102},[],{"intervention":2362,"totalTrials":367,"cells":2363},"Melphalan",{"EARLY_PHASE1":2364,"PHASE1":2379,"PHASE2":2426,"PHASE3":2478,"PHASE4":2480,"NA":2482},{"trials":2365,"activeCount":102},[2366],{"nctId":2367,"briefTitle":2368,"status":122,"phases":2369,"primaryCompletion":2370,"completion":2370,"start":1351,"enrollment":102,"conditions":2371,"interventions":2373},"NCT02447055","Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma",[89],"2016-06",[24,2372],"Myeloma-Multiple",[2374,2362,2375,1229,2376,2377,2378],"Tocilizumab","Fludarabine","Tacrolimus","Mycophenolate mofetil","Filgrastim",{"trials":2380,"activeCount":184,"soonestReadout":984},[2381,2396,2404,2414],{"nctId":2382,"briefTitle":2383,"status":137,"phases":2384,"primaryCompletion":2385,"completion":2386,"start":2387,"enrollment":98,"conditions":2388,"interventions":2392},"NCT02750254","Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation",[90],"2017-05-24","2020-10-14","2016-06-27",[2389,2390,2391],"Acute Myeloid Leukemia","Myelodysplastic Syndrome","Acute Lymphocytic Leukemia",[2375,2393,1229,2362,2394,2395],"Busulfan","Granulocyte-colony stimulating factor","Azacitidine",{"nctId":2397,"briefTitle":2398,"status":288,"phases":2399,"primaryCompletion":984,"completion":984,"start":2400,"enrollment":293,"conditions":2401,"interventions":2402},"NCT06523699","Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant",[90],"2025-04-04",[24],[2403,2362],"Recombinant glycosylated human interleukin-7",{"nctId":2405,"briefTitle":2406,"status":108,"phases":2407,"primaryCompletion":2408,"completion":2409,"start":2410,"enrollment":98,"conditions":2411,"interventions":2413},"NCT04342572","Intra-arterial Chemotherapy for Retinoblastoma",[90],"2023-01-04","2025-03-21","2020-08-11",[2412],"Retinoblastoma",[2362],{"nctId":2415,"briefTitle":2416,"status":108,"phases":2417,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":1664,"conditions":2421,"interventions":2422},"NCT03072771","Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",[90],"2021-04-07","2023-10-30","2017-08-01",[2323],[2423,2225,2424,2425,2362],"Blinatumomab","Etoposide","Cytarabine",{"trials":2427,"activeCount":184,"soonestReadout":2463},[2428,2438,2447,2459],{"nctId":2429,"briefTitle":2430,"status":108,"phases":2431,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":2434,"conditions":2435,"interventions":2436},"NCT04682405","Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)",[91],"2022-11-11","2021-05-05",51,[24],[2437,2362],"Uproleselan",{"nctId":2439,"briefTitle":2440,"status":137,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":1873,"enrollment":340,"conditions":2444,"interventions":2445},"NCT01653418","Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation",[91],"2013-08","2013-12",[24],[2446,2225,2424,2425,2362],"Bortezomib",{"nctId":2448,"briefTitle":2449,"status":122,"phases":2450,"primaryCompletion":2451,"completion":2451,"start":2452,"enrollment":102,"conditions":2453,"interventions":2455},"NCT01531244","Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma",[90,91],"2016-02","2014-12",[2454],"Melanoma",[2456,2457,2458],"dactinomycin","melphalan","Conditionally replicative adenovirus 3\u002F5-delta",{"nctId":2460,"briefTitle":2461,"status":288,"phases":2462,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":2466,"interventions":2470},"NCT06158828","Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML",[90,91],"2028-09-15","2030-05-31","2024-11-15",[2467,2468,2469,2389],"AML, Childhood","Aml","Acute Myeloid Leukemia, Pediatric",[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],"Rabbit Anti thymocyte globulin","Thiotepa","TCR alpha beta \u002F CD19+ depleted haploidentical hematopoietic progenitor cell graft","memory-like natural killer cells","IL-2","Plerixafor","Granulocyte Colony-Stimulating Factor",{"trials":2479,"activeCount":102},[],{"trials":2481,"activeCount":102},[],{"trials":2483,"activeCount":102},[],{"intervention":402,"totalTrials":2289,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2509,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2487,"activeCount":102},[],{"trials":2489,"activeCount":102},[2490,2494,2505],{"nctId":1829,"briefTitle":1830,"status":137,"phases":2491,"primaryCompletion":1832,"completion":1833,"start":1834,"enrollment":1056,"conditions":2492,"interventions":2493},[90],[29,114,115,116],[1837,1125,1124],{"nctId":2495,"briefTitle":2496,"status":108,"phases":2497,"primaryCompletion":2498,"completion":2499,"start":2500,"enrollment":951,"conditions":2501,"interventions":2503},"NCT01677559","Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies",[90],"2014-09-30","2017-08-11","2013-05-07",[2502,1875],"Adenocarcinoma",[2504,402],"MLN8237",{"nctId":1894,"briefTitle":1895,"status":108,"phases":2506,"primaryCompletion":1897,"completion":1898,"start":1899,"enrollment":293,"conditions":2507,"interventions":2508},[90],[29],[402,1124],{"trials":2510,"activeCount":456,"soonestReadout":419},[2511,2515,2519,2523,2533],{"nctId":1086,"briefTitle":1087,"status":203,"phases":2512,"primaryCompletion":1089,"completion":1090,"start":761,"enrollment":743,"conditions":2513,"interventions":2514},[91],[1092],[425,959],{"nctId":388,"briefTitle":389,"status":108,"phases":2516,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":2517,"interventions":2518},[91],[355,396,397,398,399,400],[402,403,339],{"nctId":416,"briefTitle":417,"status":203,"phases":2520,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":2521,"interventions":2522},[91],[399,423,398],[425,403,426,339],{"nctId":2524,"briefTitle":2525,"status":137,"phases":2526,"primaryCompletion":2527,"completion":2528,"start":2529,"enrollment":456,"conditions":2530,"interventions":2532},"NCT03655080","Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression",[91],"2021-02-22","2021-06-15","2019-01-09",[2531],"Cord Compression",[402],{"nctId":1114,"briefTitle":1115,"status":108,"phases":2534,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":506,"conditions":2535,"interventions":2536},[90,91],[1121],[1123,959,1124,1125],{"trials":2538,"activeCount":102},[],{"trials":2540,"activeCount":102},[],{"trials":2542,"activeCount":102},[],{"intervention":2377,"totalTrials":1131,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2551,"PHASE2":2576,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2546,"activeCount":102},[2547],{"nctId":2367,"briefTitle":2368,"status":122,"phases":2548,"primaryCompletion":2370,"completion":2370,"start":1351,"enrollment":102,"conditions":2549,"interventions":2550},[89],[24,2372],[2374,2362,2375,1229,2376,2377,2378],{"trials":2552,"activeCount":102},[2553,2564],{"nctId":2554,"briefTitle":2555,"status":137,"phases":2556,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":1818,"conditions":2559,"interventions":2560},"NCT05049863","Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)",[90],"2024-11-17","2023-02-27",[1940,1941],[2561,2562,2563],"Mycophenolate Mofetil","Allopurinol","Irinotecan",{"nctId":2565,"briefTitle":2566,"status":137,"phases":2567,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":184,"conditions":2571,"interventions":2573},"NCT02678143","Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease",[90],"2020-04-03","2021-11-16","2016-04-26",[2572],"Sickle Cell Disease",[2574,1229,2377,2575,2375],"Alemtuzumab","Sirolimus",{"trials":2577,"activeCount":456,"soonestReadout":2606},[2578,2591,2602],{"nctId":2579,"briefTitle":2580,"status":108,"phases":2581,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":27,"conditions":2584,"interventions":2587},"NCT03388008","Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation",[91],"2022-08-31","2019-12-17",[2585,2586],"Lung Transplant Rejection","Antibody-mediated Rejection",[2588,2376,2589,2561,2590,1073],"Belatacept","ATG","Methylprednisolone",{"nctId":2592,"briefTitle":2593,"status":203,"phases":2594,"primaryCompletion":2595,"completion":2595,"start":2596,"enrollment":1056,"conditions":2597,"interventions":2599},"NCT00882895","Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma",[91],"2028-06-01","2009-05-05",[2598],"Lymphoma, Non-Hodgkin",[2600,2601,2376,2377],"Anti-thymocyte globulin","Solumedrol",{"nctId":2603,"briefTitle":2604,"status":203,"phases":2605,"primaryCompletion":2606,"completion":2607,"start":2608,"enrollment":2609,"conditions":2610,"interventions":2611},"NCT02782546","Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation",[91],"2025-10-27","2028-02-13","2017-01-30",60,[2389],[2376,2377,2612,2613],"G-CSF","ALT-803",{"trials":2615,"activeCount":102},[],{"trials":2617,"activeCount":102},[],{"trials":2619,"activeCount":102},[],{"intervention":1867,"totalTrials":1131,"cells":2621},{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2640,"PHASE3":2683,"PHASE4":2685,"NA":2687},{"trials":2623,"activeCount":102},[],{"trials":2625,"activeCount":184,"soonestReadout":2634},[2626,2630],{"nctId":1859,"briefTitle":1860,"status":108,"phases":2627,"primaryCompletion":1648,"completion":1862,"start":1863,"enrollment":293,"conditions":2628,"interventions":2629},[90],[1865,1184],[374,1124,1867],{"nctId":2631,"briefTitle":2632,"status":203,"phases":2633,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":36,"conditions":2636,"interventions":2638},"NCT01061515","Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer",[90],"2026-09-27","2011-05-10",[2637],"Carcinoma",[2639,372,1867],"Intraperitoneal Oxaliplatin",{"trials":2641,"activeCount":184,"soonestReadout":1363},[2642,2652,2663,2673],{"nctId":2643,"briefTitle":2644,"status":108,"phases":2645,"primaryCompletion":2646,"completion":2647,"start":1646,"enrollment":2648,"conditions":2649,"interventions":2651},"NCT01060007","Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer",[91],"2013-04","2014-09",80,[2650],"Rectal Neoplasms",[374,373,414,1867],{"nctId":2653,"briefTitle":2654,"status":288,"phases":2655,"primaryCompletion":1363,"completion":1363,"start":2656,"enrollment":729,"conditions":2657,"interventions":2659},"NCT06374459","Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis",[90,91],"2025-01-30",[2658],"Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer",[2660,1867,2661,2662],"Zumsemetinib","Zoledronic acid","Denosumab",{"nctId":2664,"briefTitle":2665,"status":137,"phases":2666,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":960,"conditions":2670,"interventions":2671},"NCT02352831","Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma",[90,91],"2017-10-20","2018-10-19","2015-08-31",[29,114,115,116],[2672,1867],"Tosedostat",{"nctId":2674,"briefTitle":2675,"status":108,"phases":2676,"primaryCompletion":2677,"completion":2677,"start":2646,"enrollment":2678,"conditions":2679,"interventions":2681},"NCT01722162","Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer",[91],"2015-10",47,[2680],"Colorectal Neoplasms",[372,1867,2682],"Levocetirizine",{"trials":2684,"activeCount":102},[],{"trials":2686,"activeCount":102},[],{"trials":2688,"activeCount":102},[],{"intervention":2225,"totalTrials":98,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2703,"PHASE3":2730,"PHASE4":2732,"NA":2734},{"trials":2692,"activeCount":102},[],{"trials":2694,"activeCount":184,"soonestReadout":2219},[2695,2699],{"nctId":2415,"briefTitle":2416,"status":108,"phases":2696,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":1664,"conditions":2697,"interventions":2698},[90],[2323],[2423,2225,2424,2425,2362],{"nctId":2216,"briefTitle":2217,"status":288,"phases":2700,"primaryCompletion":2219,"completion":1139,"start":2220,"enrollment":1299,"conditions":2701,"interventions":2702},[90],[2222,2223],[2183,2225,1455,1229],{"trials":2704,"activeCount":184,"soonestReadout":2709},[2705,2715,2719],{"nctId":2706,"briefTitle":2707,"status":288,"phases":2708,"primaryCompletion":2709,"completion":2710,"start":2711,"enrollment":22,"conditions":2712,"interventions":2713},"NCT06687772","CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant",[91],"2027-07-31","2029-07-31","2025-01-16",[2323],[2472,2225,2714],"Anthracycline-based induction chemotherapy",{"nctId":2439,"briefTitle":2440,"status":137,"phases":2716,"primaryCompletion":2442,"completion":2443,"start":1873,"enrollment":340,"conditions":2717,"interventions":2718},[91],[24],[2446,2225,2424,2425,2362],{"nctId":2720,"briefTitle":2721,"status":108,"phases":2722,"primaryCompletion":2723,"completion":2724,"start":2725,"enrollment":1954,"conditions":2726,"interventions":2727},"NCT01969435","Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma",[91],"2015-09-30","2017-05-31","2014-03-19",[1888,2598],[2225,2728,2425,2729],"Etoposide phosphate","Melphalan HCl",{"trials":2731,"activeCount":102},[],{"trials":2733,"activeCount":102},[],{"trials":2735,"activeCount":102},[],{"intervention":2376,"totalTrials":98,"cells":2737},{"EARLY_PHASE1":2738,"PHASE1":2744,"PHASE2":2746,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2739,"activeCount":102},[2740],{"nctId":2367,"briefTitle":2368,"status":122,"phases":2741,"primaryCompletion":2370,"completion":2370,"start":1351,"enrollment":102,"conditions":2742,"interventions":2743},[89],[24,2372],[2374,2362,2375,1229,2376,2377,2378],{"trials":2745,"activeCount":102},[],{"trials":2747,"activeCount":456,"soonestReadout":2606},[2748,2752,2756,2763],{"nctId":2579,"briefTitle":2580,"status":108,"phases":2749,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":27,"conditions":2750,"interventions":2751},[91],[2585,2586],[2588,2376,2589,2561,2590,1073],{"nctId":2592,"briefTitle":2593,"status":203,"phases":2753,"primaryCompletion":2595,"completion":2595,"start":2596,"enrollment":1056,"conditions":2754,"interventions":2755},[91],[2598],[2600,2601,2376,2377],{"nctId":2757,"briefTitle":2758,"status":122,"phases":2759,"primaryCompletion":2647,"completion":577,"start":1965,"enrollment":102,"conditions":2760,"interventions":2762},"NCT00950391","Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus",[90,91],[2761],"Peripheral Nerve Injury",[2376],{"nctId":2603,"briefTitle":2604,"status":203,"phases":2764,"primaryCompletion":2606,"completion":2607,"start":2608,"enrollment":2609,"conditions":2765,"interventions":2766},[91],[2389],[2376,2377,2612,2613],{"trials":2768,"activeCount":102},[],{"trials":2770,"activeCount":102},[],{"trials":2772,"activeCount":102},[],{"intervention":621,"totalTrials":599,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2797,"PHASE4":2799,"NA":2801},{"trials":2776,"activeCount":102},[],{"trials":2778,"activeCount":102},[],{"trials":2780,"activeCount":456,"soonestReadout":46},[2781,2785,2789,2793],{"nctId":608,"briefTitle":609,"status":108,"phases":2782,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":2783,"interventions":2784},[91],[18,616,159,617],[57,619,620,621],{"nctId":44,"briefTitle":45,"status":203,"phases":2786,"primaryCompletion":46,"completion":2259,"start":2260,"enrollment":2261,"conditions":2787,"interventions":2788},[91],[1445],[47,2249,621],{"nctId":623,"briefTitle":624,"status":137,"phases":2790,"primaryCompletion":626,"completion":627,"start":628,"enrollment":442,"conditions":2791,"interventions":2792},[91],[18,159,616],[57,619,631,621,632],{"nctId":2275,"briefTitle":2276,"status":288,"phases":2794,"primaryCompletion":1090,"completion":1297,"start":2278,"enrollment":1954,"conditions":2795,"interventions":2796},[91],[18,159,1445,2271],[621,2249,2281,620,2282],{"trials":2798,"activeCount":102},[],{"trials":2800,"activeCount":102},[],{"trials":2802,"activeCount":102},[],{"intervention":2804,"totalTrials":474,"cells":2805},"Chemotherapy",{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2810,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2807,"activeCount":102},[],{"trials":2809,"activeCount":102},[],{"trials":2811,"activeCount":456,"soonestReadout":2825},[2812,2821,2833],{"nctId":2813,"briefTitle":2814,"status":288,"phases":2815,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1954,"conditions":2818,"interventions":2820},"NCT06529809","Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer",[90,91],"2031-12-31","2025-02-11",[2819],"Locally Advanced Cervical Carcinoma",[2804],{"nctId":2822,"briefTitle":2823,"status":853,"phases":2824,"primaryCompletion":2825,"completion":2826,"start":2090,"enrollment":2827,"conditions":2828,"interventions":2831},"NCT07620548","Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas",[91],"2031-02-28","2032-08-31",99,[1004,2829,2830],"Glioblastoma, IDH-wildtype","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",[2832,2804],"Cemiplimab",{"nctId":2284,"briefTitle":2285,"status":137,"phases":2834,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":2289,"conditions":2835,"interventions":2836},[91],[2291,2292,2293,2294,2295,2296],[2298,2299,2300,2301],{"trials":2838,"activeCount":102},[],{"trials":2840,"activeCount":102},[],{"trials":2842,"activeCount":102},[],{"intervention":1186,"totalTrials":474,"cells":2844},{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2853,"PHASE3":2874,"PHASE4":2876,"NA":2878},{"trials":2846,"activeCount":102},[],{"trials":2848,"activeCount":102},[2849],{"nctId":1175,"briefTitle":1176,"status":108,"phases":2850,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":2851,"interventions":2852},[90],[1183,1184,29],[1186,994,1124],{"trials":2854,"activeCount":456,"soonestReadout":2859},[2855,2865],{"nctId":2856,"briefTitle":2857,"status":203,"phases":2858,"primaryCompletion":2859,"completion":2860,"start":2861,"enrollment":383,"conditions":2862,"interventions":2864},"NCT04331041","Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma",[91],"2026-02-09","2027-04-21","2021-08-24",[116,115,2863],"Pancreas Adenocarcinoma",[1186],{"nctId":2866,"briefTitle":2867,"status":288,"phases":2868,"primaryCompletion":1419,"completion":1419,"start":2869,"enrollment":22,"conditions":2870,"interventions":2872},"NCT07126158","Stereotactic Body Radiotherapy Plus FAK and RAF\u002FMEK Inhibition in Advanced Pancreatic Adenocarcinoma",[91],"2026-04-10",[2871,115,116,29],"Pancreatic Adenocarcinoma",[1186,2873],"Avutometinib",{"trials":2875,"activeCount":102},[],{"trials":2877,"activeCount":102},[],{"trials":2879,"activeCount":102},[],{"intervention":2662,"totalTrials":474,"cells":2881},{"EARLY_PHASE1":2882,"PHASE1":2896,"PHASE2":2898,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2883,"activeCount":102},[2884],{"nctId":2885,"briefTitle":2886,"status":108,"phases":2887,"primaryCompletion":2888,"completion":2888,"start":2889,"enrollment":340,"conditions":2890,"interventions":2893},"NCT03629717","RANKL Inhibition and Breast Tissue Biomarkers",[89],"2018-12-03","2018-06-01",[2891,2892],"Breast Cancer Prevention","Mammographic Density",[2662,2894,2895],"Calcium","Vitamin D",{"trials":2897,"activeCount":102},[],{"trials":2899,"activeCount":456,"soonestReadout":2908},[2900,2904],{"nctId":2653,"briefTitle":2654,"status":288,"phases":2901,"primaryCompletion":1363,"completion":1363,"start":2656,"enrollment":729,"conditions":2902,"interventions":2903},[90,91],[2658],[2660,1867,2661,2662],{"nctId":2905,"briefTitle":2906,"status":203,"phases":2907,"primaryCompletion":2908,"completion":2090,"start":2909,"enrollment":2910,"conditions":2911,"interventions":2913},"NCT04067726","RANKL Inhibition and Mammographic Breast Density",[91],"2025-09-17","2019-08-27",210,[2912],"Dense Breasts",[2662,2894,2914],"Vitamin D3",{"trials":2916,"activeCount":102},[],{"trials":2918,"activeCount":102},[],{"trials":2920,"activeCount":102},[],{"intervention":1071,"totalTrials":474,"cells":2922},{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2931,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2924,"activeCount":102},[],{"trials":2926,"activeCount":102},[2927],{"nctId":1062,"briefTitle":1063,"status":108,"phases":2928,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1056,"conditions":2929,"interventions":2930},[90],[1069],[1071,959,1072,1073],{"trials":2932,"activeCount":456,"soonestReadout":2937},[2933,2942],{"nctId":2934,"briefTitle":2935,"status":203,"phases":2936,"primaryCompletion":2937,"completion":2938,"start":2939,"enrollment":2070,"conditions":2940,"interventions":2941},"NCT04412629","Cabozantinib in High Grade Neuroendocrine Neoplasms",[91],"2026-09-30","2027-03-31","2020-11-24",[1809],[1071],{"nctId":1104,"briefTitle":1105,"status":203,"phases":2943,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":1110,"conditions":2944,"interventions":2945},[91],[1058],[1071,959,1007],{"trials":2947,"activeCount":102},[],{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[],{"intervention":2472,"totalTrials":456,"cells":2953},{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2958,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2955,"activeCount":102},[],{"trials":2957,"activeCount":102},[],{"trials":2959,"activeCount":456,"soonestReadout":2709},[2960,2964],{"nctId":2706,"briefTitle":2707,"status":288,"phases":2961,"primaryCompletion":2709,"completion":2710,"start":2711,"enrollment":22,"conditions":2962,"interventions":2963},[91],[2323],[2472,2225,2714],{"nctId":2460,"briefTitle":2461,"status":288,"phases":2965,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":2966,"interventions":2967},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"trials":2969,"activeCount":102},[],{"trials":2971,"activeCount":102},[],{"trials":2973,"activeCount":102},[],{"intervention":2354,"totalTrials":456,"cells":2975},{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2995,"PHASE4":2997,"NA":2999},{"trials":2977,"activeCount":102},[],{"trials":2979,"activeCount":102},[],{"trials":2981,"activeCount":456,"soonestReadout":2348},[2982,2991],{"nctId":2983,"briefTitle":2984,"status":288,"phases":2985,"primaryCompletion":1196,"completion":1363,"start":2986,"enrollment":1566,"conditions":2987,"interventions":2989},"NCT06040320","Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)",[90,91],"2023-10-04",[2988],"Post-transplant Lymphoproliferative Disorder",[2354,978,2990],"CHP",{"nctId":2345,"briefTitle":2346,"status":203,"phases":2992,"primaryCompletion":2348,"completion":2349,"start":2350,"enrollment":951,"conditions":2993,"interventions":2994},[91],[2352,974],[2309,2354],{"trials":2996,"activeCount":102},[],{"trials":2998,"activeCount":102},[],{"trials":3000,"activeCount":102},[],{"intervention":1849,"totalTrials":1566,"cells":3002},{"EARLY_PHASE1":3003,"PHASE1":3040,"PHASE2":3059,"PHASE3":3094,"PHASE4":3096,"NA":3108},{"trials":3004,"activeCount":102},[3005,3016,3028],{"nctId":3006,"briefTitle":3007,"status":108,"phases":3008,"primaryCompletion":3009,"completion":3010,"start":365,"enrollment":1249,"conditions":3011,"interventions":3013},"NCT01331590","Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia",[89],"2014-10","2015-11",[3012],"Precursor Cell Lymphoblastic Leukemia-Lymphoma",[2612,3014,2424,1849,3015],"Ifosfamide","Mesna",{"nctId":3017,"briefTitle":3018,"status":137,"phases":3019,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":3022,"interventions":3023},"NCT01537861","Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma",[89],"2014-02","2012-06",[24],[2378,2446,3024,1849,1229,3025,3026,3027],"Carfilzomib","Thalidomide","Lenalidomide","Pomalidomide",{"nctId":3029,"briefTitle":3030,"status":108,"phases":3031,"primaryCompletion":3032,"completion":3032,"start":3033,"enrollment":565,"conditions":3034,"interventions":3037},"NCT00314743","Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation",[89],"2008-12","2005-10",[3035,3036],"Nausea","Vomiting",[3038,1849,3039],"Ondansetron","Aprepitant",{"trials":3041,"activeCount":102},[3042,3046,3050],{"nctId":1839,"briefTitle":1840,"status":137,"phases":3043,"primaryCompletion":1842,"completion":1843,"start":1844,"enrollment":27,"conditions":3044,"interventions":3045},[90],[1635,1846],[1848,1849,1124,374],{"nctId":1879,"briefTitle":1880,"status":108,"phases":3047,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":30,"conditions":3048,"interventions":3049},[90],[1886,1887,1888,1889],[1891,1124,374,1849,1892],{"nctId":3051,"briefTitle":3052,"status":137,"phases":3053,"primaryCompletion":3054,"completion":3055,"start":1039,"enrollment":184,"conditions":3056,"interventions":3057},"NCT04912427","Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease",[90],"2022-12-06","2024-01-26",[24],[3058,2446,1849],"Isatuximab",{"trials":3060,"activeCount":456,"soonestReadout":41},[3061,3070,3076,3083],{"nctId":3062,"briefTitle":3063,"status":122,"phases":3064,"primaryCompletion":1090,"completion":1090,"start":3065,"enrollment":102,"conditions":3066,"interventions":3068},"NCT05820763","Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant",[91],"2024-01-05",[24,3067],"Myeloma-Associated Amyloidosis",[3069,3026,1849],"Selinexor",{"nctId":39,"briefTitle":40,"status":203,"phases":3071,"primaryCompletion":41,"completion":2090,"start":3072,"enrollment":3073,"conditions":3074,"interventions":3075},[91],"2015-01-20",236,[24],[42,3026,1849],{"nctId":69,"briefTitle":70,"status":203,"phases":3077,"primaryCompletion":71,"completion":3078,"start":3079,"enrollment":208,"conditions":3080,"interventions":3082},[91],"2027-09-26","2017-11-22",[3081],"Multiple Myeloma in Relapse",[72,3027,1849],{"nctId":3084,"briefTitle":3085,"status":108,"phases":3086,"primaryCompletion":3087,"completion":3088,"start":3089,"enrollment":506,"conditions":3090,"interventions":3091},"NCT01246063","Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90,91],"2017-12-28","2018-03-23","2012-05-14",[24],[3092,3093,1849],"carfilzomib","pegylated liposomal doxorubicin",{"trials":3095,"activeCount":102},[],{"trials":3097,"activeCount":102},[3098],{"nctId":3099,"briefTitle":3100,"status":108,"phases":3101,"primaryCompletion":3102,"completion":3102,"start":3103,"enrollment":3104,"conditions":3105,"interventions":3107},"NCT01042145","Community Care for Croup (RCT)",[93],"2011-06","2009-10",87,[3106],"Croup",[1073,1849],{"trials":3109,"activeCount":102},[3110],{"nctId":3111,"briefTitle":3112,"status":108,"phases":3113,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":1181,"conditions":3117,"interventions":3120},"NCT02084134","Peri-Operative Steroid Management in Patients",[94],"2016-11-21","2016-12-31","2012-03",[3118,3119],"Pituitary Adenoma","Pituitary Diseases",[3121,3122],"hydrocortisone","dexamethasone",{"intervention":3124,"totalTrials":456,"cells":3125},"Tirzepatide",{"EARLY_PHASE1":3126,"PHASE1":3128,"PHASE2":3130,"PHASE3":3143,"PHASE4":3145,"NA":3156},{"trials":3127,"activeCount":102},[],{"trials":3129,"activeCount":102},[],{"trials":3131,"activeCount":184,"soonestReadout":3136},[3132],{"nctId":3133,"briefTitle":3134,"status":288,"phases":3135,"primaryCompletion":3136,"completion":3137,"start":3138,"enrollment":2609,"conditions":3139,"interventions":3141},"NCT06976853","Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease",[91],"2028-05","2028-08","2025-05-13",[3140],"Crohn Disease (CD)",[3124,3142],"Standard of care treatment",{"trials":3144,"activeCount":102},[],{"trials":3146,"activeCount":102},[3147],{"nctId":3148,"briefTitle":3149,"status":122,"phases":3150,"primaryCompletion":3151,"completion":3151,"start":3152,"enrollment":102,"conditions":3153,"interventions":3155},"NCT06009653","Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity",[93],"2024-05-29","2023-09-13",[15,3154],"Metabolic Disease",[3124],{"trials":3157,"activeCount":102},[],{"intervention":2425,"totalTrials":1566,"cells":3159},{"EARLY_PHASE1":3160,"PHASE1":3162,"PHASE2":3201,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3161,"activeCount":102},[],{"trials":3163,"activeCount":102},[3164,3175,3188,3197],{"nctId":3165,"briefTitle":3166,"status":108,"phases":3167,"primaryCompletion":3168,"completion":3169,"start":3170,"enrollment":1056,"conditions":3171,"interventions":3173},"NCT02728531","Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma",[90],"2019-01-16","2023-08-16","2016-04-18",[3172],"Mantle Cell Lymphoma",[3174,978,2425,1892,2378],"Bendamustine",{"nctId":3176,"briefTitle":3177,"status":108,"phases":3178,"primaryCompletion":3179,"completion":1441,"start":3180,"enrollment":1310,"conditions":3181,"interventions":3183},"NCT01161550","Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed\u002FRefractory AML",[90],"2011-08","2010-11",[3182],"Leukemia, Myeloid, Acute",[3184,3185,2425,3186,3187],"Granulocyte colony-stimulating factor","Cladribine","All-Trans Retinoic Acid","Midostaurin",{"nctId":3189,"briefTitle":3190,"status":137,"phases":3191,"primaryCompletion":3192,"completion":2288,"start":3193,"enrollment":1131,"conditions":3194,"interventions":3195},"NCT01027923","IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)",[90],"2010-07","2010-05",[3182],[2476,3196,2424,2425],"Mitoxantrone",{"nctId":2415,"briefTitle":2416,"status":108,"phases":3198,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":1664,"conditions":3199,"interventions":3200},[90],[2323],[2423,2225,2424,2425,2362],{"trials":3202,"activeCount":184,"soonestReadout":2710},[3203,3213,3221,3225,3233,3237,3246,3255],{"nctId":3204,"briefTitle":3205,"status":137,"phases":3206,"primaryCompletion":3032,"completion":3207,"start":3208,"enrollment":1623,"conditions":3209,"interventions":3210},"NCT00593645","Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation",[91],"2009-07","2007-11",[26,2389],[3211,2425,3212],"Clofarabine","Thymoglobulin",{"nctId":3214,"briefTitle":3215,"status":108,"phases":3216,"primaryCompletion":3217,"completion":577,"start":1443,"enrollment":3218,"conditions":3219,"interventions":3220},"NCT00906945","Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia",[90,91],"2012-11",39,[3182],[2612,2476,3196,2424,2425],{"nctId":2439,"briefTitle":2440,"status":137,"phases":3222,"primaryCompletion":2442,"completion":2443,"start":1873,"enrollment":340,"conditions":3223,"interventions":3224},[91],[24],[2446,2225,2424,2425,2362],{"nctId":3226,"briefTitle":3227,"status":108,"phases":3228,"primaryCompletion":3229,"completion":3229,"start":3230,"enrollment":506,"conditions":3231,"interventions":3232},"NCT02416908","Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia",[90,91],"2019-06-21","2015-06-16",[2389],[3069,3185,2612,2425],{"nctId":2720,"briefTitle":2721,"status":108,"phases":3234,"primaryCompletion":2723,"completion":2724,"start":2725,"enrollment":1954,"conditions":3235,"interventions":3236},[91],[1888,2598],[2225,2728,2425,2729],{"nctId":3238,"briefTitle":3239,"status":108,"phases":3240,"primaryCompletion":3241,"completion":3242,"start":3243,"enrollment":1249,"conditions":3244,"interventions":3245},"NCT03623373","Acalabrutinib With Bendamustine \u002F Rituximab Followed by Cytarabine \u002F Rituximab for Untreated Mantle Cell Lymphoma",[91],"2020-02-09","2025-04-14","2018-11-29",[3172],[3174,978,2096,2425],{"nctId":3247,"briefTitle":3248,"status":108,"phases":3249,"primaryCompletion":1647,"completion":1647,"start":3250,"enrollment":3251,"conditions":3252,"interventions":3253},"NCT00512252","AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia",[90,91],"2007-07",52,[3182],[3254,3196,2424,2425],"AMD3100",{"nctId":3256,"briefTitle":3257,"status":203,"phases":3258,"primaryCompletion":2710,"completion":2710,"start":3259,"enrollment":3260,"conditions":3261,"interventions":3262},"NCT02756962","Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance",[91],"2016-07-06",107,[2389],[2425],{"trials":3264,"activeCount":102},[],{"trials":3266,"activeCount":102},[],{"trials":3268,"activeCount":102},[],{"intervention":2612,"totalTrials":1310,"cells":3270},{"EARLY_PHASE1":3271,"PHASE1":3287,"PHASE2":3327,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3272,"activeCount":102},[3273,3277],{"nctId":3006,"briefTitle":3007,"status":108,"phases":3274,"primaryCompletion":3009,"completion":3010,"start":365,"enrollment":1249,"conditions":3275,"interventions":3276},[89],[3012],[2612,3014,2424,1849,3015],{"nctId":3278,"briefTitle":3279,"status":108,"phases":3280,"primaryCompletion":3281,"completion":3281,"start":1862,"enrollment":353,"conditions":3282,"interventions":3284},"NCT00797056","Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease",[89],"2012-04",[3283],"Peripheral Vascular Diseases",[2612,3285,3286],"Aspirin","Clopidogrel",{"trials":3288,"activeCount":102},[3289,3298,3308,3317],{"nctId":3290,"briefTitle":3291,"status":108,"phases":3292,"primaryCompletion":3293,"completion":3294,"start":1686,"enrollment":1299,"conditions":3295,"interventions":3296},"NCT06547112","A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization",[90],"2025-07-23","2025-08-19",[24],[3297,2612],"Motixafortide",{"nctId":3299,"briefTitle":3300,"status":108,"phases":3301,"primaryCompletion":3302,"completion":3303,"start":3304,"enrollment":3305,"conditions":3306,"interventions":3307},"NCT01065129","Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)",[90],"2014-07","2016-10-18","2010-09-02",28,[26],[2612,2476,2395],{"nctId":3309,"briefTitle":3310,"status":108,"phases":3311,"primaryCompletion":3312,"completion":3313,"start":3314,"enrollment":340,"conditions":3315,"interventions":3316},"NCT02220608","Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma",[90],"2016-07-31","2016-11-30","2015-02-20",[24],[2446,2612],{"nctId":3318,"briefTitle":3319,"status":108,"phases":3320,"primaryCompletion":3321,"completion":1238,"start":3322,"enrollment":3323,"conditions":3324,"interventions":3326},"NCT01026987","Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant",[90],"2014-04","2010-04-29",29,[3325],"Stem Cell Transplant Patients",[2612,3254],{"trials":3328,"activeCount":184,"soonestReadout":2606},[3329,3341,3349,3353,3357],{"nctId":3330,"briefTitle":3331,"status":122,"phases":3332,"primaryCompletion":2937,"completion":983,"start":3333,"enrollment":102,"conditions":3334,"interventions":3337},"NCT04354025","Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML",[91],"2023-06-30",[3335,3336],"Refractory Acute Myeloid Leukemia","Relapsed Acute Myeloid Leukemia",[3338,2375,3339,2612,3340],"Cytokine induced memory-like NK cells","Ara-C","Interleukin-2",{"nctId":3342,"briefTitle":3343,"status":108,"phases":3344,"primaryCompletion":1873,"completion":3345,"start":3346,"enrollment":1911,"conditions":3347,"interventions":3348},"NCT00733824","Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma",[90,91],"2013-09","2008-11",[2598,1888],[3254,2612],{"nctId":3214,"briefTitle":3215,"status":108,"phases":3350,"primaryCompletion":3217,"completion":577,"start":1443,"enrollment":3218,"conditions":3351,"interventions":3352},[90,91],[3182],[2612,2476,3196,2424,2425],{"nctId":3226,"briefTitle":3227,"status":108,"phases":3354,"primaryCompletion":3229,"completion":3229,"start":3230,"enrollment":506,"conditions":3355,"interventions":3356},[90,91],[2389],[3069,3185,2612,2425],{"nctId":2603,"briefTitle":2604,"status":203,"phases":3358,"primaryCompletion":2606,"completion":2607,"start":2608,"enrollment":2609,"conditions":3359,"interventions":3360},[91],[2389],[2376,2377,2612,2613],{"trials":3362,"activeCount":102},[],{"trials":3364,"activeCount":102},[],{"trials":3366,"activeCount":102},[],{"intervention":3026,"totalTrials":367,"cells":3368},{"EARLY_PHASE1":3369,"PHASE1":3375,"PHASE2":3396,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3370,"activeCount":102},[3371],{"nctId":3017,"briefTitle":3018,"status":137,"phases":3372,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":3373,"interventions":3374},[89],[24],[2378,2446,3024,1849,1229,3025,3026,3027],{"trials":3376,"activeCount":102},[3377,3387],{"nctId":3378,"briefTitle":3379,"status":108,"phases":3380,"primaryCompletion":3381,"completion":3382,"start":3383,"enrollment":1283,"conditions":3384,"interventions":3385},"NCT02086604","Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma",[90],"2017-06-09","2022-01-12","2014-09-18",[1889],[3386,3026],"Brentuximab vedotin",{"nctId":3388,"briefTitle":3389,"status":108,"phases":3390,"primaryCompletion":3391,"completion":3392,"start":3393,"enrollment":3305,"conditions":3394,"interventions":3395},"NCT01207921","Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma",[90],"2016-09-19","2021-03-05","2011-04-28",[1888],[3026],{"trials":3397,"activeCount":184,"soonestReadout":41},[3398,3402,3410,3416,3420,3428],{"nctId":3062,"briefTitle":3063,"status":122,"phases":3399,"primaryCompletion":1090,"completion":1090,"start":3065,"enrollment":102,"conditions":3400,"interventions":3401},[91],[24,3067],[3069,3026,1849],{"nctId":3403,"briefTitle":3404,"status":108,"phases":3405,"primaryCompletion":3406,"completion":3406,"start":3407,"enrollment":2648,"conditions":3408,"interventions":3409},"NCT00540007","Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma",[91],"2016-09-01","2007-09-06",[1888],[3026],{"nctId":3411,"briefTitle":3412,"status":108,"phases":3413,"primaryCompletion":1647,"completion":3116,"start":1451,"enrollment":565,"conditions":3414,"interventions":3415},"NCT00546897","Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities",[91],[3182],[3026],{"nctId":39,"briefTitle":40,"status":203,"phases":3417,"primaryCompletion":41,"completion":2090,"start":3072,"enrollment":3073,"conditions":3418,"interventions":3419},[91],[24],[42,3026,1849],{"nctId":3421,"briefTitle":3422,"status":108,"phases":3423,"primaryCompletion":3424,"completion":3009,"start":3425,"enrollment":1938,"conditions":3426,"interventions":3427},"NCT01016600","Azacitidine and Lenalidomide for Acute Myeloid Leukemia",[90,91],"2013-11","2010-04",[3182],[3026,2395],{"nctId":3429,"briefTitle":3430,"status":108,"phases":3431,"primaryCompletion":3432,"completion":381,"start":3102,"enrollment":30,"conditions":3433,"interventions":3434},"NCT01246076","Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents",[91],"2014-05",[26],[3026],{"trials":3436,"activeCount":102},[],{"trials":3438,"activeCount":102},[],{"trials":3440,"activeCount":102},[],{"intervention":2563,"totalTrials":2289,"cells":3442},{"EARLY_PHASE1":3443,"PHASE1":3445,"PHASE2":3471,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[3447,3451,3462],{"nctId":2554,"briefTitle":2555,"status":137,"phases":3448,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":1818,"conditions":3449,"interventions":3450},[90],[1940,1941],[2561,2562,2563],{"nctId":3452,"briefTitle":3453,"status":108,"phases":3454,"primaryCompletion":3455,"completion":3455,"start":2646,"enrollment":1131,"conditions":3456,"interventions":3461},"NCT01999270","Evaluation of FDOPA-PET\u002FMRI in Pediatric Patients With CNS Tumors",[90],"2016-05",[3457,3458,2038,3459,3460],"Astrocytoma, Oligoastrocytoma, Mixed","Ganglioneuroma","Ganglioglioma","Glioblastoma Multiforme Glioma",[2563,372],{"nctId":3463,"briefTitle":3464,"status":108,"phases":3465,"primaryCompletion":3466,"completion":1442,"start":3281,"enrollment":3467,"conditions":3468,"interventions":3469},"NCT01413022","FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma",[90],"2013-10",44,[1875],[374,2563,373,375,3470],"PF-04136309",{"trials":3472,"activeCount":184,"soonestReadout":983},[3473,3483,3492,3502,3513],{"nctId":3474,"briefTitle":3475,"status":108,"phases":3476,"primaryCompletion":3032,"completion":1965,"start":3477,"enrollment":3478,"conditions":3479,"interventions":3481},"NCT00682786","Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma",[91],"2002-10",135,[3480],"Rectal Carcinoma",[3482,2563],"5FU",{"nctId":3484,"briefTitle":3485,"status":108,"phases":3486,"primaryCompletion":2888,"completion":3487,"start":3488,"enrollment":1391,"conditions":3489,"interventions":3491},"NCT01928290","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",[91],"2019-10-28","2013-11-08",[3490,1650],"Stomach Neoplasms",[2563,631,374,373,375],{"nctId":3493,"briefTitle":3494,"status":288,"phases":3495,"primaryCompletion":983,"completion":3496,"start":3497,"enrollment":383,"conditions":3498,"interventions":3500},"NCT07155200","Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)",[90,91],"2029-01-31","2025-12-18",[1940,1941,3499],"Small Cell Lung Cancer",[3501,2563],"Cirtuvivint",{"nctId":3503,"briefTitle":3504,"status":122,"phases":3505,"primaryCompletion":3506,"completion":3507,"start":3508,"enrollment":102,"conditions":3509,"interventions":3511},"NCT02747537","Treating Relapsed\u002FRecurrent\u002FRefractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan",[91],"2020-01-31","2020-02-29","2016-06-24",[3510],"Pediatric Solid Tumors",[3512,2563],"Sorafenib",{"nctId":3514,"briefTitle":3515,"status":108,"phases":3516,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":506,"conditions":3519,"interventions":3522},"NCT03141034","Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma",[91],"2023-04-14","2017-11-01",[3520,3521],"Gastric Adenocarcinoma","Gastro-esophageal Junction Adenocarcinoma",[2563,1291,3523,3524],"Blood for angiome profiling","Blood for cfDNA",{"trials":3526,"activeCount":102},[],{"trials":3528,"activeCount":102},[],{"trials":3530,"activeCount":102},[],{"intervention":1594,"totalTrials":2289,"cells":3532},{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3548,"PHASE3":3584,"PHASE4":3586,"NA":3588},{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":102},[3537],{"nctId":3538,"briefTitle":3539,"status":108,"phases":3540,"primaryCompletion":3541,"completion":3542,"start":3543,"enrollment":442,"conditions":3544,"interventions":3546},"NCT00703625","Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies",[90],"2011-05-01","2011-06-01","2008-03-08",[3545],"Resistant Solid Malignancies",[3547,1594],"Temsirolimus",{"trials":3549,"activeCount":184,"soonestReadout":1936},[3550,3560,3564,3568,3572,3576,3580],{"nctId":3551,"briefTitle":3552,"status":108,"phases":3553,"primaryCompletion":3554,"completion":3555,"start":3477,"enrollment":3556,"conditions":3557,"interventions":3558},"NCT00242203","Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer",[91],"2007-08","2011-05",120,[1445],[3559,1626,1594,631],"Zometa",{"nctId":1584,"briefTitle":1585,"status":137,"phases":3561,"primaryCompletion":1587,"completion":1588,"start":1589,"enrollment":1590,"conditions":3562,"interventions":3563},[91],[1592],[1594,426],{"nctId":1600,"briefTitle":1601,"status":137,"phases":3565,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1056,"conditions":3566,"interventions":3567},[91],[1607],[1594,426,1609],{"nctId":1918,"briefTitle":1919,"status":108,"phases":3569,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":1923,"conditions":3570,"interventions":3571},[91],[1925],[1927,1124,1594],{"nctId":1618,"briefTitle":1619,"status":137,"phases":3573,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":3574,"interventions":3575},[91],[1445],[1228,631,1229,82,1626,1594,426,375],{"nctId":1933,"briefTitle":1934,"status":203,"phases":3577,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":1938,"conditions":3578,"interventions":3579},[90,91],[1199,1201,1940,1941],[1943,1124,1594],{"nctId":1949,"briefTitle":1950,"status":108,"phases":3581,"primaryCompletion":1952,"completion":1873,"start":1953,"enrollment":1954,"conditions":3582,"interventions":3583},[91],[1956,1636,29,1957],[1124,1594],{"trials":3585,"activeCount":102},[],{"trials":3587,"activeCount":102},[],{"trials":3589,"activeCount":102},[],{"intervention":2375,"totalTrials":1623,"cells":3591},{"EARLY_PHASE1":3592,"PHASE1":3598,"PHASE2":3608,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3593,"activeCount":102},[3594],{"nctId":2367,"briefTitle":2368,"status":122,"phases":3595,"primaryCompletion":2370,"completion":2370,"start":1351,"enrollment":102,"conditions":3596,"interventions":3597},[89],[24,2372],[2374,2362,2375,1229,2376,2377,2378],{"trials":3599,"activeCount":102},[3600,3604],{"nctId":2565,"briefTitle":2566,"status":137,"phases":3601,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":184,"conditions":3602,"interventions":3603},[90],[2572],[2574,1229,2377,2575,2375],{"nctId":2382,"briefTitle":2383,"status":137,"phases":3605,"primaryCompletion":2385,"completion":2386,"start":2387,"enrollment":98,"conditions":3606,"interventions":3607},[90],[2389,2390,2391],[2375,2393,1229,2362,2394,2395],{"trials":3609,"activeCount":184,"soonestReadout":2463},[3610,3614,3618,3626],{"nctId":3330,"briefTitle":3331,"status":122,"phases":3611,"primaryCompletion":2937,"completion":983,"start":3333,"enrollment":102,"conditions":3612,"interventions":3613},[91],[3335,3336],[3338,2375,3339,2612,3340],{"nctId":2460,"briefTitle":2461,"status":288,"phases":3615,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":3616,"interventions":3617},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"nctId":3619,"briefTitle":3620,"status":122,"phases":3621,"primaryCompletion":3622,"completion":3622,"start":1195,"enrollment":102,"conditions":3623,"interventions":3624},"NCT04893915","Cytokine-induced Memory-like NK Cells in Relapsed\u002FRefractory AML and MDS",[91],"2024-12-31",[3336,3335,26],[3625,2375,1229,3340],"Cytokine-induced memory-like NK cells",{"nctId":3627,"briefTitle":3628,"status":137,"phases":3629,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":3634,"interventions":3635},"NCT01898793","Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",[90,91],"2021-12-28","2022-04-04","2014-08-11",89,[3182],[2375,1229,3636,2475,2613],"Cytokine-induced killer cells",{"trials":3638,"activeCount":102},[],{"trials":3640,"activeCount":102},[],{"trials":3642,"activeCount":102},[],{"intervention":2476,"totalTrials":1131,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3657,"PHASE3":3688,"PHASE4":3690,"NA":3692},{"trials":3646,"activeCount":102},[],{"trials":3648,"activeCount":102},[3649,3653],{"nctId":3299,"briefTitle":3300,"status":108,"phases":3650,"primaryCompletion":3302,"completion":3303,"start":3304,"enrollment":3305,"conditions":3651,"interventions":3652},[90],[26],[2612,2476,2395],{"nctId":3189,"briefTitle":3190,"status":137,"phases":3654,"primaryCompletion":3192,"completion":2288,"start":3193,"enrollment":1131,"conditions":3655,"interventions":3656},[90],[3182],[2476,3196,2424,2425],{"trials":3658,"activeCount":184,"soonestReadout":2463},[3659,3669,3673,3677],{"nctId":3660,"briefTitle":3661,"status":108,"phases":3662,"primaryCompletion":3663,"completion":3115,"start":3664,"enrollment":565,"conditions":3665,"interventions":3667},"NCT01158118","Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors",[91],"2014-01-15","2011-04-01",[3182,26,2598,1888,3666,24],"Leukemia, Lymphocytic, Chronic, B-Cell",[3668,2476],"Sargramostim",{"nctId":3214,"briefTitle":3215,"status":108,"phases":3670,"primaryCompletion":3217,"completion":577,"start":1443,"enrollment":3218,"conditions":3671,"interventions":3672},[90,91],[3182],[2612,2476,3196,2424,2425],{"nctId":2460,"briefTitle":2461,"status":288,"phases":3674,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":3675,"interventions":3676},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"nctId":3678,"briefTitle":3679,"status":108,"phases":3680,"primaryCompletion":3681,"completion":3682,"start":3683,"enrollment":3684,"conditions":3685,"interventions":3686},"NCT02098109","Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma",[91],"2016-06-10","2016-09-18","2014-08-20",100,[24,2598],[3687,2378,2476],"XM02 Filgrastim",{"trials":3689,"activeCount":102},[],{"trials":3691,"activeCount":102},[],{"trials":3693,"activeCount":102},[],{"intervention":978,"totalTrials":1131,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3715,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3697,"activeCount":102},[],{"trials":3699,"activeCount":102},[3700,3704,3711],{"nctId":3165,"briefTitle":3166,"status":108,"phases":3701,"primaryCompletion":3168,"completion":3169,"start":3170,"enrollment":1056,"conditions":3702,"interventions":3703},[90],[3172],[3174,978,2425,1892,2378],{"nctId":3705,"briefTitle":3706,"status":108,"phases":3707,"primaryCompletion":1734,"completion":1734,"start":1736,"enrollment":98,"conditions":3708,"interventions":3710},"NCT02332941","Treatment -Resistant Neovascular Age-Related Macular Degeneration",[90],[3709],"Macular Degeneration",[978],{"nctId":967,"briefTitle":968,"status":137,"phases":3712,"primaryCompletion":970,"completion":971,"start":972,"enrollment":599,"conditions":3713,"interventions":3714},[90],[974],[976,977,959,978],{"trials":3716,"activeCount":184,"soonestReadout":1196},[3717,3726,3730],{"nctId":3718,"briefTitle":3719,"status":108,"phases":3720,"primaryCompletion":3721,"completion":3721,"start":1441,"enrollment":1042,"conditions":3722,"interventions":3724},"NCT01554514","Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura",[91],"2020-02-14",[3723],"Thrombotic Thrombocytopenic Purpura",[3725],"rituximab",{"nctId":2983,"briefTitle":2984,"status":288,"phases":3727,"primaryCompletion":1196,"completion":1363,"start":2986,"enrollment":1566,"conditions":3728,"interventions":3729},[90,91],[2988],[2354,978,2990],{"nctId":3238,"briefTitle":3239,"status":108,"phases":3731,"primaryCompletion":3241,"completion":3242,"start":3243,"enrollment":1249,"conditions":3732,"interventions":3733},[91],[3172],[3174,978,2096,2425],{"trials":3735,"activeCount":102},[],{"trials":3737,"activeCount":102},[],{"trials":3739,"activeCount":102},[],{"intervention":1291,"totalTrials":98,"cells":3741},{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3743,"activeCount":102},[],{"trials":3745,"activeCount":102},[],{"trials":3747,"activeCount":184,"soonestReadout":1280},[3748,3752,3762,3766,3776],{"nctId":1277,"briefTitle":1278,"status":203,"phases":3749,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":3750,"interventions":3751},[91],[1285,1286,1287,1092,1288,1289],[1291,994],{"nctId":3753,"briefTitle":3754,"status":108,"phases":3755,"primaryCompletion":3756,"completion":3757,"start":3758,"enrollment":36,"conditions":3759,"interventions":3760},"NCT03689855","Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC",[91],"2021-07-16","2024-04-22","2019-06-05",[1201,1199,1200],[1291,3761],"Atezolizumab",{"nctId":1316,"briefTitle":1317,"status":108,"phases":3763,"primaryCompletion":1319,"completion":1319,"start":1130,"enrollment":1181,"conditions":3764,"interventions":3765},[90,91],[423],[1291,994],{"nctId":3767,"briefTitle":3768,"status":122,"phases":3769,"primaryCompletion":3770,"completion":1141,"start":3771,"enrollment":102,"conditions":3772,"interventions":3774},"NCT05007769","Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC",[91],"2024-04-30","2021-10-31",[1201,3773,1200,1199],"Non-small Cell Carcinoma",[1291,3761,3775],"N-803",{"nctId":3514,"briefTitle":3515,"status":108,"phases":3777,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":506,"conditions":3778,"interventions":3779},[91],[3520,3521],[2563,1291,3523,3524],{"trials":3781,"activeCount":102},[],{"trials":3783,"activeCount":102},[],{"trials":3785,"activeCount":102},[],{"intervention":620,"totalTrials":599,"cells":3787},{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3803,"PHASE3":3824,"PHASE4":3826,"NA":3828},{"trials":3789,"activeCount":102},[],{"trials":3791,"activeCount":102},[3792],{"nctId":3793,"briefTitle":3794,"status":108,"phases":3795,"primaryCompletion":3796,"completion":3797,"start":3798,"enrollment":1938,"conditions":3799,"interventions":3802},"NCT01339442","BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer",[90],"2016-12-21","2016-12-28","2011-11-14",[2291,3800,3801],"Recurrent Breast Cancer","Stage IV Breast Cancer",[1740,620],{"trials":3804,"activeCount":184,"soonestReadout":1090},[3805,3809,3813],{"nctId":608,"briefTitle":609,"status":108,"phases":3806,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":3807,"interventions":3808},[91],[18,616,159,617],[57,619,620,621],{"nctId":2275,"briefTitle":2276,"status":288,"phases":3810,"primaryCompletion":1090,"completion":1297,"start":2278,"enrollment":1954,"conditions":3811,"interventions":3812},[91],[18,159,1445,2271],[621,2249,2281,620,2282],{"nctId":3814,"briefTitle":3815,"status":108,"phases":3816,"primaryCompletion":3817,"completion":3818,"start":3819,"enrollment":3820,"conditions":3821,"interventions":3822},"NCT01670877","Neratinib +\u002F- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer",[91],"2021-02-11","2021-03-11","2012-12-11",56,[1445],[3823,620,631],"Neratinib",{"trials":3825,"activeCount":102},[],{"trials":3827,"activeCount":102},[],{"trials":3829,"activeCount":102},[],{"intervention":3831,"totalTrials":599,"cells":3832},"Psilocybin",{"EARLY_PHASE1":3833,"PHASE1":3844,"PHASE2":3846,"PHASE3":3876,"PHASE4":3878,"NA":3880},{"trials":3834,"activeCount":102},[3835],{"nctId":3836,"briefTitle":3837,"status":108,"phases":3838,"primaryCompletion":3839,"completion":3839,"start":3840,"enrollment":1310,"conditions":3841,"interventions":3842},"NCT04501653","Precision Functional Brain Mapping in Psilocybin",[89],"2023-03-19","2021-06-01",[3831],[3831,3843],"Methylphenidate",{"trials":3845,"activeCount":102},[],{"trials":3847,"activeCount":184,"soonestReadout":3852},[3848,3857,3867],{"nctId":3849,"briefTitle":3850,"status":853,"phases":3851,"primaryCompletion":3852,"completion":3853,"start":3854,"enrollment":1954,"conditions":3855,"interventions":3856},"NCT07582120","Psilocybin-Assisted Therapy as a Treatment for Depression",[91],"2031-06","2031-12","2026-06",[21],[3831],{"nctId":3858,"briefTitle":3859,"status":122,"phases":3860,"primaryCompletion":3861,"completion":3862,"start":3863,"enrollment":102,"conditions":3864,"interventions":3866},"NCT05675800","Psilocybin for Major Depressive Disorder",[91],"2025-01-01","2025-03-31","2024-01-01",[3865],"Major Depressive Disorder",[3831],{"nctId":3868,"briefTitle":3869,"status":122,"phases":3870,"primaryCompletion":3861,"completion":3871,"start":3872,"enrollment":102,"conditions":3873,"interventions":3875},"NCT05601648","PET Synaptogenesis After Psilocybin In DEpression Recovery",[91],"2025-07-01","2023-07-01",[3865,3874],"Anhedonia",[3831],{"trials":3877,"activeCount":102},[],{"trials":3879,"activeCount":102},[],{"trials":3881,"activeCount":102},[],{"intervention":3297,"totalTrials":474,"cells":3883},{"EARLY_PHASE1":3884,"PHASE1":3886,"PHASE2":3901,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3885,"activeCount":102},[],{"trials":3887,"activeCount":102},[3888,3892],{"nctId":3290,"briefTitle":3291,"status":108,"phases":3889,"primaryCompletion":3293,"completion":3294,"start":1686,"enrollment":1299,"conditions":3890,"interventions":3891},[90],[24],[3297,2612],{"nctId":3893,"briefTitle":3894,"status":108,"phases":3895,"primaryCompletion":3896,"completion":3896,"start":3897,"enrollment":340,"conditions":3898,"interventions":3899},"NCT05618301","Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)",[90],"2025-06-24","2023-07-07",[2572],[3297,3900],"Natalizumab",{"trials":3902,"activeCount":184,"soonestReadout":3907},[3903],{"nctId":3904,"briefTitle":3905,"status":853,"phases":3906,"primaryCompletion":3907,"completion":3908,"start":3909,"enrollment":340,"conditions":3910,"interventions":3912},"NCT07392970","Motixafortide for MRD Sensitization in AML",[91],"2028-06-02","2029-12-02","2026-05-31",[2389,3911],"Measurable Residual Disease",[3297],{"trials":3914,"activeCount":102},[],{"trials":3916,"activeCount":102},[],{"trials":3918,"activeCount":102},[],{"intervention":2393,"totalTrials":474,"cells":3920},{"EARLY_PHASE1":3921,"PHASE1":3923,"PHASE2":3941,"PHASE3":3947,"PHASE4":3949,"NA":3951},{"trials":3922,"activeCount":102},[],{"trials":3924,"activeCount":102},[3925,3929],{"nctId":2382,"briefTitle":2383,"status":137,"phases":3926,"primaryCompletion":2385,"completion":2386,"start":2387,"enrollment":98,"conditions":3927,"interventions":3928},[90],[2389,2390,2391],[2375,2393,1229,2362,2394,2395],{"nctId":3930,"briefTitle":3931,"status":137,"phases":3932,"primaryCompletion":3933,"completion":3088,"start":3934,"enrollment":208,"conditions":3935,"interventions":3936},"NCT02057770","Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90],"2018-01-12","2014-02-28",[3182],[3937,3938,3939,3940],"busulfan","fludarabine phosphate","cyclophosphamide","tocilizumab",{"trials":3942,"activeCount":184,"soonestReadout":2463},[3943],{"nctId":2460,"briefTitle":2461,"status":288,"phases":3944,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":3945,"interventions":3946},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"trials":3948,"activeCount":102},[],{"trials":3950,"activeCount":102},[],{"trials":3952,"activeCount":102},[],{"intervention":2661,"totalTrials":474,"cells":3954},{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3965,"PHASE3":3978,"PHASE4":3980,"NA":3982},{"trials":3956,"activeCount":102},[],{"trials":3958,"activeCount":102},[3959],{"nctId":3960,"briefTitle":3961,"status":137,"phases":3962,"primaryCompletion":2646,"completion":2646,"start":364,"enrollment":30,"conditions":3963,"interventions":3964},"NCT00892242","Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer",[90],[2502],[2661],{"trials":3966,"activeCount":184,"soonestReadout":1363},[3967,3974],{"nctId":3968,"briefTitle":3969,"status":137,"phases":3970,"primaryCompletion":1604,"completion":1604,"start":1603,"enrollment":474,"conditions":3971,"interventions":3973},"NCT00966992","Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer",[91],[3972],"Uterine Cervical Neoplasms",[2661],{"nctId":2653,"briefTitle":2654,"status":288,"phases":3975,"primaryCompletion":1363,"completion":1363,"start":2656,"enrollment":729,"conditions":3976,"interventions":3977},[90,91],[2658],[2660,1867,2661,2662],{"trials":3979,"activeCount":102},[],{"trials":3981,"activeCount":102},[],{"trials":3983,"activeCount":102},[],{"intervention":3985,"totalTrials":474,"cells":3986},"Dasatinib",{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":4027,"PHASE4":4029,"NA":4031},{"trials":3988,"activeCount":102},[],{"trials":3990,"activeCount":102},[],{"trials":3992,"activeCount":184,"soonestReadout":3997},[3993,4004,4012],{"nctId":3994,"briefTitle":3995,"status":203,"phases":3996,"primaryCompletion":3997,"completion":3997,"start":3872,"enrollment":506,"conditions":3998,"interventions":4002},"NCT05838560","Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders",[91],"2027-10-01",[3999,4000,4001],"Schizophrenia","Treatment Resistant Depression","Aging, Premature",[3985,4003],"quercetin",{"nctId":4005,"briefTitle":4006,"status":108,"phases":4007,"primaryCompletion":4008,"completion":4008,"start":1631,"enrollment":36,"conditions":4009,"interventions":4011},"NCT00429949","A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma",[91],"2008-01",[4010],"Relapsed, Refractory or Plateau Phase Multiple Myeloma",[3985],{"nctId":4013,"briefTitle":4014,"status":108,"phases":4015,"primaryCompletion":1141,"completion":1141,"start":4016,"enrollment":112,"conditions":4017,"interventions":4025},"NCT07000734","Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study",[91],"2025-07-28",[4018,4019,4020,4021,4022,4023,4024],"Aging","Cognitive Decline","Older Adults","Cardiovascular","Sedentary Behaviors","Immune Senescence","Motor Function",[3985,4026],"Vortioxetine",{"trials":4028,"activeCount":102},[],{"trials":4030,"activeCount":102},[],{"trials":4032,"activeCount":102},[],{"intervention":4034,"totalTrials":456,"cells":4035},"Epacadostat",{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4040,"PHASE3":4064,"PHASE4":4066,"NA":4068},{"trials":4037,"activeCount":102},[],{"trials":4039,"activeCount":102},[],{"trials":4041,"activeCount":184,"soonestReadout":4056},[4042,4052],{"nctId":4043,"briefTitle":4044,"status":108,"phases":4045,"primaryCompletion":4046,"completion":4047,"start":4048,"enrollment":2434,"conditions":4049,"interventions":4050},"NCT03532295","Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas",[91],"2024-07-26","2025-10-31","2020-04-20",[2038,1004],[4034,372,4051],"Retifanlimab",{"nctId":4053,"briefTitle":4054,"status":288,"phases":4055,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":19,"conditions":4059,"interventions":4061},"NCT03516708","Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer",[90,91],"2027-07-15","2030-08-12","2020-01-06",[4060],"Rectal Cancer",[4034,4062,4063],"CAPOX chemotherapy","FOLFOX chemotherapy",{"trials":4065,"activeCount":102},[],{"trials":4067,"activeCount":102},[],{"trials":4069,"activeCount":102},[],{"intervention":4071,"totalTrials":456,"cells":4072},"Propofol",{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4086,"PHASE3":4096,"PHASE4":4098,"NA":4100},{"trials":4074,"activeCount":102},[],{"trials":4076,"activeCount":102},[4077],{"nctId":4078,"briefTitle":4079,"status":108,"phases":4080,"primaryCompletion":392,"completion":4081,"start":4082,"enrollment":960,"conditions":4083,"interventions":4085},"NCT04680910","Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I",[90],"2025-09-21","2021-01-14",[4084],"Treatment-resistant Depression",[4071],{"trials":4087,"activeCount":184,"soonestReadout":4092},[4088],{"nctId":4089,"briefTitle":4090,"status":288,"phases":4091,"primaryCompletion":4092,"completion":741,"start":4093,"enrollment":2234,"conditions":4094,"interventions":4095},"NCT06867549","Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II",[91],"2028-02-01","2025-03-04",[21],[4071],{"trials":4097,"activeCount":102},[],{"trials":4099,"activeCount":102},[],{"trials":4101,"activeCount":102},[],{"intervention":4103,"totalTrials":456,"cells":4104},"Rivastigmine",{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4106,"activeCount":102},[],{"trials":4108,"activeCount":102},[],{"trials":4110,"activeCount":184,"soonestReadout":533},[4111,4121],{"nctId":4112,"briefTitle":4113,"status":4114,"phases":4115,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":383,"conditions":4118,"interventions":4120},"NCT06382649","Rivastigmine for Antimuscarinic Delirium","SUSPENDED",[91],"2027-07","2026-11",[4119],"Anticholinergic Toxicity",[4103],{"nctId":4122,"briefTitle":4123,"status":288,"phases":4124,"primaryCompletion":533,"completion":4117,"start":4125,"enrollment":383,"conditions":4126,"interventions":4127},"NCT06399679","Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium",[91],"2024-11-04",[4119],[4103],{"trials":4129,"activeCount":102},[],{"trials":4131,"activeCount":102},[],{"trials":4133,"activeCount":102},[],{"intervention":3184,"totalTrials":456,"cells":4135},{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4144,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4137,"activeCount":102},[],{"trials":4139,"activeCount":102},[4140],{"nctId":3176,"briefTitle":3177,"status":108,"phases":4141,"primaryCompletion":3179,"completion":1441,"start":3180,"enrollment":1310,"conditions":4142,"interventions":4143},[90],[3182],[3184,3185,2425,3186,3187],{"trials":4145,"activeCount":184,"soonestReadout":2463},[4146],{"nctId":2460,"briefTitle":2461,"status":288,"phases":4147,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":4148,"interventions":4149},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"trials":4151,"activeCount":102},[],{"trials":4153,"activeCount":102},[],{"trials":4155,"activeCount":102},[],{"intervention":3027,"totalTrials":456,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4164,"PHASE2":4166,"PHASE3":4172,"PHASE4":4174,"NA":4176},{"trials":4159,"activeCount":102},[4160],{"nctId":3017,"briefTitle":3018,"status":137,"phases":4161,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":4162,"interventions":4163},[89],[24],[2378,2446,3024,1849,1229,3025,3026,3027],{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":184,"soonestReadout":71},[4168],{"nctId":69,"briefTitle":70,"status":203,"phases":4169,"primaryCompletion":71,"completion":3078,"start":3079,"enrollment":208,"conditions":4170,"interventions":4171},[91],[3081],[72,3027,1849],{"trials":4173,"activeCount":102},[],{"trials":4175,"activeCount":102},[],{"trials":4177,"activeCount":102},[],{"intervention":2282,"totalTrials":456,"cells":4179},{"EARLY_PHASE1":4180,"PHASE1":4191,"PHASE2":4193,"PHASE3":4199,"PHASE4":4201,"NA":4203},{"trials":4181,"activeCount":102},[4182],{"nctId":4183,"briefTitle":4184,"status":137,"phases":4185,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":1623,"conditions":4188,"interventions":4190},"NCT02089386","Tamoxifen to Treat Barrett's Metaplasia",[89],"2016-06-21","2014-07-09",[4189],"Barrett Metaplasia",[2282],{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":184,"soonestReadout":1090},[4195],{"nctId":2275,"briefTitle":2276,"status":288,"phases":4196,"primaryCompletion":1090,"completion":1297,"start":2278,"enrollment":1954,"conditions":4197,"interventions":4198},[91],[18,159,1445,2271],[621,2249,2281,620,2282],{"trials":4200,"activeCount":102},[],{"trials":4202,"activeCount":102},[],{"trials":4204,"activeCount":102},[],{"intervention":2894,"totalTrials":456,"cells":4206},{"EARLY_PHASE1":4207,"PHASE1":4213,"PHASE2":4215,"PHASE3":4221,"PHASE4":4223,"NA":4225},{"trials":4208,"activeCount":102},[4209],{"nctId":2885,"briefTitle":2886,"status":108,"phases":4210,"primaryCompletion":2888,"completion":2888,"start":2889,"enrollment":340,"conditions":4211,"interventions":4212},[89],[2891,2892],[2662,2894,2895],{"trials":4214,"activeCount":102},[],{"trials":4216,"activeCount":184,"soonestReadout":2908},[4217],{"nctId":2905,"briefTitle":2906,"status":203,"phases":4218,"primaryCompletion":2908,"completion":2090,"start":2909,"enrollment":2910,"conditions":4219,"interventions":4220},[91],[2912],[2662,2894,2914],{"trials":4222,"activeCount":102},[],{"trials":4224,"activeCount":102},[],{"trials":4226,"activeCount":102},[],{"intervention":1314,"totalTrials":456,"cells":4228},{"EARLY_PHASE1":4229,"PHASE1":4231,"PHASE2":4233,"PHASE3":4250,"PHASE4":4252,"NA":4254},{"trials":4230,"activeCount":102},[],{"trials":4232,"activeCount":102},[],{"trials":4234,"activeCount":184,"soonestReadout":4243},[4235,4239],{"nctId":1304,"briefTitle":1305,"status":137,"phases":4236,"primaryCompletion":1307,"completion":1308,"start":1309,"enrollment":1310,"conditions":4237,"interventions":4238},[91],[1312],[1314,994],{"nctId":4240,"briefTitle":4241,"status":288,"phases":4242,"primaryCompletion":4243,"completion":4244,"start":4245,"enrollment":951,"conditions":4246,"interventions":4249},"NCT07092514","Lenvatinib 24 mg\u002FDay Versus 10 mg\u002FDay to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)",[91],"2029-04-17","2034-10-31","2025-10-14",[4247,4248],"Thyroid Cancer","Cancer of the Thyroid",[1314],{"trials":4251,"activeCount":102},[],{"trials":4253,"activeCount":102},[],{"trials":4255,"activeCount":102},[],{"intervention":2613,"totalTrials":456,"cells":4257},{"EARLY_PHASE1":4258,"PHASE1":4260,"PHASE2":4262,"PHASE3":4272,"PHASE4":4274,"NA":4276},{"trials":4259,"activeCount":102},[],{"trials":4261,"activeCount":102},[],{"trials":4263,"activeCount":184,"soonestReadout":2606},[4264,4268],{"nctId":2603,"briefTitle":2604,"status":203,"phases":4265,"primaryCompletion":2606,"completion":2607,"start":2608,"enrollment":2609,"conditions":4266,"interventions":4267},[91],[2389],[2376,2377,2612,2613],{"nctId":3627,"briefTitle":3628,"status":137,"phases":4269,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":4270,"interventions":4271},[90,91],[3182],[2375,1229,3636,2475,2613],{"trials":4273,"activeCount":102},[],{"trials":4275,"activeCount":102},[],{"trials":4277,"activeCount":102},[],{"intervention":2475,"totalTrials":456,"cells":4279},{"EARLY_PHASE1":4280,"PHASE1":4282,"PHASE2":4284,"PHASE3":4294,"PHASE4":4296,"NA":4298},{"trials":4281,"activeCount":102},[],{"trials":4283,"activeCount":102},[],{"trials":4285,"activeCount":184,"soonestReadout":2463},[4286,4290],{"nctId":2460,"briefTitle":2461,"status":288,"phases":4287,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":4288,"interventions":4289},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"nctId":3627,"briefTitle":3628,"status":137,"phases":4291,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":4292,"interventions":4293},[90,91],[3182],[2375,1229,3636,2475,2613],{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[],{"trials":4299,"activeCount":102},[],{"intervention":4301,"totalTrials":184,"cells":4302},"Progestin",{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4307,"PHASE3":4320,"PHASE4":4322,"NA":4324},{"trials":4304,"activeCount":102},[],{"trials":4306,"activeCount":102},[],{"trials":4308,"activeCount":184,"soonestReadout":1327},[4309],{"nctId":4310,"briefTitle":4311,"status":288,"phases":4312,"primaryCompletion":1327,"completion":4313,"start":4314,"enrollment":394,"conditions":4315,"interventions":4318},"NCT05903131","Uterine Preservation Via Lifestyle Transformation",[91],"2029-10-31","2024-10-24",[4316,4317],"Endometrial Hyperplasia","Grade 1 Endometrial Cancer",[4301,4319],"Levonorgestrel-releasing IUD.",{"trials":4321,"activeCount":102},[],{"trials":4323,"activeCount":102},[],{"trials":4325,"activeCount":102},[],{"intervention":4319,"totalTrials":184,"cells":4327},{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4332,"PHASE3":4338,"PHASE4":4340,"NA":4342},{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[],{"trials":4333,"activeCount":184,"soonestReadout":1327},[4334],{"nctId":4310,"briefTitle":4311,"status":288,"phases":4335,"primaryCompletion":1327,"completion":4313,"start":4314,"enrollment":394,"conditions":4336,"interventions":4337},[91],[4316,4317],[4301,4319],{"trials":4339,"activeCount":102},[],{"trials":4341,"activeCount":102},[],{"trials":4343,"activeCount":102},[],{"intervention":4345,"totalTrials":184,"cells":4346},"Oxymetazoline Nasal Spray",{"EARLY_PHASE1":4347,"PHASE1":4349,"PHASE2":4351,"PHASE3":4363,"PHASE4":4365,"NA":4367},{"trials":4348,"activeCount":102},[],{"trials":4350,"activeCount":102},[],{"trials":4352,"activeCount":184,"soonestReadout":4357},[4353],{"nctId":4354,"briefTitle":4355,"status":288,"phases":4356,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":2648,"conditions":4359,"interventions":4361},"NCT06830109","Nasal Obstruction With Oxymetazoline and Corticosteroids",[91],"2026-12-30","2024-10-15",[4360],"Nasal Obstruction",[4345,4362],"Budesonide nasal spray",{"trials":4364,"activeCount":102},[],{"trials":4366,"activeCount":102},[],{"trials":4368,"activeCount":102},[],{"intervention":4362,"totalTrials":184,"cells":4370},{"EARLY_PHASE1":4371,"PHASE1":4373,"PHASE2":4375,"PHASE3":4381,"PHASE4":4383,"NA":4385},{"trials":4372,"activeCount":102},[],{"trials":4374,"activeCount":102},[],{"trials":4376,"activeCount":184,"soonestReadout":4357},[4377],{"nctId":4354,"briefTitle":4355,"status":288,"phases":4378,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":2648,"conditions":4379,"interventions":4380},[91],[4360],[4345,4362],{"trials":4382,"activeCount":102},[],{"trials":4384,"activeCount":102},[],{"trials":4386,"activeCount":102},[],{"intervention":1084,"totalTrials":184,"cells":4388},{"EARLY_PHASE1":4389,"PHASE1":4391,"PHASE2":4393,"PHASE3":4399,"PHASE4":4401,"NA":4403},{"trials":4390,"activeCount":102},[],{"trials":4392,"activeCount":102},[],{"trials":4394,"activeCount":184,"soonestReadout":81},[4395],{"nctId":79,"briefTitle":80,"status":203,"phases":4396,"primaryCompletion":81,"completion":1078,"start":1079,"enrollment":1080,"conditions":4397,"interventions":4398},[90,91],[1082],[82,426,959,1084],{"trials":4400,"activeCount":102},[],{"trials":4402,"activeCount":102},[],{"trials":4404,"activeCount":102},[],{"intervention":4406,"totalTrials":184,"cells":4407},"Standard of care neoadjuvant chemotherapy",{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4421,"PHASE4":4423,"NA":4425},{"trials":4409,"activeCount":102},[],{"trials":4411,"activeCount":102},[],{"trials":4413,"activeCount":184,"soonestReadout":4418},[4414],{"nctId":4415,"briefTitle":4416,"status":853,"phases":4417,"primaryCompletion":4418,"completion":4418,"start":1089,"enrollment":1299,"conditions":4419,"interventions":4420},"NCT07101666","Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer",[91],"2030-12-31",[987],[4406],{"trials":4422,"activeCount":102},[],{"trials":4424,"activeCount":102},[],{"trials":4426,"activeCount":102},[],{"intervention":4428,"totalTrials":184,"cells":4429},"Suvorexant 20 mg",{"EARLY_PHASE1":4430,"PHASE1":4432,"PHASE2":4434,"PHASE3":4447,"PHASE4":4449,"NA":4451},{"trials":4431,"activeCount":102},[],{"trials":4433,"activeCount":102},[],{"trials":4435,"activeCount":184,"soonestReadout":4440},[4436],{"nctId":4437,"briefTitle":4438,"status":288,"phases":4439,"primaryCompletion":4440,"completion":4440,"start":4441,"enrollment":4442,"conditions":4443,"interventions":4446},"NCT04629547","Sleep Trial to Prevent Alzheimer's Disease",[91],"2026-05","2022-05-25",200,[4444,4445],"Sleep","Alzheimer Disease",[4428],{"trials":4448,"activeCount":102},[],{"trials":4450,"activeCount":102},[],{"trials":4452,"activeCount":102},[],{"intervention":4454,"totalTrials":184,"cells":4455},"CUE-101",{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4460,"PHASE3":4471,"PHASE4":4473,"NA":4475},{"trials":4457,"activeCount":102},[],{"trials":4459,"activeCount":102},[],{"trials":4461,"activeCount":184,"soonestReadout":4466},[4462],{"nctId":4463,"briefTitle":4464,"status":288,"phases":4465,"primaryCompletion":4466,"completion":4466,"start":4467,"enrollment":293,"conditions":4468,"interventions":4470},"NCT04852328","Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma",[91],"2027-10-31","2021-12-06",[4469],"Oropharyngeal Squamous Cell Carcinoma",[4454],{"trials":4472,"activeCount":102},[],{"trials":4474,"activeCount":102},[],{"trials":4476,"activeCount":102},[],{"intervention":2714,"totalTrials":184,"cells":4478},{"EARLY_PHASE1":4479,"PHASE1":4481,"PHASE2":4483,"PHASE3":4489,"PHASE4":4491,"NA":4493},{"trials":4480,"activeCount":102},[],{"trials":4482,"activeCount":102},[],{"trials":4484,"activeCount":184,"soonestReadout":2709},[4485],{"nctId":2706,"briefTitle":2707,"status":288,"phases":4486,"primaryCompletion":2709,"completion":2710,"start":2711,"enrollment":22,"conditions":4487,"interventions":4488},[91],[2323],[2472,2225,2714],{"trials":4490,"activeCount":102},[],{"trials":4492,"activeCount":102},[],{"trials":4494,"activeCount":102},[],{"intervention":4496,"totalTrials":184,"cells":4497},"Elrantamab",{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4511,"PHASE4":4513,"NA":4515},{"trials":4499,"activeCount":102},[],{"trials":4501,"activeCount":102},[],{"trials":4503,"activeCount":184,"soonestReadout":2816},[4504],{"nctId":4505,"briefTitle":4506,"status":288,"phases":4507,"primaryCompletion":2816,"completion":2816,"start":4508,"enrollment":16,"conditions":4509,"interventions":4510},"NCT06483100","Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance",[91],"2024-12-20",[24],[4496],{"trials":4512,"activeCount":102},[],{"trials":4514,"activeCount":102},[],{"trials":4516,"activeCount":102},[],{"intervention":4518,"totalTrials":184,"cells":4519},"Enasidenib",{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4536,"PHASE4":4538,"NA":4540},{"trials":4521,"activeCount":102},[],{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":184,"soonestReadout":4530},[4526],{"nctId":4527,"briefTitle":4528,"status":288,"phases":4529,"primaryCompletion":4530,"completion":1012,"start":4531,"enrollment":1080,"conditions":4532,"interventions":4535},"NCT06240754","Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial",[91],"2028-01-31","2024-10-10",[4533,4534],"Clonal Cytopenia of Undetermined Significance","CCUS Clonal Cytopenia of Undetermined Significance",[4518],{"trials":4537,"activeCount":102},[],{"trials":4539,"activeCount":102},[],{"trials":4541,"activeCount":102},[],{"intervention":4543,"totalTrials":184,"cells":4544},"RIC regimen",{"EARLY_PHASE1":4545,"PHASE1":4547,"PHASE2":4549,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4546,"activeCount":102},[],{"trials":4548,"activeCount":102},[],{"trials":4550,"activeCount":184,"soonestReadout":488},[4551],{"nctId":4552,"briefTitle":4553,"status":288,"phases":4554,"primaryCompletion":488,"completion":4555,"start":4556,"enrollment":3323,"conditions":4557,"interventions":4564},"NCT03128996","Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders",[90,91],"2033-04","2017-03-20",[4558,4559,4560,4561,4562,4563],"Severe Sickle Cell Disease","Bone Marrow Failure Syndromes","Metabolic Disorders","Immunologic Disorders","Hemoglobinopathies","Non-malignant Disorders",[4543,4565],"GVHD prophylaxis regimen",{"trials":4567,"activeCount":102},[],{"trials":4569,"activeCount":102},[],{"trials":4571,"activeCount":102},[],{"intervention":4565,"totalTrials":184,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4584,"PHASE4":4586,"NA":4588},{"trials":4575,"activeCount":102},[],{"trials":4577,"activeCount":102},[],{"trials":4579,"activeCount":184,"soonestReadout":488},[4580],{"nctId":4552,"briefTitle":4553,"status":288,"phases":4581,"primaryCompletion":488,"completion":4555,"start":4556,"enrollment":3323,"conditions":4582,"interventions":4583},[90,91],[4558,4559,4560,4561,4562,4563],[4543,4565],{"trials":4585,"activeCount":102},[],{"trials":4587,"activeCount":102},[],{"trials":4589,"activeCount":102},[],{"intervention":4591,"totalTrials":184,"cells":4592},"Trastuzumab deruxtecan",{"EARLY_PHASE1":4593,"PHASE1":4595,"PHASE2":4597,"PHASE3":4608,"PHASE4":4610,"NA":4612},{"trials":4594,"activeCount":102},[],{"trials":4596,"activeCount":102},[],{"trials":4598,"activeCount":184,"soonestReadout":1986},[4599],{"nctId":4600,"briefTitle":4601,"status":853,"phases":4602,"primaryCompletion":1986,"completion":4603,"start":2090,"enrollment":2609,"conditions":4604,"interventions":4606},"NCT07619365","Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer",[91],"2031-08-31",[18,4605,1216],"Advanced Breast Cancer",[4591,4607],"Lovastatin",{"trials":4609,"activeCount":102},[],{"trials":4611,"activeCount":102},[],{"trials":4613,"activeCount":102},[],{"intervention":4607,"totalTrials":184,"cells":4615},{"EARLY_PHASE1":4616,"PHASE1":4618,"PHASE2":4620,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4617,"activeCount":102},[],{"trials":4619,"activeCount":102},[],{"trials":4621,"activeCount":184,"soonestReadout":1986},[4622],{"nctId":4600,"briefTitle":4601,"status":853,"phases":4623,"primaryCompletion":1986,"completion":4603,"start":2090,"enrollment":2609,"conditions":4624,"interventions":4625},[91],[18,4605,1216],[4591,4607],{"trials":4627,"activeCount":102},[],{"trials":4629,"activeCount":102},[],{"trials":4631,"activeCount":102},[],{"intervention":47,"totalTrials":184,"cells":4633},{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4644,"PHASE4":4646,"NA":4648},{"trials":4635,"activeCount":102},[],{"trials":4637,"activeCount":102},[],{"trials":4639,"activeCount":184,"soonestReadout":46},[4640],{"nctId":44,"briefTitle":45,"status":203,"phases":4641,"primaryCompletion":46,"completion":2259,"start":2260,"enrollment":2261,"conditions":4642,"interventions":4643},[91],[1445],[47,2249,621],{"trials":4645,"activeCount":102},[],{"trials":4647,"activeCount":102},[],{"trials":4649,"activeCount":102},[],{"intervention":4651,"totalTrials":184,"cells":4652},"Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan",{"EARLY_PHASE1":4653,"PHASE1":4655,"PHASE2":4657,"PHASE3":4682,"PHASE4":4684,"NA":4686},{"trials":4654,"activeCount":102},[],{"trials":4656,"activeCount":102},[],{"trials":4658,"activeCount":184,"soonestReadout":4663},[4659],{"nctId":4660,"briefTitle":4661,"status":203,"phases":4662,"primaryCompletion":4663,"completion":4664,"start":4665,"enrollment":1299,"conditions":4666,"interventions":4681},"NCT01821781","Immune Disorder HSCT Protocol",[91],"2025-04-25","2026-04","2013-04-29",[4667,4668,4669,4670,4671,4672,4673,4674,4675,4676,4677,4678,4679,4680],"Immune Deficiency Disorders","Severe Combined Immunodeficiency","Chronic Granulomatous Disease","X-linked Agammaglobulinemia","Wiskott-Aldrich Syndrome","Hyper-IgM","DiGeorge Syndrome","Chediak-Higashi Syndrome","Common Variable Immune Deficiency","Immune Dysregulatory Disorders","Hemophagocytic Lymphohistiocytosis","IPEX","Autoimmune Lymphoproliferative Syndrome","X-linked Lymphoproliferative Syndrome",[4651],{"trials":4683,"activeCount":102},[],{"trials":4685,"activeCount":102},[],{"trials":4687,"activeCount":102},[],{"intervention":4689,"totalTrials":184,"cells":4690},"Adherence to symptom driven budesonide\u002Fformoterol as compared to adherence to maintenance ICS and symptom-driven SABA",{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4695,"PHASE3":4708,"PHASE4":4710,"NA":4712},{"trials":4692,"activeCount":102},[],{"trials":4694,"activeCount":102},[],{"trials":4696,"activeCount":184,"soonestReadout":4701},[4697],{"nctId":4698,"briefTitle":4699,"status":203,"phases":4700,"primaryCompletion":4701,"completion":4702,"start":4703,"enrollment":2609,"conditions":4704,"interventions":4707},"NCT05111262","Symptom-driven ICS\u002FLABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers",[90,91],"2025-09-30","2025-11-30","2021-12-16",[4705,4706],"Asthma","Nonadherence, Medication",[4689],{"trials":4709,"activeCount":102},[],{"trials":4711,"activeCount":102},[],{"trials":4713,"activeCount":102},[],{"intervention":1275,"totalTrials":184,"cells":4715},{"EARLY_PHASE1":4716,"PHASE1":4718,"PHASE2":4720,"PHASE3":4726,"PHASE4":4728,"NA":4730},{"trials":4717,"activeCount":102},[],{"trials":4719,"activeCount":102},[],{"trials":4721,"activeCount":184,"soonestReadout":1269},[4722],{"nctId":1266,"briefTitle":1267,"status":853,"phases":4723,"primaryCompletion":1269,"completion":1270,"start":1089,"enrollment":1271,"conditions":4724,"interventions":4725},[90,91],[423,1273],[994,1275],{"trials":4727,"activeCount":102},[],{"trials":4729,"activeCount":102},[],{"trials":4731,"activeCount":102},[],{"intervention":4003,"totalTrials":184,"cells":4733},{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4738,"PHASE3":4744,"PHASE4":4746,"NA":4748},{"trials":4735,"activeCount":102},[],{"trials":4737,"activeCount":102},[],{"trials":4739,"activeCount":184,"soonestReadout":3997},[4740],{"nctId":3994,"briefTitle":3995,"status":203,"phases":4741,"primaryCompletion":3997,"completion":3997,"start":3872,"enrollment":506,"conditions":4742,"interventions":4743},[91],[3999,4000,4001],[3985,4003],{"trials":4745,"activeCount":102},[],{"trials":4747,"activeCount":102},[],{"trials":4749,"activeCount":102},[],{"intervention":4751,"totalTrials":184,"cells":4752},"18F-Fluoro Dopa PET\u002FMRI Imaging",{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4757,"PHASE3":4768,"PHASE4":4770,"NA":4772},{"trials":4754,"activeCount":102},[],{"trials":4756,"activeCount":102},[],{"trials":4758,"activeCount":184,"soonestReadout":4763},[4759],{"nctId":4760,"briefTitle":4761,"status":288,"phases":4762,"primaryCompletion":4763,"completion":4763,"start":4764,"enrollment":3684,"conditions":4765,"interventions":4767},"NCT05088798","Utility of 18FDOPA PET\u002FMRI for Focal Hyperinsulinism",[91],"2030-01-01","2020-09-10",[4766],"Hyperinsulinism",[4751],{"trials":4769,"activeCount":102},[],{"trials":4771,"activeCount":102},[],{"trials":4773,"activeCount":102},[],{"intervention":1915,"totalTrials":184,"cells":4775},{"EARLY_PHASE1":4776,"PHASE1":4778,"PHASE2":4780,"PHASE3":4786,"PHASE4":4788,"NA":4790},{"trials":4777,"activeCount":102},[],{"trials":4779,"activeCount":102},[],{"trials":4781,"activeCount":184,"soonestReadout":1908},[4782],{"nctId":1905,"briefTitle":1906,"status":288,"phases":4783,"primaryCompletion":1908,"completion":1909,"start":1910,"enrollment":1911,"conditions":4784,"interventions":4785},[90,91],[1913],[1915,1124,1916],{"trials":4787,"activeCount":102},[],{"trials":4789,"activeCount":102},[],{"trials":4791,"activeCount":102},[],{"intervention":1916,"totalTrials":184,"cells":4793},{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4804,"PHASE4":4806,"NA":4808},{"trials":4795,"activeCount":102},[],{"trials":4797,"activeCount":102},[],{"trials":4799,"activeCount":184,"soonestReadout":1908},[4800],{"nctId":1905,"briefTitle":1906,"status":288,"phases":4801,"primaryCompletion":1908,"completion":1909,"start":1910,"enrollment":1911,"conditions":4802,"interventions":4803},[90,91],[1913],[1915,1124,1916],{"trials":4805,"activeCount":102},[],{"trials":4807,"activeCount":102},[],{"trials":4809,"activeCount":102},[],{"intervention":3501,"totalTrials":184,"cells":4811},{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4822,"PHASE4":4824,"NA":4826},{"trials":4813,"activeCount":102},[],{"trials":4815,"activeCount":102},[],{"trials":4817,"activeCount":184,"soonestReadout":983},[4818],{"nctId":3493,"briefTitle":3494,"status":288,"phases":4819,"primaryCompletion":983,"completion":3496,"start":3497,"enrollment":383,"conditions":4820,"interventions":4821},[90,91],[1940,1941,3499],[3501,2563],{"trials":4823,"activeCount":102},[],{"trials":4825,"activeCount":102},[],{"trials":4827,"activeCount":102},[],{"intervention":4829,"totalTrials":184,"cells":4830},"APL-101",{"EARLY_PHASE1":4831,"PHASE1":4833,"PHASE2":4835,"PHASE3":4846,"PHASE4":4848,"NA":4850},{"trials":4832,"activeCount":102},[],{"trials":4834,"activeCount":102},[],{"trials":4836,"activeCount":184,"soonestReadout":1090},[4837],{"nctId":4838,"briefTitle":4839,"status":203,"phases":4840,"primaryCompletion":1090,"completion":4841,"start":141,"enrollment":27,"conditions":4842,"interventions":4844},"NCT04743505","Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)",[90,91],"2029-12-31",[4843],"Metastatic Non Small Cell Lung Cancer",[4829,4845],"Osimertinib",{"trials":4847,"activeCount":102},[],{"trials":4849,"activeCount":102},[],{"trials":4851,"activeCount":102},[],{"intervention":4845,"totalTrials":184,"cells":4853},{"EARLY_PHASE1":4854,"PHASE1":4856,"PHASE2":4858,"PHASE3":4864,"PHASE4":4866,"NA":4868},{"trials":4855,"activeCount":102},[],{"trials":4857,"activeCount":102},[],{"trials":4859,"activeCount":184,"soonestReadout":1090},[4860],{"nctId":4838,"briefTitle":4839,"status":203,"phases":4861,"primaryCompletion":1090,"completion":4841,"start":141,"enrollment":27,"conditions":4862,"interventions":4863},[90,91],[4843],[4829,4845],{"trials":4865,"activeCount":102},[],{"trials":4867,"activeCount":102},[],{"trials":4869,"activeCount":102},[],{"intervention":4871,"totalTrials":184,"cells":4872},"Ivosidenib",{"EARLY_PHASE1":4873,"PHASE1":4875,"PHASE2":4877,"PHASE3":4885,"PHASE4":4887,"NA":4889},{"trials":4874,"activeCount":102},[],{"trials":4876,"activeCount":102},[],{"trials":4878,"activeCount":184,"soonestReadout":1259},[4879],{"nctId":4880,"briefTitle":4881,"status":203,"phases":4882,"primaryCompletion":1259,"completion":1259,"start":1039,"enrollment":1299,"conditions":4883,"interventions":4884},"NCT05030441","Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1",[91],[4533],[4871],{"trials":4886,"activeCount":102},[],{"trials":4888,"activeCount":102},[],{"trials":4890,"activeCount":102},[],{"intervention":2600,"totalTrials":184,"cells":4892},{"EARLY_PHASE1":4893,"PHASE1":4895,"PHASE2":4897,"PHASE3":4903,"PHASE4":4905,"NA":4907},{"trials":4894,"activeCount":102},[],{"trials":4896,"activeCount":102},[],{"trials":4898,"activeCount":184,"soonestReadout":2595},[4899],{"nctId":2592,"briefTitle":2593,"status":203,"phases":4900,"primaryCompletion":2595,"completion":2595,"start":2596,"enrollment":1056,"conditions":4901,"interventions":4902},[91],[2598],[2600,2601,2376,2377],{"trials":4904,"activeCount":102},[],{"trials":4906,"activeCount":102},[],{"trials":4908,"activeCount":102},[],{"intervention":2601,"totalTrials":184,"cells":4910},{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4915,"PHASE3":4921,"PHASE4":4923,"NA":4925},{"trials":4912,"activeCount":102},[],{"trials":4914,"activeCount":102},[],{"trials":4916,"activeCount":184,"soonestReadout":2595},[4917],{"nctId":2592,"briefTitle":2593,"status":203,"phases":4918,"primaryCompletion":2595,"completion":2595,"start":2596,"enrollment":1056,"conditions":4919,"interventions":4920},[91],[2598],[2600,2601,2376,2377],{"trials":4922,"activeCount":102},[],{"trials":4924,"activeCount":102},[],{"trials":4926,"activeCount":102},[],{"intervention":4928,"totalTrials":184,"cells":4929},"DEC-C",{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4934,"PHASE3":4945,"PHASE4":4947,"NA":4949},{"trials":4931,"activeCount":102},[],{"trials":4933,"activeCount":102},[],{"trials":4935,"activeCount":184,"soonestReadout":4940},[4936],{"nctId":4937,"briefTitle":4938,"status":288,"phases":4939,"primaryCompletion":4940,"completion":4940,"start":4941,"enrollment":4942,"conditions":4943,"interventions":4944},"NCT04742634","Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant",[90,91],"2033-11-30","2022-05-12",209,[26],[4928],{"trials":4946,"activeCount":102},[],{"trials":4948,"activeCount":102},[],{"trials":4950,"activeCount":102},[],{"intervention":2273,"totalTrials":184,"cells":4952},{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4963,"PHASE4":4965,"NA":4967},{"trials":4954,"activeCount":102},[],{"trials":4956,"activeCount":102},[],{"trials":4958,"activeCount":184,"soonestReadout":2268},[4959],{"nctId":2265,"briefTitle":2266,"status":288,"phases":4960,"primaryCompletion":2268,"completion":2268,"start":2269,"enrollment":464,"conditions":4961,"interventions":4962},[91],[18,2271],[2249,2273],{"trials":4964,"activeCount":102},[],{"trials":4966,"activeCount":102},[],{"trials":4968,"activeCount":102},[],{"intervention":42,"totalTrials":184,"cells":4970},{"EARLY_PHASE1":4971,"PHASE1":4973,"PHASE2":4975,"PHASE3":4981,"PHASE4":4983,"NA":4985},{"trials":4972,"activeCount":102},[],{"trials":4974,"activeCount":102},[],{"trials":4976,"activeCount":184,"soonestReadout":41},[4977],{"nctId":39,"briefTitle":40,"status":203,"phases":4978,"primaryCompletion":41,"completion":2090,"start":3072,"enrollment":3073,"conditions":4979,"interventions":4980},[91],[24],[42,3026,1849],{"trials":4982,"activeCount":102},[],{"trials":4984,"activeCount":102},[],{"trials":4986,"activeCount":102},[],{"intervention":2990,"totalTrials":184,"cells":4988},{"EARLY_PHASE1":4989,"PHASE1":4991,"PHASE2":4993,"PHASE3":4999,"PHASE4":5001,"NA":5003},{"trials":4990,"activeCount":102},[],{"trials":4992,"activeCount":102},[],{"trials":4994,"activeCount":184,"soonestReadout":1196},[4995],{"nctId":2983,"briefTitle":2984,"status":288,"phases":4996,"primaryCompletion":1196,"completion":1363,"start":2986,"enrollment":1566,"conditions":4997,"interventions":4998},[90,91],[2988],[2354,978,2990],{"trials":5000,"activeCount":102},[],{"trials":5002,"activeCount":102},[],{"trials":5004,"activeCount":102},[],{"intervention":2660,"totalTrials":184,"cells":5006},{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5011,"PHASE3":5017,"PHASE4":5019,"NA":5021},{"trials":5008,"activeCount":102},[],{"trials":5010,"activeCount":102},[],{"trials":5012,"activeCount":184,"soonestReadout":1363},[5013],{"nctId":2653,"briefTitle":2654,"status":288,"phases":5014,"primaryCompletion":1363,"completion":1363,"start":2656,"enrollment":729,"conditions":5015,"interventions":5016},[90,91],[2658],[2660,1867,2661,2662],{"trials":5018,"activeCount":102},[],{"trials":5020,"activeCount":102},[],{"trials":5022,"activeCount":102},[],{"intervention":5024,"totalTrials":184,"cells":5025},"bis-octanoyl",{"EARLY_PHASE1":5026,"PHASE1":5028,"PHASE2":5030,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5027,"activeCount":102},[],{"trials":5029,"activeCount":102},[],{"trials":5031,"activeCount":184,"soonestReadout":2709},[5032],{"nctId":5033,"briefTitle":5034,"status":288,"phases":5035,"primaryCompletion":2709,"completion":5036,"start":5037,"enrollment":506,"conditions":5038,"interventions":5041},"NCT07097506","Effect of Ketone Esters on Liver Fat Content and Metabolic Function",[91],"2027-12-31","2025-09-26",[5039,15,5040],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Overweight (BMI > 25)",[5024],{"trials":5043,"activeCount":102},[],{"trials":5045,"activeCount":102},[],{"trials":5047,"activeCount":102},[],{"intervention":5049,"totalTrials":184,"cells":5050},"Atorvastatin",{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5055,"PHASE3":5065,"PHASE4":5067,"NA":5069},{"trials":5052,"activeCount":102},[],{"trials":5054,"activeCount":102},[],{"trials":5056,"activeCount":184,"soonestReadout":1196},[5057],{"nctId":5058,"briefTitle":5059,"status":288,"phases":5060,"primaryCompletion":1196,"completion":1196,"start":5061,"enrollment":960,"conditions":5062,"interventions":5063},"NCT05483010","Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)",[91],"2024-02-19",[4533,26],[5049,5064],"Rosuvastatin",{"trials":5066,"activeCount":102},[],{"trials":5068,"activeCount":102},[],{"trials":5070,"activeCount":102},[],{"intervention":5064,"totalTrials":184,"cells":5072},{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5077,"PHASE3":5083,"PHASE4":5085,"NA":5087},{"trials":5074,"activeCount":102},[],{"trials":5076,"activeCount":102},[],{"trials":5078,"activeCount":184,"soonestReadout":1196},[5079],{"nctId":5058,"briefTitle":5059,"status":288,"phases":5080,"primaryCompletion":1196,"completion":1196,"start":5061,"enrollment":960,"conditions":5081,"interventions":5082},[91],[4533,26],[5049,5064],{"trials":5084,"activeCount":102},[],{"trials":5086,"activeCount":102},[],{"trials":5088,"activeCount":102},[],{"intervention":72,"totalTrials":184,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5095,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5092,"activeCount":102},[],{"trials":5094,"activeCount":102},[],{"trials":5096,"activeCount":184,"soonestReadout":71},[5097],{"nctId":69,"briefTitle":70,"status":203,"phases":5098,"primaryCompletion":71,"completion":3078,"start":3079,"enrollment":208,"conditions":5099,"interventions":5100},[91],[3081],[72,3027,1849],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[],{"trials":5106,"activeCount":102},[],{"intervention":1943,"totalTrials":184,"cells":5108},{"EARLY_PHASE1":5109,"PHASE1":5111,"PHASE2":5113,"PHASE3":5119,"PHASE4":5121,"NA":5123},{"trials":5110,"activeCount":102},[],{"trials":5112,"activeCount":102},[],{"trials":5114,"activeCount":184,"soonestReadout":1936},[5115],{"nctId":1933,"briefTitle":1934,"status":203,"phases":5116,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":1938,"conditions":5117,"interventions":5118},[90,91],[1199,1201,1940,1941],[1943,1124,1594],{"trials":5120,"activeCount":102},[],{"trials":5122,"activeCount":102},[],{"trials":5124,"activeCount":102},[],{"intervention":5126,"totalTrials":184,"cells":5127},"Ivermectin w\u002F Albendazole",{"EARLY_PHASE1":5128,"PHASE1":5130,"PHASE2":5132,"PHASE3":5151,"PHASE4":5153,"NA":5155},{"trials":5129,"activeCount":102},[],{"trials":5131,"activeCount":102},[],{"trials":5133,"activeCount":184,"soonestReadout":5138},[5134],{"nctId":5135,"briefTitle":5136,"status":203,"phases":5137,"primaryCompletion":5138,"completion":5138,"start":5139,"enrollment":5140,"conditions":5141,"interventions":5147},"NCT06070116","Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis",[91],"2026-09-01","2024-04-05",300,[5142,5143,5144,5145,5146],"Onchocercal Subcutaneous Nodule","Onchocerciasis","Onchocerciasis, Ocular","Onchocerca Infection","Tropical Disease",[5126,5148,5149,5150],"Ivermectin + Diethylcarbamazine + Albendazole","Moxidectin + Albendazole","Moxidectin + Diethylcarbamazine + Albendazole",{"trials":5152,"activeCount":102},[],{"trials":5154,"activeCount":102},[],{"trials":5156,"activeCount":102},[],{"intervention":5148,"totalTrials":184,"cells":5158},{"EARLY_PHASE1":5159,"PHASE1":5161,"PHASE2":5163,"PHASE3":5169,"PHASE4":5171,"NA":5173},{"trials":5160,"activeCount":102},[],{"trials":5162,"activeCount":102},[],{"trials":5164,"activeCount":184,"soonestReadout":5138},[5165],{"nctId":5135,"briefTitle":5136,"status":203,"phases":5166,"primaryCompletion":5138,"completion":5138,"start":5139,"enrollment":5140,"conditions":5167,"interventions":5168},[91],[5142,5143,5144,5145,5146],[5126,5148,5149,5150],{"trials":5170,"activeCount":102},[],{"trials":5172,"activeCount":102},[],{"trials":5174,"activeCount":102},[],{"intervention":5149,"totalTrials":184,"cells":5176},{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5181,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5178,"activeCount":102},[],{"trials":5180,"activeCount":102},[],{"trials":5182,"activeCount":184,"soonestReadout":5138},[5183],{"nctId":5135,"briefTitle":5136,"status":203,"phases":5184,"primaryCompletion":5138,"completion":5138,"start":5139,"enrollment":5140,"conditions":5185,"interventions":5186},[91],[5142,5143,5144,5145,5146],[5126,5148,5149,5150],{"trials":5188,"activeCount":102},[],{"trials":5190,"activeCount":102},[],{"trials":5192,"activeCount":102},[],{"intervention":5150,"totalTrials":184,"cells":5194},{"EARLY_PHASE1":5195,"PHASE1":5197,"PHASE2":5199,"PHASE3":5205,"PHASE4":5207,"NA":5209},{"trials":5196,"activeCount":102},[],{"trials":5198,"activeCount":102},[],{"trials":5200,"activeCount":184,"soonestReadout":5138},[5201],{"nctId":5135,"briefTitle":5136,"status":203,"phases":5202,"primaryCompletion":5138,"completion":5138,"start":5139,"enrollment":5140,"conditions":5203,"interventions":5204},[91],[5142,5143,5144,5145,5146],[5126,5148,5149,5150],{"trials":5206,"activeCount":102},[],{"trials":5208,"activeCount":102},[],{"trials":5210,"activeCount":102},[],{"intervention":2281,"totalTrials":184,"cells":5212},{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5217,"PHASE3":5223,"PHASE4":5225,"NA":5227},{"trials":5214,"activeCount":102},[],{"trials":5216,"activeCount":102},[],{"trials":5218,"activeCount":184,"soonestReadout":1090},[5219],{"nctId":2275,"briefTitle":2276,"status":288,"phases":5220,"primaryCompletion":1090,"completion":1297,"start":2278,"enrollment":1954,"conditions":5221,"interventions":5222},[91],[18,159,1445,2271],[621,2249,2281,620,2282],{"trials":5224,"activeCount":102},[],{"trials":5226,"activeCount":102},[],{"trials":5228,"activeCount":102},[],{"intervention":4062,"totalTrials":184,"cells":5230},{"EARLY_PHASE1":5231,"PHASE1":5233,"PHASE2":5235,"PHASE3":5241,"PHASE4":5243,"NA":5245},{"trials":5232,"activeCount":102},[],{"trials":5234,"activeCount":102},[],{"trials":5236,"activeCount":184,"soonestReadout":4056},[5237],{"nctId":4053,"briefTitle":4054,"status":288,"phases":5238,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":19,"conditions":5239,"interventions":5240},[90,91],[4060],[4034,4062,4063],{"trials":5242,"activeCount":102},[],{"trials":5244,"activeCount":102},[],{"trials":5246,"activeCount":102},[],{"intervention":4063,"totalTrials":184,"cells":5248},{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5259,"PHASE4":5261,"NA":5263},{"trials":5250,"activeCount":102},[],{"trials":5252,"activeCount":102},[],{"trials":5254,"activeCount":184,"soonestReadout":4056},[5255],{"nctId":4053,"briefTitle":4054,"status":288,"phases":5256,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":19,"conditions":5257,"interventions":5258},[90,91],[4060],[4034,4062,4063],{"trials":5260,"activeCount":102},[],{"trials":5262,"activeCount":102},[],{"trials":5264,"activeCount":102},[],{"intervention":5266,"totalTrials":184,"cells":5267},"Bicalutamide",{"EARLY_PHASE1":5268,"PHASE1":5270,"PHASE2":5272,"PHASE3":5286,"PHASE4":5288,"NA":5290},{"trials":5269,"activeCount":102},[],{"trials":5271,"activeCount":102},[],{"trials":5273,"activeCount":184,"soonestReadout":5278},[5274],{"nctId":5275,"briefTitle":5276,"status":853,"phases":5277,"primaryCompletion":5278,"completion":2118,"start":1089,"enrollment":1299,"conditions":5279,"interventions":5284},"NCT07593079","Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer",[91],"2027-07-14",[2204,5280,5281,5282,5283],"Recurrent Prostate Cancer","Metastatic Prostate Cancer","Prostate Cancer Recurrent","Prostate Cancer Metastatic",[5266,5285],"18F-rhPSMA-7.3",{"trials":5287,"activeCount":102},[],{"trials":5289,"activeCount":102},[],{"trials":5291,"activeCount":102},[],{"intervention":5285,"totalTrials":184,"cells":5293},{"EARLY_PHASE1":5294,"PHASE1":5296,"PHASE2":5298,"PHASE3":5304,"PHASE4":5306,"NA":5308},{"trials":5295,"activeCount":102},[],{"trials":5297,"activeCount":102},[],{"trials":5299,"activeCount":184,"soonestReadout":5278},[5300],{"nctId":5275,"briefTitle":5276,"status":853,"phases":5301,"primaryCompletion":5278,"completion":2118,"start":1089,"enrollment":1299,"conditions":5302,"interventions":5303},[91],[2204,5280,5281,5282,5283],[5266,5285],{"trials":5305,"activeCount":102},[],{"trials":5307,"activeCount":102},[],{"trials":5309,"activeCount":102},[],{"intervention":5311,"totalTrials":184,"cells":5312},"CTX-009",{"EARLY_PHASE1":5313,"PHASE1":5315,"PHASE2":5317,"PHASE3":5329,"PHASE4":5331,"NA":5333},{"trials":5314,"activeCount":102},[],{"trials":5316,"activeCount":102},[],{"trials":5318,"activeCount":184,"soonestReadout":5323},[5319],{"nctId":5320,"briefTitle":5321,"status":853,"phases":5322,"primaryCompletion":5323,"completion":5324,"start":3909,"enrollment":5325,"conditions":5326,"interventions":5327},"NCT07392957","Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma",[90,91],"2029-05-31","2031-05-31",54,[1004],[5311,5328],"CTX-471",{"trials":5330,"activeCount":102},[],{"trials":5332,"activeCount":102},[],{"trials":5334,"activeCount":102},[],{"intervention":5328,"totalTrials":184,"cells":5336},{"EARLY_PHASE1":5337,"PHASE1":5339,"PHASE2":5341,"PHASE3":5347,"PHASE4":5349,"NA":5351},{"trials":5338,"activeCount":102},[],{"trials":5340,"activeCount":102},[],{"trials":5342,"activeCount":184,"soonestReadout":5323},[5343],{"nctId":5320,"briefTitle":5321,"status":853,"phases":5344,"primaryCompletion":5323,"completion":5324,"start":3909,"enrollment":5325,"conditions":5345,"interventions":5346},[90,91],[1004],[5311,5328],{"trials":5348,"activeCount":102},[],{"trials":5350,"activeCount":102},[],{"trials":5352,"activeCount":102},[],{"intervention":5354,"totalTrials":184,"cells":5355},"Treatment Plan 1: Stratum 1",{"EARLY_PHASE1":5356,"PHASE1":5358,"PHASE2":5360,"PHASE3":5374,"PHASE4":5376,"NA":5378},{"trials":5357,"activeCount":102},[],{"trials":5359,"activeCount":102},[],{"trials":5361,"activeCount":184,"soonestReadout":175},[5362],{"nctId":5363,"briefTitle":5364,"status":288,"phases":5365,"primaryCompletion":175,"completion":3853,"start":5366,"enrollment":5367,"conditions":5368,"interventions":5370},"NCT00920972","Campath\u002FFludarabine\u002FMelphalan Transplant Conditioning for Non-Malignant Diseases",[90,91],"2001-12",220,[4560,5369,4562,4563],"Hematologic, Immune, or Bone Marrow Disorders",[5354,5371,5372,5373],"Treatment Plan 2: Strata 2, 3, or 4","GVHD Regimen A: UCB Recipients","GVHD Regimen B: BM Recipients",{"trials":5375,"activeCount":102},[],{"trials":5377,"activeCount":102},[],{"trials":5379,"activeCount":102},[],{"intervention":5371,"totalTrials":184,"cells":5381},{"EARLY_PHASE1":5382,"PHASE1":5384,"PHASE2":5386,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5383,"activeCount":102},[],{"trials":5385,"activeCount":102},[],{"trials":5387,"activeCount":184,"soonestReadout":175},[5388],{"nctId":5363,"briefTitle":5364,"status":288,"phases":5389,"primaryCompletion":175,"completion":3853,"start":5366,"enrollment":5367,"conditions":5390,"interventions":5391},[90,91],[4560,5369,4562,4563],[5354,5371,5372,5373],{"trials":5393,"activeCount":102},[],{"trials":5395,"activeCount":102},[],{"trials":5397,"activeCount":102},[],{"intervention":5372,"totalTrials":184,"cells":5399},{"EARLY_PHASE1":5400,"PHASE1":5402,"PHASE2":5404,"PHASE3":5410,"PHASE4":5412,"NA":5414},{"trials":5401,"activeCount":102},[],{"trials":5403,"activeCount":102},[],{"trials":5405,"activeCount":184,"soonestReadout":175},[5406],{"nctId":5363,"briefTitle":5364,"status":288,"phases":5407,"primaryCompletion":175,"completion":3853,"start":5366,"enrollment":5367,"conditions":5408,"interventions":5409},[90,91],[4560,5369,4562,4563],[5354,5371,5372,5373],{"trials":5411,"activeCount":102},[],{"trials":5413,"activeCount":102},[],{"trials":5415,"activeCount":102},[],{"intervention":5373,"totalTrials":184,"cells":5417},{"EARLY_PHASE1":5418,"PHASE1":5420,"PHASE2":5422,"PHASE3":5428,"PHASE4":5430,"NA":5432},{"trials":5419,"activeCount":102},[],{"trials":5421,"activeCount":102},[],{"trials":5423,"activeCount":184,"soonestReadout":175},[5424],{"nctId":5363,"briefTitle":5364,"status":288,"phases":5425,"primaryCompletion":175,"completion":3853,"start":5366,"enrollment":5367,"conditions":5426,"interventions":5427},[90,91],[4560,5369,4562,4563],[5354,5371,5372,5373],{"trials":5429,"activeCount":102},[],{"trials":5431,"activeCount":102},[],{"trials":5433,"activeCount":102},[],{"intervention":5435,"totalTrials":184,"cells":5436},"Dasatinib + Quercetin",{"EARLY_PHASE1":5437,"PHASE1":5439,"PHASE2":5441,"PHASE3":5453,"PHASE4":5455,"NA":5457},{"trials":5438,"activeCount":102},[],{"trials":5440,"activeCount":102},[],{"trials":5442,"activeCount":184,"soonestReadout":5447},[5443],{"nctId":5444,"briefTitle":5445,"status":203,"phases":5446,"primaryCompletion":5447,"completion":5448,"start":516,"enrollment":565,"conditions":5449,"interventions":5452},"NCT04685590","Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study",[91],"2028-01","2029-01",[5450,5451],"Alzheimer Disease, Early Onset","Mild Cognitive Impairment",[5435],{"trials":5454,"activeCount":102},[],{"trials":5456,"activeCount":102},[],{"trials":5458,"activeCount":102},[],{"intervention":5460,"totalTrials":184,"cells":5461},"Maintenance ICS and Symptom Driven SABA",{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5477,"PHASE4":5479,"NA":5481},{"trials":5463,"activeCount":102},[],{"trials":5465,"activeCount":102},[],{"trials":5467,"activeCount":184,"soonestReadout":5472},[5468],{"nctId":5469,"briefTitle":5470,"status":203,"phases":5471,"primaryCompletion":5472,"completion":5472,"start":1039,"enrollment":506,"conditions":5473,"interventions":5475},"NCT05689983","Symptom-driven ICS\u002FLABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers",[90,91],"2025-12-01",[5474,4706],"Asthma in Children",[5460,5476],"Symptom-driven budesonide\u002Fformoterol combination",{"trials":5478,"activeCount":102},[],{"trials":5480,"activeCount":102},[],{"trials":5482,"activeCount":102},[],{"intervention":5476,"totalTrials":184,"cells":5484},{"EARLY_PHASE1":5485,"PHASE1":5487,"PHASE2":5489,"PHASE3":5495,"PHASE4":5497,"NA":5499},{"trials":5486,"activeCount":102},[],{"trials":5488,"activeCount":102},[],{"trials":5490,"activeCount":184,"soonestReadout":5472},[5491],{"nctId":5469,"briefTitle":5470,"status":203,"phases":5492,"primaryCompletion":5472,"completion":5472,"start":1039,"enrollment":506,"conditions":5493,"interventions":5494},[90,91],[5474,4706],[5460,5476],{"trials":5496,"activeCount":102},[],{"trials":5498,"activeCount":102},[],{"trials":5500,"activeCount":102},[],{"intervention":2471,"totalTrials":184,"cells":5502},{"EARLY_PHASE1":5503,"PHASE1":5505,"PHASE2":5507,"PHASE3":5513,"PHASE4":5515,"NA":5517},{"trials":5504,"activeCount":102},[],{"trials":5506,"activeCount":102},[],{"trials":5508,"activeCount":184,"soonestReadout":2463},[5509],{"nctId":2460,"briefTitle":2461,"status":288,"phases":5510,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":5511,"interventions":5512},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"trials":5514,"activeCount":102},[],{"trials":5516,"activeCount":102},[],{"trials":5518,"activeCount":102},[],{"intervention":2473,"totalTrials":184,"cells":5520},{"EARLY_PHASE1":5521,"PHASE1":5523,"PHASE2":5525,"PHASE3":5531,"PHASE4":5533,"NA":5535},{"trials":5522,"activeCount":102},[],{"trials":5524,"activeCount":102},[],{"trials":5526,"activeCount":184,"soonestReadout":2463},[5527],{"nctId":2460,"briefTitle":2461,"status":288,"phases":5528,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":5529,"interventions":5530},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"trials":5532,"activeCount":102},[],{"trials":5534,"activeCount":102},[],{"trials":5536,"activeCount":102},[],{"intervention":2474,"totalTrials":184,"cells":5538},{"EARLY_PHASE1":5539,"PHASE1":5541,"PHASE2":5543,"PHASE3":5549,"PHASE4":5551,"NA":5553},{"trials":5540,"activeCount":102},[],{"trials":5542,"activeCount":102},[],{"trials":5544,"activeCount":184,"soonestReadout":2463},[5545],{"nctId":2460,"briefTitle":2461,"status":288,"phases":5546,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":1142,"conditions":5547,"interventions":5548},[90,91],[2467,2468,2469,2389],[2471,2393,2375,2472,2362,2473,2474,2475,2476,2477],{"trials":5550,"activeCount":102},[],{"trials":5552,"activeCount":102},[],{"trials":5554,"activeCount":102},[],{"intervention":5556,"totalTrials":184,"cells":5557},"KNO3",{"EARLY_PHASE1":5558,"PHASE1":5560,"PHASE2":5562,"PHASE3":5572,"PHASE4":5574,"NA":5576},{"trials":5559,"activeCount":102},[],{"trials":5561,"activeCount":102},[],{"trials":5563,"activeCount":184,"soonestReadout":1196},[5564],{"nctId":5565,"briefTitle":5566,"status":288,"phases":5567,"primaryCompletion":1196,"completion":2709,"start":612,"enrollment":5568,"conditions":5569,"interventions":5571},"NCT05562167","The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)",[91],75,[5570],"Heart Failure",[5556],{"trials":5573,"activeCount":102},[],{"trials":5575,"activeCount":102},[],{"trials":5577,"activeCount":102},[],{"intervention":5579,"totalTrials":184,"cells":5580},"Bupivacaine\u002FEpinephrine",{"EARLY_PHASE1":5581,"PHASE1":5583,"PHASE2":5585,"PHASE3":5596,"PHASE4":5598,"NA":5600},{"trials":5582,"activeCount":102},[],{"trials":5584,"activeCount":102},[],{"trials":5586,"activeCount":184,"soonestReadout":1107},[5587],{"nctId":5588,"briefTitle":5589,"status":288,"phases":5590,"primaryCompletion":1107,"completion":5591,"start":5592,"enrollment":2234,"conditions":5593,"interventions":5594},"NCT06429501","Local Anesthesia for Facial Fractures",[91],"2027-07-01","2024-04-02",[181],[5579,5595],"Saline",{"trials":5597,"activeCount":102},[],{"trials":5599,"activeCount":102},[],{"trials":5601,"activeCount":102},[],{"intervention":5603,"totalTrials":184,"cells":5604},"Lemborexant 10 mg",{"EARLY_PHASE1":5605,"PHASE1":5607,"PHASE2":5609,"PHASE3":5621,"PHASE4":5623,"NA":5625},{"trials":5606,"activeCount":102},[],{"trials":5608,"activeCount":102},[],{"trials":5610,"activeCount":184,"soonestReadout":5615},[5611],{"nctId":5612,"briefTitle":5613,"status":288,"phases":5614,"primaryCompletion":5615,"completion":5615,"start":5616,"enrollment":5617,"conditions":5618,"interventions":5619},"NCT06274528","DORA and LP in Alzheimer's Disease Biomarkers",[91],"2030-03-31","2024-03-11",201,[4445],[5603,5620],"Lemborexant 20mg",{"trials":5622,"activeCount":102},[],{"trials":5624,"activeCount":102},[],{"trials":5626,"activeCount":102},[],{"intervention":5620,"totalTrials":184,"cells":5628},{"EARLY_PHASE1":5629,"PHASE1":5631,"PHASE2":5633,"PHASE3":5639,"PHASE4":5641,"NA":5643},{"trials":5630,"activeCount":102},[],{"trials":5632,"activeCount":102},[],{"trials":5634,"activeCount":184,"soonestReadout":5615},[5635],{"nctId":5612,"briefTitle":5613,"status":288,"phases":5636,"primaryCompletion":5615,"completion":5615,"start":5616,"enrollment":5617,"conditions":5637,"interventions":5638},[91],[4445],[5603,5620],{"trials":5640,"activeCount":102},[],{"trials":5642,"activeCount":102},[],{"trials":5644,"activeCount":102},[],{"intervention":3142,"totalTrials":184,"cells":5646},{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5651,"PHASE3":5657,"PHASE4":5659,"NA":5661},{"trials":5648,"activeCount":102},[],{"trials":5650,"activeCount":102},[],{"trials":5652,"activeCount":184,"soonestReadout":3136},[5653],{"nctId":3133,"briefTitle":3134,"status":288,"phases":5654,"primaryCompletion":3136,"completion":3137,"start":3138,"enrollment":2609,"conditions":5655,"interventions":5656},[91],[3140],[3124,3142],{"trials":5658,"activeCount":102},[],{"trials":5660,"activeCount":102},[],{"trials":5662,"activeCount":102},[],{"intervention":5664,"totalTrials":184,"cells":5665},"[C-11]-CS1P1",{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5670,"PHASE3":5682,"PHASE4":5684,"NA":5686},{"trials":5667,"activeCount":102},[],{"trials":5669,"activeCount":102},[],{"trials":5671,"activeCount":184,"soonestReadout":1139},[5672],{"nctId":5673,"briefTitle":5674,"status":288,"phases":5675,"primaryCompletion":1139,"completion":5676,"start":5677,"enrollment":5678,"conditions":5679,"interventions":5681},"NCT07462507","Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1",[91],"2033-06-30","2026-04-16",104,[5680,1262],"Central Nervous System Cancer",[5664],{"trials":5683,"activeCount":102},[],{"trials":5685,"activeCount":102},[],{"trials":5687,"activeCount":102},[],{"intervention":77,"totalTrials":184,"cells":5689},{"EARLY_PHASE1":5690,"PHASE1":5692,"PHASE2":5694,"PHASE3":5700,"PHASE4":5702,"NA":5704},{"trials":5691,"activeCount":102},[],{"trials":5693,"activeCount":102},[],{"trials":5695,"activeCount":184,"soonestReadout":76},[5696],{"nctId":74,"briefTitle":75,"status":203,"phases":5697,"primaryCompletion":76,"completion":2056,"start":2057,"enrollment":383,"conditions":5698,"interventions":5699},[90,91],[2038],[77,1151],{"trials":5701,"activeCount":102},[],{"trials":5703,"activeCount":102},[],{"trials":5705,"activeCount":102},[],{"intervention":1149,"totalTrials":184,"cells":5707},{"EARLY_PHASE1":5708,"PHASE1":5710,"PHASE2":5712,"PHASE3":5718,"PHASE4":5720,"NA":5722},{"trials":5709,"activeCount":102},[],{"trials":5711,"activeCount":102},[],{"trials":5713,"activeCount":184,"soonestReadout":1139},[5714],{"nctId":1136,"briefTitle":1137,"status":853,"phases":5715,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":1142,"conditions":5716,"interventions":5717},[90,91],[1144,1145,1146,1147],[1149,1150,959,1151],{"trials":5719,"activeCount":102},[],{"trials":5721,"activeCount":102},[],{"trials":5723,"activeCount":102},[],{"intervention":1150,"totalTrials":184,"cells":5725},{"EARLY_PHASE1":5726,"PHASE1":5728,"PHASE2":5730,"PHASE3":5736,"PHASE4":5738,"NA":5740},{"trials":5727,"activeCount":102},[],{"trials":5729,"activeCount":102},[],{"trials":5731,"activeCount":184,"soonestReadout":1139},[5732],{"nctId":1136,"briefTitle":1137,"status":853,"phases":5733,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":1142,"conditions":5734,"interventions":5735},[90,91],[1144,1145,1146,1147],[1149,1150,959,1151],{"trials":5737,"activeCount":102},[],{"trials":5739,"activeCount":102},[],{"trials":5741,"activeCount":102},[],{"intervention":2832,"totalTrials":184,"cells":5743},{"EARLY_PHASE1":5744,"PHASE1":5746,"PHASE2":5748,"PHASE3":5754,"PHASE4":5756,"NA":5758},{"trials":5745,"activeCount":102},[],{"trials":5747,"activeCount":102},[],{"trials":5749,"activeCount":184,"soonestReadout":2825},[5750],{"nctId":2822,"briefTitle":2823,"status":853,"phases":5751,"primaryCompletion":2825,"completion":2826,"start":2090,"enrollment":2827,"conditions":5752,"interventions":5753},[91],[1004,2829,2830],[2832,2804],{"trials":5755,"activeCount":102},[],{"trials":5757,"activeCount":102},[],{"trials":5759,"activeCount":102},[],{"intervention":5761,"totalTrials":184,"cells":5762},"Propranolol Hydrochloride",{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5778,"PHASE4":5780,"NA":5782},{"trials":5764,"activeCount":102},[],{"trials":5766,"activeCount":102},[],{"trials":5768,"activeCount":184,"soonestReadout":4092},[5769],{"nctId":5770,"briefTitle":5771,"status":288,"phases":5772,"primaryCompletion":4092,"completion":5773,"start":5774,"enrollment":208,"conditions":5775,"interventions":5777},"NCT06445166","Propranolol for the Treatment of Kaposi Sarcoma in Adults",[91],"2028-08-01","2025-08-20",[5776],"Kaposi Sarcoma",[5761],{"trials":5779,"activeCount":102},[],{"trials":5781,"activeCount":102},[],{"trials":5783,"activeCount":102},[],{"intervention":5785,"totalTrials":184,"cells":5786},"Zimberelimab",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5803,"PHASE4":5805,"NA":5807},{"trials":5788,"activeCount":102},[],{"trials":5790,"activeCount":102},[],{"trials":5792,"activeCount":184,"soonestReadout":5797},[5793],{"nctId":5794,"briefTitle":5795,"status":203,"phases":5796,"primaryCompletion":5797,"completion":4418,"start":5798,"enrollment":293,"conditions":5799,"interventions":5800},"NCT04791839","Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer",[91],"2026-10-31","2021-08-04",[1199,3773,1201],[5785,5801,5802],"Domvanalimab","Etrumadenant",{"trials":5804,"activeCount":102},[],{"trials":5806,"activeCount":102},[],{"trials":5808,"activeCount":102},[],{"intervention":5801,"totalTrials":184,"cells":5810},{"EARLY_PHASE1":5811,"PHASE1":5813,"PHASE2":5815,"PHASE3":5821,"PHASE4":5823,"NA":5825},{"trials":5812,"activeCount":102},[],{"trials":5814,"activeCount":102},[],{"trials":5816,"activeCount":184,"soonestReadout":5797},[5817],{"nctId":5794,"briefTitle":5795,"status":203,"phases":5818,"primaryCompletion":5797,"completion":4418,"start":5798,"enrollment":293,"conditions":5819,"interventions":5820},[91],[1199,3773,1201],[5785,5801,5802],{"trials":5822,"activeCount":102},[],{"trials":5824,"activeCount":102},[],{"trials":5826,"activeCount":102},[],{"intervention":5802,"totalTrials":184,"cells":5828},{"EARLY_PHASE1":5829,"PHASE1":5831,"PHASE2":5833,"PHASE3":5839,"PHASE4":5841,"NA":5843},{"trials":5830,"activeCount":102},[],{"trials":5832,"activeCount":102},[],{"trials":5834,"activeCount":184,"soonestReadout":5797},[5835],{"nctId":5794,"briefTitle":5795,"status":203,"phases":5836,"primaryCompletion":5797,"completion":4418,"start":5798,"enrollment":293,"conditions":5837,"interventions":5838},[91],[1199,3773,1201],[5785,5801,5802],{"trials":5840,"activeCount":102},[],{"trials":5842,"activeCount":102},[],{"trials":5844,"activeCount":102},[],{"intervention":2873,"totalTrials":184,"cells":5846},{"EARLY_PHASE1":5847,"PHASE1":5849,"PHASE2":5851,"PHASE3":5857,"PHASE4":5859,"NA":5861},{"trials":5848,"activeCount":102},[],{"trials":5850,"activeCount":102},[],{"trials":5852,"activeCount":184,"soonestReadout":1419},[5853],{"nctId":2866,"briefTitle":2867,"status":288,"phases":5854,"primaryCompletion":1419,"completion":1419,"start":2869,"enrollment":22,"conditions":5855,"interventions":5856},[91],[2871,115,116,29],[1186,2873],{"trials":5858,"activeCount":102},[],{"trials":5860,"activeCount":102},[],{"trials":5862,"activeCount":102},[],{"intervention":1161,"totalTrials":184,"cells":5864},{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5875,"PHASE4":5877,"NA":5879},{"trials":5866,"activeCount":102},[],{"trials":5868,"activeCount":102},[],{"trials":5870,"activeCount":184,"soonestReadout":1156},[5871],{"nctId":1153,"briefTitle":1154,"status":853,"phases":5872,"primaryCompletion":1156,"completion":1156,"start":1089,"enrollment":442,"conditions":5873,"interventions":5874},[91],[1158,1159],[1007,959,1161],{"trials":5876,"activeCount":102},[],{"trials":5878,"activeCount":102},[],{"trials":5880,"activeCount":102},[],{"intervention":5882,"totalTrials":184,"cells":5883},"Tofersen",{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5899,"PHASE4":5901,"NA":5903},{"trials":5885,"activeCount":102},[],{"trials":5887,"activeCount":102},[],{"trials":5889,"activeCount":184,"soonestReadout":5894},[5890],{"nctId":5891,"briefTitle":5892,"status":288,"phases":5893,"primaryCompletion":5894,"completion":3136,"start":5895,"enrollment":293,"conditions":5896,"interventions":5898},"NCT07294144","Tofersen in Non-SOD1 ALS",[91],"2027-01","2025-12-29",[5897],"ALS (Amyotrophic Lateral Sclerosis)",[5882],{"trials":5900,"activeCount":102},[],{"trials":5902,"activeCount":102},[],{"trials":5904,"activeCount":102},[],{"intervention":5906,"totalTrials":184,"cells":5907},"nebulized budesonide via NasoNeb",{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5912,"PHASE3":5922,"PHASE4":5924,"NA":5926},{"trials":5909,"activeCount":102},[],{"trials":5911,"activeCount":102},[],{"trials":5913,"activeCount":184,"soonestReadout":4440},[5914],{"nctId":5915,"briefTitle":5916,"status":853,"phases":5917,"primaryCompletion":4440,"completion":4440,"start":564,"enrollment":1954,"conditions":5918,"interventions":5920},"NCT07270302","Nebulized Nasal Steroids",[90,91],[5919],"Chronic Rhinosinusitis",[5906,5921],"budesonide lavage via NeilMed",{"trials":5923,"activeCount":102},[],{"trials":5925,"activeCount":102},[],{"trials":5927,"activeCount":102},[],{"intervention":5921,"totalTrials":184,"cells":5929},{"EARLY_PHASE1":5930,"PHASE1":5932,"PHASE2":5934,"PHASE3":5940,"PHASE4":5942,"NA":5944},{"trials":5931,"activeCount":102},[],{"trials":5933,"activeCount":102},[],{"trials":5935,"activeCount":184,"soonestReadout":4440},[5936],{"nctId":5915,"briefTitle":5916,"status":853,"phases":5937,"primaryCompletion":4440,"completion":4440,"start":564,"enrollment":1954,"conditions":5938,"interventions":5939},[90,91],[5919],[5906,5921],{"trials":5941,"activeCount":102},[],{"trials":5943,"activeCount":102},[],{"trials":5945,"activeCount":102},[],{"intervention":1498,"totalTrials":184,"cells":5947},{"EARLY_PHASE1":5948,"PHASE1":5950,"PHASE2":5952,"PHASE3":5958,"PHASE4":5960,"NA":5962},{"trials":5949,"activeCount":102},[],{"trials":5951,"activeCount":102},[],{"trials":5953,"activeCount":184,"soonestReadout":1491},[5954],{"nctId":1488,"briefTitle":1489,"status":853,"phases":5955,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":383,"conditions":5956,"interventions":5957},[91],[1494,1453,1495,1496],[1498,403],{"trials":5959,"activeCount":102},[],{"trials":5961,"activeCount":102},[],{"trials":5963,"activeCount":102},[],{"intervention":5965,"totalTrials":184,"cells":5966},"5-Fluorouracil",{"EARLY_PHASE1":5967,"PHASE1":5969,"PHASE2":5971,"PHASE3":5983,"PHASE4":5985,"NA":5987},{"trials":5968,"activeCount":102},[],{"trials":5970,"activeCount":102},[],{"trials":5972,"activeCount":184,"soonestReadout":983},[5973],{"nctId":5974,"briefTitle":5975,"status":288,"phases":5976,"primaryCompletion":983,"completion":1054,"start":5977,"enrollment":743,"conditions":5978,"interventions":5982},"NCT07419464","5-Fluorouracil Response and Optimization STudy (The FROST Trial)",[91],"2026-04-21",[5979,5980,5981],"Squamous Cell Carcinoma of Head and Neck","Metastatic Squamous Cell Carcinoma","Recurrent Squamous Cell Carcinoma of the Head and Neck",[5965],{"trials":5984,"activeCount":102},[],{"trials":5986,"activeCount":102},[],{"trials":5988,"activeCount":102},[],{"intervention":1332,"totalTrials":184,"cells":5990},{"EARLY_PHASE1":5991,"PHASE1":5993,"PHASE2":5995,"PHASE3":6001,"PHASE4":6003,"NA":6005},{"trials":5992,"activeCount":102},[],{"trials":5994,"activeCount":102},[],{"trials":5996,"activeCount":184,"soonestReadout":1326},[5997],{"nctId":1323,"briefTitle":1324,"status":203,"phases":5998,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":293,"conditions":5999,"interventions":6000},[91],[1286,1330],[1332,994,426],{"trials":6002,"activeCount":102},[],{"trials":6004,"activeCount":102},[],{"trials":6006,"activeCount":102},[],{"intervention":1048,"totalTrials":98,"cells":6008},{"EARLY_PHASE1":6009,"PHASE1":6011,"PHASE2":6021,"PHASE3":6031,"PHASE4":6033,"NA":6035},{"trials":6010,"activeCount":102},[],{"trials":6012,"activeCount":102},[6013,6017],{"nctId":1036,"briefTitle":1037,"status":108,"phases":6014,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":6015,"interventions":6016},[90],[1044],[1046,1047,959,1007,1048],{"nctId":2102,"briefTitle":2103,"status":137,"phases":6018,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":1056,"conditions":6019,"interventions":6020},[90],[1082,1592,2109,2110],[1370,1048],{"trials":6022,"activeCount":184,"soonestReadout":2118},[6023,6027],{"nctId":2115,"briefTitle":2116,"status":203,"phases":6024,"primaryCompletion":2118,"completion":1909,"start":2119,"enrollment":1131,"conditions":6025,"interventions":6026},[91],[2121],[1048,1370],{"nctId":2124,"briefTitle":2125,"status":122,"phases":6028,"primaryCompletion":2127,"completion":2128,"start":2129,"enrollment":102,"conditions":6029,"interventions":6030},[91],[1312],[1370,2132,2133],{"trials":6032,"activeCount":102},[],{"trials":6034,"activeCount":102},[],{"trials":6036,"activeCount":102},[6037],{"nctId":6038,"briefTitle":6039,"status":6040,"phases":6041,"conditions":6042,"interventions":6044},"NCT03914872","Expanded Access Neoantigen Vaccine in Solid Tumors","NO_LONGER_AVAILABLE",[],[6043],"Solid Tumor, Adult",[2133],{"intervention":5595,"totalTrials":599,"cells":6046},{"EARLY_PHASE1":6047,"PHASE1":6049,"PHASE2":6051,"PHASE3":6057,"PHASE4":6069,"NA":6071},{"trials":6048,"activeCount":102},[],{"trials":6050,"activeCount":102},[],{"trials":6052,"activeCount":184,"soonestReadout":1107},[6053],{"nctId":5588,"briefTitle":5589,"status":288,"phases":6054,"primaryCompletion":1107,"completion":5591,"start":5592,"enrollment":2234,"conditions":6055,"interventions":6056},[91],[181],[5579,5595],{"trials":6058,"activeCount":102},[6059],{"nctId":6060,"briefTitle":6061,"status":108,"phases":6062,"primaryCompletion":6063,"completion":3054,"start":6064,"enrollment":6065,"conditions":6066,"interventions":6067},"NCT04415658","Intravenous Thyroxine for Heart-Eligible Organ Donors",[92],"2022-11-06","2020-12-01",838,[580,5570],[6068,5595],"Thyroxine",{"trials":6070,"activeCount":102},[],{"trials":6072,"activeCount":102},[6073,6082],{"nctId":6074,"briefTitle":6075,"status":108,"phases":6076,"primaryCompletion":1604,"completion":1604,"start":1863,"enrollment":1818,"conditions":6077,"interventions":6080},"NCT00845897","Botulinum Toxin Effects on Plantar Ulcer Recurrence",[94],[6078,954,6079],"Diabetes Mellitus","Plantar Ulcers",[6081,5595],"Botulinum Toxin",{"nctId":6083,"briefTitle":6084,"status":108,"phases":6085,"primaryCompletion":365,"completion":365,"start":3250,"enrollment":353,"conditions":6086,"interventions":6091},"NCT00941889","The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata",[94],[6087,6088,6089,6090],"HIV Positive","Anal Condylomata","Anal Warts","HIV Infections",[5595,6092],"Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine",{"intervention":2914,"totalTrials":456,"cells":6094},{"EARLY_PHASE1":6095,"PHASE1":6097,"PHASE2":6099,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6096,"activeCount":102},[],{"trials":6098,"activeCount":102},[],{"trials":6100,"activeCount":184,"soonestReadout":2908},[6101],{"nctId":2905,"briefTitle":2906,"status":203,"phases":6102,"primaryCompletion":2908,"completion":2090,"start":2909,"enrollment":2910,"conditions":6103,"interventions":6104},[91],[2912],[2662,2894,2914],{"trials":6106,"activeCount":102},[],{"trials":6108,"activeCount":102},[],{"trials":6110,"activeCount":102},[6111],{"nctId":6112,"briefTitle":6113,"status":108,"phases":6114,"primaryCompletion":6115,"completion":6115,"start":6116,"enrollment":6117,"conditions":6118,"interventions":6124},"NCT00736632","Vitamin D, Insulin Resistance, and Cardiovascular Disease",[94],"2019-01-13","2006-05",125,[6119,6120,6121,6122,6123],"Vitamin D Deficiency","Insulin Resistance","Type 2 Diabetes Mellitus","Cardiovascular Disease","Hypertension",[2914],{"intervention":1229,"totalTrials":1664,"cells":6126},{"EARLY_PHASE1":6127,"PHASE1":6148,"PHASE2":6182,"PHASE3":6206,"PHASE4":6208,"NA":6210},{"trials":6128,"activeCount":102},[6129,6140,6144],{"nctId":6130,"briefTitle":6131,"status":122,"phases":6132,"primaryCompletion":6133,"completion":6134,"start":6135,"enrollment":102,"conditions":6136,"interventions":6138},"NCT02419170","Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)",[89],"2019-10","2023-10","2016-07",[6137,1354,1356],"Carcinoma, Non-Small-Cell-Lung",[1229,6139],"Personalized mature dendritic cell vaccine",{"nctId":2367,"briefTitle":2368,"status":122,"phases":6141,"primaryCompletion":2370,"completion":2370,"start":1351,"enrollment":102,"conditions":6142,"interventions":6143},[89],[24,2372],[2374,2362,2375,1229,2376,2377,2378],{"nctId":3017,"briefTitle":3018,"status":137,"phases":6145,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":6146,"interventions":6147},[89],[24],[2378,2446,3024,1849,1229,3025,3026,3027],{"trials":6149,"activeCount":474,"soonestReadout":1280},[6150,6154,6158,6162,6170,6174,6178],{"nctId":2565,"briefTitle":2566,"status":137,"phases":6151,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":184,"conditions":6152,"interventions":6153},[90],[2572],[2574,1229,2377,2575,2375],{"nctId":2382,"briefTitle":2383,"status":137,"phases":6155,"primaryCompletion":2385,"completion":2386,"start":2387,"enrollment":98,"conditions":6156,"interventions":6157},[90],[2389,2390,2391],[2375,2393,1229,2362,2394,2395],{"nctId":1704,"briefTitle":1705,"status":122,"phases":6159,"primaryCompletion":432,"completion":1707,"start":1708,"enrollment":102,"conditions":6160,"interventions":6161},[90],[18,159],[1711,1228,1229,82],{"nctId":6163,"briefTitle":6164,"status":288,"phases":6165,"primaryCompletion":1280,"completion":2091,"start":6166,"enrollment":960,"conditions":6167,"interventions":6168},"NCT06623630","Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function",[90],"2024-12-04",[24],[1229,6169],"Ciltacabtagene Autoleucel",{"nctId":1221,"briefTitle":1222,"status":853,"phases":6171,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":6172,"interventions":6173},[90],[1082],[82,426,994,1228,1229,1230,1231,1232],{"nctId":3930,"briefTitle":3931,"status":137,"phases":6175,"primaryCompletion":3933,"completion":3088,"start":3934,"enrollment":208,"conditions":6176,"interventions":6177},[90],[3182],[3937,3938,3939,3940],{"nctId":2216,"briefTitle":2217,"status":288,"phases":6179,"primaryCompletion":2219,"completion":1139,"start":2220,"enrollment":1299,"conditions":6180,"interventions":6181},[90],[2222,2223],[2183,2225,1455,1229],{"trials":6183,"activeCount":102},[6184,6194,6198,6202],{"nctId":6185,"briefTitle":6186,"status":108,"phases":6187,"primaryCompletion":3432,"completion":6188,"start":1952,"enrollment":1056,"conditions":6189,"interventions":6191},"NCT01000285","EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma",[90,91],"2016-04",[6190],"Leukemia-Lymphoma, Adult T-Cell",[2446,2424,6192,1228,1073,1229,6193],"Vincristine","Raltegravir",{"nctId":1618,"briefTitle":1619,"status":137,"phases":6195,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":6196,"interventions":6197},[91],[1445],[1228,631,1229,82,1626,1594,426,375],{"nctId":3619,"briefTitle":3620,"status":122,"phases":6199,"primaryCompletion":3622,"completion":3622,"start":1195,"enrollment":102,"conditions":6200,"interventions":6201},[91],[3336,3335,26],[3625,2375,1229,3340],{"nctId":3627,"briefTitle":3628,"status":137,"phases":6203,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":6204,"interventions":6205},[90,91],[3182],[2375,1229,3636,2475,2613],{"trials":6207,"activeCount":102},[],{"trials":6209,"activeCount":102},[],{"trials":6211,"activeCount":102},[],{"intervention":6213,"totalTrials":599,"cells":6214},"Nitrous Oxide",{"EARLY_PHASE1":6215,"PHASE1":6228,"PHASE2":6249,"PHASE3":6258,"PHASE4":6260,"NA":6262},{"trials":6216,"activeCount":102},[6217],{"nctId":6218,"briefTitle":6219,"status":137,"phases":6220,"primaryCompletion":6221,"completion":6221,"start":6222,"enrollment":184,"conditions":6223,"interventions":6227},"NCT02757521","Nitrous TRD Bipolar Depression",[89],"2016-12-06","2016-03-25",[6224,6225,6226],"Treatment- Resistant Bipolar Disorder","Bipolar Disorder","Bipolar Depressive Disorder",[6213],{"trials":6229,"activeCount":456,"soonestReadout":290},[6230,6239],{"nctId":6231,"briefTitle":6232,"status":173,"phases":6233,"primaryCompletion":290,"completion":175,"start":6234,"enrollment":1954,"conditions":6235,"interventions":6238},"NCT03736538","Nitrous Oxide- Suicidal Ideation",[90],"2018-10-30",[3865,21,6236,6237],"Mood Disorders","Suicidal Ideation",[6213],{"nctId":6240,"briefTitle":6241,"status":288,"phases":6242,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":2609,"conditions":6245,"interventions":6248},"NCT02994433","NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits",[90],"2027-04-30","2017-01-27",[6246,6247],"Depressive Disorder, Major","Depressive Disorder, Treatment-Resistant",[6213],{"trials":6250,"activeCount":102},[6251],{"nctId":6252,"briefTitle":6253,"status":108,"phases":6254,"primaryCompletion":6255,"completion":6255,"start":3217,"enrollment":36,"conditions":6256,"interventions":6257},"NCT02139540","Nitrous Oxide as Treatment for Major Depression - a Pilot Study",[91],"2015-04",[21,3865],[6213],{"trials":6259,"activeCount":102},[],{"trials":6261,"activeCount":102},[],{"trials":6263,"activeCount":102},[],{"intervention":6265,"totalTrials":474,"cells":6266},"NT-I7",{"EARLY_PHASE1":6267,"PHASE1":6269,"PHASE2":6296,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6268,"activeCount":102},[],{"trials":6270,"activeCount":456,"soonestReadout":2268},[6271,6279,6288],{"nctId":6272,"briefTitle":6273,"status":288,"phases":6274,"primaryCompletion":2268,"completion":1269,"start":6275,"enrollment":30,"conditions":6276,"interventions":6277},"NCT07052305","NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed\u002FRefractory Large B-cell Lymphoma",[90],"2026-03-12",[2336],[6265,6278],"CAR T-cell therapy",{"nctId":6280,"briefTitle":6281,"status":122,"phases":6282,"primaryCompletion":6283,"completion":6283,"start":6284,"enrollment":102,"conditions":6285,"interventions":6287},"NCT04498325","Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)",[90],"2022-04-30","2021-07-31",[718,6286],"SARS-CoV-2",[6265],{"nctId":6289,"briefTitle":6290,"status":853,"phases":6291,"primaryCompletion":6292,"completion":1787,"start":3909,"enrollment":3251,"conditions":6293,"interventions":6295},"NCT07200089","Recombinant Human IL-7 (NT-I7) in Relapsed\u002FRefractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)",[90],"2028-02-10",[24,3081,6294],"Multiple Myeloma, Refractory",[6265],{"trials":6297,"activeCount":102},[],{"trials":6299,"activeCount":102},[],{"trials":6301,"activeCount":102},[],{"trials":6303,"activeCount":102},[],{"intervention":6305,"totalTrials":474,"cells":6306},"Personalized neoantigen DNA vaccine",{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6339,"PHASE3":6341,"PHASE4":6343,"NA":6345},{"trials":6308,"activeCount":102},[],{"trials":6310,"activeCount":456,"soonestReadout":6324},[6311,6320,6330],{"nctId":6312,"briefTitle":6313,"status":137,"phases":6314,"primaryCompletion":6315,"completion":6316,"start":6317,"enrollment":1080,"conditions":6318,"interventions":6319},"NCT03122106","Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy",[90],"2021-09-03","2022-08-13","2018-01-05",[29,116,115],[6305],{"nctId":6321,"briefTitle":6322,"status":203,"phases":6323,"primaryCompletion":6324,"completion":6325,"start":1282,"enrollment":27,"conditions":6326,"interventions":6328},"NCT05743595","Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",[90],"2026-04-07","2029-03-09",[6327],"Unmethylated Glioblastoma",[6329,4051],"Personalized Neoantigen DNA vaccine",{"nctId":6331,"briefTitle":6332,"status":288,"phases":6333,"primaryCompletion":6334,"completion":2825,"start":6335,"enrollment":1623,"conditions":6336,"interventions":6338},"NCT03988283","Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors",[90],"2029-03-31","2024-10-02",[6337],"Pediatric Recurrent Central Nervous System Tumors",[6305],{"trials":6340,"activeCount":102},[],{"trials":6342,"activeCount":102},[],{"trials":6344,"activeCount":102},[],{"trials":6346,"activeCount":102},[],{"intervention":6348,"totalTrials":456,"cells":6349},"DSP-0390",{"EARLY_PHASE1":6350,"PHASE1":6363,"PHASE2":6372,"PHASE3":6374,"PHASE4":6376,"NA":6378},{"trials":6351,"activeCount":184,"soonestReadout":6356},[6352],{"nctId":6353,"briefTitle":6354,"status":288,"phases":6355,"primaryCompletion":6356,"completion":6357,"start":6358,"enrollment":1299,"conditions":6359,"interventions":6362},"NCT06636162","Window of Opportunity Study of DSP-0390 in Gliomas",[89],"2027-04-17","2027-05-17","2025-04-03",[6360,6361],"Glioma, Malignant","IDH Mutation",[6348],{"trials":6364,"activeCount":184,"soonestReadout":1537},[6365],{"nctId":6366,"briefTitle":6367,"status":853,"phases":6368,"primaryCompletion":1537,"completion":1259,"start":1492,"enrollment":1299,"conditions":6369,"interventions":6371},"NCT07545954","DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer",[90],[1940,6370],"Small Cell Lung Cancer Extensive Stage",[6348,3761],{"trials":6373,"activeCount":102},[],{"trials":6375,"activeCount":102},[],{"trials":6377,"activeCount":102},[],{"trials":6379,"activeCount":102},[],{"intervention":6381,"totalTrials":2289,"cells":6382},"Decitabine",{"EARLY_PHASE1":6383,"PHASE1":6385,"PHASE2":6432,"PHASE3":6463,"PHASE4":6465,"NA":6467},{"trials":6384,"activeCount":102},[],{"trials":6386,"activeCount":184,"soonestReadout":1259},[6387,6395,6405,6412,6418],{"nctId":6388,"briefTitle":6389,"status":853,"phases":6390,"primaryCompletion":1259,"completion":2816,"start":2090,"enrollment":27,"conditions":6391,"interventions":6393},"NCT07617363","ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS",[90],[2389,6392],"High-risk Myelodysplastic Syndrome",[6394,6381],"ATRN-119",{"nctId":6396,"briefTitle":6397,"status":108,"phases":6398,"primaryCompletion":6399,"completion":3555,"start":6400,"enrollment":1249,"conditions":6401,"interventions":6403},"NCT00671697","Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia",[90],"2010-01","2008-05",[6402],"Myelodysplastic Syndromes and Leukemia, Myeloid, Acute",[6404,6381],"Arsenic Trioxide",{"nctId":6406,"briefTitle":6407,"status":108,"phases":6408,"primaryCompletion":2287,"completion":3432,"start":3193,"enrollment":1042,"conditions":6409,"interventions":6410},"NCT01001143","Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)",[90],[3182],[6381,6411],"Bexarotene",{"nctId":6413,"briefTitle":6414,"status":108,"phases":6415,"primaryCompletion":3432,"completion":2451,"start":364,"enrollment":30,"conditions":6416,"interventions":6417},"NCT00986804","Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant",[90],[3182,26],[6381],{"nctId":6419,"briefTitle":6420,"status":122,"phases":6421,"primaryCompletion":6422,"completion":6422,"start":6423,"enrollment":102,"conditions":6424,"interventions":6430},"NCT02564536","Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)\u002FMyelodysplastic Syndrome (MDS)",[90],"2020-06-30","2017-06",[6425,6426,6427,6428,26,6429],"Chronic Myelomonocytic Leukemia","Juvenile Myelomonocytic Leukemia","Atypical Chronic Myeloid Leukemia","Myeloproliferative Neoplasm","Myelofibrosis",[6431,6381],"Pacritinib",{"trials":6433,"activeCount":102},[6434,6445,6455],{"nctId":6435,"briefTitle":6436,"status":108,"phases":6437,"primaryCompletion":6438,"completion":6439,"start":6440,"enrollment":6441,"conditions":6442,"interventions":6443},"NCT01687400","Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes",[91],"2017-06-23","2017-11-13","2013-02-12",114,[3182,26],[6444],"decitabine",{"nctId":6446,"briefTitle":6447,"status":137,"phases":6448,"primaryCompletion":6449,"completion":6450,"start":6451,"enrollment":1818,"conditions":6452,"interventions":6454},"NCT03063203","Single Agent Decitabine in TP53 Mutated Relapsed\u002FRefractory Acute Myeloid Leukemia",[91],"2021-02-13","2022-03-16","2017-07-14",[2389,6453],"Acute Myeloid Leukemia, Relapsed, Adult",[6381],{"nctId":6456,"briefTitle":6457,"status":108,"phases":6458,"primaryCompletion":6459,"completion":1736,"start":382,"enrollment":3251,"conditions":6460,"interventions":6461},"NCT00691938","LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)",[90,91],"2013-07",[3182,26],[6462,6381],"LBH589",{"trials":6464,"activeCount":102},[],{"trials":6466,"activeCount":102},[],{"trials":6468,"activeCount":102},[],{"intervention":372,"totalTrials":1623,"cells":6470},{"EARLY_PHASE1":6471,"PHASE1":6473,"PHASE2":6483,"PHASE3":6509,"PHASE4":6511,"NA":6513},{"trials":6472,"activeCount":102},[],{"trials":6474,"activeCount":184,"soonestReadout":2634},[6475,6479],{"nctId":3452,"briefTitle":3453,"status":108,"phases":6476,"primaryCompletion":3455,"completion":3455,"start":2646,"enrollment":1131,"conditions":6477,"interventions":6478},[90],[3457,3458,2038,3459,3460],[2563,372],{"nctId":2631,"briefTitle":2632,"status":203,"phases":6480,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":36,"conditions":6481,"interventions":6482},[90],[2637],[2639,372,1867],{"trials":6484,"activeCount":102},[6485,6489,6493,6497,6501],{"nctId":361,"briefTitle":362,"status":137,"phases":6486,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":6487,"interventions":6488},[91],[369,370],[339,372,373,374,375],{"nctId":4043,"briefTitle":4044,"status":108,"phases":6490,"primaryCompletion":4046,"completion":4047,"start":4048,"enrollment":2434,"conditions":6491,"interventions":6492},[91],[2038,1004],[4034,372,4051],{"nctId":1448,"briefTitle":1449,"status":108,"phases":6494,"primaryCompletion":490,"completion":490,"start":1451,"enrollment":27,"conditions":6495,"interventions":6496},[91],[1453],[1455,403,372],{"nctId":2674,"briefTitle":2675,"status":108,"phases":6498,"primaryCompletion":2677,"completion":2677,"start":2646,"enrollment":2678,"conditions":6499,"interventions":6500},[91],[2680],[372,1867,2682],{"nctId":6502,"briefTitle":6503,"status":108,"phases":6504,"primaryCompletion":490,"completion":490,"start":6400,"enrollment":6505,"conditions":6506,"interventions":6508},"NCT00868192","Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma",[91],38,[6507,1541],"Ovarian Carcinoma",[1652,372],{"trials":6510,"activeCount":102},[],{"trials":6512,"activeCount":102},[],{"trials":6514,"activeCount":102},[],{"intervention":631,"totalTrials":1623,"cells":6516},{"EARLY_PHASE1":6517,"PHASE1":6519,"PHASE2":6525,"PHASE3":6556,"PHASE4":6558,"NA":6560},{"trials":6518,"activeCount":102},[],{"trials":6520,"activeCount":184,"soonestReadout":983},[6521],{"nctId":980,"briefTitle":981,"status":288,"phases":6522,"primaryCompletion":983,"completion":984,"start":985,"enrollment":383,"conditions":6523,"interventions":6524},[90],[987,988,989,990,991],[993,959,994,631,995],{"trials":6526,"activeCount":102},[6527,6531,6535,6544,6548,6552],{"nctId":3551,"briefTitle":3552,"status":108,"phases":6528,"primaryCompletion":3554,"completion":3555,"start":3477,"enrollment":3556,"conditions":6529,"interventions":6530},[91],[1445],[3559,1626,1594,631],{"nctId":3484,"briefTitle":3485,"status":108,"phases":6532,"primaryCompletion":2888,"completion":3487,"start":3488,"enrollment":1391,"conditions":6533,"interventions":6534},[91],[3490,1650],[2563,631,374,373,375],{"nctId":6536,"briefTitle":6537,"status":122,"phases":6538,"primaryCompletion":6539,"completion":6539,"start":1873,"enrollment":102,"conditions":6540,"interventions":6541},"NCT01557764","Lapatinib With Trastuzumab in Treating Patients With HER2-Negative\u002FHER2 Mutant Metastatic Breast Cancer",[91],"2016-03",[1445],[6542,6543],"lapatinib ditosylate","trastuzumab",{"nctId":623,"briefTitle":624,"status":137,"phases":6545,"primaryCompletion":626,"completion":627,"start":628,"enrollment":442,"conditions":6546,"interventions":6547},[91],[18,159,616],[57,619,631,621,632],{"nctId":1618,"briefTitle":1619,"status":137,"phases":6549,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":6550,"interventions":6551},[91],[1445],[1228,631,1229,82,1626,1594,426,375],{"nctId":3814,"briefTitle":3815,"status":108,"phases":6553,"primaryCompletion":3817,"completion":3818,"start":3819,"enrollment":3820,"conditions":6554,"interventions":6555},[91],[1445],[3823,620,631],{"trials":6557,"activeCount":102},[],{"trials":6559,"activeCount":102},[],{"trials":6561,"activeCount":102},[],{"intervention":1228,"totalTrials":1623,"cells":6563},{"EARLY_PHASE1":6564,"PHASE1":6566,"PHASE2":6585,"PHASE3":6626,"PHASE4":6628,"NA":6630},{"trials":6565,"activeCount":102},[],{"trials":6567,"activeCount":184,"soonestReadout":1224},[6568,6577,6581],{"nctId":6569,"briefTitle":6570,"status":108,"phases":6571,"primaryCompletion":6572,"completion":6573,"start":6574,"enrollment":1283,"conditions":6575,"interventions":6576},"NCT01851733","MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme",[90],"2018-04-12","2018-05-30","2013-08-13",[1004],[1228],{"nctId":1704,"briefTitle":1705,"status":122,"phases":6578,"primaryCompletion":432,"completion":1707,"start":1708,"enrollment":102,"conditions":6579,"interventions":6580},[90],[18,159],[1711,1228,1229,82],{"nctId":1221,"briefTitle":1222,"status":853,"phases":6582,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":6583,"interventions":6584},[90],[1082],[82,426,994,1228,1229,1230,1231,1232],{"trials":6586,"activeCount":102},[6587,6591,6610,6614],{"nctId":6185,"briefTitle":6186,"status":108,"phases":6588,"primaryCompletion":3432,"completion":6188,"start":1952,"enrollment":1056,"conditions":6589,"interventions":6590},[90,91],[6190],[2446,2424,6192,1228,1073,1229,6193],{"nctId":6592,"briefTitle":6593,"status":108,"phases":6594,"primaryCompletion":6595,"completion":6595,"start":6596,"enrollment":792,"conditions":6597,"interventions":6608},"NCT02584309","Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",[91],"2022-07-17","2016-02-22",[6598,1925,6599,6600,6601,6602,6603,6604,6605,6606,6607],"Sarcoma, Soft Tissue","Undifferentiated Pleomorphic Sarcoma","Leiomyosarcoma","Liposarcoma","Synovial Sarcoma","Myxofibrosarcoma","Angiosarcoma","Fibrosarcoma","Malignant Peripheral Nerve Sheath Tumor","Epithelioid Sarcoma",[6609,1228],"Dexrazoxane",{"nctId":1618,"briefTitle":1619,"status":137,"phases":6611,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":6612,"interventions":6613},[91],[1445],[1228,631,1229,82,1626,1594,426,375],{"nctId":6615,"briefTitle":6616,"status":137,"phases":6617,"primaryCompletion":6618,"completion":6618,"start":6619,"enrollment":1131,"conditions":6620,"interventions":6625},"NCT02372409","Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors",[91],"2023-03-23","2015-08-14",[2038,6621,6622,1004,6623,2000,2001,6624,1998],"Pilocytic Astrocytoma","Anaplastic Astrocytoma","Mixed Oligoastrocytoma","Optic Glioma",[1228,2424],{"trials":6627,"activeCount":102},[],{"trials":6629,"activeCount":102},[],{"trials":6631,"activeCount":102},[],{"intervention":3761,"totalTrials":98,"cells":6633},{"EARLY_PHASE1":6634,"PHASE1":6636,"PHASE2":6642,"PHASE3":6670,"PHASE4":6672,"NA":6674},{"trials":6635,"activeCount":102},[],{"trials":6637,"activeCount":184,"soonestReadout":1537},[6638],{"nctId":6366,"briefTitle":6367,"status":853,"phases":6639,"primaryCompletion":1537,"completion":1259,"start":1492,"enrollment":1299,"conditions":6640,"interventions":6641},[90],[1940,6370],[6348,3761],{"trials":6643,"activeCount":102},[6644,6653,6657,6666],{"nctId":6645,"briefTitle":6646,"status":137,"phases":6647,"primaryCompletion":6648,"completion":6649,"start":6650,"enrollment":1310,"conditions":6651,"interventions":6652},"NCT04373369","Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer",[91],"2022-08-18","2025-08-11","2020-10-07",[2121],[1034,3761],{"nctId":3753,"briefTitle":3754,"status":108,"phases":6654,"primaryCompletion":3756,"completion":3757,"start":3758,"enrollment":36,"conditions":6655,"interventions":6656},[91],[1201,1199,1200],[1291,3761],{"nctId":6658,"briefTitle":6659,"status":137,"phases":6660,"primaryCompletion":907,"completion":907,"start":6661,"enrollment":1623,"conditions":6662,"interventions":6664},"NCT05060003","Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection",[91],"2022-11-08",[6663],"Stage II Melanoma",[3761,6665],"Tiragolumab",{"nctId":3767,"briefTitle":3768,"status":122,"phases":6667,"primaryCompletion":3770,"completion":1141,"start":3771,"enrollment":102,"conditions":6668,"interventions":6669},[91],[1201,3773,1200,1199],[1291,3761,3775],{"trials":6671,"activeCount":102},[],{"trials":6673,"activeCount":102},[],{"trials":6675,"activeCount":102},[],{"intervention":6431,"totalTrials":599,"cells":6677},{"EARLY_PHASE1":6678,"PHASE1":6680,"PHASE2":6704,"PHASE3":6715,"PHASE4":6717,"NA":6719},{"trials":6679,"activeCount":102},[],{"trials":6681,"activeCount":184,"soonestReadout":2938},[6682,6692,6696],{"nctId":6683,"briefTitle":6684,"status":288,"phases":6685,"primaryCompletion":2938,"completion":1012,"start":6686,"enrollment":1080,"conditions":6687,"interventions":6691},"NCT06538181","Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome",[90],"2025-02-13",[6688,6689,6690],"E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome","VEXAS","Vexas Syndrome",[6431],{"nctId":6419,"briefTitle":6420,"status":122,"phases":6693,"primaryCompletion":6422,"completion":6422,"start":6423,"enrollment":102,"conditions":6694,"interventions":6695},[90],[6425,6426,6427,6428,26,6429],[6431,6381],{"nctId":6697,"briefTitle":6698,"status":137,"phases":6699,"primaryCompletion":6700,"completion":6700,"start":6701,"enrollment":2289,"conditions":6702,"interventions":6703},"NCT02342353","Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)",[90],"2018-02-06","2015-05-18",[1354,1356,1553],[6431,2045],{"trials":6705,"activeCount":102},[6706],{"nctId":6707,"briefTitle":6708,"status":137,"phases":6709,"primaryCompletion":6710,"completion":6711,"start":6712,"enrollment":1310,"conditions":6713,"interventions":6714},"NCT02277093","Pacritinib to Inhibit JAK\u002FSTAT Signaling in Refractory Colorectal Cancer",[91],"2016-03-31","2016-10-27","2015-09-22",[369],[6431],{"trials":6716,"activeCount":102},[],{"trials":6718,"activeCount":102},[],{"trials":6720,"activeCount":102},[],{"intervention":3069,"totalTrials":474,"cells":6722},{"EARLY_PHASE1":6723,"PHASE1":6725,"PHASE2":6733,"PHASE3":6743,"PHASE4":6745,"NA":6747},{"trials":6724,"activeCount":102},[],{"trials":6726,"activeCount":184,"soonestReadout":984},[6727],{"nctId":6728,"briefTitle":6729,"status":288,"phases":6730,"primaryCompletion":984,"completion":2219,"start":1378,"enrollment":1299,"conditions":6731,"interventions":6732},"NCT07200102","Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma",[90],[24],[3069],{"trials":6734,"activeCount":102},[6735,6739],{"nctId":3062,"briefTitle":3063,"status":122,"phases":6736,"primaryCompletion":1090,"completion":1090,"start":3065,"enrollment":102,"conditions":6737,"interventions":6738},[91],[24,3067],[3069,3026,1849],{"nctId":3226,"briefTitle":3227,"status":108,"phases":6740,"primaryCompletion":3229,"completion":3229,"start":3230,"enrollment":506,"conditions":6741,"interventions":6742},[90,91],[2389],[3069,3185,2612,2425],{"trials":6744,"activeCount":102},[],{"trials":6746,"activeCount":102},[],{"trials":6748,"activeCount":102},[],{"intervention":6750,"totalTrials":474,"cells":6751},"Duvelisib",{"EARLY_PHASE1":6752,"PHASE1":6754,"PHASE2":6766,"PHASE3":6786,"PHASE4":6788,"NA":6790},{"trials":6753,"activeCount":102},[],{"trials":6755,"activeCount":184,"soonestReadout":6760},[6756],{"nctId":6757,"briefTitle":6758,"status":203,"phases":6759,"primaryCompletion":6760,"completion":6761,"start":6762,"enrollment":383,"conditions":6763,"interventions":6765},"NCT05044039","Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy",[90],"2026-01-06","2030-05-22","2022-02-28",[6764,2391],"Non-hodgkin Lymphoma",[6750],{"trials":6767,"activeCount":102},[6768,6777],{"nctId":6769,"briefTitle":6770,"status":108,"phases":6771,"primaryCompletion":6772,"completion":6773,"start":6774,"enrollment":3305,"conditions":6775,"interventions":6776},"NCT04372602","Duvelisib to Combat COVID-19",[91],"2022-02-06","2022-03-02","2020-10-12",[718],[6750],{"nctId":6778,"briefTitle":6779,"status":137,"phases":6780,"primaryCompletion":6781,"completion":6781,"start":6782,"enrollment":1818,"conditions":6783,"interventions":6785},"NCT04331119","Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas",[91],"2026-04-22","2020-07-23",[6784],"T-Cell Lymphoma",[6750],{"trials":6787,"activeCount":102},[],{"trials":6789,"activeCount":102},[],{"trials":6791,"activeCount":102},[],{"intervention":6793,"totalTrials":456,"cells":6794},"Abatacept",{"EARLY_PHASE1":6795,"PHASE1":6797,"PHASE2":6813,"PHASE3":6825,"PHASE4":6827,"NA":6829},{"trials":6796,"activeCount":102},[],{"trials":6798,"activeCount":184,"soonestReadout":6803},[6799],{"nctId":6800,"briefTitle":6801,"status":288,"phases":6802,"primaryCompletion":6803,"completion":6804,"start":6805,"enrollment":6806,"conditions":6807,"interventions":6811},"NCT06008808","Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation",[90],"2027-09-08","2027-11-27","2024-05-07",41,[6808,6809,6810],"Graft Vs Host Disease","Graft-versus-host-disease","Graft Versus Host Disease",[6812,6793],"Ruxolitinib",{"trials":6814,"activeCount":102},[6815],{"nctId":6816,"briefTitle":6817,"status":108,"phases":6818,"primaryCompletion":380,"completion":6819,"start":6820,"enrollment":30,"conditions":6821,"interventions":6823},"NCT00784459","The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics",[91],"2012-02","2008-10",[6822],"Atopic Asthma",[6824],"abatacept",{"trials":6826,"activeCount":102},[],{"trials":6828,"activeCount":102},[],{"trials":6830,"activeCount":102},[],{"intervention":4051,"totalTrials":456,"cells":6832},{"EARLY_PHASE1":6833,"PHASE1":6835,"PHASE2":6841,"PHASE3":6847,"PHASE4":6849,"NA":6851},{"trials":6834,"activeCount":102},[],{"trials":6836,"activeCount":184,"soonestReadout":6324},[6837],{"nctId":6321,"briefTitle":6322,"status":203,"phases":6838,"primaryCompletion":6324,"completion":6325,"start":1282,"enrollment":27,"conditions":6839,"interventions":6840},[90],[6327],[6329,4051],{"trials":6842,"activeCount":102},[6843],{"nctId":4043,"briefTitle":4044,"status":108,"phases":6844,"primaryCompletion":4046,"completion":4047,"start":4048,"enrollment":2434,"conditions":6845,"interventions":6846},[91],[2038,1004],[4034,372,4051],{"trials":6848,"activeCount":102},[],{"trials":6850,"activeCount":102},[],{"trials":6852,"activeCount":102},[],{"intervention":2096,"totalTrials":456,"cells":6854},{"EARLY_PHASE1":6855,"PHASE1":6857,"PHASE2":6863,"PHASE3":6869,"PHASE4":6871,"NA":6873},{"trials":6856,"activeCount":102},[],{"trials":6858,"activeCount":184,"soonestReadout":2090},[6859],{"nctId":2087,"briefTitle":2088,"status":203,"phases":6860,"primaryCompletion":2090,"completion":2091,"start":2092,"enrollment":208,"conditions":6861,"interventions":6862},[90],[2094],[1370,2096],{"trials":6864,"activeCount":102},[6865],{"nctId":3238,"briefTitle":3239,"status":108,"phases":6866,"primaryCompletion":3241,"completion":3242,"start":3243,"enrollment":1249,"conditions":6867,"interventions":6868},[91],[3172],[3174,978,2096,2425],{"trials":6870,"activeCount":102},[],{"trials":6872,"activeCount":102},[],{"trials":6874,"activeCount":102},[],{"intervention":1455,"totalTrials":456,"cells":6876},{"EARLY_PHASE1":6877,"PHASE1":6879,"PHASE2":6885,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6878,"activeCount":102},[],{"trials":6880,"activeCount":184,"soonestReadout":2219},[6881],{"nctId":2216,"briefTitle":2217,"status":288,"phases":6882,"primaryCompletion":2219,"completion":1139,"start":2220,"enrollment":1299,"conditions":6883,"interventions":6884},[90],[2222,2223],[2183,2225,1455,1229],{"trials":6886,"activeCount":102},[6887],{"nctId":1448,"briefTitle":1449,"status":108,"phases":6888,"primaryCompletion":490,"completion":490,"start":1451,"enrollment":27,"conditions":6889,"interventions":6890},[91],[1453],[1455,403,372],{"trials":6892,"activeCount":102},[],{"trials":6894,"activeCount":102},[],{"trials":6896,"activeCount":102},[],{"intervention":977,"totalTrials":1131,"cells":6898},{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6949,"PHASE3":6951,"PHASE4":6953,"NA":6955},{"trials":6900,"activeCount":102},[],{"trials":6902,"activeCount":184,"soonestReadout":1327},[6903,6914,6921,6925,6929,6939],{"nctId":6904,"briefTitle":6905,"status":288,"phases":6906,"primaryCompletion":1327,"completion":6907,"start":6908,"enrollment":353,"conditions":6909,"interventions":6912},"NCT06529822","Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease",[90],"2033-03-31","2025-03-20",[6910,6911],"Muscle-Invasive Bladder Carcinoma","Gastroesophageal Adenocarcinoma",[6913,977],"Synthetic long peptide personalized cancer vaccine",{"nctId":6915,"briefTitle":6916,"status":122,"phases":6917,"primaryCompletion":612,"completion":6918,"start":124,"enrollment":102,"conditions":6919,"interventions":6920},"NCT03068832","Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors",[90],"2026-02-28",[2222],[2026,977],{"nctId":967,"briefTitle":968,"status":137,"phases":6922,"primaryCompletion":970,"completion":971,"start":972,"enrollment":599,"conditions":6923,"interventions":6924},[90],[974],[976,977,959,978],{"nctId":1192,"briefTitle":1193,"status":122,"phases":6926,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":102,"conditions":6927,"interventions":6928},[90],[1199,1200,1201,1202],[994,1204,977],{"nctId":6930,"briefTitle":6931,"status":137,"phases":6932,"primaryCompletion":6933,"completion":6934,"start":6935,"enrollment":1566,"conditions":6936,"interventions":6937},"NCT03956056","Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy",[90],"2022-07-21","2023-07-06","2020-02-13",[116,29,115],[6938,977],"Neoantigen Peptide Vaccine",{"nctId":6940,"briefTitle":6941,"status":122,"phases":6942,"primaryCompletion":6943,"completion":6943,"start":6944,"enrollment":102,"conditions":6945,"interventions":6947},"NCT02427581","Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy",[90],"2025-12-31","2015-09-29",[1082,1592,6946],"Triple-Negative Breast Cancer",[6948,977],"Personalized synthetic long peptide vaccine",{"trials":6950,"activeCount":102},[],{"trials":6952,"activeCount":102},[],{"trials":6954,"activeCount":102},[],{"trials":6956,"activeCount":102},[],{"intervention":2027,"totalTrials":474,"cells":6958},{"EARLY_PHASE1":6959,"PHASE1":6961,"PHASE2":6980,"PHASE3":6982,"PHASE4":6984,"NA":6986},{"trials":6960,"activeCount":102},[],{"trials":6962,"activeCount":184,"soonestReadout":1224},[6963,6967,6971],{"nctId":2017,"briefTitle":2018,"status":137,"phases":6964,"primaryCompletion":2020,"completion":2020,"start":2021,"enrollment":184,"conditions":6965,"interventions":6966},[90],[2023,2024],[2026,2027,1151],{"nctId":1221,"briefTitle":1222,"status":853,"phases":6968,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":6969,"interventions":6970},[90],[1082],[82,426,994,1228,1229,1230,1231,1232],{"nctId":6972,"briefTitle":6973,"status":108,"phases":6974,"primaryCompletion":6975,"completion":6975,"start":6976,"enrollment":1015,"conditions":6977,"interventions":6978},"NCT05111353","Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery",[90],"2025-11-03","2022-12-15",[116,29,115],[6979,2027],"Optimized neoantigen synthetic long peptide vaccine",{"trials":6981,"activeCount":102},[],{"trials":6983,"activeCount":102},[],{"trials":6985,"activeCount":102},[],{"trials":6987,"activeCount":102},[],{"intervention":3014,"totalTrials":456,"cells":6989},{"EARLY_PHASE1":6990,"PHASE1":6996,"PHASE2":7008,"PHASE3":7010,"PHASE4":7012,"NA":7014},{"trials":6991,"activeCount":102},[6992],{"nctId":3006,"briefTitle":3007,"status":108,"phases":6993,"primaryCompletion":3009,"completion":3010,"start":365,"enrollment":1249,"conditions":6994,"interventions":6995},[89],[3012],[2612,3014,2424,1849,3015],{"trials":6997,"activeCount":184,"soonestReadout":2869},[6998],{"nctId":6999,"briefTitle":7000,"status":203,"phases":7001,"primaryCompletion":2869,"completion":1936,"start":7002,"enrollment":1131,"conditions":7003,"interventions":7006},"NCT05813327","Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma",[90],"2024-03-14",[1925,7004,7005],"Sts","Sarcoma,Soft Tissue",[7007,3014,3015],"ADI PEG20",{"trials":7009,"activeCount":102},[],{"trials":7011,"activeCount":102},[],{"trials":7013,"activeCount":102},[],{"trials":7015,"activeCount":102},[],{"intervention":3015,"totalTrials":456,"cells":7017},{"EARLY_PHASE1":7018,"PHASE1":7024,"PHASE2":7030,"PHASE3":7032,"PHASE4":7034,"NA":7036},{"trials":7019,"activeCount":102},[7020],{"nctId":3006,"briefTitle":3007,"status":108,"phases":7021,"primaryCompletion":3009,"completion":3010,"start":365,"enrollment":1249,"conditions":7022,"interventions":7023},[89],[3012],[2612,3014,2424,1849,3015],{"trials":7025,"activeCount":184,"soonestReadout":2869},[7026],{"nctId":6999,"briefTitle":7000,"status":203,"phases":7027,"primaryCompletion":2869,"completion":1936,"start":7002,"enrollment":1131,"conditions":7028,"interventions":7029},[90],[1925,7004,7005],[7007,3014,3015],{"trials":7031,"activeCount":102},[],{"trials":7033,"activeCount":102},[],{"trials":7035,"activeCount":102},[],{"trials":7037,"activeCount":102},[],{"intervention":62,"totalTrials":456,"cells":7039},{"EARLY_PHASE1":7040,"PHASE1":7042,"PHASE2":7058,"PHASE3":7060,"PHASE4":7062,"NA":7064},{"trials":7041,"activeCount":102},[],{"trials":7043,"activeCount":184,"soonestReadout":61},[7044,7050],{"nctId":59,"briefTitle":60,"status":203,"phases":7045,"primaryCompletion":61,"completion":1269,"start":7046,"enrollment":27,"conditions":7047,"interventions":7049},[90],"2015-01-07",[18,616,7048],"Malignant Neoplasm of Breast",[62],{"nctId":7051,"briefTitle":7052,"status":108,"phases":7053,"primaryCompletion":7054,"completion":2452,"start":3103,"enrollment":1080,"conditions":7055,"interventions":7056},"NCT00807781","Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer",[90],"2014-03",[1216],[7057],"Mammaglobin-A DNA vaccine",{"trials":7059,"activeCount":102},[],{"trials":7061,"activeCount":102},[],{"trials":7063,"activeCount":102},[],{"trials":7065,"activeCount":102},[],{"intervention":7067,"totalTrials":184,"cells":7068},"Tulmimetostat",{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7084,"PHASE3":7086,"PHASE4":7088,"NA":7090},{"trials":7070,"activeCount":102},[],{"trials":7072,"activeCount":184,"soonestReadout":7077},[7073],{"nctId":7074,"briefTitle":7075,"status":203,"phases":7076,"primaryCompletion":7077,"completion":3496,"start":7078,"enrollment":30,"conditions":7079,"interventions":7083},"NCT05944562","Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome",[90],"2027-02-28","2024-01-09",[7080,7081,7082],"Mycosis Fungoides","Sezary Syndrome","Mycosis Fungoides\u002FSezary Syndrome",[7067],{"trials":7085,"activeCount":102},[],{"trials":7087,"activeCount":102},[],{"trials":7089,"activeCount":102},[],{"trials":7091,"activeCount":102},[],{"intervention":6913,"totalTrials":184,"cells":7093},{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7102,"PHASE3":7104,"PHASE4":7106,"NA":7108},{"trials":7095,"activeCount":102},[],{"trials":7097,"activeCount":184,"soonestReadout":1327},[7098],{"nctId":6904,"briefTitle":6905,"status":288,"phases":7099,"primaryCompletion":1327,"completion":6907,"start":6908,"enrollment":353,"conditions":7100,"interventions":7101},[90],[6910,6911],[6913,977],{"trials":7103,"activeCount":102},[],{"trials":7105,"activeCount":102},[],{"trials":7107,"activeCount":102},[],{"trials":7109,"activeCount":102},[],{"intervention":7111,"totalTrials":184,"cells":7112},"WS-CART-CS1",{"EARLY_PHASE1":7113,"PHASE1":7115,"PHASE2":7126,"PHASE3":7128,"PHASE4":7130,"NA":7132},{"trials":7114,"activeCount":102},[],{"trials":7116,"activeCount":184,"soonestReadout":1537},[7117],{"nctId":7118,"briefTitle":7119,"status":288,"phases":7120,"primaryCompletion":1537,"completion":7121,"start":7122,"enrollment":208,"conditions":7123,"interventions":7124},"NCT06185751","Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma",[90],"2040-08-31","2024-08-22",[24],[7111,7125],"Lymphodepleting chemotherapy",{"trials":7127,"activeCount":102},[],{"trials":7129,"activeCount":102},[],{"trials":7131,"activeCount":102},[],{"trials":7133,"activeCount":102},[],{"intervention":7125,"totalTrials":184,"cells":7135},{"EARLY_PHASE1":7136,"PHASE1":7138,"PHASE2":7144,"PHASE3":7146,"PHASE4":7148,"NA":7150},{"trials":7137,"activeCount":102},[],{"trials":7139,"activeCount":184,"soonestReadout":1537},[7140],{"nctId":7118,"briefTitle":7119,"status":288,"phases":7141,"primaryCompletion":1537,"completion":7121,"start":7122,"enrollment":208,"conditions":7142,"interventions":7143},[90],[24],[7111,7125],{"trials":7145,"activeCount":102},[],{"trials":7147,"activeCount":102},[],{"trials":7149,"activeCount":102},[],{"trials":7151,"activeCount":102},[],{"intervention":7153,"totalTrials":184,"cells":7154},"TTI-101",{"EARLY_PHASE1":7155,"PHASE1":7157,"PHASE2":7167,"PHASE3":7169,"PHASE4":7171,"NA":7173},{"trials":7156,"activeCount":102},[],{"trials":7158,"activeCount":184,"soonestReadout":7163},[7159],{"nctId":7160,"briefTitle":7161,"status":288,"phases":7162,"primaryCompletion":7163,"completion":7163,"start":7164,"enrollment":1056,"conditions":7165,"interventions":7166},"NCT06141031","Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma",[90],"2029-06-30","2024-01-16",[29],[7153],{"trials":7168,"activeCount":102},[],{"trials":7170,"activeCount":102},[],{"trials":7172,"activeCount":102},[],{"trials":7174,"activeCount":102},[],{"intervention":7176,"totalTrials":184,"cells":7177},"Siltuximab",{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7191,"PHASE3":7193,"PHASE4":7195,"NA":7197},{"trials":7179,"activeCount":102},[],{"trials":7181,"activeCount":184,"soonestReadout":7186},[7182],{"nctId":7183,"briefTitle":7184,"status":288,"phases":7185,"primaryCompletion":7186,"completion":7187,"start":1987,"enrollment":293,"conditions":7188,"interventions":7190},"NCT06990711","A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation",[90],"2027-12-30","2028-06-30",[7189],"Antibody Mediated Rejection of Lung Transplant",[7176],{"trials":7192,"activeCount":102},[],{"trials":7194,"activeCount":102},[],{"trials":7196,"activeCount":102},[],{"trials":7198,"activeCount":102},[],{"intervention":7200,"totalTrials":184,"cells":7201},"Group 1-64CU-DOTA-ECL1i",{"EARLY_PHASE1":7202,"PHASE1":7204,"PHASE2":7215,"PHASE3":7217,"PHASE4":7219,"NA":7221},{"trials":7203,"activeCount":102},[],{"trials":7205,"activeCount":184,"soonestReadout":7210},[7206],{"nctId":7207,"briefTitle":7208,"status":288,"phases":7209,"primaryCompletion":7210,"completion":7210,"start":125,"enrollment":3684,"conditions":7211,"interventions":7213},"NCT04537403","PET Detection of CCR2 in Human Atherosclerosis",[90],"2025-09-01",[7212],"Carotid Atherosclerosis",[7200,7214],"Group 2 64CU-DOTA-ECL1i",{"trials":7216,"activeCount":102},[],{"trials":7218,"activeCount":102},[],{"trials":7220,"activeCount":102},[],{"trials":7222,"activeCount":102},[],{"intervention":7214,"totalTrials":184,"cells":7224},{"EARLY_PHASE1":7225,"PHASE1":7227,"PHASE2":7233,"PHASE3":7235,"PHASE4":7237,"NA":7239},{"trials":7226,"activeCount":102},[],{"trials":7228,"activeCount":184,"soonestReadout":7210},[7229],{"nctId":7207,"briefTitle":7208,"status":288,"phases":7230,"primaryCompletion":7210,"completion":7210,"start":125,"enrollment":3684,"conditions":7231,"interventions":7232},[90],[7212],[7200,7214],{"trials":7234,"activeCount":102},[],{"trials":7236,"activeCount":102},[],{"trials":7238,"activeCount":102},[],{"trials":7240,"activeCount":102},[],{"intervention":1795,"totalTrials":184,"cells":7242},{"EARLY_PHASE1":7243,"PHASE1":7245,"PHASE2":7251,"PHASE3":7253,"PHASE4":7255,"NA":7257},{"trials":7244,"activeCount":102},[],{"trials":7246,"activeCount":184,"soonestReadout":1787},[7247],{"nctId":1784,"briefTitle":1785,"status":288,"phases":7248,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1056,"conditions":7249,"interventions":7250},[90],[1791,1792,1793],[1060,1795],{"trials":7252,"activeCount":102},[],{"trials":7254,"activeCount":102},[],{"trials":7256,"activeCount":102},[],{"trials":7258,"activeCount":102},[],{"intervention":6394,"totalTrials":184,"cells":7260},{"EARLY_PHASE1":7261,"PHASE1":7263,"PHASE2":7269,"PHASE3":7271,"PHASE4":7273,"NA":7275},{"trials":7262,"activeCount":102},[],{"trials":7264,"activeCount":184,"soonestReadout":1259},[7265],{"nctId":6388,"briefTitle":6389,"status":853,"phases":7266,"primaryCompletion":1259,"completion":2816,"start":2090,"enrollment":27,"conditions":7267,"interventions":7268},[90],[2389,6392],[6394,6381],{"trials":7270,"activeCount":102},[],{"trials":7272,"activeCount":102},[],{"trials":7274,"activeCount":102},[],{"trials":7276,"activeCount":102},[],{"intervention":6278,"totalTrials":184,"cells":7278},{"EARLY_PHASE1":7279,"PHASE1":7281,"PHASE2":7287,"PHASE3":7289,"PHASE4":7291,"NA":7293},{"trials":7280,"activeCount":102},[],{"trials":7282,"activeCount":184,"soonestReadout":2268},[7283],{"nctId":6272,"briefTitle":6273,"status":288,"phases":7284,"primaryCompletion":2268,"completion":1269,"start":6275,"enrollment":30,"conditions":7285,"interventions":7286},[90],[2336],[6265,6278],{"trials":7288,"activeCount":102},[],{"trials":7290,"activeCount":102},[],{"trials":7292,"activeCount":102},[],{"trials":7294,"activeCount":102},[],{"intervention":7007,"totalTrials":184,"cells":7296},{"EARLY_PHASE1":7297,"PHASE1":7299,"PHASE2":7305,"PHASE3":7307,"PHASE4":7309,"NA":7311},{"trials":7298,"activeCount":102},[],{"trials":7300,"activeCount":184,"soonestReadout":2869},[7301],{"nctId":6999,"briefTitle":7000,"status":203,"phases":7302,"primaryCompletion":2869,"completion":1936,"start":7002,"enrollment":1131,"conditions":7303,"interventions":7304},[90],[1925,7004,7005],[7007,3014,3015],{"trials":7306,"activeCount":102},[],{"trials":7308,"activeCount":102},[],{"trials":7310,"activeCount":102},[],{"trials":7312,"activeCount":102},[],{"intervention":993,"totalTrials":184,"cells":7314},{"EARLY_PHASE1":7315,"PHASE1":7317,"PHASE2":7323,"PHASE3":7325,"PHASE4":7327,"NA":7329},{"trials":7316,"activeCount":102},[],{"trials":7318,"activeCount":184,"soonestReadout":983},[7319],{"nctId":980,"briefTitle":981,"status":288,"phases":7320,"primaryCompletion":983,"completion":984,"start":985,"enrollment":383,"conditions":7321,"interventions":7322},[90],[987,988,989,990,991],[993,959,994,631,995],{"trials":7324,"activeCount":102},[],{"trials":7326,"activeCount":102},[],{"trials":7328,"activeCount":102},[],{"trials":7330,"activeCount":102},[],{"intervention":995,"totalTrials":184,"cells":7332},{"EARLY_PHASE1":7333,"PHASE1":7335,"PHASE2":7341,"PHASE3":7343,"PHASE4":7345,"NA":7347},{"trials":7334,"activeCount":102},[],{"trials":7336,"activeCount":184,"soonestReadout":983},[7337],{"nctId":980,"briefTitle":981,"status":288,"phases":7338,"primaryCompletion":983,"completion":984,"start":985,"enrollment":383,"conditions":7339,"interventions":7340},[90],[987,988,989,990,991],[993,959,994,631,995],{"trials":7342,"activeCount":102},[],{"trials":7344,"activeCount":102},[],{"trials":7346,"activeCount":102},[],{"trials":7348,"activeCount":102},[],{"intervention":7350,"totalTrials":184,"cells":7351},"PMD-026",{"EARLY_PHASE1":7352,"PHASE1":7354,"PHASE2":7364,"PHASE3":7366,"PHASE4":7368,"NA":7370},{"trials":7353,"activeCount":102},[],{"trials":7355,"activeCount":184,"soonestReadout":7360},[7356],{"nctId":7357,"briefTitle":7358,"status":288,"phases":7359,"primaryCompletion":7360,"completion":7360,"start":7361,"enrollment":1056,"conditions":7362,"interventions":7363},"NCT07379125","Therapeutic RSK1 Targeting in Myelofibrosis",[90],"2028-12-31","2026-05-20",[6429],[7350],{"trials":7365,"activeCount":102},[],{"trials":7367,"activeCount":102},[],{"trials":7369,"activeCount":102},[],{"trials":7371,"activeCount":102},[],{"intervention":87,"totalTrials":184,"cells":7373},{"EARLY_PHASE1":7374,"PHASE1":7376,"PHASE2":7384,"PHASE3":7386,"PHASE4":7388,"NA":7390},{"trials":7375,"activeCount":102},[],{"trials":7377,"activeCount":184,"soonestReadout":86},[7378],{"nctId":84,"briefTitle":85,"status":203,"phases":7379,"primaryCompletion":86,"completion":1108,"start":7380,"enrollment":340,"conditions":7381,"interventions":7383},[90],"2019-10-15",[1528,7382],"Cancer of the Endometrium",[87],{"trials":7385,"activeCount":102},[],{"trials":7387,"activeCount":102},[],{"trials":7389,"activeCount":102},[],{"trials":7391,"activeCount":102},[],{"intervention":52,"totalTrials":184,"cells":7393},{"EARLY_PHASE1":7394,"PHASE1":7396,"PHASE2":7404,"PHASE3":7406,"PHASE4":7408,"NA":7410},{"trials":7395,"activeCount":102},[],{"trials":7397,"activeCount":184,"soonestReadout":51},[7398],{"nctId":49,"briefTitle":50,"status":203,"phases":7399,"primaryCompletion":51,"completion":7400,"start":7401,"enrollment":1299,"conditions":7402,"interventions":7403},[90],"2027-03-25","2018-12-14",[26],[52],{"trials":7405,"activeCount":102},[],{"trials":7407,"activeCount":102},[],{"trials":7409,"activeCount":102},[],{"trials":7411,"activeCount":102},[],{"intervention":2403,"totalTrials":184,"cells":7413},{"EARLY_PHASE1":7414,"PHASE1":7416,"PHASE2":7422,"PHASE3":7424,"PHASE4":7426,"NA":7428},{"trials":7415,"activeCount":102},[],{"trials":7417,"activeCount":184,"soonestReadout":984},[7418],{"nctId":2397,"briefTitle":2398,"status":288,"phases":7419,"primaryCompletion":984,"completion":984,"start":2400,"enrollment":293,"conditions":7420,"interventions":7421},[90],[24],[2403,2362],{"trials":7423,"activeCount":102},[],{"trials":7425,"activeCount":102},[],{"trials":7427,"activeCount":102},[],{"trials":7429,"activeCount":102},[],{"intervention":7431,"totalTrials":184,"cells":7432},"WU-CART-007",{"EARLY_PHASE1":7433,"PHASE1":7435,"PHASE2":7457,"PHASE3":7459,"PHASE4":7461,"NA":7463},{"trials":7434,"activeCount":102},[],{"trials":7436,"activeCount":184,"soonestReadout":1089},[7437],{"nctId":7438,"briefTitle":7439,"status":203,"phases":7440,"primaryCompletion":1089,"completion":1089,"start":7441,"enrollment":1131,"conditions":7442,"interventions":7456},"NCT05377827","Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies",[90],"2023-10-10",[7443,2389,7444,7445,7446,7447,7448,7449,7450,7451,7452,7453,7081,7454,7455],"T-Cell Non-Hodgkin Lymphoma","Angioimmunoblastic T-cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","Peripheral T Cell Lymphoma","Anaplastic Large Cell Lymphoma","Adult T Cell Leukemia","Adult T Cell Lymphoma","T Cell Prolymphocytic Leukemia","Extranodal NK\u002FT-cell Lymphoma","Transformed Mycosis Fungoides","Primary Cutaneous Gamma-Delta T-Cell Lymphoma","Hepatosplenic T-cell Lymphoma",[7431],{"trials":7458,"activeCount":102},[],{"trials":7460,"activeCount":102},[],{"trials":7462,"activeCount":102},[],{"trials":7464,"activeCount":102},[],{"intervention":1020,"totalTrials":184,"cells":7466},{"EARLY_PHASE1":7467,"PHASE1":7469,"PHASE2":7475,"PHASE3":7477,"PHASE4":7479,"NA":7481},{"trials":7468,"activeCount":102},[],{"trials":7470,"activeCount":184,"soonestReadout":1012},[7471],{"nctId":1009,"briefTitle":1010,"status":288,"phases":7472,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":7473,"interventions":7474},[90],[1017,1018],[1020,1021,959],{"trials":7476,"activeCount":102},[],{"trials":7478,"activeCount":102},[],{"trials":7480,"activeCount":102},[],{"trials":7482,"activeCount":102},[],{"intervention":1021,"totalTrials":184,"cells":7484},{"EARLY_PHASE1":7485,"PHASE1":7487,"PHASE2":7493,"PHASE3":7495,"PHASE4":7497,"NA":7499},{"trials":7486,"activeCount":102},[],{"trials":7488,"activeCount":184,"soonestReadout":1012},[7489],{"nctId":1009,"briefTitle":1010,"status":288,"phases":7490,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":7491,"interventions":7492},[90],[1017,1018],[1020,1021,959],{"trials":7494,"activeCount":102},[],{"trials":7496,"activeCount":102},[],{"trials":7498,"activeCount":102},[],{"trials":7500,"activeCount":102},[],{"intervention":1369,"totalTrials":184,"cells":7502},{"EARLY_PHASE1":7503,"PHASE1":7505,"PHASE2":7511,"PHASE3":7513,"PHASE4":7515,"NA":7517},{"trials":7504,"activeCount":102},[],{"trials":7506,"activeCount":184,"soonestReadout":1281},[7507],{"nctId":1360,"briefTitle":1361,"status":288,"phases":7508,"primaryCompletion":1281,"completion":1363,"start":1364,"enrollment":565,"conditions":7509,"interventions":7510},[90],[1366,1367],[1369,1124,403,1370],{"trials":7512,"activeCount":102},[],{"trials":7514,"activeCount":102},[],{"trials":7516,"activeCount":102},[],{"trials":7518,"activeCount":102},[],{"intervention":2340,"totalTrials":184,"cells":7520},{"EARLY_PHASE1":7521,"PHASE1":7523,"PHASE2":7529,"PHASE3":7531,"PHASE4":7533,"NA":7535},{"trials":7522,"activeCount":102},[],{"trials":7524,"activeCount":184,"soonestReadout":2332},[7525],{"nctId":2329,"briefTitle":2330,"status":203,"phases":7526,"primaryCompletion":2332,"completion":2333,"start":2334,"enrollment":30,"conditions":7527,"interventions":7528},[90],[2336,2324,2337,2338],[2309,2340,2341],{"trials":7530,"activeCount":102},[],{"trials":7532,"activeCount":102},[],{"trials":7534,"activeCount":102},[],{"trials":7536,"activeCount":102},[],{"intervention":2341,"totalTrials":184,"cells":7538},{"EARLY_PHASE1":7539,"PHASE1":7541,"PHASE2":7547,"PHASE3":7549,"PHASE4":7551,"NA":7553},{"trials":7540,"activeCount":102},[],{"trials":7542,"activeCount":184,"soonestReadout":2332},[7543],{"nctId":2329,"briefTitle":2330,"status":203,"phases":7544,"primaryCompletion":2332,"completion":2333,"start":2334,"enrollment":30,"conditions":7545,"interventions":7546},[90],[2336,2324,2337,2338],[2309,2340,2341],{"trials":7548,"activeCount":102},[],{"trials":7550,"activeCount":102},[],{"trials":7552,"activeCount":102},[],{"trials":7554,"activeCount":102},[],{"intervention":7556,"totalTrials":184,"cells":7557},"Zunsemetinib",{"EARLY_PHASE1":7558,"PHASE1":7560,"PHASE2":7570,"PHASE3":7572,"PHASE4":7574,"NA":7576},{"trials":7559,"activeCount":102},[],{"trials":7561,"activeCount":184,"soonestReadout":1280},[7562],{"nctId":7563,"briefTitle":7564,"status":288,"phases":7565,"primaryCompletion":1280,"completion":2464,"start":7566,"enrollment":2434,"conditions":7567,"interventions":7568},"NCT06648434","MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma",[90],"2025-06-13",[1913,29,115],[7556,7569],"mFOLFIRINOX",{"trials":7571,"activeCount":102},[],{"trials":7573,"activeCount":102},[],{"trials":7575,"activeCount":102},[],{"trials":7577,"activeCount":102},[],{"intervention":7569,"totalTrials":184,"cells":7579},{"EARLY_PHASE1":7580,"PHASE1":7582,"PHASE2":7588,"PHASE3":7590,"PHASE4":7592,"NA":7594},{"trials":7581,"activeCount":102},[],{"trials":7583,"activeCount":184,"soonestReadout":1280},[7584],{"nctId":7563,"briefTitle":7564,"status":288,"phases":7585,"primaryCompletion":1280,"completion":2464,"start":7566,"enrollment":2434,"conditions":7586,"interventions":7587},[90],[1913,29,115],[7556,7569],{"trials":7589,"activeCount":102},[],{"trials":7591,"activeCount":102},[],{"trials":7593,"activeCount":102},[],{"trials":7595,"activeCount":102},[],{"intervention":6169,"totalTrials":184,"cells":7597},{"EARLY_PHASE1":7598,"PHASE1":7600,"PHASE2":7606,"PHASE3":7608,"PHASE4":7610,"NA":7612},{"trials":7599,"activeCount":102},[],{"trials":7601,"activeCount":184,"soonestReadout":1280},[7602],{"nctId":6163,"briefTitle":6164,"status":288,"phases":7603,"primaryCompletion":1280,"completion":2091,"start":6166,"enrollment":960,"conditions":7604,"interventions":7605},[90],[24],[1229,6169],{"trials":7607,"activeCount":102},[],{"trials":7609,"activeCount":102},[],{"trials":7611,"activeCount":102},[],{"trials":7613,"activeCount":102},[],{"intervention":1230,"totalTrials":184,"cells":7615},{"EARLY_PHASE1":7616,"PHASE1":7618,"PHASE2":7624,"PHASE3":7626,"PHASE4":7628,"NA":7630},{"trials":7617,"activeCount":102},[],{"trials":7619,"activeCount":184,"soonestReadout":1224},[7620],{"nctId":1221,"briefTitle":1222,"status":853,"phases":7621,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":7622,"interventions":7623},[90],[1082],[82,426,994,1228,1229,1230,1231,1232],{"trials":7625,"activeCount":102},[],{"trials":7627,"activeCount":102},[],{"trials":7629,"activeCount":102},[],{"trials":7631,"activeCount":102},[],{"intervention":1231,"totalTrials":184,"cells":7633},{"EARLY_PHASE1":7634,"PHASE1":7636,"PHASE2":7642,"PHASE3":7644,"PHASE4":7646,"NA":7648},{"trials":7635,"activeCount":102},[],{"trials":7637,"activeCount":184,"soonestReadout":1224},[7638],{"nctId":1221,"briefTitle":1222,"status":853,"phases":7639,"primaryCompletion":1224,"completion":1225,"start":1089,"enrollment":293,"conditions":7640,"interventions":7641},[90],[1082],[82,426,994,1228,1229,1230,1231,1232],{"trials":7643,"activeCount":102},[],{"trials":7645,"activeCount":102},[],{"trials":7647,"activeCount":102},[],{"trials":7649,"activeCount":102},[],{"intervention":67,"totalTrials":184,"cells":7651},{"EARLY_PHASE1":7652,"PHASE1":7654,"PHASE2":7663,"PHASE3":7665,"PHASE4":7667,"NA":7669},{"trials":7653,"activeCount":102},[],{"trials":7655,"activeCount":184,"soonestReadout":66},[7656],{"nctId":64,"briefTitle":65,"status":203,"phases":7657,"primaryCompletion":66,"completion":7658,"start":7659,"enrollment":367,"conditions":7660,"interventions":7661},[90],"2027-09-03","2020-07-14",[1004],[67,7662],"Plasmid encoded IL-12",{"trials":7664,"activeCount":102},[],{"trials":7666,"activeCount":102},[],{"trials":7668,"activeCount":102},[],{"trials":7670,"activeCount":102},[],{"intervention":7662,"totalTrials":184,"cells":7672},{"EARLY_PHASE1":7673,"PHASE1":7675,"PHASE2":7681,"PHASE3":7683,"PHASE4":7685,"NA":7687},{"trials":7674,"activeCount":102},[],{"trials":7676,"activeCount":184,"soonestReadout":66},[7677],{"nctId":64,"briefTitle":65,"status":203,"phases":7678,"primaryCompletion":66,"completion":7658,"start":7659,"enrollment":367,"conditions":7679,"interventions":7680},[90],[1004],[67,7662],{"trials":7682,"activeCount":102},[],{"trials":7684,"activeCount":102},[],{"trials":7686,"activeCount":102},[],{"trials":7688,"activeCount":102},[],{"intervention":2639,"totalTrials":184,"cells":7690},{"EARLY_PHASE1":7691,"PHASE1":7693,"PHASE2":7699,"PHASE3":7701,"PHASE4":7703,"NA":7705},{"trials":7692,"activeCount":102},[],{"trials":7694,"activeCount":184,"soonestReadout":2634},[7695],{"nctId":2631,"briefTitle":2632,"status":203,"phases":7696,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":36,"conditions":7697,"interventions":7698},[90],[2637],[2639,372,1867],{"trials":7700,"activeCount":102},[],{"trials":7702,"activeCount":102},[],{"trials":7704,"activeCount":102},[],{"trials":7706,"activeCount":102},[],{"intervention":7708,"totalTrials":184,"cells":7709},"[18F]RO-948",{"EARLY_PHASE1":7710,"PHASE1":7712,"PHASE2":7724,"PHASE3":7726,"PHASE4":7728,"NA":7730},{"trials":7711,"activeCount":102},[],{"trials":7713,"activeCount":184,"soonestReadout":7718},[7714],{"nctId":7715,"briefTitle":7716,"status":203,"phases":7717,"primaryCompletion":7718,"completion":7718,"start":7719,"enrollment":6505,"conditions":7720,"interventions":7721},"NCT05464368","R21 Roche: 3-Way Tau Tracers in AD",[90],"2027-06","2023-02-01",[4445],[7708,7722,7723],"18F-MK6240","18F-GTP1",{"trials":7725,"activeCount":102},[],{"trials":7727,"activeCount":102},[],{"trials":7729,"activeCount":102},[],{"trials":7731,"activeCount":102},[],{"intervention":7722,"totalTrials":184,"cells":7733},{"EARLY_PHASE1":7734,"PHASE1":7736,"PHASE2":7742,"PHASE3":7744,"PHASE4":7746,"NA":7748},{"trials":7735,"activeCount":102},[],{"trials":7737,"activeCount":184,"soonestReadout":7718},[7738],{"nctId":7715,"briefTitle":7716,"status":203,"phases":7739,"primaryCompletion":7718,"completion":7718,"start":7719,"enrollment":6505,"conditions":7740,"interventions":7741},[90],[4445],[7708,7722,7723],{"trials":7743,"activeCount":102},[],{"trials":7745,"activeCount":102},[],{"trials":7747,"activeCount":102},[],{"trials":7749,"activeCount":102},[],{"intervention":7723,"totalTrials":184,"cells":7751},{"EARLY_PHASE1":7752,"PHASE1":7754,"PHASE2":7760,"PHASE3":7762,"PHASE4":7764,"NA":7766},{"trials":7753,"activeCount":102},[],{"trials":7755,"activeCount":184,"soonestReadout":7718},[7756],{"nctId":7715,"briefTitle":7716,"status":203,"phases":7757,"primaryCompletion":7718,"completion":7718,"start":7719,"enrollment":6505,"conditions":7758,"interventions":7759},[90],[4445],[7708,7722,7723],{"trials":7761,"activeCount":102},[],{"trials":7763,"activeCount":102},[],{"trials":7765,"activeCount":102},[],{"trials":7767,"activeCount":102},[],{"intervention":6812,"totalTrials":98,"cells":7769},{"EARLY_PHASE1":7770,"PHASE1":7772,"PHASE2":7789,"PHASE3":7808,"PHASE4":7810,"NA":7812},{"trials":7771,"activeCount":102},[],{"trials":7773,"activeCount":184,"soonestReadout":6803},[7774,7778],{"nctId":6800,"briefTitle":6801,"status":288,"phases":7775,"primaryCompletion":6803,"completion":6804,"start":6805,"enrollment":6806,"conditions":7776,"interventions":7777},[90],[6808,6809,6810],[6812,6793],{"nctId":7779,"briefTitle":7780,"status":137,"phases":7781,"primaryCompletion":7782,"completion":7783,"start":7784,"enrollment":2289,"conditions":7785,"interventions":7787},"NCT03386214","Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis",[90],"2021-09-12","2021-10-04","2018-04-23",[7786],"Myelofibroses",[7788,6812],"Pevonedistat",{"trials":7790,"activeCount":102},[7791,7797],{"nctId":7792,"briefTitle":7793,"status":122,"phases":7794,"primaryCompletion":6284,"completion":1588,"start":6422,"enrollment":102,"conditions":7795,"interventions":7796},"NCT04354714","Ruxolitinib to Combat COVID-19",[91],[718],[6812],{"nctId":7798,"briefTitle":7799,"status":137,"phases":7800,"primaryCompletion":7801,"completion":7802,"start":7803,"enrollment":474,"conditions":7804,"interventions":7806},"NCT04543279","Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia",[91],"2022-07-01","2022-07-30","2021-05-03",[6429,7805],"Thrombocytopenia",[7807,6812],"Fostamatinib",{"trials":7809,"activeCount":102},[],{"trials":7811,"activeCount":102},[],{"trials":7813,"activeCount":102},[7814],{"nctId":7815,"briefTitle":7816,"status":6040,"phases":7817,"conditions":7818,"interventions":7820},"NCT01730755","Ruxolitinib for Chuvash Polycythemia",[],[7819],"Erythrocytosis, Familial, 2",[6812],{"intervention":7822,"totalTrials":456,"cells":7823},"Sildenafil",{"EARLY_PHASE1":7824,"PHASE1":7834,"PHASE2":7836,"PHASE3":7838,"PHASE4":7840,"NA":7849},{"trials":7825,"activeCount":184,"soonestReadout":4466},[7826],{"nctId":7827,"briefTitle":7828,"status":853,"phases":7829,"primaryCompletion":4466,"completion":2268,"start":1141,"enrollment":1566,"conditions":7830,"interventions":7832},"NCT07039760","Asciminib With or Without Sildenafil for Brain Tumors",[89],[7831],"Brain Tumor",[7833,7822],"Asciminib",{"trials":7835,"activeCount":102},[],{"trials":7837,"activeCount":102},[],{"trials":7839,"activeCount":102},[],{"trials":7841,"activeCount":102},[7842],{"nctId":7843,"briefTitle":7844,"status":108,"phases":7845,"primaryCompletion":2288,"completion":1964,"start":6399,"enrollment":1299,"conditions":7846,"interventions":7848},"NCT01060020","Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis",[93],[7847],"Aortic Stenosis",[7822],{"trials":7850,"activeCount":102},[],{"intervention":7852,"totalTrials":456,"cells":7853},"64Cu-LLP2A",{"EARLY_PHASE1":7854,"PHASE1":7876,"PHASE2":7878,"PHASE3":7880,"PHASE4":7882,"NA":7884},{"trials":7855,"activeCount":184,"soonestReadout":2938},[7856,7868],{"nctId":7857,"briefTitle":7858,"status":288,"phases":7859,"primaryCompletion":2938,"completion":2938,"start":7860,"enrollment":383,"conditions":7861,"interventions":7867},"NCT06636175","64Cu-LLP2A for Imaging Hematologic Malignancies",[89],"2025-02-26",[24,7862,974,7863,7864,7865,7866],"Low-Grade Lymphoma","Marginal Zone Lymphoma","Lymphoplasmacytic Lymphoma","Small Lymphocytic Lymphoma","Chronic Lymphocytic Leukemia",[7852],{"nctId":7869,"briefTitle":7870,"status":137,"phases":7871,"primaryCompletion":7872,"completion":7872,"start":7873,"enrollment":340,"conditions":7874,"interventions":7875},"NCT03804424","64Cu-LLP2A for Imaging Multiple Myeloma",[89],"2021-10-01","2018-11-20",[24],[7852],{"trials":7877,"activeCount":102},[],{"trials":7879,"activeCount":102},[],{"trials":7881,"activeCount":102},[],{"trials":7883,"activeCount":102},[],{"trials":7885,"activeCount":102},[],{"intervention":1990,"totalTrials":184,"cells":7887},{"EARLY_PHASE1":7888,"PHASE1":7894,"PHASE2":7896,"PHASE3":7898,"PHASE4":7900,"NA":7902},{"trials":7889,"activeCount":184,"soonestReadout":1012},[7890],{"nctId":1983,"briefTitle":1984,"status":288,"phases":7891,"primaryCompletion":1012,"completion":1986,"start":1987,"enrollment":1566,"conditions":7892,"interventions":7893},[89],[1004],[1990,1151],{"trials":7895,"activeCount":102},[],{"trials":7897,"activeCount":102},[],{"trials":7899,"activeCount":102},[],{"trials":7901,"activeCount":102},[],{"trials":7903,"activeCount":102},[],{"intervention":7905,"totalTrials":184,"cells":7906},"JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous",{"EARLY_PHASE1":7907,"PHASE1":7917,"PHASE2":7919,"PHASE3":7921,"PHASE4":7923,"NA":7925},{"trials":7908,"activeCount":184,"soonestReadout":290},[7909],{"nctId":7910,"briefTitle":7911,"status":203,"phases":7912,"primaryCompletion":290,"completion":175,"start":505,"enrollment":1299,"conditions":7913,"interventions":7916},"NCT06366672","Evaluating the Human Immune Response to the JYNNEOS Vaccine",[89],[7914,7915],"Vaccinia","Virus Diseases",[7905],{"trials":7918,"activeCount":102},[],{"trials":7920,"activeCount":102},[],{"trials":7922,"activeCount":102},[],{"trials":7924,"activeCount":102},[],{"trials":7926,"activeCount":102},[],{"intervention":540,"totalTrials":184,"cells":7928},{"EARLY_PHASE1":7929,"PHASE1":7935,"PHASE2":7937,"PHASE3":7939,"PHASE4":7941,"NA":7943},{"trials":7930,"activeCount":184,"soonestReadout":533},[7931],{"nctId":530,"briefTitle":531,"status":288,"phases":7932,"primaryCompletion":533,"completion":534,"start":535,"enrollment":22,"conditions":7933,"interventions":7934},[89],[537,538],[540,525],{"trials":7936,"activeCount":102},[],{"trials":7938,"activeCount":102},[],{"trials":7940,"activeCount":102},[],{"trials":7942,"activeCount":102},[],{"trials":7944,"activeCount":102},[],{"intervention":7946,"totalTrials":184,"cells":7947},"Cu-DOTA-ECL1i",{"EARLY_PHASE1":7948,"PHASE1":7958,"PHASE2":7960,"PHASE3":7962,"PHASE4":7964,"NA":7966},{"trials":7949,"activeCount":184,"soonestReadout":5036},[7950],{"nctId":7951,"briefTitle":7952,"status":288,"phases":7953,"primaryCompletion":5036,"completion":5036,"start":7954,"enrollment":142,"conditions":7955,"interventions":7957},"NCT03492762","PET Imaging CCR2 in Lung Inflammation",[89],"2018-02-27",[7956],"Lung Inflammation",[7946],{"trials":7959,"activeCount":102},[],{"trials":7961,"activeCount":102},[],{"trials":7963,"activeCount":102},[],{"trials":7965,"activeCount":102},[],{"trials":7967,"activeCount":102},[],{"intervention":7969,"totalTrials":184,"cells":7970},"Cu-64-RYM2",{"EARLY_PHASE1":7971,"PHASE1":7981,"PHASE2":7983,"PHASE3":7985,"PHASE4":7987,"NA":7989},{"trials":7972,"activeCount":184,"soonestReadout":2938},[7973],{"nctId":7974,"briefTitle":7975,"status":288,"phases":7976,"primaryCompletion":2938,"completion":2938,"start":6975,"enrollment":3305,"conditions":7977,"interventions":7979},"NCT07473102","PET Imaging of MMP Activation in AAA: Clinical Component",[89],[7978],"Abdominal Aortic Aneurysm",[7969,7980],"PET imaging using Cu-64",{"trials":7982,"activeCount":102},[],{"trials":7984,"activeCount":102},[],{"trials":7986,"activeCount":102},[],{"trials":7988,"activeCount":102},[],{"trials":7990,"activeCount":102},[],{"intervention":7980,"totalTrials":184,"cells":7992},{"EARLY_PHASE1":7993,"PHASE1":7999,"PHASE2":8001,"PHASE3":8003,"PHASE4":8005,"NA":8007},{"trials":7994,"activeCount":184,"soonestReadout":2938},[7995],{"nctId":7974,"briefTitle":7975,"status":288,"phases":7996,"primaryCompletion":2938,"completion":2938,"start":6975,"enrollment":3305,"conditions":7997,"interventions":7998},[89],[7978],[7969,7980],{"trials":8000,"activeCount":102},[],{"trials":8002,"activeCount":102},[],{"trials":8004,"activeCount":102},[],{"trials":8006,"activeCount":102},[],{"trials":8008,"activeCount":102},[],{"intervention":7833,"totalTrials":184,"cells":8010},{"EARLY_PHASE1":8011,"PHASE1":8017,"PHASE2":8019,"PHASE3":8021,"PHASE4":8023,"NA":8025},{"trials":8012,"activeCount":184,"soonestReadout":4466},[8013],{"nctId":7827,"briefTitle":7828,"status":853,"phases":8014,"primaryCompletion":4466,"completion":2268,"start":1141,"enrollment":1566,"conditions":8015,"interventions":8016},[89],[7831],[7833,7822],{"trials":8018,"activeCount":102},[],{"trials":8020,"activeCount":102},[],{"trials":8022,"activeCount":102},[],{"trials":8024,"activeCount":102},[],{"trials":8026,"activeCount":102},[],{"intervention":8028,"totalTrials":1623,"cells":8029},"Amoxicillin",{"EARLY_PHASE1":8030,"PHASE1":8032,"PHASE2":8034,"PHASE3":8036,"PHASE4":8038,"NA":8054},{"trials":8031,"activeCount":102},[],{"trials":8033,"activeCount":102},[],{"trials":8035,"activeCount":102},[],{"trials":8037,"activeCount":102},[],{"trials":8039,"activeCount":102},[8040],{"nctId":8041,"briefTitle":8042,"status":108,"phases":8043,"primaryCompletion":8044,"completion":1965,"start":1648,"enrollment":8045,"conditions":8046,"interventions":8049},"NCT00377403","Treatment of Acute Sinusitis",[93],"2009-05",172,[8047,8048],"Acute Respiratory Infections","Acute Rhinosinusitis",[163,8028,8050,8051,8052,8053],"Dextromethorphan hydrobromide with guaifenesin","Guaifenesin","Pseudoephedrine Sustained Action","Saline spray",{"trials":8055,"activeCount":456,"soonestReadout":4117},[8056,8070,8078,8087,8096,8103],{"nctId":8057,"briefTitle":8058,"status":288,"phases":8059,"primaryCompletion":8060,"completion":8060,"start":8061,"enrollment":8062,"conditions":8063,"interventions":8068},"NCT06869850","Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition",[94],"2027-12-01","2025-09-22",1600,[8064,8065,8066,8067],"Severe Acute Malnutrition","Cognitive Impairment","Kwashiorkor","Severe Wasting",[8028,8069],"Sulfadoxine",{"nctId":8071,"briefTitle":8072,"status":108,"phases":8073,"primaryCompletion":8074,"completion":8074,"start":1550,"enrollment":8075,"conditions":8076,"interventions":8077},"NCT03094247","Feeding Malnourished Children Different Types of Fatty Acids to Promote Neurocognitive Development",[94],"2021-03-23",2897,[8064],[8028],{"nctId":8079,"briefTitle":8080,"status":108,"phases":8081,"primaryCompletion":3555,"completion":3555,"start":364,"enrollment":8082,"conditions":8083,"interventions":8085},"NCT01000298","Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition",[94],2700,[8066,8084],"Marasmus",[8028,8086],"Cefdinir",{"nctId":8088,"briefTitle":8089,"status":288,"phases":8090,"primaryCompletion":4117,"completion":4117,"start":8091,"enrollment":8092,"conditions":8093,"interventions":8095},"NCT06154174","Choline to Improve Malnutrition and Enhance Cognition",[94],"2023-12-05",1500,[8064,8065,8094,8066],"Wasting",[8028],{"nctId":8097,"briefTitle":8098,"status":108,"phases":8099,"primaryCompletion":3302,"completion":3302,"start":3020,"enrollment":8100,"conditions":8101,"interventions":8102},"NCT02053857","Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition",[94],141,[8066,8084],[8028],{"nctId":8104,"briefTitle":8105,"status":108,"phases":8106,"primaryCompletion":8107,"completion":8107,"start":8108,"enrollment":8109,"conditions":8110,"interventions":8112},"NCT03647150","Treatment of High-Risk Moderate Acute Malnutrition Using Expanded Admission Criteria",[94],"2020-06-05","2018-11-13",1322,[8111],"Malnutrition",[8113],"amoxicillin",{"intervention":8115,"totalTrials":456,"cells":8116},"[11C]-CS1P1",{"EARLY_PHASE1":8117,"PHASE1":8119,"PHASE2":8121,"PHASE3":8123,"PHASE4":8125,"NA":8127},{"trials":8118,"activeCount":102},[],{"trials":8120,"activeCount":102},[],{"trials":8122,"activeCount":102},[],{"trials":8124,"activeCount":102},[],{"trials":8126,"activeCount":102},[],{"trials":8128,"activeCount":456,"soonestReadout":8133},[8129,8137],{"nctId":8130,"briefTitle":8131,"status":288,"phases":8132,"primaryCompletion":8133,"completion":8133,"start":8134,"enrollment":2648,"conditions":8135,"interventions":8136},"NCT06129838","Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1",[],"2027-05","2023-05-05",[4445],[8115],{"nctId":8138,"briefTitle":8139,"status":173,"phases":8140,"primaryCompletion":1108,"completion":1012,"start":8141,"enrollment":2648,"conditions":8142,"interventions":8143},"NCT06084533","CS1P1 PET Studies of Neuroinflammation in Parkinson Disease",[],"2024-01-10",[32],[8115],{"intervention":8145,"totalTrials":456,"cells":8146},"18F-Fluselenamyl",{"EARLY_PHASE1":8147,"PHASE1":8149,"PHASE2":8151,"PHASE3":8153,"PHASE4":8155,"NA":8157},{"trials":8148,"activeCount":102},[],{"trials":8150,"activeCount":102},[],{"trials":8152,"activeCount":102},[],{"trials":8154,"activeCount":102},[],{"trials":8156,"activeCount":102},[],{"trials":8158,"activeCount":456,"soonestReadout":175},[8159,8166],{"nctId":8160,"briefTitle":8161,"status":203,"phases":8162,"primaryCompletion":175,"completion":175,"start":8163,"enrollment":2609,"conditions":8164,"interventions":8165},"NCT05731440","Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease",[],"2022-11-18",[4445],[8145],{"nctId":8167,"briefTitle":8168,"status":288,"phases":8169,"primaryCompletion":175,"completion":175,"start":8170,"enrollment":2609,"conditions":8171,"interventions":8172},"NCT06439992","Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl",[],"2023-11-07",[4445],[8145],{"intervention":8174,"totalTrials":2289,"cells":8175},"Albendazole",{"EARLY_PHASE1":8176,"PHASE1":8178,"PHASE2":8180,"PHASE3":8182,"PHASE4":8196,"NA":8198},{"trials":8177,"activeCount":102},[],{"trials":8179,"activeCount":102},[],{"trials":8181,"activeCount":102},[],{"trials":8183,"activeCount":102},[8184],{"nctId":8185,"briefTitle":8186,"status":108,"phases":8187,"primaryCompletion":8188,"completion":8188,"start":726,"enrollment":8189,"conditions":8190,"interventions":8192},"NCT04410406","Moxidectin for LF, Cote d'Ivoire (DOLF)",[92],"2024-10-01",164,[8191],"Lymphatic Filariasis",[8193,8194,8174,8195],"Ivermectin","Diethylcarbamazine","Moxidectin",{"trials":8197,"activeCount":102},[],{"trials":8199,"activeCount":184,"soonestReadout":533},[8200,8209,8216,8224,8242,8251,8264],{"nctId":8201,"briefTitle":8202,"status":108,"phases":8203,"primaryCompletion":2370,"completion":2370,"start":3321,"enrollment":8204,"conditions":8205,"interventions":8206},"NCT02351687","Package of Interventions After Recovering From Moderate Acute Malnutrition",[94],1499,[8111],[8207,8174,8208],"Sulfadoxine-pyrimethamine","Zinc",{"nctId":8210,"briefTitle":8211,"status":122,"phases":8212,"primaryCompletion":8213,"start":1464,"enrollment":102,"conditions":8214,"interventions":8215},"NCT01395381","Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition",[94],"2014-01",[8066,8084],[8174],{"nctId":8217,"briefTitle":8218,"status":108,"phases":8219,"primaryCompletion":6255,"completion":6255,"start":3009,"enrollment":8220,"conditions":8221,"interventions":8223},"NCT02253095","Combined Package of Interventions for Environmental Enteropathy",[94],253,[8222],"Environmental Enteropathy",[8174],{"nctId":8225,"briefTitle":8226,"status":108,"phases":8227,"primaryCompletion":8228,"completion":8229,"start":8230,"enrollment":8231,"conditions":8232,"interventions":8237},"NCT03079388","Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi)",[94],"2019-09-24","2020-02-24","2017-02-27",1489,[8233,8234,8235,8236],"Pregnancy","Malnutrition in Pregnancy","Nutrition Disorders","Stunting",[8238,8239,8240,8174,8241],"Monthly intermittent preventive treatment of malaria during pregnancy","Standard intermittent preventive treatment of malaria during pregnancy","Azithromycin","Bacterial vaginosis testing and treatment",{"nctId":8243,"briefTitle":8244,"status":108,"phases":8245,"primaryCompletion":8246,"completion":1351,"start":3555,"enrollment":8247,"conditions":8248,"interventions":8250},"NCT01905423","Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis",[],"2015-03",17108,[8191,8249],"Soil Transmitted Helminth Infections",[8174,8194,8174,8194],{"nctId":8252,"briefTitle":8253,"status":203,"phases":8254,"primaryCompletion":533,"completion":533,"start":8255,"enrollment":8256,"conditions":8257,"interventions":8262},"NCT05949190","Improving Cognition and Gestational Duration With Targeted Nutrition",[94],"2023-08-18",1660,[8234,8258,8259,8260,8261],"Preterm Birth","Child Development","Postpartum Depression","Antepartum Depression",[8240,8174,8263],"Sulfadoxine pyrimethamine",{"nctId":8265,"briefTitle":8266,"status":108,"phases":8267,"primaryCompletion":380,"completion":380,"start":1964,"enrollment":8268,"conditions":8269,"interventions":8271},"NCT01440608","Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy",[94],225,[8270],"Enteropathy",[8174],{"intervention":8240,"totalTrials":98,"cells":8273},{"EARLY_PHASE1":8274,"PHASE1":8276,"PHASE2":8278,"PHASE3":8287,"PHASE4":8300,"NA":8302},{"trials":8275,"activeCount":102},[],{"trials":8277,"activeCount":102},[],{"trials":8279,"activeCount":102},[8280],{"nctId":8281,"briefTitle":8282,"status":108,"phases":8283,"primaryCompletion":3321,"completion":3432,"start":380,"enrollment":506,"conditions":8284,"interventions":8286},"NCT01486758","Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis",[91],[8285],"RSV Bronchiolitis",[8240],{"trials":8288,"activeCount":102},[8289],{"nctId":8290,"briefTitle":8291,"status":137,"phases":8292,"primaryCompletion":8293,"completion":8293,"start":8294,"enrollment":293,"conditions":8295,"interventions":8297},"NCT04341727","Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",[92],"2021-04-01","2020-04-04",[8296],"Coronavirus Infection",[8298,8240,8299],"Hydroxychloroquine Sulfate","Chloroquine Sulfate",{"trials":8301,"activeCount":102},[],{"trials":8303,"activeCount":184,"soonestReadout":533},[8304,8308,8312],{"nctId":8225,"briefTitle":8226,"status":108,"phases":8305,"primaryCompletion":8228,"completion":8229,"start":8230,"enrollment":8231,"conditions":8306,"interventions":8307},[94],[8233,8234,8235,8236],[8238,8239,8240,8174,8241],{"nctId":8252,"briefTitle":8253,"status":203,"phases":8309,"primaryCompletion":533,"completion":533,"start":8255,"enrollment":8256,"conditions":8310,"interventions":8311},[94],[8234,8258,8259,8260,8261],[8240,8174,8263],{"nctId":8313,"briefTitle":8314,"status":108,"phases":8315,"primaryCompletion":8316,"completion":8316,"start":1996,"enrollment":1299,"conditions":8317,"interventions":8320},"NCT03098485","Healthy Patients & Effect of Antibiotics",[94],"2022-08-30",[8318,8319],"Microbiota","Anti-bacterial Agents",[8321,8240,8322],"Levofloxacin","Cefpodoxime",{"intervention":8324,"totalTrials":474,"cells":8325},"Metformin",{"EARLY_PHASE1":8326,"PHASE1":8328,"PHASE2":8330,"PHASE3":8332,"PHASE4":8334,"NA":8345},{"trials":8327,"activeCount":102},[],{"trials":8329,"activeCount":102},[],{"trials":8331,"activeCount":102},[],{"trials":8333,"activeCount":102},[],{"trials":8335,"activeCount":102},[8336],{"nctId":8337,"briefTitle":8338,"status":108,"phases":8339,"primaryCompletion":2287,"completion":2287,"start":8340,"enrollment":8341,"conditions":8342,"interventions":8343},"NCT00834652","Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight",[93],"2007-09",206,[21],[8344,8324],"Sertraline",{"trials":8346,"activeCount":184,"soonestReadout":984},[8347,8357],{"nctId":8348,"briefTitle":8349,"status":853,"phases":8350,"primaryCompletion":984,"completion":1259,"start":8351,"enrollment":8352,"conditions":8353,"interventions":8355},"NCT07589387","Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3",[94],"2026-05-01",2800,[8354],"Diabete Mellitus",[8324,8356],"Glimepiride",{"nctId":8358,"briefTitle":8359,"status":108,"phases":8360,"primaryCompletion":1441,"completion":1873,"start":8361,"enrollment":8362,"conditions":8363,"interventions":8365},"NCT00577590","Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM",[94],"2003-10",78,[8364],"Diabetes Mellitus, Type II",[8324,8366,8367],"Rosiglitazone","Lovaza",{"intervention":8263,"totalTrials":456,"cells":8369},{"EARLY_PHASE1":8370,"PHASE1":8372,"PHASE2":8374,"PHASE3":8376,"PHASE4":8378,"NA":8380},{"trials":8371,"activeCount":102},[],{"trials":8373,"activeCount":102},[],{"trials":8375,"activeCount":102},[],{"trials":8377,"activeCount":102},[],{"trials":8379,"activeCount":102},[],{"trials":8381,"activeCount":184,"soonestReadout":533},[8382,8393],{"nctId":8383,"briefTitle":8384,"status":108,"phases":8385,"primaryCompletion":8386,"completion":8386,"start":8387,"enrollment":8388,"conditions":8389,"interventions":8392},"NCT06002438","Eggs for Gut Health",[94],"2024-12-19","2023-10-09",461,[8390,8236,8391,8064],"Moderate Acute Malnutrition","Environmental Enteric Dysfunction",[8263],{"nctId":8252,"briefTitle":8253,"status":203,"phases":8394,"primaryCompletion":533,"completion":533,"start":8255,"enrollment":8256,"conditions":8395,"interventions":8396},[94],[8234,8258,8259,8260,8261],[8240,8174,8263],{"intervention":8398,"totalTrials":456,"cells":8399},"Semaglutide",{"EARLY_PHASE1":8400,"PHASE1":8402,"PHASE2":8404,"PHASE3":8415,"PHASE4":8417,"NA":8419},{"trials":8401,"activeCount":102},[],{"trials":8403,"activeCount":102},[],{"trials":8405,"activeCount":102},[8406],{"nctId":8407,"briefTitle":8408,"status":122,"phases":8409,"primaryCompletion":1419,"completion":8410,"start":8411,"enrollment":102,"conditions":8412,"interventions":8413},"NCT05829460","Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia",[91],"2032-04-30","2025-03-12",[4316],[8398,8414],"LNG-IUD",{"trials":8416,"activeCount":102},[],{"trials":8418,"activeCount":102},[],{"trials":8420,"activeCount":184,"soonestReadout":5773},[8421],{"nctId":8422,"briefTitle":8423,"status":288,"phases":8424,"primaryCompletion":5773,"completion":8425,"start":6649,"enrollment":506,"conditions":8426,"interventions":8428},"NCT07091500","Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity",[94],"2029-08-01",[15,8427],"Skeletal Muscle",[8398],{"intervention":8430,"totalTrials":184,"cells":8431},"50\u002F50 Mixture of Lidocaine 1% injection + Bupivacaine 0.25% Injectable Solution",{"EARLY_PHASE1":8432,"PHASE1":8434,"PHASE2":8436,"PHASE3":8438,"PHASE4":8440,"NA":8442},{"trials":8433,"activeCount":102},[],{"trials":8435,"activeCount":102},[],{"trials":8437,"activeCount":102},[],{"trials":8439,"activeCount":102},[],{"trials":8441,"activeCount":102},[],{"trials":8443,"activeCount":184,"soonestReadout":206},[8444],{"nctId":8445,"briefTitle":8446,"status":288,"phases":8447,"primaryCompletion":206,"completion":176,"start":8448,"enrollment":3684,"conditions":8449,"interventions":8451},"NCT07322445","Multi-modal Imaging of Myofascial Pain - Phase 2",[94],"2025-10-01",[8450],"Myofascial Pain",[8430],{"intervention":8453,"totalTrials":184,"cells":8454},"anti-CD20 MS treatment",{"EARLY_PHASE1":8455,"PHASE1":8457,"PHASE2":8459,"PHASE3":8461,"PHASE4":8463,"NA":8465},{"trials":8456,"activeCount":102},[],{"trials":8458,"activeCount":102},[],{"trials":8460,"activeCount":102},[],{"trials":8462,"activeCount":102},[],{"trials":8464,"activeCount":102},[],{"trials":8466,"activeCount":184,"soonestReadout":1280},[8467],{"nctId":8468,"briefTitle":8469,"status":288,"phases":8470,"primaryCompletion":1280,"completion":1280,"start":8471,"enrollment":208,"conditions":8472,"interventions":8474},"NCT06591429","Smoldering Inflammation in MS",[],"2024-06-19",[8473],"Multiple Sclerosis",[8453],{"intervention":8476,"totalTrials":184,"cells":8477},"[18F] FZTA",{"EARLY_PHASE1":8478,"PHASE1":8480,"PHASE2":8482,"PHASE3":8484,"PHASE4":8486,"NA":8488},{"trials":8479,"activeCount":102},[],{"trials":8481,"activeCount":102},[],{"trials":8483,"activeCount":102},[],{"trials":8485,"activeCount":102},[],{"trials":8487,"activeCount":102},[],{"trials":8489,"activeCount":184,"soonestReadout":881},[8490],{"nctId":8491,"briefTitle":8492,"status":288,"phases":8493,"primaryCompletion":881,"completion":8494,"start":8495,"enrollment":2648,"conditions":8496,"interventions":8497},"NCT07115017","This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.",[],"2029-12","2025-08-22",[8473],[8476],{"intervention":8499,"totalTrials":184,"cells":8500},"Androgen deprivation therapy",{"EARLY_PHASE1":8501,"PHASE1":8503,"PHASE2":8505,"PHASE3":8507,"PHASE4":8509,"NA":8511},{"trials":8502,"activeCount":102},[],{"trials":8504,"activeCount":102},[],{"trials":8506,"activeCount":102},[],{"trials":8508,"activeCount":102},[],{"trials":8510,"activeCount":102},[],{"trials":8512,"activeCount":184,"soonestReadout":8517},[8513],{"nctId":8514,"briefTitle":8515,"status":203,"phases":8516,"primaryCompletion":8517,"completion":8518,"start":8519,"enrollment":3305,"conditions":8520,"interventions":8522},"NCT05628363","Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer",[94],"2025-10-25","2030-07-25","2023-01-18",[2204,8521],"Cancer of the Prostate",[8499],{"intervention":8524,"totalTrials":184,"cells":8525},"Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care",{"EARLY_PHASE1":8526,"PHASE1":8528,"PHASE2":8530,"PHASE3":8532,"PHASE4":8534,"NA":8536},{"trials":8527,"activeCount":102},[],{"trials":8529,"activeCount":102},[],{"trials":8531,"activeCount":102},[],{"trials":8533,"activeCount":102},[],{"trials":8535,"activeCount":102},[],{"trials":8537,"activeCount":184,"soonestReadout":3622},[8538],{"nctId":8539,"briefTitle":8540,"status":203,"phases":8541,"primaryCompletion":3622,"completion":3861,"start":8542,"enrollment":1590,"conditions":8543,"interventions":8547},"NCT03709784","Spinraza in Adult Spinal Muscular Atrophy",[],"2018-08-16",[8544,8545,8546],"Spinal Muscular Atrophy","Spinal Muscular Atrophy Type II","Spinal Muscular Atrophy Type 3",[8524],{"intervention":8549,"totalTrials":184,"cells":8550},"Hormonal assessment",{"EARLY_PHASE1":8551,"PHASE1":8553,"PHASE2":8555,"PHASE3":8557,"PHASE4":8559,"NA":8561},{"trials":8552,"activeCount":102},[],{"trials":8554,"activeCount":102},[],{"trials":8556,"activeCount":102},[],{"trials":8558,"activeCount":102},[],{"trials":8560,"activeCount":102},[],{"trials":8562,"activeCount":184,"soonestReadout":8567},[8563],{"nctId":8564,"briefTitle":8565,"status":288,"phases":8566,"primaryCompletion":8567,"completion":4763,"start":8568,"enrollment":3556,"conditions":8569,"interventions":8572},"NCT06785129","Endometriosis and Migraine",[],"2028-01-01","2025-02-12",[8570,8571],"Migraine","Endometriosis",[8549],{"intervention":8356,"totalTrials":184,"cells":8574},{"EARLY_PHASE1":8575,"PHASE1":8577,"PHASE2":8579,"PHASE3":8581,"PHASE4":8583,"NA":8585},{"trials":8576,"activeCount":102},[],{"trials":8578,"activeCount":102},[],{"trials":8580,"activeCount":102},[],{"trials":8582,"activeCount":102},[],{"trials":8584,"activeCount":102},[],{"trials":8586,"activeCount":184,"soonestReadout":984},[8587],{"nctId":8348,"briefTitle":8349,"status":853,"phases":8588,"primaryCompletion":984,"completion":1259,"start":8351,"enrollment":8352,"conditions":8589,"interventions":8590},[94],[8354],[8324,8356],{"intervention":8069,"totalTrials":184,"cells":8592},{"EARLY_PHASE1":8593,"PHASE1":8595,"PHASE2":8597,"PHASE3":8599,"PHASE4":8601,"NA":8603},{"trials":8594,"activeCount":102},[],{"trials":8596,"activeCount":102},[],{"trials":8598,"activeCount":102},[],{"trials":8600,"activeCount":102},[],{"trials":8602,"activeCount":102},[],{"trials":8604,"activeCount":184,"soonestReadout":8060},[8605],{"nctId":8057,"briefTitle":8058,"status":288,"phases":8606,"primaryCompletion":8060,"completion":8060,"start":8061,"enrollment":8062,"conditions":8607,"interventions":8608},[94],[8064,8065,8066,8067],[8028,8069],{"intervention":8610,"totalTrials":184,"cells":8611},"10 mg glipizide ingestion",{"EARLY_PHASE1":8612,"PHASE1":8614,"PHASE2":8616,"PHASE3":8618,"PHASE4":8620,"NA":8622},{"trials":8613,"activeCount":102},[],{"trials":8615,"activeCount":102},[],{"trials":8617,"activeCount":102},[],{"trials":8619,"activeCount":102},[],{"trials":8621,"activeCount":102},[],{"trials":8623,"activeCount":184,"soonestReadout":8628},[8624],{"nctId":8625,"briefTitle":8626,"status":288,"phases":8627,"primaryCompletion":8628,"completion":905,"start":8629,"enrollment":506,"conditions":8630,"interventions":8632},"NCT06830096","Role of KATP Channel Loss in Type 2 Diabetes",[94],"2026-03-31","2025-03-07",[8631],"Obesity and Type 2 Diabetes",[8610],{"intervention":8634,"totalTrials":184,"cells":8635},"CDK4\u002F6 + Endocrine therapy",{"EARLY_PHASE1":8636,"PHASE1":8638,"PHASE2":8640,"PHASE3":8642,"PHASE4":8644,"NA":8646},{"trials":8637,"activeCount":102},[],{"trials":8639,"activeCount":102},[],{"trials":8641,"activeCount":102},[],{"trials":8643,"activeCount":102},[],{"trials":8645,"activeCount":102},[],{"trials":8647,"activeCount":184,"soonestReadout":8652},[8648],{"nctId":8649,"briefTitle":8650,"status":288,"phases":8651,"primaryCompletion":8652,"completion":8652,"start":8653,"enrollment":16,"conditions":8654,"interventions":8656},"NCT05977036","BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer",[94],"2034-09-30","2024-09-25",[1216,8655],"Unresectable Breast Cancer",[8634],{"intervention":8658,"totalTrials":184,"cells":8659},"Glecaprevir-pibrentasvir",{"EARLY_PHASE1":8660,"PHASE1":8662,"PHASE2":8664,"PHASE3":8666,"PHASE4":8668,"NA":8670},{"trials":8661,"activeCount":102},[],{"trials":8663,"activeCount":102},[],{"trials":8665,"activeCount":102},[],{"trials":8667,"activeCount":102},[],{"trials":8669,"activeCount":102},[],{"trials":8671,"activeCount":184,"soonestReadout":6918},[8672],{"nctId":8673,"briefTitle":8674,"status":288,"phases":8675,"primaryCompletion":6918,"completion":6918,"start":8676,"enrollment":1954,"conditions":8677,"interventions":8679},"NCT06367465","Feasibility and Acceptability of HCV Treatment in Pregnancy",[],"2024-02-01",[8678,912],"Hepatitis C",[8658],{"intervention":8681,"totalTrials":184,"cells":8682},"Peripheral Blood Draw",{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8689,"PHASE4":8691,"NA":8693},{"trials":8684,"activeCount":102},[],{"trials":8686,"activeCount":102},[],{"trials":8688,"activeCount":102},[],{"trials":8690,"activeCount":102},[],{"trials":8692,"activeCount":102},[],{"trials":8694,"activeCount":184,"soonestReadout":1419},[8695],{"nctId":8696,"briefTitle":8697,"status":288,"phases":8698,"primaryCompletion":1419,"completion":1419,"start":8699,"enrollment":8700,"conditions":8701,"interventions":8706},"NCT02604563","Aging, Geriatric Syndromes and Clonal Hematopoiesis",[],"2016-03-10",2000,[8702,8703,8704,8705],"Geriatrics","Aged","Geriatric Syndromes","Cardiovascular Diseases",[8681,8707],"Buccal Swab",{"intervention":8707,"totalTrials":184,"cells":8709},{"EARLY_PHASE1":8710,"PHASE1":8712,"PHASE2":8714,"PHASE3":8716,"PHASE4":8718,"NA":8720},{"trials":8711,"activeCount":102},[],{"trials":8713,"activeCount":102},[],{"trials":8715,"activeCount":102},[],{"trials":8717,"activeCount":102},[],{"trials":8719,"activeCount":102},[],{"trials":8721,"activeCount":184,"soonestReadout":1419},[8722],{"nctId":8696,"briefTitle":8697,"status":288,"phases":8723,"primaryCompletion":1419,"completion":1419,"start":8699,"enrollment":8700,"conditions":8724,"interventions":8725},[],[8702,8703,8704,8705],[8681,8707],{"intervention":8727,"totalTrials":184,"cells":8728},"Continue Oxytocin",{"EARLY_PHASE1":8729,"PHASE1":8731,"PHASE2":8733,"PHASE3":8735,"PHASE4":8737,"NA":8739},{"trials":8730,"activeCount":102},[],{"trials":8732,"activeCount":102},[],{"trials":8734,"activeCount":102},[],{"trials":8736,"activeCount":102},[],{"trials":8738,"activeCount":102},[],{"trials":8740,"activeCount":184,"soonestReadout":8745},[8741],{"nctId":8742,"briefTitle":8743,"status":288,"phases":8744,"primaryCompletion":8745,"completion":2118,"start":7801,"enrollment":8746,"conditions":8747,"interventions":8749},"NCT04303702","The Role of Oxytocin in the Second Stage of Labor",[94],"2027-06-01",400,[8748],"Labor Complication",[8727],{"intervention":8751,"totalTrials":184,"cells":8752},"Carbon Dioxide",{"EARLY_PHASE1":8753,"PHASE1":8755,"PHASE2":8757,"PHASE3":8759,"PHASE4":8761,"NA":8763},{"trials":8754,"activeCount":102},[],{"trials":8756,"activeCount":102},[],{"trials":8758,"activeCount":102},[],{"trials":8760,"activeCount":102},[],{"trials":8762,"activeCount":102},[],{"trials":8764,"activeCount":184,"soonestReadout":8628},[8765],{"nctId":8766,"briefTitle":8767,"status":288,"phases":8768,"primaryCompletion":8628,"completion":8628,"start":1538,"enrollment":3556,"conditions":8769,"interventions":8773},"NCT04406818","Metabolic and Hemodynamic Reserve in Pediatric SCA",[94],[8770,8771,2572,8772],"Child, Only","Brain Diseases","Anemia, Sickle Cell",[8751],{"intervention":8775,"totalTrials":184,"cells":8776},"F 18 T807",{"EARLY_PHASE1":8777,"PHASE1":8779,"PHASE2":8781,"PHASE3":8783,"PHASE4":8785,"NA":8787},{"trials":8778,"activeCount":102},[],{"trials":8780,"activeCount":102},[],{"trials":8782,"activeCount":102},[],{"trials":8784,"activeCount":102},[],{"trials":8786,"activeCount":102},[],{"trials":8788,"activeCount":184,"soonestReadout":8793},[8789],{"nctId":8790,"briefTitle":8791,"status":173,"phases":8792,"primaryCompletion":8793,"completion":8793,"start":8794,"enrollment":8795,"conditions":8796,"interventions":8797},"NCT02414178","F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)",[],"2026-01","2021-03-01",130,[4445],[8775],{"intervention":8799,"totalTrials":184,"cells":8800},"64Cu-25%-CANF-Comb",{"EARLY_PHASE1":8801,"PHASE1":8803,"PHASE2":8805,"PHASE3":8807,"PHASE4":8809,"NA":8811},{"trials":8802,"activeCount":102},[],{"trials":8804,"activeCount":102},[],{"trials":8806,"activeCount":102},[],{"trials":8808,"activeCount":102},[],{"trials":8810,"activeCount":102},[],{"trials":8812,"activeCount":184,"soonestReadout":1196},[8813],{"nctId":8814,"briefTitle":8815,"status":288,"phases":8816,"primaryCompletion":1196,"completion":1196,"start":8817,"enrollment":2648,"conditions":8818,"interventions":8821},"NCT05838547","CANF-Comb-II PET-MR in Atherosclerosis Multisite",[],"2023-03-21",[7212,8819,8820],"Asymptomatic Carotid Artery Stenosis","Carotid Artery Atheroma",[8799,8799],{"intervention":8823,"totalTrials":184,"cells":8824},"Cancer Personalized Profiling",{"EARLY_PHASE1":8825,"PHASE1":8827,"PHASE2":8829,"PHASE3":8831,"PHASE4":8833,"NA":8835},{"trials":8826,"activeCount":102},[],{"trials":8828,"activeCount":102},[],{"trials":8830,"activeCount":102},[],{"trials":8832,"activeCount":102},[],{"trials":8834,"activeCount":102},[],{"trials":8836,"activeCount":184,"soonestReadout":1787},[8837],{"nctId":8838,"briefTitle":8839,"status":288,"phases":8840,"primaryCompletion":1787,"completion":1787,"start":8841,"enrollment":506,"conditions":8842,"interventions":8843},"NCT05281731","Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma",[94],"2022-04-18",[1004,2023],[8823],{"intervention":1073,"totalTrials":98,"cells":8845},{"EARLY_PHASE1":8846,"PHASE1":8848,"PHASE2":8862,"PHASE3":8872,"PHASE4":8874,"NA":8880},{"trials":8847,"activeCount":102},[],{"trials":8849,"activeCount":102},[8850,8858],{"nctId":8851,"briefTitle":8852,"status":137,"phases":8853,"primaryCompletion":8854,"completion":8855,"start":2568,"enrollment":1080,"conditions":8856,"interventions":8857},"NCT04083898","Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma",[90],"2023-03-13","2024-03-07",[24],[3058,3174,1073],{"nctId":1062,"briefTitle":1063,"status":108,"phases":8859,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1056,"conditions":8860,"interventions":8861},[90],[1069],[1071,959,1072,1073],{"trials":8863,"activeCount":102},[8864,8868],{"nctId":2579,"briefTitle":2580,"status":108,"phases":8865,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":27,"conditions":8866,"interventions":8867},[91],[2585,2586],[2588,2376,2589,2561,2590,1073],{"nctId":6185,"briefTitle":6186,"status":108,"phases":8869,"primaryCompletion":3432,"completion":6188,"start":1952,"enrollment":1056,"conditions":8870,"interventions":8871},[90,91],[6190],[2446,2424,6192,1228,1073,1229,6193],{"trials":8873,"activeCount":102},[],{"trials":8875,"activeCount":102},[8876],{"nctId":3099,"briefTitle":3100,"status":108,"phases":8877,"primaryCompletion":3102,"completion":3102,"start":3103,"enrollment":3104,"conditions":8878,"interventions":8879},[93],[3106],[1073,1849],{"trials":8881,"activeCount":102},[],{"intervention":8883,"totalTrials":474,"cells":8884},"Tadalafil",{"EARLY_PHASE1":8885,"PHASE1":8887,"PHASE2":8900,"PHASE3":8902,"PHASE4":8904,"NA":8921},{"trials":8886,"activeCount":102},[],{"trials":8888,"activeCount":102},[8889],{"nctId":8890,"briefTitle":8891,"status":108,"phases":8892,"primaryCompletion":8893,"completion":8893,"start":8894,"enrollment":1056,"conditions":8895,"interventions":8899},"NCT04757662","Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma",[90],"2023-06-07","2021-05-14",[8896,8897,2024,8898],"Grade III Astrocytoma","Grade IV Astrocytoma","Astrocytoma, Grade III",[8883],{"trials":8901,"activeCount":102},[],{"trials":8903,"activeCount":102},[],{"trials":8905,"activeCount":102},[8906,8914],{"nctId":8907,"briefTitle":8908,"status":137,"phases":8909,"primaryCompletion":8910,"completion":8910,"start":490,"enrollment":340,"conditions":8911,"interventions":8913},"NCT01275339","Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study",[93],"2017-04-14",[7847,8912],"LV Remodeling, Hypertrophy",[8883],{"nctId":8915,"briefTitle":8916,"status":137,"phases":8917,"primaryCompletion":1573,"completion":3281,"start":8918,"enrollment":184,"conditions":8919,"interventions":8920},"NCT01272388","Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study",[93],"2011-01",[7847],[8883],{"trials":8922,"activeCount":102},[],{"intervention":163,"totalTrials":474,"cells":8924},{"EARLY_PHASE1":8925,"PHASE1":8927,"PHASE2":8929,"PHASE3":8949,"PHASE4":8951,"NA":8957},{"trials":8926,"activeCount":102},[],{"trials":8928,"activeCount":102},[],{"trials":8930,"activeCount":102},[8931,8945],{"nctId":8932,"briefTitle":8933,"status":108,"phases":8934,"primaryCompletion":8935,"completion":4701,"start":8936,"enrollment":8937,"conditions":8938,"interventions":8941},"NCT03978767","Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial",[91],"2025-07-31","2019-06-10",287,[8939,8940],"Preeclampsia Severe","Preeclampsia Postpartum",[8942,8943,163,8944],"Ibuprofen 600 mg","Ketorolac","Oxycodone",{"nctId":151,"briefTitle":152,"status":108,"phases":8946,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":8947,"interventions":8948},[91],[18,158,159],[97,161,162,163,164,165],{"trials":8950,"activeCount":102},[],{"trials":8952,"activeCount":102},[8953],{"nctId":8041,"briefTitle":8042,"status":108,"phases":8954,"primaryCompletion":8044,"completion":1965,"start":1648,"enrollment":8045,"conditions":8955,"interventions":8956},[93],[8047,8048],[163,8028,8050,8051,8052,8053],{"trials":8958,"activeCount":102},[],{"intervention":8960,"totalTrials":474,"cells":8961},"Everolimus",{"EARLY_PHASE1":8962,"PHASE1":8964,"PHASE2":8966,"PHASE3":8986,"PHASE4":8988,"NA":9001},{"trials":8963,"activeCount":102},[],{"trials":8965,"activeCount":102},[],{"trials":8967,"activeCount":102},[8968,8977],{"nctId":8969,"briefTitle":8970,"status":137,"phases":8971,"primaryCompletion":8972,"completion":8972,"start":8973,"enrollment":112,"conditions":8974,"interventions":8975},"NCT01784861","VEGFR\u002FPDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors",[90,91],"2020-08-19","2013-05-03",[2502,1875],[8976,8960],"X-82",{"nctId":8978,"briefTitle":8979,"status":108,"phases":8980,"primaryCompletion":8981,"completion":8981,"start":8982,"enrollment":1566,"conditions":8983,"interventions":8985},"NCT02352844","Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations",[91],"2017-08-15","2015-10-07",[8984,1030],"Solid Malignancy",[8960],{"trials":8987,"activeCount":102},[],{"trials":8989,"activeCount":102},[8990],{"nctId":8991,"briefTitle":8992,"status":137,"phases":8993,"primaryCompletion":8994,"completion":8994,"start":8995,"enrollment":184,"conditions":8996,"interventions":8999},"NCT02974686","Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation",[93],"2019-09","2016-11",[8997,8998],"Kidney Transplant Rejection","Gastrointestinal Disorder, Functional",[8960,9000],"Mycophenolic Acid",{"trials":9002,"activeCount":102},[],{"intervention":9004,"totalTrials":474,"cells":9005},"Sitagliptin",{"EARLY_PHASE1":9006,"PHASE1":9008,"PHASE2":9010,"PHASE3":9012,"PHASE4":9028,"NA":9039},{"trials":9007,"activeCount":102},[],{"trials":9009,"activeCount":102},[],{"trials":9011,"activeCount":102},[],{"trials":9013,"activeCount":102},[9014,9020],{"nctId":9015,"briefTitle":9016,"status":108,"phases":9017,"primaryCompletion":3102,"completion":3021,"start":1647,"enrollment":1299,"conditions":9018,"interventions":9019},"NCT01093651","Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV",[91,92],[953,6120],[9004],{"nctId":9021,"briefTitle":9022,"status":108,"phases":9023,"primaryCompletion":3009,"completion":2452,"start":9024,"enrollment":6505,"conditions":9025,"interventions":9027},"NCT01552694","Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation",[92],"2012-10",[2194,9026,6122],"Macrophage Infiltration",[9004],{"trials":9029,"activeCount":102},[9030],{"nctId":9031,"briefTitle":9032,"status":108,"phases":9033,"primaryCompletion":9034,"completion":9035,"start":3345,"enrollment":1911,"conditions":9036,"interventions":9038},"NCT01928199","Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant",[93],"2020-06","2020-10",[9037],"Posttransplant Diabetes Mellitus",[9004],{"trials":9040,"activeCount":102},[],{"intervention":3185,"totalTrials":474,"cells":9042},{"EARLY_PHASE1":9043,"PHASE1":9045,"PHASE2":9051,"PHASE3":9057,"PHASE4":9059,"NA":9069},{"trials":9044,"activeCount":102},[],{"trials":9046,"activeCount":102},[9047],{"nctId":3176,"briefTitle":3177,"status":108,"phases":9048,"primaryCompletion":3179,"completion":1441,"start":3180,"enrollment":1310,"conditions":9049,"interventions":9050},[90],[3182],[3184,3185,2425,3186,3187],{"trials":9052,"activeCount":102},[9053],{"nctId":3226,"briefTitle":3227,"status":108,"phases":9054,"primaryCompletion":3229,"completion":3229,"start":3230,"enrollment":506,"conditions":9055,"interventions":9056},[90,91],[2389],[3069,3185,2612,2425],{"trials":9058,"activeCount":102},[],{"trials":9060,"activeCount":102},[9061],{"nctId":9062,"briefTitle":9063,"status":108,"phases":9064,"primaryCompletion":9065,"completion":9065,"start":3487,"enrollment":2678,"conditions":9066,"interventions":9068},"NCT03963375","Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis",[93],"2025-05-27",[8473,9067],"Multiple Sclerosis, Relapsing-Remitting",[3185],{"trials":9070,"activeCount":102},[],{"intervention":9072,"totalTrials":456,"cells":9073},"Budesonide",{"EARLY_PHASE1":9074,"PHASE1":9076,"PHASE2":9078,"PHASE3":9089,"PHASE4":9091,"NA":9105},{"trials":9075,"activeCount":102},[],{"trials":9077,"activeCount":102},[],{"trials":9079,"activeCount":102},[9080],{"nctId":9081,"briefTitle":9082,"status":122,"phases":9083,"primaryCompletion":9084,"completion":9085,"start":3840,"enrollment":102,"conditions":9086,"interventions":9088},"NCT04422275","Coronavirus Smell Therapy for Anosmia Recovery",[91],"2023-06-01","2023-12-31",[9087],"Anosmia",[9072],{"trials":9090,"activeCount":102},[],{"trials":9092,"activeCount":102},[9093],{"nctId":9094,"briefTitle":9095,"status":108,"phases":9096,"primaryCompletion":9097,"completion":9097,"start":9098,"enrollment":2648,"conditions":9099,"interventions":9103},"NCT02696850","The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis",[93],"2017-04-13","2016-01-01",[9100,9101,9102],"Rhinosinusitis","Chronic Eosinophilic Rhinosinusitis","Allergic Rhinosinusitis",[9072,9104],"Saline alone",{"trials":9106,"activeCount":102},[],{"intervention":9108,"totalTrials":456,"cells":9109},"Placebos",{"EARLY_PHASE1":9110,"PHASE1":9112,"PHASE2":9126,"PHASE3":9128,"PHASE4":9130,"NA":9141},{"trials":9111,"activeCount":102},[],{"trials":9113,"activeCount":102},[9114],{"nctId":9115,"briefTitle":9116,"status":108,"phases":9117,"primaryCompletion":9118,"completion":9119,"start":9120,"enrollment":3305,"conditions":9121,"interventions":9124},"NCT03014830","Alirocumab and Reverse Cholesterol Transport",[90],"2018-06-04","2018-07-30","2017-06-01",[9122,9123],"Atherosclerosis","Coronary Heart Disease",[9125,9108],"Alirocumab",{"trials":9127,"activeCount":102},[],{"trials":9129,"activeCount":102},[],{"trials":9131,"activeCount":102},[9132],{"nctId":9133,"briefTitle":9134,"status":137,"phases":9135,"primaryCompletion":3622,"completion":3622,"start":9136,"enrollment":1080,"conditions":9137,"interventions":9139},"NCT03893318","IV Lidocaine in Pediatric AIS",[93],"2019-07-30",[9138],"Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery",[9140,9108],"IV lidocaine",{"trials":9142,"activeCount":102},[],{"intervention":9144,"totalTrials":456,"cells":9145},"Mifepristone",{"EARLY_PHASE1":9146,"PHASE1":9148,"PHASE2":9150,"PHASE3":9159,"PHASE4":9161,"NA":9180},{"trials":9147,"activeCount":102},[],{"trials":9149,"activeCount":102},[],{"trials":9151,"activeCount":102},[9152],{"nctId":9153,"briefTitle":9154,"status":108,"phases":9155,"primaryCompletion":2646,"completion":2646,"start":1873,"enrollment":1080,"conditions":9156,"interventions":9158},"NCT01333098","Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders",[90,91],[9157],"Anxiety Disorders",[9144],{"trials":9160,"activeCount":102},[],{"trials":9162,"activeCount":102},[9163],{"nctId":9164,"briefTitle":9165,"status":108,"phases":9166,"primaryCompletion":9167,"completion":9168,"start":7801,"enrollment":293,"conditions":9169,"interventions":9178},"NCT05322252","Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial",[93],"2025-06-14","2025-07-14",[9170,9171,9172,9173,9174,9175,9176,9177,912],"Abortion, Second Trimester","PPROM","Rupture, Spontaneous","Fetal Demise","Fetal Death","Fetal Demise From Miscarriage","Fetal Death Before 22 Weeks With Retention of Dead Fetus","Pregnancy Loss",[9144,9179],"Misoprostol",{"trials":9181,"activeCount":102},[],{"intervention":9183,"totalTrials":456,"cells":9184},"Regadenoson",{"EARLY_PHASE1":9185,"PHASE1":9195,"PHASE2":9197,"PHASE3":9199,"PHASE4":9201,"NA":9209},{"trials":9186,"activeCount":102},[9187],{"nctId":9188,"briefTitle":9189,"status":108,"phases":9190,"primaryCompletion":380,"completion":380,"start":9191,"enrollment":1954,"conditions":9192,"interventions":9194},"NCT00881218","Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson",[89],"2009-06",[9193],"Ischemic Heart Disease",[9183],{"trials":9196,"activeCount":102},[],{"trials":9198,"activeCount":102},[],{"trials":9200,"activeCount":102},[],{"trials":9202,"activeCount":102},[9203],{"nctId":9204,"briefTitle":9205,"status":108,"phases":9206,"primaryCompletion":1734,"completion":1734,"start":1464,"enrollment":960,"conditions":9207,"interventions":9208},"NCT01779869","Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson",[93],[9193],[9183],{"trials":9210,"activeCount":102},[],{"intervention":8193,"totalTrials":456,"cells":9212},{"EARLY_PHASE1":9213,"PHASE1":9215,"PHASE2":9217,"PHASE3":9219,"PHASE4":9225,"NA":9236},{"trials":9214,"activeCount":102},[],{"trials":9216,"activeCount":102},[],{"trials":9218,"activeCount":102},[],{"trials":9220,"activeCount":102},[9221],{"nctId":8185,"briefTitle":8186,"status":108,"phases":9222,"primaryCompletion":8188,"completion":8188,"start":726,"enrollment":8189,"conditions":9223,"interventions":9224},[92],[8191],[8193,8194,8174,8195],{"trials":9226,"activeCount":102},[9227],{"nctId":9228,"briefTitle":9229,"status":108,"phases":9230,"primaryCompletion":9231,"completion":124,"start":9232,"enrollment":6806,"conditions":9233,"interventions":9235},"NCT05085665","Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events",[93],"2021-08-31","2021-07-30",[9234],"Loiasis",[8193],{"trials":9237,"activeCount":102},[],{"intervention":9239,"totalTrials":456,"cells":9240},"Eplerenone",{"EARLY_PHASE1":9241,"PHASE1":9243,"PHASE2":9245,"PHASE3":9247,"PHASE4":9249,"NA":9266},{"trials":9242,"activeCount":102},[],{"trials":9244,"activeCount":102},[],{"trials":9246,"activeCount":102},[],{"trials":9248,"activeCount":102},[],{"trials":9250,"activeCount":102},[9251,9260],{"nctId":9252,"briefTitle":9253,"status":137,"phases":9254,"primaryCompletion":6539,"completion":2370,"start":2442,"enrollment":442,"conditions":9255,"interventions":9259},"NCT01971593","The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease",[93],[9256,9257,9258],"Tetralogy of Fallot","Transposition of the Great Vessels With an Arterial Switch","Single Ventricle With a Fontan Palliation",[9239],{"nctId":9261,"briefTitle":9262,"status":122,"phases":9263,"primaryCompletion":2452,"completion":1734,"start":380,"enrollment":102,"conditions":9264,"interventions":9265},"NCT01275352","CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression",[93],[6123],[9239],{"trials":9267,"activeCount":102},[],{"intervention":9269,"totalTrials":456,"cells":9270},"Paricalcitol",{"EARLY_PHASE1":9271,"PHASE1":9273,"PHASE2":9283,"PHASE3":9285,"PHASE4":9287,"NA":9298},{"trials":9272,"activeCount":102},[],{"trials":9274,"activeCount":102},[9275],{"nctId":9276,"briefTitle":9277,"status":108,"phases":9278,"primaryCompletion":8074,"completion":9279,"start":9280,"enrollment":1299,"conditions":9281,"interventions":9282},"NCT03883919","Liposomal Irinotecan Plus 5-FU \u002F LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy",[90],"2022-07-02","2019-07-11",[29,116,115],[414,373,1264,9269],{"trials":9284,"activeCount":102},[],{"trials":9286,"activeCount":102},[],{"trials":9288,"activeCount":102},[9289],{"nctId":9290,"briefTitle":9291,"status":108,"phases":9292,"primaryCompletion":2287,"completion":3345,"start":1431,"enrollment":142,"conditions":9293,"interventions":9296},"NCT00823303","Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3\u002F4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)",[93],[9294,9295],"Secondary Hyperparathyroidism","Chronic Kidney Disease",[9269,9297],"Calcitriol",{"trials":9299,"activeCount":102},[],{"intervention":9301,"totalTrials":184,"cells":9302},"Vortioxetine 10 mg",{"EARLY_PHASE1":9303,"PHASE1":9305,"PHASE2":9307,"PHASE3":9309,"PHASE4":9311,"NA":9323},{"trials":9304,"activeCount":102},[],{"trials":9306,"activeCount":102},[],{"trials":9308,"activeCount":102},[],{"trials":9310,"activeCount":102},[],{"trials":9312,"activeCount":102},[9313],{"nctId":9314,"briefTitle":9315,"status":108,"phases":9316,"primaryCompletion":9317,"completion":9317,"start":9318,"enrollment":9319,"conditions":9320,"interventions":9322},"NCT03272711","Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training",[93],"2019-01-24","2016-08-31",129,[9321],"Age-related Cognitive Decline",[9301],{"trials":9324,"activeCount":102},[],{"intervention":9104,"totalTrials":184,"cells":9326},{"EARLY_PHASE1":9327,"PHASE1":9329,"PHASE2":9331,"PHASE3":9333,"PHASE4":9335,"NA":9341},{"trials":9328,"activeCount":102},[],{"trials":9330,"activeCount":102},[],{"trials":9332,"activeCount":102},[],{"trials":9334,"activeCount":102},[],{"trials":9336,"activeCount":102},[9337],{"nctId":9094,"briefTitle":9095,"status":108,"phases":9338,"primaryCompletion":9097,"completion":9097,"start":9098,"enrollment":2648,"conditions":9339,"interventions":9340},[93],[9100,9101,9102],[9072,9104],{"trials":9342,"activeCount":102},[],{"intervention":9140,"totalTrials":184,"cells":9344},{"EARLY_PHASE1":9345,"PHASE1":9347,"PHASE2":9349,"PHASE3":9351,"PHASE4":9353,"NA":9359},{"trials":9346,"activeCount":102},[],{"trials":9348,"activeCount":102},[],{"trials":9350,"activeCount":102},[],{"trials":9352,"activeCount":102},[],{"trials":9354,"activeCount":102},[9355],{"nctId":9133,"briefTitle":9134,"status":137,"phases":9356,"primaryCompletion":3622,"completion":3622,"start":9136,"enrollment":1080,"conditions":9357,"interventions":9358},[93],[9138],[9140,9108],{"trials":9360,"activeCount":102},[],{"intervention":8050,"totalTrials":184,"cells":9362},{"EARLY_PHASE1":9363,"PHASE1":9365,"PHASE2":9367,"PHASE3":9369,"PHASE4":9371,"NA":9377},{"trials":9364,"activeCount":102},[],{"trials":9366,"activeCount":102},[],{"trials":9368,"activeCount":102},[],{"trials":9370,"activeCount":102},[],{"trials":9372,"activeCount":102},[9373],{"nctId":8041,"briefTitle":8042,"status":108,"phases":9374,"primaryCompletion":8044,"completion":1965,"start":1648,"enrollment":8045,"conditions":9375,"interventions":9376},[93],[8047,8048],[163,8028,8050,8051,8052,8053],{"trials":9378,"activeCount":102},[],{"intervention":8051,"totalTrials":184,"cells":9380},{"EARLY_PHASE1":9381,"PHASE1":9383,"PHASE2":9385,"PHASE3":9387,"PHASE4":9389,"NA":9395},{"trials":9382,"activeCount":102},[],{"trials":9384,"activeCount":102},[],{"trials":9386,"activeCount":102},[],{"trials":9388,"activeCount":102},[],{"trials":9390,"activeCount":102},[9391],{"nctId":8041,"briefTitle":8042,"status":108,"phases":9392,"primaryCompletion":8044,"completion":1965,"start":1648,"enrollment":8045,"conditions":9393,"interventions":9394},[93],[8047,8048],[163,8028,8050,8051,8052,8053],{"trials":9396,"activeCount":102},[],{"intervention":8052,"totalTrials":184,"cells":9398},{"EARLY_PHASE1":9399,"PHASE1":9401,"PHASE2":9403,"PHASE3":9405,"PHASE4":9407,"NA":9413},{"trials":9400,"activeCount":102},[],{"trials":9402,"activeCount":102},[],{"trials":9404,"activeCount":102},[],{"trials":9406,"activeCount":102},[],{"trials":9408,"activeCount":102},[9409],{"nctId":8041,"briefTitle":8042,"status":108,"phases":9410,"primaryCompletion":8044,"completion":1965,"start":1648,"enrollment":8045,"conditions":9411,"interventions":9412},[93],[8047,8048],[163,8028,8050,8051,8052,8053],{"trials":9414,"activeCount":102},[],{"intervention":8053,"totalTrials":184,"cells":9416},{"EARLY_PHASE1":9417,"PHASE1":9419,"PHASE2":9421,"PHASE3":9423,"PHASE4":9425,"NA":9431},{"trials":9418,"activeCount":102},[],{"trials":9420,"activeCount":102},[],{"trials":9422,"activeCount":102},[],{"trials":9424,"activeCount":102},[],{"trials":9426,"activeCount":102},[9427],{"nctId":8041,"briefTitle":8042,"status":108,"phases":9428,"primaryCompletion":8044,"completion":1965,"start":1648,"enrollment":8045,"conditions":9429,"interventions":9430},[93],[8047,8048],[163,8028,8050,8051,8052,8053],{"trials":9432,"activeCount":102},[],{"intervention":9434,"totalTrials":184,"cells":9435},"metoprolol",{"EARLY_PHASE1":9436,"PHASE1":9438,"PHASE2":9440,"PHASE3":9442,"PHASE4":9444,"NA":9457},{"trials":9437,"activeCount":102},[],{"trials":9439,"activeCount":102},[],{"trials":9441,"activeCount":102},[],{"trials":9443,"activeCount":102},[],{"trials":9445,"activeCount":102},[9446],{"nctId":9447,"briefTitle":9448,"status":108,"phases":9449,"primaryCompletion":9450,"completion":9451,"start":3010,"enrollment":2234,"conditions":9452,"interventions":9456},"NCT02746575","Pilot - Peri-operative Beta Blockade",[93],"2016-10","2017-10",[9453,9454,9455],"Adrenergic Beta-Receptor Blockader","Troponin Levels","Cardiomyopathy, Post-surgical",[9434],{"trials":9458,"activeCount":102},[],{"intervention":9460,"totalTrials":184,"cells":9461},"Vedolizumab 300 MG Injection [Entyvio]",{"EARLY_PHASE1":9462,"PHASE1":9464,"PHASE2":9466,"PHASE3":9468,"PHASE4":9470,"NA":9482},{"trials":9463,"activeCount":102},[],{"trials":9465,"activeCount":102},[],{"trials":9467,"activeCount":102},[],{"trials":9469,"activeCount":102},[],{"trials":9471,"activeCount":102},[9472],{"nctId":9473,"briefTitle":9474,"status":108,"phases":9475,"primaryCompletion":9476,"completion":9477,"start":9478,"enrollment":565,"conditions":9479,"interventions":9481},"NCT03142321","Defining Predictors of RT Response to Vedolizumab in IBD",[93],"2024-05-22","2024-10-28","2018-06-08",[9480],"Crohn Disease of Small Intestine",[9460],{"trials":9483,"activeCount":102},[],{"intervention":9485,"totalTrials":184,"cells":9486},"Dimethyl Fumarate",{"EARLY_PHASE1":9487,"PHASE1":9489,"PHASE2":9491,"PHASE3":9493,"PHASE4":9495,"NA":9503},{"trials":9488,"activeCount":102},[],{"trials":9490,"activeCount":102},[],{"trials":9492,"activeCount":102},[],{"trials":9494,"activeCount":102},[],{"trials":9496,"activeCount":102},[9497],{"nctId":9498,"briefTitle":9499,"status":122,"phases":9500,"primaryCompletion":6188,"completion":6188,"start":6188,"enrollment":102,"conditions":9501,"interventions":9502},"NCT02675413","Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS",[93],[8473,9067],[9485],{"trials":9504,"activeCount":102},[],{"intervention":9506,"totalTrials":184,"cells":9507},"Bupropion XL 300",{"EARLY_PHASE1":9508,"PHASE1":9510,"PHASE2":9512,"PHASE3":9514,"PHASE4":9516,"NA":9526},{"trials":9509,"activeCount":102},[],{"trials":9511,"activeCount":102},[],{"trials":9513,"activeCount":102},[],{"trials":9515,"activeCount":102},[],{"trials":9517,"activeCount":102},[9518],{"nctId":9519,"briefTitle":9520,"status":108,"phases":9521,"primaryCompletion":9522,"completion":9522,"start":9523,"enrollment":421,"conditions":9524,"interventions":9525},"NCT02209597","Clinical Study of Generic and Brand Bupropion in Depression",[93],"2016-08-14","2014-06-25",[3865],[9506],{"trials":9527,"activeCount":102},[],{"intervention":9529,"totalTrials":184,"cells":9530},"Aripiprazole Augmentation",{"EARLY_PHASE1":9531,"PHASE1":9533,"PHASE2":9535,"PHASE3":9537,"PHASE4":9539,"NA":9557},{"trials":9532,"activeCount":102},[],{"trials":9534,"activeCount":102},[],{"trials":9536,"activeCount":102},[],{"trials":9538,"activeCount":102},[],{"trials":9540,"activeCount":102},[9541],{"nctId":9542,"briefTitle":9543,"status":108,"phases":9544,"primaryCompletion":9545,"completion":1621,"start":9546,"enrollment":9547,"conditions":9548,"interventions":9552},"NCT02960763","Optimizing Outcomes of Treatment-Resistant Depression in Older Adults",[93],"2020-09-28","2017-02-24",742,[4000,3865,9549,9550,9551],"Treatment-Refractory Depression","Late Life Depression","Geriatric Depression",[9529,9553,9554,9555,9556],"Bupropion Augmentation","Switch to bupropion","Lithium Augmentation","Switch to nortriptyline",{"trials":9558,"activeCount":102},[],{"intervention":9553,"totalTrials":184,"cells":9560},{"EARLY_PHASE1":9561,"PHASE1":9563,"PHASE2":9565,"PHASE3":9567,"PHASE4":9569,"NA":9575},{"trials":9562,"activeCount":102},[],{"trials":9564,"activeCount":102},[],{"trials":9566,"activeCount":102},[],{"trials":9568,"activeCount":102},[],{"trials":9570,"activeCount":102},[9571],{"nctId":9542,"briefTitle":9543,"status":108,"phases":9572,"primaryCompletion":9545,"completion":1621,"start":9546,"enrollment":9547,"conditions":9573,"interventions":9574},[93],[4000,3865,9549,9550,9551],[9529,9553,9554,9555,9556],{"trials":9576,"activeCount":102},[],{"intervention":9554,"totalTrials":184,"cells":9578},{"EARLY_PHASE1":9579,"PHASE1":9581,"PHASE2":9583,"PHASE3":9585,"PHASE4":9587,"NA":9593},{"trials":9580,"activeCount":102},[],{"trials":9582,"activeCount":102},[],{"trials":9584,"activeCount":102},[],{"trials":9586,"activeCount":102},[],{"trials":9588,"activeCount":102},[9589],{"nctId":9542,"briefTitle":9543,"status":108,"phases":9590,"primaryCompletion":9545,"completion":1621,"start":9546,"enrollment":9547,"conditions":9591,"interventions":9592},[93],[4000,3865,9549,9550,9551],[9529,9553,9554,9555,9556],{"trials":9594,"activeCount":102},[],{"intervention":9555,"totalTrials":184,"cells":9596},{"EARLY_PHASE1":9597,"PHASE1":9599,"PHASE2":9601,"PHASE3":9603,"PHASE4":9605,"NA":9611},{"trials":9598,"activeCount":102},[],{"trials":9600,"activeCount":102},[],{"trials":9602,"activeCount":102},[],{"trials":9604,"activeCount":102},[],{"trials":9606,"activeCount":102},[9607],{"nctId":9542,"briefTitle":9543,"status":108,"phases":9608,"primaryCompletion":9545,"completion":1621,"start":9546,"enrollment":9547,"conditions":9609,"interventions":9610},[93],[4000,3865,9549,9550,9551],[9529,9553,9554,9555,9556],{"trials":9612,"activeCount":102},[],{"intervention":9556,"totalTrials":184,"cells":9614},{"EARLY_PHASE1":9615,"PHASE1":9617,"PHASE2":9619,"PHASE3":9621,"PHASE4":9623,"NA":9629},{"trials":9616,"activeCount":102},[],{"trials":9618,"activeCount":102},[],{"trials":9620,"activeCount":102},[],{"trials":9622,"activeCount":102},[],{"trials":9624,"activeCount":102},[9625],{"nctId":9542,"briefTitle":9543,"status":108,"phases":9626,"primaryCompletion":9545,"completion":1621,"start":9546,"enrollment":9547,"conditions":9627,"interventions":9628},[93],[4000,3865,9549,9550,9551],[9529,9553,9554,9555,9556],{"trials":9630,"activeCount":102},[],{"intervention":9632,"totalTrials":184,"cells":9633},"Infliximab",{"EARLY_PHASE1":9634,"PHASE1":9636,"PHASE2":9638,"PHASE3":9640,"PHASE4":9642,"NA":9653},{"trials":9635,"activeCount":102},[],{"trials":9637,"activeCount":102},[],{"trials":9639,"activeCount":102},[],{"trials":9641,"activeCount":102},[],{"trials":9643,"activeCount":102},[9644],{"nctId":9645,"briefTitle":9646,"status":108,"phases":9647,"primaryCompletion":9648,"completion":9648,"start":9649,"enrollment":394,"conditions":9650,"interventions":9652},"NCT05340764","Safety of Reduced Infliximab Infusion Time",[93],"2023-05-04","2020-08-01",[9651],"Inflammatory Bowel Diseases",[9632],{"trials":9654,"activeCount":102},[],{"intervention":9656,"totalTrials":184,"cells":9657},"Lidocaine 1% Injectable Solution",{"EARLY_PHASE1":9658,"PHASE1":9660,"PHASE2":9662,"PHASE3":9664,"PHASE4":9666,"NA":9679},{"trials":9659,"activeCount":102},[],{"trials":9661,"activeCount":102},[],{"trials":9663,"activeCount":102},[],{"trials":9665,"activeCount":102},[],{"trials":9667,"activeCount":102},[9668],{"nctId":9669,"briefTitle":9670,"status":122,"phases":9671,"primaryCompletion":9672,"completion":9672,"start":9673,"enrollment":102,"conditions":9674,"interventions":9678},"NCT04359017","Systemic Absorption of Lidocaine After Hematoma Block",[93],"2023-12-01","2020-11-01",[9675,9676,130,9677],"Radius Fracture Distal","Hematoma","Pediatrics",[9656],{"trials":9680,"activeCount":102},[],{"intervention":9682,"totalTrials":184,"cells":9683},"regional anesthesia and PAI",{"EARLY_PHASE1":9684,"PHASE1":9686,"PHASE2":9688,"PHASE3":9690,"PHASE4":9692,"NA":9705},{"trials":9685,"activeCount":102},[],{"trials":9687,"activeCount":102},[],{"trials":9689,"activeCount":102},[],{"trials":9691,"activeCount":102},[],{"trials":9693,"activeCount":102},[9694],{"nctId":9695,"briefTitle":9696,"status":108,"phases":9697,"primaryCompletion":9698,"completion":9698,"start":9699,"enrollment":9700,"conditions":9701,"interventions":9703},"NCT06410612","Block and Periarticular Injection Study",[93],"2025-05-12","2024-03-04",174,[9702],"Pain, Postoperative",[9682,9704],"PAI",{"trials":9706,"activeCount":102},[],{"intervention":9704,"totalTrials":184,"cells":9708},{"EARLY_PHASE1":9709,"PHASE1":9711,"PHASE2":9713,"PHASE3":9715,"PHASE4":9717,"NA":9723},{"trials":9710,"activeCount":102},[],{"trials":9712,"activeCount":102},[],{"trials":9714,"activeCount":102},[],{"trials":9716,"activeCount":102},[],{"trials":9718,"activeCount":102},[9719],{"nctId":9695,"briefTitle":9696,"status":108,"phases":9720,"primaryCompletion":9698,"completion":9698,"start":9699,"enrollment":9700,"conditions":9721,"interventions":9722},[93],[9702],[9682,9704],{"trials":9724,"activeCount":102},[],{"intervention":9726,"totalTrials":184,"cells":9727},"Acthar",{"EARLY_PHASE1":9728,"PHASE1":9730,"PHASE2":9732,"PHASE3":9734,"PHASE4":9736,"NA":9746},{"trials":9729,"activeCount":102},[],{"trials":9731,"activeCount":102},[],{"trials":9733,"activeCount":102},[],{"trials":9735,"activeCount":102},[],{"trials":9737,"activeCount":102},[9738],{"nctId":9739,"briefTitle":9740,"status":137,"phases":9741,"primaryCompletion":9742,"completion":9742,"start":2370,"enrollment":456,"conditions":9743,"interventions":9745},"NCT02769702","Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis",[93],"2017-01-06",[9744],"Uveitis",[9726],{"trials":9747,"activeCount":102},[],{"intervention":9749,"totalTrials":184,"cells":9750},"Efavirenz 600mg",{"EARLY_PHASE1":9751,"PHASE1":9753,"PHASE2":9755,"PHASE3":9757,"PHASE4":9759,"NA":9770},{"trials":9752,"activeCount":102},[],{"trials":9754,"activeCount":102},[],{"trials":9756,"activeCount":102},[],{"trials":9758,"activeCount":102},[],{"trials":9760,"activeCount":102},[9761],{"nctId":9762,"briefTitle":9763,"status":108,"phases":9764,"primaryCompletion":9765,"completion":9765,"start":9766,"enrollment":1623,"conditions":9767,"interventions":9769},"NCT07193875","Efavirenz (EFV) Intensification",[93],"2024-12-16","2023-02-09",[9768],"HIV",[9749],{"trials":9771,"activeCount":102},[],{"intervention":9297,"totalTrials":184,"cells":9773},{"EARLY_PHASE1":9774,"PHASE1":9776,"PHASE2":9778,"PHASE3":9780,"PHASE4":9782,"NA":9788},{"trials":9775,"activeCount":102},[],{"trials":9777,"activeCount":102},[],{"trials":9779,"activeCount":102},[],{"trials":9781,"activeCount":102},[],{"trials":9783,"activeCount":102},[9784],{"nctId":9290,"briefTitle":9291,"status":108,"phases":9785,"primaryCompletion":2287,"completion":3345,"start":1431,"enrollment":142,"conditions":9786,"interventions":9787},[93],[9294,9295],[9269,9297],{"trials":9789,"activeCount":102},[],{"intervention":9791,"totalTrials":184,"cells":9792},"Fidaxomicin",{"EARLY_PHASE1":9793,"PHASE1":9795,"PHASE2":9797,"PHASE3":9799,"PHASE4":9801,"NA":9810},{"trials":9794,"activeCount":102},[],{"trials":9796,"activeCount":102},[],{"trials":9798,"activeCount":102},[],{"trials":9800,"activeCount":102},[],{"trials":9802,"activeCount":102},[9803],{"nctId":9804,"briefTitle":9805,"status":122,"phases":9806,"primaryCompletion":2443,"completion":2443,"start":1873,"enrollment":102,"conditions":9807,"interventions":9809},"NCT01552668","Fidaxomicin to Prevent Clostridium Difficile Colonization",[93],[9808],"Clostridium Difficile Infection",[9791],{"trials":9811,"activeCount":102},[],{"intervention":9813,"totalTrials":184,"cells":9814},"Oral Vancomycin",{"EARLY_PHASE1":9815,"PHASE1":9817,"PHASE2":9819,"PHASE3":9821,"PHASE4":9823,"NA":9834},{"trials":9816,"activeCount":102},[],{"trials":9818,"activeCount":102},[],{"trials":9820,"activeCount":102},[],{"trials":9822,"activeCount":102},[],{"trials":9824,"activeCount":102},[9825],{"nctId":9826,"briefTitle":9827,"status":108,"phases":9828,"primaryCompletion":9829,"completion":9829,"start":9830,"enrollment":1080,"conditions":9831,"interventions":9833},"NCT03388268","TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment",[93],"2021-01-31","2017-12-29",[9808,9832],"Diarrhea",[9813],{"trials":9835,"activeCount":102},[],{"intervention":9837,"totalTrials":184,"cells":9838},"Caffeine citrate",{"EARLY_PHASE1":9839,"PHASE1":9841,"PHASE2":9843,"PHASE3":9845,"PHASE4":9847,"NA":9858},{"trials":9840,"activeCount":102},[],{"trials":9842,"activeCount":102},[],{"trials":9844,"activeCount":102},[],{"trials":9846,"activeCount":102},[],{"trials":9848,"activeCount":102},[9849],{"nctId":9850,"briefTitle":9851,"status":108,"phases":9852,"primaryCompletion":1963,"completion":1351,"start":3346,"enrollment":421,"conditions":9853,"interventions":9857},"NCT00809055","MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine",[93],[9854,9855,9856],"Apnea of Prematurity","Intraventricular Hemorrhage","Brain Injury",[9837],{"trials":9859,"activeCount":102},[],{"intervention":9000,"totalTrials":184,"cells":9861},{"EARLY_PHASE1":9862,"PHASE1":9864,"PHASE2":9866,"PHASE3":9868,"PHASE4":9870,"NA":9876},{"trials":9863,"activeCount":102},[],{"trials":9865,"activeCount":102},[],{"trials":9867,"activeCount":102},[],{"trials":9869,"activeCount":102},[],{"trials":9871,"activeCount":102},[9872],{"nctId":8991,"briefTitle":8992,"status":137,"phases":9873,"primaryCompletion":8994,"completion":8994,"start":8995,"enrollment":184,"conditions":9874,"interventions":9875},[93],[8997,8998],[8960,9000],{"trials":9877,"activeCount":102},[],{"intervention":9879,"totalTrials":184,"cells":9880},"Assess AAA rupture risk by PET-CTA scans",{"EARLY_PHASE1":9881,"PHASE1":9883,"PHASE2":9885,"PHASE3":9887,"PHASE4":9889,"NA":9900},{"trials":9882,"activeCount":102},[],{"trials":9884,"activeCount":102},[],{"trials":9886,"activeCount":102},[],{"trials":9888,"activeCount":102},[],{"trials":9890,"activeCount":102},[9891],{"nctId":9892,"briefTitle":9893,"status":137,"phases":9894,"primaryCompletion":9895,"completion":9895,"start":2420,"enrollment":456,"conditions":9896,"interventions":9898},"NCT03231397","Predictors of AAA Expansion and\u002For Rupture",[93],"2020-04-30",[9897],"Abdominal Aortic Aneurysm (AAA)",[9879,9899],"18F-fludeoxyglucose",{"trials":9901,"activeCount":102},[],{"intervention":9899,"totalTrials":184,"cells":9903},{"EARLY_PHASE1":9904,"PHASE1":9906,"PHASE2":9908,"PHASE3":9910,"PHASE4":9912,"NA":9918},{"trials":9905,"activeCount":102},[],{"trials":9907,"activeCount":102},[],{"trials":9909,"activeCount":102},[],{"trials":9911,"activeCount":102},[],{"trials":9913,"activeCount":102},[9914],{"nctId":9892,"briefTitle":9893,"status":137,"phases":9915,"primaryCompletion":9895,"completion":9895,"start":2420,"enrollment":456,"conditions":9916,"interventions":9917},[93],[9897],[9879,9899],{"trials":9919,"activeCount":102},[],{"intervention":9921,"totalTrials":184,"cells":9922},"hand mixed vancomycin",{"EARLY_PHASE1":9923,"PHASE1":9925,"PHASE2":9927,"PHASE3":9929,"PHASE4":9931,"NA":9943},{"trials":9924,"activeCount":102},[],{"trials":9926,"activeCount":102},[],{"trials":9928,"activeCount":102},[],{"trials":9930,"activeCount":102},[],{"trials":9932,"activeCount":102},[9933],{"nctId":9934,"briefTitle":9935,"status":108,"phases":9936,"primaryCompletion":9937,"completion":9937,"start":9938,"enrollment":2609,"conditions":9939,"interventions":9941},"NCT03928522","Antibiotic Elution in Total Knee Arthroplasty",[93],"2019-09-30","2019-01-28",[9940],"Total Knee Replacement",[9921,9942],"hand mixed tobramycin",{"trials":9944,"activeCount":102},[],{"intervention":9942,"totalTrials":184,"cells":9946},{"EARLY_PHASE1":9947,"PHASE1":9949,"PHASE2":9951,"PHASE3":9953,"PHASE4":9955,"NA":9961},{"trials":9948,"activeCount":102},[],{"trials":9950,"activeCount":102},[],{"trials":9952,"activeCount":102},[],{"trials":9954,"activeCount":102},[],{"trials":9956,"activeCount":102},[9957],{"nctId":9934,"briefTitle":9935,"status":108,"phases":9958,"primaryCompletion":9937,"completion":9937,"start":9938,"enrollment":2609,"conditions":9959,"interventions":9960},[93],[9940],[9921,9942],{"trials":9962,"activeCount":102},[],{"intervention":9964,"totalTrials":184,"cells":9965},"Cardioplegia Solution",{"EARLY_PHASE1":9966,"PHASE1":9968,"PHASE2":9970,"PHASE3":9972,"PHASE4":9974,"NA":9988},{"trials":9967,"activeCount":102},[],{"trials":9969,"activeCount":102},[],{"trials":9971,"activeCount":102},[],{"trials":9973,"activeCount":102},[],{"trials":9975,"activeCount":102},[9976],{"nctId":9977,"briefTitle":9978,"status":108,"phases":9979,"primaryCompletion":9084,"completion":9980,"start":9981,"enrollment":9982,"conditions":9983,"interventions":9986},"NCT05076604","Effects of Microplegia on Transfusion Rates After Cardiac Surgery",[93],"2023-08-01","2019-03-25",314,[9984,9985],"Aortic Valve Disease","Mitral Valve Disease",[9964,9987],"Microplegic Solution No. 1",{"trials":9989,"activeCount":102},[],{"intervention":9987,"totalTrials":184,"cells":9991},{"EARLY_PHASE1":9992,"PHASE1":9994,"PHASE2":9996,"PHASE3":9998,"PHASE4":10000,"NA":10006},{"trials":9993,"activeCount":102},[],{"trials":9995,"activeCount":102},[],{"trials":9997,"activeCount":102},[],{"trials":9999,"activeCount":102},[],{"trials":10001,"activeCount":102},[10002],{"nctId":9977,"briefTitle":9978,"status":108,"phases":10003,"primaryCompletion":9084,"completion":9980,"start":9981,"enrollment":9982,"conditions":10004,"interventions":10005},[93],[9984,9985],[9964,9987],{"trials":10007,"activeCount":102},[],{"intervention":10009,"totalTrials":184,"cells":10010},"Methenamine Hippurate 1000 MG",{"EARLY_PHASE1":10011,"PHASE1":10013,"PHASE2":10015,"PHASE3":10017,"PHASE4":10019,"NA":10033},{"trials":10012,"activeCount":102},[],{"trials":10014,"activeCount":102},[],{"trials":10016,"activeCount":102},[],{"trials":10018,"activeCount":102},[],{"trials":10020,"activeCount":102},[10021],{"nctId":10022,"briefTitle":10023,"status":122,"phases":10024,"primaryCompletion":10025,"completion":10025,"start":10026,"enrollment":102,"conditions":10027,"interventions":10031},"NCT03996057","Methenamine in a Non-antibiotic, Multimodal Approach to UTI Prevention",[93],"2022-02-11","2018-06-20",[10028,10029,10030],"UTI","Female Urogenital Diseases","UTI - Lower Urinary Tract Infection",[10009,10032],"Vaginal estrogen",{"trials":10034,"activeCount":102},[],{"intervention":10032,"totalTrials":184,"cells":10036},{"EARLY_PHASE1":10037,"PHASE1":10039,"PHASE2":10041,"PHASE3":10043,"PHASE4":10045,"NA":10051},{"trials":10038,"activeCount":102},[],{"trials":10040,"activeCount":102},[],{"trials":10042,"activeCount":102},[],{"trials":10044,"activeCount":102},[],{"trials":10046,"activeCount":102},[10047],{"nctId":10022,"briefTitle":10023,"status":122,"phases":10048,"primaryCompletion":10025,"completion":10025,"start":10026,"enrollment":102,"conditions":10049,"interventions":10050},[93],[10028,10029,10030],[10009,10032],{"trials":10052,"activeCount":102},[],{"intervention":10054,"totalTrials":184,"cells":10055},"Tobramycin Powder",{"EARLY_PHASE1":10056,"PHASE1":10058,"PHASE2":10060,"PHASE3":10062,"PHASE4":10064,"NA":10073},{"trials":10057,"activeCount":102},[],{"trials":10059,"activeCount":102},[],{"trials":10061,"activeCount":102},[],{"trials":10063,"activeCount":102},[],{"trials":10065,"activeCount":102},[10066],{"nctId":10067,"briefTitle":10068,"status":108,"phases":10069,"primaryCompletion":9649,"completion":9673,"start":3721,"enrollment":1299,"conditions":10070,"interventions":10072},"NCT04297631","Intraarticular Antibiotic in TKA",[93],[10071],"Antibotics in Cementless Knees",[10054],{"trials":10074,"activeCount":102},[],{"intervention":10076,"totalTrials":184,"cells":10077},"Nitrous oxide gas for inhalation",{"EARLY_PHASE1":10078,"PHASE1":10080,"PHASE2":10082,"PHASE3":10084,"PHASE4":10086,"NA":10095},{"trials":10079,"activeCount":102},[],{"trials":10081,"activeCount":102},[],{"trials":10083,"activeCount":102},[],{"trials":10085,"activeCount":102},[],{"trials":10087,"activeCount":102},[10088],{"nctId":10089,"briefTitle":10090,"status":108,"phases":10091,"primaryCompletion":6423,"completion":552,"start":9450,"enrollment":506,"conditions":10092,"interventions":10094},"NCT03365011","Nitrous Oxide Treatment for Tinnitus",[93],[10093],"Tinnitus",[10076],{"trials":10096,"activeCount":102},[],{"intervention":10098,"totalTrials":184,"cells":10099},"Once daily immunosuppression regimen",{"EARLY_PHASE1":10100,"PHASE1":10102,"PHASE2":10104,"PHASE3":10106,"PHASE4":10108,"NA":10118},{"trials":10101,"activeCount":102},[],{"trials":10103,"activeCount":102},[],{"trials":10105,"activeCount":102},[],{"trials":10107,"activeCount":102},[],{"trials":10109,"activeCount":102},[10110],{"nctId":10111,"briefTitle":10112,"status":137,"phases":10113,"primaryCompletion":450,"completion":450,"start":9118,"enrollment":2434,"conditions":10114,"interventions":10116},"NCT03555448","Once Daily Immunosuppression Regimen",[93],[10115],"Kidney Transplant; Complications",[10098,10117],"Twice daily immunosuppression regimen",{"trials":10119,"activeCount":102},[],{"intervention":10117,"totalTrials":184,"cells":10121},{"EARLY_PHASE1":10122,"PHASE1":10124,"PHASE2":10126,"PHASE3":10128,"PHASE4":10130,"NA":10136},{"trials":10123,"activeCount":102},[],{"trials":10125,"activeCount":102},[],{"trials":10127,"activeCount":102},[],{"trials":10129,"activeCount":102},[],{"trials":10131,"activeCount":102},[10132],{"nctId":10111,"briefTitle":10112,"status":137,"phases":10133,"primaryCompletion":450,"completion":450,"start":9118,"enrollment":2434,"conditions":10134,"interventions":10135},[93],[10115],[10098,10117],{"trials":10137,"activeCount":102},[],{"intervention":10139,"totalTrials":184,"cells":10140},"Mometasone Furoate Nasal Irrigation",{"EARLY_PHASE1":10141,"PHASE1":10143,"PHASE2":10145,"PHASE3":10147,"PHASE4":10149,"NA":10161},{"trials":10142,"activeCount":102},[],{"trials":10144,"activeCount":102},[],{"trials":10146,"activeCount":102},[],{"trials":10148,"activeCount":102},[],{"trials":10150,"activeCount":102},[10151],{"nctId":10152,"briefTitle":10153,"status":108,"phases":10154,"primaryCompletion":10155,"completion":10156,"start":1524,"enrollment":1433,"conditions":10157,"interventions":10159},"NCT03705793","Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis",[93],"2020-02-15","2020-03-15",[10158,9102,9101],"Chronic Rhinosinusitis (Diagnosis)",[10139,10160],"Mometasone Nasal Spray",{"trials":10162,"activeCount":102},[],{"intervention":10160,"totalTrials":184,"cells":10164},{"EARLY_PHASE1":10165,"PHASE1":10167,"PHASE2":10169,"PHASE3":10171,"PHASE4":10173,"NA":10179},{"trials":10166,"activeCount":102},[],{"trials":10168,"activeCount":102},[],{"trials":10170,"activeCount":102},[],{"trials":10172,"activeCount":102},[],{"trials":10174,"activeCount":102},[10175],{"nctId":10152,"briefTitle":10153,"status":108,"phases":10176,"primaryCompletion":10155,"completion":10156,"start":1524,"enrollment":1433,"conditions":10177,"interventions":10178},[93],[10158,9102,9101],[10139,10160],{"trials":10180,"activeCount":102},[],{"intervention":10182,"totalTrials":184,"cells":10183},"Lidocaine 4%",{"EARLY_PHASE1":10184,"PHASE1":10186,"PHASE2":10188,"PHASE3":10190,"PHASE4":10192,"NA":10205},{"trials":10185,"activeCount":102},[],{"trials":10187,"activeCount":102},[],{"trials":10189,"activeCount":102},[],{"trials":10191,"activeCount":102},[],{"trials":10193,"activeCount":102},[10194],{"nctId":10195,"briefTitle":10196,"status":122,"phases":10197,"primaryCompletion":10198,"completion":10198,"start":10199,"enrollment":102,"conditions":10200,"interventions":10204},"NCT03181464","Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics",[93],"2019-01-30","2018-04-17",[10201,10202,10203],"Postdural Puncture Headache","Cerebrospinal Fluid Leak","Spinal; Puncture, Complications, Headache",[10182],{"trials":10206,"activeCount":102},[],{"intervention":10208,"totalTrials":184,"cells":10209},"Combination NRT",{"EARLY_PHASE1":10210,"PHASE1":10212,"PHASE2":10214,"PHASE3":10216,"PHASE4":10218,"NA":10232},{"trials":10211,"activeCount":102},[],{"trials":10213,"activeCount":102},[],{"trials":10215,"activeCount":102},[],{"trials":10217,"activeCount":102},[],{"trials":10219,"activeCount":102},[10220],{"nctId":10221,"briefTitle":10222,"status":108,"phases":10223,"primaryCompletion":10224,"completion":10225,"start":10226,"enrollment":10227,"conditions":10228,"interventions":10230},"NCT02351167","Genetically Informed Smoking Cessation Trial",[93],"2018-12-26","2019-08-31","2015-05-20",822,[10229],"Smoking Cessation",[10208,10231],"Varenicline",{"trials":10233,"activeCount":102},[],{"intervention":10231,"totalTrials":184,"cells":10235},{"EARLY_PHASE1":10236,"PHASE1":10238,"PHASE2":10240,"PHASE3":10242,"PHASE4":10244,"NA":10250},{"trials":10237,"activeCount":102},[],{"trials":10239,"activeCount":102},[],{"trials":10241,"activeCount":102},[],{"trials":10243,"activeCount":102},[],{"trials":10245,"activeCount":102},[10246],{"nctId":10221,"briefTitle":10222,"status":108,"phases":10247,"primaryCompletion":10224,"completion":10225,"start":10226,"enrollment":10227,"conditions":10248,"interventions":10249},[93],[10229],[10208,10231],{"trials":10251,"activeCount":102},[],{"intervention":10253,"totalTrials":184,"cells":10254},"FDA-approved antidepressant or antipsychotic treatment",{"EARLY_PHASE1":10255,"PHASE1":10257,"PHASE2":10259,"PHASE3":10261,"PHASE4":10263,"NA":10276},{"trials":10256,"activeCount":102},[],{"trials":10258,"activeCount":102},[],{"trials":10260,"activeCount":102},[],{"trials":10262,"activeCount":102},[],{"trials":10264,"activeCount":102},[10265],{"nctId":10266,"briefTitle":10267,"status":137,"phases":10268,"primaryCompletion":10269,"completion":10269,"start":10270,"enrollment":1131,"conditions":10271,"interventions":10275},"NCT03537547","Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder",[93],"2019-08-19","2018-05-04",[3865,21,10272,10273,10274],"Depressive Disorder","Depressive Episode","Depression, Unipolar",[10253],{"trials":10277,"activeCount":102},[],{"intervention":9179,"totalTrials":184,"cells":10279},{"EARLY_PHASE1":10280,"PHASE1":10282,"PHASE2":10284,"PHASE3":10286,"PHASE4":10288,"NA":10294},{"trials":10281,"activeCount":102},[],{"trials":10283,"activeCount":102},[],{"trials":10285,"activeCount":102},[],{"trials":10287,"activeCount":102},[],{"trials":10289,"activeCount":102},[10290],{"nctId":9164,"briefTitle":9165,"status":108,"phases":10291,"primaryCompletion":9167,"completion":9168,"start":7801,"enrollment":293,"conditions":10292,"interventions":10293},[93],[9170,9171,9172,9173,9174,9175,9176,9177,912],[9144,9179],{"trials":10295,"activeCount":102},[],{"intervention":10297,"totalTrials":184,"cells":10298},"Bupivicaine HCL",{"EARLY_PHASE1":10299,"PHASE1":10301,"PHASE2":10303,"PHASE3":10305,"PHASE4":10307,"NA":10320},{"trials":10300,"activeCount":102},[],{"trials":10302,"activeCount":102},[],{"trials":10304,"activeCount":102},[],{"trials":10306,"activeCount":102},[],{"trials":10308,"activeCount":102},[10309],{"nctId":10310,"briefTitle":10311,"status":137,"phases":10312,"primaryCompletion":10313,"completion":10314,"start":10315,"enrollment":2234,"conditions":10316,"interventions":10318},"NCT02662036","Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction",[93],"2018-02-26","2018-03-08","2016-02-29",[10317],"Mammaplasty",[10297,10319],"Liposomal bupivacaine",{"trials":10321,"activeCount":102},[],{"intervention":10319,"totalTrials":184,"cells":10323},{"EARLY_PHASE1":10324,"PHASE1":10326,"PHASE2":10328,"PHASE3":10330,"PHASE4":10332,"NA":10338},{"trials":10325,"activeCount":102},[],{"trials":10327,"activeCount":102},[],{"trials":10329,"activeCount":102},[],{"trials":10331,"activeCount":102},[],{"trials":10333,"activeCount":102},[10334],{"nctId":10310,"briefTitle":10311,"status":137,"phases":10335,"primaryCompletion":10313,"completion":10314,"start":10315,"enrollment":2234,"conditions":10336,"interventions":10337},[93],[10317],[10297,10319],{"trials":10339,"activeCount":102},[],{"intervention":10341,"totalTrials":184,"cells":10342},"SGLT2 inhibitor",{"EARLY_PHASE1":10343,"PHASE1":10345,"PHASE2":10347,"PHASE3":10349,"PHASE4":10351,"NA":10362},{"trials":10344,"activeCount":102},[],{"trials":10346,"activeCount":102},[],{"trials":10348,"activeCount":102},[],{"trials":10350,"activeCount":102},[],{"trials":10352,"activeCount":102},[10353],{"nctId":10354,"briefTitle":10355,"status":108,"phases":10356,"primaryCompletion":10357,"completion":10357,"start":10358,"enrollment":36,"conditions":10359,"interventions":10361},"NCT05541484","Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency",[93],"2023-12-23","2022-10-14",[10360],"Diabetes Mellitus, Type 1",[10341],{"trials":10363,"activeCount":102},[],{"intervention":10365,"totalTrials":184,"cells":10366},"Ambrisentan",{"EARLY_PHASE1":10367,"PHASE1":10369,"PHASE2":10371,"PHASE3":10373,"PHASE4":10375,"NA":10385},{"trials":10368,"activeCount":102},[],{"trials":10370,"activeCount":102},[],{"trials":10372,"activeCount":102},[],{"trials":10374,"activeCount":102},[],{"trials":10376,"activeCount":102},[10377],{"nctId":10378,"briefTitle":10379,"status":108,"phases":10380,"primaryCompletion":10381,"completion":10381,"start":1441,"enrollment":3305,"conditions":10382,"interventions":10384},"NCT01971580","The Effects of Ambrisentan on Exercise Capacity in Fontan Patients",[93],"2015-05",[10383],"Single Ventricle Fontan Palliation",[10365],{"trials":10386,"activeCount":102},[],{"intervention":10388,"totalTrials":184,"cells":10389},"Chlorhexidine",{"EARLY_PHASE1":10390,"PHASE1":10392,"PHASE2":10394,"PHASE3":10396,"PHASE4":10398,"NA":10413},{"trials":10391,"activeCount":102},[],{"trials":10393,"activeCount":102},[],{"trials":10395,"activeCount":102},[],{"trials":10397,"activeCount":102},[],{"trials":10399,"activeCount":102},[10400],{"nctId":10401,"briefTitle":10402,"status":108,"phases":10403,"primaryCompletion":10404,"completion":10405,"start":2677,"enrollment":10406,"conditions":10407,"interventions":10411},"NCT02572791","Staph Household Intervention for Eradication (SHINE)",[93],"2024-11","2024-12",835,[10408,10409,10410],"Skin and Subcutaneous Tissue Bacterial Infections","Staphylococcus Aureus","MRSA - Methicillin Resistant Staphylococcus Aureus Infection",[10388,10412],"Mupirocin",{"trials":10414,"activeCount":102},[],{"intervention":10412,"totalTrials":184,"cells":10416},{"EARLY_PHASE1":10417,"PHASE1":10419,"PHASE2":10421,"PHASE3":10423,"PHASE4":10425,"NA":10431},{"trials":10418,"activeCount":102},[],{"trials":10420,"activeCount":102},[],{"trials":10422,"activeCount":102},[],{"trials":10424,"activeCount":102},[],{"trials":10426,"activeCount":102},[10427],{"nctId":10401,"briefTitle":10402,"status":108,"phases":10428,"primaryCompletion":10404,"completion":10405,"start":2677,"enrollment":10406,"conditions":10429,"interventions":10430},[93],[10408,10409,10410],[10388,10412],{"trials":10432,"activeCount":102},[],{"intervention":10434,"totalTrials":184,"cells":10435},"Methadone 0.1mg\u002Fkg",{"EARLY_PHASE1":10436,"PHASE1":10438,"PHASE2":10440,"PHASE3":10442,"PHASE4":10444,"NA":10456},{"trials":10437,"activeCount":102},[],{"trials":10439,"activeCount":102},[],{"trials":10441,"activeCount":102},[],{"trials":10443,"activeCount":102},[],{"trials":10445,"activeCount":102},[10446],{"nctId":10447,"briefTitle":10448,"status":108,"phases":10449,"primaryCompletion":3555,"completion":3555,"start":8044,"enrollment":1911,"conditions":10450,"interventions":10452},"NCT00921843","Methadone in Pediatric Anesthesia",[93],[10451],"Anesthesia",[10434,10453,10454,10455],"Methadone 0.2mg\u002Fkg","Methadone 0.3mg\u002Fkg","Control",{"trials":10457,"activeCount":102},[],{"intervention":10453,"totalTrials":184,"cells":10459},{"EARLY_PHASE1":10460,"PHASE1":10462,"PHASE2":10464,"PHASE3":10466,"PHASE4":10468,"NA":10474},{"trials":10461,"activeCount":102},[],{"trials":10463,"activeCount":102},[],{"trials":10465,"activeCount":102},[],{"trials":10467,"activeCount":102},[],{"trials":10469,"activeCount":102},[10470],{"nctId":10447,"briefTitle":10448,"status":108,"phases":10471,"primaryCompletion":3555,"completion":3555,"start":8044,"enrollment":1911,"conditions":10472,"interventions":10473},[93],[10451],[10434,10453,10454,10455],{"trials":10475,"activeCount":102},[],{"intervention":10454,"totalTrials":184,"cells":10477},{"EARLY_PHASE1":10478,"PHASE1":10480,"PHASE2":10482,"PHASE3":10484,"PHASE4":10486,"NA":10492},{"trials":10479,"activeCount":102},[],{"trials":10481,"activeCount":102},[],{"trials":10483,"activeCount":102},[],{"trials":10485,"activeCount":102},[],{"trials":10487,"activeCount":102},[10488],{"nctId":10447,"briefTitle":10448,"status":108,"phases":10489,"primaryCompletion":3555,"completion":3555,"start":8044,"enrollment":1911,"conditions":10490,"interventions":10491},[93],[10451],[10434,10453,10454,10455],{"trials":10493,"activeCount":102},[],{"intervention":10495,"totalTrials":184,"cells":10496},"Spinal Anesthesia",{"EARLY_PHASE1":10497,"PHASE1":10499,"PHASE2":10501,"PHASE3":10503,"PHASE4":10505,"NA":10519},{"trials":10498,"activeCount":102},[],{"trials":10500,"activeCount":102},[],{"trials":10502,"activeCount":102},[],{"trials":10504,"activeCount":102},[],{"trials":10506,"activeCount":102},[10507],{"nctId":10508,"briefTitle":10509,"status":137,"phases":10510,"primaryCompletion":627,"completion":627,"start":10511,"enrollment":184,"conditions":10512,"interventions":10517},"NCT03940651","Cardiac and Renal Biomarkers in Arthroplasty Surgery",[93],"2019-09-04",[10513,10451,10514,10515,10516],"Renal Injury","Myocardial Injury","Arthropathy of Knee","Arthropathy of Hip",[10495,10518],"General Anesthetics",{"trials":10520,"activeCount":102},[],{"intervention":10518,"totalTrials":184,"cells":10522},{"EARLY_PHASE1":10523,"PHASE1":10525,"PHASE2":10527,"PHASE3":10529,"PHASE4":10531,"NA":10537},{"trials":10524,"activeCount":102},[],{"trials":10526,"activeCount":102},[],{"trials":10528,"activeCount":102},[],{"trials":10530,"activeCount":102},[],{"trials":10532,"activeCount":102},[10533],{"nctId":10508,"briefTitle":10509,"status":137,"phases":10534,"primaryCompletion":627,"completion":627,"start":10511,"enrollment":184,"conditions":10535,"interventions":10536},[93],[10513,10451,10514,10515,10516],[10495,10518],{"trials":10538,"activeCount":102},[],{"intervention":10540,"totalTrials":184,"cells":10541},"Memantine",{"EARLY_PHASE1":10542,"PHASE1":10544,"PHASE2":10546,"PHASE3":10548,"PHASE4":10550,"NA":10560},{"trials":10543,"activeCount":102},[],{"trials":10545,"activeCount":102},[],{"trials":10547,"activeCount":102},[],{"trials":10549,"activeCount":102},[],{"trials":10551,"activeCount":102},[10552],{"nctId":10553,"briefTitle":10554,"status":108,"phases":10555,"primaryCompletion":3103,"completion":3103,"start":10556,"enrollment":3218,"conditions":10557,"interventions":10558},"NCT00768261","Corticolimbic Degeneration and Treatment of Dementia",[93],"2004-11",[494],[10540,10559],"Donepezil",{"trials":10561,"activeCount":102},[],{"intervention":10559,"totalTrials":184,"cells":10563},{"EARLY_PHASE1":10564,"PHASE1":10566,"PHASE2":10568,"PHASE3":10570,"PHASE4":10572,"NA":10578},{"trials":10565,"activeCount":102},[],{"trials":10567,"activeCount":102},[],{"trials":10569,"activeCount":102},[],{"trials":10571,"activeCount":102},[],{"trials":10573,"activeCount":102},[10574],{"nctId":10553,"briefTitle":10554,"status":108,"phases":10575,"primaryCompletion":3103,"completion":3103,"start":10556,"enrollment":3218,"conditions":10576,"interventions":10577},[93],[494],[10540,10559],{"trials":10579,"activeCount":102},[],{"intervention":10581,"totalTrials":184,"cells":10582},"Postpartum Antibiotics",{"EARLY_PHASE1":10583,"PHASE1":10585,"PHASE2":10587,"PHASE3":10589,"PHASE4":10591,"NA":10601},{"trials":10584,"activeCount":102},[],{"trials":10586,"activeCount":102},[],{"trials":10588,"activeCount":102},[],{"trials":10590,"activeCount":102},[],{"trials":10592,"activeCount":102},[10593],{"nctId":10594,"briefTitle":10595,"status":137,"phases":10596,"primaryCompletion":3302,"completion":3302,"start":1952,"enrollment":2648,"conditions":10597,"interventions":10599},"NCT01585129","Treatment Utility of Postpartum Antibiotics in Chorioamnionitis",[93],[10598],"The Primary Outcome of This Study Will be the Rate of Endometritis",[10581,10600],"No postpartum antibiotics",{"trials":10602,"activeCount":102},[],{"intervention":10600,"totalTrials":184,"cells":10604},{"EARLY_PHASE1":10605,"PHASE1":10607,"PHASE2":10609,"PHASE3":10611,"PHASE4":10613,"NA":10619},{"trials":10606,"activeCount":102},[],{"trials":10608,"activeCount":102},[],{"trials":10610,"activeCount":102},[],{"trials":10612,"activeCount":102},[],{"trials":10614,"activeCount":102},[10615],{"nctId":10594,"briefTitle":10595,"status":137,"phases":10616,"primaryCompletion":3302,"completion":3302,"start":1952,"enrollment":2648,"conditions":10617,"interventions":10618},[93],[10598],[10581,10600],{"trials":10620,"activeCount":102},[],{"intervention":10622,"totalTrials":184,"cells":10623},"Dalbavancin",{"EARLY_PHASE1":10624,"PHASE1":10626,"PHASE2":10628,"PHASE3":10630,"PHASE4":10632,"NA":10643},{"trials":10625,"activeCount":102},[],{"trials":10627,"activeCount":102},[],{"trials":10629,"activeCount":102},[],{"trials":10631,"activeCount":102},[],{"trials":10633,"activeCount":102},[10634],{"nctId":10635,"briefTitle":10636,"status":137,"phases":10637,"primaryCompletion":10638,"completion":10638,"start":10639,"enrollment":1310,"conditions":10640,"interventions":10642},"NCT03372941","Hospital Avoidance Strategies for ABSSSI",[93],"2021-10-14","2019-03-04",[10641],"Skin Infection",[10622],{"trials":10644,"activeCount":102},[],{"intervention":10646,"totalTrials":456,"cells":10647},"DHEA",{"EARLY_PHASE1":10648,"PHASE1":10650,"PHASE2":10662,"PHASE3":10664,"PHASE4":10675,"NA":10677},{"trials":10649,"activeCount":102},[],{"trials":10651,"activeCount":102},[10652],{"nctId":10653,"briefTitle":10654,"status":137,"phases":10655,"primaryCompletion":10656,"completion":10657,"start":10658,"enrollment":1310,"conditions":10659,"interventions":10661},"NCT02683148","DHEA in Synovial Sarcoma Patients",[90],"2018-09-09","2019-04-04","2016-09-13",[6602,10660],"Sarcoma, Synovial",[10646],{"trials":10663,"activeCount":102},[],{"trials":10665,"activeCount":102},[10666],{"nctId":10667,"briefTitle":10668,"status":108,"phases":10669,"completion":10670,"start":10671,"enrollment":9,"conditions":10672,"interventions":10674},"NCT00205686","Effects of DHEA and Exercise in the Elderly",[92],"2005-09","2001-04",[10673],"Healthy Volunteers",[10646],{"trials":10676,"activeCount":102},[],{"trials":10678,"activeCount":102},[],{"intervention":10680,"totalTrials":456,"cells":10681},"Tranexamic Acid",{"EARLY_PHASE1":10682,"PHASE1":10684,"PHASE2":10686,"PHASE3":10700,"PHASE4":10709,"NA":10711},{"trials":10683,"activeCount":102},[],{"trials":10685,"activeCount":102},[],{"trials":10687,"activeCount":102},[10688],{"nctId":10689,"briefTitle":10690,"status":108,"phases":10691,"primaryCompletion":10692,"completion":10693,"start":2451,"enrollment":10694,"conditions":10695,"interventions":10699},"NCT02535949","Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury",[91],"2017-07-04","2017-07-07",150,[10696,10697,10698],"Hemorrhage","Shock","Wounds and Injuries",[10680],{"trials":10701,"activeCount":102},[10702],{"nctId":10703,"briefTitle":10704,"status":108,"phases":10705,"primaryCompletion":1883,"completion":1883,"start":7054,"enrollment":9,"conditions":10706,"interventions":10708},"NCT02053363","Tranexamic Acid Dosing in Adult Spinal Deformity Surgery",[91,92],[10707],"Adult Spinal Deformity",[10680],{"trials":10710,"activeCount":102},[],{"trials":10712,"activeCount":102},[],{"intervention":10714,"totalTrials":456,"cells":10715},"LGG",{"EARLY_PHASE1":10716,"PHASE1":10718,"PHASE2":10730,"PHASE3":10732,"PHASE4":10744,"NA":10746},{"trials":10717,"activeCount":102},[],{"trials":10719,"activeCount":102},[10720],{"nctId":10721,"briefTitle":10722,"status":137,"phases":10723,"primaryCompletion":10724,"completion":10725,"start":10726,"enrollment":112,"conditions":10727,"interventions":10729},"NCT01790035","Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer",[90],"2017-01-12","2021-12-12","2014-08-19",[10728],"Gastrointestinal Neoplasms",[10714],{"trials":10731,"activeCount":102},[],{"trials":10733,"activeCount":102},[10734],{"nctId":10735,"briefTitle":10736,"status":108,"phases":10737,"primaryCompletion":10738,"completion":10738,"start":3302,"enrollment":10739,"conditions":10740,"interventions":10742},"NCT01773967","Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis",[91,92],"2018-08",971,[10741],"Gastroenteritis",[10714,10743],"micro-crystalline cellulose",{"trials":10745,"activeCount":102},[],{"trials":10747,"activeCount":102},[],{"intervention":10749,"totalTrials":456,"cells":10750},"Lithium Carbonate",{"EARLY_PHASE1":10751,"PHASE1":10753,"PHASE2":10755,"PHASE3":10766,"PHASE4":10779,"NA":10781},{"trials":10752,"activeCount":102},[],{"trials":10754,"activeCount":102},[],{"trials":10756,"activeCount":102},[10757],{"nctId":10758,"briefTitle":10759,"status":108,"phases":10760,"primaryCompletion":10761,"completion":10762,"start":10763,"enrollment":1042,"conditions":10764,"interventions":10765},"NCT01553916","Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain",[90,91],"2016-09-12","2017-06-05","2012-04-26",[1941],[10749],{"trials":10767,"activeCount":102},[10768],{"nctId":10769,"briefTitle":10770,"status":108,"phases":10771,"primaryCompletion":3032,"completion":3032,"start":10772,"enrollment":10773,"conditions":10774,"interventions":10775},"NCT00057681","Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents",[92],"2003-02",379,[6225],[10776,10777,10778],"Lithium carbonate","Valproate","Risperidone",{"trials":10780,"activeCount":102},[],{"trials":10782,"activeCount":102},[],{"intervention":10784,"totalTrials":184,"cells":10785},"Short storage RBC age",{"EARLY_PHASE1":10786,"PHASE1":10788,"PHASE2":10790,"PHASE3":10792,"PHASE4":10802,"NA":10804},{"trials":10787,"activeCount":102},[],{"trials":10789,"activeCount":102},[],{"trials":10791,"activeCount":102},[],{"trials":10793,"activeCount":102},[10794],{"nctId":10795,"briefTitle":10796,"status":108,"phases":10797,"primaryCompletion":1350,"completion":1350,"start":8213,"enrollment":10798,"conditions":10799,"interventions":10801},"NCT01977547","Age of Blood in Children in Pediatric Intensive Care Units",[92],1538,[10800],"Anemia",[10784],{"trials":10803,"activeCount":102},[],{"trials":10805,"activeCount":102},[],{"intervention":10807,"totalTrials":184,"cells":10808},"D-Mannose",{"EARLY_PHASE1":10809,"PHASE1":10811,"PHASE2":10813,"PHASE3":10815,"PHASE4":10826,"NA":10828},{"trials":10810,"activeCount":102},[],{"trials":10812,"activeCount":102},[],{"trials":10814,"activeCount":102},[],{"trials":10816,"activeCount":102},[10817],{"nctId":10818,"briefTitle":10819,"status":137,"phases":10820,"primaryCompletion":10821,"completion":10821,"start":10822,"enrollment":1911,"conditions":10823,"interventions":10825},"NCT03395288","Nutraceutical Efficacy for rUTI",[91,92],"2020-04-25","2018-03-22",[10824],"Urinary Tract Infections",[10807],{"trials":10827,"activeCount":102},[],{"trials":10829,"activeCount":102},[],{"intervention":10831,"totalTrials":184,"cells":10832},"Pharmacogenetic",{"EARLY_PHASE1":10833,"PHASE1":10835,"PHASE2":10837,"PHASE3":10839,"PHASE4":10851,"NA":10853},{"trials":10834,"activeCount":102},[],{"trials":10836,"activeCount":102},[],{"trials":10838,"activeCount":102},[],{"trials":10840,"activeCount":102},[10841],{"nctId":10842,"briefTitle":10843,"status":108,"phases":10844,"primaryCompletion":9450,"completion":8995,"start":10845,"enrollment":10846,"conditions":10847,"interventions":10849},"NCT01006733","Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT",[92],"2011-03",1598,[10848],"Thromboembolism",[10831,10850],"Target INR 1.8",{"trials":10852,"activeCount":102},[],{"trials":10854,"activeCount":102},[],{"intervention":10850,"totalTrials":184,"cells":10856},{"EARLY_PHASE1":10857,"PHASE1":10859,"PHASE2":10861,"PHASE3":10863,"PHASE4":10869,"NA":10871},{"trials":10858,"activeCount":102},[],{"trials":10860,"activeCount":102},[],{"trials":10862,"activeCount":102},[],{"trials":10864,"activeCount":102},[10865],{"nctId":10842,"briefTitle":10843,"status":108,"phases":10866,"primaryCompletion":9450,"completion":8995,"start":10845,"enrollment":10846,"conditions":10867,"interventions":10868},[92],[10848],[10831,10850],{"trials":10870,"activeCount":102},[],{"trials":10872,"activeCount":102},[],{"intervention":10874,"totalTrials":184,"cells":10875},"Zyprexa",{"EARLY_PHASE1":10876,"PHASE1":10878,"PHASE2":10880,"PHASE3":10882,"PHASE4":10892,"NA":10894},{"trials":10877,"activeCount":102},[],{"trials":10879,"activeCount":102},[],{"trials":10881,"activeCount":102},[],{"trials":10883,"activeCount":102},[10884],{"nctId":10885,"briefTitle":10886,"status":122,"phases":10887,"primaryCompletion":1646,"completion":1646,"start":1646,"enrollment":102,"conditions":10888,"interventions":10889},"NCT00910780","Metabolic Effects of Antipsychotic Substitution in Children",[91,92],[953],[10890,10874,10891],"Aripiprazole","Risperdal",{"trials":10893,"activeCount":102},[],{"trials":10895,"activeCount":102},[],{"intervention":10891,"totalTrials":184,"cells":10897},{"EARLY_PHASE1":10898,"PHASE1":10900,"PHASE2":10902,"PHASE3":10904,"PHASE4":10910,"NA":10912},{"trials":10899,"activeCount":102},[],{"trials":10901,"activeCount":102},[],{"trials":10903,"activeCount":102},[],{"trials":10905,"activeCount":102},[10906],{"nctId":10885,"briefTitle":10886,"status":122,"phases":10907,"primaryCompletion":1646,"completion":1646,"start":1646,"enrollment":102,"conditions":10908,"interventions":10909},[91,92],[953],[10890,10874,10891],{"trials":10911,"activeCount":102},[],{"trials":10913,"activeCount":102},[],{"intervention":10915,"totalTrials":184,"cells":10916},"Topical ocular hypotensive eye drops.",{"EARLY_PHASE1":10917,"PHASE1":10919,"PHASE2":10921,"PHASE3":10923,"PHASE4":10937,"NA":10939},{"trials":10918,"activeCount":102},[],{"trials":10920,"activeCount":102},[],{"trials":10922,"activeCount":102},[],{"trials":10924,"activeCount":102},[10925],{"nctId":10926,"briefTitle":10927,"status":108,"phases":10928,"primaryCompletion":10929,"completion":10930,"start":10931,"enrollment":10932,"conditions":10933,"interventions":10936},"NCT00000125","Ocular Hypertension Treatment Study (OHTS)",[92],"2002-06","2019-06-30","1994-02",1636,[10934,10935],"Ocular Hypertension","Glaucoma",[10915],{"trials":10938,"activeCount":102},[],{"trials":10940,"activeCount":102},[],{"intervention":10942,"totalTrials":184,"cells":10943},"Desirudin",{"EARLY_PHASE1":10944,"PHASE1":10946,"PHASE2":10948,"PHASE3":10950,"PHASE4":10960,"NA":10962},{"trials":10945,"activeCount":102},[],{"trials":10947,"activeCount":102},[],{"trials":10949,"activeCount":102},[],{"trials":10951,"activeCount":102},[10952],{"nctId":10953,"briefTitle":10954,"status":108,"phases":10955,"primaryCompletion":6820,"completion":6820,"start":6116,"enrollment":3556,"conditions":10956,"interventions":10958},"NCT00329433","Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery",[91,92],[10957],"Deep Venous Thrombosis",[10942,10959],"Heparin",{"trials":10961,"activeCount":102},[],{"trials":10963,"activeCount":102},[],{"intervention":10959,"totalTrials":184,"cells":10965},{"EARLY_PHASE1":10966,"PHASE1":10968,"PHASE2":10970,"PHASE3":10972,"PHASE4":10978,"NA":10980},{"trials":10967,"activeCount":102},[],{"trials":10969,"activeCount":102},[],{"trials":10971,"activeCount":102},[],{"trials":10973,"activeCount":102},[10974],{"nctId":10953,"briefTitle":10954,"status":108,"phases":10975,"primaryCompletion":6820,"completion":6820,"start":6116,"enrollment":3556,"conditions":10976,"interventions":10977},[91,92],[10957],[10942,10959],{"trials":10979,"activeCount":102},[],{"trials":10981,"activeCount":102},[],{"intervention":10983,"totalTrials":184,"cells":10984},"0.12% chlorhexidine solution",{"EARLY_PHASE1":10985,"PHASE1":10987,"PHASE2":10989,"PHASE3":10991,"PHASE4":11002,"NA":11004},{"trials":10986,"activeCount":102},[],{"trials":10988,"activeCount":102},[],{"trials":10990,"activeCount":102},[],{"trials":10992,"activeCount":102},[10993],{"nctId":10994,"briefTitle":10995,"status":137,"phases":10996,"primaryCompletion":10997,"completion":10997,"start":10998,"enrollment":10694,"conditions":10999,"interventions":11001},"NCT01446874","Prevention of Post-operative Pneumonia (POPP)",[91,92],"2015-12-13","2011-09-22",[11000,1481,988],"Post-operative Pneumonia",[10983],{"trials":11003,"activeCount":102},[],{"trials":11005,"activeCount":102},[],{"intervention":11007,"totalTrials":184,"cells":11008},"Oral azithromycin",{"EARLY_PHASE1":11009,"PHASE1":11011,"PHASE2":11013,"PHASE3":11015,"PHASE4":11025,"NA":11027},{"trials":11010,"activeCount":102},[],{"trials":11012,"activeCount":102},[],{"trials":11014,"activeCount":102},[],{"trials":11016,"activeCount":102},[11017],{"nctId":11018,"briefTitle":11019,"status":108,"phases":11020,"primaryCompletion":11021,"completion":11021,"start":8995,"enrollment":4442,"conditions":11022,"interventions":11024},"NCT02911935","Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II",[91,92],"2021-04",[11023],"Respiratory Syncytial Virus, Bronchiolitis",[11007],{"trials":11026,"activeCount":102},[],{"trials":11028,"activeCount":102},[],{"intervention":11030,"totalTrials":184,"cells":11031},"Alternating Acetaminophen and Ibuprofen",{"EARLY_PHASE1":11032,"PHASE1":11034,"PHASE2":11036,"PHASE3":11038,"PHASE4":11050,"NA":11052},{"trials":11033,"activeCount":102},[],{"trials":11035,"activeCount":102},[],{"trials":11037,"activeCount":102},[],{"trials":11039,"activeCount":102},[11040],{"nctId":11041,"briefTitle":11042,"status":108,"phases":11043,"primaryCompletion":11044,"completion":11044,"start":9545,"enrollment":1954,"conditions":11045,"interventions":11048},"NCT04551196","Management of Post-Tonsillectomy Pain in Pediatric Patients",[92],"2022-11-10",[9702,11046,11047],"Tonsillar Hypertrophy","Tonsillitis",[11030,11049],"Combined Acetaminophen and Ibuprofen",{"trials":11051,"activeCount":102},[],{"trials":11053,"activeCount":102},[],{"intervention":11049,"totalTrials":184,"cells":11055},{"EARLY_PHASE1":11056,"PHASE1":11058,"PHASE2":11060,"PHASE3":11062,"PHASE4":11068,"NA":11070},{"trials":11057,"activeCount":102},[],{"trials":11059,"activeCount":102},[],{"trials":11061,"activeCount":102},[],{"trials":11063,"activeCount":102},[11064],{"nctId":11041,"briefTitle":11042,"status":108,"phases":11065,"primaryCompletion":11044,"completion":11044,"start":9545,"enrollment":1954,"conditions":11066,"interventions":11067},[92],[9702,11046,11047],[11030,11049],{"trials":11069,"activeCount":102},[],{"trials":11071,"activeCount":102},[],{"intervention":11073,"totalTrials":184,"cells":11074},"Ketamine 50 MG\u002FML",{"EARLY_PHASE1":11075,"PHASE1":11077,"PHASE2":11079,"PHASE3":11081,"PHASE4":11091,"NA":11093},{"trials":11076,"activeCount":102},[],{"trials":11078,"activeCount":102},[],{"trials":11080,"activeCount":102},[],{"trials":11082,"activeCount":102},[11083],{"nctId":11084,"briefTitle":11085,"status":108,"phases":11086,"primaryCompletion":11087,"completion":11087,"start":11088,"enrollment":208,"conditions":11089,"interventions":11090},"NCT04227704","Ketamine to Prevent PPD After Cesarean",[92],"2021-08-09","2020-11-12",[8260],[11073,10455],{"trials":11092,"activeCount":102},[],{"trials":11094,"activeCount":102},[],{"intervention":8195,"totalTrials":184,"cells":11096},{"EARLY_PHASE1":11097,"PHASE1":11099,"PHASE2":11101,"PHASE3":11103,"PHASE4":11109,"NA":11111},{"trials":11098,"activeCount":102},[],{"trials":11100,"activeCount":102},[],{"trials":11102,"activeCount":102},[],{"trials":11104,"activeCount":102},[11105],{"nctId":8185,"briefTitle":8186,"status":108,"phases":11106,"primaryCompletion":8188,"completion":8188,"start":726,"enrollment":8189,"conditions":11107,"interventions":11108},[92],[8191],[8193,8194,8174,8195],{"trials":11110,"activeCount":102},[],{"trials":11112,"activeCount":102},[],{"intervention":10743,"totalTrials":184,"cells":11114},{"EARLY_PHASE1":11115,"PHASE1":11117,"PHASE2":11119,"PHASE3":11121,"PHASE4":11127,"NA":11129},{"trials":11116,"activeCount":102},[],{"trials":11118,"activeCount":102},[],{"trials":11120,"activeCount":102},[],{"trials":11122,"activeCount":102},[11123],{"nctId":10735,"briefTitle":10736,"status":108,"phases":11124,"primaryCompletion":10738,"completion":10738,"start":3302,"enrollment":10739,"conditions":11125,"interventions":11126},[91,92],[10741],[10714,10743],{"trials":11128,"activeCount":102},[],{"trials":11130,"activeCount":102},[],{"intervention":584,"totalTrials":184,"cells":11132},{"EARLY_PHASE1":11133,"PHASE1":11135,"PHASE2":11137,"PHASE3":11139,"PHASE4":11145,"NA":11147},{"trials":11134,"activeCount":102},[],{"trials":11136,"activeCount":102},[],{"trials":11138,"activeCount":102},[],{"trials":11140,"activeCount":102},[11141],{"nctId":572,"briefTitle":573,"status":108,"phases":11142,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":11143,"interventions":11144},[91,92],[580,581,582],[584,525],{"trials":11146,"activeCount":102},[],{"trials":11148,"activeCount":102},[],{"intervention":11150,"totalTrials":184,"cells":11151},"Transdermal Testosterone gel",{"EARLY_PHASE1":11152,"PHASE1":11154,"PHASE2":11156,"PHASE3":11158,"PHASE4":11170,"NA":11172},{"trials":11153,"activeCount":102},[],{"trials":11155,"activeCount":102},[],{"trials":11157,"activeCount":102},[],{"trials":11159,"activeCount":102},[11160],{"nctId":11161,"briefTitle":11162,"status":108,"phases":11163,"primaryCompletion":1431,"completion":1603,"start":10556,"enrollment":208,"conditions":11164,"interventions":11169},"NCT00345969","Exercise and Testosterone Therapy in Elderly Men With Physical Frailty",[92],[11165,11166,11167,11168],"Physical Frailty","Hip Fracture","Elective Hip Replacement","Hypogonadism",[11150],{"trials":11171,"activeCount":102},[],{"trials":11173,"activeCount":102},[],{"intervention":11175,"totalTrials":184,"cells":11176},"Ulipristal Acetate",{"EARLY_PHASE1":11177,"PHASE1":11179,"PHASE2":11181,"PHASE3":11183,"PHASE4":11195,"NA":11197},{"trials":11178,"activeCount":102},[],{"trials":11180,"activeCount":102},[],{"trials":11182,"activeCount":102},[],{"trials":11184,"activeCount":102},[11185],{"nctId":11186,"briefTitle":11187,"status":108,"phases":11188,"primaryCompletion":11189,"completion":11189,"start":11190,"enrollment":16,"conditions":11191,"interventions":11194},"NCT03118297","Intervention to End Recurrent Unscheduled Bleeding Trial",[92],"2018-01-31","2017-05-01",[11192,11193],"Contraception","Bleeding",[11175],{"trials":11196,"activeCount":102},[],{"trials":11198,"activeCount":102},[],{"intervention":11200,"totalTrials":184,"cells":11201},"Argatroban",{"EARLY_PHASE1":11202,"PHASE1":11204,"PHASE2":11206,"PHASE3":11208,"PHASE4":11219,"NA":11221},{"trials":11203,"activeCount":102},[],{"trials":11205,"activeCount":102},[],{"trials":11207,"activeCount":102},[],{"trials":11209,"activeCount":102},[11210],{"nctId":11211,"briefTitle":11212,"status":108,"phases":11213,"primaryCompletion":9672,"completion":1686,"start":7380,"enrollment":11214,"conditions":11215,"interventions":11217},"NCT03735979","Multi-arm Optimization of Stroke Thrombolysis",[92],514,[11216],"Acute Ischemic Stroke",[11200,11218],"Eptifibatide",{"trials":11220,"activeCount":102},[],{"trials":11222,"activeCount":102},[],{"intervention":11218,"totalTrials":184,"cells":11224},{"EARLY_PHASE1":11225,"PHASE1":11227,"PHASE2":11229,"PHASE3":11231,"PHASE4":11237,"NA":11239},{"trials":11226,"activeCount":102},[],{"trials":11228,"activeCount":102},[],{"trials":11230,"activeCount":102},[],{"trials":11232,"activeCount":102},[11233],{"nctId":11211,"briefTitle":11212,"status":108,"phases":11234,"primaryCompletion":9672,"completion":1686,"start":7380,"enrollment":11214,"conditions":11235,"interventions":11236},[92],[11216],[11200,11218],{"trials":11238,"activeCount":102},[],{"trials":11240,"activeCount":102},[],{"intervention":11242,"totalTrials":184,"cells":11243},"Dalfampridine\u002FPlacebo",{"EARLY_PHASE1":11244,"PHASE1":11246,"PHASE2":11248,"PHASE3":11250,"PHASE4":11259,"NA":11261},{"trials":11245,"activeCount":102},[],{"trials":11247,"activeCount":102},[],{"trials":11249,"activeCount":102},[],{"trials":11251,"activeCount":102},[11252],{"nctId":11253,"briefTitle":11254,"status":108,"phases":11255,"primaryCompletion":2443,"completion":2443,"start":3555,"enrollment":1433,"conditions":11256,"interventions":11258},"NCT01337986","Ampyra for Optic Neuritis in Multiple Sclerosis",[91,92],[8473,11257],"Optic Neuritis",[11242],{"trials":11260,"activeCount":102},[],{"trials":11262,"activeCount":102},[],{"intervention":11264,"totalTrials":184,"cells":11265},"Sertraline\u002Fomega-3",{"EARLY_PHASE1":11266,"PHASE1":11268,"PHASE2":11270,"PHASE3":11272,"PHASE4":11286,"NA":11288},{"trials":11267,"activeCount":102},[],{"trials":11269,"activeCount":102},[],{"trials":11271,"activeCount":102},[],{"trials":11273,"activeCount":102},[11274],{"nctId":11275,"briefTitle":11276,"status":108,"phases":11277,"primaryCompletion":9191,"completion":1646,"start":11278,"enrollment":11279,"conditions":11280,"interventions":11284},"NCT00116857","Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors",[92],"2005-02",122,[8705,21,11281,11282,11283],"Heart Diseases","Myocardial Infarction","Angina, Unstable",[11264,11285],"Sertraline\u002FCorn Oil",{"trials":11287,"activeCount":102},[],{"trials":11289,"activeCount":102},[],{"intervention":11285,"totalTrials":184,"cells":11291},{"EARLY_PHASE1":11292,"PHASE1":11294,"PHASE2":11296,"PHASE3":11298,"PHASE4":11304,"NA":11306},{"trials":11293,"activeCount":102},[],{"trials":11295,"activeCount":102},[],{"trials":11297,"activeCount":102},[],{"trials":11299,"activeCount":102},[11300],{"nctId":11275,"briefTitle":11276,"status":108,"phases":11301,"primaryCompletion":9191,"completion":1646,"start":11278,"enrollment":11279,"conditions":11302,"interventions":11303},[92],[8705,21,11281,11282,11283],[11264,11285],{"trials":11305,"activeCount":102},[],{"trials":11307,"activeCount":102},[],{"intervention":11309,"totalTrials":184,"cells":11310},"Ganciclovir",{"EARLY_PHASE1":11311,"PHASE1":11313,"PHASE2":11315,"PHASE3":11317,"PHASE4":11328,"NA":11330},{"trials":11312,"activeCount":102},[],{"trials":11314,"activeCount":102},[],{"trials":11316,"activeCount":102},[],{"trials":11318,"activeCount":102},[11319],{"nctId":11320,"briefTitle":11321,"status":137,"phases":11322,"primaryCompletion":3208,"completion":1400,"start":11323,"enrollment":3218,"conditions":11324,"interventions":11326},"NCT00241345","Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant",[92],"2004-06",[11325],"Cytomegalovirus Infections",[11327,11309],"Valganciclovir",{"trials":11329,"activeCount":102},[],{"trials":11331,"activeCount":102},[],{"intervention":8298,"totalTrials":184,"cells":11333},{"EARLY_PHASE1":11334,"PHASE1":11336,"PHASE2":11338,"PHASE3":11340,"PHASE4":11346,"NA":11348},{"trials":11335,"activeCount":102},[],{"trials":11337,"activeCount":102},[],{"trials":11339,"activeCount":102},[],{"trials":11341,"activeCount":102},[11342],{"nctId":8290,"briefTitle":8291,"status":137,"phases":11343,"primaryCompletion":8293,"completion":8293,"start":8294,"enrollment":293,"conditions":11344,"interventions":11345},[92],[8296],[8298,8240,8299],{"trials":11347,"activeCount":102},[],{"trials":11349,"activeCount":102},[],{"intervention":8299,"totalTrials":184,"cells":11351},{"EARLY_PHASE1":11352,"PHASE1":11354,"PHASE2":11356,"PHASE3":11358,"PHASE4":11364,"NA":11366},{"trials":11353,"activeCount":102},[],{"trials":11355,"activeCount":102},[],{"trials":11357,"activeCount":102},[],{"trials":11359,"activeCount":102},[11360],{"nctId":8290,"briefTitle":8291,"status":137,"phases":11361,"primaryCompletion":8293,"completion":8293,"start":8294,"enrollment":293,"conditions":11362,"interventions":11363},[92],[8296],[8298,8240,8299],{"trials":11365,"activeCount":102},[],{"trials":11367,"activeCount":102},[],{"intervention":6068,"totalTrials":184,"cells":11369},{"EARLY_PHASE1":11370,"PHASE1":11372,"PHASE2":11374,"PHASE3":11376,"PHASE4":11382,"NA":11384},{"trials":11371,"activeCount":102},[],{"trials":11373,"activeCount":102},[],{"trials":11375,"activeCount":102},[],{"trials":11377,"activeCount":102},[11378],{"nctId":6060,"briefTitle":6061,"status":108,"phases":11379,"primaryCompletion":6063,"completion":3054,"start":6064,"enrollment":6065,"conditions":11380,"interventions":11381},[92],[580,5570],[6068,5595],{"trials":11383,"activeCount":102},[],{"trials":11385,"activeCount":102},[],{"intervention":11387,"totalTrials":184,"cells":11388},"MR or M-M-R II ® vaccine",{"EARLY_PHASE1":11389,"PHASE1":11391,"PHASE2":11393,"PHASE3":11395,"PHASE4":11407,"NA":11409},{"trials":11390,"activeCount":102},[],{"trials":11392,"activeCount":102},[],{"trials":11394,"activeCount":102},[],{"trials":11396,"activeCount":102},[11397],{"nctId":11398,"briefTitle":11399,"status":108,"phases":11400,"primaryCompletion":11401,"completion":11402,"start":11403,"enrollment":11404,"conditions":11405,"interventions":11406},"NCT04333732","CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION",[92],"2021-08-10","2021-12-03","2020-09-04",3411,[731],[11387],{"trials":11408,"activeCount":102},[],{"trials":11410,"activeCount":102},[],{"intervention":11412,"totalTrials":184,"cells":11413},"Recombinant tissue plasminogen activator",{"EARLY_PHASE1":11414,"PHASE1":11416,"PHASE2":11418,"PHASE3":11420,"PHASE4":11434,"NA":11436},{"trials":11415,"activeCount":102},[],{"trials":11417,"activeCount":102},[],{"trials":11419,"activeCount":102},[],{"trials":11421,"activeCount":102},[11422],{"nctId":11423,"briefTitle":11424,"status":108,"phases":11425,"primaryCompletion":1996,"completion":1996,"start":1646,"enrollment":11426,"conditions":11427,"interventions":11433},"NCT00790335","Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis",[92],692,[11428,11429,11430,11431,11432],"Deep Vein Thrombosis","Venous Thrombosis","Postphlebitic Syndrome","Venous Thromboembolism","Post Thrombotic Syndrome",[11412],{"trials":11435,"activeCount":102},[],{"trials":11437,"activeCount":102},[],{"intervention":374,"totalTrials":367,"cells":11439},{"EARLY_PHASE1":11440,"PHASE1":11442,"PHASE2":11460,"PHASE3":11499,"PHASE4":11501,"NA":11503},{"trials":11441,"activeCount":102},[],{"trials":11443,"activeCount":102},[11444,11448,11452,11456],{"nctId":3463,"briefTitle":3464,"status":108,"phases":11445,"primaryCompletion":3466,"completion":1442,"start":3281,"enrollment":3467,"conditions":11446,"interventions":11447},[90],[1875],[374,2563,373,375,3470],{"nctId":1839,"briefTitle":1840,"status":137,"phases":11449,"primaryCompletion":1842,"completion":1843,"start":1844,"enrollment":27,"conditions":11450,"interventions":11451},[90],[1635,1846],[1848,1849,1124,374],{"nctId":1859,"briefTitle":1860,"status":108,"phases":11453,"primaryCompletion":1648,"completion":1862,"start":1863,"enrollment":293,"conditions":11454,"interventions":11455},[90],[1865,1184],[374,1124,1867],{"nctId":1879,"briefTitle":1880,"status":108,"phases":11457,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":30,"conditions":11458,"interventions":11459},[90],[1886,1887,1888,1889],[1891,1124,374,1849,1892],{"trials":11461,"activeCount":102},[11462,11466,11470,11474,11489],{"nctId":2643,"briefTitle":2644,"status":108,"phases":11463,"primaryCompletion":2646,"completion":2647,"start":1646,"enrollment":2648,"conditions":11464,"interventions":11465},[91],[2650],[374,373,414,1867],{"nctId":361,"briefTitle":362,"status":137,"phases":11467,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":11468,"interventions":11469},[91],[369,370],[339,372,373,374,375],{"nctId":3484,"briefTitle":3485,"status":108,"phases":11471,"primaryCompletion":2888,"completion":3487,"start":3488,"enrollment":1391,"conditions":11472,"interventions":11473},[91],[3490,1650],[2563,631,374,373,375],{"nctId":11475,"briefTitle":11476,"status":108,"phases":11477,"primaryCompletion":11478,"completion":11479,"start":11480,"enrollment":1299,"conditions":11481,"interventions":11488},"NCT02641691","Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum",[91],"2020-02-04","2020-03-29","2016-05-27",[11482,11483,11484,4060,11485,11486,11487],"Cancer of Rectum","Cancer of the Rectum","Neoplasm, Rectum","Rectum Cancer","Rectum Neoplasms","Adenocarcinoma of the Rectum",[374,373,375],{"nctId":11490,"briefTitle":11491,"status":122,"phases":11492,"primaryCompletion":11493,"completion":11494,"start":950,"enrollment":102,"conditions":11495,"interventions":11497},"NCT02296671","Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers",[91],"2018-09","2022-02",[11496],"Esophagogastric Cancer",[1652,374,373,375,11498],"Germline genotyping analyses for TSER",{"trials":11500,"activeCount":102},[],{"trials":11502,"activeCount":102},[],{"trials":11504,"activeCount":102},[],{"intervention":2424,"totalTrials":367,"cells":11506},{"EARLY_PHASE1":11507,"PHASE1":11513,"PHASE2":11523,"PHASE3":11549,"PHASE4":11551,"NA":11553},{"trials":11508,"activeCount":102},[11509],{"nctId":3006,"briefTitle":3007,"status":108,"phases":11510,"primaryCompletion":3009,"completion":3010,"start":365,"enrollment":1249,"conditions":11511,"interventions":11512},[89],[3012],[2612,3014,2424,1849,3015],{"trials":11514,"activeCount":102},[11515,11519],{"nctId":3189,"briefTitle":3190,"status":137,"phases":11516,"primaryCompletion":3192,"completion":2288,"start":3193,"enrollment":1131,"conditions":11517,"interventions":11518},[90],[3182],[2476,3196,2424,2425],{"nctId":2415,"briefTitle":2416,"status":108,"phases":11520,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":1664,"conditions":11521,"interventions":11522},[90],[2323],[2423,2225,2424,2425,2362],{"trials":11524,"activeCount":102},[11525,11529,11533,11537,11541,11545],{"nctId":6185,"briefTitle":6186,"status":108,"phases":11526,"primaryCompletion":3432,"completion":6188,"start":1952,"enrollment":1056,"conditions":11527,"interventions":11528},[90,91],[6190],[2446,2424,6192,1228,1073,1229,6193],{"nctId":3214,"briefTitle":3215,"status":108,"phases":11530,"primaryCompletion":3217,"completion":577,"start":1443,"enrollment":3218,"conditions":11531,"interventions":11532},[90,91],[3182],[2612,2476,3196,2424,2425],{"nctId":2439,"briefTitle":2440,"status":137,"phases":11534,"primaryCompletion":2442,"completion":2443,"start":1873,"enrollment":340,"conditions":11535,"interventions":11536},[91],[24],[2446,2225,2424,2425,2362],{"nctId":6615,"briefTitle":6616,"status":137,"phases":11538,"primaryCompletion":6618,"completion":6618,"start":6619,"enrollment":1131,"conditions":11539,"interventions":11540},[91],[2038,6621,6622,1004,6623,2000,2001,6624,1998],[1228,2424],{"nctId":3247,"briefTitle":3248,"status":108,"phases":11542,"primaryCompletion":1647,"completion":1647,"start":3250,"enrollment":3251,"conditions":11543,"interventions":11544},[90,91],[3182],[3254,3196,2424,2425],{"nctId":1474,"briefTitle":1475,"status":108,"phases":11546,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":951,"conditions":11547,"interventions":11548},[91],[1480,1481,1482],[1484,1485,1486],{"trials":11550,"activeCount":102},[],{"trials":11552,"activeCount":102},[],{"trials":11554,"activeCount":102},[],{"intervention":2395,"totalTrials":2289,"cells":11556},{"EARLY_PHASE1":11557,"PHASE1":11559,"PHASE2":11599,"PHASE3":11621,"PHASE4":11623,"NA":11625},{"trials":11558,"activeCount":102},[],{"trials":11560,"activeCount":102},[11561,11565,11575,11579,11587],{"nctId":3299,"briefTitle":3300,"status":108,"phases":11562,"primaryCompletion":3302,"completion":3303,"start":3304,"enrollment":3305,"conditions":11563,"interventions":11564},[90],[26],[2612,2476,2395],{"nctId":11566,"briefTitle":11567,"status":108,"phases":11568,"primaryCompletion":11569,"completion":11570,"start":11571,"enrollment":2070,"conditions":11572,"interventions":11573},"NCT01913951","Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes",[90],"2016-12-05","2024-04-29","2013-11-22",[26],[11574,2395],"vosaroxin",{"nctId":2382,"briefTitle":2383,"status":137,"phases":11576,"primaryCompletion":2385,"completion":2386,"start":2387,"enrollment":98,"conditions":11577,"interventions":11578},[90],[2389,2390,2391],[2375,2393,1229,2362,2394,2395],{"nctId":11580,"briefTitle":11581,"status":108,"phases":11582,"primaryCompletion":7054,"completion":6255,"start":3281,"enrollment":1664,"conditions":11583,"interventions":11584},"NCT01390311","Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant",[90],[3182,26],[2395,11585,11586],"Pre-DLI Salvage Chemotherapy","Donor Leukocyte",{"nctId":11588,"briefTitle":11589,"status":108,"phases":11590,"primaryCompletion":11591,"completion":11592,"start":11593,"enrollment":1299,"conditions":11594,"interventions":11597},"NCT02995655","CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia",[90],"2018-09-13","2019-04-29","2017-04-07",[26,2389,11595,11596],"AML","MDS",[11598,2395],"CX-01",{"trials":11600,"activeCount":102},[11601,11609,11613],{"nctId":11602,"briefTitle":11603,"status":108,"phases":11604,"primaryCompletion":11605,"completion":1604,"start":11606,"enrollment":208,"conditions":11607,"interventions":11608},"NCT00384956","A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes",[91],"2008-08","2006-08",[26],[2395],{"nctId":3421,"briefTitle":3422,"status":108,"phases":11610,"primaryCompletion":3424,"completion":3009,"start":3425,"enrollment":1938,"conditions":11611,"interventions":11612},[90,91],[3182],[3026,2395],{"nctId":11614,"briefTitle":11615,"status":137,"phases":11616,"primaryCompletion":1119,"completion":11617,"start":11618,"enrollment":5325,"conditions":11619,"interventions":11620},"NCT01747499","Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation",[90,91],"2018-12-24","2013-04-15",[3182,26,3012],[2395],{"trials":11622,"activeCount":102},[],{"trials":11624,"activeCount":102},[],{"trials":11626,"activeCount":102},[],{"intervention":373,"totalTrials":1623,"cells":11628},{"EARLY_PHASE1":11629,"PHASE1":11631,"PHASE2":11641,"PHASE3":11663,"PHASE4":11665,"NA":11667},{"trials":11630,"activeCount":102},[],{"trials":11632,"activeCount":102},[11633,11637],{"nctId":3463,"briefTitle":3464,"status":108,"phases":11634,"primaryCompletion":3466,"completion":1442,"start":3281,"enrollment":3467,"conditions":11635,"interventions":11636},[90],[1875],[374,2563,373,375,3470],{"nctId":9276,"briefTitle":9277,"status":108,"phases":11638,"primaryCompletion":8074,"completion":9279,"start":9280,"enrollment":1299,"conditions":11639,"interventions":11640},[90],[29,116,115],[414,373,1264,9269],{"trials":11642,"activeCount":102},[11643,11647,11651,11655,11659],{"nctId":2643,"briefTitle":2644,"status":108,"phases":11644,"primaryCompletion":2646,"completion":2647,"start":1646,"enrollment":2648,"conditions":11645,"interventions":11646},[91],[2650],[374,373,414,1867],{"nctId":361,"briefTitle":362,"status":137,"phases":11648,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":11649,"interventions":11650},[91],[369,370],[339,372,373,374,375],{"nctId":3484,"briefTitle":3485,"status":108,"phases":11652,"primaryCompletion":2888,"completion":3487,"start":3488,"enrollment":1391,"conditions":11653,"interventions":11654},[91],[3490,1650],[2563,631,374,373,375],{"nctId":11475,"briefTitle":11476,"status":108,"phases":11656,"primaryCompletion":11478,"completion":11479,"start":11480,"enrollment":1299,"conditions":11657,"interventions":11658},[91],[11482,11483,11484,4060,11485,11486,11487],[374,373,375],{"nctId":11490,"briefTitle":11491,"status":122,"phases":11660,"primaryCompletion":11493,"completion":11494,"start":950,"enrollment":102,"conditions":11661,"interventions":11662},[91],[11496],[1652,374,373,375,11498],{"trials":11664,"activeCount":102},[],{"trials":11666,"activeCount":102},[],{"trials":11668,"activeCount":102},[],{"intervention":375,"totalTrials":1623,"cells":11670},{"EARLY_PHASE1":11671,"PHASE1":11673,"PHASE2":11679,"PHASE3":11705,"PHASE4":11707,"NA":11709},{"trials":11672,"activeCount":102},[],{"trials":11674,"activeCount":102},[11675],{"nctId":3463,"briefTitle":3464,"status":108,"phases":11676,"primaryCompletion":3466,"completion":1442,"start":3281,"enrollment":3467,"conditions":11677,"interventions":11678},[90],[1875],[374,2563,373,375,3470],{"trials":11680,"activeCount":102},[11681,11685,11689,11693,11697,11701],{"nctId":361,"briefTitle":362,"status":137,"phases":11682,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":11683,"interventions":11684},[91],[369,370],[339,372,373,374,375],{"nctId":3484,"briefTitle":3485,"status":108,"phases":11686,"primaryCompletion":2888,"completion":3487,"start":3488,"enrollment":1391,"conditions":11687,"interventions":11688},[91],[3490,1650],[2563,631,374,373,375],{"nctId":1618,"briefTitle":1619,"status":137,"phases":11690,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":11691,"interventions":11692},[91],[1445],[1228,631,1229,82,1626,1594,426,375],{"nctId":11475,"briefTitle":11476,"status":108,"phases":11694,"primaryCompletion":11478,"completion":11479,"start":11480,"enrollment":1299,"conditions":11695,"interventions":11696},[91],[11482,11483,11484,4060,11485,11486,11487],[374,373,375],{"nctId":428,"briefTitle":429,"status":108,"phases":11698,"primaryCompletion":431,"completion":432,"start":433,"enrollment":293,"conditions":11699,"interventions":11700},[91],[435],[437,403,375,339],{"nctId":11490,"briefTitle":11491,"status":122,"phases":11702,"primaryCompletion":11493,"completion":11494,"start":950,"enrollment":102,"conditions":11703,"interventions":11704},[91],[11496],[1652,374,373,375,11498],{"trials":11706,"activeCount":102},[],{"trials":11708,"activeCount":102},[],{"trials":11710,"activeCount":102},[],{"intervention":619,"totalTrials":98,"cells":11712},{"EARLY_PHASE1":11713,"PHASE1":11715,"PHASE2":11717,"PHASE3":11747,"PHASE4":11749,"NA":11751},{"trials":11714,"activeCount":102},[],{"trials":11716,"activeCount":102},[],{"trials":11718,"activeCount":102},[11719,11723,11727,11735,11743],{"nctId":608,"briefTitle":609,"status":108,"phases":11720,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":11721,"interventions":11722},[91],[18,616,159,617],[57,619,620,621],{"nctId":623,"briefTitle":624,"status":137,"phases":11724,"primaryCompletion":626,"completion":627,"start":628,"enrollment":442,"conditions":11725,"interventions":11726},[91],[18,159,616],[57,619,631,621,632],{"nctId":11728,"briefTitle":11729,"status":108,"phases":11730,"primaryCompletion":11731,"completion":1442,"start":8361,"enrollment":11732,"conditions":11733,"interventions":11734},"NCT00084396","Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and\u002For Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer",[91],"2007-03",115,[18],[2299],{"nctId":11736,"briefTitle":11737,"status":137,"phases":11738,"primaryCompletion":1648,"completion":1430,"start":11739,"enrollment":599,"conditions":11740,"interventions":11741},"NCT00263198","PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer",[91],"2006-03",[1445],[11742,619],"PTK787\u002FZK222584",{"nctId":2284,"briefTitle":2285,"status":137,"phases":11744,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":2289,"conditions":11745,"interventions":11746},[91],[2291,2292,2293,2294,2295,2296],[2298,2299,2300,2301],{"trials":11748,"activeCount":102},[],{"trials":11750,"activeCount":102},[],{"trials":11752,"activeCount":102},[],{"intervention":3547,"totalTrials":98,"cells":11754},{"EARLY_PHASE1":11755,"PHASE1":11757,"PHASE2":11784,"PHASE3":11793,"PHASE4":11795,"NA":11797},{"trials":11756,"activeCount":102},[],{"trials":11758,"activeCount":102},[11759,11763,11769,11777],{"nctId":3538,"briefTitle":3539,"status":108,"phases":11760,"primaryCompletion":3541,"completion":3542,"start":3543,"enrollment":442,"conditions":11761,"interventions":11762},[90],[3545],[3547,1594],{"nctId":11764,"briefTitle":11765,"status":108,"phases":11766,"primaryCompletion":2647,"completion":2647,"start":8044,"enrollment":743,"conditions":11767,"interventions":11768},"NCT00770263","Erlotinib and Temsirolimus for Solid Tumors",[90],[1184],[2045,3547],{"nctId":11770,"briefTitle":11771,"status":108,"phases":11772,"primaryCompletion":3102,"completion":365,"start":11773,"enrollment":3305,"conditions":11774,"interventions":11775},"NCT00703170","Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies",[90],"2008-03",[3545],[3547,11776],"Pegylated liposomal doxorubicin",{"nctId":11778,"briefTitle":11779,"status":108,"phases":11780,"primaryCompletion":3102,"completion":365,"start":11781,"enrollment":340,"conditions":11782,"interventions":11783},"NCT00796796","Temsirolimus and Radiation for Non-Small Cell Lung Cancer",[90],"2009-03",[1553],[3547],{"trials":11785,"activeCount":102},[11786],{"nctId":11787,"briefTitle":11788,"status":137,"phases":11789,"primaryCompletion":1464,"completion":6188,"start":11790,"enrollment":1566,"conditions":11791,"interventions":11792},"NCT00921310","Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer",[90,91],"2009-09",[1553],[1652,3547],{"trials":11794,"activeCount":102},[],{"trials":11796,"activeCount":102},[],{"trials":11798,"activeCount":102},[],{"intervention":3254,"totalTrials":98,"cells":11800},{"EARLY_PHASE1":11801,"PHASE1":11803,"PHASE2":11809,"PHASE3":11837,"PHASE4":11839,"NA":11841},{"trials":11802,"activeCount":102},[],{"trials":11804,"activeCount":102},[11805],{"nctId":3318,"briefTitle":3319,"status":108,"phases":11806,"primaryCompletion":3321,"completion":1238,"start":3322,"enrollment":3323,"conditions":11807,"interventions":11808},[90],[3325],[2612,3254],{"trials":11810,"activeCount":102},[11811,11815,11819,11826],{"nctId":3342,"briefTitle":3343,"status":108,"phases":11812,"primaryCompletion":1873,"completion":3345,"start":3346,"enrollment":1911,"conditions":11813,"interventions":11814},[90,91],[2598,1888],[3254,2612],{"nctId":3247,"briefTitle":3248,"status":108,"phases":11816,"primaryCompletion":1647,"completion":1647,"start":3250,"enrollment":3251,"conditions":11817,"interventions":11818},[90,91],[3182],[3254,3196,2424,2425],{"nctId":11820,"briefTitle":11821,"status":108,"phases":11822,"primaryCompletion":8918,"completion":6819,"start":1603,"enrollment":1142,"conditions":11823,"interventions":11825},"NCT00914849","Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies",[91],[11824],"Hematologic Neoplasms",[3254],{"nctId":11827,"briefTitle":11828,"status":108,"phases":11829,"primaryCompletion":364,"completion":1872,"start":11830,"enrollment":11831,"conditions":11832,"interventions":11836},"NCT00241358","Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies",[90,91],"2004-05",92,[3182,11833,11834,11835,26,24,2598,1888],"Leukemia, Myelogenous, Chronic","Leukemia, Lymphoblastic, Acute","Lymphocytic Leukemia, Chronic",[3254],{"trials":11838,"activeCount":102},[],{"trials":11840,"activeCount":102},[],{"trials":11842,"activeCount":102},[],{"intervention":2446,"totalTrials":98,"cells":11844},{"EARLY_PHASE1":11845,"PHASE1":11851,"PHASE2":11861,"PHASE3":11871,"PHASE4":11873,"NA":11875},{"trials":11846,"activeCount":102},[11847],{"nctId":3017,"briefTitle":3018,"status":137,"phases":11848,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":11849,"interventions":11850},[89],[24],[2378,2446,3024,1849,1229,3025,3026,3027],{"trials":11852,"activeCount":102},[11853,11857],{"nctId":3309,"briefTitle":3310,"status":108,"phases":11854,"primaryCompletion":3312,"completion":3313,"start":3314,"enrollment":340,"conditions":11855,"interventions":11856},[90],[24],[2446,2612],{"nctId":3051,"briefTitle":3052,"status":137,"phases":11858,"primaryCompletion":3054,"completion":3055,"start":1039,"enrollment":184,"conditions":11859,"interventions":11860},[90],[24],[3058,2446,1849],{"trials":11862,"activeCount":102},[11863,11867],{"nctId":6185,"briefTitle":6186,"status":108,"phases":11864,"primaryCompletion":3432,"completion":6188,"start":1952,"enrollment":1056,"conditions":11865,"interventions":11866},[90,91],[6190],[2446,2424,6192,1228,1073,1229,6193],{"nctId":2439,"briefTitle":2440,"status":137,"phases":11868,"primaryCompletion":2442,"completion":2443,"start":1873,"enrollment":340,"conditions":11869,"interventions":11870},[91],[24],[2446,2225,2424,2425,2362],{"trials":11872,"activeCount":102},[],{"trials":11874,"activeCount":102},[],{"trials":11876,"activeCount":102},[],{"intervention":414,"totalTrials":599,"cells":11878},{"EARLY_PHASE1":11879,"PHASE1":11881,"PHASE2":11887,"PHASE3":11901,"PHASE4":11903,"NA":11905},{"trials":11880,"activeCount":102},[],{"trials":11882,"activeCount":102},[11883],{"nctId":9276,"briefTitle":9277,"status":108,"phases":11884,"primaryCompletion":8074,"completion":9279,"start":9280,"enrollment":1299,"conditions":11885,"interventions":11886},[90],[29,116,115],[414,373,1264,9269],{"trials":11888,"activeCount":102},[11889,11893,11897],{"nctId":2643,"briefTitle":2644,"status":108,"phases":11890,"primaryCompletion":2646,"completion":2647,"start":1646,"enrollment":2648,"conditions":11891,"interventions":11892},[91],[2650],[374,373,414,1867],{"nctId":405,"briefTitle":406,"status":108,"phases":11894,"primaryCompletion":408,"completion":409,"start":410,"enrollment":293,"conditions":11895,"interventions":11896},[91],[355],[413,339,339,403,414,403,339],{"nctId":1427,"briefTitle":1428,"status":108,"phases":11898,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":11899,"interventions":11900},[91],[29],[403,414,1436,1124],{"trials":11902,"activeCount":102},[],{"trials":11904,"activeCount":102},[],{"trials":11906,"activeCount":102},[],{"intervention":2378,"totalTrials":599,"cells":11908},{"EARLY_PHASE1":11909,"PHASE1":11919,"PHASE2":11925,"PHASE3":11931,"PHASE4":11933,"NA":11935},{"trials":11910,"activeCount":102},[11911,11915],{"nctId":2367,"briefTitle":2368,"status":122,"phases":11912,"primaryCompletion":2370,"completion":2370,"start":1351,"enrollment":102,"conditions":11913,"interventions":11914},[89],[24,2372],[2374,2362,2375,1229,2376,2377,2378],{"nctId":3017,"briefTitle":3018,"status":137,"phases":11916,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":11917,"interventions":11918},[89],[24],[2378,2446,3024,1849,1229,3025,3026,3027],{"trials":11920,"activeCount":102},[11921],{"nctId":3165,"briefTitle":3166,"status":108,"phases":11922,"primaryCompletion":3168,"completion":3169,"start":3170,"enrollment":1056,"conditions":11923,"interventions":11924},[90],[3172],[3174,978,2425,1892,2378],{"trials":11926,"activeCount":102},[11927],{"nctId":3678,"briefTitle":3679,"status":108,"phases":11928,"primaryCompletion":3681,"completion":3682,"start":3683,"enrollment":3684,"conditions":11929,"interventions":11930},[91],[24,2598],[3687,2378,2476],{"trials":11932,"activeCount":102},[],{"trials":11934,"activeCount":102},[],{"trials":11936,"activeCount":102},[],{"intervention":357,"totalTrials":599,"cells":11938},{"EARLY_PHASE1":11939,"PHASE1":11941,"PHASE2":11947,"PHASE3":11970,"PHASE4":11972,"NA":11974},{"trials":11940,"activeCount":102},[],{"trials":11942,"activeCount":102},[11943],{"nctId":347,"briefTitle":348,"status":108,"phases":11944,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":11945,"interventions":11946},[90],[355],[357,339],{"trials":11948,"activeCount":102},[11949,11957,11966],{"nctId":11950,"briefTitle":11951,"status":137,"phases":11952,"primaryCompletion":11953,"completion":11953,"start":11954,"enrollment":960,"conditions":11955,"interventions":11956},"NCT02193152","Pazopanib in Molecularly Selected Patients With Advanced NSCLC",[91],"2019-12-24","2015-04-27",[1353,1354,1356],[357],{"nctId":11958,"briefTitle":11959,"status":108,"phases":11960,"primaryCompletion":11961,"completion":11962,"start":11963,"enrollment":3820,"conditions":11964,"interventions":11965},"NCT02300545","Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy",[91],"2019-05-31","2020-07-11","2015-04-08",[6598,1925],[357],{"nctId":1960,"briefTitle":1961,"status":137,"phases":11967,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":456,"conditions":11968,"interventions":11969},[91],[29],[1124,357],{"trials":11971,"activeCount":102},[],{"trials":11973,"activeCount":102},[],{"trials":11975,"activeCount":102},[],{"intervention":1652,"totalTrials":599,"cells":11977},{"EARLY_PHASE1":11978,"PHASE1":11980,"PHASE2":11982,"PHASE3":12000,"PHASE4":12002,"NA":12004},{"trials":11979,"activeCount":102},[],{"trials":11981,"activeCount":102},[],{"trials":11983,"activeCount":102},[11984,11988,11992,11996],{"nctId":11787,"briefTitle":11788,"status":137,"phases":11985,"primaryCompletion":1464,"completion":6188,"start":11790,"enrollment":1566,"conditions":11986,"interventions":11987},[90,91],[1553],[1652,3547],{"nctId":1643,"briefTitle":1644,"status":137,"phases":11989,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":367,"conditions":11990,"interventions":11991},[91],[1650],[1652,426],{"nctId":6502,"briefTitle":6503,"status":108,"phases":11993,"primaryCompletion":490,"completion":490,"start":6400,"enrollment":6505,"conditions":11994,"interventions":11995},[91],[6507,1541],[1652,372],{"nctId":11490,"briefTitle":11491,"status":122,"phases":11997,"primaryCompletion":11493,"completion":11494,"start":950,"enrollment":102,"conditions":11998,"interventions":11999},[91],[11496],[1652,374,373,375,11498],{"trials":12001,"activeCount":102},[],{"trials":12003,"activeCount":102},[],{"trials":12005,"activeCount":102},[],{"intervention":2045,"totalTrials":599,"cells":12007},{"EARLY_PHASE1":12008,"PHASE1":12010,"PHASE2":12020,"PHASE3":12035,"PHASE4":12037,"NA":12039},{"trials":12009,"activeCount":102},[],{"trials":12011,"activeCount":102},[12012,12016],{"nctId":11764,"briefTitle":11765,"status":108,"phases":12013,"primaryCompletion":2647,"completion":2647,"start":8044,"enrollment":743,"conditions":12014,"interventions":12015},[90],[1184],[2045,3547],{"nctId":6697,"briefTitle":6698,"status":137,"phases":12017,"primaryCompletion":6700,"completion":6700,"start":6701,"enrollment":2289,"conditions":12018,"interventions":12019},[90],[1354,1356,1553],[6431,2045],{"trials":12021,"activeCount":102},[12022,12026],{"nctId":2031,"briefTitle":2032,"status":122,"phases":12023,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":102,"conditions":12024,"interventions":12025},[91],[2038,2039,2040,1146,2041,1147,2042,2043],[2045,1151],{"nctId":12027,"briefTitle":12028,"status":137,"phases":12029,"primaryCompletion":12030,"completion":12030,"start":11731,"enrollment":1131,"conditions":12031,"interventions":12033},"NCT00442507","Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction",[91],"2009-01",[1650,12032],"Esophageal Diseases",[2045,12034],"Avastin",{"trials":12036,"activeCount":102},[],{"trials":12038,"activeCount":102},[],{"trials":12040,"activeCount":102},[],{"intervention":3174,"totalTrials":474,"cells":12042},{"EARLY_PHASE1":12043,"PHASE1":12045,"PHASE2":12055,"PHASE3":12061,"PHASE4":12063,"NA":12065},{"trials":12044,"activeCount":102},[],{"trials":12046,"activeCount":102},[12047,12051],{"nctId":3165,"briefTitle":3166,"status":108,"phases":12048,"primaryCompletion":3168,"completion":3169,"start":3170,"enrollment":1056,"conditions":12049,"interventions":12050},[90],[3172],[3174,978,2425,1892,2378],{"nctId":8851,"briefTitle":8852,"status":137,"phases":12052,"primaryCompletion":8854,"completion":8855,"start":2568,"enrollment":1080,"conditions":12053,"interventions":12054},[90],[24],[3058,3174,1073],{"trials":12056,"activeCount":102},[12057],{"nctId":3238,"briefTitle":3239,"status":108,"phases":12058,"primaryCompletion":3241,"completion":3242,"start":3243,"enrollment":1249,"conditions":12059,"interventions":12060},[91],[3172],[3174,978,2096,2425],{"trials":12062,"activeCount":102},[],{"trials":12064,"activeCount":102},[],{"trials":12066,"activeCount":102},[],{"intervention":1892,"totalTrials":474,"cells":12068},{"EARLY_PHASE1":12069,"PHASE1":12071,"PHASE2":12081,"PHASE3":12093,"PHASE4":12095,"NA":12097},{"trials":12070,"activeCount":102},[],{"trials":12072,"activeCount":102},[12073,12077],{"nctId":3165,"briefTitle":3166,"status":108,"phases":12074,"primaryCompletion":3168,"completion":3169,"start":3170,"enrollment":1056,"conditions":12075,"interventions":12076},[90],[3172],[3174,978,2425,1892,2378],{"nctId":1879,"briefTitle":1880,"status":108,"phases":12078,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":30,"conditions":12079,"interventions":12080},[90],[1886,1887,1888,1889],[1891,1124,374,1849,1892],{"trials":12082,"activeCount":102},[12083],{"nctId":12084,"briefTitle":12085,"status":108,"phases":12086,"primaryCompletion":12087,"completion":12088,"start":12089,"enrollment":565,"conditions":12090,"interventions":12091},"NCT02369458","Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies",[91],"2022-06-01","2024-11-01","2015-04-14",[355,1393],[12092,1892],"Mitomycin-C",{"trials":12094,"activeCount":102},[],{"trials":12096,"activeCount":102},[],{"trials":12098,"activeCount":102},[],{"intervention":3025,"totalTrials":474,"cells":12100},{"EARLY_PHASE1":12101,"PHASE1":12107,"PHASE2":12120,"PHASE3":12132,"PHASE4":12134,"NA":12136},{"trials":12102,"activeCount":102},[12103],{"nctId":3017,"briefTitle":3018,"status":137,"phases":12104,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":12105,"interventions":12106},[89],[24],[2378,2446,3024,1849,1229,3025,3026,3027],{"trials":12108,"activeCount":102},[12109],{"nctId":12110,"briefTitle":12111,"status":108,"phases":12112,"primaryCompletion":12113,"completion":12113,"start":12114,"enrollment":1664,"conditions":12115,"interventions":12118},"NCT01661400","Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors",[90],"2023-12-27","2012-10-26",[2038,12116,2043,2039,12117,2040,2412],"Neuroectodermal Tumors, Primitive","Sarcoma, Ewing",[12119,3025],"Metronomic Cyclophosphamide",{"trials":12121,"activeCount":102},[12122],{"nctId":12123,"briefTitle":12124,"status":108,"phases":12125,"completion":12126,"start":12127,"enrollment":474,"conditions":12128,"interventions":12130},"NCT00284505","Use of Thalidomide in Patients With Arachnoiditis",[91],"2006-07","2005-07",[12129],"Arachnoiditis",[12131],"thalidomide",{"trials":12133,"activeCount":102},[],{"trials":12135,"activeCount":102},[],{"trials":12137,"activeCount":102},[],{"intervention":1395,"totalTrials":474,"cells":12139},{"EARLY_PHASE1":12140,"PHASE1":12142,"PHASE2":12148,"PHASE3":12163,"PHASE4":12165,"NA":12167},{"trials":12141,"activeCount":102},[],{"trials":12143,"activeCount":102},[12144],{"nctId":1521,"briefTitle":1522,"status":108,"phases":12145,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":340,"conditions":12146,"interventions":12147},[90],[1528,1529,1530],[1395,82,426],{"trials":12149,"activeCount":102},[12150,12154],{"nctId":1385,"briefTitle":1386,"status":108,"phases":12151,"primaryCompletion":1388,"completion":1389,"start":1390,"enrollment":1391,"conditions":12152,"interventions":12153},[91],[397,399,400,453,355,1393],[1395,403,1395],{"nctId":12155,"briefTitle":12156,"status":108,"phases":12157,"primaryCompletion":12158,"completion":12158,"start":12159,"enrollment":614,"conditions":12160,"interventions":12162},"NCT02311582","MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas",[90,91],"2024-04-15","2015-08-05",[12161],"Malignant Glioma",[1395],{"trials":12164,"activeCount":102},[],{"trials":12166,"activeCount":102},[],{"trials":12168,"activeCount":102},[],{"intervention":3211,"totalTrials":474,"cells":12170},{"EARLY_PHASE1":12171,"PHASE1":12173,"PHASE2":12182,"PHASE3":12195,"PHASE4":12197,"NA":12199},{"trials":12172,"activeCount":102},[],{"trials":12174,"activeCount":102},[12175],{"nctId":12176,"briefTitle":12177,"status":108,"phases":12178,"primaryCompletion":1873,"completion":12179,"start":12030,"enrollment":208,"conditions":12180,"interventions":12181},"NCT00727766","Oral Clofarabine for Acute Myeloid Leukemia",[90],"2014-11",[3182],[3211],{"trials":12183,"activeCount":102},[12184,12188],{"nctId":3204,"briefTitle":3205,"status":137,"phases":12185,"primaryCompletion":3032,"completion":3207,"start":3208,"enrollment":1623,"conditions":12186,"interventions":12187},[91],[26,2389],[3211,2425,3212],{"nctId":12189,"briefTitle":12190,"status":137,"phases":12191,"primaryCompletion":12192,"completion":1400,"start":1863,"enrollment":2289,"conditions":12193,"interventions":12194},"NCT00241371","A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma",[91],"2005-11",[24],[3211],{"trials":12196,"activeCount":102},[],{"trials":12198,"activeCount":102},[],{"trials":12200,"activeCount":102},[],{"intervention":12202,"totalTrials":474,"cells":12203},"arsenic trioxide",{"EARLY_PHASE1":12204,"PHASE1":12206,"PHASE2":12212,"PHASE3":12235,"PHASE4":12237,"NA":12239},{"trials":12205,"activeCount":102},[],{"trials":12207,"activeCount":102},[12208],{"nctId":6396,"briefTitle":6397,"status":108,"phases":12209,"primaryCompletion":6399,"completion":3555,"start":6400,"enrollment":1249,"conditions":12210,"interventions":12211},[90],[6402],[6404,6381],{"trials":12213,"activeCount":102},[12214,12223],{"nctId":12215,"briefTitle":12216,"status":108,"phases":12217,"primaryCompletion":12218,"completion":12218,"start":12219,"enrollment":1249,"conditions":12220,"interventions":12222},"NCT00008697","Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia",[90,91],"2002-04","1998-11",[12221],"Leukemia",[12202],{"nctId":12224,"briefTitle":12225,"status":137,"phases":12226,"primaryCompletion":12227,"completion":12228,"start":12229,"enrollment":98,"conditions":12230,"interventions":12233},"NCT00006220","Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy",[90,91],"2000-11","2002-02","1999-06",[12221,12231,12232,26],"Lymphoma","Multiple Myeloma and Plasma Cell Neoplasm",[12202,12234],"tretinoin",{"trials":12236,"activeCount":102},[],{"trials":12238,"activeCount":102},[],{"trials":12240,"activeCount":102},[],{"intervention":3196,"totalTrials":474,"cells":12242},{"EARLY_PHASE1":12243,"PHASE1":12245,"PHASE2":12251,"PHASE3":12261,"PHASE4":12263,"NA":12265},{"trials":12244,"activeCount":102},[],{"trials":12246,"activeCount":102},[12247],{"nctId":3189,"briefTitle":3190,"status":137,"phases":12248,"primaryCompletion":3192,"completion":2288,"start":3193,"enrollment":1131,"conditions":12249,"interventions":12250},[90],[3182],[2476,3196,2424,2425],{"trials":12252,"activeCount":102},[12253,12257],{"nctId":3214,"briefTitle":3215,"status":108,"phases":12254,"primaryCompletion":3217,"completion":577,"start":1443,"enrollment":3218,"conditions":12255,"interventions":12256},[90,91],[3182],[2612,2476,3196,2424,2425],{"nctId":3247,"briefTitle":3248,"status":108,"phases":12258,"primaryCompletion":1647,"completion":1647,"start":3250,"enrollment":3251,"conditions":12259,"interventions":12260},[90,91],[3182],[3254,3196,2424,2425],{"trials":12262,"activeCount":102},[],{"trials":12264,"activeCount":102},[],{"trials":12266,"activeCount":102},[],{"intervention":3024,"totalTrials":474,"cells":12268},{"EARLY_PHASE1":12269,"PHASE1":12275,"PHASE2":12284,"PHASE3":12290,"PHASE4":12292,"NA":12294},{"trials":12270,"activeCount":102},[12271],{"nctId":3017,"briefTitle":3018,"status":137,"phases":12272,"primaryCompletion":3020,"completion":2452,"start":3021,"enrollment":1623,"conditions":12273,"interventions":12274},[89],[24],[2378,2446,3024,1849,1229,3025,3026,3027],{"trials":12276,"activeCount":102},[12277],{"nctId":12278,"briefTitle":12279,"status":108,"phases":12280,"primaryCompletion":1736,"completion":1735,"start":12281,"enrollment":1056,"conditions":12282,"interventions":12283},"NCT01137747","Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia",[90],"2010-10",[12221],[3024],{"trials":12285,"activeCount":102},[12286],{"nctId":3084,"briefTitle":3085,"status":108,"phases":12287,"primaryCompletion":3087,"completion":3088,"start":3089,"enrollment":506,"conditions":12288,"interventions":12289},[90,91],[24],[3092,3093,1849],{"trials":12291,"activeCount":102},[],{"trials":12293,"activeCount":102},[],{"trials":12295,"activeCount":102},[],{"intervention":12297,"totalTrials":456,"cells":12298},"Zonisamide 100Mg Cap",{"EARLY_PHASE1":12299,"PHASE1":12301,"PHASE2":12303,"PHASE3":12320,"PHASE4":12322,"NA":12324},{"trials":12300,"activeCount":102},[],{"trials":12302,"activeCount":102},[],{"trials":12304,"activeCount":102},[12305,12313],{"nctId":12306,"briefTitle":12307,"status":137,"phases":12308,"primaryCompletion":12309,"completion":12309,"start":1587,"enrollment":474,"conditions":12310,"interventions":12312},"NCT04774250","Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)",[91],"2022-12-23",[12311],"Hearing Loss, Noise-Induced",[12297],{"nctId":12314,"briefTitle":12315,"status":137,"phases":12316,"primaryCompletion":12317,"completion":12317,"start":7783,"enrollment":30,"conditions":12318,"interventions":12319},"NCT04768569","Noise-Induced Hearing Loss-Acute Exposure Treatment",[91],"2023-09-29",[12311],[12297],{"trials":12321,"activeCount":102},[],{"trials":12323,"activeCount":102},[],{"trials":12325,"activeCount":102},[],{"intervention":1626,"totalTrials":456,"cells":12327},{"EARLY_PHASE1":12328,"PHASE1":12330,"PHASE2":12332,"PHASE3":12342,"PHASE4":12344,"NA":12346},{"trials":12329,"activeCount":102},[],{"trials":12331,"activeCount":102},[],{"trials":12333,"activeCount":102},[12334,12338],{"nctId":3551,"briefTitle":3552,"status":108,"phases":12335,"primaryCompletion":3554,"completion":3555,"start":3477,"enrollment":3556,"conditions":12336,"interventions":12337},[91],[1445],[3559,1626,1594,631],{"nctId":1618,"briefTitle":1619,"status":137,"phases":12339,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":12340,"interventions":12341},[91],[1445],[1228,631,1229,82,1626,1594,426,375],{"trials":12343,"activeCount":102},[],{"trials":12345,"activeCount":102},[],{"trials":12347,"activeCount":102},[],{"intervention":1740,"totalTrials":456,"cells":12349},{"EARLY_PHASE1":12350,"PHASE1":12352,"PHASE2":12358,"PHASE3":12364,"PHASE4":12366,"NA":12368},{"trials":12351,"activeCount":102},[],{"trials":12353,"activeCount":102},[12354],{"nctId":3793,"briefTitle":3794,"status":108,"phases":12355,"primaryCompletion":3796,"completion":3797,"start":3798,"enrollment":1938,"conditions":12356,"interventions":12357},[90],[2291,3800,3801],[1740,620],{"trials":12359,"activeCount":102},[12360],{"nctId":1731,"briefTitle":1732,"status":122,"phases":12361,"primaryCompletion":1734,"completion":1735,"start":1736,"enrollment":102,"conditions":12362,"interventions":12363},[91],[1445],[1739,1740],{"trials":12365,"activeCount":102},[],{"trials":12367,"activeCount":102},[],{"trials":12369,"activeCount":102},[],{"intervention":3340,"totalTrials":456,"cells":12371},{"EARLY_PHASE1":12372,"PHASE1":12374,"PHASE2":12376,"PHASE3":12386,"PHASE4":12388,"NA":12390},{"trials":12373,"activeCount":102},[],{"trials":12375,"activeCount":102},[],{"trials":12377,"activeCount":102},[12378,12382],{"nctId":3330,"briefTitle":3331,"status":122,"phases":12379,"primaryCompletion":2937,"completion":983,"start":3333,"enrollment":102,"conditions":12380,"interventions":12381},[91],[3335,3336],[3338,2375,3339,2612,3340],{"nctId":3619,"briefTitle":3620,"status":122,"phases":12383,"primaryCompletion":3622,"completion":3622,"start":1195,"enrollment":102,"conditions":12384,"interventions":12385},[91],[3336,3335,26],[3625,2375,1229,3340],{"trials":12387,"activeCount":102},[],{"trials":12389,"activeCount":102},[],{"trials":12391,"activeCount":102},[],{"intervention":1264,"totalTrials":456,"cells":12393},{"EARLY_PHASE1":12394,"PHASE1":12396,"PHASE2":12402,"PHASE3":12408,"PHASE4":12410,"NA":12412},{"trials":12395,"activeCount":102},[],{"trials":12397,"activeCount":102},[12398],{"nctId":9276,"briefTitle":9277,"status":108,"phases":12399,"primaryCompletion":8074,"completion":9279,"start":9280,"enrollment":1299,"conditions":12400,"interventions":12401},[90],[29,116,115],[414,373,1264,9269],{"trials":12403,"activeCount":102},[12404],{"nctId":1256,"briefTitle":1257,"status":122,"phases":12405,"primaryCompletion":1090,"completion":1259,"start":1260,"enrollment":102,"conditions":12406,"interventions":12407},[91],[1082,1262],[994,1264],{"trials":12409,"activeCount":102},[],{"trials":12411,"activeCount":102},[],{"trials":12413,"activeCount":102},[],{"intervention":12415,"totalTrials":456,"cells":12416},"Estradiol",{"EARLY_PHASE1":12417,"PHASE1":12419,"PHASE2":12421,"PHASE3":12441,"PHASE4":12443,"NA":12445},{"trials":12418,"activeCount":102},[],{"trials":12420,"activeCount":102},[],{"trials":12422,"activeCount":102},[12423,12433],{"nctId":12424,"briefTitle":12425,"status":108,"phases":12426,"primaryCompletion":12427,"completion":12427,"start":12428,"enrollment":2678,"conditions":12429,"interventions":12430},"NCT02455453","Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography",[91],"2019-01-03","2015-04-28",[18],[12431,12415,12432],"18F-FFNP","18F-FDG",{"nctId":12434,"briefTitle":12435,"status":108,"phases":12436,"primaryCompletion":10845,"completion":1736,"start":12437,"enrollment":12438,"conditions":12439,"interventions":12440},"NCT00324259","Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer",[91],"2004-08",66,[1445],[12415],{"trials":12442,"activeCount":102},[],{"trials":12444,"activeCount":102},[],{"trials":12446,"activeCount":102},[],{"intervention":6193,"totalTrials":456,"cells":12448},{"EARLY_PHASE1":12449,"PHASE1":12451,"PHASE2":12453,"PHASE3":12467,"PHASE4":12469,"NA":12471},{"trials":12450,"activeCount":102},[],{"trials":12452,"activeCount":102},[],{"trials":12454,"activeCount":102},[12455,12463],{"nctId":12456,"briefTitle":12457,"status":122,"phases":12458,"primaryCompletion":2443,"completion":2452,"start":12459,"enrollment":102,"conditions":12460,"interventions":12462},"NCT01620736","Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load",[91],"2012-01",[12461],"Human T-cell Leukemia Virus Type 1 Infection",[6193],{"nctId":6185,"briefTitle":6186,"status":108,"phases":12464,"primaryCompletion":3432,"completion":6188,"start":1952,"enrollment":1056,"conditions":12465,"interventions":12466},[90,91],[6190],[2446,2424,6192,1228,1073,1229,6193],{"trials":12468,"activeCount":102},[],{"trials":12470,"activeCount":102},[],{"trials":12472,"activeCount":102},[],{"intervention":2590,"totalTrials":456,"cells":12474},{"EARLY_PHASE1":12475,"PHASE1":12477,"PHASE2":12479,"PHASE3":12494,"PHASE4":12496,"NA":12498},{"trials":12476,"activeCount":102},[],{"trials":12478,"activeCount":102},[],{"trials":12480,"activeCount":102},[12481,12485],{"nctId":2579,"briefTitle":2580,"status":108,"phases":12482,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":27,"conditions":12483,"interventions":12484},[91],[2585,2586],[2588,2376,2589,2561,2590,1073],{"nctId":12486,"briefTitle":12487,"status":122,"phases":12488,"primaryCompletion":3518,"completion":3518,"start":12489,"enrollment":102,"conditions":12490,"interventions":12492},"NCT02049073","Prevention of Noise-induced Hearing Loss",[90,91],"2017-10-31",[12491],"Noise-induced Hearing Loss",[12493,2590],"Zonisamide",{"trials":12495,"activeCount":102},[],{"trials":12497,"activeCount":102},[],{"trials":12499,"activeCount":102},[],{"intervention":1034,"totalTrials":456,"cells":12501},{"EARLY_PHASE1":12502,"PHASE1":12504,"PHASE2":12510,"PHASE3":12516,"PHASE4":12518,"NA":12520},{"trials":12503,"activeCount":102},[],{"trials":12505,"activeCount":102},[12506],{"nctId":1023,"briefTitle":1024,"status":137,"phases":12507,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":960,"conditions":12508,"interventions":12509},[90],[1030,1031,987,1032],[1034,959,994],{"trials":12511,"activeCount":102},[12512],{"nctId":6645,"briefTitle":6646,"status":137,"phases":12513,"primaryCompletion":6648,"completion":6649,"start":6650,"enrollment":1310,"conditions":12514,"interventions":12515},[91],[2121],[1034,3761],{"trials":12517,"activeCount":102},[],{"trials":12519,"activeCount":102},[],{"trials":12521,"activeCount":102},[],{"intervention":165,"totalTrials":456,"cells":12523},{"EARLY_PHASE1":12524,"PHASE1":12536,"PHASE2":12538,"PHASE3":12544,"PHASE4":12546,"NA":12548},{"trials":12525,"activeCount":102},[12526],{"nctId":12527,"briefTitle":12528,"status":108,"phases":12529,"primaryCompletion":1039,"completion":1039,"start":12530,"enrollment":12531,"conditions":12532,"interventions":12534},"NCT04230681","Hydromorphone vs Fentanyl in Children Undergoing Tonsillectomy Surgery",[89],"2020-02-26",189,[12533,11047],"Obstructive Sleep Apnea",[12535,165],"Hydromorphone",{"trials":12537,"activeCount":102},[],{"trials":12539,"activeCount":102},[12540],{"nctId":151,"briefTitle":152,"status":108,"phases":12541,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":12542,"interventions":12543},[91],[18,158,159],[97,161,162,163,164,165],{"trials":12545,"activeCount":102},[],{"trials":12547,"activeCount":102},[],{"trials":12549,"activeCount":102},[],{"intervention":413,"totalTrials":456,"cells":12551},{"EARLY_PHASE1":12552,"PHASE1":12554,"PHASE2":12563,"PHASE3":12569,"PHASE4":12571,"NA":12573},{"trials":12553,"activeCount":102},[],{"trials":12555,"activeCount":102},[12556],{"nctId":12557,"briefTitle":12558,"status":137,"phases":12559,"primaryCompletion":2370,"completion":2370,"start":12560,"enrollment":1299,"conditions":12561,"interventions":12562},"NCT01555853","Phase I\u002FII Study of Abraxane in Recurrent and Refractory Lymphoma",[90],"2012-07",[2598,1888],[413],{"trials":12564,"activeCount":102},[12565],{"nctId":405,"briefTitle":406,"status":108,"phases":12566,"primaryCompletion":408,"completion":409,"start":410,"enrollment":293,"conditions":12567,"interventions":12568},[91],[355],[413,339,339,403,414,403,339],{"trials":12570,"activeCount":102},[],{"trials":12572,"activeCount":102},[],{"trials":12574,"activeCount":102},[],{"intervention":2013,"totalTrials":456,"cells":12576},{"EARLY_PHASE1":12577,"PHASE1":12583,"PHASE2":12585,"PHASE3":12591,"PHASE4":12593,"NA":12595},{"trials":12578,"activeCount":102},[12579],{"nctId":2005,"briefTitle":2006,"status":108,"phases":12580,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":36,"conditions":12581,"interventions":12582},[89],[1004],[1151,2013],{"trials":12584,"activeCount":102},[],{"trials":12586,"activeCount":102},[12587],{"nctId":2065,"briefTitle":2066,"status":108,"phases":12588,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":2070,"conditions":12589,"interventions":12590},[90,91],[2023],[2013,2073,1151],{"trials":12592,"activeCount":102},[],{"trials":12594,"activeCount":102},[],{"trials":12596,"activeCount":102},[],{"intervention":12598,"totalTrials":456,"cells":12599},"Niacinamide",{"EARLY_PHASE1":12600,"PHASE1":12602,"PHASE2":12612,"PHASE3":12620,"PHASE4":12622,"NA":12624},{"trials":12601,"activeCount":102},[],{"trials":12603,"activeCount":102},[12604],{"nctId":12605,"briefTitle":12606,"status":108,"phases":12607,"primaryCompletion":12608,"completion":1400,"start":1574,"enrollment":506,"conditions":12609,"interventions":12611},"NCT00316472","The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients",[90],"2007-04",[12610],"Hyperphosphatemia",[12598],{"trials":12613,"activeCount":102},[12614],{"nctId":12615,"briefTitle":12616,"status":108,"phases":12617,"completion":3250,"start":1648,"enrollment":1818,"conditions":12618,"interventions":12619},"NCT00508885","The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients",[90,91],[12610],[12598],{"trials":12621,"activeCount":102},[],{"trials":12623,"activeCount":102},[],{"trials":12625,"activeCount":102},[],{"intervention":8943,"totalTrials":456,"cells":12627},{"EARLY_PHASE1":12628,"PHASE1":12630,"PHASE2":12632,"PHASE3":12647,"PHASE4":12649,"NA":12651},{"trials":12629,"activeCount":102},[],{"trials":12631,"activeCount":102},[],{"trials":12633,"activeCount":102},[12634,12638],{"nctId":8932,"briefTitle":8933,"status":108,"phases":12635,"primaryCompletion":8935,"completion":4701,"start":8936,"enrollment":8937,"conditions":12636,"interventions":12637},[91],[8939,8940],[8942,8943,163,8944],{"nctId":12639,"briefTitle":12640,"status":137,"phases":12641,"primaryCompletion":6943,"completion":6943,"start":3863,"enrollment":6806,"conditions":12642,"interventions":12644},"NCT06083571","Intranasal Ketorolac Trial",[91],[12643],"Headache, Migraine",[8943,12645,12646],"Prochlorperazine","Diphenhydramine",{"trials":12648,"activeCount":102},[],{"trials":12650,"activeCount":102},[],{"trials":12652,"activeCount":102},[],{"intervention":12654,"totalTrials":456,"cells":12655},"theophylline",{"EARLY_PHASE1":12656,"PHASE1":12658,"PHASE2":12660,"PHASE3":12685,"PHASE4":12687,"NA":12689},{"trials":12657,"activeCount":102},[],{"trials":12659,"activeCount":102},[],{"trials":12661,"activeCount":102},[12662,12672],{"nctId":12663,"briefTitle":12664,"status":108,"phases":12665,"primaryCompletion":12666,"completion":12667,"start":12668,"enrollment":12669,"conditions":12670,"interventions":12671},"NCT05947643","Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)",[91],"2025-04-24","2025-08-04","2022-11-22",77,[718],[12654],{"nctId":12673,"briefTitle":12674,"status":108,"phases":12675,"primaryCompletion":12676,"completion":12676,"start":12677,"enrollment":27,"conditions":12678,"interventions":12682},"NCT03990766","Smell Changes & Efficacy of Nasal Theophylline",[91],"2021-01-15","2019-05-15",[719,9087,12679,12680,12681],"Viral Infection","Theophylline Causing Adverse Effects in Therapeutic Use","Smell Disorder",[12683,12684],"Theophylline","Saline Nasal",{"trials":12686,"activeCount":102},[],{"trials":12688,"activeCount":102},[],{"trials":12690,"activeCount":102},[],{"intervention":12692,"totalTrials":456,"cells":12693},"Stellate Ganglion Block",{"EARLY_PHASE1":12694,"PHASE1":12696,"PHASE2":12698,"PHASE3":12718,"PHASE4":12720,"NA":12722},{"trials":12695,"activeCount":102},[],{"trials":12697,"activeCount":102},[],{"trials":12699,"activeCount":102},[12700,12709],{"nctId":12701,"briefTitle":12702,"status":108,"phases":12703,"primaryCompletion":12704,"completion":12704,"start":12705,"enrollment":1299,"conditions":12706,"interventions":12708},"NCT05445921","Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction",[90,91],"2022-12-12","2022-09-01",[9087,12707,720,719],"Hyposmia",[12692],{"nctId":12710,"briefTitle":12711,"status":108,"phases":12712,"primaryCompletion":12713,"completion":12713,"start":12714,"enrollment":565,"conditions":12715,"interventions":12717},"NCT06253806","Stellate Ganglion Block for COVID-induced Parosmia",[91],"2024-09-16","2023-10-25",[12716],"COVID-19-Induced Parosmia",[12692],{"trials":12719,"activeCount":102},[],{"trials":12721,"activeCount":102},[],{"trials":12723,"activeCount":102},[],{"intervention":3093,"totalTrials":456,"cells":12725},{"EARLY_PHASE1":12726,"PHASE1":12728,"PHASE2":12734,"PHASE3":12740,"PHASE4":12742,"NA":12744},{"trials":12727,"activeCount":102},[],{"trials":12729,"activeCount":102},[12730],{"nctId":11770,"briefTitle":11771,"status":108,"phases":12731,"primaryCompletion":3102,"completion":365,"start":11773,"enrollment":3305,"conditions":12732,"interventions":12733},[90],[3545],[3547,11776],{"trials":12735,"activeCount":102},[12736],{"nctId":3084,"briefTitle":3085,"status":108,"phases":12737,"primaryCompletion":3087,"completion":3088,"start":3089,"enrollment":506,"conditions":12738,"interventions":12739},[90,91],[24],[3092,3093,1849],{"trials":12741,"activeCount":102},[],{"trials":12743,"activeCount":102},[],{"trials":12745,"activeCount":102},[],{"intervention":12747,"totalTrials":456,"cells":12748},"Cefazolin",{"EARLY_PHASE1":12749,"PHASE1":12751,"PHASE2":12765,"PHASE3":12777,"PHASE4":12779,"NA":12781},{"trials":12750,"activeCount":102},[],{"trials":12752,"activeCount":102},[12753],{"nctId":12754,"briefTitle":12755,"status":108,"phases":12756,"primaryCompletion":12757,"completion":12757,"start":12758,"enrollment":1042,"conditions":12759,"interventions":12762},"NCT03213249","Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy",[90],"2018-09-26","2017-07-25",[12760,12761],"Breast Implant Infection","Mammoplasty",[12747,12763,12764],"Gentamicin","Bacitracin",{"trials":12766,"activeCount":102},[12767],{"nctId":12768,"briefTitle":12769,"status":108,"phases":12770,"primaryCompletion":12771,"completion":12771,"start":12772,"enrollment":1954,"conditions":12773,"interventions":12776},"NCT03578965","Does Antibiotic Prophylaxis Reduce Wound Complications After Vulvar Excision of Premalignant Lesions",[91],"2021-11-23","2018-07-13",[12774,12775],"Premalignant Vulvar Lesion","Benign Vulvar Lesion",[12747],{"trials":12778,"activeCount":102},[],{"trials":12780,"activeCount":102},[],{"trials":12782,"activeCount":102},[],{"intervention":12784,"totalTrials":456,"cells":12785},"BL-8040",{"EARLY_PHASE1":12786,"PHASE1":12788,"PHASE2":12790,"PHASE3":12817,"PHASE4":12819,"NA":12821},{"trials":12787,"activeCount":102},[],{"trials":12789,"activeCount":102},[],{"trials":12791,"activeCount":102},[12792,12803],{"nctId":12793,"briefTitle":12794,"status":137,"phases":12795,"primaryCompletion":10025,"completion":12796,"start":12797,"enrollment":1566,"conditions":12798,"interventions":12801},"NCT02763384","BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia\u002F Lymphoblastic Lymphoma",[91],"2022-05-22","2016-12-02",[12799,12800],"T-Acute Lymphoblastic Leukemia","Adult T Lymphoblastic Lymphoma",[12784,12802],"Nelarabine",{"nctId":12804,"briefTitle":12805,"status":108,"phases":12806,"primaryCompletion":6572,"completion":12807,"start":6710,"enrollment":1954,"conditions":12808,"interventions":12816},"NCT02639559","Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies",[91],"2023-04-07",[12809,12810,12811,12812,12813,1888,12814,12815,24,2390,6428],"Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Chronic Myelogenous Leukemia","Non-Hodgkin's Lymphoma","Non-Hodgkin Lymphoma","Hodgkins Disease","Hodgkin's Disease",[12784],{"trials":12818,"activeCount":102},[],{"trials":12820,"activeCount":102},[],{"trials":12822,"activeCount":102},[],{"intervention":3559,"totalTrials":184,"cells":12824},{"EARLY_PHASE1":12825,"PHASE1":12827,"PHASE2":12829,"PHASE3":12835,"PHASE4":12837,"NA":12839},{"trials":12826,"activeCount":102},[],{"trials":12828,"activeCount":102},[],{"trials":12830,"activeCount":102},[12831],{"nctId":3551,"briefTitle":3552,"status":108,"phases":12832,"primaryCompletion":3554,"completion":3555,"start":3477,"enrollment":3556,"conditions":12833,"interventions":12834},[91],[1445],[3559,1626,1594,631],{"trials":12836,"activeCount":102},[],{"trials":12838,"activeCount":102},[],{"trials":12840,"activeCount":102},[],{"intervention":3482,"totalTrials":184,"cells":12842},{"EARLY_PHASE1":12843,"PHASE1":12845,"PHASE2":12847,"PHASE3":12853,"PHASE4":12855,"NA":12857},{"trials":12844,"activeCount":102},[],{"trials":12846,"activeCount":102},[],{"trials":12848,"activeCount":102},[12849],{"nctId":3474,"briefTitle":3475,"status":108,"phases":12850,"primaryCompletion":3032,"completion":1965,"start":3477,"enrollment":3478,"conditions":12851,"interventions":12852},[91],[3480],[3482,2563],{"trials":12854,"activeCount":102},[],{"trials":12856,"activeCount":102},[],{"trials":12858,"activeCount":102},[],{"intervention":12860,"totalTrials":184,"cells":12861},"Active Comparator: Second Intervention",{"EARLY_PHASE1":12862,"PHASE1":12864,"PHASE2":12866,"PHASE3":12881,"PHASE4":12883,"NA":12885},{"trials":12863,"activeCount":102},[],{"trials":12865,"activeCount":102},[],{"trials":12867,"activeCount":102},[12868],{"nctId":12869,"briefTitle":12870,"status":108,"phases":12871,"primaryCompletion":1647,"completion":3116,"start":12872,"enrollment":2070,"conditions":12873,"interventions":12878},"NCT00455325","Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)",[91],"2004-09",[12874,12875,6123,12876,12877],"Metabolic Syndrome X","Overweight","Dyslipidemias","Prediabetic State",[12860,12879,12880],"Active Comparator: Third Intervention","Active Comparator: Fourth Intervention",{"trials":12882,"activeCount":102},[],{"trials":12884,"activeCount":102},[],{"trials":12886,"activeCount":102},[],{"intervention":12879,"totalTrials":184,"cells":12888},{"EARLY_PHASE1":12889,"PHASE1":12891,"PHASE2":12893,"PHASE3":12899,"PHASE4":12901,"NA":12903},{"trials":12890,"activeCount":102},[],{"trials":12892,"activeCount":102},[],{"trials":12894,"activeCount":102},[12895],{"nctId":12869,"briefTitle":12870,"status":108,"phases":12896,"primaryCompletion":1647,"completion":3116,"start":12872,"enrollment":2070,"conditions":12897,"interventions":12898},[91],[12874,12875,6123,12876,12877],[12860,12879,12880],{"trials":12900,"activeCount":102},[],{"trials":12902,"activeCount":102},[],{"trials":12904,"activeCount":102},[],{"intervention":12880,"totalTrials":184,"cells":12906},{"EARLY_PHASE1":12907,"PHASE1":12909,"PHASE2":12911,"PHASE3":12917,"PHASE4":12919,"NA":12921},{"trials":12908,"activeCount":102},[],{"trials":12910,"activeCount":102},[],{"trials":12912,"activeCount":102},[12913],{"nctId":12869,"briefTitle":12870,"status":108,"phases":12914,"primaryCompletion":1647,"completion":3116,"start":12872,"enrollment":2070,"conditions":12915,"interventions":12916},[91],[12874,12875,6123,12876,12877],[12860,12879,12880],{"trials":12918,"activeCount":102},[],{"trials":12920,"activeCount":102},[],{"trials":12922,"activeCount":102},[],{"intervention":12924,"totalTrials":184,"cells":12925},"epoetin alfa",{"EARLY_PHASE1":12926,"PHASE1":12928,"PHASE2":12930,"PHASE3":12939,"PHASE4":12941,"NA":12943},{"trials":12927,"activeCount":102},[],{"trials":12929,"activeCount":102},[],{"trials":12931,"activeCount":102},[12932],{"nctId":12933,"briefTitle":12934,"status":122,"phases":12935,"primaryCompletion":3103,"completion":3103,"start":3208,"enrollment":102,"conditions":12936,"interventions":12938},"NCT00528593","Epoetin Alfa for HIV-Associated Neuropathy Trial",[91],[6090,12937],"Neuropathy",[12924],{"trials":12940,"activeCount":102},[],{"trials":12942,"activeCount":102},[],{"trials":12944,"activeCount":102},[],{"intervention":2437,"totalTrials":184,"cells":12946},{"EARLY_PHASE1":12947,"PHASE1":12949,"PHASE2":12951,"PHASE3":12957,"PHASE4":12959,"NA":12961},{"trials":12948,"activeCount":102},[],{"trials":12950,"activeCount":102},[],{"trials":12952,"activeCount":102},[12953],{"nctId":2429,"briefTitle":2430,"status":108,"phases":12954,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":2434,"conditions":12955,"interventions":12956},[91],[24],[2437,2362],{"trials":12958,"activeCount":102},[],{"trials":12960,"activeCount":102},[],{"trials":12962,"activeCount":102},[],{"intervention":3338,"totalTrials":184,"cells":12964},{"EARLY_PHASE1":12965,"PHASE1":12967,"PHASE2":12969,"PHASE3":12975,"PHASE4":12977,"NA":12979},{"trials":12966,"activeCount":102},[],{"trials":12968,"activeCount":102},[],{"trials":12970,"activeCount":102},[12971],{"nctId":3330,"briefTitle":3331,"status":122,"phases":12972,"primaryCompletion":2937,"completion":983,"start":3333,"enrollment":102,"conditions":12973,"interventions":12974},[91],[3335,3336],[3338,2375,3339,2612,3340],{"trials":12976,"activeCount":102},[],{"trials":12978,"activeCount":102},[],{"trials":12980,"activeCount":102},[],{"intervention":3339,"totalTrials":184,"cells":12982},{"EARLY_PHASE1":12983,"PHASE1":12985,"PHASE2":12987,"PHASE3":12993,"PHASE4":12995,"NA":12997},{"trials":12984,"activeCount":102},[],{"trials":12986,"activeCount":102},[],{"trials":12988,"activeCount":102},[12989],{"nctId":3330,"briefTitle":3331,"status":122,"phases":12990,"primaryCompletion":2937,"completion":983,"start":3333,"enrollment":102,"conditions":12991,"interventions":12992},[91],[3335,3336],[3338,2375,3339,2612,3340],{"trials":12994,"activeCount":102},[],{"trials":12996,"activeCount":102},[],{"trials":12998,"activeCount":102},[],{"intervention":13000,"totalTrials":184,"cells":13001},"Omega-3 supplement",{"EARLY_PHASE1":13002,"PHASE1":13004,"PHASE2":13006,"PHASE3":13016,"PHASE4":13018,"NA":13020},{"trials":13003,"activeCount":102},[],{"trials":13005,"activeCount":102},[],{"trials":13007,"activeCount":102},[13008],{"nctId":13009,"briefTitle":13010,"status":108,"phases":13011,"primaryCompletion":11591,"completion":11591,"start":13012,"enrollment":13013,"conditions":13014,"interventions":13015},"NCT02021669","Omega-3 for Depression and Other Cardiac Risk Factors - 2",[91],"2014-05-14",144,[21],[13000],{"trials":13017,"activeCount":102},[],{"trials":13019,"activeCount":102},[],{"trials":13021,"activeCount":102},[],{"intervention":13023,"totalTrials":184,"cells":13024},"Nintedanib",{"EARLY_PHASE1":13025,"PHASE1":13027,"PHASE2":13029,"PHASE3":13040,"PHASE4":13042,"NA":13044},{"trials":13026,"activeCount":102},[],{"trials":13028,"activeCount":102},[],{"trials":13030,"activeCount":102},[13031],{"nctId":13032,"briefTitle":13033,"status":108,"phases":13034,"primaryCompletion":13035,"completion":13036,"start":13037,"enrollment":1299,"conditions":13038,"interventions":13039},"NCT02299141","Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer",[91],"2020-01-09","2025-04-23","2015-05-07",[1553,1354,1356],[13023],{"trials":13041,"activeCount":102},[],{"trials":13043,"activeCount":102},[],{"trials":13045,"activeCount":102},[],{"intervention":13047,"totalTrials":184,"cells":13048},"Red blood cell transfusion",{"EARLY_PHASE1":13049,"PHASE1":13051,"PHASE2":13053,"PHASE3":13063,"PHASE4":13065,"NA":13067},{"trials":13050,"activeCount":102},[],{"trials":13052,"activeCount":102},[],{"trials":13054,"activeCount":102},[13055],{"nctId":13056,"briefTitle":13057,"status":108,"phases":13058,"primaryCompletion":381,"completion":381,"start":3208,"enrollment":3820,"conditions":13059,"interventions":13062},"NCT00968227","Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage",[90,91],[13060,13061],"Subarachnoid Hemorrhage","Vasospasm",[13047],{"trials":13064,"activeCount":102},[],{"trials":13066,"activeCount":102},[],{"trials":13068,"activeCount":102},[],{"intervention":13070,"totalTrials":184,"cells":13071},"Granix",{"EARLY_PHASE1":13072,"PHASE1":13074,"PHASE2":13076,"PHASE3":13088,"PHASE4":13090,"NA":13092},{"trials":13073,"activeCount":102},[],{"trials":13075,"activeCount":102},[],{"trials":13077,"activeCount":102},[13078],{"nctId":13079,"briefTitle":13080,"status":137,"phases":13081,"primaryCompletion":13082,"completion":13083,"start":3072,"enrollment":13084,"conditions":13085,"interventions":13086},"NCT02112045","A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation",[91],"2017-12-13","2019-09-10",90,[24],[13070,13087],"High dose melphalan",{"trials":13089,"activeCount":102},[],{"trials":13091,"activeCount":102},[],{"trials":13093,"activeCount":102},[],{"intervention":13087,"totalTrials":184,"cells":13095},{"EARLY_PHASE1":13096,"PHASE1":13098,"PHASE2":13100,"PHASE3":13106,"PHASE4":13108,"NA":13110},{"trials":13097,"activeCount":102},[],{"trials":13099,"activeCount":102},[],{"trials":13101,"activeCount":102},[13102],{"nctId":13079,"briefTitle":13080,"status":137,"phases":13103,"primaryCompletion":13082,"completion":13083,"start":3072,"enrollment":13084,"conditions":13104,"interventions":13105},[91],[24],[13070,13087],{"trials":13107,"activeCount":102},[],{"trials":13109,"activeCount":102},[],{"trials":13111,"activeCount":102},[],{"intervention":12431,"totalTrials":184,"cells":13113},{"EARLY_PHASE1":13114,"PHASE1":13116,"PHASE2":13118,"PHASE3":13124,"PHASE4":13126,"NA":13128},{"trials":13115,"activeCount":102},[],{"trials":13117,"activeCount":102},[],{"trials":13119,"activeCount":102},[13120],{"nctId":12424,"briefTitle":12425,"status":108,"phases":13121,"primaryCompletion":12427,"completion":12427,"start":12428,"enrollment":2678,"conditions":13122,"interventions":13123},[91],[18],[12431,12415,12432],{"trials":13125,"activeCount":102},[],{"trials":13127,"activeCount":102},[],{"trials":13129,"activeCount":102},[],{"intervention":12432,"totalTrials":184,"cells":13131},{"EARLY_PHASE1":13132,"PHASE1":13134,"PHASE2":13136,"PHASE3":13142,"PHASE4":13144,"NA":13146},{"trials":13133,"activeCount":102},[],{"trials":13135,"activeCount":102},[],{"trials":13137,"activeCount":102},[13138],{"nctId":12424,"briefTitle":12425,"status":108,"phases":13139,"primaryCompletion":12427,"completion":12427,"start":12428,"enrollment":2678,"conditions":13140,"interventions":13141},[91],[18],[12431,12415,12432],{"trials":13143,"activeCount":102},[],{"trials":13145,"activeCount":102},[],{"trials":13147,"activeCount":102},[],{"intervention":13149,"totalTrials":184,"cells":13150},"Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan",{"EARLY_PHASE1":13151,"PHASE1":13153,"PHASE2":13155,"PHASE3":13164,"PHASE4":13166,"NA":13168},{"trials":13152,"activeCount":102},[],{"trials":13154,"activeCount":102},[],{"trials":13156,"activeCount":102},[13157],{"nctId":13158,"briefTitle":13159,"status":108,"phases":13160,"primaryCompletion":3321,"completion":3302,"start":6399,"enrollment":36,"conditions":13161,"interventions":13163},"NCT01005576","Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia",[91],[13162],"Severe Thalassemia",[13149],{"trials":13165,"activeCount":102},[],{"trials":13167,"activeCount":102},[],{"trials":13169,"activeCount":102},[],{"intervention":8976,"totalTrials":184,"cells":13171},{"EARLY_PHASE1":13172,"PHASE1":13174,"PHASE2":13176,"PHASE3":13182,"PHASE4":13184,"NA":13186},{"trials":13173,"activeCount":102},[],{"trials":13175,"activeCount":102},[],{"trials":13177,"activeCount":102},[13178],{"nctId":8969,"briefTitle":8970,"status":137,"phases":13179,"primaryCompletion":8972,"completion":8972,"start":8973,"enrollment":112,"conditions":13180,"interventions":13181},[90,91],[2502,1875],[8976,8960],{"trials":13183,"activeCount":102},[],{"trials":13185,"activeCount":102},[],{"trials":13187,"activeCount":102},[],{"intervention":13189,"totalTrials":184,"cells":13190},"Conservative treatment Arm",{"EARLY_PHASE1":13191,"PHASE1":13193,"PHASE2":13195,"PHASE3":13206,"PHASE4":13208,"NA":13210},{"trials":13192,"activeCount":102},[],{"trials":13194,"activeCount":102},[],{"trials":13196,"activeCount":102},[13197],{"nctId":13198,"briefTitle":13199,"status":108,"phases":13200,"primaryCompletion":13201,"completion":13201,"start":13202,"enrollment":3684,"conditions":13203,"interventions":13205},"NCT05756647","Mandibular Advancement vs Home Treatment for Primary Snoring",[91],"2023-07-03","2022-11-07",[13204],"Snoring",[13189],{"trials":13207,"activeCount":102},[],{"trials":13209,"activeCount":102},[],{"trials":13211,"activeCount":102},[],{"intervention":2588,"totalTrials":184,"cells":13213},{"EARLY_PHASE1":13214,"PHASE1":13216,"PHASE2":13218,"PHASE3":13224,"PHASE4":13226,"NA":13228},{"trials":13215,"activeCount":102},[],{"trials":13217,"activeCount":102},[],{"trials":13219,"activeCount":102},[13220],{"nctId":2579,"briefTitle":2580,"status":108,"phases":13221,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":27,"conditions":13222,"interventions":13223},[91],[2585,2586],[2588,2376,2589,2561,2590,1073],{"trials":13225,"activeCount":102},[],{"trials":13227,"activeCount":102},[],{"trials":13229,"activeCount":102},[],{"intervention":2589,"totalTrials":184,"cells":13231},{"EARLY_PHASE1":13232,"PHASE1":13234,"PHASE2":13236,"PHASE3":13242,"PHASE4":13244,"NA":13246},{"trials":13233,"activeCount":102},[],{"trials":13235,"activeCount":102},[],{"trials":13237,"activeCount":102},[13238],{"nctId":2579,"briefTitle":2580,"status":108,"phases":13239,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":27,"conditions":13240,"interventions":13241},[91],[2585,2586],[2588,2376,2589,2561,2590,1073],{"trials":13243,"activeCount":102},[],{"trials":13245,"activeCount":102},[],{"trials":13247,"activeCount":102},[],{"intervention":13249,"totalTrials":184,"cells":13250},"89Zr-trastuzumab",{"EARLY_PHASE1":13251,"PHASE1":13253,"PHASE2":13255,"PHASE3":13265,"PHASE4":13267,"NA":13269},{"trials":13252,"activeCount":102},[],{"trials":13254,"activeCount":102},[],{"trials":13256,"activeCount":102},[13257],{"nctId":13258,"briefTitle":13259,"status":122,"phases":13260,"primaryCompletion":9085,"completion":9085,"start":1588,"enrollment":102,"conditions":13261,"interventions":13264},"NCT04757090","89Zr-Trastuzumab PET\u002FCT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111",[91],[13262,13263],"HER2-positive Solid Tumor","HER-2 Positive Cancer",[13249],{"trials":13266,"activeCount":102},[],{"trials":13268,"activeCount":102},[],{"trials":13270,"activeCount":102},[],{"intervention":13272,"totalTrials":184,"cells":13273},"Ethyol",{"EARLY_PHASE1":13274,"PHASE1":13276,"PHASE2":13278,"PHASE3":13288,"PHASE4":13290,"NA":13292},{"trials":13275,"activeCount":102},[],{"trials":13277,"activeCount":102},[],{"trials":13279,"activeCount":102},[13280],{"nctId":13281,"briefTitle":13282,"status":108,"phases":13283,"completion":13284,"start":13285,"enrollment":27,"conditions":13286,"interventions":13287},"NCT00167908","Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer",[91],"2007-05","2001-10",[399],[13272],{"trials":13289,"activeCount":102},[],{"trials":13291,"activeCount":102},[],{"trials":13293,"activeCount":102},[],{"intervention":13295,"totalTrials":184,"cells":13296},"MEDI4736",{"EARLY_PHASE1":13297,"PHASE1":13299,"PHASE2":13301,"PHASE3":13320,"PHASE4":13322,"NA":13324},{"trials":13298,"activeCount":102},[],{"trials":13300,"activeCount":102},[],{"trials":13302,"activeCount":102},[13303],{"nctId":13304,"briefTitle":13305,"status":137,"phases":13306,"primaryCompletion":13307,"completion":13308,"start":10761,"enrollment":599,"conditions":13309,"interventions":13319},"NCT02669914","MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors",[91],"2017-09-21","2018-01-11",[1354,1356,18,159,2271,13310,29,115,369,13311,13312,13313,13314,13315,1607,13316,13317,13318],"Gastroesophageal Cancer","Colorectal Carcinoma","Renal Cancer","Kidney Cancer","Cancer of the Kidney","Cancer of Kidney","Ovary Cancer","Cancer of the Ovary","Cancer of Ovary",[13295],{"trials":13321,"activeCount":102},[],{"trials":13323,"activeCount":102},[],{"trials":13325,"activeCount":102},[],{"intervention":13327,"totalTrials":184,"cells":13328},"Carvedilol",{"EARLY_PHASE1":13329,"PHASE1":13331,"PHASE2":13333,"PHASE3":13347,"PHASE4":13349,"NA":13351},{"trials":13330,"activeCount":102},[],{"trials":13332,"activeCount":102},[],{"trials":13334,"activeCount":102},[13335],{"nctId":13336,"briefTitle":13337,"status":137,"phases":13338,"primaryCompletion":13339,"completion":13340,"start":13341,"enrollment":1623,"conditions":13342,"interventions":13345},"NCT06844669","HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy",[91],"2026-02-16","2026-05-07","2025-04-16",[13343,13344],"HER2-positive Breast Cancer","HER2+ Breast Cancer",[13327,13346],"Empagliflozin",{"trials":13348,"activeCount":102},[],{"trials":13350,"activeCount":102},[],{"trials":13352,"activeCount":102},[],{"intervention":13346,"totalTrials":184,"cells":13354},{"EARLY_PHASE1":13355,"PHASE1":13357,"PHASE2":13359,"PHASE3":13365,"PHASE4":13367,"NA":13369},{"trials":13356,"activeCount":102},[],{"trials":13358,"activeCount":102},[],{"trials":13360,"activeCount":102},[13361],{"nctId":13336,"briefTitle":13337,"status":137,"phases":13362,"primaryCompletion":13339,"completion":13340,"start":13341,"enrollment":1623,"conditions":13363,"interventions":13364},[91],[13343,13344],[13327,13346],{"trials":13366,"activeCount":102},[],{"trials":13368,"activeCount":102},[],{"trials":13370,"activeCount":102},[],{"intervention":13372,"totalTrials":184,"cells":13373},"QUARTET LDQT",{"EARLY_PHASE1":13374,"PHASE1":13376,"PHASE2":13378,"PHASE3":13391,"PHASE4":13393,"NA":13395},{"trials":13375,"activeCount":102},[],{"trials":13377,"activeCount":102},[],{"trials":13379,"activeCount":102},[13380],{"nctId":13381,"briefTitle":13382,"status":108,"phases":13383,"primaryCompletion":13384,"completion":13385,"start":13386,"enrollment":13387,"conditions":13388,"interventions":13389},"NCT03640312","Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension",[91],"2022-05-31","2024-07-31","2019-08-30",62,[6123],[13372,13390],"Candesartan",{"trials":13392,"activeCount":102},[],{"trials":13394,"activeCount":102},[],{"trials":13396,"activeCount":102},[],{"intervention":13390,"totalTrials":184,"cells":13398},{"EARLY_PHASE1":13399,"PHASE1":13401,"PHASE2":13403,"PHASE3":13409,"PHASE4":13411,"NA":13413},{"trials":13400,"activeCount":102},[],{"trials":13402,"activeCount":102},[],{"trials":13404,"activeCount":102},[13405],{"nctId":13381,"briefTitle":13382,"status":108,"phases":13406,"primaryCompletion":13384,"completion":13385,"start":13386,"enrollment":13387,"conditions":13407,"interventions":13408},[91],[6123],[13372,13390],{"trials":13410,"activeCount":102},[],{"trials":13412,"activeCount":102},[],{"trials":13414,"activeCount":102},[],{"intervention":13416,"totalTrials":184,"cells":13417},"Crizanlizumab",{"EARLY_PHASE1":13418,"PHASE1":13420,"PHASE2":13422,"PHASE3":13433,"PHASE4":13435,"NA":13437},{"trials":13419,"activeCount":102},[],{"trials":13421,"activeCount":102},[],{"trials":13423,"activeCount":102},[13424],{"nctId":13425,"briefTitle":13426,"status":108,"phases":13427,"primaryCompletion":13428,"completion":6943,"start":13429,"enrollment":1056,"conditions":13430,"interventions":13432},"NCT04611880","Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)",[91],"2025-04-02","2021-01-25",[13431],"RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy",[13416],{"trials":13434,"activeCount":102},[],{"trials":13436,"activeCount":102},[],{"trials":13438,"activeCount":102},[],{"intervention":6542,"totalTrials":184,"cells":13440},{"EARLY_PHASE1":13441,"PHASE1":13443,"PHASE2":13445,"PHASE3":13451,"PHASE4":13453,"NA":13455},{"trials":13442,"activeCount":102},[],{"trials":13444,"activeCount":102},[],{"trials":13446,"activeCount":102},[13447],{"nctId":6536,"briefTitle":6537,"status":122,"phases":13448,"primaryCompletion":6539,"completion":6539,"start":1873,"enrollment":102,"conditions":13449,"interventions":13450},[91],[1445],[6542,6543],{"trials":13452,"activeCount":102},[],{"trials":13454,"activeCount":102},[],{"trials":13456,"activeCount":102},[],{"intervention":13458,"totalTrials":184,"cells":13459},"[F-18] flurothymidine",{"EARLY_PHASE1":13460,"PHASE1":13462,"PHASE2":13464,"PHASE3":13474,"PHASE4":13476,"NA":13478},{"trials":13461,"activeCount":102},[],{"trials":13463,"activeCount":102},[],{"trials":13465,"activeCount":102},[13466],{"nctId":13467,"briefTitle":13468,"status":122,"phases":13469,"primaryCompletion":13470,"completion":13470,"start":13471,"enrollment":102,"conditions":13472,"interventions":13473},"NCT04271436","Immune Checkpoint Blockade Therapy Using 18F-FLT PET\u002FCT",[91],"2025-01-31","2021-04-22",[35],[13458],{"trials":13475,"activeCount":102},[],{"trials":13477,"activeCount":102},[],{"trials":13479,"activeCount":102},[],{"intervention":13481,"totalTrials":184,"cells":13482},"venlafaxine XR",{"EARLY_PHASE1":13483,"PHASE1":13485,"PHASE2":13487,"PHASE3":13498,"PHASE4":13500,"NA":13502},{"trials":13484,"activeCount":102},[],{"trials":13486,"activeCount":102},[],{"trials":13488,"activeCount":102},[13489],{"nctId":13490,"briefTitle":13491,"status":108,"phases":13492,"primaryCompletion":13493,"completion":13493,"start":13494,"enrollment":1056,"conditions":13495,"interventions":13496},"NCT02181231","Buprenorphine Used With Treatment Resistant Depression in Older Adults",[90,91],"2018-04-30","2016-06-01",[3865,21],[13481,13497],"buprenorphine",{"trials":13499,"activeCount":102},[],{"trials":13501,"activeCount":102},[],{"trials":13503,"activeCount":102},[],{"intervention":8414,"totalTrials":184,"cells":13505},{"EARLY_PHASE1":13506,"PHASE1":13508,"PHASE2":13510,"PHASE3":13516,"PHASE4":13518,"NA":13520},{"trials":13507,"activeCount":102},[],{"trials":13509,"activeCount":102},[],{"trials":13511,"activeCount":102},[13512],{"nctId":8407,"briefTitle":8408,"status":122,"phases":13513,"primaryCompletion":1419,"completion":8410,"start":8411,"enrollment":102,"conditions":13514,"interventions":13515},[91],[4316],[8398,8414],{"trials":13517,"activeCount":102},[],{"trials":13519,"activeCount":102},[],{"trials":13521,"activeCount":102},[],{"intervention":632,"totalTrials":184,"cells":13523},{"EARLY_PHASE1":13524,"PHASE1":13526,"PHASE2":13528,"PHASE3":13534,"PHASE4":13536,"NA":13538},{"trials":13525,"activeCount":102},[],{"trials":13527,"activeCount":102},[],{"trials":13529,"activeCount":102},[13530],{"nctId":623,"briefTitle":624,"status":137,"phases":13531,"primaryCompletion":626,"completion":627,"start":628,"enrollment":442,"conditions":13532,"interventions":13533},[91],[18,159,616],[57,619,631,621,632],{"trials":13535,"activeCount":102},[],{"trials":13537,"activeCount":102},[],{"trials":13539,"activeCount":102},[],{"intervention":6192,"totalTrials":184,"cells":13541},{"EARLY_PHASE1":13542,"PHASE1":13544,"PHASE2":13546,"PHASE3":13552,"PHASE4":13554,"NA":13556},{"trials":13543,"activeCount":102},[],{"trials":13545,"activeCount":102},[],{"trials":13547,"activeCount":102},[13548],{"nctId":6185,"briefTitle":6186,"status":108,"phases":13549,"primaryCompletion":3432,"completion":6188,"start":1952,"enrollment":1056,"conditions":13550,"interventions":13551},[90,91],[6190],[2446,2424,6192,1228,1073,1229,6193],{"trials":13553,"activeCount":102},[],{"trials":13555,"activeCount":102},[],{"trials":13557,"activeCount":102},[],{"intervention":13559,"totalTrials":184,"cells":13560},"Megestrol Acetate",{"EARLY_PHASE1":13561,"PHASE1":13563,"PHASE2":13565,"PHASE3":13575,"PHASE4":13577,"NA":13579},{"trials":13562,"activeCount":102},[],{"trials":13564,"activeCount":102},[],{"trials":13566,"activeCount":102},[13567],{"nctId":13568,"briefTitle":13569,"status":122,"phases":13570,"primaryCompletion":577,"completion":577,"start":3345,"enrollment":102,"conditions":13571,"interventions":13573},"NCT01501396","Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite",[91],[13572],"Anorexia",[13559,13574],"Mirtazapine",{"trials":13576,"activeCount":102},[],{"trials":13578,"activeCount":102},[],{"trials":13580,"activeCount":102},[],{"intervention":13574,"totalTrials":184,"cells":13582},{"EARLY_PHASE1":13583,"PHASE1":13585,"PHASE2":13587,"PHASE3":13593,"PHASE4":13595,"NA":13597},{"trials":13584,"activeCount":102},[],{"trials":13586,"activeCount":102},[],{"trials":13588,"activeCount":102},[13589],{"nctId":13568,"briefTitle":13569,"status":122,"phases":13590,"primaryCompletion":577,"completion":577,"start":3345,"enrollment":102,"conditions":13591,"interventions":13592},[91],[13572],[13559,13574],{"trials":13594,"activeCount":102},[],{"trials":13596,"activeCount":102},[],{"trials":13598,"activeCount":102},[],{"intervention":6462,"totalTrials":184,"cells":13600},{"EARLY_PHASE1":13601,"PHASE1":13603,"PHASE2":13605,"PHASE3":13611,"PHASE4":13613,"NA":13615},{"trials":13602,"activeCount":102},[],{"trials":13604,"activeCount":102},[],{"trials":13606,"activeCount":102},[13607],{"nctId":6456,"briefTitle":6457,"status":108,"phases":13608,"primaryCompletion":6459,"completion":1736,"start":382,"enrollment":3251,"conditions":13609,"interventions":13610},[90,91],[3182,26],[6462,6381],{"trials":13612,"activeCount":102},[],{"trials":13614,"activeCount":102},[],{"trials":13616,"activeCount":102},[],{"intervention":13618,"totalTrials":184,"cells":13619},"GSK1120212",{"EARLY_PHASE1":13620,"PHASE1":13622,"PHASE2":13624,"PHASE3":13635,"PHASE4":13637,"NA":13639},{"trials":13621,"activeCount":102},[],{"trials":13623,"activeCount":102},[],{"trials":13625,"activeCount":102},[13626],{"nctId":13627,"briefTitle":13628,"status":108,"phases":13629,"primaryCompletion":1734,"completion":1351,"start":13630,"enrollment":1299,"conditions":13631,"interventions":13634},"NCT01553851","GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer",[91],"2013-02",[13632,13633],"Neoplasms, Oral","Mouth Neoplasms",[13618],{"trials":13636,"activeCount":102},[],{"trials":13638,"activeCount":102},[],{"trials":13640,"activeCount":102},[],{"intervention":6609,"totalTrials":184,"cells":13642},{"EARLY_PHASE1":13643,"PHASE1":13645,"PHASE2":13647,"PHASE3":13653,"PHASE4":13655,"NA":13657},{"trials":13644,"activeCount":102},[],{"trials":13646,"activeCount":102},[],{"trials":13648,"activeCount":102},[13649],{"nctId":6592,"briefTitle":6593,"status":108,"phases":13650,"primaryCompletion":6595,"completion":6595,"start":6596,"enrollment":792,"conditions":13651,"interventions":13652},[91],[6598,1925,6599,6600,6601,6602,6603,6604,6605,6606,6607],[6609,1228],{"trials":13654,"activeCount":102},[],{"trials":13656,"activeCount":102},[],{"trials":13658,"activeCount":102},[],{"intervention":13660,"totalTrials":184,"cells":13661},"Ibrutinib",{"EARLY_PHASE1":13662,"PHASE1":13664,"PHASE2":13666,"PHASE3":13675,"PHASE4":13677,"NA":13679},{"trials":13663,"activeCount":102},[],{"trials":13665,"activeCount":102},[],{"trials":13667,"activeCount":102},[13668],{"nctId":13669,"briefTitle":13670,"status":108,"phases":13671,"primaryCompletion":13672,"completion":13672,"start":6135,"enrollment":27,"conditions":13673,"interventions":13674},"NCT02643667","Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer",[91],"2023-04-12",[2204],[13660],{"trials":13676,"activeCount":102},[],{"trials":13678,"activeCount":102},[],{"trials":13680,"activeCount":102},[],{"intervention":13682,"totalTrials":184,"cells":13683},"Flotetuzumab",{"EARLY_PHASE1":13684,"PHASE1":13686,"PHASE2":13688,"PHASE3":13698,"PHASE4":13700,"NA":13702},{"trials":13685,"activeCount":102},[],{"trials":13687,"activeCount":102},[],{"trials":13689,"activeCount":102},[13690],{"nctId":13691,"briefTitle":13692,"status":137,"phases":13693,"primaryCompletion":13694,"completion":4046,"start":13695,"enrollment":1310,"conditions":13696,"interventions":13697},"NCT04582864","Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)",[91],"2024-03-29","2021-05-20",[3336],[13682],{"trials":13699,"activeCount":102},[],{"trials":13701,"activeCount":102},[],{"trials":13703,"activeCount":102},[],{"intervention":13705,"totalTrials":184,"cells":13706},"CDX-301",{"EARLY_PHASE1":13707,"PHASE1":13709,"PHASE2":13711,"PHASE3":13722,"PHASE4":13724,"NA":13726},{"trials":13708,"activeCount":102},[],{"trials":13710,"activeCount":102},[],{"trials":13712,"activeCount":102},[13713],{"nctId":13714,"briefTitle":13715,"status":137,"phases":13716,"primaryCompletion":13717,"completion":13717,"start":13718,"enrollment":960,"conditions":13719,"interventions":13720},"NCT04536077","Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients",[91],"2023-11-21","2021-08-13",[29,115,116],[13705,13721],"CDX-1140",{"trials":13723,"activeCount":102},[],{"trials":13725,"activeCount":102},[],{"trials":13727,"activeCount":102},[],{"intervention":13721,"totalTrials":184,"cells":13729},{"EARLY_PHASE1":13730,"PHASE1":13732,"PHASE2":13734,"PHASE3":13740,"PHASE4":13742,"NA":13744},{"trials":13731,"activeCount":102},[],{"trials":13733,"activeCount":102},[],{"trials":13735,"activeCount":102},[13736],{"nctId":13714,"briefTitle":13715,"status":137,"phases":13737,"primaryCompletion":13717,"completion":13717,"start":13718,"enrollment":960,"conditions":13738,"interventions":13739},[91],[29,115,116],[13705,13721],{"trials":13741,"activeCount":102},[],{"trials":13743,"activeCount":102},[],{"trials":13745,"activeCount":102},[],{"intervention":13747,"totalTrials":184,"cells":13748},"ADI-PEG20",{"EARLY_PHASE1":13749,"PHASE1":13751,"PHASE2":13753,"PHASE3":13764,"PHASE4":13766,"NA":13768},{"trials":13750,"activeCount":102},[],{"trials":13752,"activeCount":102},[],{"trials":13754,"activeCount":102},[13755],{"nctId":13756,"briefTitle":13757,"status":122,"phases":13758,"primaryCompletion":13759,"completion":13760,"start":13759,"enrollment":102,"conditions":13761,"interventions":13763},"NCT05829239","ADI-PEG20, Obesity and Prediabetes",[91],"2024-04-01","2024-05-01",[15,13762],"PreDiabetes",[13747],{"trials":13765,"activeCount":102},[],{"trials":13767,"activeCount":102},[],{"trials":13769,"activeCount":102},[],{"intervention":1609,"totalTrials":184,"cells":13771},{"EARLY_PHASE1":13772,"PHASE1":13774,"PHASE2":13776,"PHASE3":13782,"PHASE4":13784,"NA":13786},{"trials":13773,"activeCount":102},[],{"trials":13775,"activeCount":102},[],{"trials":13777,"activeCount":102},[13778],{"nctId":1600,"briefTitle":1601,"status":137,"phases":13779,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1056,"conditions":13780,"interventions":13781},[91],[1607],[1594,426,1609],{"trials":13783,"activeCount":102},[],{"trials":13785,"activeCount":102},[],{"trials":13787,"activeCount":102},[],{"intervention":6665,"totalTrials":184,"cells":13789},{"EARLY_PHASE1":13790,"PHASE1":13792,"PHASE2":13794,"PHASE3":13800,"PHASE4":13802,"NA":13804},{"trials":13791,"activeCount":102},[],{"trials":13793,"activeCount":102},[],{"trials":13795,"activeCount":102},[13796],{"nctId":6658,"briefTitle":6659,"status":137,"phases":13797,"primaryCompletion":907,"completion":907,"start":6661,"enrollment":1623,"conditions":13798,"interventions":13799},[91],[6663],[3761,6665],{"trials":13801,"activeCount":102},[],{"trials":13803,"activeCount":102},[],{"trials":13805,"activeCount":102},[],{"intervention":1927,"totalTrials":184,"cells":13807},{"EARLY_PHASE1":13808,"PHASE1":13810,"PHASE2":13812,"PHASE3":13818,"PHASE4":13820,"NA":13822},{"trials":13809,"activeCount":102},[],{"trials":13811,"activeCount":102},[],{"trials":13813,"activeCount":102},[13814],{"nctId":1918,"briefTitle":1919,"status":108,"phases":13815,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":1923,"conditions":13816,"interventions":13817},[91],[1925],[1927,1124,1594],{"trials":13819,"activeCount":102},[],{"trials":13821,"activeCount":102},[],{"trials":13823,"activeCount":102},[],{"intervention":1616,"totalTrials":184,"cells":13825},{"EARLY_PHASE1":13826,"PHASE1":13828,"PHASE2":13830,"PHASE3":13836,"PHASE4":13838,"NA":13840},{"trials":13827,"activeCount":102},[],{"trials":13829,"activeCount":102},[],{"trials":13831,"activeCount":102},[13832],{"nctId":1611,"briefTitle":1612,"status":137,"phases":13833,"primaryCompletion":382,"completion":382,"start":1574,"enrollment":340,"conditions":13834,"interventions":13835},[91],[1553],[1616,426],{"trials":13837,"activeCount":102},[],{"trials":13839,"activeCount":102},[],{"trials":13841,"activeCount":102},[],{"intervention":13843,"totalTrials":184,"cells":13844},"Oxymetazoline + Triamcinolone",{"EARLY_PHASE1":13845,"PHASE1":13847,"PHASE2":13849,"PHASE3":13860,"PHASE4":13862,"NA":13864},{"trials":13846,"activeCount":102},[],{"trials":13848,"activeCount":102},[],{"trials":13850,"activeCount":102},[13851],{"nctId":13852,"briefTitle":13853,"status":137,"phases":13854,"primaryCompletion":13855,"completion":13855,"start":13856,"enrollment":474,"conditions":13857,"interventions":13859},"NCT07168148","Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants",[91],"2026-03-19","2025-11-10",[4360,13858],"Chronic Rhinitis",[13843],{"trials":13861,"activeCount":102},[],{"trials":13863,"activeCount":102},[],{"trials":13865,"activeCount":102},[],{"intervention":3668,"totalTrials":184,"cells":13867},{"EARLY_PHASE1":13868,"PHASE1":13870,"PHASE2":13872,"PHASE3":13878,"PHASE4":13880,"NA":13882},{"trials":13869,"activeCount":102},[],{"trials":13871,"activeCount":102},[],{"trials":13873,"activeCount":102},[13874],{"nctId":3660,"briefTitle":3661,"status":108,"phases":13875,"primaryCompletion":3663,"completion":3115,"start":3664,"enrollment":565,"conditions":13876,"interventions":13877},[91],[3182,26,2598,1888,3666,24],[3668,2476],{"trials":13879,"activeCount":102},[],{"trials":13881,"activeCount":102},[],{"trials":13883,"activeCount":102},[],{"intervention":11742,"totalTrials":184,"cells":13885},{"EARLY_PHASE1":13886,"PHASE1":13888,"PHASE2":13890,"PHASE3":13896,"PHASE4":13898,"NA":13900},{"trials":13887,"activeCount":102},[],{"trials":13889,"activeCount":102},[],{"trials":13891,"activeCount":102},[13892],{"nctId":11736,"briefTitle":11737,"status":137,"phases":13893,"primaryCompletion":1648,"completion":1430,"start":11739,"enrollment":599,"conditions":13894,"interventions":13895},[91],[1445],[11742,619],{"trials":13897,"activeCount":102},[],{"trials":13899,"activeCount":102},[],{"trials":13901,"activeCount":102},[],{"intervention":13903,"totalTrials":184,"cells":13904},"Autologous fecal microbiota therapy",{"EARLY_PHASE1":13905,"PHASE1":13907,"PHASE2":13909,"PHASE3":13918,"PHASE4":13920,"NA":13922},{"trials":13906,"activeCount":102},[],{"trials":13908,"activeCount":102},[],{"trials":13910,"activeCount":102},[13911],{"nctId":13912,"briefTitle":13913,"status":108,"phases":13914,"primaryCompletion":1350,"completion":1350,"start":7054,"enrollment":340,"conditions":13915,"interventions":13917},"NCT02046525","Autologous Fecal Therapy",[91],[13916],"Infectious Disease of Digestive Tract",[13903],{"trials":13919,"activeCount":102},[],{"trials":13921,"activeCount":102},[],{"trials":13923,"activeCount":102},[],{"intervention":13925,"totalTrials":184,"cells":13926},"Nitrous Oxide 25%",{"EARLY_PHASE1":13927,"PHASE1":13929,"PHASE2":13931,"PHASE3":13942,"PHASE4":13944,"NA":13946},{"trials":13928,"activeCount":102},[],{"trials":13930,"activeCount":102},[],{"trials":13932,"activeCount":102},[13933],{"nctId":13934,"briefTitle":13935,"status":108,"phases":13936,"primaryCompletion":13937,"completion":13937,"start":13938,"enrollment":30,"conditions":13939,"interventions":13940},"NCT03283670","Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies",[91],"2020-02-18","2016-11-22",[6246,6247],[13925,13941],"Nitrous Oxide 50%",{"trials":13943,"activeCount":102},[],{"trials":13945,"activeCount":102},[],{"trials":13947,"activeCount":102},[],{"intervention":13941,"totalTrials":184,"cells":13949},{"EARLY_PHASE1":13950,"PHASE1":13952,"PHASE2":13954,"PHASE3":13960,"PHASE4":13962,"NA":13964},{"trials":13951,"activeCount":102},[],{"trials":13953,"activeCount":102},[],{"trials":13955,"activeCount":102},[13956],{"nctId":13934,"briefTitle":13935,"status":108,"phases":13957,"primaryCompletion":13937,"completion":13937,"start":13938,"enrollment":30,"conditions":13958,"interventions":13959},[91],[6246,6247],[13925,13941],{"trials":13961,"activeCount":102},[],{"trials":13963,"activeCount":102},[],{"trials":13965,"activeCount":102},[],{"intervention":13967,"totalTrials":184,"cells":13968},"Ondansetron 16 mg with Tariquidar",{"EARLY_PHASE1":13969,"PHASE1":13971,"PHASE2":13973,"PHASE3":13985,"PHASE4":13987,"NA":13989},{"trials":13970,"activeCount":102},[],{"trials":13972,"activeCount":102},[],{"trials":13974,"activeCount":102},[13975],{"nctId":13976,"briefTitle":13977,"status":108,"phases":13978,"primaryCompletion":13979,"completion":13980,"start":9829,"enrollment":30,"conditions":13981,"interventions":13983},"NCT04603066","Tariquidar-ondansetron Combination in Neuropathic Pain",[90,91],"2023-10-21","2023-11-03",[13982],"Neuropathic Pain",[13967,13984],"Ondansetron 16 mg with Placebo",{"trials":13986,"activeCount":102},[],{"trials":13988,"activeCount":102},[],{"trials":13990,"activeCount":102},[],{"intervention":13984,"totalTrials":184,"cells":13992},{"EARLY_PHASE1":13993,"PHASE1":13995,"PHASE2":13997,"PHASE3":14003,"PHASE4":14005,"NA":14007},{"trials":13994,"activeCount":102},[],{"trials":13996,"activeCount":102},[],{"trials":13998,"activeCount":102},[13999],{"nctId":13976,"briefTitle":13977,"status":108,"phases":14000,"primaryCompletion":13979,"completion":13980,"start":9829,"enrollment":30,"conditions":14001,"interventions":14002},[90,91],[13982],[13967,13984],{"trials":14004,"activeCount":102},[],{"trials":14006,"activeCount":102},[],{"trials":14008,"activeCount":102},[],{"intervention":14010,"totalTrials":184,"cells":14011},"Baricitinib 2 MG [Olumiant]",{"EARLY_PHASE1":14012,"PHASE1":14014,"PHASE2":14016,"PHASE3":14031,"PHASE4":14033,"NA":14035},{"trials":14013,"activeCount":102},[],{"trials":14015,"activeCount":102},[],{"trials":14017,"activeCount":102},[14018],{"nctId":14019,"briefTitle":14020,"status":137,"phases":14021,"primaryCompletion":14022,"completion":14022,"start":14023,"enrollment":456,"conditions":14024,"interventions":14027},"NCT05263505","Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid",[91],"2023-09-11","2022-02-21",[14025,14026],"Mucous Membrane Pemphigoid","Cicatrizing Conjunctivitis",[14010,14028,14029,14030],"Methotrexate","Azathioprine","Mycophenolate",{"trials":14032,"activeCount":102},[],{"trials":14034,"activeCount":102},[],{"trials":14036,"activeCount":102},[],{"intervention":14028,"totalTrials":184,"cells":14038},{"EARLY_PHASE1":14039,"PHASE1":14041,"PHASE2":14043,"PHASE3":14049,"PHASE4":14051,"NA":14053},{"trials":14040,"activeCount":102},[],{"trials":14042,"activeCount":102},[],{"trials":14044,"activeCount":102},[14045],{"nctId":14019,"briefTitle":14020,"status":137,"phases":14046,"primaryCompletion":14022,"completion":14022,"start":14023,"enrollment":456,"conditions":14047,"interventions":14048},[91],[14025,14026],[14010,14028,14029,14030],{"trials":14050,"activeCount":102},[],{"trials":14052,"activeCount":102},[],{"trials":14054,"activeCount":102},[],{"intervention":14029,"totalTrials":184,"cells":14056},{"EARLY_PHASE1":14057,"PHASE1":14059,"PHASE2":14061,"PHASE3":14067,"PHASE4":14069,"NA":14071},{"trials":14058,"activeCount":102},[],{"trials":14060,"activeCount":102},[],{"trials":14062,"activeCount":102},[14063],{"nctId":14019,"briefTitle":14020,"status":137,"phases":14064,"primaryCompletion":14022,"completion":14022,"start":14023,"enrollment":456,"conditions":14065,"interventions":14066},[91],[14025,14026],[14010,14028,14029,14030],{"trials":14068,"activeCount":102},[],{"trials":14070,"activeCount":102},[],{"trials":14072,"activeCount":102},[],{"intervention":14030,"totalTrials":184,"cells":14074},{"EARLY_PHASE1":14075,"PHASE1":14077,"PHASE2":14079,"PHASE3":14085,"PHASE4":14087,"NA":14089},{"trials":14076,"activeCount":102},[],{"trials":14078,"activeCount":102},[],{"trials":14080,"activeCount":102},[14081],{"nctId":14019,"briefTitle":14020,"status":137,"phases":14082,"primaryCompletion":14022,"completion":14022,"start":14023,"enrollment":456,"conditions":14083,"interventions":14084},[91],[14025,14026],[14010,14028,14029,14030],{"trials":14086,"activeCount":102},[],{"trials":14088,"activeCount":102},[],{"trials":14090,"activeCount":102},[],{"intervention":14092,"totalTrials":184,"cells":14093},"Drug-Carbamazepine",{"EARLY_PHASE1":14094,"PHASE1":14096,"PHASE2":14098,"PHASE3":14110,"PHASE4":14112,"NA":14114},{"trials":14095,"activeCount":102},[],{"trials":14097,"activeCount":102},[],{"trials":14099,"activeCount":102},[14100],{"nctId":14101,"briefTitle":14102,"status":137,"phases":14103,"primaryCompletion":14104,"completion":14104,"start":12459,"enrollment":1299,"conditions":14105,"interventions":14108},"NCT01379469","Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency",[91],"2017-02",[14106,14107],"Alpha-1-antitrypsin Deficiency","Liver Cirrhosis",[14092,14109],"Carbamazepine (Tegretol XR) Placebo",{"trials":14111,"activeCount":102},[],{"trials":14113,"activeCount":102},[],{"trials":14115,"activeCount":102},[],{"intervention":14109,"totalTrials":184,"cells":14117},{"EARLY_PHASE1":14118,"PHASE1":14120,"PHASE2":14122,"PHASE3":14128,"PHASE4":14130,"NA":14132},{"trials":14119,"activeCount":102},[],{"trials":14121,"activeCount":102},[],{"trials":14123,"activeCount":102},[14124],{"nctId":14101,"briefTitle":14102,"status":137,"phases":14125,"primaryCompletion":14104,"completion":14104,"start":12459,"enrollment":1299,"conditions":14126,"interventions":14127},[91],[14106,14107],[14092,14109],{"trials":14129,"activeCount":102},[],{"trials":14131,"activeCount":102},[],{"trials":14133,"activeCount":102},[],{"intervention":2132,"totalTrials":184,"cells":14135},{"EARLY_PHASE1":14136,"PHASE1":14138,"PHASE2":14140,"PHASE3":14146,"PHASE4":14148,"NA":14150},{"trials":14137,"activeCount":102},[],{"trials":14139,"activeCount":102},[],{"trials":14141,"activeCount":102},[14142],{"nctId":2124,"briefTitle":2125,"status":122,"phases":14143,"primaryCompletion":2127,"completion":2128,"start":2129,"enrollment":102,"conditions":14144,"interventions":14145},[91],[1312],[1370,2132,2133],{"trials":14147,"activeCount":102},[],{"trials":14149,"activeCount":102},[],{"trials":14151,"activeCount":102},[],{"intervention":14153,"totalTrials":184,"cells":14154},"SAB378",{"EARLY_PHASE1":14155,"PHASE1":14157,"PHASE2":14159,"PHASE3":14172,"PHASE4":14174,"NA":14176},{"trials":14156,"activeCount":102},[],{"trials":14158,"activeCount":102},[],{"trials":14160,"activeCount":102},[14161],{"nctId":14162,"briefTitle":14163,"status":122,"phases":14164,"primaryCompletion":6399,"completion":6399,"start":1632,"enrollment":102,"conditions":14165,"interventions":14168},"NCT00723918","Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy",[91],[14166,14167],"HIV-associated Neuropathy","Polyneuropathy",[14153,14169,14170,14171],"methadone","SAB placebo","Methadone placebo",{"trials":14173,"activeCount":102},[],{"trials":14175,"activeCount":102},[],{"trials":14177,"activeCount":102},[],{"intervention":14170,"totalTrials":184,"cells":14179},{"EARLY_PHASE1":14180,"PHASE1":14182,"PHASE2":14184,"PHASE3":14190,"PHASE4":14192,"NA":14194},{"trials":14181,"activeCount":102},[],{"trials":14183,"activeCount":102},[],{"trials":14185,"activeCount":102},[14186],{"nctId":14162,"briefTitle":14163,"status":122,"phases":14187,"primaryCompletion":6399,"completion":6399,"start":1632,"enrollment":102,"conditions":14188,"interventions":14189},[91],[14166,14167],[14153,14169,14170,14171],{"trials":14191,"activeCount":102},[],{"trials":14193,"activeCount":102},[],{"trials":14195,"activeCount":102},[],{"intervention":14171,"totalTrials":184,"cells":14197},{"EARLY_PHASE1":14198,"PHASE1":14200,"PHASE2":14202,"PHASE3":14208,"PHASE4":14210,"NA":14212},{"trials":14199,"activeCount":102},[],{"trials":14201,"activeCount":102},[],{"trials":14203,"activeCount":102},[14204],{"nctId":14162,"briefTitle":14163,"status":122,"phases":14205,"primaryCompletion":6399,"completion":6399,"start":1632,"enrollment":102,"conditions":14206,"interventions":14207},[91],[14166,14167],[14153,14169,14170,14171],{"trials":14209,"activeCount":102},[],{"trials":14211,"activeCount":102},[],{"trials":14213,"activeCount":102},[],{"intervention":14215,"totalTrials":184,"cells":14216},"VTS-270",{"EARLY_PHASE1":14217,"PHASE1":14219,"PHASE2":14221,"PHASE3":14232,"PHASE4":14234,"NA":14236},{"trials":14218,"activeCount":102},[],{"trials":14220,"activeCount":102},[],{"trials":14222,"activeCount":102},[14223],{"nctId":14224,"briefTitle":14225,"status":108,"phases":14226,"primaryCompletion":14227,"completion":14227,"start":14228,"enrollment":599,"conditions":14229,"interventions":14231},"NCT03471143","Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C",[90,91],"2024-10-04","2019-02-22",[14230],"Niemann-Pick Disease, Type C",[14215],{"trials":14233,"activeCount":102},[],{"trials":14235,"activeCount":102},[],{"trials":14237,"activeCount":102},[],{"intervention":1436,"totalTrials":184,"cells":14239},{"EARLY_PHASE1":14240,"PHASE1":14242,"PHASE2":14244,"PHASE3":14250,"PHASE4":14252,"NA":14254},{"trials":14241,"activeCount":102},[],{"trials":14243,"activeCount":102},[],{"trials":14245,"activeCount":102},[14246],{"nctId":1427,"briefTitle":1428,"status":108,"phases":14247,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":14248,"interventions":14249},[91],[29],[403,414,1436,1124],{"trials":14251,"activeCount":102},[],{"trials":14253,"activeCount":102},[],{"trials":14255,"activeCount":102},[],{"intervention":14257,"totalTrials":184,"cells":14258},"CIML NK Cell",{"EARLY_PHASE1":14259,"PHASE1":14261,"PHASE2":14263,"PHASE3":14273,"PHASE4":14275,"NA":14277},{"trials":14260,"activeCount":102},[],{"trials":14262,"activeCount":102},[],{"trials":14264,"activeCount":102},[14265],{"nctId":14266,"briefTitle":14267,"status":108,"phases":14268,"primaryCompletion":14269,"completion":14269,"start":14270,"enrollment":13387,"conditions":14271,"interventions":14272},"NCT03068819","Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant",[90,91],"2025-06-15","2017-10-23",[2389],[14257],{"trials":14274,"activeCount":102},[],{"trials":14276,"activeCount":102},[],{"trials":14278,"activeCount":102},[],{"intervention":3512,"totalTrials":184,"cells":14280},{"EARLY_PHASE1":14281,"PHASE1":14283,"PHASE2":14285,"PHASE3":14291,"PHASE4":14293,"NA":14295},{"trials":14282,"activeCount":102},[],{"trials":14284,"activeCount":102},[],{"trials":14286,"activeCount":102},[14287],{"nctId":3503,"briefTitle":3504,"status":122,"phases":14288,"primaryCompletion":3506,"completion":3507,"start":3508,"enrollment":102,"conditions":14289,"interventions":14290},[91],[3510],[3512,2563],{"trials":14292,"activeCount":102},[],{"trials":14294,"activeCount":102},[],{"trials":14296,"activeCount":102},[],{"intervention":7807,"totalTrials":184,"cells":14298},{"EARLY_PHASE1":14299,"PHASE1":14301,"PHASE2":14303,"PHASE3":14309,"PHASE4":14311,"NA":14313},{"trials":14300,"activeCount":102},[],{"trials":14302,"activeCount":102},[],{"trials":14304,"activeCount":102},[14305],{"nctId":7798,"briefTitle":7799,"status":137,"phases":14306,"primaryCompletion":7801,"completion":7802,"start":7803,"enrollment":474,"conditions":14307,"interventions":14308},[91],[6429,7805],[7807,6812],{"trials":14310,"activeCount":102},[],{"trials":14312,"activeCount":102},[],{"trials":14314,"activeCount":102},[],{"intervention":1766,"totalTrials":184,"cells":14316},{"EARLY_PHASE1":14317,"PHASE1":14319,"PHASE2":14321,"PHASE3":14327,"PHASE4":14329,"NA":14331},{"trials":14318,"activeCount":102},[],{"trials":14320,"activeCount":102},[],{"trials":14322,"activeCount":102},[14323],{"nctId":1755,"briefTitle":1756,"status":108,"phases":14324,"primaryCompletion":1758,"completion":1758,"start":1759,"enrollment":442,"conditions":14325,"interventions":14326},[91],[1761,1762,1763,1764],[82,1766,1370],{"trials":14328,"activeCount":102},[],{"trials":14330,"activeCount":102},[],{"trials":14332,"activeCount":102},[],{"intervention":14334,"totalTrials":184,"cells":14335},"Low-Dose Naltrexone",{"EARLY_PHASE1":14336,"PHASE1":14338,"PHASE2":14340,"PHASE3":14351,"PHASE4":14353,"NA":14355},{"trials":14337,"activeCount":102},[],{"trials":14339,"activeCount":102},[],{"trials":14341,"activeCount":102},[14342],{"nctId":14343,"briefTitle":14344,"status":108,"phases":14345,"primaryCompletion":1001,"completion":1001,"start":14346,"enrollment":1181,"conditions":14347,"interventions":14350},"NCT04409041","Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia",[91],"2019-09-01",[14348,14349],"Lichen Planopilaris","Frontal Fibrosing Alopecia",[14334],{"trials":14352,"activeCount":102},[],{"trials":14354,"activeCount":102},[],{"trials":14356,"activeCount":102},[],{"intervention":12493,"totalTrials":184,"cells":14358},{"EARLY_PHASE1":14359,"PHASE1":14361,"PHASE2":14363,"PHASE3":14369,"PHASE4":14371,"NA":14373},{"trials":14360,"activeCount":102},[],{"trials":14362,"activeCount":102},[],{"trials":14364,"activeCount":102},[14365],{"nctId":12486,"briefTitle":12487,"status":122,"phases":14366,"primaryCompletion":3518,"completion":3518,"start":12489,"enrollment":102,"conditions":14367,"interventions":14368},[90,91],[12491],[12493,2590],{"trials":14370,"activeCount":102},[],{"trials":14372,"activeCount":102},[],{"trials":14374,"activeCount":102},[],{"intervention":12234,"totalTrials":184,"cells":14376},{"EARLY_PHASE1":14377,"PHASE1":14379,"PHASE2":14381,"PHASE3":14387,"PHASE4":14389,"NA":14391},{"trials":14378,"activeCount":102},[],{"trials":14380,"activeCount":102},[],{"trials":14382,"activeCount":102},[14383],{"nctId":12224,"briefTitle":12225,"status":137,"phases":14384,"primaryCompletion":12227,"completion":12228,"start":12229,"enrollment":98,"conditions":14385,"interventions":14386},[90,91],[12221,12231,12232,26],[12202,12234],{"trials":14388,"activeCount":102},[],{"trials":14390,"activeCount":102},[],{"trials":14392,"activeCount":102},[],{"intervention":12092,"totalTrials":184,"cells":14394},{"EARLY_PHASE1":14395,"PHASE1":14397,"PHASE2":14399,"PHASE3":14405,"PHASE4":14407,"NA":14409},{"trials":14396,"activeCount":102},[],{"trials":14398,"activeCount":102},[],{"trials":14400,"activeCount":102},[14401],{"nctId":12084,"briefTitle":12085,"status":108,"phases":14402,"primaryCompletion":12087,"completion":12088,"start":12089,"enrollment":565,"conditions":14403,"interventions":14404},[91],[355,1393],[12092,1892],{"trials":14406,"activeCount":102},[],{"trials":14408,"activeCount":102},[],{"trials":14410,"activeCount":102},[],{"intervention":14412,"totalTrials":184,"cells":14413},"Transdermal patch",{"EARLY_PHASE1":14414,"PHASE1":14416,"PHASE2":14418,"PHASE3":14431,"PHASE4":14433,"NA":14435},{"trials":14415,"activeCount":102},[],{"trials":14417,"activeCount":102},[],{"trials":14419,"activeCount":102},[14420],{"nctId":14421,"briefTitle":14422,"status":108,"phases":14423,"primaryCompletion":9980,"completion":3863,"start":14424,"enrollment":3218,"conditions":14425,"interventions":14427},"NCT05010707","Transgender Estradiol Affirming Therapy",[91],"2021-08-02",[14426],"Transgenderism",[14412,14428,14429,14430],"Daily Sublingual","BID Sublingual","Spironolactone",{"trials":14432,"activeCount":102},[],{"trials":14434,"activeCount":102},[],{"trials":14436,"activeCount":102},[],{"intervention":14428,"totalTrials":184,"cells":14438},{"EARLY_PHASE1":14439,"PHASE1":14441,"PHASE2":14443,"PHASE3":14449,"PHASE4":14451,"NA":14453},{"trials":14440,"activeCount":102},[],{"trials":14442,"activeCount":102},[],{"trials":14444,"activeCount":102},[14445],{"nctId":14421,"briefTitle":14422,"status":108,"phases":14446,"primaryCompletion":9980,"completion":3863,"start":14424,"enrollment":3218,"conditions":14447,"interventions":14448},[91],[14426],[14412,14428,14429,14430],{"trials":14450,"activeCount":102},[],{"trials":14452,"activeCount":102},[],{"trials":14454,"activeCount":102},[],{"intervention":14429,"totalTrials":184,"cells":14456},{"EARLY_PHASE1":14457,"PHASE1":14459,"PHASE2":14461,"PHASE3":14467,"PHASE4":14469,"NA":14471},{"trials":14458,"activeCount":102},[],{"trials":14460,"activeCount":102},[],{"trials":14462,"activeCount":102},[14463],{"nctId":14421,"briefTitle":14422,"status":108,"phases":14464,"primaryCompletion":9980,"completion":3863,"start":14424,"enrollment":3218,"conditions":14465,"interventions":14466},[91],[14426],[14412,14428,14429,14430],{"trials":14468,"activeCount":102},[],{"trials":14470,"activeCount":102},[],{"trials":14472,"activeCount":102},[],{"intervention":14430,"totalTrials":184,"cells":14474},{"EARLY_PHASE1":14475,"PHASE1":14477,"PHASE2":14479,"PHASE3":14485,"PHASE4":14487,"NA":14489},{"trials":14476,"activeCount":102},[],{"trials":14478,"activeCount":102},[],{"trials":14480,"activeCount":102},[14481],{"nctId":14421,"briefTitle":14422,"status":108,"phases":14482,"primaryCompletion":9980,"completion":3863,"start":14424,"enrollment":3218,"conditions":14483,"interventions":14484},[91],[14426],[14412,14428,14429,14430],{"trials":14486,"activeCount":102},[],{"trials":14488,"activeCount":102},[],{"trials":14490,"activeCount":102},[],{"intervention":14492,"totalTrials":184,"cells":14493},"Erismodegib",{"EARLY_PHASE1":14494,"PHASE1":14496,"PHASE2":14498,"PHASE3":14508,"PHASE4":14510,"NA":14512},{"trials":14495,"activeCount":102},[],{"trials":14497,"activeCount":102},[],{"trials":14499,"activeCount":102},[14500],{"nctId":14501,"briefTitle":14502,"status":122,"phases":14503,"primaryCompletion":14504,"completion":14505,"start":3321,"enrollment":102,"conditions":14506,"interventions":14507},"NCT01757327","LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer",[91],"2016-12","2019-12",[1445],[14492],{"trials":14509,"activeCount":102},[],{"trials":14511,"activeCount":102},[],{"trials":14513,"activeCount":102},[],{"intervention":2728,"totalTrials":184,"cells":14515},{"EARLY_PHASE1":14516,"PHASE1":14518,"PHASE2":14520,"PHASE3":14526,"PHASE4":14528,"NA":14530},{"trials":14517,"activeCount":102},[],{"trials":14519,"activeCount":102},[],{"trials":14521,"activeCount":102},[14522],{"nctId":2720,"briefTitle":2721,"status":108,"phases":14523,"primaryCompletion":2723,"completion":2724,"start":2725,"enrollment":1954,"conditions":14524,"interventions":14525},[91],[1888,2598],[2225,2728,2425,2729],{"trials":14527,"activeCount":102},[],{"trials":14529,"activeCount":102},[],{"trials":14531,"activeCount":102},[],{"intervention":2729,"totalTrials":184,"cells":14533},{"EARLY_PHASE1":14534,"PHASE1":14536,"PHASE2":14538,"PHASE3":14544,"PHASE4":14546,"NA":14548},{"trials":14535,"activeCount":102},[],{"trials":14537,"activeCount":102},[],{"trials":14539,"activeCount":102},[14540],{"nctId":2720,"briefTitle":2721,"status":108,"phases":14541,"primaryCompletion":2723,"completion":2724,"start":2725,"enrollment":1954,"conditions":14542,"interventions":14543},[91],[1888,2598],[2225,2728,2425,2729],{"trials":14545,"activeCount":102},[],{"trials":14547,"activeCount":102},[],{"trials":14549,"activeCount":102},[],{"intervention":14551,"totalTrials":184,"cells":14552},"Sphenopalatine Block",{"EARLY_PHASE1":14553,"PHASE1":14555,"PHASE2":14557,"PHASE3":14569,"PHASE4":14571,"NA":14573},{"trials":14554,"activeCount":102},[],{"trials":14556,"activeCount":102},[],{"trials":14558,"activeCount":102},[14559],{"nctId":14560,"briefTitle":14561,"status":122,"phases":14562,"primaryCompletion":14563,"completion":14563,"start":14564,"enrollment":102,"conditions":14565,"interventions":14568},"NCT04466826","Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients",[91],"2021-02-05","2021-01-02",[14566,14567],"Migraine in Children","Pain, Neuropathic",[14551],{"trials":14570,"activeCount":102},[],{"trials":14572,"activeCount":102},[],{"trials":14574,"activeCount":102},[],{"intervention":14576,"totalTrials":184,"cells":14577},"Intraperitoneal 5FU",{"EARLY_PHASE1":14578,"PHASE1":14580,"PHASE2":14582,"PHASE3":14592,"PHASE4":14594,"NA":14596},{"trials":14579,"activeCount":102},[],{"trials":14581,"activeCount":102},[],{"trials":14583,"activeCount":102},[14584],{"nctId":14585,"briefTitle":14586,"status":137,"phases":14587,"primaryCompletion":1632,"completion":1632,"start":6116,"enrollment":1056,"conditions":14588,"interventions":14590},"NCT00352755","A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin\u002F5FU\u002FLeucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis",[91],[14589],"Peritoneal Neoplasms",[14576,14591],"FOLFOX",{"trials":14593,"activeCount":102},[],{"trials":14595,"activeCount":102},[],{"trials":14597,"activeCount":102},[],{"intervention":14591,"totalTrials":184,"cells":14599},{"EARLY_PHASE1":14600,"PHASE1":14602,"PHASE2":14604,"PHASE3":14610,"PHASE4":14612,"NA":14614},{"trials":14601,"activeCount":102},[],{"trials":14603,"activeCount":102},[],{"trials":14605,"activeCount":102},[14606],{"nctId":14585,"briefTitle":14586,"status":137,"phases":14607,"primaryCompletion":1632,"completion":1632,"start":6116,"enrollment":1056,"conditions":14608,"interventions":14609},[91],[14589],[14576,14591],{"trials":14611,"activeCount":102},[],{"trials":14613,"activeCount":102},[],{"trials":14615,"activeCount":102},[],{"intervention":2456,"totalTrials":184,"cells":14617},{"EARLY_PHASE1":14618,"PHASE1":14620,"PHASE2":14622,"PHASE3":14628,"PHASE4":14630,"NA":14632},{"trials":14619,"activeCount":102},[],{"trials":14621,"activeCount":102},[],{"trials":14623,"activeCount":102},[14624],{"nctId":2448,"briefTitle":2449,"status":122,"phases":14625,"primaryCompletion":2451,"completion":2451,"start":2452,"enrollment":102,"conditions":14626,"interventions":14627},[90,91],[2454],[2456,2457,2458],{"trials":14629,"activeCount":102},[],{"trials":14631,"activeCount":102},[],{"trials":14633,"activeCount":102},[],{"intervention":2458,"totalTrials":184,"cells":14635},{"EARLY_PHASE1":14636,"PHASE1":14638,"PHASE2":14640,"PHASE3":14646,"PHASE4":14648,"NA":14650},{"trials":14637,"activeCount":102},[],{"trials":14639,"activeCount":102},[],{"trials":14641,"activeCount":102},[14642],{"nctId":2448,"briefTitle":2449,"status":122,"phases":14643,"primaryCompletion":2451,"completion":2451,"start":2452,"enrollment":102,"conditions":14644,"interventions":14645},[90,91],[2454],[2456,2457,2458],{"trials":14647,"activeCount":102},[],{"trials":14649,"activeCount":102},[],{"trials":14651,"activeCount":102},[],{"intervention":14653,"totalTrials":184,"cells":14654},"tofacitinib",{"EARLY_PHASE1":14655,"PHASE1":14657,"PHASE2":14659,"PHASE3":14671,"PHASE4":14673,"NA":14675},{"trials":14656,"activeCount":102},[],{"trials":14658,"activeCount":102},[],{"trials":14660,"activeCount":102},[14661],{"nctId":14662,"briefTitle":14663,"status":14664,"phases":14665,"primaryCompletion":14666,"completion":14667,"start":10657,"enrollment":98,"conditions":14668,"interventions":14670},"NCT03580343","Tofacitinib for Inflammatory Eye Disease","UNKNOWN",[91],"2019-12-01","2021-04-04",[9744,14669],"Scleritis",[14653],{"trials":14672,"activeCount":102},[],{"trials":14674,"activeCount":102},[],{"trials":14676,"activeCount":102},[],{"intervention":2672,"totalTrials":184,"cells":14678},{"EARLY_PHASE1":14679,"PHASE1":14681,"PHASE2":14683,"PHASE3":14689,"PHASE4":14691,"NA":14693},{"trials":14680,"activeCount":102},[],{"trials":14682,"activeCount":102},[],{"trials":14684,"activeCount":102},[14685],{"nctId":2664,"briefTitle":2665,"status":137,"phases":14686,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":960,"conditions":14687,"interventions":14688},[90,91],[29,114,115,116],[2672,1867],{"trials":14690,"activeCount":102},[],{"trials":14692,"activeCount":102},[],{"trials":14694,"activeCount":102},[],{"intervention":14696,"totalTrials":184,"cells":14697},"CC-4047",{"EARLY_PHASE1":14698,"PHASE1":14700,"PHASE2":14702,"PHASE3":14711,"PHASE4":14713,"NA":14715},{"trials":14699,"activeCount":102},[],{"trials":14701,"activeCount":102},[],{"trials":14703,"activeCount":102},[14704],{"nctId":14705,"briefTitle":14706,"status":108,"phases":14707,"primaryCompletion":12281,"completion":1964,"start":1431,"enrollment":1249,"conditions":14708,"interventions":14710},"NCT00770757","CC-4047 (Pomalidomide) for Graft vs. Host Disease",[91],[14709],"Graft vs Host Disease",[14696],{"trials":14712,"activeCount":102},[],{"trials":14714,"activeCount":102},[],{"trials":14716,"activeCount":102},[],{"intervention":8942,"totalTrials":184,"cells":14718},{"EARLY_PHASE1":14719,"PHASE1":14721,"PHASE2":14723,"PHASE3":14729,"PHASE4":14731,"NA":14733},{"trials":14720,"activeCount":102},[],{"trials":14722,"activeCount":102},[],{"trials":14724,"activeCount":102},[14725],{"nctId":8932,"briefTitle":8933,"status":108,"phases":14726,"primaryCompletion":8935,"completion":4701,"start":8936,"enrollment":8937,"conditions":14727,"interventions":14728},[91],[8939,8940],[8942,8943,163,8944],{"trials":14730,"activeCount":102},[],{"trials":14732,"activeCount":102},[],{"trials":14734,"activeCount":102},[],{"intervention":14736,"totalTrials":184,"cells":14737},"LS301",{"EARLY_PHASE1":14738,"PHASE1":14740,"PHASE2":14742,"PHASE3":14753,"PHASE4":14755,"NA":14757},{"trials":14739,"activeCount":102},[],{"trials":14741,"activeCount":102},[],{"trials":14743,"activeCount":102},[14744],{"nctId":14745,"briefTitle":14746,"status":122,"phases":14747,"primaryCompletion":9085,"completion":9085,"start":1588,"enrollment":102,"conditions":14748,"interventions":14752},"NCT04105062","LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery",[90,91],[29,14749,987,14750,14751],"Liver Cancer","Gastrointestinal Stromal Cancer","Metastatic Cancer",[14736],{"trials":14754,"activeCount":102},[],{"trials":14756,"activeCount":102},[],{"trials":14758,"activeCount":102},[],{"intervention":14760,"totalTrials":184,"cells":14761},"Plavix",{"EARLY_PHASE1":14762,"PHASE1":14764,"PHASE2":14766,"PHASE3":14774,"PHASE4":14776,"NA":14778},{"trials":14763,"activeCount":102},[],{"trials":14765,"activeCount":102},[],{"trials":14767,"activeCount":102},[14768],{"nctId":14769,"briefTitle":14770,"status":137,"phases":14771,"primaryCompletion":11790,"completion":11790,"start":1605,"enrollment":565,"conditions":14772,"interventions":14773},"NCT00263211","A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients",[91],[1445],[14760,3285],{"trials":14775,"activeCount":102},[],{"trials":14777,"activeCount":102},[],{"trials":14779,"activeCount":102},[],{"intervention":14781,"totalTrials":184,"cells":14782},"Rociletinib",{"EARLY_PHASE1":14783,"PHASE1":14785,"PHASE2":14787,"PHASE3":14797,"PHASE4":14799,"NA":14801},{"trials":14784,"activeCount":102},[],{"trials":14786,"activeCount":102},[],{"trials":14788,"activeCount":102},[14789],{"nctId":14790,"briefTitle":14791,"status":122,"phases":14792,"primaryCompletion":14793,"completion":14794,"start":3455,"enrollment":102,"conditions":14795,"interventions":14796},"NCT02705339","Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)",[91],"2019-11","2020-04",[1553,1354,1356],[14781],{"trials":14798,"activeCount":102},[],{"trials":14800,"activeCount":102},[],{"trials":14802,"activeCount":102},[],{"intervention":14804,"totalTrials":184,"cells":14805},"Gabapentin gelatin capsules 300mg",{"EARLY_PHASE1":14806,"PHASE1":14808,"PHASE2":14810,"PHASE3":14820,"PHASE4":14822,"NA":14824},{"trials":14807,"activeCount":102},[],{"trials":14809,"activeCount":102},[],{"trials":14811,"activeCount":102},[14812],{"nctId":14813,"briefTitle":14814,"status":108,"phases":14815,"primaryCompletion":14816,"completion":14816,"start":14817,"enrollment":1142,"conditions":14818,"interventions":14819},"NCT05184192","Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction",[91],"2023-08-29","2022-01-10",[718,719,9087,12707,720],[14804],{"trials":14821,"activeCount":102},[],{"trials":14823,"activeCount":102},[],{"trials":14825,"activeCount":102},[],{"intervention":1123,"totalTrials":184,"cells":14827},{"EARLY_PHASE1":14828,"PHASE1":14830,"PHASE2":14832,"PHASE3":14838,"PHASE4":14840,"NA":14842},{"trials":14829,"activeCount":102},[],{"trials":14831,"activeCount":102},[],{"trials":14833,"activeCount":102},[14834],{"nctId":1114,"briefTitle":1115,"status":108,"phases":14835,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":506,"conditions":14836,"interventions":14837},[90,91],[1121],[1123,959,1124,1125],{"trials":14839,"activeCount":102},[],{"trials":14841,"activeCount":102},[],{"trials":14843,"activeCount":102},[],{"intervention":14845,"totalTrials":184,"cells":14846},"Prednisolone",{"EARLY_PHASE1":14847,"PHASE1":14849,"PHASE2":14851,"PHASE3":14863,"PHASE4":14865,"NA":14867},{"trials":14848,"activeCount":102},[],{"trials":14850,"activeCount":102},[],{"trials":14852,"activeCount":102},[14853],{"nctId":14854,"briefTitle":14855,"status":108,"phases":14856,"primaryCompletion":14857,"completion":14858,"start":14859,"enrollment":208,"conditions":14860,"interventions":14862},"NCT02167217","Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy",[91],"2017-02-22","2017-03-22","2014-04-17",[14861],"Duchenne Muscular Dystrophy",[14845],{"trials":14864,"activeCount":102},[],{"trials":14866,"activeCount":102},[],{"trials":14868,"activeCount":102},[],{"intervention":14870,"totalTrials":184,"cells":14871},"Timolol Gel",{"EARLY_PHASE1":14872,"PHASE1":14874,"PHASE2":14876,"PHASE3":14887,"PHASE4":14889,"NA":14891},{"trials":14873,"activeCount":102},[],{"trials":14875,"activeCount":102},[],{"trials":14877,"activeCount":102},[14878],{"nctId":14879,"briefTitle":14880,"status":108,"phases":14881,"primaryCompletion":14882,"completion":14882,"start":14883,"enrollment":27,"conditions":14884,"interventions":14886},"NCT04139018","Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia",[91],"2020-05-20","2019-10-20",[14885],"Hereditary Hemorrhagic Telangiectasia",[14870],{"trials":14888,"activeCount":102},[],{"trials":14890,"activeCount":102},[],{"trials":14892,"activeCount":102},[],{"intervention":14894,"totalTrials":184,"cells":14895},"sodium bicarbonate buffered lidocaine",{"EARLY_PHASE1":14896,"PHASE1":14898,"PHASE2":14900,"PHASE3":14910,"PHASE4":14912,"NA":14914},{"trials":14897,"activeCount":102},[],{"trials":14899,"activeCount":102},[],{"trials":14901,"activeCount":102},[14902],{"nctId":14903,"briefTitle":14904,"status":108,"phases":14905,"primaryCompletion":9024,"completion":490,"start":365,"enrollment":3820,"conditions":14906,"interventions":14908},"NCT01405768","Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs)",[91],[14907],"Uterine Cervical Dysplasia",[14894,14909],"Non-buffered lidocaine",{"trials":14911,"activeCount":102},[],{"trials":14913,"activeCount":102},[],{"trials":14915,"activeCount":102},[],{"intervention":14909,"totalTrials":184,"cells":14917},{"EARLY_PHASE1":14918,"PHASE1":14920,"PHASE2":14922,"PHASE3":14928,"PHASE4":14930,"NA":14932},{"trials":14919,"activeCount":102},[],{"trials":14921,"activeCount":102},[],{"trials":14923,"activeCount":102},[14924],{"nctId":14903,"briefTitle":14904,"status":108,"phases":14925,"primaryCompletion":9024,"completion":490,"start":365,"enrollment":3820,"conditions":14926,"interventions":14927},[91],[14907],[14894,14909],{"trials":14929,"activeCount":102},[],{"trials":14931,"activeCount":102},[],{"trials":14933,"activeCount":102},[],{"intervention":3625,"totalTrials":184,"cells":14935},{"EARLY_PHASE1":14936,"PHASE1":14938,"PHASE2":14940,"PHASE3":14946,"PHASE4":14948,"NA":14950},{"trials":14937,"activeCount":102},[],{"trials":14939,"activeCount":102},[],{"trials":14941,"activeCount":102},[14942],{"nctId":3619,"briefTitle":3620,"status":122,"phases":14943,"primaryCompletion":3622,"completion":3622,"start":1195,"enrollment":102,"conditions":14944,"interventions":14945},[91],[3336,3335,26],[3625,2375,1229,3340],{"trials":14947,"activeCount":102},[],{"trials":14949,"activeCount":102},[],{"trials":14951,"activeCount":102},[],{"intervention":14953,"totalTrials":184,"cells":14954},"Insulin",{"EARLY_PHASE1":14955,"PHASE1":14957,"PHASE2":14959,"PHASE3":14970,"PHASE4":14972,"NA":14974},{"trials":14956,"activeCount":102},[],{"trials":14958,"activeCount":102},[],{"trials":14960,"activeCount":102},[14961],{"nctId":14962,"briefTitle":14963,"status":137,"phases":14964,"primaryCompletion":14965,"completion":14965,"start":6935,"enrollment":184,"conditions":14966,"interventions":14969},"NCT04079881","Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes",[90,91],"2020-07-01",[14967,14968],"Type 1 Diabetes","Hyperglycemia, Postprandial",[14953],{"trials":14971,"activeCount":102},[],{"trials":14973,"activeCount":102},[],{"trials":14975,"activeCount":102},[],{"intervention":14977,"totalTrials":184,"cells":14978},"INCB039110",{"EARLY_PHASE1":14979,"PHASE1":14981,"PHASE2":14983,"PHASE3":14993,"PHASE4":14995,"NA":14997},{"trials":14980,"activeCount":102},[],{"trials":14982,"activeCount":102},[],{"trials":14984,"activeCount":102},[14985],{"nctId":14986,"briefTitle":14987,"status":122,"phases":14988,"primaryCompletion":14989,"completion":14989,"start":10738,"enrollment":102,"conditions":14990,"interventions":14992},"NCT02909569","Relieving Chronic Itch: Oral Medication",[91],"2018-10-09",[14991],"Pruritis",[14977],{"trials":14994,"activeCount":102},[],{"trials":14996,"activeCount":102},[],{"trials":14998,"activeCount":102},[],{"intervention":2682,"totalTrials":184,"cells":15000},{"EARLY_PHASE1":15001,"PHASE1":15003,"PHASE2":15005,"PHASE3":15011,"PHASE4":15013,"NA":15015},{"trials":15002,"activeCount":102},[],{"trials":15004,"activeCount":102},[],{"trials":15006,"activeCount":102},[15007],{"nctId":2674,"briefTitle":2675,"status":108,"phases":15008,"primaryCompletion":2677,"completion":2677,"start":2646,"enrollment":2678,"conditions":15009,"interventions":15010},[91],[2680],[372,1867,2682],{"trials":15012,"activeCount":102},[],{"trials":15014,"activeCount":102},[],{"trials":15016,"activeCount":102},[],{"intervention":15018,"totalTrials":184,"cells":15019},"PTK787\u002FZK 222584",{"EARLY_PHASE1":15020,"PHASE1":15022,"PHASE2":15024,"PHASE3":15032,"PHASE4":15034,"NA":15036},{"trials":15021,"activeCount":102},[],{"trials":15023,"activeCount":102},[],{"trials":15025,"activeCount":102},[15026],{"nctId":15027,"briefTitle":15028,"status":137,"phases":15029,"primaryCompletion":3032,"completion":3032,"start":10670,"enrollment":36,"conditions":15030,"interventions":15031},"NCT00240162","PTK\u002FZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma",[91],[24],[15018],{"trials":15033,"activeCount":102},[],{"trials":15035,"activeCount":102},[],{"trials":15037,"activeCount":102},[],{"intervention":3687,"totalTrials":184,"cells":15039},{"EARLY_PHASE1":15040,"PHASE1":15042,"PHASE2":15044,"PHASE3":15050,"PHASE4":15052,"NA":15054},{"trials":15041,"activeCount":102},[],{"trials":15043,"activeCount":102},[],{"trials":15045,"activeCount":102},[15046],{"nctId":3678,"briefTitle":3679,"status":108,"phases":15047,"primaryCompletion":3681,"completion":3682,"start":3683,"enrollment":3684,"conditions":15048,"interventions":15049},[91],[24,2598],[3687,2378,2476],{"trials":15051,"activeCount":102},[],{"trials":15053,"activeCount":102},[],{"trials":15055,"activeCount":102},[],{"intervention":12645,"totalTrials":184,"cells":15057},{"EARLY_PHASE1":15058,"PHASE1":15060,"PHASE2":15062,"PHASE3":15068,"PHASE4":15070,"NA":15072},{"trials":15059,"activeCount":102},[],{"trials":15061,"activeCount":102},[],{"trials":15063,"activeCount":102},[15064],{"nctId":12639,"briefTitle":12640,"status":137,"phases":15065,"primaryCompletion":6943,"completion":6943,"start":3863,"enrollment":6806,"conditions":15066,"interventions":15067},[91],[12643],[8943,12645,12646],{"trials":15069,"activeCount":102},[],{"trials":15071,"activeCount":102},[],{"trials":15073,"activeCount":102},[],{"intervention":12646,"totalTrials":184,"cells":15075},{"EARLY_PHASE1":15076,"PHASE1":15078,"PHASE2":15080,"PHASE3":15086,"PHASE4":15088,"NA":15090},{"trials":15077,"activeCount":102},[],{"trials":15079,"activeCount":102},[],{"trials":15081,"activeCount":102},[15082],{"nctId":12639,"briefTitle":12640,"status":137,"phases":15083,"primaryCompletion":6943,"completion":6943,"start":3863,"enrollment":6806,"conditions":15084,"interventions":15085},[91],[12643],[8943,12645,12646],{"trials":15087,"activeCount":102},[],{"trials":15089,"activeCount":102},[],{"trials":15091,"activeCount":102},[],{"intervention":15093,"totalTrials":184,"cells":15094},"Vigabatrin",{"EARLY_PHASE1":15095,"PHASE1":15097,"PHASE2":15099,"PHASE3":15111,"PHASE4":15113,"NA":15115},{"trials":15096,"activeCount":102},[],{"trials":15098,"activeCount":102},[],{"trials":15100,"activeCount":102},[15101],{"nctId":15102,"briefTitle":15103,"status":108,"phases":15104,"primaryCompletion":15105,"completion":15106,"start":15107,"enrollment":599,"conditions":15108,"interventions":15110},"NCT04321395","Vigabatrin and Insulin Sensitivity",[91],"2023-12-30","2024-05-15","2021-08-23",[15109,15],"NAFLD",[15093],{"trials":15112,"activeCount":102},[],{"trials":15114,"activeCount":102},[],{"trials":15116,"activeCount":102},[],{"intervention":15118,"totalTrials":184,"cells":15119},"Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg\u002Fm2",{"EARLY_PHASE1":15120,"PHASE1":15122,"PHASE2":15124,"PHASE3":15132,"PHASE4":15134,"NA":15136},{"trials":15121,"activeCount":102},[],{"trials":15123,"activeCount":102},[],{"trials":15125,"activeCount":102},[15126],{"nctId":15127,"briefTitle":15128,"status":122,"phases":15129,"primaryCompletion":12560,"completion":3432,"start":3102,"enrollment":102,"conditions":15130,"interventions":15131},"NCT01281943","Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer",[91],[1846],[15118],{"trials":15133,"activeCount":102},[],{"trials":15135,"activeCount":102},[],{"trials":15137,"activeCount":102},[],{"intervention":3775,"totalTrials":184,"cells":15139},{"EARLY_PHASE1":15140,"PHASE1":15142,"PHASE2":15144,"PHASE3":15150,"PHASE4":15152,"NA":15154},{"trials":15141,"activeCount":102},[],{"trials":15143,"activeCount":102},[],{"trials":15145,"activeCount":102},[15146],{"nctId":3767,"briefTitle":3768,"status":122,"phases":15147,"primaryCompletion":3770,"completion":1141,"start":3771,"enrollment":102,"conditions":15148,"interventions":15149},[91],[1201,3773,1200,1199],[1291,3761,3775],{"trials":15151,"activeCount":102},[],{"trials":15153,"activeCount":102},[],{"trials":15155,"activeCount":102},[],{"intervention":15157,"totalTrials":184,"cells":15158},"Theophylline Powder",{"EARLY_PHASE1":15159,"PHASE1":15161,"PHASE2":15163,"PHASE3":15177,"PHASE4":15179,"NA":15181},{"trials":15160,"activeCount":102},[],{"trials":15162,"activeCount":102},[],{"trials":15164,"activeCount":102},[15165],{"nctId":15166,"briefTitle":15167,"status":108,"phases":15168,"primaryCompletion":15169,"completion":15169,"start":15170,"enrollment":2434,"conditions":15171,"interventions":15176},"NCT04789499","Smell in Covid-19 and Efficacy of Nasal Theophylline",[91],"2021-12-30","2021-03-15",[765,9087,719,15172,15173,12707,15174,15175],"Covid-19 Pandemic","SARS-CoV-2 Infection","Ageusia","Hypogeusia",[15157],{"trials":15178,"activeCount":102},[],{"trials":15180,"activeCount":102},[],{"trials":15182,"activeCount":102},[],{"intervention":12034,"totalTrials":184,"cells":15184},{"EARLY_PHASE1":15185,"PHASE1":15187,"PHASE2":15189,"PHASE3":15195,"PHASE4":15197,"NA":15199},{"trials":15186,"activeCount":102},[],{"trials":15188,"activeCount":102},[],{"trials":15190,"activeCount":102},[15191],{"nctId":12027,"briefTitle":12028,"status":137,"phases":15192,"primaryCompletion":12030,"completion":12030,"start":11731,"enrollment":1131,"conditions":15193,"interventions":15194},[91],[1650,12032],[2045,12034],{"trials":15196,"activeCount":102},[],{"trials":15198,"activeCount":102},[],{"trials":15200,"activeCount":102},[],{"intervention":1134,"totalTrials":184,"cells":15202},{"EARLY_PHASE1":15203,"PHASE1":15205,"PHASE2":15207,"PHASE3":15213,"PHASE4":15215,"NA":15217},{"trials":15204,"activeCount":102},[],{"trials":15206,"activeCount":102},[],{"trials":15208,"activeCount":102},[15209],{"nctId":1127,"briefTitle":1128,"status":137,"phases":15210,"primaryCompletion":626,"completion":626,"start":1130,"enrollment":1131,"conditions":15211,"interventions":15212},[90,91],[423],[1134,959],{"trials":15214,"activeCount":102},[],{"trials":15216,"activeCount":102},[],{"trials":15218,"activeCount":102},[],{"intervention":15220,"totalTrials":184,"cells":15221},"Testosterone gel",{"EARLY_PHASE1":15222,"PHASE1":15224,"PHASE2":15226,"PHASE3":15237,"PHASE4":15239,"NA":15241},{"trials":15223,"activeCount":102},[],{"trials":15225,"activeCount":102},[],{"trials":15227,"activeCount":102},[15228],{"nctId":15229,"briefTitle":15230,"status":108,"phases":15231,"primaryCompletion":15232,"completion":15232,"start":12437,"enrollment":1080,"conditions":15233,"interventions":15236},"NCT00280267","Testosterone Therapy After Hip Fracture in Elderly Women",[91],"2006-12",[11166,15234,15235],"Testosterone Deficiency","Muscle Weakness",[15220],{"trials":15238,"activeCount":102},[],{"trials":15240,"activeCount":102},[],{"trials":15242,"activeCount":102},[],{"intervention":3523,"totalTrials":184,"cells":15244},{"EARLY_PHASE1":15245,"PHASE1":15247,"PHASE2":15249,"PHASE3":15255,"PHASE4":15257,"NA":15259},{"trials":15246,"activeCount":102},[],{"trials":15248,"activeCount":102},[],{"trials":15250,"activeCount":102},[15251],{"nctId":3514,"briefTitle":3515,"status":108,"phases":15252,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":506,"conditions":15253,"interventions":15254},[91],[3520,3521],[2563,1291,3523,3524],{"trials":15256,"activeCount":102},[],{"trials":15258,"activeCount":102},[],{"trials":15260,"activeCount":102},[],{"intervention":3524,"totalTrials":184,"cells":15262},{"EARLY_PHASE1":15263,"PHASE1":15265,"PHASE2":15267,"PHASE3":15273,"PHASE4":15275,"NA":15277},{"trials":15264,"activeCount":102},[],{"trials":15266,"activeCount":102},[],{"trials":15268,"activeCount":102},[15269],{"nctId":3514,"briefTitle":3515,"status":108,"phases":15270,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":506,"conditions":15271,"interventions":15272},[91],[3520,3521],[2563,1291,3523,3524],{"trials":15274,"activeCount":102},[],{"trials":15276,"activeCount":102},[],{"trials":15278,"activeCount":102},[],{"intervention":437,"totalTrials":184,"cells":15280},{"EARLY_PHASE1":15281,"PHASE1":15283,"PHASE2":15285,"PHASE3":15291,"PHASE4":15293,"NA":15295},{"trials":15282,"activeCount":102},[],{"trials":15284,"activeCount":102},[],{"trials":15286,"activeCount":102},[15287],{"nctId":428,"briefTitle":429,"status":108,"phases":15288,"primaryCompletion":431,"completion":432,"start":433,"enrollment":293,"conditions":15289,"interventions":15290},[91],[435],[437,403,375,339],{"trials":15292,"activeCount":102},[],{"trials":15294,"activeCount":102},[],{"trials":15296,"activeCount":102},[],{"intervention":15298,"totalTrials":184,"cells":15299},"[11C] desmethyl-loperamide",{"EARLY_PHASE1":15300,"PHASE1":15302,"PHASE2":15304,"PHASE3":15316,"PHASE4":15318,"NA":15320},{"trials":15301,"activeCount":102},[],{"trials":15303,"activeCount":102},[],{"trials":15305,"activeCount":102},[15306],{"nctId":15307,"briefTitle":15308,"status":108,"phases":15309,"primaryCompletion":2370,"completion":15310,"start":1441,"enrollment":1249,"conditions":15311,"interventions":15313},"NCT01668147","Efavirenz and Ritonavir on Human Brain P-Glycoprotein",[90,91],"2016-08",[15312],"Drug Effects",[15298,15314,15315],"Oral ritonavir","Oral efavirenz",{"trials":15317,"activeCount":102},[],{"trials":15319,"activeCount":102},[],{"trials":15321,"activeCount":102},[],{"intervention":15314,"totalTrials":184,"cells":15323},{"EARLY_PHASE1":15324,"PHASE1":15326,"PHASE2":15328,"PHASE3":15334,"PHASE4":15336,"NA":15338},{"trials":15325,"activeCount":102},[],{"trials":15327,"activeCount":102},[],{"trials":15329,"activeCount":102},[15330],{"nctId":15307,"briefTitle":15308,"status":108,"phases":15331,"primaryCompletion":2370,"completion":15310,"start":1441,"enrollment":1249,"conditions":15332,"interventions":15333},[90,91],[15312],[15298,15314,15315],{"trials":15335,"activeCount":102},[],{"trials":15337,"activeCount":102},[],{"trials":15339,"activeCount":102},[],{"intervention":15315,"totalTrials":184,"cells":15341},{"EARLY_PHASE1":15342,"PHASE1":15344,"PHASE2":15346,"PHASE3":15352,"PHASE4":15354,"NA":15356},{"trials":15343,"activeCount":102},[],{"trials":15345,"activeCount":102},[],{"trials":15347,"activeCount":102},[15348],{"nctId":15307,"briefTitle":15308,"status":108,"phases":15349,"primaryCompletion":2370,"completion":15310,"start":1441,"enrollment":1249,"conditions":15350,"interventions":15351},[90,91],[15312],[15298,15314,15315],{"trials":15353,"activeCount":102},[],{"trials":15355,"activeCount":102},[],{"trials":15357,"activeCount":102},[],{"intervention":11498,"totalTrials":184,"cells":15359},{"EARLY_PHASE1":15360,"PHASE1":15362,"PHASE2":15364,"PHASE3":15370,"PHASE4":15372,"NA":15374},{"trials":15361,"activeCount":102},[],{"trials":15363,"activeCount":102},[],{"trials":15365,"activeCount":102},[15366],{"nctId":11490,"briefTitle":11491,"status":122,"phases":15367,"primaryCompletion":11493,"completion":11494,"start":950,"enrollment":102,"conditions":15368,"interventions":15369},[91],[11496],[1652,374,373,375,11498],{"trials":15371,"activeCount":102},[],{"trials":15373,"activeCount":102},[],{"trials":15375,"activeCount":102},[],{"intervention":15377,"totalTrials":184,"cells":15378},"Inhaled beclomethasone",{"EARLY_PHASE1":15379,"PHASE1":15381,"PHASE2":15383,"PHASE3":15393,"PHASE4":15395,"NA":15397},{"trials":15380,"activeCount":102},[],{"trials":15382,"activeCount":102},[],{"trials":15384,"activeCount":102},[15385],{"nctId":15386,"briefTitle":15387,"status":108,"phases":15388,"primaryCompletion":9829,"completion":9829,"start":15389,"enrollment":960,"conditions":15390,"interventions":15392},"NCT02351180","Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients",[90,91],"2017-02-01",[15391],"Lung Transplant Infection",[15377],{"trials":15394,"activeCount":102},[],{"trials":15396,"activeCount":102},[],{"trials":15398,"activeCount":102},[],{"intervention":15400,"totalTrials":184,"cells":15401},"Fecal microbiota transplant",{"EARLY_PHASE1":15402,"PHASE1":15404,"PHASE2":15406,"PHASE3":15415,"PHASE4":15417,"NA":15419},{"trials":15403,"activeCount":102},[],{"trials":15405,"activeCount":102},[],{"trials":15407,"activeCount":102},[15408],{"nctId":15409,"briefTitle":15410,"status":108,"phases":15411,"primaryCompletion":1588,"completion":1588,"start":15412,"enrollment":184,"conditions":15413,"interventions":15414},"NCT03367910","Fecal Microbiota Transplantation (FMT) for MDRO UTI",[90,91],"2018-02-08",[10824],[15400],{"trials":15416,"activeCount":102},[],{"trials":15418,"activeCount":102},[],{"trials":15420,"activeCount":102},[],{"intervention":15422,"totalTrials":184,"cells":15423},"IVM w\u002F ALB",{"EARLY_PHASE1":15424,"PHASE1":15426,"PHASE2":15428,"PHASE3":15441,"PHASE4":15443,"NA":15445},{"trials":15425,"activeCount":102},[],{"trials":15427,"activeCount":102},[],{"trials":15429,"activeCount":102},[15430],{"nctId":15431,"briefTitle":15432,"status":108,"phases":15433,"primaryCompletion":15434,"completion":12087,"start":15435,"enrollment":15436,"conditions":15437,"interventions":15438},"NCT04188301","Safety and Efficacy of IDA for Onchocerciasis",[91],"2022-03-14","2019-12-06",154,[5143],[15422,15439,15440],"Single dose of IDA","Three daily doses of IDA",{"trials":15442,"activeCount":102},[],{"trials":15444,"activeCount":102},[],{"trials":15446,"activeCount":102},[],{"intervention":15439,"totalTrials":184,"cells":15448},{"EARLY_PHASE1":15449,"PHASE1":15451,"PHASE2":15453,"PHASE3":15459,"PHASE4":15461,"NA":15463},{"trials":15450,"activeCount":102},[],{"trials":15452,"activeCount":102},[],{"trials":15454,"activeCount":102},[15455],{"nctId":15431,"briefTitle":15432,"status":108,"phases":15456,"primaryCompletion":15434,"completion":12087,"start":15435,"enrollment":15436,"conditions":15457,"interventions":15458},[91],[5143],[15422,15439,15440],{"trials":15460,"activeCount":102},[],{"trials":15462,"activeCount":102},[],{"trials":15464,"activeCount":102},[],{"intervention":15440,"totalTrials":184,"cells":15466},{"EARLY_PHASE1":15467,"PHASE1":15469,"PHASE2":15471,"PHASE3":15477,"PHASE4":15479,"NA":15481},{"trials":15468,"activeCount":102},[],{"trials":15470,"activeCount":102},[],{"trials":15472,"activeCount":102},[15473],{"nctId":15431,"briefTitle":15432,"status":108,"phases":15474,"primaryCompletion":15434,"completion":12087,"start":15435,"enrollment":15436,"conditions":15475,"interventions":15476},[91],[5143],[15422,15439,15440],{"trials":15478,"activeCount":102},[],{"trials":15480,"activeCount":102},[],{"trials":15482,"activeCount":102},[],{"intervention":15484,"totalTrials":184,"cells":15485},"Standard of care chemotherapy regimen",{"EARLY_PHASE1":15486,"PHASE1":15488,"PHASE2":15490,"PHASE3":15500,"PHASE4":15502,"NA":15504},{"trials":15487,"activeCount":102},[],{"trials":15489,"activeCount":102},[],{"trials":15491,"activeCount":102},[15492],{"nctId":15493,"briefTitle":15494,"status":137,"phases":15495,"primaryCompletion":15496,"completion":15497,"start":3721,"enrollment":599,"conditions":15498,"interventions":15499},"NCT04162665","Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer",[91],"2023-12-18","2024-11-21",[3520],[15484],{"trials":15501,"activeCount":102},[],{"trials":15503,"activeCount":102},[],{"trials":15505,"activeCount":102},[],{"intervention":1484,"totalTrials":184,"cells":15507},{"EARLY_PHASE1":15508,"PHASE1":15510,"PHASE2":15512,"PHASE3":15518,"PHASE4":15520,"NA":15522},{"trials":15509,"activeCount":102},[],{"trials":15511,"activeCount":102},[],{"trials":15513,"activeCount":102},[15514],{"nctId":1474,"briefTitle":1475,"status":108,"phases":15515,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":951,"conditions":15516,"interventions":15517},[91],[1480,1481,1482],[1484,1485,1486],{"trials":15519,"activeCount":102},[],{"trials":15521,"activeCount":102},[],{"trials":15523,"activeCount":102},[],{"intervention":2298,"totalTrials":184,"cells":15525},{"EARLY_PHASE1":15526,"PHASE1":15528,"PHASE2":15530,"PHASE3":15536,"PHASE4":15538,"NA":15540},{"trials":15527,"activeCount":102},[],{"trials":15529,"activeCount":102},[],{"trials":15531,"activeCount":102},[15532],{"nctId":2284,"briefTitle":2285,"status":137,"phases":15533,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":2289,"conditions":15534,"interventions":15535},[91],[2291,2292,2293,2294,2295,2296],[2298,2299,2300,2301],{"trials":15537,"activeCount":102},[],{"trials":15539,"activeCount":102},[],{"trials":15541,"activeCount":102},[],{"intervention":15543,"totalTrials":184,"cells":15544},"Pantoprazole",{"EARLY_PHASE1":15545,"PHASE1":15547,"PHASE2":15549,"PHASE3":15563,"PHASE4":15565,"NA":15567},{"trials":15546,"activeCount":102},[],{"trials":15548,"activeCount":102},[],{"trials":15550,"activeCount":102},[15551],{"nctId":15552,"briefTitle":15553,"status":137,"phases":15554,"primaryCompletion":15555,"completion":15555,"start":15556,"enrollment":3820,"conditions":15557,"interventions":15562},"NCT05251233","Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy",[91],"2024-06-29","2022-04-21",[29,116,1957,15558,15559,15560,15561],"Pancreas Neuroendocrine Tumor","Pancreatitis","Distal Extrahepatic Cholangiocarcinoma","Duodenal Cancer",[15543],{"trials":15564,"activeCount":102},[],{"trials":15566,"activeCount":102},[],{"trials":15568,"activeCount":102},[],{"intervention":12684,"totalTrials":184,"cells":15570},{"EARLY_PHASE1":15571,"PHASE1":15573,"PHASE2":15575,"PHASE3":15581,"PHASE4":15583,"NA":15585},{"trials":15572,"activeCount":102},[],{"trials":15574,"activeCount":102},[],{"trials":15576,"activeCount":102},[15577],{"nctId":12673,"briefTitle":12674,"status":108,"phases":15578,"primaryCompletion":12676,"completion":12676,"start":12677,"enrollment":27,"conditions":15579,"interventions":15580},[91],[719,9087,12679,12680,12681],[12683,12684],{"trials":15582,"activeCount":102},[],{"trials":15584,"activeCount":102},[],{"trials":15586,"activeCount":102},[],{"intervention":15588,"totalTrials":184,"cells":15589},"High ACE Activity Fresh Frozen Plasma",{"EARLY_PHASE1":15590,"PHASE1":15592,"PHASE2":15594,"PHASE3":15604,"PHASE4":15606,"NA":15608},{"trials":15591,"activeCount":102},[],{"trials":15593,"activeCount":102},[],{"trials":15595,"activeCount":102},[15596],{"nctId":15597,"briefTitle":15598,"status":137,"phases":15599,"primaryCompletion":15600,"completion":15600,"start":762,"enrollment":456,"conditions":15601,"interventions":15603},"NCT04679311","Treatment of Angiotensin Converting Enzyme Inhibitor-induced Angioedema",[91],"2023-01-31",[15602],"Angioedema Caused by Angiotensin-Converting-Enzyme Inhibitor",[15588],{"trials":15605,"activeCount":102},[],{"trials":15607,"activeCount":102},[],{"trials":15609,"activeCount":102},[],{"intervention":455,"totalTrials":184,"cells":15611},{"EARLY_PHASE1":15612,"PHASE1":15614,"PHASE2":15616,"PHASE3":15622,"PHASE4":15624,"NA":15626},{"trials":15613,"activeCount":102},[],{"trials":15615,"activeCount":102},[],{"trials":15617,"activeCount":102},[15618],{"nctId":446,"briefTitle":447,"status":108,"phases":15619,"primaryCompletion":449,"completion":450,"start":451,"enrollment":394,"conditions":15620,"interventions":15621},[90,91],[453],[339,455],{"trials":15623,"activeCount":102},[],{"trials":15625,"activeCount":102},[],{"trials":15627,"activeCount":102},[],{"intervention":15629,"totalTrials":184,"cells":15630},"Apremilast",{"EARLY_PHASE1":15631,"PHASE1":15633,"PHASE2":15635,"PHASE3":15646,"PHASE4":15648,"NA":15650},{"trials":15632,"activeCount":102},[],{"trials":15634,"activeCount":102},[],{"trials":15636,"activeCount":102},[15637],{"nctId":15638,"briefTitle":15639,"status":108,"phases":15640,"primaryCompletion":1002,"completion":15641,"start":15642,"enrollment":340,"conditions":15643,"interventions":15645},"NCT03239106","A Study Examining the Medication Apremilast as Treatment for Chronic Itch",[91],"2019-09-19","2017-12-01",[15644],"Itch",[15629],{"trials":15647,"activeCount":102},[],{"trials":15649,"activeCount":102},[],{"trials":15651,"activeCount":102},[],{"intervention":15653,"totalTrials":184,"cells":15654},"Lidocaine Hydrochloride",{"EARLY_PHASE1":15655,"PHASE1":15657,"PHASE2":15659,"PHASE3":15671,"PHASE4":15673,"NA":15675},{"trials":15656,"activeCount":102},[],{"trials":15658,"activeCount":102},[],{"trials":15660,"activeCount":102},[15661],{"nctId":15662,"briefTitle":15663,"status":108,"phases":15664,"primaryCompletion":9545,"completion":8293,"start":15665,"enrollment":442,"conditions":15666,"interventions":15669},"NCT03254394","Lidocaine for Oxaliplatin-induced Neuropathy",[90,91],"2017-09-15",[15667,15668,369],"Neuropathy, Painful","Chemotherapy-induced Peripheral Neuropathy",[15653,15670],"FOLFOX regimen",{"trials":15672,"activeCount":102},[],{"trials":15674,"activeCount":102},[],{"trials":15676,"activeCount":102},[],{"intervention":12802,"totalTrials":184,"cells":15678},{"EARLY_PHASE1":15679,"PHASE1":15681,"PHASE2":15683,"PHASE3":15689,"PHASE4":15691,"NA":15693},{"trials":15680,"activeCount":102},[],{"trials":15682,"activeCount":102},[],{"trials":15684,"activeCount":102},[15685],{"nctId":12793,"briefTitle":12794,"status":137,"phases":15686,"primaryCompletion":10025,"completion":12796,"start":12797,"enrollment":1566,"conditions":15687,"interventions":15688},[91],[12799,12800],[12784,12802],{"trials":15690,"activeCount":102},[],{"trials":15692,"activeCount":102},[],{"trials":15694,"activeCount":102},[],{"intervention":15696,"totalTrials":184,"cells":15697},"dantrolene sodium",{"EARLY_PHASE1":15698,"PHASE1":15700,"PHASE2":15702,"PHASE3":15714,"PHASE4":15716,"NA":15718},{"trials":15699,"activeCount":102},[],{"trials":15701,"activeCount":102},[],{"trials":15703,"activeCount":102},[15704],{"nctId":15705,"briefTitle":15706,"status":108,"phases":15707,"primaryCompletion":15708,"completion":15708,"start":1996,"enrollment":36,"conditions":15709,"interventions":15713},"NCT02829268","A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome",[90,91],"2023-02",[15710,6078,15711,15712],"Wolfram Syndrome","Optic Nerve Atrophy","Ataxia",[15696],{"trials":15715,"activeCount":102},[],{"trials":15717,"activeCount":102},[],{"trials":15719,"activeCount":102},[],{"intervention":15721,"totalTrials":184,"cells":15722},"Nitric Oxide",{"EARLY_PHASE1":15723,"PHASE1":15725,"PHASE2":15727,"PHASE3":15736,"PHASE4":15738,"NA":15740},{"trials":15724,"activeCount":102},[],{"trials":15726,"activeCount":102},[],{"trials":15728,"activeCount":102},[15729],{"nctId":15730,"briefTitle":15731,"status":108,"phases":15732,"primaryCompletion":3102,"completion":3102,"start":4008,"enrollment":1818,"conditions":15733,"interventions":15735},"NCT00585013","Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass",[90,91],[15734],"Congenital Heart Disease",[15721],{"trials":15737,"activeCount":102},[],{"trials":15739,"activeCount":102},[],{"trials":15741,"activeCount":102},[],{"intervention":15743,"totalTrials":184,"cells":15744},"Vigamox",{"EARLY_PHASE1":15745,"PHASE1":15747,"PHASE2":15749,"PHASE3":15759,"PHASE4":15761,"NA":15763},{"trials":15746,"activeCount":102},[],{"trials":15748,"activeCount":102},[],{"trials":15750,"activeCount":102},[15751],{"nctId":15752,"briefTitle":15753,"status":122,"phases":15754,"primaryCompletion":3862,"completion":3862,"start":15755,"enrollment":102,"conditions":15756,"interventions":15758},"NCT04204122","Vigamox Treatment for Ocular Graft-Versus-Host Disease",[91],"2020-06-15",[15757],"Ocular Graft-versus-host Disease",[15743],{"trials":15760,"activeCount":102},[],{"trials":15762,"activeCount":102},[],{"trials":15764,"activeCount":102},[],{"intervention":4026,"totalTrials":184,"cells":15766},{"EARLY_PHASE1":15767,"PHASE1":15769,"PHASE2":15771,"PHASE3":15777,"PHASE4":15779,"NA":15781},{"trials":15768,"activeCount":102},[],{"trials":15770,"activeCount":102},[],{"trials":15772,"activeCount":102},[15773],{"nctId":4013,"briefTitle":4014,"status":108,"phases":15774,"primaryCompletion":1141,"completion":1141,"start":4016,"enrollment":112,"conditions":15775,"interventions":15776},[91],[4018,4019,4020,4021,4022,4023,4024],[3985,4026],{"trials":15778,"activeCount":102},[],{"trials":15780,"activeCount":102},[],{"trials":15782,"activeCount":102},[],{"intervention":162,"totalTrials":184,"cells":15784},{"EARLY_PHASE1":15785,"PHASE1":15787,"PHASE2":15789,"PHASE3":15795,"PHASE4":15797,"NA":15799},{"trials":15786,"activeCount":102},[],{"trials":15788,"activeCount":102},[],{"trials":15790,"activeCount":102},[15791],{"nctId":151,"briefTitle":152,"status":108,"phases":15792,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":15793,"interventions":15794},[91],[18,158,159],[97,161,162,163,164,165],{"trials":15796,"activeCount":102},[],{"trials":15798,"activeCount":102},[],{"trials":15800,"activeCount":102},[],{"intervention":2073,"totalTrials":184,"cells":15802},{"EARLY_PHASE1":15803,"PHASE1":15805,"PHASE2":15807,"PHASE3":15813,"PHASE4":15815,"NA":15817},{"trials":15804,"activeCount":102},[],{"trials":15806,"activeCount":102},[],{"trials":15808,"activeCount":102},[15809],{"nctId":2065,"briefTitle":2066,"status":108,"phases":15810,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":2070,"conditions":15811,"interventions":15812},[90,91],[2023],[2013,2073,1151],{"trials":15814,"activeCount":102},[],{"trials":15816,"activeCount":102},[],{"trials":15818,"activeCount":102},[],{"intervention":15820,"totalTrials":184,"cells":15821},"Dacarbazine",{"EARLY_PHASE1":15822,"PHASE1":15824,"PHASE2":15826,"PHASE3":15835,"PHASE4":15837,"NA":15839},{"trials":15823,"activeCount":102},[],{"trials":15825,"activeCount":102},[],{"trials":15827,"activeCount":102},[15828],{"nctId":15829,"briefTitle":15830,"status":108,"phases":15831,"primaryCompletion":882,"completion":882,"start":11781,"enrollment":2648,"conditions":15832,"interventions":15834},"NCT00802880","Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma",[91],[15833],"Sarcoma",[15820],{"trials":15836,"activeCount":102},[],{"trials":15838,"activeCount":102},[],{"trials":15840,"activeCount":102},[],{"intervention":3636,"totalTrials":184,"cells":15842},{"EARLY_PHASE1":15843,"PHASE1":15845,"PHASE2":15847,"PHASE3":15853,"PHASE4":15855,"NA":15857},{"trials":15844,"activeCount":102},[],{"trials":15846,"activeCount":102},[],{"trials":15848,"activeCount":102},[15849],{"nctId":3627,"briefTitle":3628,"status":137,"phases":15850,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":15851,"interventions":15852},[90,91],[3182],[2375,1229,3636,2475,2613],{"trials":15854,"activeCount":102},[],{"trials":15856,"activeCount":102},[],{"trials":15858,"activeCount":102},[],{"intervention":15860,"totalTrials":184,"cells":15861},"Dara-SC",{"EARLY_PHASE1":15862,"PHASE1":15864,"PHASE2":15866,"PHASE3":15875,"PHASE4":15877,"NA":15879},{"trials":15863,"activeCount":102},[],{"trials":15865,"activeCount":102},[],{"trials":15867,"activeCount":102},[15868],{"nctId":15869,"briefTitle":15870,"status":122,"phases":15871,"primaryCompletion":8628,"completion":8628,"start":15872,"enrollment":102,"conditions":15873,"interventions":15874},"NCT04150692","Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed\u002FRefractory Multiple Myeloma",[91],"2021-01-08",[24],[15860],{"trials":15876,"activeCount":102},[],{"trials":15878,"activeCount":102},[],{"trials":15880,"activeCount":102},[],{"intervention":3823,"totalTrials":184,"cells":15882},{"EARLY_PHASE1":15883,"PHASE1":15885,"PHASE2":15887,"PHASE3":15893,"PHASE4":15895,"NA":15897},{"trials":15884,"activeCount":102},[],{"trials":15886,"activeCount":102},[],{"trials":15888,"activeCount":102},[15889],{"nctId":3814,"briefTitle":3815,"status":108,"phases":15890,"primaryCompletion":3817,"completion":3818,"start":3819,"enrollment":3820,"conditions":15891,"interventions":15892},[91],[1445],[3823,620,631],{"trials":15894,"activeCount":102},[],{"trials":15896,"activeCount":102},[],{"trials":15898,"activeCount":102},[],{"intervention":15900,"totalTrials":184,"cells":15901},"KNO3, potassium nitrate",{"EARLY_PHASE1":15902,"PHASE1":15904,"PHASE2":15906,"PHASE3":15915,"PHASE4":15917,"NA":15919},{"trials":15903,"activeCount":102},[],{"trials":15905,"activeCount":102},[],{"trials":15907,"activeCount":102},[15908],{"nctId":15909,"briefTitle":15910,"status":108,"phases":15911,"primaryCompletion":3771,"completion":15912,"start":12489,"enrollment":383,"conditions":15913,"interventions":15914},"NCT02797184","Inorganic NItrate and EXercise Performance in Heart Failure (iNIX-HF): Dose Response",[90,91],"2021-12-15",[5570],[15900],{"trials":15916,"activeCount":102},[],{"trials":15918,"activeCount":102},[],{"trials":15920,"activeCount":102},[],{"intervention":15922,"totalTrials":184,"cells":15923},"Simvastatin, 80 mg\u002Fday for 21 days",{"EARLY_PHASE1":15924,"PHASE1":15926,"PHASE2":15928,"PHASE3":15936,"PHASE4":15938,"NA":15940},{"trials":15925,"activeCount":102},[],{"trials":15927,"activeCount":102},[],{"trials":15929,"activeCount":102},[15930],{"nctId":15931,"briefTitle":15932,"status":108,"phases":15933,"primaryCompletion":13630,"completion":2443,"start":11605,"enrollment":383,"conditions":15934,"interventions":15935},"NCT00795288","Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)",[90,91],[13060],[15922],{"trials":15937,"activeCount":102},[],{"trials":15939,"activeCount":102},[],{"trials":15941,"activeCount":102},[],{"intervention":15943,"totalTrials":474,"cells":15944},"Endotoxin",{"EARLY_PHASE1":15945,"PHASE1":15961,"PHASE2":15970,"PHASE3":15972,"PHASE4":15974,"NA":15976},{"trials":15946,"activeCount":102},[15947,15954],{"nctId":15948,"briefTitle":15949,"status":108,"phases":15950,"primaryCompletion":11773,"completion":11773,"start":11731,"enrollment":33,"conditions":15951,"interventions":15952},"NCT00741013","Quantifying Airway Inflammation With Radiologic Tests",[89],[7956],[15953,15943],"Lovastatin pill and placebo IV",{"nctId":15955,"briefTitle":15956,"status":108,"phases":15957,"primaryCompletion":1995,"completion":1995,"start":3432,"enrollment":474,"conditions":15958,"interventions":15959},"NCT02151552","Assessing NOS Uptake With PET Imaging in Lung Inflammation",[89],[7956],[15943,15960],"[18F](+\u002F-)NOS",{"trials":15962,"activeCount":102},[15963],{"nctId":15964,"briefTitle":15965,"status":108,"phases":15966,"primaryCompletion":3281,"completion":3281,"start":1963,"enrollment":1042,"conditions":15967,"interventions":15969},"NCT01407796","PET Imaging of Endotoxin-induced iNOS Activation",[90],[15968],"Pneumonia",[15943,15960],{"trials":15971,"activeCount":102},[],{"trials":15973,"activeCount":102},[],{"trials":15975,"activeCount":102},[],{"trials":15977,"activeCount":102},[],{"intervention":15960,"totalTrials":474,"cells":15979},{"EARLY_PHASE1":15980,"PHASE1":15993,"PHASE2":15999,"PHASE3":16001,"PHASE4":16003,"NA":16005},{"trials":15981,"activeCount":102},[15982,15989],{"nctId":15983,"briefTitle":15984,"status":108,"phases":15985,"primaryCompletion":3021,"completion":3021,"start":11790,"enrollment":442,"conditions":15986,"interventions":15988},"NCT01066637","iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.",[89],[15987],"Patients With Post Orthotopic Heart Transplantation Status",[15960],{"nctId":15955,"briefTitle":15956,"status":108,"phases":15990,"primaryCompletion":1995,"completion":1995,"start":3432,"enrollment":474,"conditions":15991,"interventions":15992},[89],[7956],[15943,15960],{"trials":15994,"activeCount":102},[15995],{"nctId":15964,"briefTitle":15965,"status":108,"phases":15996,"primaryCompletion":3281,"completion":3281,"start":1963,"enrollment":1042,"conditions":15997,"interventions":15998},[90],[15968],[15943,15960],{"trials":16000,"activeCount":102},[],{"trials":16002,"activeCount":102},[],{"trials":16004,"activeCount":102},[],{"trials":16006,"activeCount":102},[],{"intervention":16008,"totalTrials":456,"cells":16009},"64Cu-DOTA-ECL1i",{"EARLY_PHASE1":16010,"PHASE1":16012,"PHASE2":16029,"PHASE3":16031,"PHASE4":16033,"NA":16035},{"trials":16011,"activeCount":102},[],{"trials":16013,"activeCount":102},[16014,16021],{"nctId":16015,"briefTitle":16016,"status":137,"phases":16017,"primaryCompletion":16018,"completion":16018,"start":110,"enrollment":1310,"conditions":16019,"interventions":16020},"NCT04217057","Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer",[90],"2023-02-07",[399],[16008],{"nctId":16022,"briefTitle":16023,"status":14664,"phases":16024,"primaryCompletion":16025,"completion":16025,"start":16026,"enrollment":13084,"conditions":16027,"interventions":16028},"NCT05107596","Evaluation of CCR2 in Patients Post Myocardial Infarction",[90],"2025-11-24","2018-11-24",[11281],[16008],{"trials":16030,"activeCount":102},[],{"trials":16032,"activeCount":102},[],{"trials":16034,"activeCount":102},[],{"trials":16036,"activeCount":102},[],{"intervention":2026,"totalTrials":456,"cells":16038},{"EARLY_PHASE1":16039,"PHASE1":16041,"PHASE2":16051,"PHASE3":16053,"PHASE4":16055,"NA":16057},{"trials":16040,"activeCount":102},[],{"trials":16042,"activeCount":102},[16043,16047],{"nctId":6915,"briefTitle":6916,"status":122,"phases":16044,"primaryCompletion":612,"completion":6918,"start":124,"enrollment":102,"conditions":16045,"interventions":16046},[90],[2222],[2026,977],{"nctId":2017,"briefTitle":2018,"status":137,"phases":16048,"primaryCompletion":2020,"completion":2020,"start":2021,"enrollment":184,"conditions":16049,"interventions":16050},[90],[2023,2024],[2026,2027,1151],{"trials":16052,"activeCount":102},[],{"trials":16054,"activeCount":102},[],{"trials":16056,"activeCount":102},[],{"trials":16058,"activeCount":102},[],{"intervention":2374,"totalTrials":456,"cells":16060},{"EARLY_PHASE1":16061,"PHASE1":16067,"PHASE2":16073,"PHASE3":16075,"PHASE4":16077,"NA":16079},{"trials":16062,"activeCount":102},[16063],{"nctId":2367,"briefTitle":2368,"status":122,"phases":16064,"primaryCompletion":2370,"completion":2370,"start":1351,"enrollment":102,"conditions":16065,"interventions":16066},[89],[24,2372],[2374,2362,2375,1229,2376,2377,2378],{"trials":16068,"activeCount":102},[16069],{"nctId":3930,"briefTitle":3931,"status":137,"phases":16070,"primaryCompletion":3933,"completion":3088,"start":3934,"enrollment":208,"conditions":16071,"interventions":16072},[90],[3182],[3937,3938,3939,3940],{"trials":16074,"activeCount":102},[],{"trials":16076,"activeCount":102},[],{"trials":16078,"activeCount":102},[],{"trials":16080,"activeCount":102},[],{"intervention":16082,"totalTrials":456,"cells":16083},"brentuximab vedotin",{"EARLY_PHASE1":16084,"PHASE1":16086,"PHASE2":16102,"PHASE3":16104,"PHASE4":16106,"NA":16108},{"trials":16085,"activeCount":102},[],{"trials":16087,"activeCount":102},[16088,16098],{"nctId":16089,"briefTitle":16090,"status":108,"phases":16091,"primaryCompletion":16092,"completion":3114,"start":16093,"enrollment":1818,"conditions":16094,"interventions":16097},"NCT01700751","Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation",[90],"2015-11-11","2013-02-25",[16095,16096,26],"Leukemia, Acute Myeloid","Leukemia, Lymphoblastic,Acute",[16082],{"nctId":3378,"briefTitle":3379,"status":108,"phases":16099,"primaryCompletion":3381,"completion":3382,"start":3383,"enrollment":1283,"conditions":16100,"interventions":16101},[90],[1889],[3386,3026],{"trials":16103,"activeCount":102},[],{"trials":16105,"activeCount":102},[],{"trials":16107,"activeCount":102},[],{"trials":16109,"activeCount":102},[],{"intervention":16111,"totalTrials":456,"cells":16112},"Glucose-dependent Insulinotropic Polypeptide",{"EARLY_PHASE1":16113,"PHASE1":16115,"PHASE2":16131,"PHASE3":16133,"PHASE4":16135,"NA":16137},{"trials":16114,"activeCount":102},[],{"trials":16116,"activeCount":102},[16117,16125],{"nctId":16118,"briefTitle":16119,"status":108,"phases":16120,"primaryCompletion":490,"completion":490,"start":3032,"enrollment":506,"conditions":16121,"interventions":16122},"NCT00798915","Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus",[90],[953],[16111,16123,16124],"Xenin-25","Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",{"nctId":16126,"briefTitle":16127,"status":108,"phases":16128,"primaryCompletion":3020,"completion":3020,"start":3103,"enrollment":6505,"conditions":16129,"interventions":16130},"NCT00949663","Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function",[90],[6121],[16111,16123,16124],{"trials":16132,"activeCount":102},[],{"trials":16134,"activeCount":102},[],{"trials":16136,"activeCount":102},[],{"trials":16138,"activeCount":102},[],{"intervention":16123,"totalTrials":456,"cells":16140},{"EARLY_PHASE1":16141,"PHASE1":16143,"PHASE2":16153,"PHASE3":16155,"PHASE4":16157,"NA":16159},{"trials":16142,"activeCount":102},[],{"trials":16144,"activeCount":102},[16145,16149],{"nctId":16118,"briefTitle":16119,"status":108,"phases":16146,"primaryCompletion":490,"completion":490,"start":3032,"enrollment":506,"conditions":16147,"interventions":16148},[90],[953],[16111,16123,16124],{"nctId":16126,"briefTitle":16127,"status":108,"phases":16150,"primaryCompletion":3020,"completion":3020,"start":3103,"enrollment":6505,"conditions":16151,"interventions":16152},[90],[6121],[16111,16123,16124],{"trials":16154,"activeCount":102},[],{"trials":16156,"activeCount":102},[],{"trials":16158,"activeCount":102},[],{"trials":16160,"activeCount":102},[],{"intervention":16124,"totalTrials":456,"cells":16162},{"EARLY_PHASE1":16163,"PHASE1":16165,"PHASE2":16175,"PHASE3":16177,"PHASE4":16179,"NA":16181},{"trials":16164,"activeCount":102},[],{"trials":16166,"activeCount":102},[16167,16171],{"nctId":16118,"briefTitle":16119,"status":108,"phases":16168,"primaryCompletion":490,"completion":490,"start":3032,"enrollment":506,"conditions":16169,"interventions":16170},[90],[953],[16111,16123,16124],{"nctId":16126,"briefTitle":16127,"status":108,"phases":16172,"primaryCompletion":3020,"completion":3020,"start":3103,"enrollment":6505,"conditions":16173,"interventions":16174},[90],[6121],[16111,16123,16124],{"trials":16176,"activeCount":102},[],{"trials":16178,"activeCount":102},[],{"trials":16180,"activeCount":102},[],{"trials":16182,"activeCount":102},[],{"intervention":3058,"totalTrials":456,"cells":16184},{"EARLY_PHASE1":16185,"PHASE1":16187,"PHASE2":16197,"PHASE3":16199,"PHASE4":16201,"NA":16203},{"trials":16186,"activeCount":102},[],{"trials":16188,"activeCount":102},[16189,16193],{"nctId":8851,"briefTitle":8852,"status":137,"phases":16190,"primaryCompletion":8854,"completion":8855,"start":2568,"enrollment":1080,"conditions":16191,"interventions":16192},[90],[24],[3058,3174,1073],{"nctId":3051,"briefTitle":3052,"status":137,"phases":16194,"primaryCompletion":3054,"completion":3055,"start":1039,"enrollment":184,"conditions":16195,"interventions":16196},[90],[24],[3058,2446,1849],{"trials":16198,"activeCount":102},[],{"trials":16200,"activeCount":102},[],{"trials":16202,"activeCount":102},[],{"trials":16204,"activeCount":102},[],{"intervention":2562,"totalTrials":184,"cells":16206},{"EARLY_PHASE1":16207,"PHASE1":16209,"PHASE2":16215,"PHASE3":16217,"PHASE4":16219,"NA":16221},{"trials":16208,"activeCount":102},[],{"trials":16210,"activeCount":102},[16211],{"nctId":2554,"briefTitle":2555,"status":137,"phases":16212,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":1818,"conditions":16213,"interventions":16214},[90],[1940,1941],[2561,2562,2563],{"trials":16216,"activeCount":102},[],{"trials":16218,"activeCount":102},[],{"trials":16220,"activeCount":102},[],{"trials":16222,"activeCount":102},[],{"intervention":16224,"totalTrials":184,"cells":16225},"levodopa solution 2mg\u002Fml for i.v. use",{"EARLY_PHASE1":16226,"PHASE1":16228,"PHASE2":16238,"PHASE3":16240,"PHASE4":16242,"NA":16244},{"trials":16227,"activeCount":102},[],{"trials":16229,"activeCount":102},[16230],{"nctId":16231,"briefTitle":16232,"status":108,"phases":16233,"primaryCompletion":12281,"completion":12281,"start":16234,"enrollment":19,"conditions":16235,"interventions":16237},"NCT00634556","Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)",[90],"2006-02",[16236],"Tourette Syndrome",[16224],{"trials":16239,"activeCount":102},[],{"trials":16241,"activeCount":102},[],{"trials":16243,"activeCount":102},[],{"trials":16245,"activeCount":102},[],{"intervention":3900,"totalTrials":184,"cells":16247},{"EARLY_PHASE1":16248,"PHASE1":16250,"PHASE2":16256,"PHASE3":16258,"PHASE4":16260,"NA":16262},{"trials":16249,"activeCount":102},[],{"trials":16251,"activeCount":102},[16252],{"nctId":3893,"briefTitle":3894,"status":108,"phases":16253,"primaryCompletion":3896,"completion":3896,"start":3897,"enrollment":340,"conditions":16254,"interventions":16255},[90],[2572],[3297,3900],{"trials":16257,"activeCount":102},[],{"trials":16259,"activeCount":102},[],{"trials":16261,"activeCount":102},[],{"trials":16263,"activeCount":102},[],{"intervention":2574,"totalTrials":184,"cells":16265},{"EARLY_PHASE1":16266,"PHASE1":16268,"PHASE2":16274,"PHASE3":16276,"PHASE4":16278,"NA":16280},{"trials":16267,"activeCount":102},[],{"trials":16269,"activeCount":102},[16270],{"nctId":2565,"briefTitle":2566,"status":137,"phases":16271,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":184,"conditions":16272,"interventions":16273},[90],[2572],[2574,1229,2377,2575,2375],{"trials":16275,"activeCount":102},[],{"trials":16277,"activeCount":102},[],{"trials":16279,"activeCount":102},[],{"trials":16281,"activeCount":102},[],{"intervention":2575,"totalTrials":184,"cells":16283},{"EARLY_PHASE1":16284,"PHASE1":16286,"PHASE2":16292,"PHASE3":16294,"PHASE4":16296,"NA":16298},{"trials":16285,"activeCount":102},[],{"trials":16287,"activeCount":102},[16288],{"nctId":2565,"briefTitle":2566,"status":137,"phases":16289,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":184,"conditions":16290,"interventions":16291},[90],[2572],[2574,1229,2377,2575,2375],{"trials":16293,"activeCount":102},[],{"trials":16295,"activeCount":102},[],{"trials":16297,"activeCount":102},[],{"trials":16299,"activeCount":102},[],{"intervention":16301,"totalTrials":184,"cells":16302},"CD34-TK75 transduced donor lymphocytes",{"EARLY_PHASE1":16303,"PHASE1":16305,"PHASE2":16313,"PHASE3":16315,"PHASE4":16317,"NA":16319},{"trials":16304,"activeCount":102},[],{"trials":16306,"activeCount":102},[16307],{"nctId":16308,"briefTitle":16309,"status":108,"phases":16310,"primaryCompletion":3217,"completion":3217,"start":12281,"enrollment":1566,"conditions":16311,"interventions":16312},"NCT00871702","Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease",[90],[12221,2598,1888,26,24],[16301],{"trials":16314,"activeCount":102},[],{"trials":16316,"activeCount":102},[],{"trials":16318,"activeCount":102},[],{"trials":16320,"activeCount":102},[],{"intervention":16322,"totalTrials":184,"cells":16323},"Graded Glucose Infusion with Placebo",{"EARLY_PHASE1":16324,"PHASE1":16326,"PHASE2":16341,"PHASE3":16343,"PHASE4":16345,"NA":16347},{"trials":16325,"activeCount":102},[],{"trials":16327,"activeCount":102},[16328],{"nctId":16329,"briefTitle":16330,"status":122,"phases":16331,"primaryCompletion":16332,"completion":16332,"start":1464,"enrollment":102,"conditions":16333,"interventions":16335},"NCT01951716","Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy",[90],"2018-07",[16334],"Does the Vagus Nerve Mediate the Effects of Xenin-25",[16322,16336,16337,16338,16339,16340],"Graded Glucose Infusion with GIP Alone","Graded Glucose Infusion with xenin-25 alone","Graded Glucose Infusion with GIP plus xenin-25","Meal Tolerance Test with Placebo","Meal Tolerance Test with xenin-25",{"trials":16342,"activeCount":102},[],{"trials":16344,"activeCount":102},[],{"trials":16346,"activeCount":102},[],{"trials":16348,"activeCount":102},[],{"intervention":16336,"totalTrials":184,"cells":16350},{"EARLY_PHASE1":16351,"PHASE1":16353,"PHASE2":16359,"PHASE3":16361,"PHASE4":16363,"NA":16365},{"trials":16352,"activeCount":102},[],{"trials":16354,"activeCount":102},[16355],{"nctId":16329,"briefTitle":16330,"status":122,"phases":16356,"primaryCompletion":16332,"completion":16332,"start":1464,"enrollment":102,"conditions":16357,"interventions":16358},[90],[16334],[16322,16336,16337,16338,16339,16340],{"trials":16360,"activeCount":102},[],{"trials":16362,"activeCount":102},[],{"trials":16364,"activeCount":102},[],{"trials":16366,"activeCount":102},[],{"intervention":16337,"totalTrials":184,"cells":16368},{"EARLY_PHASE1":16369,"PHASE1":16371,"PHASE2":16377,"PHASE3":16379,"PHASE4":16381,"NA":16383},{"trials":16370,"activeCount":102},[],{"trials":16372,"activeCount":102},[16373],{"nctId":16329,"briefTitle":16330,"status":122,"phases":16374,"primaryCompletion":16332,"completion":16332,"start":1464,"enrollment":102,"conditions":16375,"interventions":16376},[90],[16334],[16322,16336,16337,16338,16339,16340],{"trials":16378,"activeCount":102},[],{"trials":16380,"activeCount":102},[],{"trials":16382,"activeCount":102},[],{"trials":16384,"activeCount":102},[],{"intervention":16338,"totalTrials":184,"cells":16386},{"EARLY_PHASE1":16387,"PHASE1":16389,"PHASE2":16395,"PHASE3":16397,"PHASE4":16399,"NA":16401},{"trials":16388,"activeCount":102},[],{"trials":16390,"activeCount":102},[16391],{"nctId":16329,"briefTitle":16330,"status":122,"phases":16392,"primaryCompletion":16332,"completion":16332,"start":1464,"enrollment":102,"conditions":16393,"interventions":16394},[90],[16334],[16322,16336,16337,16338,16339,16340],{"trials":16396,"activeCount":102},[],{"trials":16398,"activeCount":102},[],{"trials":16400,"activeCount":102},[],{"trials":16402,"activeCount":102},[],{"intervention":16339,"totalTrials":184,"cells":16404},{"EARLY_PHASE1":16405,"PHASE1":16407,"PHASE2":16413,"PHASE3":16415,"PHASE4":16417,"NA":16419},{"trials":16406,"activeCount":102},[],{"trials":16408,"activeCount":102},[16409],{"nctId":16329,"briefTitle":16330,"status":122,"phases":16410,"primaryCompletion":16332,"completion":16332,"start":1464,"enrollment":102,"conditions":16411,"interventions":16412},[90],[16334],[16322,16336,16337,16338,16339,16340],{"trials":16414,"activeCount":102},[],{"trials":16416,"activeCount":102},[],{"trials":16418,"activeCount":102},[],{"trials":16420,"activeCount":102},[],{"intervention":16340,"totalTrials":184,"cells":16422},{"EARLY_PHASE1":16423,"PHASE1":16425,"PHASE2":16431,"PHASE3":16433,"PHASE4":16435,"NA":16437},{"trials":16424,"activeCount":102},[],{"trials":16426,"activeCount":102},[16427],{"nctId":16329,"briefTitle":16330,"status":122,"phases":16428,"primaryCompletion":16332,"completion":16332,"start":1464,"enrollment":102,"conditions":16429,"interventions":16430},[90],[16334],[16322,16336,16337,16338,16339,16340],{"trials":16432,"activeCount":102},[],{"trials":16434,"activeCount":102},[],{"trials":16436,"activeCount":102},[],{"trials":16438,"activeCount":102},[],{"intervention":16440,"totalTrials":184,"cells":16441},"onabotulinumtoxinA",{"EARLY_PHASE1":16442,"PHASE1":16444,"PHASE2":16456,"PHASE3":16458,"PHASE4":16460,"NA":16462},{"trials":16443,"activeCount":102},[],{"trials":16445,"activeCount":102},[16446],{"nctId":16447,"briefTitle":16448,"status":122,"phases":16449,"primaryCompletion":1351,"completion":1351,"start":882,"enrollment":102,"conditions":16450,"interventions":16455},"NCT02202070","Botox for Treatment of TMJ Disorder With Bruxism",[90],[16451,16452,16453,16454],"Temporomandibular Joint Disorders","Bruxism","Temporomandibular Joint Dysfunction Syndrome","Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint",[16440],{"trials":16457,"activeCount":102},[],{"trials":16459,"activeCount":102},[],{"trials":16461,"activeCount":102},[],{"trials":16463,"activeCount":102},[],{"intervention":11574,"totalTrials":184,"cells":16465},{"EARLY_PHASE1":16466,"PHASE1":16468,"PHASE2":16474,"PHASE3":16476,"PHASE4":16478,"NA":16480},{"trials":16467,"activeCount":102},[],{"trials":16469,"activeCount":102},[16470],{"nctId":11566,"briefTitle":11567,"status":108,"phases":16471,"primaryCompletion":11569,"completion":11570,"start":11571,"enrollment":2070,"conditions":16472,"interventions":16473},[90],[26],[11574,2395],{"trials":16475,"activeCount":102},[],{"trials":16477,"activeCount":102},[],{"trials":16479,"activeCount":102},[],{"trials":16481,"activeCount":102},[],{"intervention":2394,"totalTrials":184,"cells":16483},{"EARLY_PHASE1":16484,"PHASE1":16486,"PHASE2":16492,"PHASE3":16494,"PHASE4":16496,"NA":16498},{"trials":16485,"activeCount":102},[],{"trials":16487,"activeCount":102},[16488],{"nctId":2382,"briefTitle":2383,"status":137,"phases":16489,"primaryCompletion":2385,"completion":2386,"start":2387,"enrollment":98,"conditions":16490,"interventions":16491},[90],[2389,2390,2391],[2375,2393,1229,2362,2394,2395],{"trials":16493,"activeCount":102},[],{"trials":16495,"activeCount":102},[],{"trials":16497,"activeCount":102},[],{"trials":16499,"activeCount":102},[],{"intervention":16501,"totalTrials":184,"cells":16502},"Colloidal silver nanoparticles",{"EARLY_PHASE1":16503,"PHASE1":16505,"PHASE2":16514,"PHASE3":16516,"PHASE4":16518,"NA":16520},{"trials":16504,"activeCount":102},[],{"trials":16506,"activeCount":102},[16507],{"nctId":16508,"briefTitle":16509,"status":122,"phases":16510,"primaryCompletion":1350,"completion":1350,"start":16511,"enrollment":102,"conditions":16512,"interventions":16513},"NCT03243201","Silver Nanoparticle Investigation for Treating Chronic Sinusitis",[90],"2018-01",[10158],[16501],{"trials":16515,"activeCount":102},[],{"trials":16517,"activeCount":102},[],{"trials":16519,"activeCount":102},[],{"trials":16521,"activeCount":102},[],{"intervention":16523,"totalTrials":184,"cells":16524},"carbidopa-levodopa",{"EARLY_PHASE1":16525,"PHASE1":16527,"PHASE2":16538,"PHASE3":16540,"PHASE4":16542,"NA":16544},{"trials":16526,"activeCount":102},[],{"trials":16528,"activeCount":102},[16529],{"nctId":16530,"briefTitle":16531,"status":108,"phases":16532,"primaryCompletion":1921,"completion":1921,"start":16533,"enrollment":1080,"conditions":16534,"interventions":16537},"NCT03929068","Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis",[90],"2019-05-13",[16535,16536],"Amyotrophic Lateral Sclerosis","Motor Neuron Disease",[16523],{"trials":16539,"activeCount":102},[],{"trials":16541,"activeCount":102},[],{"trials":16543,"activeCount":102},[],{"trials":16545,"activeCount":102},[],{"intervention":16547,"totalTrials":184,"cells":16548},"ATI-2231",{"EARLY_PHASE1":16549,"PHASE1":16551,"PHASE2":16563,"PHASE3":16565,"PHASE4":16567,"NA":16569},{"trials":16550,"activeCount":102},[],{"trials":16552,"activeCount":102},[16553],{"nctId":16554,"briefTitle":16555,"status":122,"phases":16556,"primaryCompletion":16557,"completion":16557,"start":16558,"enrollment":102,"conditions":16559,"interventions":16562},"NCT05791474","ATI-2231 in Advanced Solid Tumor Malignancies",[90],"2025-06-30","2023-11-15",[16560,16561],"Advanced Solid Tumor","Advanced Solid Tumor Malignancies",[16547],{"trials":16564,"activeCount":102},[],{"trials":16566,"activeCount":102},[],{"trials":16568,"activeCount":102},[],{"trials":16570,"activeCount":102},[],{"intervention":16572,"totalTrials":184,"cells":16573},"ApoGraft",{"EARLY_PHASE1":16574,"PHASE1":16576,"PHASE2":16588,"PHASE3":16590,"PHASE4":16592,"NA":16594},{"trials":16575,"activeCount":102},[],{"trials":16577,"activeCount":102},[16578],{"nctId":16579,"briefTitle":16580,"status":137,"phases":16581,"primaryCompletion":16582,"completion":16582,"start":16583,"enrollment":599,"conditions":16584,"interventions":16587},"NCT04006652","ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients",[90],"2022-12-19","2020-12-16",[16585,16586],"Acute Graft Versus Host Disease","Haploidentical Hematopoietic Stem Cell Transplant",[16572],{"trials":16589,"activeCount":102},[],{"trials":16591,"activeCount":102},[],{"trials":16593,"activeCount":102},[],{"trials":16595,"activeCount":102},[],{"intervention":16597,"totalTrials":184,"cells":16598},"d-cycloserine and mifepristone",{"EARLY_PHASE1":16599,"PHASE1":16601,"PHASE2":16611,"PHASE3":16613,"PHASE4":16615,"NA":16617},{"trials":16600,"activeCount":102},[],{"trials":16602,"activeCount":102},[16603],{"nctId":16604,"briefTitle":16605,"status":137,"phases":16606,"primaryCompletion":16607,"completion":16607,"start":16608,"enrollment":1080,"conditions":16609,"interventions":16610},"NCT02099825","Medication Enhanced Rapid Therapy",[90],"2022-10","2014-01-13",[9157],[16597],{"trials":16612,"activeCount":102},[],{"trials":16614,"activeCount":102},[],{"trials":16616,"activeCount":102},[],{"trials":16618,"activeCount":102},[],{"intervention":16620,"totalTrials":184,"cells":16621},"Aflibercept every 2 months",{"EARLY_PHASE1":16622,"PHASE1":16624,"PHASE2":16636,"PHASE3":16638,"PHASE4":16640,"NA":16642},{"trials":16623,"activeCount":102},[],{"trials":16625,"activeCount":102},[16626],{"nctId":16627,"briefTitle":16628,"status":108,"phases":16629,"primaryCompletion":16630,"completion":1832,"start":3217,"enrollment":367,"conditions":16631,"interventions":16634},"NCT01579760","Intravitreal Aflibercept Injection for Radiation Retinopathy",[90],"2019-01",[16632,16633],"Radiation Retinopathy","Macular Edema",[16620,16635],"Aflibercept monthly",{"trials":16637,"activeCount":102},[],{"trials":16639,"activeCount":102},[],{"trials":16641,"activeCount":102},[],{"trials":16643,"activeCount":102},[],{"intervention":16635,"totalTrials":184,"cells":16645},{"EARLY_PHASE1":16646,"PHASE1":16648,"PHASE2":16654,"PHASE3":16656,"PHASE4":16658,"NA":16660},{"trials":16647,"activeCount":102},[],{"trials":16649,"activeCount":102},[16650],{"nctId":16627,"briefTitle":16628,"status":108,"phases":16651,"primaryCompletion":16630,"completion":1832,"start":3217,"enrollment":367,"conditions":16652,"interventions":16653},[90],[16632,16633],[16620,16635],{"trials":16655,"activeCount":102},[],{"trials":16657,"activeCount":102},[],{"trials":16659,"activeCount":102},[],{"trials":16661,"activeCount":102},[],{"intervention":16663,"totalTrials":184,"cells":16664},"Intrasite Vancomycin",{"EARLY_PHASE1":16665,"PHASE1":16667,"PHASE2":16677,"PHASE3":16679,"PHASE4":16681,"NA":16683},{"trials":16666,"activeCount":102},[],{"trials":16668,"activeCount":102},[16669],{"nctId":16670,"briefTitle":16671,"status":137,"phases":16672,"primaryCompletion":2443,"completion":2443,"start":1464,"enrollment":340,"conditions":16673,"interventions":16675},"NCT01764750","Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics",[90],[16674],"Surgical Site Infection",[16663,16676],"IV Vancomycin",{"trials":16678,"activeCount":102},[],{"trials":16680,"activeCount":102},[],{"trials":16682,"activeCount":102},[],{"trials":16684,"activeCount":102},[],{"intervention":16676,"totalTrials":184,"cells":16686},{"EARLY_PHASE1":16687,"PHASE1":16689,"PHASE2":16695,"PHASE3":16697,"PHASE4":16699,"NA":16701},{"trials":16688,"activeCount":102},[],{"trials":16690,"activeCount":102},[16691],{"nctId":16670,"briefTitle":16671,"status":137,"phases":16692,"primaryCompletion":2443,"completion":2443,"start":1464,"enrollment":340,"conditions":16693,"interventions":16694},[90],[16674],[16663,16676],{"trials":16696,"activeCount":102},[],{"trials":16698,"activeCount":102},[],{"trials":16700,"activeCount":102},[],{"trials":16702,"activeCount":102},[],{"intervention":16704,"totalTrials":184,"cells":16705},"Lo-Xenin",{"EARLY_PHASE1":16706,"PHASE1":16708,"PHASE2":16724,"PHASE3":16726,"PHASE4":16728,"NA":16730},{"trials":16707,"activeCount":102},[],{"trials":16709,"activeCount":102},[16710],{"nctId":16711,"briefTitle":16712,"status":108,"phases":16713,"primaryCompletion":16714,"completion":16714,"start":3302,"enrollment":1249,"conditions":16715,"interventions":16721},"NCT02204813","To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery",[90],"2015-11-17",[16716,16717,16718,16719,16720],"Bypass, Gastric","Roux-en-Y Gastric Bypass","Vertical Sleeve Gastrectomy","Gastric Banding","Bariatric Surgery",[16704,16722,16723],"Hi-Xenin","Extra Hi-Xenin",{"trials":16725,"activeCount":102},[],{"trials":16727,"activeCount":102},[],{"trials":16729,"activeCount":102},[],{"trials":16731,"activeCount":102},[],{"intervention":16722,"totalTrials":184,"cells":16733},{"EARLY_PHASE1":16734,"PHASE1":16736,"PHASE2":16742,"PHASE3":16744,"PHASE4":16746,"NA":16748},{"trials":16735,"activeCount":102},[],{"trials":16737,"activeCount":102},[16738],{"nctId":16711,"briefTitle":16712,"status":108,"phases":16739,"primaryCompletion":16714,"completion":16714,"start":3302,"enrollment":1249,"conditions":16740,"interventions":16741},[90],[16716,16717,16718,16719,16720],[16704,16722,16723],{"trials":16743,"activeCount":102},[],{"trials":16745,"activeCount":102},[],{"trials":16747,"activeCount":102},[],{"trials":16749,"activeCount":102},[],{"intervention":16723,"totalTrials":184,"cells":16751},{"EARLY_PHASE1":16752,"PHASE1":16754,"PHASE2":16760,"PHASE3":16762,"PHASE4":16764,"NA":16766},{"trials":16753,"activeCount":102},[],{"trials":16755,"activeCount":102},[16756],{"nctId":16711,"briefTitle":16712,"status":108,"phases":16757,"primaryCompletion":16714,"completion":16714,"start":3302,"enrollment":1249,"conditions":16758,"interventions":16759},[90],[16716,16717,16718,16719,16720],[16704,16722,16723],{"trials":16761,"activeCount":102},[],{"trials":16763,"activeCount":102},[],{"trials":16765,"activeCount":102},[],{"trials":16767,"activeCount":102},[],{"intervention":976,"totalTrials":184,"cells":16769},{"EARLY_PHASE1":16770,"PHASE1":16772,"PHASE2":16778,"PHASE3":16780,"PHASE4":16782,"NA":16784},{"trials":16771,"activeCount":102},[],{"trials":16773,"activeCount":102},[16774],{"nctId":967,"briefTitle":968,"status":137,"phases":16775,"primaryCompletion":970,"completion":971,"start":972,"enrollment":599,"conditions":16776,"interventions":16777},[90],[974],[976,977,959,978],{"trials":16779,"activeCount":102},[],{"trials":16781,"activeCount":102},[],{"trials":16783,"activeCount":102},[],{"trials":16785,"activeCount":102},[],{"intervention":1690,"totalTrials":184,"cells":16787},{"EARLY_PHASE1":16788,"PHASE1":16790,"PHASE2":16796,"PHASE3":16798,"PHASE4":16800,"NA":16802},{"trials":16789,"activeCount":102},[],{"trials":16791,"activeCount":102},[16792],{"nctId":1681,"briefTitle":1682,"status":122,"phases":16793,"primaryCompletion":1684,"completion":1685,"start":1686,"enrollment":102,"conditions":16794,"interventions":16795},[90],[1688],[82,1690],{"trials":16797,"activeCount":102},[],{"trials":16799,"activeCount":102},[],{"trials":16801,"activeCount":102},[],{"trials":16803,"activeCount":102},[],{"intervention":16805,"totalTrials":184,"cells":16806},"6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine",{"EARLY_PHASE1":16807,"PHASE1":16809,"PHASE2":16817,"PHASE3":16819,"PHASE4":16821,"NA":16823},{"trials":16808,"activeCount":102},[],{"trials":16810,"activeCount":102},[16811],{"nctId":16812,"briefTitle":16813,"status":137,"phases":16814,"primaryCompletion":6135,"completion":6135,"start":8246,"enrollment":1310,"conditions":16815,"interventions":16816},"NCT02371031","FDOPA-PET\u002FMRI for the Pre-operative Evaluation of Gliomas",[90],[2038,12161],[16805],{"trials":16818,"activeCount":102},[],{"trials":16820,"activeCount":102},[],{"trials":16822,"activeCount":102},[],{"trials":16824,"activeCount":102},[],{"intervention":1837,"totalTrials":184,"cells":16826},{"EARLY_PHASE1":16827,"PHASE1":16829,"PHASE2":16835,"PHASE3":16837,"PHASE4":16839,"NA":16841},{"trials":16828,"activeCount":102},[],{"trials":16830,"activeCount":102},[16831],{"nctId":1829,"briefTitle":1830,"status":137,"phases":16832,"primaryCompletion":1832,"completion":1833,"start":1834,"enrollment":1056,"conditions":16833,"interventions":16834},[90],[29,114,115,116],[1837,1125,1124],{"trials":16836,"activeCount":102},[],{"trials":16838,"activeCount":102},[],{"trials":16840,"activeCount":102},[],{"trials":16842,"activeCount":102},[],{"intervention":16844,"totalTrials":184,"cells":16845},"F-18-ISO",{"EARLY_PHASE1":16846,"PHASE1":16848,"PHASE2":16858,"PHASE3":16860,"PHASE4":16862,"NA":16864},{"trials":16847,"activeCount":102},[],{"trials":16849,"activeCount":102},[16850],{"nctId":16851,"briefTitle":16852,"status":108,"phases":16853,"primaryCompletion":16854,"completion":16854,"start":12030,"enrollment":1938,"conditions":16855,"interventions":16857},"NCT00968656","Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1",[90],"2011-11",[18,399,16856],"Diffuse Large B-cell Lymphoma",[16844],{"trials":16859,"activeCount":102},[],{"trials":16861,"activeCount":102},[],{"trials":16863,"activeCount":102},[],{"trials":16865,"activeCount":102},[],{"intervention":16867,"totalTrials":184,"cells":16868},"aclarubicin",{"EARLY_PHASE1":16869,"PHASE1":16871,"PHASE2":16881,"PHASE3":16883,"PHASE4":16885,"NA":16887},{"trials":16870,"activeCount":102},[],{"trials":16872,"activeCount":102},[16873],{"nctId":16874,"briefTitle":16875,"status":108,"phases":16876,"primaryCompletion":6782,"completion":6782,"start":11569,"enrollment":599,"conditions":16877,"interventions":16880},"NCT02723448","Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy",[90],[16878,16879],"Vasculopathy, Retinal, With Cerebral Leukodystrophy","Cerebroretinal Vasculopathy, Hereditary",[16867],{"trials":16882,"activeCount":102},[],{"trials":16884,"activeCount":102},[],{"trials":16886,"activeCount":102},[],{"trials":16888,"activeCount":102},[],{"intervention":3470,"totalTrials":184,"cells":16890},{"EARLY_PHASE1":16891,"PHASE1":16893,"PHASE2":16899,"PHASE3":16901,"PHASE4":16903,"NA":16905},{"trials":16892,"activeCount":102},[],{"trials":16894,"activeCount":102},[16895],{"nctId":3463,"briefTitle":3464,"status":108,"phases":16896,"primaryCompletion":3466,"completion":1442,"start":3281,"enrollment":3467,"conditions":16897,"interventions":16898},[90],[1875],[374,2563,373,375,3470],{"trials":16900,"activeCount":102},[],{"trials":16902,"activeCount":102},[],{"trials":16904,"activeCount":102},[],{"trials":16906,"activeCount":102},[],{"intervention":1006,"totalTrials":184,"cells":16908},{"EARLY_PHASE1":16909,"PHASE1":16911,"PHASE2":16917,"PHASE3":16919,"PHASE4":16921,"NA":16923},{"trials":16910,"activeCount":102},[],{"trials":16912,"activeCount":102},[16913],{"nctId":997,"briefTitle":998,"status":137,"phases":16914,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":474,"conditions":16915,"interventions":16916},[90],[1004],[1006,959,1007],{"trials":16918,"activeCount":102},[],{"trials":16920,"activeCount":102},[],{"trials":16922,"activeCount":102},[],{"trials":16924,"activeCount":102},[],{"intervention":1544,"totalTrials":184,"cells":16926},{"EARLY_PHASE1":16927,"PHASE1":16929,"PHASE2":16935,"PHASE3":16937,"PHASE4":16939,"NA":16941},{"trials":16928,"activeCount":102},[],{"trials":16930,"activeCount":102},[16931],{"nctId":1533,"briefTitle":1534,"status":122,"phases":16932,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":102,"conditions":16933,"interventions":16934},[90],[1540,1541,1542],[1544,82,426],{"trials":16936,"activeCount":102},[],{"trials":16938,"activeCount":102},[],{"trials":16940,"activeCount":102},[],{"trials":16942,"activeCount":102},[],{"intervention":3186,"totalTrials":184,"cells":16944},{"EARLY_PHASE1":16945,"PHASE1":16947,"PHASE2":16953,"PHASE3":16955,"PHASE4":16957,"NA":16959},{"trials":16946,"activeCount":102},[],{"trials":16948,"activeCount":102},[16949],{"nctId":3176,"briefTitle":3177,"status":108,"phases":16950,"primaryCompletion":3179,"completion":1441,"start":3180,"enrollment":1310,"conditions":16951,"interventions":16952},[90],[3182],[3184,3185,2425,3186,3187],{"trials":16954,"activeCount":102},[],{"trials":16956,"activeCount":102},[],{"trials":16958,"activeCount":102},[],{"trials":16960,"activeCount":102},[],{"intervention":3187,"totalTrials":184,"cells":16962},{"EARLY_PHASE1":16963,"PHASE1":16965,"PHASE2":16971,"PHASE3":16973,"PHASE4":16975,"NA":16977},{"trials":16964,"activeCount":102},[],{"trials":16966,"activeCount":102},[16967],{"nctId":3176,"briefTitle":3177,"status":108,"phases":16968,"primaryCompletion":3179,"completion":1441,"start":3180,"enrollment":1310,"conditions":16969,"interventions":16970},[90],[3182],[3184,3185,2425,3186,3187],{"trials":16972,"activeCount":102},[],{"trials":16974,"activeCount":102},[],{"trials":16976,"activeCount":102},[],{"trials":16978,"activeCount":102},[],{"intervention":16980,"totalTrials":184,"cells":16981},"fludeoxyglucose F 18",{"EARLY_PHASE1":16982,"PHASE1":16984,"PHASE2":16995,"PHASE3":16997,"PHASE4":16999,"NA":17001},{"trials":16983,"activeCount":102},[],{"trials":16985,"activeCount":102},[16986],{"nctId":16987,"briefTitle":16988,"status":137,"phases":16989,"primaryCompletion":16990,"completion":16990,"start":16991,"enrollment":599,"conditions":16992,"interventions":16993},"NCT02891616","18F-FLT PET Imaging in Patients With Advanced Melanoma",[90],"2017-12-31","2016-10-10",[2454],[16980,16994],"18F-fluorothymidine",{"trials":16996,"activeCount":102},[],{"trials":16998,"activeCount":102},[],{"trials":17000,"activeCount":102},[],{"trials":17002,"activeCount":102},[],{"intervention":16994,"totalTrials":184,"cells":17004},{"EARLY_PHASE1":17005,"PHASE1":17007,"PHASE2":17013,"PHASE3":17015,"PHASE4":17017,"NA":17019},{"trials":17006,"activeCount":102},[],{"trials":17008,"activeCount":102},[17009],{"nctId":16987,"briefTitle":16988,"status":137,"phases":17010,"primaryCompletion":16990,"completion":16990,"start":16991,"enrollment":599,"conditions":17011,"interventions":17012},[90],[2454],[16980,16994],{"trials":17014,"activeCount":102},[],{"trials":17016,"activeCount":102},[],{"trials":17018,"activeCount":102},[],{"trials":17020,"activeCount":102},[],{"intervention":17022,"totalTrials":184,"cells":17023},"Personalized polyepitope DNA vaccine",{"EARLY_PHASE1":17024,"PHASE1":17026,"PHASE2":17036,"PHASE3":17038,"PHASE4":17040,"NA":17042},{"trials":17025,"activeCount":102},[],{"trials":17027,"activeCount":102},[17028],{"nctId":17029,"briefTitle":17030,"status":108,"phases":17031,"primaryCompletion":17032,"completion":17032,"start":17033,"enrollment":1056,"conditions":17034,"interventions":17035},"NCT02348320","Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy",[90],"2020-03-12","2015-06-17",[1082,6946,1592],[17022],{"trials":17037,"activeCount":102},[],{"trials":17039,"activeCount":102},[],{"trials":17041,"activeCount":102},[],{"trials":17043,"activeCount":102},[],{"intervention":1848,"totalTrials":184,"cells":17045},{"EARLY_PHASE1":17046,"PHASE1":17048,"PHASE2":17054,"PHASE3":17056,"PHASE4":17058,"NA":17060},{"trials":17047,"activeCount":102},[],{"trials":17049,"activeCount":102},[17050],{"nctId":1839,"briefTitle":1840,"status":137,"phases":17051,"primaryCompletion":1842,"completion":1843,"start":1844,"enrollment":27,"conditions":17052,"interventions":17053},[90],[1635,1846],[1848,1849,1124,374],{"trials":17055,"activeCount":102},[],{"trials":17057,"activeCount":102},[],{"trials":17059,"activeCount":102},[],{"trials":17061,"activeCount":102},[],{"intervention":17063,"totalTrials":184,"cells":17064},"Bethanechol",{"EARLY_PHASE1":17065,"PHASE1":17067,"PHASE2":17076,"PHASE3":17078,"PHASE4":17080,"NA":17082},{"trials":17066,"activeCount":102},[],{"trials":17068,"activeCount":102},[17069],{"nctId":17070,"briefTitle":17071,"status":108,"phases":17072,"primaryCompletion":1589,"completion":1589,"start":17073,"enrollment":1954,"conditions":17074,"interventions":17075},"NCT01434901","The Effects of Bethanechol on Glucose Homeostasis",[90],"2011-08-15",[6121],[17063,17063,17063],{"trials":17077,"activeCount":102},[],{"trials":17079,"activeCount":102},[],{"trials":17081,"activeCount":102},[],{"trials":17083,"activeCount":102},[],{"intervention":17085,"totalTrials":184,"cells":17086},"Itacitinib",{"EARLY_PHASE1":17087,"PHASE1":17089,"PHASE2":17099,"PHASE3":17101,"PHASE4":17103,"NA":17105},{"trials":17088,"activeCount":102},[],{"trials":17090,"activeCount":102},[17091],{"nctId":17092,"briefTitle":17093,"status":108,"phases":17094,"primaryCompletion":17095,"completion":17096,"start":10511,"enrollment":614,"conditions":17097,"interventions":17098},"NCT03755414","Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation",[90],"2024-04-26","2024-05-26",[12809,2391,26,12813,1888],[17085],{"trials":17100,"activeCount":102},[],{"trials":17102,"activeCount":102},[],{"trials":17104,"activeCount":102},[],{"trials":17106,"activeCount":102},[],{"intervention":17108,"totalTrials":184,"cells":17109},"Glyburide",{"EARLY_PHASE1":17110,"PHASE1":17112,"PHASE2":17120,"PHASE3":17122,"PHASE4":17124,"NA":17126},{"trials":17111,"activeCount":102},[],{"trials":17113,"activeCount":102},[17114],{"nctId":17115,"briefTitle":17116,"status":108,"phases":17117,"primaryCompletion":3432,"completion":1736,"start":1464,"enrollment":36,"conditions":17118,"interventions":17119},"NCT01716338","Glyburide Healthy Volunteer Study",[90],[10673],[17108],{"trials":17121,"activeCount":102},[],{"trials":17123,"activeCount":102},[],{"trials":17125,"activeCount":102},[],{"trials":17127,"activeCount":102},[],{"intervention":17129,"totalTrials":184,"cells":17130},"F18-FFNP",{"EARLY_PHASE1":17131,"PHASE1":17133,"PHASE2":17141,"PHASE3":17143,"PHASE4":17145,"NA":17147},{"trials":17132,"activeCount":102},[],{"trials":17134,"activeCount":102},[17135],{"nctId":17136,"briefTitle":17137,"status":108,"phases":17138,"primaryCompletion":8918,"completion":8918,"start":1631,"enrollment":1299,"conditions":17139,"interventions":17140},"NCT00968409","Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)",[90],[18],[17129],{"trials":17142,"activeCount":102},[],{"trials":17144,"activeCount":102},[],{"trials":17146,"activeCount":102},[],{"trials":17148,"activeCount":102},[],{"intervention":17150,"totalTrials":184,"cells":17151},"rBBX-01",{"EARLY_PHASE1":17152,"PHASE1":17154,"PHASE2":17162,"PHASE3":17164,"PHASE4":17166,"NA":17168},{"trials":17153,"activeCount":102},[],{"trials":17155,"activeCount":102},[17156],{"nctId":17157,"briefTitle":17158,"status":108,"phases":17159,"primaryCompletion":1646,"completion":364,"start":6820,"enrollment":1566,"conditions":17160,"interventions":17161},"NCT00869388","A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors",[90],[1184],[17150],{"trials":17163,"activeCount":102},[],{"trials":17165,"activeCount":102},[],{"trials":17167,"activeCount":102},[],{"trials":17169,"activeCount":102},[],{"intervention":1358,"totalTrials":184,"cells":17171},{"EARLY_PHASE1":17172,"PHASE1":17174,"PHASE2":17180,"PHASE3":17182,"PHASE4":17184,"NA":17186},{"trials":17173,"activeCount":102},[],{"trials":17175,"activeCount":102},[17176],{"nctId":1346,"briefTitle":1347,"status":122,"phases":17177,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":102,"conditions":17178,"interventions":17179},[90],[1184,1353,1354,1355,1356],[403,1124,1358],{"trials":17181,"activeCount":102},[],{"trials":17183,"activeCount":102},[],{"trials":17185,"activeCount":102},[],{"trials":17187,"activeCount":102},[],{"intervention":1204,"totalTrials":184,"cells":17189},{"EARLY_PHASE1":17190,"PHASE1":17192,"PHASE2":17198,"PHASE3":17200,"PHASE4":17202,"NA":17204},{"trials":17191,"activeCount":102},[],{"trials":17193,"activeCount":102},[17194],{"nctId":1192,"briefTitle":1193,"status":122,"phases":17195,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":102,"conditions":17196,"interventions":17197},[90],[1199,1200,1201,1202],[994,1204,977],{"trials":17199,"activeCount":102},[],{"trials":17201,"activeCount":102},[],{"trials":17203,"activeCount":102},[],{"trials":17205,"activeCount":102},[],{"intervention":11585,"totalTrials":184,"cells":17207},{"EARLY_PHASE1":17208,"PHASE1":17210,"PHASE2":17216,"PHASE3":17218,"PHASE4":17220,"NA":17222},{"trials":17209,"activeCount":102},[],{"trials":17211,"activeCount":102},[17212],{"nctId":11580,"briefTitle":11581,"status":108,"phases":17213,"primaryCompletion":7054,"completion":6255,"start":3281,"enrollment":1664,"conditions":17214,"interventions":17215},[90],[3182,26],[2395,11585,11586],{"trials":17217,"activeCount":102},[],{"trials":17219,"activeCount":102},[],{"trials":17221,"activeCount":102},[],{"trials":17223,"activeCount":102},[],{"intervention":11586,"totalTrials":184,"cells":17225},{"EARLY_PHASE1":17226,"PHASE1":17228,"PHASE2":17234,"PHASE3":17236,"PHASE4":17238,"NA":17240},{"trials":17227,"activeCount":102},[],{"trials":17229,"activeCount":102},[17230],{"nctId":11580,"briefTitle":11581,"status":108,"phases":17231,"primaryCompletion":7054,"completion":6255,"start":3281,"enrollment":1664,"conditions":17232,"interventions":17233},[90],[3182,26],[2395,11585,11586],{"trials":17235,"activeCount":102},[],{"trials":17237,"activeCount":102},[],{"trials":17239,"activeCount":102},[],{"trials":17241,"activeCount":102},[],{"intervention":17243,"totalTrials":184,"cells":17244},"Maraviroc",{"EARLY_PHASE1":17245,"PHASE1":17247,"PHASE2":17256,"PHASE3":17258,"PHASE4":17260,"NA":17262},{"trials":17246,"activeCount":102},[],{"trials":17248,"activeCount":102},[17249],{"nctId":17250,"briefTitle":17251,"status":108,"phases":17252,"primaryCompletion":1441,"completion":3217,"start":8918,"enrollment":27,"conditions":17253,"interventions":17255},"NCT01133210","Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)",[90],[17254],"Hypertriglyceridemia",[17243],{"trials":17257,"activeCount":102},[],{"trials":17259,"activeCount":102},[],{"trials":17261,"activeCount":102},[],{"trials":17263,"activeCount":102},[],{"intervention":17265,"totalTrials":184,"cells":17266},"Belimumab",{"EARLY_PHASE1":17267,"PHASE1":17269,"PHASE2":17280,"PHASE3":17282,"PHASE4":17284,"NA":17286},{"trials":17268,"activeCount":102},[],{"trials":17270,"activeCount":102},[17271],{"nctId":17272,"briefTitle":17273,"status":108,"phases":17274,"primaryCompletion":17275,"completion":17276,"start":17277,"enrollment":340,"conditions":17278,"interventions":17279},"NCT03207958","Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation",[90],"2022-06-04","2024-02-09","2018-05-16",[6808,6809],[17265],{"trials":17281,"activeCount":102},[],{"trials":17283,"activeCount":102},[],{"trials":17285,"activeCount":102},[],{"trials":17287,"activeCount":102},[],{"intervention":11598,"totalTrials":184,"cells":17289},{"EARLY_PHASE1":17290,"PHASE1":17292,"PHASE2":17298,"PHASE3":17300,"PHASE4":17302,"NA":17304},{"trials":17291,"activeCount":102},[],{"trials":17293,"activeCount":102},[17294],{"nctId":11588,"briefTitle":11589,"status":108,"phases":17295,"primaryCompletion":11591,"completion":11592,"start":11593,"enrollment":1299,"conditions":17296,"interventions":17297},[90],[26,2389,11595,11596],[11598,2395],{"trials":17299,"activeCount":102},[],{"trials":17301,"activeCount":102},[],{"trials":17303,"activeCount":102},[],{"trials":17305,"activeCount":102},[],{"intervention":6411,"totalTrials":184,"cells":17307},{"EARLY_PHASE1":17308,"PHASE1":17310,"PHASE2":17316,"PHASE3":17318,"PHASE4":17320,"NA":17322},{"trials":17309,"activeCount":102},[],{"trials":17311,"activeCount":102},[17312],{"nctId":6406,"briefTitle":6407,"status":108,"phases":17313,"primaryCompletion":2287,"completion":3432,"start":3193,"enrollment":1042,"conditions":17314,"interventions":17315},[90],[3182],[6381,6411],{"trials":17317,"activeCount":102},[],{"trials":17319,"activeCount":102},[],{"trials":17321,"activeCount":102},[],{"trials":17323,"activeCount":102},[],{"intervention":1218,"totalTrials":184,"cells":17325},{"EARLY_PHASE1":17326,"PHASE1":17328,"PHASE2":17334,"PHASE3":17336,"PHASE4":17338,"NA":17340},{"trials":17327,"activeCount":102},[],{"trials":17329,"activeCount":102},[17330],{"nctId":1210,"briefTitle":1211,"status":137,"phases":17331,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":184,"conditions":17332,"interventions":17333},[90],[1216],[1218,994,1219],{"trials":17335,"activeCount":102},[],{"trials":17337,"activeCount":102},[],{"trials":17339,"activeCount":102},[],{"trials":17341,"activeCount":102},[],{"intervention":1219,"totalTrials":184,"cells":17343},{"EARLY_PHASE1":17344,"PHASE1":17346,"PHASE2":17352,"PHASE3":17354,"PHASE4":17356,"NA":17358},{"trials":17345,"activeCount":102},[],{"trials":17347,"activeCount":102},[17348],{"nctId":1210,"briefTitle":1211,"status":137,"phases":17349,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":184,"conditions":17350,"interventions":17351},[90],[1216],[1218,994,1219],{"trials":17353,"activeCount":102},[],{"trials":17355,"activeCount":102},[],{"trials":17357,"activeCount":102},[],{"trials":17359,"activeCount":102},[],{"intervention":2504,"totalTrials":184,"cells":17361},{"EARLY_PHASE1":17362,"PHASE1":17364,"PHASE2":17370,"PHASE3":17372,"PHASE4":17374,"NA":17376},{"trials":17363,"activeCount":102},[],{"trials":17365,"activeCount":102},[17366],{"nctId":2495,"briefTitle":2496,"status":108,"phases":17367,"primaryCompletion":2498,"completion":2499,"start":2500,"enrollment":951,"conditions":17368,"interventions":17369},[90],[2502,1875],[2504,402],{"trials":17371,"activeCount":102},[],{"trials":17373,"activeCount":102},[],{"trials":17375,"activeCount":102},[],{"trials":17377,"activeCount":102},[],{"intervention":131,"totalTrials":184,"cells":17379},{"EARLY_PHASE1":17380,"PHASE1":17382,"PHASE2":17388,"PHASE3":17390,"PHASE4":17392,"NA":17394},{"trials":17381,"activeCount":102},[],{"trials":17383,"activeCount":102},[17384],{"nctId":120,"briefTitle":121,"status":122,"phases":17385,"primaryCompletion":124,"completion":124,"start":125,"enrollment":102,"conditions":17386,"interventions":17387},[90],[127,128],[130,131,97],{"trials":17389,"activeCount":102},[],{"trials":17391,"activeCount":102},[],{"trials":17393,"activeCount":102},[],{"trials":17395,"activeCount":102},[],{"intervention":1046,"totalTrials":184,"cells":17397},{"EARLY_PHASE1":17398,"PHASE1":17400,"PHASE2":17406,"PHASE3":17408,"PHASE4":17410,"NA":17412},{"trials":17399,"activeCount":102},[],{"trials":17401,"activeCount":102},[17402],{"nctId":1036,"briefTitle":1037,"status":108,"phases":17403,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":17404,"interventions":17405},[90],[1044],[1046,1047,959,1007,1048],{"trials":17407,"activeCount":102},[],{"trials":17409,"activeCount":102},[],{"trials":17411,"activeCount":102},[],{"trials":17413,"activeCount":102},[],{"intervention":1047,"totalTrials":184,"cells":17415},{"EARLY_PHASE1":17416,"PHASE1":17418,"PHASE2":17424,"PHASE3":17426,"PHASE4":17428,"NA":17430},{"trials":17417,"activeCount":102},[],{"trials":17419,"activeCount":102},[17420],{"nctId":1036,"briefTitle":1037,"status":108,"phases":17421,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":17422,"interventions":17423},[90],[1044],[1046,1047,959,1007,1048],{"trials":17425,"activeCount":102},[],{"trials":17427,"activeCount":102},[],{"trials":17429,"activeCount":102},[],{"trials":17431,"activeCount":102},[],{"intervention":17433,"totalTrials":184,"cells":17434},"64Cu-DOTA-U3-1287",{"EARLY_PHASE1":17435,"PHASE1":17437,"PHASE2":17447,"PHASE3":17449,"PHASE4":17451,"NA":17453},{"trials":17436,"activeCount":102},[],{"trials":17438,"activeCount":102},[17439],{"nctId":17440,"briefTitle":17441,"status":137,"phases":17442,"primaryCompletion":1464,"completion":17443,"start":3281,"enrollment":1566,"conditions":17444,"interventions":17445},"NCT01479023","Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors",[90],"2013-03",[2637,15833,12231],[17433,17446],"U3-1287",{"trials":17448,"activeCount":102},[],{"trials":17450,"activeCount":102},[],{"trials":17452,"activeCount":102},[],{"trials":17454,"activeCount":102},[],{"intervention":17446,"totalTrials":184,"cells":17456},{"EARLY_PHASE1":17457,"PHASE1":17459,"PHASE2":17465,"PHASE3":17467,"PHASE4":17469,"NA":17471},{"trials":17458,"activeCount":102},[],{"trials":17460,"activeCount":102},[17461],{"nctId":17440,"briefTitle":17441,"status":137,"phases":17462,"primaryCompletion":1464,"completion":17443,"start":3281,"enrollment":1566,"conditions":17463,"interventions":17464},[90],[2637,15833,12231],[17433,17446],{"trials":17466,"activeCount":102},[],{"trials":17468,"activeCount":102},[],{"trials":17470,"activeCount":102},[],{"trials":17472,"activeCount":102},[],{"intervention":17474,"totalTrials":184,"cells":17475},"Fecal microbiota transplantation",{"EARLY_PHASE1":17476,"PHASE1":17478,"PHASE2":17488,"PHASE3":17490,"PHASE4":17492,"NA":17494},{"trials":17477,"activeCount":102},[],{"trials":17479,"activeCount":102},[17480],{"nctId":17481,"briefTitle":17482,"status":108,"phases":17483,"primaryCompletion":17484,"completion":17484,"start":381,"enrollment":184,"conditions":17485,"interventions":17487},"NCT02312986","FMT for Multidrug Resistant Organism Reversal",[90],"2020-07-31",[17486],"Infection With Multi-drug Resistant Organisms",[17474],{"trials":17489,"activeCount":102},[],{"trials":17491,"activeCount":102},[],{"trials":17493,"activeCount":102},[],{"trials":17495,"activeCount":102},[],{"intervention":6938,"totalTrials":184,"cells":17497},{"EARLY_PHASE1":17498,"PHASE1":17500,"PHASE2":17506,"PHASE3":17508,"PHASE4":17510,"NA":17512},{"trials":17499,"activeCount":102},[],{"trials":17501,"activeCount":102},[17502],{"nctId":6930,"briefTitle":6931,"status":137,"phases":17503,"primaryCompletion":6933,"completion":6934,"start":6935,"enrollment":1566,"conditions":17504,"interventions":17505},[90],[116,29,115],[6938,977],{"trials":17507,"activeCount":102},[],{"trials":17509,"activeCount":102},[],{"trials":17511,"activeCount":102},[],{"trials":17513,"activeCount":102},[],{"intervention":17515,"totalTrials":184,"cells":17516},"64Cu-DOTA-ECLIi",{"EARLY_PHASE1":17517,"PHASE1":17519,"PHASE2":17529,"PHASE3":17531,"PHASE4":17533,"NA":17535},{"trials":17518,"activeCount":102},[],{"trials":17520,"activeCount":102},[17521],{"nctId":17522,"briefTitle":17523,"status":108,"phases":17524,"primaryCompletion":17525,"completion":17525,"start":17526,"enrollment":1466,"conditions":17527,"interventions":17528},"NCT03851237","CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy",[90],"2025-12-19","2019-01-02",[1121],[17515],{"trials":17530,"activeCount":102},[],{"trials":17532,"activeCount":102},[],{"trials":17534,"activeCount":102},[],{"trials":17536,"activeCount":102},[],{"intervention":1877,"totalTrials":184,"cells":17538},{"EARLY_PHASE1":17539,"PHASE1":17541,"PHASE2":17547,"PHASE3":17549,"PHASE4":17551,"NA":17553},{"trials":17540,"activeCount":102},[],{"trials":17542,"activeCount":102},[17543],{"nctId":1869,"briefTitle":1870,"status":137,"phases":17544,"primaryCompletion":1872,"completion":1873,"start":1431,"enrollment":1056,"conditions":17545,"interventions":17546},[90],[1875],[1124,1877],{"trials":17548,"activeCount":102},[],{"trials":17550,"activeCount":102},[],{"trials":17552,"activeCount":102},[],{"trials":17554,"activeCount":102},[],{"intervention":17556,"totalTrials":184,"cells":17557},"pegylated liposomal doxorubicin hydrochloride",{"EARLY_PHASE1":17558,"PHASE1":17560,"PHASE2":17572,"PHASE3":17574,"PHASE4":17576,"NA":17578},{"trials":17559,"activeCount":102},[],{"trials":17561,"activeCount":102},[17562],{"nctId":17563,"briefTitle":17564,"status":108,"phases":17565,"primaryCompletion":17566,"completion":17566,"start":17567,"enrollment":1664,"conditions":17568,"interventions":17570},"NCT00003207","Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers",[90],"2002-07","1998-03",[15833,17569],"Unspecified Adult Solid Tumor, Protocol Specific",[17556,17571],"PSC 833",{"trials":17573,"activeCount":102},[],{"trials":17575,"activeCount":102},[],{"trials":17577,"activeCount":102},[],{"trials":17579,"activeCount":102},[],{"intervention":17571,"totalTrials":184,"cells":17581},{"EARLY_PHASE1":17582,"PHASE1":17584,"PHASE2":17590,"PHASE3":17592,"PHASE4":17594,"NA":17596},{"trials":17583,"activeCount":102},[],{"trials":17585,"activeCount":102},[17586],{"nctId":17563,"briefTitle":17564,"status":108,"phases":17587,"primaryCompletion":17566,"completion":17566,"start":17567,"enrollment":1664,"conditions":17588,"interventions":17589},[90],[15833,17569],[17556,17571],{"trials":17591,"activeCount":102},[],{"trials":17593,"activeCount":102},[],{"trials":17595,"activeCount":102},[],{"trials":17597,"activeCount":102},[],{"intervention":1711,"totalTrials":184,"cells":17599},{"EARLY_PHASE1":17600,"PHASE1":17602,"PHASE2":17608,"PHASE3":17610,"PHASE4":17612,"NA":17614},{"trials":17601,"activeCount":102},[],{"trials":17603,"activeCount":102},[17604],{"nctId":1704,"briefTitle":1705,"status":122,"phases":17605,"primaryCompletion":432,"completion":1707,"start":1708,"enrollment":102,"conditions":17606,"interventions":17607},[90],[18,159],[1711,1228,1229,82],{"trials":17609,"activeCount":102},[],{"trials":17611,"activeCount":102},[],{"trials":17613,"activeCount":102},[],{"trials":17615,"activeCount":102},[],{"intervention":17617,"totalTrials":184,"cells":17618},"Xenin-25 without atropine",{"EARLY_PHASE1":17619,"PHASE1":17621,"PHASE2":17636,"PHASE3":17638,"PHASE4":17640,"NA":17642},{"trials":17620,"activeCount":102},[],{"trials":17622,"activeCount":102},[17623],{"nctId":17624,"briefTitle":17625,"status":108,"phases":17626,"primaryCompletion":10381,"completion":10381,"start":17627,"enrollment":1080,"conditions":17628,"interventions":17630},"NCT01951729","The Role of Cholinergic Signaling for Mediating the Effects of GIP and\u002For Xenin-25 on Insulin Secretion",[90],"2013-03-13",[17629],"Pre-diabetes",[10455,17617,17631,17632,17633,17634,17635],"GIP without atropine","Xenin-25 with atropine","GIP with atropine","GIP plus Xenin-25 without atropine","GIP plus Xenin-25 with atropine",{"trials":17637,"activeCount":102},[],{"trials":17639,"activeCount":102},[],{"trials":17641,"activeCount":102},[],{"trials":17643,"activeCount":102},[],{"intervention":17631,"totalTrials":184,"cells":17645},{"EARLY_PHASE1":17646,"PHASE1":17648,"PHASE2":17654,"PHASE3":17656,"PHASE4":17658,"NA":17660},{"trials":17647,"activeCount":102},[],{"trials":17649,"activeCount":102},[17650],{"nctId":17624,"briefTitle":17625,"status":108,"phases":17651,"primaryCompletion":10381,"completion":10381,"start":17627,"enrollment":1080,"conditions":17652,"interventions":17653},[90],[17629],[10455,17617,17631,17632,17633,17634,17635],{"trials":17655,"activeCount":102},[],{"trials":17657,"activeCount":102},[],{"trials":17659,"activeCount":102},[],{"trials":17661,"activeCount":102},[],{"intervention":17632,"totalTrials":184,"cells":17663},{"EARLY_PHASE1":17664,"PHASE1":17666,"PHASE2":17672,"PHASE3":17674,"PHASE4":17676,"NA":17678},{"trials":17665,"activeCount":102},[],{"trials":17667,"activeCount":102},[17668],{"nctId":17624,"briefTitle":17625,"status":108,"phases":17669,"primaryCompletion":10381,"completion":10381,"start":17627,"enrollment":1080,"conditions":17670,"interventions":17671},[90],[17629],[10455,17617,17631,17632,17633,17634,17635],{"trials":17673,"activeCount":102},[],{"trials":17675,"activeCount":102},[],{"trials":17677,"activeCount":102},[],{"trials":17679,"activeCount":102},[],{"intervention":17633,"totalTrials":184,"cells":17681},{"EARLY_PHASE1":17682,"PHASE1":17684,"PHASE2":17690,"PHASE3":17692,"PHASE4":17694,"NA":17696},{"trials":17683,"activeCount":102},[],{"trials":17685,"activeCount":102},[17686],{"nctId":17624,"briefTitle":17625,"status":108,"phases":17687,"primaryCompletion":10381,"completion":10381,"start":17627,"enrollment":1080,"conditions":17688,"interventions":17689},[90],[17629],[10455,17617,17631,17632,17633,17634,17635],{"trials":17691,"activeCount":102},[],{"trials":17693,"activeCount":102},[],{"trials":17695,"activeCount":102},[],{"trials":17697,"activeCount":102},[],{"intervention":17634,"totalTrials":184,"cells":17699},{"EARLY_PHASE1":17700,"PHASE1":17702,"PHASE2":17708,"PHASE3":17710,"PHASE4":17712,"NA":17714},{"trials":17701,"activeCount":102},[],{"trials":17703,"activeCount":102},[17704],{"nctId":17624,"briefTitle":17625,"status":108,"phases":17705,"primaryCompletion":10381,"completion":10381,"start":17627,"enrollment":1080,"conditions":17706,"interventions":17707},[90],[17629],[10455,17617,17631,17632,17633,17634,17635],{"trials":17709,"activeCount":102},[],{"trials":17711,"activeCount":102},[],{"trials":17713,"activeCount":102},[],{"trials":17715,"activeCount":102},[],{"intervention":17635,"totalTrials":184,"cells":17717},{"EARLY_PHASE1":17718,"PHASE1":17720,"PHASE2":17726,"PHASE3":17728,"PHASE4":17730,"NA":17732},{"trials":17719,"activeCount":102},[],{"trials":17721,"activeCount":102},[17722],{"nctId":17624,"briefTitle":17625,"status":108,"phases":17723,"primaryCompletion":10381,"completion":10381,"start":17627,"enrollment":1080,"conditions":17724,"interventions":17725},[90],[17629],[10455,17617,17631,17632,17633,17634,17635],{"trials":17727,"activeCount":102},[],{"trials":17729,"activeCount":102},[],{"trials":17731,"activeCount":102},[],{"trials":17733,"activeCount":102},[],{"intervention":1891,"totalTrials":184,"cells":17735},{"EARLY_PHASE1":17736,"PHASE1":17738,"PHASE2":17744,"PHASE3":17746,"PHASE4":17748,"NA":17750},{"trials":17737,"activeCount":102},[],{"trials":17739,"activeCount":102},[17740],{"nctId":1879,"briefTitle":1880,"status":108,"phases":17741,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":30,"conditions":17742,"interventions":17743},[90],[1886,1887,1888,1889],[1891,1124,374,1849,1892],{"trials":17745,"activeCount":102},[],{"trials":17747,"activeCount":102},[],{"trials":17749,"activeCount":102},[],{"trials":17751,"activeCount":102},[],{"intervention":17753,"totalTrials":184,"cells":17754},"Tauroursoursodeoxycholic acid, brand name Tudcabil",{"EARLY_PHASE1":17755,"PHASE1":17757,"PHASE2":17768,"PHASE3":17770,"PHASE4":17772,"NA":17774},{"trials":17756,"activeCount":102},[],{"trials":17758,"activeCount":102},[17759],{"nctId":17760,"briefTitle":17761,"status":108,"phases":17762,"primaryCompletion":17763,"completion":17763,"start":17764,"enrollment":1664,"conditions":17765,"interventions":17767},"NCT04114292","TUDCA as a Therapy for Ulcerative Colitis (UC)",[90],"2022-06-07","2019-01-17",[17766],"Ulcerative Colitis",[17753],{"trials":17769,"activeCount":102},[],{"trials":17771,"activeCount":102},[],{"trials":17773,"activeCount":102},[],{"trials":17775,"activeCount":102},[],{"intervention":17777,"totalTrials":184,"cells":17778},"Propranolol",{"EARLY_PHASE1":17779,"PHASE1":17781,"PHASE2":17790,"PHASE3":17792,"PHASE4":17794,"NA":17796},{"trials":17780,"activeCount":102},[],{"trials":17782,"activeCount":102},[17783],{"nctId":17784,"briefTitle":17785,"status":108,"phases":17786,"primaryCompletion":1736,"completion":381,"start":1965,"enrollment":30,"conditions":17787,"interventions":17789},"NCT01308944","Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients",[90],[17788,1541,1542],"Invasive Epithelial Ovarian Cancer",[17777],{"trials":17791,"activeCount":102},[],{"trials":17793,"activeCount":102},[],{"trials":17795,"activeCount":102},[],{"trials":17797,"activeCount":102},[],{"intervention":7788,"totalTrials":184,"cells":17799},{"EARLY_PHASE1":17800,"PHASE1":17802,"PHASE2":17808,"PHASE3":17810,"PHASE4":17812,"NA":17814},{"trials":17801,"activeCount":102},[],{"trials":17803,"activeCount":102},[17804],{"nctId":7779,"briefTitle":7780,"status":137,"phases":17805,"primaryCompletion":7782,"completion":7783,"start":7784,"enrollment":2289,"conditions":17806,"interventions":17807},[90],[7786],[7788,6812],{"trials":17809,"activeCount":102},[],{"trials":17811,"activeCount":102},[],{"trials":17813,"activeCount":102},[],{"trials":17815,"activeCount":102},[],{"intervention":17817,"totalTrials":184,"cells":17818},"trivalent influenza vaccine",{"EARLY_PHASE1":17819,"PHASE1":17821,"PHASE2":17830,"PHASE3":17832,"PHASE4":17834,"NA":17836},{"trials":17820,"activeCount":102},[],{"trials":17822,"activeCount":102},[17823],{"nctId":17824,"briefTitle":17825,"status":137,"phases":17826,"primaryCompletion":3345,"completion":3345,"start":2288,"enrollment":36,"conditions":17827,"interventions":17829},"NCT01695733","Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy",[90],[17828],"Neoplasms",[17817],{"trials":17831,"activeCount":102},[],{"trials":17833,"activeCount":102},[],{"trials":17835,"activeCount":102},[],{"trials":17837,"activeCount":102},[],{"intervention":17839,"totalTrials":184,"cells":17840},"[18F]ASEM",{"EARLY_PHASE1":17841,"PHASE1":17843,"PHASE2":17854,"PHASE3":17856,"PHASE4":17858,"NA":17860},{"trials":17842,"activeCount":102},[],{"trials":17844,"activeCount":102},[17845],{"nctId":17846,"briefTitle":17847,"status":137,"phases":17848,"primaryCompletion":17849,"completion":17849,"start":6648,"enrollment":17850,"conditions":17851,"interventions":17852},"NCT05462340","PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia",[90],"2025-01-07",117,[3999],[17839,17853],"[18F]AZAN",{"trials":17855,"activeCount":102},[],{"trials":17857,"activeCount":102},[],{"trials":17859,"activeCount":102},[],{"trials":17861,"activeCount":102},[],{"intervention":17853,"totalTrials":184,"cells":17863},{"EARLY_PHASE1":17864,"PHASE1":17866,"PHASE2":17872,"PHASE3":17874,"PHASE4":17876,"NA":17878},{"trials":17865,"activeCount":102},[],{"trials":17867,"activeCount":102},[17868],{"nctId":17846,"briefTitle":17847,"status":137,"phases":17869,"primaryCompletion":17849,"completion":17849,"start":6648,"enrollment":17850,"conditions":17870,"interventions":17871},[90],[3999],[17839,17853],{"trials":17873,"activeCount":102},[],{"trials":17875,"activeCount":102},[],{"trials":17877,"activeCount":102},[],{"trials":17879,"activeCount":102},[],{"intervention":12119,"totalTrials":184,"cells":17881},{"EARLY_PHASE1":17882,"PHASE1":17884,"PHASE2":17890,"PHASE3":17892,"PHASE4":17894,"NA":17896},{"trials":17883,"activeCount":102},[],{"trials":17885,"activeCount":102},[17886],{"nctId":12110,"briefTitle":12111,"status":108,"phases":17887,"primaryCompletion":12113,"completion":12113,"start":12114,"enrollment":1664,"conditions":17888,"interventions":17889},[90],[2038,12116,2043,2039,12117,2040,2412],[12119,3025],{"trials":17891,"activeCount":102},[],{"trials":17893,"activeCount":102},[],{"trials":17895,"activeCount":102},[],{"trials":17897,"activeCount":102},[],{"intervention":1252,"totalTrials":184,"cells":17899},{"EARLY_PHASE1":17900,"PHASE1":17902,"PHASE2":17908,"PHASE3":17910,"PHASE4":17912,"NA":17914},{"trials":17901,"activeCount":102},[],{"trials":17903,"activeCount":102},[17904],{"nctId":1243,"briefTitle":1244,"status":137,"phases":17905,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":17906,"interventions":17907},[90],[423],[1252,994],{"trials":17909,"activeCount":102},[],{"trials":17911,"activeCount":102},[],{"trials":17913,"activeCount":102},[],{"trials":17915,"activeCount":102},[],{"intervention":17917,"totalTrials":184,"cells":17918},"Lucentis",{"EARLY_PHASE1":17919,"PHASE1":17921,"PHASE2":17930,"PHASE3":17932,"PHASE4":17934,"NA":17936},{"trials":17920,"activeCount":102},[],{"trials":17922,"activeCount":102},[17923],{"nctId":17924,"briefTitle":17925,"status":108,"phases":17926,"primaryCompletion":11781,"completion":11781,"start":3250,"enrollment":1818,"conditions":17927,"interventions":17929},"NCT00500344","CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography",[90],[17928],"Age-related Macular Degeneration",[17917],{"trials":17931,"activeCount":102},[],{"trials":17933,"activeCount":102},[],{"trials":17935,"activeCount":102},[],{"trials":17937,"activeCount":102},[],{"intervention":17939,"totalTrials":184,"cells":17940},"Ondansetron 8mg with Saline & Tariquidar",{"EARLY_PHASE1":17941,"PHASE1":17943,"PHASE2":17954,"PHASE3":17956,"PHASE4":17958,"NA":17960},{"trials":17942,"activeCount":102},[],{"trials":17944,"activeCount":102},[17945],{"nctId":17946,"briefTitle":17947,"status":137,"phases":17948,"primaryCompletion":17949,"completion":17949,"start":17950,"enrollment":1664,"conditions":17951,"interventions":17952},"NCT03809234","Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers",[90],"2020-11-30","2019-05-20",[13982],[17939,17953],"Ondansetron 16mg with Saline & Tariquidar",{"trials":17955,"activeCount":102},[],{"trials":17957,"activeCount":102},[],{"trials":17959,"activeCount":102},[],{"trials":17961,"activeCount":102},[],{"intervention":17953,"totalTrials":184,"cells":17963},{"EARLY_PHASE1":17964,"PHASE1":17966,"PHASE2":17972,"PHASE3":17974,"PHASE4":17976,"NA":17978},{"trials":17965,"activeCount":102},[],{"trials":17967,"activeCount":102},[17968],{"nctId":17946,"briefTitle":17947,"status":137,"phases":17969,"primaryCompletion":17949,"completion":17949,"start":17950,"enrollment":1664,"conditions":17970,"interventions":17971},[90],[13982],[17939,17953],{"trials":17973,"activeCount":102},[],{"trials":17975,"activeCount":102},[],{"trials":17977,"activeCount":102},[],{"trials":17979,"activeCount":102},[],{"intervention":17981,"totalTrials":184,"cells":17982},"sunitinib and rapamycin",{"EARLY_PHASE1":17983,"PHASE1":17985,"PHASE2":17993,"PHASE3":17995,"PHASE4":17997,"NA":17999},{"trials":17984,"activeCount":102},[],{"trials":17986,"activeCount":102},[17987],{"nctId":17988,"briefTitle":17989,"status":108,"phases":17990,"primaryCompletion":1872,"completion":490,"start":3208,"enrollment":1042,"conditions":17991,"interventions":17992},"NCT00555256","A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)",[90],[1354],[17981],{"trials":17994,"activeCount":102},[],{"trials":17996,"activeCount":102},[],{"trials":17998,"activeCount":102},[],{"trials":18000,"activeCount":102},[],{"intervention":9125,"totalTrials":184,"cells":18002},{"EARLY_PHASE1":18003,"PHASE1":18005,"PHASE2":18011,"PHASE3":18013,"PHASE4":18015,"NA":18017},{"trials":18004,"activeCount":102},[],{"trials":18006,"activeCount":102},[18007],{"nctId":9115,"briefTitle":9116,"status":108,"phases":18008,"primaryCompletion":9118,"completion":9119,"start":9120,"enrollment":3305,"conditions":18009,"interventions":18010},[90],[9122,9123],[9125,9108],{"trials":18012,"activeCount":102},[],{"trials":18014,"activeCount":102},[],{"trials":18016,"activeCount":102},[],{"trials":18018,"activeCount":102},[],{"intervention":3938,"totalTrials":184,"cells":18020},{"EARLY_PHASE1":18021,"PHASE1":18023,"PHASE2":18029,"PHASE3":18031,"PHASE4":18033,"NA":18035},{"trials":18022,"activeCount":102},[],{"trials":18024,"activeCount":102},[18025],{"nctId":3930,"briefTitle":3931,"status":137,"phases":18026,"primaryCompletion":3933,"completion":3088,"start":3934,"enrollment":208,"conditions":18027,"interventions":18028},[90],[3182],[3937,3938,3939,3940],{"trials":18030,"activeCount":102},[],{"trials":18032,"activeCount":102},[],{"trials":18034,"activeCount":102},[],{"trials":18036,"activeCount":102},[],{"intervention":18038,"totalTrials":184,"cells":18039},"Tc-99m tilmanocept",{"EARLY_PHASE1":18040,"PHASE1":18042,"PHASE2":18053,"PHASE3":18055,"PHASE4":18057,"NA":18059},{"trials":18041,"activeCount":102},[],{"trials":18043,"activeCount":102},[18044],{"nctId":18045,"briefTitle":18046,"status":137,"phases":18047,"primaryCompletion":6283,"completion":6283,"start":18048,"enrollment":1664,"conditions":18049,"interventions":18052},"NCT04096716","Mapping Draining Lymph Nodes in CNS Malignancies",[90],"2019-12-03",[18050,18051],"Central Nervous System Neoplasms","Central Nervous System Tumor",[18038],{"trials":18054,"activeCount":102},[],{"trials":18056,"activeCount":102},[],{"trials":18058,"activeCount":102},[],{"trials":18060,"activeCount":102},[],{"intervention":2423,"totalTrials":184,"cells":18062},{"EARLY_PHASE1":18063,"PHASE1":18065,"PHASE2":18071,"PHASE3":18073,"PHASE4":18075,"NA":18077},{"trials":18064,"activeCount":102},[],{"trials":18066,"activeCount":102},[18067],{"nctId":2415,"briefTitle":2416,"status":108,"phases":18068,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":1664,"conditions":18069,"interventions":18070},[90],[2323],[2423,2225,2424,2425,2362],{"trials":18072,"activeCount":102},[],{"trials":18074,"activeCount":102},[],{"trials":18076,"activeCount":102},[],{"trials":18078,"activeCount":102},[],{"intervention":12763,"totalTrials":184,"cells":18080},{"EARLY_PHASE1":18081,"PHASE1":18083,"PHASE2":18089,"PHASE3":18091,"PHASE4":18093,"NA":18095},{"trials":18082,"activeCount":102},[],{"trials":18084,"activeCount":102},[18085],{"nctId":12754,"briefTitle":12755,"status":108,"phases":18086,"primaryCompletion":12757,"completion":12757,"start":12758,"enrollment":1042,"conditions":18087,"interventions":18088},[90],[12760,12761],[12747,12763,12764],{"trials":18090,"activeCount":102},[],{"trials":18092,"activeCount":102},[],{"trials":18094,"activeCount":102},[],{"trials":18096,"activeCount":102},[],{"intervention":12764,"totalTrials":184,"cells":18098},{"EARLY_PHASE1":18099,"PHASE1":18101,"PHASE2":18107,"PHASE3":18109,"PHASE4":18111,"NA":18113},{"trials":18100,"activeCount":102},[],{"trials":18102,"activeCount":102},[18103],{"nctId":12754,"briefTitle":12755,"status":108,"phases":18104,"primaryCompletion":12757,"completion":12757,"start":12758,"enrollment":1042,"conditions":18105,"interventions":18106},[90],[12760,12761],[12747,12763,12764],{"trials":18108,"activeCount":102},[],{"trials":18110,"activeCount":102},[],{"trials":18112,"activeCount":102},[],{"trials":18114,"activeCount":102},[],{"intervention":18116,"totalTrials":184,"cells":18117},"Baricitinib",{"EARLY_PHASE1":18118,"PHASE1":18120,"PHASE2":18131,"PHASE3":18133,"PHASE4":18135,"NA":18137},{"trials":18119,"activeCount":102},[],{"trials":18121,"activeCount":102},[18122],{"nctId":18123,"briefTitle":18124,"status":108,"phases":18125,"primaryCompletion":18126,"completion":18127,"start":18128,"enrollment":442,"conditions":18129,"interventions":18130},"NCT04131738","Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation",[90],"2021-11-30","2022-08-17","2020-04-07",[6809,6808],[18116],{"trials":18132,"activeCount":102},[],{"trials":18134,"activeCount":102},[],{"trials":18136,"activeCount":102},[],{"trials":18138,"activeCount":102},[],{"intervention":1072,"totalTrials":184,"cells":18140},{"EARLY_PHASE1":18141,"PHASE1":18143,"PHASE2":18149,"PHASE3":18151,"PHASE4":18153,"NA":18155},{"trials":18142,"activeCount":102},[],{"trials":18144,"activeCount":102},[18145],{"nctId":1062,"briefTitle":1063,"status":108,"phases":18146,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1056,"conditions":18147,"interventions":18148},[90],[1069],[1071,959,1072,1073],{"trials":18150,"activeCount":102},[],{"trials":18152,"activeCount":102},[],{"trials":18154,"activeCount":102},[],{"trials":18156,"activeCount":102},[],{"intervention":18158,"totalTrials":184,"cells":18159},"Ketamine Infusion plus RO DBT",{"EARLY_PHASE1":18160,"PHASE1":18162,"PHASE2":18172,"PHASE3":18174,"PHASE4":18176,"NA":18178},{"trials":18161,"activeCount":102},[],{"trials":18163,"activeCount":102},[18164],{"nctId":18165,"briefTitle":18166,"status":108,"phases":18167,"primaryCompletion":18168,"completion":18169,"start":2986,"enrollment":960,"conditions":18170,"interventions":18171},"NCT06138691","KET-RO Plus RO DBT for Treatment Resistant Depression",[90],"2025-01-11","2025-02-22",[4000],[18158],{"trials":18173,"activeCount":102},[],{"trials":18175,"activeCount":102},[],{"trials":18177,"activeCount":102},[],{"trials":18179,"activeCount":102},[],{"intervention":18181,"totalTrials":184,"cells":18182},"Fenobam",{"EARLY_PHASE1":18183,"PHASE1":18185,"PHASE2":18194,"PHASE3":18196,"PHASE4":18198,"NA":18200},{"trials":18184,"activeCount":102},[],{"trials":18186,"activeCount":102},[18187],{"nctId":18188,"briefTitle":18189,"status":108,"phases":18190,"primaryCompletion":7054,"completion":577,"start":2287,"enrollment":353,"conditions":18191,"interventions":18193},"NCT01806415","Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers",[90],[18192],"Healthy",[18181],{"trials":18195,"activeCount":102},[],{"trials":18197,"activeCount":102},[],{"trials":18199,"activeCount":102},[],{"trials":18201,"activeCount":102},[],{"intervention":18203,"totalTrials":184,"cells":18204},"Avelumab",{"EARLY_PHASE1":18205,"PHASE1":18207,"PHASE2":18219,"PHASE3":18221,"PHASE4":18223,"NA":18225},{"trials":18206,"activeCount":102},[],{"trials":18208,"activeCount":102},[18209],{"nctId":18210,"briefTitle":18211,"status":137,"phases":18212,"primaryCompletion":18213,"completion":18213,"start":18214,"enrollment":367,"conditions":18215,"interventions":18218},"NCT03267836","Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma",[90],"2023-04-06","2018-01-10",[18216,18217],"Meningioma","Meningioma, Adult",[18203],{"trials":18220,"activeCount":102},[],{"trials":18222,"activeCount":102},[],{"trials":18224,"activeCount":102},[],{"trials":18226,"activeCount":102},[],{"intervention":18228,"totalTrials":184,"cells":18229},"Simvastatin",{"EARLY_PHASE1":18230,"PHASE1":18232,"PHASE2":18240,"PHASE3":18242,"PHASE4":18244,"NA":18246},{"trials":18231,"activeCount":102},[],{"trials":18233,"activeCount":102},[18234],{"nctId":18235,"briefTitle":18236,"status":122,"phases":18237,"primaryCompletion":2106,"completion":2106,"start":2106,"enrollment":102,"conditions":18238,"interventions":18239},"NCT05542095","Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia",[90],[719,718],[18228],{"trials":18241,"activeCount":102},[],{"trials":18243,"activeCount":102},[],{"trials":18245,"activeCount":102},[],{"trials":18247,"activeCount":102},[],{"intervention":6948,"totalTrials":184,"cells":18249},{"EARLY_PHASE1":18250,"PHASE1":18252,"PHASE2":18258,"PHASE3":18260,"PHASE4":18262,"NA":18264},{"trials":18251,"activeCount":102},[],{"trials":18253,"activeCount":102},[18254],{"nctId":6940,"briefTitle":6941,"status":122,"phases":18255,"primaryCompletion":6943,"completion":6943,"start":6944,"enrollment":102,"conditions":18256,"interventions":18257},[90],[1082,1592,6946],[6948,977],{"trials":18259,"activeCount":102},[],{"trials":18261,"activeCount":102},[],{"trials":18263,"activeCount":102},[],{"trials":18265,"activeCount":102},[],{"intervention":6979,"totalTrials":184,"cells":18267},{"EARLY_PHASE1":18268,"PHASE1":18270,"PHASE2":18276,"PHASE3":18278,"PHASE4":18280,"NA":18282},{"trials":18269,"activeCount":102},[],{"trials":18271,"activeCount":102},[18272],{"nctId":6972,"briefTitle":6973,"status":108,"phases":18273,"primaryCompletion":6975,"completion":6975,"start":6976,"enrollment":1015,"conditions":18274,"interventions":18275},[90],[116,29,115],[6979,2027],{"trials":18277,"activeCount":102},[],{"trials":18279,"activeCount":102},[],{"trials":18281,"activeCount":102},[],{"trials":18283,"activeCount":102},[],{"intervention":18285,"totalTrials":456,"cells":18286},"Ga-68 Galmydar",{"EARLY_PHASE1":18287,"PHASE1":18306,"PHASE2":18308,"PHASE3":18310,"PHASE4":18312,"NA":18314},{"trials":18288,"activeCount":102},[18289,18298],{"nctId":18290,"briefTitle":18291,"status":108,"phases":18292,"primaryCompletion":18293,"completion":17525,"start":2432,"enrollment":1080,"conditions":18294,"interventions":18296},"NCT05625490","Myocardial Perfusion Imaging Galmydar Rest\u002FStress",[89],"2025-12-17",[18295],"Coronary Artery Disease",[18285,18297],"13N-ammonia",{"nctId":18299,"briefTitle":18300,"status":108,"phases":18301,"primaryCompletion":18302,"completion":18302,"start":18303,"enrollment":2289,"conditions":18304,"interventions":18305},"NCT05280782","Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group",[89],"2022-05-01","2022-01-05",[18295],[18285],{"trials":18307,"activeCount":102},[],{"trials":18309,"activeCount":102},[],{"trials":18311,"activeCount":102},[],{"trials":18313,"activeCount":102},[],{"trials":18315,"activeCount":102},[],{"intervention":2895,"totalTrials":456,"cells":18317},{"EARLY_PHASE1":18318,"PHASE1":18330,"PHASE2":18332,"PHASE3":18334,"PHASE4":18336,"NA":18338},{"trials":18319,"activeCount":102},[18320,18326],{"nctId":18321,"briefTitle":18322,"status":108,"phases":18323,"primaryCompletion":1646,"completion":1646,"start":12192,"enrollment":1380,"conditions":18324,"interventions":18325},"NCT00263185","High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status",[89],[1445],[2895],{"nctId":2885,"briefTitle":2886,"status":108,"phases":18327,"primaryCompletion":2888,"completion":2888,"start":2889,"enrollment":340,"conditions":18328,"interventions":18329},[89],[2891,2892],[2662,2894,2895],{"trials":18331,"activeCount":102},[],{"trials":18333,"activeCount":102},[],{"trials":18335,"activeCount":102},[],{"trials":18337,"activeCount":102},[],{"trials":18339,"activeCount":102},[],{"intervention":18297,"totalTrials":184,"cells":18341},{"EARLY_PHASE1":18342,"PHASE1":18348,"PHASE2":18350,"PHASE3":18352,"PHASE4":18354,"NA":18356},{"trials":18343,"activeCount":102},[18344],{"nctId":18290,"briefTitle":18291,"status":108,"phases":18345,"primaryCompletion":18293,"completion":17525,"start":2432,"enrollment":1080,"conditions":18346,"interventions":18347},[89],[18295],[18285,18297],{"trials":18349,"activeCount":102},[],{"trials":18351,"activeCount":102},[],{"trials":18353,"activeCount":102},[],{"trials":18355,"activeCount":102},[],{"trials":18357,"activeCount":102},[],{"intervention":18359,"totalTrials":184,"cells":18360},"Etanercept",{"EARLY_PHASE1":18361,"PHASE1":18371,"PHASE2":18373,"PHASE3":18375,"PHASE4":18377,"NA":18379},{"trials":18362,"activeCount":102},[18363],{"nctId":18364,"briefTitle":18365,"status":108,"phases":18366,"primaryCompletion":3432,"completion":3432,"start":18367,"enrollment":1299,"conditions":18368,"interventions":18370},"NCT00802815","Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis",[89],"2005-04",[18369],"Inclusion Body Myositis",[18359],{"trials":18372,"activeCount":102},[],{"trials":18374,"activeCount":102},[],{"trials":18376,"activeCount":102},[],{"trials":18378,"activeCount":102},[],{"trials":18380,"activeCount":102},[],{"intervention":18382,"totalTrials":184,"cells":18383},"18F-FluorApoTrace",{"EARLY_PHASE1":18384,"PHASE1":18393,"PHASE2":18395,"PHASE3":18397,"PHASE4":18399,"NA":18401},{"trials":18385,"activeCount":102},[18386],{"nctId":18387,"briefTitle":18388,"status":137,"phases":18389,"primaryCompletion":18390,"completion":18390,"start":4467,"enrollment":1566,"conditions":18391,"interventions":18392},"NCT05048732","Imaging Apoptosis for Lymphoma Treatment Response",[89],"2024-02-10",[2323],[18382],{"trials":18394,"activeCount":102},[],{"trials":18396,"activeCount":102},[],{"trials":18398,"activeCount":102},[],{"trials":18400,"activeCount":102},[],{"trials":18402,"activeCount":102},[],{"intervention":3843,"totalTrials":184,"cells":18404},{"EARLY_PHASE1":18405,"PHASE1":18411,"PHASE2":18413,"PHASE3":18415,"PHASE4":18417,"NA":18419},{"trials":18406,"activeCount":102},[18407],{"nctId":3836,"briefTitle":3837,"status":108,"phases":18408,"primaryCompletion":3839,"completion":3839,"start":3840,"enrollment":1310,"conditions":18409,"interventions":18410},[89],[3831],[3831,3843],{"trials":18412,"activeCount":102},[],{"trials":18414,"activeCount":102},[],{"trials":18416,"activeCount":102},[],{"trials":18418,"activeCount":102},[],{"trials":18420,"activeCount":102},[],{"intervention":15953,"totalTrials":184,"cells":18422},{"EARLY_PHASE1":18423,"PHASE1":18429,"PHASE2":18431,"PHASE3":18433,"PHASE4":18435,"NA":18437},{"trials":18424,"activeCount":102},[18425],{"nctId":15948,"briefTitle":15949,"status":108,"phases":18426,"primaryCompletion":11773,"completion":11773,"start":11731,"enrollment":33,"conditions":18427,"interventions":18428},[89],[7956],[15953,15943],{"trials":18430,"activeCount":102},[],{"trials":18432,"activeCount":102},[],{"trials":18434,"activeCount":102},[],{"trials":18436,"activeCount":102},[],{"trials":18438,"activeCount":102},[],{"intervention":18440,"totalTrials":184,"cells":18441},"Ioversol",{"EARLY_PHASE1":18442,"PHASE1":18451,"PHASE2":18453,"PHASE3":18455,"PHASE4":18457,"NA":18459},{"trials":18443,"activeCount":102},[18444],{"nctId":18445,"briefTitle":18446,"status":108,"phases":18447,"primaryCompletion":3009,"completion":10381,"start":18448,"enrollment":36,"conditions":18449,"interventions":18450},"NCT02117115","Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation",[89],"2014-06",[26,3182,11833,24],[18440],{"trials":18452,"activeCount":102},[],{"trials":18454,"activeCount":102},[],{"trials":18456,"activeCount":102},[],{"trials":18458,"activeCount":102},[],{"trials":18460,"activeCount":102},[],{"intervention":18462,"totalTrials":184,"cells":18463},"Active Arm N-acetyl cysteine",{"EARLY_PHASE1":18464,"PHASE1":18477,"PHASE2":18479,"PHASE3":18481,"PHASE4":18483,"NA":18485},{"trials":18465,"activeCount":102},[18466],{"nctId":18467,"briefTitle":18468,"status":108,"phases":18469,"primaryCompletion":9231,"completion":18470,"start":18471,"enrollment":1015,"conditions":18472,"interventions":18476},"NCT03253328","N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes",[89],"2022-06-27","2017-03-01",[6078,18473,18474,18475],"Critical Limb Ischemia","Lower Limb Amputation Knee","Peripheral Arterial Disease",[18462],{"trials":18478,"activeCount":102},[],{"trials":18480,"activeCount":102},[],{"trials":18482,"activeCount":102},[],{"trials":18484,"activeCount":102},[],{"trials":18486,"activeCount":102},[],{"intervention":18488,"totalTrials":184,"cells":18489},"Insulin protocol",{"EARLY_PHASE1":18490,"PHASE1":18500,"PHASE2":18502,"PHASE3":18504,"PHASE4":18506,"NA":18508},{"trials":18491,"activeCount":102},[18492],{"nctId":18493,"briefTitle":18494,"status":108,"phases":18495,"primaryCompletion":10381,"completion":10381,"start":3345,"enrollment":1080,"conditions":18496,"interventions":18499},"NCT02012465","Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients",[89],[12231,18497,18498],"Diabetes Mellitus, Type 2","Hyperglycemia",[18488],{"trials":18501,"activeCount":102},[],{"trials":18503,"activeCount":102},[],{"trials":18505,"activeCount":102},[],{"trials":18507,"activeCount":102},[],{"trials":18509,"activeCount":102},[],{"intervention":12535,"totalTrials":184,"cells":18511},{"EARLY_PHASE1":18512,"PHASE1":18518,"PHASE2":18520,"PHASE3":18522,"PHASE4":18524,"NA":18526},{"trials":18513,"activeCount":102},[18514],{"nctId":12527,"briefTitle":12528,"status":108,"phases":18515,"primaryCompletion":1039,"completion":1039,"start":12530,"enrollment":12531,"conditions":18516,"interventions":18517},[89],[12533,11047],[12535,165],{"trials":18519,"activeCount":102},[],{"trials":18521,"activeCount":102},[],{"trials":18523,"activeCount":102},[],{"trials":18525,"activeCount":102},[],{"trials":18527,"activeCount":102},[],{"intervention":18529,"totalTrials":184,"cells":18530},"Targeted infusion of remifentanil",{"EARLY_PHASE1":18531,"PHASE1":18542,"PHASE2":18544,"PHASE3":18546,"PHASE4":18548,"NA":18550},{"trials":18532,"activeCount":102},[18533],{"nctId":18534,"briefTitle":18535,"status":108,"phases":18536,"primaryCompletion":18537,"completion":18537,"start":18538,"enrollment":12669,"conditions":18539,"interventions":18541},"NCT02898792","Remifentanil in Adults With OSA",[89],"2018-05-02","2016-09-16",[18540],"Apnea, Sleep",[18529],{"trials":18543,"activeCount":102},[],{"trials":18545,"activeCount":102},[],{"trials":18547,"activeCount":102},[],{"trials":18549,"activeCount":102},[],{"trials":18551,"activeCount":102},[],{"intervention":18553,"totalTrials":184,"cells":18554},"Fluad® and Afluria® vaccination",{"EARLY_PHASE1":18555,"PHASE1":18565,"PHASE2":18567,"PHASE3":18569,"PHASE4":18571,"NA":18573},{"trials":18556,"activeCount":102},[18557],{"nctId":18558,"briefTitle":18559,"status":137,"phases":18560,"primaryCompletion":18561,"completion":18561,"start":18562,"enrollment":456,"conditions":18563,"interventions":18564},"NCT07386509","WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.",[89],"2022-11-04","2020-03-17",[18192],[18553],{"trials":18566,"activeCount":102},[],{"trials":18568,"activeCount":102},[],{"trials":18570,"activeCount":102},[],{"trials":18572,"activeCount":102},[],{"trials":18574,"activeCount":102},[],{"intervention":18576,"totalTrials":184,"cells":18577},"Influenza Vaccine",{"EARLY_PHASE1":18578,"PHASE1":18589,"PHASE2":18591,"PHASE3":18593,"PHASE4":18595,"NA":18597},{"trials":18579,"activeCount":102},[18580],{"nctId":18581,"briefTitle":18582,"status":108,"phases":18583,"primaryCompletion":124,"completion":18584,"start":18585,"enrollment":1310,"conditions":18586,"interventions":18588},"NCT03748524","Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine",[89],"2022-06-20","2018-10-29",[18587],"Immunity, Cellular",[18576],{"trials":18590,"activeCount":102},[],{"trials":18592,"activeCount":102},[],{"trials":18594,"activeCount":102},[],{"trials":18596,"activeCount":102},[],{"trials":18598,"activeCount":102},[],{"intervention":6139,"totalTrials":184,"cells":18600},{"EARLY_PHASE1":18601,"PHASE1":18607,"PHASE2":18609,"PHASE3":18611,"PHASE4":18613,"NA":18615},{"trials":18602,"activeCount":102},[18603],{"nctId":6130,"briefTitle":6131,"status":122,"phases":18604,"primaryCompletion":6133,"completion":6134,"start":6135,"enrollment":102,"conditions":18605,"interventions":18606},[89],[6137,1354,1356],[1229,6139],{"trials":18608,"activeCount":102},[],{"trials":18610,"activeCount":102},[],{"trials":18612,"activeCount":102},[],{"trials":18614,"activeCount":102},[],{"trials":18616,"activeCount":102},[],{"intervention":18618,"totalTrials":184,"cells":18619},"[18F]FluorThanatrace",{"EARLY_PHASE1":18620,"PHASE1":18630,"PHASE2":18632,"PHASE3":18634,"PHASE4":18636,"NA":18638},{"trials":18621,"activeCount":102},[18622],{"nctId":18623,"briefTitle":18624,"status":14664,"phases":18625,"primaryCompletion":18626,"completion":18627,"start":8246,"enrollment":1954,"conditions":18628,"interventions":18629},"NCT02469129","PET Imaging of PARP Activity in Cancer",[89],"2024-07","2025-07",[35],[18618],{"trials":18631,"activeCount":102},[],{"trials":18633,"activeCount":102},[],{"trials":18635,"activeCount":102},[],{"trials":18637,"activeCount":102},[],{"trials":18639,"activeCount":102},[],{"intervention":18641,"totalTrials":184,"cells":18642},"Ginseng",{"EARLY_PHASE1":18643,"PHASE1":18655,"PHASE2":18657,"PHASE3":18659,"PHASE4":18661,"NA":18663},{"trials":18644,"activeCount":102},[18645],{"nctId":18646,"briefTitle":18647,"status":108,"phases":18648,"primaryCompletion":18649,"completion":18650,"start":18651,"enrollment":1042,"conditions":18652,"interventions":18653},"NCT00781534","A Clinical Trial of Ginseng in Diabetes",[89],"2004-12","2008-09","2003-09",[953],[18641,18641,18654],"ginsenoside RE",{"trials":18656,"activeCount":102},[],{"trials":18658,"activeCount":102},[],{"trials":18660,"activeCount":102},[],{"trials":18662,"activeCount":102},[],{"trials":18664,"activeCount":102},[],{"intervention":18654,"totalTrials":184,"cells":18666},{"EARLY_PHASE1":18667,"PHASE1":18673,"PHASE2":18675,"PHASE3":18677,"PHASE4":18679,"NA":18681},{"trials":18668,"activeCount":102},[18669],{"nctId":18646,"briefTitle":18647,"status":108,"phases":18670,"primaryCompletion":18649,"completion":18650,"start":18651,"enrollment":1042,"conditions":18671,"interventions":18672},[89],[953],[18641,18641,18654],{"trials":18674,"activeCount":102},[],{"trials":18676,"activeCount":102},[],{"trials":18678,"activeCount":102},[],{"trials":18680,"activeCount":102},[],{"trials":18682,"activeCount":102},[],{"intervention":18684,"totalTrials":184,"cells":18685},"Remifentanil",{"EARLY_PHASE1":18686,"PHASE1":18695,"PHASE2":18697,"PHASE3":18699,"PHASE4":18701,"NA":18703},{"trials":18687,"activeCount":102},[18688],{"nctId":18689,"briefTitle":18690,"status":108,"phases":18691,"primaryCompletion":12489,"completion":12489,"start":18692,"enrollment":293,"conditions":18693,"interventions":18694},"NCT03958396","Remifentanil in Children With Obstructive Sleep Apnea",[89],"2015-09-01",[12533],[18684],{"trials":18696,"activeCount":102},[],{"trials":18698,"activeCount":102},[],{"trials":18700,"activeCount":102},[],{"trials":18702,"activeCount":102},[],{"trials":18704,"activeCount":102},[],{"intervention":3286,"totalTrials":184,"cells":18706},{"EARLY_PHASE1":18707,"PHASE1":18713,"PHASE2":18715,"PHASE3":18717,"PHASE4":18719,"NA":18721},{"trials":18708,"activeCount":102},[18709],{"nctId":3278,"briefTitle":3279,"status":108,"phases":18710,"primaryCompletion":3281,"completion":3281,"start":1862,"enrollment":353,"conditions":18711,"interventions":18712},[89],[3283],[2612,3285,3286],{"trials":18714,"activeCount":102},[],{"trials":18716,"activeCount":102},[],{"trials":18718,"activeCount":102},[],{"trials":18720,"activeCount":102},[],{"trials":18722,"activeCount":102},[],{"intervention":18724,"totalTrials":184,"cells":18725},"Ritonavir",{"EARLY_PHASE1":18726,"PHASE1":18735,"PHASE2":18737,"PHASE3":18739,"PHASE4":18741,"NA":18743},{"trials":18727,"activeCount":102},[18728],{"nctId":18729,"briefTitle":18730,"status":108,"phases":18731,"primaryCompletion":381,"completion":577,"start":2442,"enrollment":340,"conditions":18732,"interventions":18733},"NCT01935830","LAAM-HAART PET Imaging",[89],[10673],[18724,18734],"Efavirenz",{"trials":18736,"activeCount":102},[],{"trials":18738,"activeCount":102},[],{"trials":18740,"activeCount":102},[],{"trials":18742,"activeCount":102},[],{"trials":18744,"activeCount":102},[],{"intervention":18734,"totalTrials":184,"cells":18746},{"EARLY_PHASE1":18747,"PHASE1":18753,"PHASE2":18755,"PHASE3":18757,"PHASE4":18759,"NA":18761},{"trials":18748,"activeCount":102},[18749],{"nctId":18729,"briefTitle":18730,"status":108,"phases":18750,"primaryCompletion":381,"completion":577,"start":2442,"enrollment":340,"conditions":18751,"interventions":18752},[89],[10673],[18724,18734],{"trials":18754,"activeCount":102},[],{"trials":18756,"activeCount":102},[],{"trials":18758,"activeCount":102},[],{"trials":18760,"activeCount":102},[],{"trials":18762,"activeCount":102},[],{"intervention":18764,"totalTrials":184,"cells":18765},"Indocynanine Green",{"EARLY_PHASE1":18766,"PHASE1":18775,"PHASE2":18777,"PHASE3":18779,"PHASE4":18781,"NA":18783},{"trials":18767,"activeCount":102},[18768],{"nctId":18769,"briefTitle":18770,"status":108,"phases":18771,"primaryCompletion":1734,"completion":1351,"start":3020,"enrollment":1299,"conditions":18772,"interventions":18774},"NCT02316795","Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma",[89],[18,159,2271,2454,18773],"Malignant Melanoma",[18764],{"trials":18776,"activeCount":102},[],{"trials":18778,"activeCount":102},[],{"trials":18780,"activeCount":102},[],{"trials":18782,"activeCount":102},[],{"trials":18784,"activeCount":102},[],{"intervention":18786,"totalTrials":184,"cells":18787},"Pyrimethamine",{"EARLY_PHASE1":18788,"PHASE1":18798,"PHASE2":18800,"PHASE3":18802,"PHASE4":18804,"NA":18806},{"trials":18789,"activeCount":102},[18790],{"nctId":18791,"briefTitle":18792,"status":108,"phases":18793,"primaryCompletion":18794,"completion":12667,"start":18795,"enrollment":33,"conditions":18796,"interventions":18797},"NCT05678348","Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma",[89],"2025-07-11","2023-08-03",[399,398],[18786],{"trials":18799,"activeCount":102},[],{"trials":18801,"activeCount":102},[],{"trials":18803,"activeCount":102},[],{"trials":18805,"activeCount":102},[],{"trials":18807,"activeCount":102},[],{"intervention":18809,"totalTrials":184,"cells":18810},"5-fluorouracil 5% cream",{"EARLY_PHASE1":18811,"PHASE1":18823,"PHASE2":18825,"PHASE3":18827,"PHASE4":18829,"NA":18831},{"trials":18812,"activeCount":102},[18813],{"nctId":18814,"briefTitle":18815,"status":108,"phases":18816,"primaryCompletion":8246,"completion":8246,"start":3466,"enrollment":18817,"conditions":18818,"interventions":18820},"NCT02019355","Actinic Keratosis Study",[89],132,[18819],"Actinic Keratosis",[18809,18821,18822],"Calcipotriol 0.005% ointment","Vaseline",{"trials":18824,"activeCount":102},[],{"trials":18826,"activeCount":102},[],{"trials":18828,"activeCount":102},[],{"trials":18830,"activeCount":102},[],{"trials":18832,"activeCount":102},[],{"intervention":18821,"totalTrials":184,"cells":18834},{"EARLY_PHASE1":18835,"PHASE1":18841,"PHASE2":18843,"PHASE3":18845,"PHASE4":18847,"NA":18849},{"trials":18836,"activeCount":102},[18837],{"nctId":18814,"briefTitle":18815,"status":108,"phases":18838,"primaryCompletion":8246,"completion":8246,"start":3466,"enrollment":18817,"conditions":18839,"interventions":18840},[89],[18819],[18809,18821,18822],{"trials":18842,"activeCount":102},[],{"trials":18844,"activeCount":102},[],{"trials":18846,"activeCount":102},[],{"trials":18848,"activeCount":102},[],{"trials":18850,"activeCount":102},[],{"intervention":18822,"totalTrials":184,"cells":18852},{"EARLY_PHASE1":18853,"PHASE1":18859,"PHASE2":18861,"PHASE3":18863,"PHASE4":18865,"NA":18867},{"trials":18854,"activeCount":102},[18855],{"nctId":18814,"briefTitle":18815,"status":108,"phases":18856,"primaryCompletion":8246,"completion":8246,"start":3466,"enrollment":18817,"conditions":18857,"interventions":18858},[89],[18819],[18809,18821,18822],{"trials":18860,"activeCount":102},[],{"trials":18862,"activeCount":102},[],{"trials":18864,"activeCount":102},[],{"trials":18866,"activeCount":102},[],{"trials":18868,"activeCount":102},[],{"intervention":18870,"totalTrials":184,"cells":18871},"Imovax",{"EARLY_PHASE1":18872,"PHASE1":18884,"PHASE2":18886,"PHASE3":18888,"PHASE4":18890,"NA":18892},{"trials":18873,"activeCount":102},[18874],{"nctId":18875,"briefTitle":18876,"status":108,"phases":18877,"primaryCompletion":9065,"completion":8448,"start":18878,"enrollment":293,"conditions":18879,"interventions":18881},"NCT07399951","Washington University WU 409: Immune Responses to Rabies Vaccine.",[89],"2023-07-18",[18880],"Healthy Participants",[18870,18882,18883],"RabAvert","HyperRAB",{"trials":18885,"activeCount":102},[],{"trials":18887,"activeCount":102},[],{"trials":18889,"activeCount":102},[],{"trials":18891,"activeCount":102},[],{"trials":18893,"activeCount":102},[],{"intervention":18882,"totalTrials":184,"cells":18895},{"EARLY_PHASE1":18896,"PHASE1":18902,"PHASE2":18904,"PHASE3":18906,"PHASE4":18908,"NA":18910},{"trials":18897,"activeCount":102},[18898],{"nctId":18875,"briefTitle":18876,"status":108,"phases":18899,"primaryCompletion":9065,"completion":8448,"start":18878,"enrollment":293,"conditions":18900,"interventions":18901},[89],[18880],[18870,18882,18883],{"trials":18903,"activeCount":102},[],{"trials":18905,"activeCount":102},[],{"trials":18907,"activeCount":102},[],{"trials":18909,"activeCount":102},[],{"trials":18911,"activeCount":102},[],{"intervention":18883,"totalTrials":184,"cells":18913},{"EARLY_PHASE1":18914,"PHASE1":18920,"PHASE2":18922,"PHASE3":18924,"PHASE4":18926,"NA":18928},{"trials":18915,"activeCount":102},[18916],{"nctId":18875,"briefTitle":18876,"status":108,"phases":18917,"primaryCompletion":9065,"completion":8448,"start":18878,"enrollment":293,"conditions":18918,"interventions":18919},[89],[18880],[18870,18882,18883],{"trials":18921,"activeCount":102},[],{"trials":18923,"activeCount":102},[],{"trials":18925,"activeCount":102},[],{"trials":18927,"activeCount":102},[],{"trials":18929,"activeCount":102},[],{"intervention":18931,"totalTrials":184,"cells":18932},"Empagliflozin 25 mg",{"EARLY_PHASE1":18933,"PHASE1":18943,"PHASE2":18945,"PHASE3":18947,"PHASE4":18949,"NA":18951},{"trials":18934,"activeCount":102},[18935],{"nctId":18936,"briefTitle":18937,"status":14664,"phases":18938,"primaryCompletion":18939,"completion":3333,"start":18127,"enrollment":1056,"conditions":18940,"interventions":18942},"NCT05512130","Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy",[89],"2023-03-01",[18941],"Epilepsy",[18931],{"trials":18944,"activeCount":102},[],{"trials":18946,"activeCount":102},[],{"trials":18948,"activeCount":102},[],{"trials":18950,"activeCount":102},[],{"trials":18952,"activeCount":102},[],{"intervention":18954,"totalTrials":184,"cells":18955},"Cu[64]-25%CANF-Comb",{"EARLY_PHASE1":18956,"PHASE1":18964,"PHASE2":18966,"PHASE3":18968,"PHASE4":18970,"NA":18972},{"trials":18957,"activeCount":102},[18958],{"nctId":18959,"briefTitle":18960,"status":108,"phases":18961,"primaryCompletion":6255,"completion":6255,"start":3009,"enrollment":2289,"conditions":18962,"interventions":18963},"NCT02498379","PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)",[89],[9122],[18954],{"trials":18965,"activeCount":102},[],{"trials":18967,"activeCount":102},[],{"trials":18969,"activeCount":102},[],{"trials":18971,"activeCount":102},[],{"trials":18973,"activeCount":102},[],{"intervention":18975,"totalTrials":184,"cells":18976},"SMART Pack",{"EARLY_PHASE1":18977,"PHASE1":18994,"PHASE2":18996,"PHASE3":18998,"PHASE4":19000,"NA":19002},{"trials":18978,"activeCount":102},[18979],{"nctId":18980,"briefTitle":18981,"status":108,"phases":18982,"primaryCompletion":17484,"completion":18983,"start":18984,"enrollment":18985,"conditions":18986,"interventions":18989},"NCT04070287","Innovative Tools to Expand HIV Self-Testing",[89],"2020-09-01","2019-07-01",388,[18987,18988],"HIV\u002FAIDS","Sexually Transmitted Diseases",[18975,18990,18991,18992,18993],"Luv Box","Bili Vibes","BeterDoc","IUNGO",{"trials":18995,"activeCount":102},[],{"trials":18997,"activeCount":102},[],{"trials":18999,"activeCount":102},[],{"trials":19001,"activeCount":102},[],{"trials":19003,"activeCount":102},[],{"intervention":18990,"totalTrials":184,"cells":19005},{"EARLY_PHASE1":19006,"PHASE1":19012,"PHASE2":19014,"PHASE3":19016,"PHASE4":19018,"NA":19020},{"trials":19007,"activeCount":102},[19008],{"nctId":18980,"briefTitle":18981,"status":108,"phases":19009,"primaryCompletion":17484,"completion":18983,"start":18984,"enrollment":18985,"conditions":19010,"interventions":19011},[89],[18987,18988],[18975,18990,18991,18992,18993],{"trials":19013,"activeCount":102},[],{"trials":19015,"activeCount":102},[],{"trials":19017,"activeCount":102},[],{"trials":19019,"activeCount":102},[],{"trials":19021,"activeCount":102},[],{"intervention":18991,"totalTrials":184,"cells":19023},{"EARLY_PHASE1":19024,"PHASE1":19030,"PHASE2":19032,"PHASE3":19034,"PHASE4":19036,"NA":19038},{"trials":19025,"activeCount":102},[19026],{"nctId":18980,"briefTitle":18981,"status":108,"phases":19027,"primaryCompletion":17484,"completion":18983,"start":18984,"enrollment":18985,"conditions":19028,"interventions":19029},[89],[18987,18988],[18975,18990,18991,18992,18993],{"trials":19031,"activeCount":102},[],{"trials":19033,"activeCount":102},[],{"trials":19035,"activeCount":102},[],{"trials":19037,"activeCount":102},[],{"trials":19039,"activeCount":102},[],{"intervention":18992,"totalTrials":184,"cells":19041},{"EARLY_PHASE1":19042,"PHASE1":19048,"PHASE2":19050,"PHASE3":19052,"PHASE4":19054,"NA":19056},{"trials":19043,"activeCount":102},[19044],{"nctId":18980,"briefTitle":18981,"status":108,"phases":19045,"primaryCompletion":17484,"completion":18983,"start":18984,"enrollment":18985,"conditions":19046,"interventions":19047},[89],[18987,18988],[18975,18990,18991,18992,18993],{"trials":19049,"activeCount":102},[],{"trials":19051,"activeCount":102},[],{"trials":19053,"activeCount":102},[],{"trials":19055,"activeCount":102},[],{"trials":19057,"activeCount":102},[],{"intervention":18993,"totalTrials":184,"cells":19059},{"EARLY_PHASE1":19060,"PHASE1":19066,"PHASE2":19068,"PHASE3":19070,"PHASE4":19072,"NA":19074},{"trials":19061,"activeCount":102},[19062],{"nctId":18980,"briefTitle":18981,"status":108,"phases":19063,"primaryCompletion":17484,"completion":18983,"start":18984,"enrollment":18985,"conditions":19064,"interventions":19065},[89],[18987,18988],[18975,18990,18991,18992,18993],{"trials":19067,"activeCount":102},[],{"trials":19069,"activeCount":102},[],{"trials":19071,"activeCount":102},[],{"trials":19073,"activeCount":102},[],{"trials":19075,"activeCount":102},[],{"intervention":19077,"totalTrials":184,"cells":19078},"89Zr-Trastuzumab Human Dosimetry and Safety",{"EARLY_PHASE1":19079,"PHASE1":19089,"PHASE2":19091,"PHASE3":19093,"PHASE4":19095,"NA":19097},{"trials":19080,"activeCount":102},[19081],{"nctId":19082,"briefTitle":19083,"status":108,"phases":19084,"primaryCompletion":16990,"completion":19085,"start":3020,"enrollment":3251,"conditions":19086,"interventions":19087},"NCT02065609","89ZrTrastuzumab Breast Imaging With Positron Emission Tomography",[89],"2018-02-13",[18],[19077,19088],"HER2 Positive Lesion Detection and Safety",{"trials":19090,"activeCount":102},[],{"trials":19092,"activeCount":102},[],{"trials":19094,"activeCount":102},[],{"trials":19096,"activeCount":102},[],{"trials":19098,"activeCount":102},[],{"intervention":19088,"totalTrials":184,"cells":19100},{"EARLY_PHASE1":19101,"PHASE1":19107,"PHASE2":19109,"PHASE3":19111,"PHASE4":19113,"NA":19115},{"trials":19102,"activeCount":102},[19103],{"nctId":19082,"briefTitle":19083,"status":108,"phases":19104,"primaryCompletion":16990,"completion":19085,"start":3020,"enrollment":3251,"conditions":19105,"interventions":19106},[89],[18],[19077,19088],{"trials":19108,"activeCount":102},[],{"trials":19110,"activeCount":102},[],{"trials":19112,"activeCount":102},[],{"trials":19114,"activeCount":102},[],{"trials":19116,"activeCount":102},[],{"intervention":19118,"totalTrials":184,"cells":19119},"Zileuton",{"EARLY_PHASE1":19120,"PHASE1":19131,"PHASE2":19133,"PHASE3":19135,"PHASE4":19137,"NA":19139},{"trials":19121,"activeCount":102},[19122],{"nctId":19123,"briefTitle":19124,"status":108,"phases":19125,"primaryCompletion":7054,"completion":7054,"start":365,"enrollment":3218,"conditions":19126,"interventions":19127},"NCT01174056","Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging",[89],[7956],[19118,19128,19129,19130],"Pioglitazone placebo","Zileuton placebo","Pioglitazone",{"trials":19132,"activeCount":102},[],{"trials":19134,"activeCount":102},[],{"trials":19136,"activeCount":102},[],{"trials":19138,"activeCount":102},[],{"trials":19140,"activeCount":102},[],{"intervention":19128,"totalTrials":184,"cells":19142},{"EARLY_PHASE1":19143,"PHASE1":19149,"PHASE2":19151,"PHASE3":19153,"PHASE4":19155,"NA":19157},{"trials":19144,"activeCount":102},[19145],{"nctId":19123,"briefTitle":19124,"status":108,"phases":19146,"primaryCompletion":7054,"completion":7054,"start":365,"enrollment":3218,"conditions":19147,"interventions":19148},[89],[7956],[19118,19128,19129,19130],{"trials":19150,"activeCount":102},[],{"trials":19152,"activeCount":102},[],{"trials":19154,"activeCount":102},[],{"trials":19156,"activeCount":102},[],{"trials":19158,"activeCount":102},[],{"intervention":19129,"totalTrials":184,"cells":19160},{"EARLY_PHASE1":19161,"PHASE1":19167,"PHASE2":19169,"PHASE3":19171,"PHASE4":19173,"NA":19175},{"trials":19162,"activeCount":102},[19163],{"nctId":19123,"briefTitle":19124,"status":108,"phases":19164,"primaryCompletion":7054,"completion":7054,"start":365,"enrollment":3218,"conditions":19165,"interventions":19166},[89],[7956],[19118,19128,19129,19130],{"trials":19168,"activeCount":102},[],{"trials":19170,"activeCount":102},[],{"trials":19172,"activeCount":102},[],{"trials":19174,"activeCount":102},[],{"trials":19176,"activeCount":102},[],{"intervention":19130,"totalTrials":184,"cells":19178},{"EARLY_PHASE1":19179,"PHASE1":19185,"PHASE2":19187,"PHASE3":19189,"PHASE4":19191,"NA":19193},{"trials":19180,"activeCount":102},[19181],{"nctId":19123,"briefTitle":19124,"status":108,"phases":19182,"primaryCompletion":7054,"completion":7054,"start":365,"enrollment":3218,"conditions":19183,"interventions":19184},[89],[7956],[19118,19128,19129,19130],{"trials":19186,"activeCount":102},[],{"trials":19188,"activeCount":102},[],{"trials":19190,"activeCount":102},[],{"trials":19192,"activeCount":102},[],{"trials":19194,"activeCount":102},[],{"intervention":19196,"totalTrials":184,"cells":19197},"Rhodamine 6G",{"EARLY_PHASE1":19198,"PHASE1":19207,"PHASE2":19209,"PHASE3":19211,"PHASE4":19213,"NA":19215},{"trials":19199,"activeCount":102},[19200],{"nctId":19201,"briefTitle":19202,"status":4114,"phases":19203,"primaryCompletion":19204,"completion":10405,"start":972,"enrollment":1080,"conditions":19205,"interventions":19206},"NCT04528758","F-18 Rhodamine 6G PET Imaging for Myocardial Blood Flow",[89],"2024-06",[18295],[19196],{"trials":19208,"activeCount":102},[],{"trials":19210,"activeCount":102},[],{"trials":19212,"activeCount":102},[],{"trials":19214,"activeCount":102},[],{"trials":19216,"activeCount":102},[],{"intervention":19218,"totalTrials":184,"cells":19219},"[18F]FluorbetaOx",{"EARLY_PHASE1":19220,"PHASE1":19231,"PHASE2":19233,"PHASE3":19235,"PHASE4":19237,"NA":19239},{"trials":19221,"activeCount":102},[19222],{"nctId":19223,"briefTitle":19224,"status":108,"phases":19225,"primaryCompletion":19226,"completion":19226,"start":19227,"enrollment":1954,"conditions":19228,"interventions":19230},"NCT01648296","Fatty Acid Radiotracer Comparison Study in Heart Failure Patients",[89],"2014-06-04","2012-09-13",[5570,15,6121,19229],"Health Normal Volunteer Subjects",[19218],{"trials":19232,"activeCount":102},[],{"trials":19234,"activeCount":102},[],{"trials":19236,"activeCount":102},[],{"trials":19238,"activeCount":102},[],{"trials":19240,"activeCount":102},[],{"intervention":3039,"totalTrials":184,"cells":19242},{"EARLY_PHASE1":19243,"PHASE1":19249,"PHASE2":19251,"PHASE3":19253,"PHASE4":19255,"NA":19257},{"trials":19244,"activeCount":102},[19245],{"nctId":3029,"briefTitle":3030,"status":108,"phases":19246,"primaryCompletion":3032,"completion":3032,"start":3033,"enrollment":565,"conditions":19247,"interventions":19248},[89],[3035,3036],[3038,1849,3039],{"trials":19250,"activeCount":102},[],{"trials":19252,"activeCount":102},[],{"trials":19254,"activeCount":102},[],{"trials":19256,"activeCount":102},[],{"trials":19258,"activeCount":102},[],{"intervention":19260,"totalTrials":184,"cells":19261},"Clarithromycin 500mg",{"EARLY_PHASE1":19262,"PHASE1":19277,"PHASE2":19279,"PHASE3":19281,"PHASE4":19283,"NA":19285},{"trials":19263,"activeCount":102},[19264],{"nctId":19265,"briefTitle":19266,"status":108,"phases":19267,"primaryCompletion":11961,"completion":6422,"start":19268,"enrollment":19269,"conditions":19270,"interventions":19273},"NCT04525664","Assessment and Management of Chronic Dyspepsia in Eastern Uganda",[89],"2018-10-01",376,[19271,19272],"Helicobacter Pylori Infection","Dyspepsia",[19260,19274,19275,19276],"Amoxicillin 1000 MG","Omeprazole 40 MG","Omeprazole 20 MG Oral",{"trials":19278,"activeCount":102},[],{"trials":19280,"activeCount":102},[],{"trials":19282,"activeCount":102},[],{"trials":19284,"activeCount":102},[],{"trials":19286,"activeCount":102},[],{"intervention":19274,"totalTrials":184,"cells":19288},{"EARLY_PHASE1":19289,"PHASE1":19295,"PHASE2":19297,"PHASE3":19299,"PHASE4":19301,"NA":19303},{"trials":19290,"activeCount":102},[19291],{"nctId":19265,"briefTitle":19266,"status":108,"phases":19292,"primaryCompletion":11961,"completion":6422,"start":19268,"enrollment":19269,"conditions":19293,"interventions":19294},[89],[19271,19272],[19260,19274,19275,19276],{"trials":19296,"activeCount":102},[],{"trials":19298,"activeCount":102},[],{"trials":19300,"activeCount":102},[],{"trials":19302,"activeCount":102},[],{"trials":19304,"activeCount":102},[],{"intervention":19275,"totalTrials":184,"cells":19306},{"EARLY_PHASE1":19307,"PHASE1":19313,"PHASE2":19315,"PHASE3":19317,"PHASE4":19319,"NA":19321},{"trials":19308,"activeCount":102},[19309],{"nctId":19265,"briefTitle":19266,"status":108,"phases":19310,"primaryCompletion":11961,"completion":6422,"start":19268,"enrollment":19269,"conditions":19311,"interventions":19312},[89],[19271,19272],[19260,19274,19275,19276],{"trials":19314,"activeCount":102},[],{"trials":19316,"activeCount":102},[],{"trials":19318,"activeCount":102},[],{"trials":19320,"activeCount":102},[],{"trials":19322,"activeCount":102},[],{"intervention":19276,"totalTrials":184,"cells":19324},{"EARLY_PHASE1":19325,"PHASE1":19331,"PHASE2":19333,"PHASE3":19335,"PHASE4":19337,"NA":19339},{"trials":19326,"activeCount":102},[19327],{"nctId":19265,"briefTitle":19266,"status":108,"phases":19328,"primaryCompletion":11961,"completion":6422,"start":19268,"enrollment":19269,"conditions":19329,"interventions":19330},[89],[19271,19272],[19260,19274,19275,19276],{"trials":19332,"activeCount":102},[],{"trials":19334,"activeCount":102},[],{"trials":19336,"activeCount":102},[],{"trials":19338,"activeCount":102},[],{"trials":19340,"activeCount":102},[],{"intervention":19342,"totalTrials":184,"cells":19343},"Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate",{"EARLY_PHASE1":19344,"PHASE1":19354,"PHASE2":19356,"PHASE3":19358,"PHASE4":19360,"NA":19362},{"trials":19345,"activeCount":102},[19346],{"nctId":19347,"briefTitle":19348,"status":108,"phases":19349,"primaryCompletion":8918,"completion":19350,"start":3192,"enrollment":367,"conditions":19351,"interventions":19353},"NCT00949403","Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease",[89],"2011-01-19",[19352],"Fatty Liver",[19342],{"trials":19355,"activeCount":102},[],{"trials":19357,"activeCount":102},[],{"trials":19359,"activeCount":102},[],{"trials":19361,"activeCount":102},[],{"trials":19363,"activeCount":102},[],{"intervention":19365,"totalTrials":184,"cells":19366},"Ezetimibe",{"EARLY_PHASE1":19367,"PHASE1":19376,"PHASE2":19378,"PHASE3":19380,"PHASE4":19382,"NA":19384},{"trials":19368,"activeCount":102},[19369],{"nctId":19370,"briefTitle":19371,"status":108,"phases":19372,"primaryCompletion":3103,"completion":1872,"start":9191,"enrollment":33,"conditions":19373,"interventions":19375},"NCT00863265","Phytosterols, Ezetimibe, and Cholesterol Metabolism",[89],[19374,9123],"Hypercholesterolemia",[19365],{"trials":19377,"activeCount":102},[],{"trials":19379,"activeCount":102},[],{"trials":19381,"activeCount":102},[],{"trials":19383,"activeCount":102},[],{"trials":19385,"activeCount":102},[],{"intervention":558,"totalTrials":340,"cells":19387},{"EARLY_PHASE1":19388,"PHASE1":19390,"PHASE2":19392,"PHASE3":19394,"PHASE4":19411,"NA":19432},{"trials":19389,"activeCount":102},[],{"trials":19391,"activeCount":102},[],{"trials":19393,"activeCount":102},[],{"trials":19395,"activeCount":102},[19396,19400,19407],{"nctId":548,"briefTitle":549,"status":108,"phases":19397,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":19398,"interventions":19399},[92],[556],[558,559,558],{"nctId":19401,"briefTitle":19402,"status":122,"phases":19403,"primaryCompletion":19404,"completion":19404,"start":19404,"enrollment":102,"conditions":19405,"interventions":19406},"NCT06048263","The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series",[91,92],"2025-10-15",[8260],[558],{"nctId":586,"briefTitle":587,"status":108,"phases":19408,"primaryCompletion":589,"completion":589,"start":590,"enrollment":353,"conditions":19409,"interventions":19410},[92],[592],[558,525],{"trials":19412,"activeCount":102},[19413,19423],{"nctId":19414,"briefTitle":19415,"status":108,"phases":19416,"primaryCompletion":18126,"completion":19417,"start":19418,"enrollment":208,"conditions":19419,"interventions":19422},"NCT04504175","Ketamine for Older Adults Pilot",[93],"2022-03-15","2020-10-22",[4000,19420,19421,9550,9551],"Refractory Depression","Therapy-Resistant Depression",[558],{"nctId":19424,"briefTitle":19425,"status":108,"phases":19426,"primaryCompletion":19427,"completion":19427,"start":10772,"enrollment":506,"conditions":19428,"interventions":19430},"NCT00205712","Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids",[93],"2007-10",[19429],"Psychoses, Substance-Induced",[558,19431],"Dexmedetomidine",{"trials":19433,"activeCount":102},[19434,19443,19451,19460,19470],{"nctId":19435,"briefTitle":19436,"status":108,"phases":19437,"primaryCompletion":19438,"completion":19438,"start":6188,"enrollment":1818,"conditions":19439,"interventions":19442},"NCT02761330","Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia",[94],"2019-09-11",[21,556,19440,19441],"Seizures","Cognitive Disorders",[558],{"nctId":19444,"briefTitle":19445,"status":108,"phases":19446,"primaryCompletion":3455,"completion":19447,"start":3424,"enrollment":293,"conditions":19448,"interventions":19449},"NCT01988922","CYP2B6 Polymorphisms in Ketamine",[94],"2017-05",[10673],[19450],"ketamine",{"nctId":19452,"briefTitle":19453,"status":108,"phases":19454,"primaryCompletion":19455,"completion":19456,"start":3281,"enrollment":1299,"conditions":19457,"interventions":19458},"NCT01179009","Treatment Resistant Depression (Pilot)",[94],"2014-06-06","2015-06-05",[6247],[558,19459],"Clonidine",{"nctId":19461,"briefTitle":19462,"status":137,"phases":19463,"primaryCompletion":19464,"completion":19464,"start":6255,"enrollment":1249,"conditions":19465,"interventions":19468},"NCT02430818","Comparing Ketamine and Morphine in the Treatment of Acute Fracture Pain",[94],"2017-09",[19466,19467],"Acute Pain","Fractures",[19450,19469],"morphine",{"nctId":19471,"briefTitle":19472,"status":108,"phases":19473,"primaryCompletion":1736,"completion":1736,"start":3281,"enrollment":19474,"conditions":19475,"interventions":19478},"NCT01669642","Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children",[94],111,[19476,19477],"Abscess","Fracture",[558],{"intervention":3285,"totalTrials":599,"cells":19480},{"EARLY_PHASE1":19481,"PHASE1":19487,"PHASE2":19489,"PHASE3":19495,"PHASE4":19497,"NA":19508},{"trials":19482,"activeCount":102},[19483],{"nctId":3278,"briefTitle":3279,"status":108,"phases":19484,"primaryCompletion":3281,"completion":3281,"start":1862,"enrollment":353,"conditions":19485,"interventions":19486},[89],[3283],[2612,3285,3286],{"trials":19488,"activeCount":102},[],{"trials":19490,"activeCount":102},[19491],{"nctId":14769,"briefTitle":14770,"status":137,"phases":19492,"primaryCompletion":11790,"completion":11790,"start":1605,"enrollment":565,"conditions":19493,"interventions":19494},[91],[1445],[14760,3285],{"trials":19496,"activeCount":102},[],{"trials":19498,"activeCount":102},[19499],{"nctId":19500,"briefTitle":19501,"status":122,"phases":19502,"primaryCompletion":16630,"completion":19503,"start":1996,"enrollment":102,"conditions":19504,"interventions":19507},"NCT03027167","Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty",[93],"2023-01",[19505,19506],"DVT - Deep Vein Thrombosis","PE - Pulmonary Thromboembolism",[3285],{"trials":19509,"activeCount":102},[19510],{"nctId":19511,"briefTitle":19512,"status":137,"phases":19513,"primaryCompletion":19514,"completion":19514,"start":3116,"enrollment":5678,"conditions":19515,"interventions":19517},"NCT01547390","Early Prevention of Preeclampsia Study",[94],"2015-07-20",[19516],"Preeclampsia",[3285],{"intervention":161,"totalTrials":599,"cells":19519},{"EARLY_PHASE1":19520,"PHASE1":19522,"PHASE2":19524,"PHASE3":19530,"PHASE4":19540,"NA":19551},{"trials":19521,"activeCount":102},[],{"trials":19523,"activeCount":102},[],{"trials":19525,"activeCount":102},[19526],{"nctId":151,"briefTitle":152,"status":108,"phases":19527,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":19528,"interventions":19529},[91],[18,158,159],[97,161,162,163,164,165],{"trials":19531,"activeCount":102},[19532],{"nctId":19533,"briefTitle":19534,"status":137,"phases":19535,"completion":16234,"start":19536,"enrollment":19537,"conditions":19538,"interventions":19539},"NCT00317850","Gabapentin for the Treatment of Tinnitus",[91,92],"2004-04",160,[10093],[161],{"trials":19541,"activeCount":102},[19542],{"nctId":19543,"briefTitle":19544,"status":108,"phases":19545,"primaryCompletion":19546,"completion":19546,"start":3508,"enrollment":19547,"conditions":19548,"interventions":19550},"NCT02926573","Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients",[93],"2017-06-21",123,[399,19466,19549],"Postoperative Pain",[161],{"trials":19552,"activeCount":102},[19553],{"nctId":19554,"briefTitle":19555,"status":137,"phases":19556,"primaryCompletion":19557,"completion":19557,"start":19558,"enrollment":474,"conditions":19559,"interventions":19561},"NCT04106011","Cognitive Changes With Gabapentin Treatment",[],"2021-02-18","2020-01-10",[19560,955],"Neuralgia Peripheral",[161],{"intervention":10778,"totalTrials":599,"cells":19563},{"EARLY_PHASE1":19564,"PHASE1":19566,"PHASE2":19568,"PHASE3":19570,"PHASE4":19576,"NA":19591},{"trials":19565,"activeCount":102},[],{"trials":19567,"activeCount":102},[],{"trials":19569,"activeCount":102},[],{"trials":19571,"activeCount":102},[19572],{"nctId":10769,"briefTitle":10770,"status":108,"phases":19573,"primaryCompletion":3032,"completion":3032,"start":10772,"enrollment":10773,"conditions":19574,"interventions":19575},[92],[6225],[10776,10777,10778],{"trials":19577,"activeCount":102},[19578],{"nctId":19579,"briefTitle":19580,"status":108,"phases":19581,"primaryCompletion":10845,"completion":365,"start":1574,"enrollment":13013,"conditions":19582,"interventions":19587},"NCT00205699","Metabolic Effects of Antipsychotics in Children",[93],[19583,19584,19585,19586,6225],"Aggression","Attention Deficit-Hyperactivity","Oppositional Defiant Disorder","Pervasive Development Disorders",[19588,19589,19590],"risperidone","olanzapine","aripiprazole",{"trials":19592,"activeCount":102},[19593,19601],{"nctId":19594,"briefTitle":19595,"status":108,"phases":19596,"completion":10929,"start":19597,"enrollment":2609,"conditions":19598,"interventions":19600},"NCT00374764","Comparison of Applied Behavioral Analysis (ABA) Versus ABA and Risperidone",[94],"2000-07",[19599],"Autistic Disorder",[10778],{"nctId":19602,"briefTitle":19603,"status":108,"phases":19604,"primaryCompletion":3032,"completion":3032,"start":19605,"enrollment":394,"conditions":19606,"interventions":19608},"NCT00515723","Glucose and Lipid Metabolism on Antipsychotic Medication",[94],"2001-09",[3999,19607,6121,18498],"Schizoaffective Disorder",[19588,19589,19609,19610],"quetiapine","ziprasidone",{"intervention":10455,"totalTrials":599,"cells":19612},{"EARLY_PHASE1":19613,"PHASE1":19615,"PHASE2":19621,"PHASE3":19623,"PHASE4":19629,"NA":19635},{"trials":19614,"activeCount":102},[],{"trials":19616,"activeCount":102},[19617],{"nctId":17624,"briefTitle":17625,"status":108,"phases":19618,"primaryCompletion":10381,"completion":10381,"start":17627,"enrollment":1080,"conditions":19619,"interventions":19620},[90],[17629],[10455,17617,17631,17632,17633,17634,17635],{"trials":19622,"activeCount":102},[],{"trials":19624,"activeCount":102},[19625],{"nctId":11084,"briefTitle":11085,"status":108,"phases":19626,"primaryCompletion":11087,"completion":11087,"start":11088,"enrollment":208,"conditions":19627,"interventions":19628},[92],[8260],[11073,10455],{"trials":19630,"activeCount":102},[19631],{"nctId":10447,"briefTitle":10448,"status":108,"phases":19632,"primaryCompletion":3555,"completion":3555,"start":8044,"enrollment":1911,"conditions":19633,"interventions":19634},[93],[10451],[10434,10453,10454,10455],{"trials":19636,"activeCount":102},[19637],{"nctId":19638,"briefTitle":19639,"status":108,"phases":19640,"primaryCompletion":19641,"completion":19641,"start":2452,"enrollment":2609,"conditions":19642,"interventions":19644},"NCT02300077","Methadone in Ambulatory Surgery",[94],"2018-02-12",[19643,10451],"Post-operative Pain",[14169,10455],{"intervention":149,"totalTrials":474,"cells":19646},{"EARLY_PHASE1":19647,"PHASE1":19649,"PHASE2":19651,"PHASE3":19657,"PHASE4":19659,"NA":19661},{"trials":19648,"activeCount":102},[],{"trials":19650,"activeCount":102},[],{"trials":19652,"activeCount":102},[19653],{"nctId":135,"briefTitle":136,"status":137,"phases":19654,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":19655,"interventions":19656},[91],[144,145,146,147],[97,149,130],{"trials":19658,"activeCount":102},[],{"trials":19660,"activeCount":102},[],{"trials":19662,"activeCount":102},[19663,19672],{"nctId":19664,"briefTitle":19665,"status":108,"phases":19666,"primaryCompletion":19667,"completion":19667,"start":19668,"enrollment":2678,"conditions":19669,"interventions":19670},"NCT00761085","Methadone in Pediatric and Adult Sickle Cell Patients",[94],"2010-11-07","2008-01-01",[2572],[149,19671],"Methadone",{"nctId":19461,"briefTitle":19462,"status":137,"phases":19673,"primaryCompletion":19464,"completion":19464,"start":6255,"enrollment":1249,"conditions":19674,"interventions":19675},[94],[19466,19467],[19450,19469],{"intervention":14169,"totalTrials":474,"cells":19677},{"EARLY_PHASE1":19678,"PHASE1":19680,"PHASE2":19682,"PHASE3":19688,"PHASE4":19690,"NA":19692},{"trials":19679,"activeCount":102},[],{"trials":19681,"activeCount":102},[],{"trials":19683,"activeCount":102},[19684],{"nctId":14162,"briefTitle":14163,"status":122,"phases":19685,"primaryCompletion":6399,"completion":6399,"start":1632,"enrollment":102,"conditions":19686,"interventions":19687},[91],[14166,14167],[14153,14169,14170,14171],{"trials":19689,"activeCount":102},[],{"trials":19691,"activeCount":102},[],{"trials":19693,"activeCount":102},[19694,19698],{"nctId":19664,"briefTitle":19665,"status":108,"phases":19695,"primaryCompletion":19667,"completion":19667,"start":19668,"enrollment":2678,"conditions":19696,"interventions":19697},[94],[2572],[149,19671],{"nctId":19638,"briefTitle":19639,"status":108,"phases":19699,"primaryCompletion":19641,"completion":19641,"start":2452,"enrollment":2609,"conditions":19700,"interventions":19701},[94],[19643,10451],[14169,10455],{"intervention":19589,"totalTrials":474,"cells":19703},{"EARLY_PHASE1":19704,"PHASE1":19706,"PHASE2":19708,"PHASE3":19710,"PHASE4":19712,"NA":19718},{"trials":19705,"activeCount":102},[],{"trials":19707,"activeCount":102},[],{"trials":19709,"activeCount":102},[],{"trials":19711,"activeCount":102},[],{"trials":19713,"activeCount":102},[19714],{"nctId":19579,"briefTitle":19580,"status":108,"phases":19715,"primaryCompletion":10845,"completion":365,"start":1574,"enrollment":13013,"conditions":19716,"interventions":19717},[93],[19583,19584,19585,19586,6225],[19588,19589,19590],{"trials":19719,"activeCount":102},[19720,19729],{"nctId":19721,"briefTitle":19722,"status":108,"phases":19723,"primaryCompletion":3021,"completion":3021,"start":1431,"enrollment":743,"conditions":19724,"interventions":19726},"NCT00910988","Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone",[94],[18498,19725],"Hyperlipidemia",[19727,19728],"Olanzapine","Ziprasidone",{"nctId":19602,"briefTitle":19603,"status":108,"phases":19730,"primaryCompletion":3032,"completion":3032,"start":19605,"enrollment":394,"conditions":19731,"interventions":19732},[94],[3999,19607,6121,18498],[19588,19589,19609,19610],{"intervention":19734,"totalTrials":474,"cells":19735},"3 drug dose - IDA",{"EARLY_PHASE1":19736,"PHASE1":19738,"PHASE2":19740,"PHASE3":19742,"PHASE4":19744,"NA":19746},{"trials":19737,"activeCount":102},[],{"trials":19739,"activeCount":102},[],{"trials":19741,"activeCount":102},[],{"trials":19743,"activeCount":102},[],{"trials":19745,"activeCount":102},[],{"trials":19747,"activeCount":102},[19748,19763,19772],{"nctId":19749,"briefTitle":19750,"status":108,"phases":19751,"primaryCompletion":3079,"completion":19752,"start":19753,"enrollment":19754,"conditions":19755,"interventions":19760},"NCT03177993","Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji",[94],"2019-10-24","2017-07-13",4773,[19756,19757,19758,19759],"Lymphatic Filariases","Scabies","Impetigo","Soil Transmitted Helminths",[19734,19761,19762],"3 drug dose - IDA with second dose of ivermectin","2 drug dose - DA",{"nctId":19764,"briefTitle":19765,"status":108,"phases":19766,"primaryCompletion":19767,"completion":19768,"start":6135,"enrollment":19769,"conditions":19770,"interventions":19771},"NCT02899936","Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis",[94],"2017-04-27","2018-05-31",23789,[8191],[19734,19762],{"nctId":19773,"briefTitle":19774,"status":108,"phases":19775,"primaryCompletion":19776,"completion":19776,"start":19777,"enrollment":19778,"conditions":19779,"interventions":19780},"NCT03352206","Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis",[],"2019-11-01","2017-10-18",20092,[19756],[19762,19734],{"intervention":19762,"totalTrials":474,"cells":19782},{"EARLY_PHASE1":19783,"PHASE1":19785,"PHASE2":19787,"PHASE3":19789,"PHASE4":19791,"NA":19793},{"trials":19784,"activeCount":102},[],{"trials":19786,"activeCount":102},[],{"trials":19788,"activeCount":102},[],{"trials":19790,"activeCount":102},[],{"trials":19792,"activeCount":102},[],{"trials":19794,"activeCount":102},[19795,19799,19803],{"nctId":19749,"briefTitle":19750,"status":108,"phases":19796,"primaryCompletion":3079,"completion":19752,"start":19753,"enrollment":19754,"conditions":19797,"interventions":19798},[94],[19756,19757,19758,19759],[19734,19761,19762],{"nctId":19764,"briefTitle":19765,"status":108,"phases":19800,"primaryCompletion":19767,"completion":19768,"start":6135,"enrollment":19769,"conditions":19801,"interventions":19802},[94],[8191],[19734,19762],{"nctId":19773,"briefTitle":19774,"status":108,"phases":19804,"primaryCompletion":19776,"completion":19776,"start":19777,"enrollment":19778,"conditions":19805,"interventions":19806},[],[19756],[19762,19734],{"intervention":10890,"totalTrials":474,"cells":19808},{"EARLY_PHASE1":19809,"PHASE1":19811,"PHASE2":19813,"PHASE3":19815,"PHASE4":19821,"NA":19827},{"trials":19810,"activeCount":102},[],{"trials":19812,"activeCount":102},[],{"trials":19814,"activeCount":102},[],{"trials":19816,"activeCount":102},[19817],{"nctId":10885,"briefTitle":10886,"status":122,"phases":19818,"primaryCompletion":1646,"completion":1646,"start":1646,"enrollment":102,"conditions":19819,"interventions":19820},[91,92],[953],[10890,10874,10891],{"trials":19822,"activeCount":102},[19823],{"nctId":19579,"briefTitle":19580,"status":108,"phases":19824,"primaryCompletion":10845,"completion":365,"start":1574,"enrollment":13013,"conditions":19825,"interventions":19826},[93],[19583,19584,19585,19586,6225],[19588,19589,19590],{"trials":19828,"activeCount":102},[19829],{"nctId":19830,"briefTitle":19831,"status":108,"phases":19832,"primaryCompletion":3021,"completion":490,"start":8044,"enrollment":1181,"conditions":19833,"interventions":19834},"NCT00953745","Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression",[94],[3865],[19835,10890],"Escitalopram",{"intervention":3212,"totalTrials":474,"cells":19837},{"EARLY_PHASE1":19838,"PHASE1":19840,"PHASE2":19850,"PHASE3":19856,"PHASE4":19858,"NA":19860},{"trials":19839,"activeCount":102},[],{"trials":19841,"activeCount":102},[19842],{"nctId":19843,"briefTitle":19844,"status":108,"phases":19845,"primaryCompletion":11773,"completion":11773,"start":1648,"enrollment":1131,"conditions":19846,"interventions":19848},"NCT00545519","A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma",[90],[19847],"Relapsed Or Refractory Multiple Myeloma",[19849],"thymoglobulin",{"trials":19851,"activeCount":102},[19852],{"nctId":3204,"briefTitle":3205,"status":137,"phases":19853,"primaryCompletion":3032,"completion":3207,"start":3208,"enrollment":1623,"conditions":19854,"interventions":19855},[91],[26,2389],[3211,2425,3212],{"trials":19857,"activeCount":102},[],{"trials":19859,"activeCount":102},[],{"trials":19861,"activeCount":102},[19862],{"nctId":19863,"briefTitle":19864,"status":137,"phases":19865,"completion":16234,"start":1605,"enrollment":13084,"conditions":19866,"interventions":19868},"NCT00235781","Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients",[94],[19867],"Kidney Transplantation",[3212],{"intervention":3038,"totalTrials":456,"cells":19870},{"EARLY_PHASE1":19871,"PHASE1":19877,"PHASE2":19879,"PHASE3":19881,"PHASE4":19883,"NA":19885},{"trials":19872,"activeCount":102},[19873],{"nctId":3029,"briefTitle":3030,"status":108,"phases":19874,"primaryCompletion":3032,"completion":3032,"start":3033,"enrollment":565,"conditions":19875,"interventions":19876},[89],[3035,3036],[3038,1849,3039],{"trials":19878,"activeCount":102},[],{"trials":19880,"activeCount":102},[],{"trials":19882,"activeCount":102},[],{"trials":19884,"activeCount":102},[],{"trials":19886,"activeCount":102},[19887],{"nctId":19888,"briefTitle":19889,"status":108,"phases":19890,"primaryCompletion":19891,"completion":19891,"start":19892,"enrollment":1042,"conditions":19893,"interventions":19894},"NCT02901054","CSF Pharmacokinetics of Ondansetron",[94],"2016-11-17","2016-08-25",[955],[3038],{"intervention":19728,"totalTrials":456,"cells":19896},{"EARLY_PHASE1":19897,"PHASE1":19899,"PHASE2":19901,"PHASE3":19903,"PHASE4":19905,"NA":19907},{"trials":19898,"activeCount":102},[],{"trials":19900,"activeCount":102},[],{"trials":19902,"activeCount":102},[],{"trials":19904,"activeCount":102},[],{"trials":19906,"activeCount":102},[],{"trials":19908,"activeCount":102},[19909,19913],{"nctId":19721,"briefTitle":19722,"status":108,"phases":19910,"primaryCompletion":3021,"completion":3021,"start":1431,"enrollment":743,"conditions":19911,"interventions":19912},[94],[18498,19725],[19727,19728],{"nctId":19602,"briefTitle":19603,"status":108,"phases":19914,"primaryCompletion":3032,"completion":3032,"start":19605,"enrollment":394,"conditions":19915,"interventions":19916},[94],[3999,19607,6121,18498],[19588,19589,19609,19610],{"intervention":19918,"totalTrials":456,"cells":19919},"Progesterone",{"EARLY_PHASE1":19920,"PHASE1":19922,"PHASE2":19924,"PHASE3":19926,"PHASE4":19928,"NA":19930},{"trials":19921,"activeCount":102},[],{"trials":19923,"activeCount":102},[],{"trials":19925,"activeCount":102},[],{"trials":19927,"activeCount":102},[],{"trials":19929,"activeCount":102},[],{"trials":19931,"activeCount":102},[19932,19942],{"nctId":19933,"briefTitle":19934,"status":108,"phases":19935,"primaryCompletion":17443,"completion":17443,"start":8340,"enrollment":1911,"conditions":19936,"interventions":19938},"NCT00805207","Sex Steroids, Sleep, and Metabolic Dysfunction in Women",[94],[19937,12533,15],"Polycystic Ovary Syndrome (PCOS)",[19918,19939,19940,19941],"testosterone","glucocorticoid","Estrogen",{"nctId":19943,"briefTitle":19944,"status":137,"phases":19945,"primaryCompletion":4008,"completion":4008,"start":12437,"enrollment":33,"conditions":19946,"interventions":19948},"NCT00565916","Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism",[94],[19947],"Postmenopausal Syndrome",[19941,19918],{"intervention":19939,"totalTrials":456,"cells":19950},{"EARLY_PHASE1":19951,"PHASE1":19953,"PHASE2":19955,"PHASE3":19957,"PHASE4":19971,"NA":19973},{"trials":19952,"activeCount":102},[],{"trials":19954,"activeCount":102},[],{"trials":19956,"activeCount":102},[],{"trials":19958,"activeCount":102},[19959],{"nctId":19960,"briefTitle":19961,"status":108,"phases":19962,"primaryCompletion":19963,"completion":19964,"start":19965,"enrollment":9319,"conditions":19966,"interventions":19969},"NCT02938923","Starting a Testosterone and Exercise Program After Hip Injury",[92],"2023-08-31","2023-11-06","2019-03-05",[11166,19967,19968],"Frailty","Sarcopenia",[19970],"Testosterone",{"trials":19972,"activeCount":102},[],{"trials":19974,"activeCount":102},[19975],{"nctId":19933,"briefTitle":19934,"status":108,"phases":19976,"primaryCompletion":17443,"completion":17443,"start":8340,"enrollment":1911,"conditions":19977,"interventions":19978},[94],[19937,12533,15],[19918,19939,19940,19941],{"intervention":19940,"totalTrials":456,"cells":19980},{"EARLY_PHASE1":19981,"PHASE1":19983,"PHASE2":19985,"PHASE3":19987,"PHASE4":19989,"NA":19991},{"trials":19982,"activeCount":102},[],{"trials":19984,"activeCount":102},[],{"trials":19986,"activeCount":102},[],{"trials":19988,"activeCount":102},[],{"trials":19990,"activeCount":102},[],{"trials":19992,"activeCount":102},[19993,19997],{"nctId":19933,"briefTitle":19934,"status":108,"phases":19994,"primaryCompletion":17443,"completion":17443,"start":8340,"enrollment":1911,"conditions":19995,"interventions":19996},[94],[19937,12533,15],[19918,19939,19940,19941],{"nctId":19998,"briefTitle":19999,"status":14664,"phases":20000,"primaryCompletion":20001,"completion":20001,"start":1309,"enrollment":506,"conditions":20002,"interventions":20006},"NCT04499196","Glucocorticoids and Pulmonary Hypertension",[],"2022-07-29",[20003,20004,20005],"Pulmonary Hypertension Due to Lung Diseases and Hypoxia","Pulmonary Hypertension","Bronchopulmonary Dysplasia",[20007],"GlucoCorticoid",{"intervention":19941,"totalTrials":456,"cells":20009},{"EARLY_PHASE1":20010,"PHASE1":20012,"PHASE2":20014,"PHASE3":20016,"PHASE4":20018,"NA":20020},{"trials":20011,"activeCount":102},[],{"trials":20013,"activeCount":102},[],{"trials":20015,"activeCount":102},[],{"trials":20017,"activeCount":102},[],{"trials":20019,"activeCount":102},[],{"trials":20021,"activeCount":102},[20022,20026],{"nctId":19933,"briefTitle":19934,"status":108,"phases":20023,"primaryCompletion":17443,"completion":17443,"start":8340,"enrollment":1911,"conditions":20024,"interventions":20025},[94],[19937,12533,15],[19918,19939,19940,19941],{"nctId":19943,"briefTitle":19944,"status":137,"phases":20027,"primaryCompletion":4008,"completion":4008,"start":12437,"enrollment":33,"conditions":20028,"interventions":20029},[94],[19947],[19941,19918],{"intervention":20031,"totalTrials":456,"cells":20032},"tauroursodeoxycholic acid",{"EARLY_PHASE1":20033,"PHASE1":20035,"PHASE2":20037,"PHASE3":20039,"PHASE4":20041,"NA":20043},{"trials":20034,"activeCount":102},[],{"trials":20036,"activeCount":102},[],{"trials":20038,"activeCount":102},[],{"trials":20040,"activeCount":102},[],{"trials":20042,"activeCount":102},[],{"trials":20044,"activeCount":102},[20045,20054],{"nctId":20046,"briefTitle":20047,"status":108,"phases":20048,"primaryCompletion":2452,"completion":2452,"start":20049,"enrollment":20050,"conditions":20051,"interventions":20052},"NCT00771901","Effect of Endoplasmic Reticulum Stress on Metabolic Function",[94],"2008-02",101,[6120,953,15],[20031,20053],"sodium phenylbutyrate",{"nctId":20055,"briefTitle":20056,"status":108,"phases":20057,"primaryCompletion":20058,"completion":20058,"start":3345,"enrollment":27,"conditions":20059,"interventions":20063},"NCT01877551","Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance",[94],"2018-05",[20060,20061,20062],"HIV Related Insulin Resistance","Protease Inhibitor Related Insulin Resistance","Endoplasmic Reticulum Stress",[20064],"Tauroursodeoxycholic acid",{"intervention":11327,"totalTrials":456,"cells":20066},{"EARLY_PHASE1":20067,"PHASE1":20069,"PHASE2":20071,"PHASE3":20073,"PHASE4":20079,"NA":20081},{"trials":20068,"activeCount":102},[],{"trials":20070,"activeCount":102},[],{"trials":20072,"activeCount":102},[],{"trials":20074,"activeCount":102},[20075],{"nctId":11320,"briefTitle":11321,"status":137,"phases":20076,"primaryCompletion":3208,"completion":1400,"start":11323,"enrollment":3218,"conditions":20077,"interventions":20078},[92],[11325],[11327,11309],{"trials":20080,"activeCount":102},[],{"trials":20082,"activeCount":102},[20083],{"nctId":20084,"briefTitle":20085,"status":108,"phases":20086,"completion":10670,"start":20087,"enrollment":3556,"conditions":20088,"interventions":20090},"NCT00374686","Study of Prophylactic Vs Preemptive Valganciclovir",[94],"2003-03",[20089],"Cytomegalovirus Infection",[11327],{"intervention":13497,"totalTrials":456,"cells":20092},{"EARLY_PHASE1":20093,"PHASE1":20095,"PHASE2":20097,"PHASE3":20103,"PHASE4":20105,"NA":20107},{"trials":20094,"activeCount":102},[],{"trials":20096,"activeCount":102},[],{"trials":20098,"activeCount":102},[20099],{"nctId":13490,"briefTitle":13491,"status":108,"phases":20100,"primaryCompletion":13493,"completion":13493,"start":13494,"enrollment":1056,"conditions":20101,"interventions":20102},[90,91],[3865,21],[13481,13497],{"trials":20104,"activeCount":102},[],{"trials":20106,"activeCount":102},[],{"trials":20108,"activeCount":102},[20109],{"nctId":20110,"briefTitle":20111,"status":108,"phases":20112,"primaryCompletion":14504,"completion":14504,"start":3281,"enrollment":208,"conditions":20113,"interventions":20114},"NCT01648270","Buprenorphine Disposition and Cyclosporine",[94],[18192],[13497],{"intervention":20116,"totalTrials":456,"cells":20117},"Fenofibrate",{"EARLY_PHASE1":20118,"PHASE1":20120,"PHASE2":20122,"PHASE3":20124,"PHASE4":20126,"NA":20128},{"trials":20119,"activeCount":102},[],{"trials":20121,"activeCount":102},[],{"trials":20123,"activeCount":102},[],{"trials":20125,"activeCount":102},[],{"trials":20127,"activeCount":102},[],{"trials":20129,"activeCount":102},[20130,20139],{"nctId":20131,"briefTitle":20132,"status":108,"phases":20133,"primaryCompletion":20134,"completion":20134,"start":17443,"enrollment":2234,"conditions":20135,"interventions":20138},"NCT01752842","Lipid Biomarkers for Diabetic Heart Disease",[94],"2018-02-23",[20136,20137],"Type II Diabetes Mellitus","Diabetes Complications",[20116],{"nctId":20140,"briefTitle":20141,"status":108,"phases":20142,"primaryCompletion":3032,"completion":3032,"start":20143,"enrollment":2434,"conditions":20144,"interventions":20146},"NCT00262964","Obesity and Nonalcoholic Fatty Liver Disease",[94],"2004-10",[20145],"Non-alcoholic Fatty Liver Disease",[20147,20148],"Niacin","fenofibrate",{"intervention":20150,"totalTrials":456,"cells":20151},"2% Mupirocin Ointment",{"EARLY_PHASE1":20152,"PHASE1":20154,"PHASE2":20156,"PHASE3":20158,"PHASE4":20160,"NA":20162},{"trials":20153,"activeCount":102},[],{"trials":20155,"activeCount":102},[],{"trials":20157,"activeCount":102},[],{"trials":20159,"activeCount":102},[],{"trials":20161,"activeCount":102},[],{"trials":20163,"activeCount":102},[20164,20177],{"nctId":20165,"briefTitle":20166,"status":108,"phases":20167,"primaryCompletion":6399,"completion":1963,"start":20168,"enrollment":20169,"conditions":20170,"interventions":20175},"NCT00731783","Staphylococcus Aureus Decolonization Study",[94],"2008-07",183,[20171,20172,20173,10409,20174],"Staphylococcal Skin Infections","Abscesses","Furunculosis","MRSA Infection",[20150,20176],"4% Chlorhexidine liquid soap",{"nctId":20178,"briefTitle":20179,"status":108,"phases":20180,"primaryCompletion":20181,"completion":20182,"start":2646,"enrollment":20183,"conditions":20184,"interventions":20186},"NCT01814371","Individualized vs. Household MRSA Decolonization",[94],"2017-02-26","2017-11-28",474,[20185,19476,20173,10409,20174],"Staphylococcal Skin Infection",[20187],"2% mupirocin ointment",{"intervention":8344,"totalTrials":456,"cells":20189},{"EARLY_PHASE1":20190,"PHASE1":20192,"PHASE2":20194,"PHASE3":20196,"PHASE4":20198,"NA":20204},{"trials":20191,"activeCount":102},[],{"trials":20193,"activeCount":102},[],{"trials":20195,"activeCount":102},[],{"trials":20197,"activeCount":102},[],{"trials":20199,"activeCount":102},[20200],{"nctId":8337,"briefTitle":8338,"status":108,"phases":20201,"primaryCompletion":2287,"completion":2287,"start":8340,"enrollment":8341,"conditions":20202,"interventions":20203},[93],[21],[8344,8324],{"trials":20205,"activeCount":102},[20206],{"nctId":20207,"briefTitle":20208,"status":108,"phases":20209,"primaryCompletion":8213,"completion":8213,"start":1431,"enrollment":20210,"conditions":20211,"interventions":20214},"NCT01027559","fMRI Study of Treatment Changes in Major Depression",[94],97,[20212,20213],"Major Depression","Treatment",[8344],{"intervention":19431,"totalTrials":456,"cells":20216},{"EARLY_PHASE1":20217,"PHASE1":20219,"PHASE2":20221,"PHASE3":20223,"PHASE4":20225,"NA":20231},{"trials":20218,"activeCount":102},[],{"trials":20220,"activeCount":102},[],{"trials":20222,"activeCount":102},[],{"trials":20224,"activeCount":102},[],{"trials":20226,"activeCount":102},[20227],{"nctId":19424,"briefTitle":19425,"status":108,"phases":20228,"primaryCompletion":19427,"completion":19427,"start":10772,"enrollment":506,"conditions":20229,"interventions":20230},[93],[19429],[558,19431],{"trials":20232,"activeCount":102},[20233],{"nctId":20234,"briefTitle":20235,"status":108,"phases":20236,"primaryCompletion":12087,"completion":3872,"start":20237,"enrollment":1056,"conditions":20238,"interventions":20240},"NCT04206059","Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine",[94],"2021-01-20",[4444,20239],"Sedation Complication",[19431],{"intervention":10777,"totalTrials":456,"cells":20242},{"EARLY_PHASE1":20243,"PHASE1":20245,"PHASE2":20247,"PHASE3":20249,"PHASE4":20255,"NA":20257},{"trials":20244,"activeCount":102},[],{"trials":20246,"activeCount":102},[],{"trials":20248,"activeCount":102},[],{"trials":20250,"activeCount":102},[20251],{"nctId":10769,"briefTitle":10770,"status":108,"phases":20252,"primaryCompletion":3032,"completion":3032,"start":10772,"enrollment":10773,"conditions":20253,"interventions":20254},[92],[6225],[10776,10777,10778],{"trials":20256,"activeCount":102},[],{"trials":20258,"activeCount":102},[20259],{"nctId":20260,"briefTitle":20261,"status":108,"phases":20262,"primaryCompletion":3032,"completion":3032,"start":18649,"enrollment":8189,"conditions":20263,"interventions":20264},"NCT00167934","Determining Metabolic Effects of Valproate and Antipsychotic Therapy",[94],[3999],[10777],{"intervention":8194,"totalTrials":456,"cells":20266},{"EARLY_PHASE1":20267,"PHASE1":20269,"PHASE2":20271,"PHASE3":20273,"PHASE4":20279,"NA":20281},{"trials":20268,"activeCount":102},[],{"trials":20270,"activeCount":102},[],{"trials":20272,"activeCount":102},[],{"trials":20274,"activeCount":102},[20275],{"nctId":8185,"briefTitle":8186,"status":108,"phases":20276,"primaryCompletion":8188,"completion":8188,"start":726,"enrollment":8189,"conditions":20277,"interventions":20278},[92],[8191],[8193,8194,8174,8195],{"trials":20280,"activeCount":102},[],{"trials":20282,"activeCount":102},[20283],{"nctId":8243,"briefTitle":8244,"status":108,"phases":20284,"primaryCompletion":8246,"completion":1351,"start":3555,"enrollment":8247,"conditions":20285,"interventions":20286},[],[8191,8249],[8174,8194,8174,8194],{"intervention":8944,"totalTrials":456,"cells":20288},{"EARLY_PHASE1":20289,"PHASE1":20291,"PHASE2":20293,"PHASE3":20299,"PHASE4":20301,"NA":20303},{"trials":20290,"activeCount":102},[],{"trials":20292,"activeCount":102},[],{"trials":20294,"activeCount":102},[20295],{"nctId":8932,"briefTitle":8933,"status":108,"phases":20296,"primaryCompletion":8935,"completion":4701,"start":8936,"enrollment":8937,"conditions":20297,"interventions":20298},[91],[8939,8940],[8942,8943,163,8944],{"trials":20300,"activeCount":102},[],{"trials":20302,"activeCount":102},[],{"trials":20304,"activeCount":102},[20305],{"nctId":20306,"briefTitle":20307,"status":122,"phases":20308,"primaryCompletion":20309,"completion":20309,"start":20310,"enrollment":102,"conditions":20311,"interventions":20315},"NCT04523623","Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries",[94],"2021-06-21","2020-07-28",[20312,20313,20314],"Forearm Injuries","Pain, Acute","Pediatric ALL",[8944,20316],"Ibuprofen",{"intervention":20318,"totalTrials":456,"cells":20319},"midazolam",{"EARLY_PHASE1":20320,"PHASE1":20322,"PHASE2":20324,"PHASE3":20330,"PHASE4":20332,"NA":20334},{"trials":20321,"activeCount":102},[],{"trials":20323,"activeCount":102},[],{"trials":20325,"activeCount":102},[20326],{"nctId":151,"briefTitle":152,"status":108,"phases":20327,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":20328,"interventions":20329},[91],[18,158,159],[97,161,162,163,164,165],{"trials":20331,"activeCount":102},[],{"trials":20333,"activeCount":102},[],{"trials":20335,"activeCount":102},[20336],{"nctId":20337,"briefTitle":20338,"status":137,"phases":20339,"primaryCompletion":9191,"completion":1603,"start":11606,"enrollment":3467,"conditions":20340,"interventions":20342},"NCT00894465","Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)",[94],[20341],"Vesicoureteral Reflux",[20318],{"intervention":15670,"totalTrials":456,"cells":20344},{"EARLY_PHASE1":20345,"PHASE1":20347,"PHASE2":20349,"PHASE3":20355,"PHASE4":20357,"NA":20359},{"trials":20346,"activeCount":102},[],{"trials":20348,"activeCount":102},[],{"trials":20350,"activeCount":102},[20351],{"nctId":15662,"briefTitle":15663,"status":108,"phases":20352,"primaryCompletion":9545,"completion":8293,"start":15665,"enrollment":442,"conditions":20353,"interventions":20354},[90,91],[15667,15668,369],[15653,15670],{"trials":20356,"activeCount":102},[],{"trials":20358,"activeCount":102},[],{"trials":20360,"activeCount":102},[20361],{"nctId":20362,"briefTitle":20363,"status":108,"phases":20364,"primaryCompletion":20365,"completion":20366,"start":14965,"enrollment":1380,"conditions":20367,"interventions":20369},"NCT03904043","Non-Operative Management and Early Response Assessment in Rectal Cancer",[94],"2024-08-21","2026-01-25",[20368],"Adenocarcinoma of the Lower Rectum",[15670,20370],"CAPOX regimen",{"intervention":20372,"totalTrials":184,"cells":20373},"Indocyanine Green",{"EARLY_PHASE1":20374,"PHASE1":20376,"PHASE2":20378,"PHASE3":20380,"PHASE4":20382,"NA":20384},{"trials":20375,"activeCount":102},[],{"trials":20377,"activeCount":102},[],{"trials":20379,"activeCount":102},[],{"trials":20381,"activeCount":102},[],{"trials":20383,"activeCount":102},[],{"trials":20385,"activeCount":102},[20386],{"nctId":20387,"briefTitle":20388,"status":108,"phases":20389,"primaryCompletion":20390,"completion":20391,"start":20392,"enrollment":20393,"conditions":20394,"interventions":20397},"NCT01969448","Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction",[94],"2016-04-27","2017-04-17","2013-03-28",79,[20395,18,20396],"Ductal Carcinoma in Situ - Category","Prophylactic Mastectomy",[20372],{"intervention":20399,"totalTrials":184,"cells":20400},"Setraline",{"EARLY_PHASE1":20401,"PHASE1":20403,"PHASE2":20405,"PHASE3":20407,"PHASE4":20409,"NA":20411},{"trials":20402,"activeCount":102},[],{"trials":20404,"activeCount":102},[],{"trials":20406,"activeCount":102},[],{"trials":20408,"activeCount":102},[],{"trials":20410,"activeCount":102},[],{"trials":20412,"activeCount":102},[20413],{"nctId":20414,"briefTitle":20415,"status":108,"phases":20416,"primaryCompletion":3020,"completion":3020,"start":13630,"enrollment":2678,"conditions":20417,"interventions":20419},"NCT01996644","A Double Blind Clinical Trial of DCS for Food Anxiety",[94],[20418],"Anorexia and Bulimia Nervosa",[20399],{"intervention":20421,"totalTrials":184,"cells":20422},"Buprenorphine Control",{"EARLY_PHASE1":20423,"PHASE1":20425,"PHASE2":20427,"PHASE3":20429,"PHASE4":20431,"NA":20433},{"trials":20424,"activeCount":102},[],{"trials":20426,"activeCount":102},[],{"trials":20428,"activeCount":102},[],{"trials":20430,"activeCount":102},[],{"trials":20432,"activeCount":102},[],{"trials":20434,"activeCount":102},[20435],{"nctId":20436,"briefTitle":20437,"status":108,"phases":20438,"primaryCompletion":20439,"completion":20439,"start":1647,"enrollment":36,"conditions":20440,"interventions":20441},"NCT01576575","Buprenorphine Disposition and CYP3A",[94],"2014-03-29",[18192],[20421,20442,20443,20444],"Buprenorphine + Rifampin","Buprenorphine + Grapefruit juice","Buprenorphine + Ketoconazole",{"intervention":20442,"totalTrials":184,"cells":20446},{"EARLY_PHASE1":20447,"PHASE1":20449,"PHASE2":20451,"PHASE3":20453,"PHASE4":20455,"NA":20457},{"trials":20448,"activeCount":102},[],{"trials":20450,"activeCount":102},[],{"trials":20452,"activeCount":102},[],{"trials":20454,"activeCount":102},[],{"trials":20456,"activeCount":102},[],{"trials":20458,"activeCount":102},[20459],{"nctId":20436,"briefTitle":20437,"status":108,"phases":20460,"primaryCompletion":20439,"completion":20439,"start":1647,"enrollment":36,"conditions":20461,"interventions":20462},[94],[18192],[20421,20442,20443,20444],{"intervention":20443,"totalTrials":184,"cells":20464},{"EARLY_PHASE1":20465,"PHASE1":20467,"PHASE2":20469,"PHASE3":20471,"PHASE4":20473,"NA":20475},{"trials":20466,"activeCount":102},[],{"trials":20468,"activeCount":102},[],{"trials":20470,"activeCount":102},[],{"trials":20472,"activeCount":102},[],{"trials":20474,"activeCount":102},[],{"trials":20476,"activeCount":102},[20477],{"nctId":20436,"briefTitle":20437,"status":108,"phases":20478,"primaryCompletion":20439,"completion":20439,"start":1647,"enrollment":36,"conditions":20479,"interventions":20480},[94],[18192],[20421,20442,20443,20444],{"intervention":20444,"totalTrials":184,"cells":20482},{"EARLY_PHASE1":20483,"PHASE1":20485,"PHASE2":20487,"PHASE3":20489,"PHASE4":20491,"NA":20493},{"trials":20484,"activeCount":102},[],{"trials":20486,"activeCount":102},[],{"trials":20488,"activeCount":102},[],{"trials":20490,"activeCount":102},[],{"trials":20492,"activeCount":102},[],{"trials":20494,"activeCount":102},[20495],{"nctId":20436,"briefTitle":20437,"status":108,"phases":20496,"primaryCompletion":20439,"completion":20439,"start":1647,"enrollment":36,"conditions":20497,"interventions":20498},[94],[18192],[20421,20442,20443,20444],{"intervention":20500,"totalTrials":184,"cells":20501},"Ultrasound-guided peripheral nerve block with 2% lidocaine",{"EARLY_PHASE1":20502,"PHASE1":20504,"PHASE2":20506,"PHASE3":20508,"PHASE4":20510,"NA":20512},{"trials":20503,"activeCount":102},[],{"trials":20505,"activeCount":102},[],{"trials":20507,"activeCount":102},[],{"trials":20509,"activeCount":102},[],{"trials":20511,"activeCount":102},[],{"trials":20513,"activeCount":102},[20514],{"nctId":20515,"briefTitle":20516,"status":108,"phases":20517,"primaryCompletion":20518,"completion":20519,"start":1736,"enrollment":2289,"conditions":20520,"interventions":20522},"NCT02148588","Peripheral Sensory Input in Central Post Stroke Pain (CPSP)",[94],"2016-12-15","2017-01-25",[20521],"Central Post Stroke Pain",[20500],{"intervention":20524,"totalTrials":184,"cells":20525},"Sapropterin",{"EARLY_PHASE1":20526,"PHASE1":20528,"PHASE2":20530,"PHASE3":20532,"PHASE4":20534,"NA":20536},{"trials":20527,"activeCount":102},[],{"trials":20529,"activeCount":102},[],{"trials":20531,"activeCount":102},[],{"trials":20533,"activeCount":102},[],{"trials":20535,"activeCount":102},[],{"trials":20537,"activeCount":102},[20538],{"nctId":20539,"briefTitle":20540,"status":108,"phases":20541,"primaryCompletion":20058,"completion":20058,"start":20168,"enrollment":1271,"conditions":20542,"interventions":20544},"NCT00730080","Sapropterin in Individuals With Phenylketonuria",[],[20543],"Phenylketonuria",[20524],{"intervention":20546,"totalTrials":184,"cells":20547},"Nicotine patch",{"EARLY_PHASE1":20548,"PHASE1":20550,"PHASE2":20552,"PHASE3":20554,"PHASE4":20556,"NA":20558},{"trials":20549,"activeCount":102},[],{"trials":20551,"activeCount":102},[],{"trials":20553,"activeCount":102},[],{"trials":20555,"activeCount":102},[],{"trials":20557,"activeCount":102},[],{"trials":20559,"activeCount":102},[20560],{"nctId":20561,"briefTitle":20562,"status":14664,"phases":20563,"primaryCompletion":1389,"completion":1389,"start":20564,"enrollment":3684,"conditions":20565,"interventions":20566},"NCT03383224","PRISM-GENOMICS-Smoking Cessation for Patients With Coronary Artery Disease Undergoing Cardiac Catheterization or Having a Heart Attack at Barnes Hospital in St. Louis Mo",[94],"2015-07-21",[18295,10229],[20546],{"intervention":8207,"totalTrials":184,"cells":20568},{"EARLY_PHASE1":20569,"PHASE1":20571,"PHASE2":20573,"PHASE3":20575,"PHASE4":20577,"NA":20579},{"trials":20570,"activeCount":102},[],{"trials":20572,"activeCount":102},[],{"trials":20574,"activeCount":102},[],{"trials":20576,"activeCount":102},[],{"trials":20578,"activeCount":102},[],{"trials":20580,"activeCount":102},[20581],{"nctId":8201,"briefTitle":8202,"status":108,"phases":20582,"primaryCompletion":2370,"completion":2370,"start":3321,"enrollment":8204,"conditions":20583,"interventions":20584},[94],[8111],[8207,8174,8208],{"intervention":8208,"totalTrials":184,"cells":20586},{"EARLY_PHASE1":20587,"PHASE1":20589,"PHASE2":20591,"PHASE3":20593,"PHASE4":20595,"NA":20597},{"trials":20588,"activeCount":102},[],{"trials":20590,"activeCount":102},[],{"trials":20592,"activeCount":102},[],{"trials":20594,"activeCount":102},[],{"trials":20596,"activeCount":102},[],{"trials":20598,"activeCount":102},[20599],{"nctId":8201,"briefTitle":8202,"status":108,"phases":20600,"primaryCompletion":2370,"completion":2370,"start":3321,"enrollment":8204,"conditions":20601,"interventions":20602},[94],[8111],[8207,8174,8208],{"intervention":20604,"totalTrials":184,"cells":20605},"efalizumab",{"EARLY_PHASE1":20606,"PHASE1":20608,"PHASE2":20610,"PHASE3":20612,"PHASE4":20614,"NA":20616},{"trials":20607,"activeCount":102},[],{"trials":20609,"activeCount":102},[],{"trials":20611,"activeCount":102},[],{"trials":20613,"activeCount":102},[],{"trials":20615,"activeCount":102},[],{"trials":20617,"activeCount":102},[20618],{"nctId":20619,"briefTitle":20620,"status":108,"phases":20621,"primaryCompletion":12192,"completion":12192,"start":20622,"enrollment":599,"conditions":20623,"interventions":20625},"NCT00133107","Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus",[94],"2005-01",[20624],"Lichen Planus, Oral",[20604],{"intervention":20627,"totalTrials":184,"cells":20628},"[5,5,5-2H3]leucine",{"EARLY_PHASE1":20629,"PHASE1":20631,"PHASE2":20633,"PHASE3":20635,"PHASE4":20637,"NA":20639},{"trials":20630,"activeCount":102},[],{"trials":20632,"activeCount":102},[],{"trials":20634,"activeCount":102},[],{"trials":20636,"activeCount":102},[],{"trials":20638,"activeCount":102},[],{"trials":20640,"activeCount":102},[20641],{"nctId":20642,"briefTitle":20643,"status":108,"phases":20644,"primaryCompletion":364,"completion":1963,"start":6400,"enrollment":3323,"conditions":20645,"interventions":20648},"NCT00828451","Collaborative Research Group for Necrotizing Enterocolitis",[94],[20646,20647],"Prematurity","Necrotizing Enterocolitis",[20627],{"intervention":20650,"totalTrials":184,"cells":20651},"Suvorexant",{"EARLY_PHASE1":20652,"PHASE1":20654,"PHASE2":20656,"PHASE3":20658,"PHASE4":20660,"NA":20662},{"trials":20653,"activeCount":102},[],{"trials":20655,"activeCount":102},[],{"trials":20657,"activeCount":102},[],{"trials":20659,"activeCount":102},[],{"trials":20661,"activeCount":102},[],{"trials":20663,"activeCount":102},[20664],{"nctId":20665,"briefTitle":20666,"status":108,"phases":20667,"primaryCompletion":20668,"completion":20669,"start":8995,"enrollment":565,"conditions":20670,"interventions":20672},"NCT03077620","Sleep Quality and Amyloid-Beta Kinetics",[94],"2021-03-28","2021-03-30",[20671],"Amyloid-beta",[20650],{"intervention":19761,"totalTrials":184,"cells":20674},{"EARLY_PHASE1":20675,"PHASE1":20677,"PHASE2":20679,"PHASE3":20681,"PHASE4":20683,"NA":20685},{"trials":20676,"activeCount":102},[],{"trials":20678,"activeCount":102},[],{"trials":20680,"activeCount":102},[],{"trials":20682,"activeCount":102},[],{"trials":20684,"activeCount":102},[],{"trials":20686,"activeCount":102},[20687],{"nctId":19749,"briefTitle":19750,"status":108,"phases":20688,"primaryCompletion":3079,"completion":19752,"start":19753,"enrollment":19754,"conditions":20689,"interventions":20690},[94],[19756,19757,19758,19759],[19734,19761,19762],{"intervention":20692,"totalTrials":184,"cells":20693},"Ponatinib",{"EARLY_PHASE1":20694,"PHASE1":20696,"PHASE2":20698,"PHASE3":20700,"PHASE4":20702,"NA":20704},{"trials":20695,"activeCount":102},[],{"trials":20697,"activeCount":102},[],{"trials":20699,"activeCount":102},[],{"trials":20701,"activeCount":102},[],{"trials":20703,"activeCount":102},[],{"trials":20705,"activeCount":102},[20706],{"nctId":20707,"briefTitle":20708,"status":122,"phases":20709,"primaryCompletion":16332,"completion":20710,"start":20711,"enrollment":102,"conditions":20712,"interventions":20714},"NCT01888562","Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma",[94],"2023-07","2016-01",[20713],"Endometrial Neoplasms",[20692],{"intervention":20716,"totalTrials":184,"cells":20717},"Chloroquine",{"EARLY_PHASE1":20718,"PHASE1":20720,"PHASE2":20722,"PHASE3":20724,"PHASE4":20726,"NA":20728},{"trials":20719,"activeCount":102},[],{"trials":20721,"activeCount":102},[],{"trials":20723,"activeCount":102},[],{"trials":20725,"activeCount":102},[],{"trials":20727,"activeCount":102},[],{"trials":20729,"activeCount":102},[20730],{"nctId":20731,"briefTitle":20732,"status":108,"phases":20733,"primaryCompletion":364,"completion":364,"start":1574,"enrollment":8,"conditions":20734,"interventions":20735},"NCT00455403","Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)",[94],[12874,12875,6123,12876,12877],[20716],{"intervention":20053,"totalTrials":184,"cells":20737},{"EARLY_PHASE1":20738,"PHASE1":20740,"PHASE2":20742,"PHASE3":20744,"PHASE4":20746,"NA":20748},{"trials":20739,"activeCount":102},[],{"trials":20741,"activeCount":102},[],{"trials":20743,"activeCount":102},[],{"trials":20745,"activeCount":102},[],{"trials":20747,"activeCount":102},[],{"trials":20749,"activeCount":102},[20750],{"nctId":20046,"briefTitle":20047,"status":108,"phases":20751,"primaryCompletion":2452,"completion":2452,"start":20049,"enrollment":20050,"conditions":20752,"interventions":20753},[94],[6120,953,15],[20031,20053],{"intervention":20755,"totalTrials":184,"cells":20756},"Sodium Oxybate",{"EARLY_PHASE1":20757,"PHASE1":20759,"PHASE2":20761,"PHASE3":20763,"PHASE4":20765,"NA":20767},{"trials":20758,"activeCount":102},[],{"trials":20760,"activeCount":102},[],{"trials":20762,"activeCount":102},[],{"trials":20764,"activeCount":102},[],{"trials":20766,"activeCount":102},[],{"trials":20768,"activeCount":102},[20769],{"nctId":20770,"briefTitle":20771,"status":108,"phases":20772,"primaryCompletion":6135,"completion":6135,"start":2443,"enrollment":22,"conditions":20773,"interventions":20774},"NCT02063217","Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction",[94],[20671],[20755],{"intervention":20776,"totalTrials":184,"cells":20777},"0.3mg\u002Fkg IV methadone HCl",{"EARLY_PHASE1":20778,"PHASE1":20780,"PHASE2":20782,"PHASE3":20784,"PHASE4":20786,"NA":20788},{"trials":20779,"activeCount":102},[],{"trials":20781,"activeCount":102},[],{"trials":20783,"activeCount":102},[],{"trials":20785,"activeCount":102},[],{"trials":20787,"activeCount":102},[],{"trials":20789,"activeCount":102},[20790],{"nctId":20791,"briefTitle":20792,"status":108,"phases":20793,"primaryCompletion":20794,"completion":20794,"start":2260,"enrollment":2434,"conditions":20795,"interventions":20796},"NCT01990573","Methadone in Pediatric Anesthesiology II",[94],"2018-06-30",[955],[20776,20797],"0.4mg\u002Fkg IV methadon HCl",{"intervention":20797,"totalTrials":184,"cells":20799},{"EARLY_PHASE1":20800,"PHASE1":20802,"PHASE2":20804,"PHASE3":20806,"PHASE4":20808,"NA":20810},{"trials":20801,"activeCount":102},[],{"trials":20803,"activeCount":102},[],{"trials":20805,"activeCount":102},[],{"trials":20807,"activeCount":102},[],{"trials":20809,"activeCount":102},[],{"trials":20811,"activeCount":102},[20812],{"nctId":20791,"briefTitle":20792,"status":108,"phases":20813,"primaryCompletion":20794,"completion":20794,"start":2260,"enrollment":2434,"conditions":20814,"interventions":20815},[94],[955],[20776,20797],{"intervention":20817,"totalTrials":184,"cells":20818},"oxytocin",{"EARLY_PHASE1":20819,"PHASE1":20821,"PHASE2":20823,"PHASE3":20825,"PHASE4":20827,"NA":20829},{"trials":20820,"activeCount":102},[],{"trials":20822,"activeCount":102},[],{"trials":20824,"activeCount":102},[],{"trials":20826,"activeCount":102},[],{"trials":20828,"activeCount":102},[],{"trials":20830,"activeCount":102},[20831],{"nctId":20832,"briefTitle":20833,"status":108,"phases":20834,"primaryCompletion":20835,"completion":20835,"start":20836,"enrollment":293,"conditions":20837,"interventions":20839},"NCT03898882","Pharmacokinetics of Oxytocin at Cesarean Delivery",[],"2020-02-28","2019-05-24",[20838],"Postpartum Hemorrhage",[20817],{"intervention":20841,"totalTrials":184,"cells":20842},"Ivermectin 3Mg Tab",{"EARLY_PHASE1":20843,"PHASE1":20845,"PHASE2":20847,"PHASE3":20849,"PHASE4":20851,"NA":20853},{"trials":20844,"activeCount":102},[],{"trials":20846,"activeCount":102},[],{"trials":20848,"activeCount":102},[],{"trials":20850,"activeCount":102},[],{"trials":20852,"activeCount":102},[],{"trials":20854,"activeCount":102},[20855],{"nctId":20856,"briefTitle":20857,"status":108,"phases":20858,"primaryCompletion":20859,"completion":20859,"start":20860,"enrollment":20861,"conditions":20862,"interventions":20863},"NCT03517462","Ocular Changes After Ivermectin - (DOLF IVM\u002FOncho)",[94],"2019-08-23","2018-08-06",231,[5143],[20841],{"intervention":20865,"totalTrials":184,"cells":20866},"Immunotherapy",{"EARLY_PHASE1":20867,"PHASE1":20869,"PHASE2":20871,"PHASE3":20873,"PHASE4":20875,"NA":20877},{"trials":20868,"activeCount":102},[],{"trials":20870,"activeCount":102},[],{"trials":20872,"activeCount":102},[],{"trials":20874,"activeCount":102},[],{"trials":20876,"activeCount":102},[],{"trials":20878,"activeCount":102},[20879],{"nctId":20880,"briefTitle":20881,"status":137,"phases":20882,"primaryCompletion":2127,"completion":2127,"start":20883,"enrollment":5325,"conditions":20884,"interventions":20890},"NCT03370861","How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes",[],"2017-11-08",[20885,2454,20886,20887,20888,20889],"Autoimmunity","Merkel Cell Carcinoma","Squamous Cell Carcinoma of the Skin","Basal Cell Carcinoma","Skin Cancer",[20865],{"intervention":20176,"totalTrials":184,"cells":20892},{"EARLY_PHASE1":20893,"PHASE1":20895,"PHASE2":20897,"PHASE3":20899,"PHASE4":20901,"NA":20903},{"trials":20894,"activeCount":102},[],{"trials":20896,"activeCount":102},[],{"trials":20898,"activeCount":102},[],{"trials":20900,"activeCount":102},[],{"trials":20902,"activeCount":102},[],{"trials":20904,"activeCount":102},[20905],{"nctId":20165,"briefTitle":20166,"status":108,"phases":20906,"primaryCompletion":6399,"completion":1963,"start":20168,"enrollment":20169,"conditions":20907,"interventions":20908},[94],[20171,20172,20173,10409,20174],[20150,20176],{"intervention":3121,"totalTrials":184,"cells":20910},{"EARLY_PHASE1":20911,"PHASE1":20913,"PHASE2":20915,"PHASE3":20917,"PHASE4":20919,"NA":20921},{"trials":20912,"activeCount":102},[],{"trials":20914,"activeCount":102},[],{"trials":20916,"activeCount":102},[],{"trials":20918,"activeCount":102},[],{"trials":20920,"activeCount":102},[],{"trials":20922,"activeCount":102},[20923],{"nctId":3111,"briefTitle":3112,"status":108,"phases":20924,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":1181,"conditions":20925,"interventions":20926},[94],[3118,3119],[3121,3122],{"intervention":20928,"totalTrials":184,"cells":20929},"Bisphosphonate",{"EARLY_PHASE1":20930,"PHASE1":20932,"PHASE2":20934,"PHASE3":20936,"PHASE4":20938,"NA":20940},{"trials":20931,"activeCount":102},[],{"trials":20933,"activeCount":102},[],{"trials":20935,"activeCount":102},[],{"trials":20937,"activeCount":102},[],{"trials":20939,"activeCount":102},[],{"trials":20941,"activeCount":102},[20942],{"nctId":20943,"briefTitle":20944,"status":108,"phases":20945,"primaryCompletion":20946,"completion":20946,"start":6188,"enrollment":6505,"conditions":20947,"interventions":20951},"NCT02731040","Exome Sequencing for Atypical Femoral Fractures",[],"2018-03-29",[20948,20949,20950],"Atypical Femoral Fractures","Osteoporosis","Bisphosphonate Therapy",[20928],{"intervention":19609,"totalTrials":184,"cells":20953},{"EARLY_PHASE1":20954,"PHASE1":20956,"PHASE2":20958,"PHASE3":20960,"PHASE4":20962,"NA":20964},{"trials":20955,"activeCount":102},[],{"trials":20957,"activeCount":102},[],{"trials":20959,"activeCount":102},[],{"trials":20961,"activeCount":102},[],{"trials":20963,"activeCount":102},[],{"trials":20965,"activeCount":102},[20966],{"nctId":19602,"briefTitle":19603,"status":108,"phases":20967,"primaryCompletion":3032,"completion":3032,"start":19605,"enrollment":394,"conditions":20968,"interventions":20969},[94],[3999,19607,6121,18498],[19588,19589,19609,19610],{"intervention":20971,"totalTrials":184,"cells":20972},"Montelukast 5-mg orally added to standard therapy",{"EARLY_PHASE1":20973,"PHASE1":20975,"PHASE2":20977,"PHASE3":20979,"PHASE4":20981,"NA":20983},{"trials":20974,"activeCount":102},[],{"trials":20976,"activeCount":102},[],{"trials":20978,"activeCount":102},[],{"trials":20980,"activeCount":102},[],{"trials":20982,"activeCount":102},[],{"trials":20984,"activeCount":102},[20985],{"nctId":20986,"briefTitle":20987,"status":137,"phases":20988,"primaryCompletion":20143,"completion":11278,"start":19605,"enrollment":27,"conditions":20989,"interventions":20990},"NCT00353184","Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years",[94],[4705],[20971],{"intervention":20992,"totalTrials":184,"cells":20993},"Lactate Clearance",{"EARLY_PHASE1":20994,"PHASE1":20996,"PHASE2":20998,"PHASE3":21000,"PHASE4":21002,"NA":21004},{"trials":20995,"activeCount":102},[],{"trials":20997,"activeCount":102},[],{"trials":20999,"activeCount":102},[],{"trials":21001,"activeCount":102},[],{"trials":21003,"activeCount":102},[],{"trials":21005,"activeCount":102},[21006],{"nctId":21007,"briefTitle":21008,"status":137,"phases":21009,"primaryCompletion":3424,"completion":3424,"start":3192,"enrollment":33,"conditions":21010,"interventions":21011},"NCT01128413","Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)",[94],[10697],[20992,21012,21013],"500ml Normal Saline Bolus","Clinician Discretion Intravenous Fluid Management",{"intervention":21012,"totalTrials":184,"cells":21015},{"EARLY_PHASE1":21016,"PHASE1":21018,"PHASE2":21020,"PHASE3":21022,"PHASE4":21024,"NA":21026},{"trials":21017,"activeCount":102},[],{"trials":21019,"activeCount":102},[],{"trials":21021,"activeCount":102},[],{"trials":21023,"activeCount":102},[],{"trials":21025,"activeCount":102},[],{"trials":21027,"activeCount":102},[21028],{"nctId":21007,"briefTitle":21008,"status":137,"phases":21029,"primaryCompletion":3424,"completion":3424,"start":3192,"enrollment":33,"conditions":21030,"interventions":21031},[94],[10697],[20992,21012,21013],{"intervention":21013,"totalTrials":184,"cells":21033},{"EARLY_PHASE1":21034,"PHASE1":21036,"PHASE2":21038,"PHASE3":21040,"PHASE4":21042,"NA":21044},{"trials":21035,"activeCount":102},[],{"trials":21037,"activeCount":102},[],{"trials":21039,"activeCount":102},[],{"trials":21041,"activeCount":102},[],{"trials":21043,"activeCount":102},[],{"trials":21045,"activeCount":102},[21046],{"nctId":21007,"briefTitle":21008,"status":137,"phases":21047,"primaryCompletion":3424,"completion":3424,"start":3192,"enrollment":33,"conditions":21048,"interventions":21049},[94],[10697],[20992,21012,21013],{"intervention":21051,"totalTrials":184,"cells":21052},"transdermal estradiol",{"EARLY_PHASE1":21053,"PHASE1":21055,"PHASE2":21057,"PHASE3":21059,"PHASE4":21061,"NA":21063},{"trials":21054,"activeCount":102},[],{"trials":21056,"activeCount":102},[],{"trials":21058,"activeCount":102},[],{"trials":21060,"activeCount":102},[],{"trials":21062,"activeCount":102},[],{"trials":21064,"activeCount":102},[21065],{"nctId":21066,"briefTitle":21067,"status":108,"phases":21068,"primaryCompletion":6399,"completion":8918,"start":3346,"enrollment":9319,"conditions":21069,"interventions":21070},"NCT00789802","A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC",[94],[11192,11193],[21051,21071,21072],"naproxen","oral placebo",{"intervention":21071,"totalTrials":184,"cells":21074},{"EARLY_PHASE1":21075,"PHASE1":21077,"PHASE2":21079,"PHASE3":21081,"PHASE4":21083,"NA":21085},{"trials":21076,"activeCount":102},[],{"trials":21078,"activeCount":102},[],{"trials":21080,"activeCount":102},[],{"trials":21082,"activeCount":102},[],{"trials":21084,"activeCount":102},[],{"trials":21086,"activeCount":102},[21087],{"nctId":21066,"briefTitle":21067,"status":108,"phases":21088,"primaryCompletion":6399,"completion":8918,"start":3346,"enrollment":9319,"conditions":21089,"interventions":21090},[94],[11192,11193],[21051,21071,21072],{"intervention":21072,"totalTrials":184,"cells":21092},{"EARLY_PHASE1":21093,"PHASE1":21095,"PHASE2":21097,"PHASE3":21099,"PHASE4":21101,"NA":21103},{"trials":21094,"activeCount":102},[],{"trials":21096,"activeCount":102},[],{"trials":21098,"activeCount":102},[],{"trials":21100,"activeCount":102},[],{"trials":21102,"activeCount":102},[],{"trials":21104,"activeCount":102},[21105],{"nctId":21066,"briefTitle":21067,"status":108,"phases":21106,"primaryCompletion":6399,"completion":8918,"start":3346,"enrollment":9319,"conditions":21107,"interventions":21108},[94],[11192,11193],[21051,21071,21072],{"intervention":21110,"totalTrials":184,"cells":21111},"2% lidocaine gel",{"EARLY_PHASE1":21112,"PHASE1":21114,"PHASE2":21116,"PHASE3":21118,"PHASE4":21120,"NA":21122},{"trials":21113,"activeCount":102},[],{"trials":21115,"activeCount":102},[],{"trials":21117,"activeCount":102},[],{"trials":21119,"activeCount":102},[],{"trials":21121,"activeCount":102},[],{"trials":21123,"activeCount":102},[21124],{"nctId":21125,"briefTitle":21126,"status":108,"phases":21127,"primaryCompletion":380,"completion":380,"start":3179,"enrollment":4442,"conditions":21128,"interventions":21129},"NCT01411995","Cervical Lidocaine for Intrauterine Device Insertion Pain",[94],[955],[21110,21130],"Water based lubricant",{"intervention":21130,"totalTrials":184,"cells":21132},{"EARLY_PHASE1":21133,"PHASE1":21135,"PHASE2":21137,"PHASE3":21139,"PHASE4":21141,"NA":21143},{"trials":21134,"activeCount":102},[],{"trials":21136,"activeCount":102},[],{"trials":21138,"activeCount":102},[],{"trials":21140,"activeCount":102},[],{"trials":21142,"activeCount":102},[],{"trials":21144,"activeCount":102},[21145],{"nctId":21125,"briefTitle":21126,"status":108,"phases":21146,"primaryCompletion":380,"completion":380,"start":3179,"enrollment":4442,"conditions":21147,"interventions":21148},[94],[955],[21110,21130],{"intervention":21150,"totalTrials":184,"cells":21151},"Gadolinium contrast",{"EARLY_PHASE1":21152,"PHASE1":21154,"PHASE2":21156,"PHASE3":21158,"PHASE4":21160,"NA":21162},{"trials":21153,"activeCount":102},[],{"trials":21155,"activeCount":102},[],{"trials":21157,"activeCount":102},[],{"trials":21159,"activeCount":102},[],{"trials":21161,"activeCount":102},[],{"trials":21163,"activeCount":102},[21164],{"nctId":21165,"briefTitle":21166,"status":137,"phases":21167,"primaryCompletion":21168,"completion":21168,"start":21169,"enrollment":3323,"conditions":21170,"interventions":21172},"NCT02584413","Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma",[94],"2019-02-07","2013-04-16",[21171],"Neurofibromatosis Type 1",[21150],{"intervention":8238,"totalTrials":184,"cells":21174},{"EARLY_PHASE1":21175,"PHASE1":21177,"PHASE2":21179,"PHASE3":21181,"PHASE4":21183,"NA":21185},{"trials":21176,"activeCount":102},[],{"trials":21178,"activeCount":102},[],{"trials":21180,"activeCount":102},[],{"trials":21182,"activeCount":102},[],{"trials":21184,"activeCount":102},[],{"trials":21186,"activeCount":102},[21187],{"nctId":8225,"briefTitle":8226,"status":108,"phases":21188,"primaryCompletion":8228,"completion":8229,"start":8230,"enrollment":8231,"conditions":21189,"interventions":21190},[94],[8233,8234,8235,8236],[8238,8239,8240,8174,8241],{"intervention":8239,"totalTrials":184,"cells":21192},{"EARLY_PHASE1":21193,"PHASE1":21195,"PHASE2":21197,"PHASE3":21199,"PHASE4":21201,"NA":21203},{"trials":21194,"activeCount":102},[],{"trials":21196,"activeCount":102},[],{"trials":21198,"activeCount":102},[],{"trials":21200,"activeCount":102},[],{"trials":21202,"activeCount":102},[],{"trials":21204,"activeCount":102},[21205],{"nctId":8225,"briefTitle":8226,"status":108,"phases":21206,"primaryCompletion":8228,"completion":8229,"start":8230,"enrollment":8231,"conditions":21207,"interventions":21208},[94],[8233,8234,8235,8236],[8238,8239,8240,8174,8241],{"intervention":8241,"totalTrials":184,"cells":21210},{"EARLY_PHASE1":21211,"PHASE1":21213,"PHASE2":21215,"PHASE3":21217,"PHASE4":21219,"NA":21221},{"trials":21212,"activeCount":102},[],{"trials":21214,"activeCount":102},[],{"trials":21216,"activeCount":102},[],{"trials":21218,"activeCount":102},[],{"trials":21220,"activeCount":102},[],{"trials":21222,"activeCount":102},[21223],{"nctId":8225,"briefTitle":8226,"status":108,"phases":21224,"primaryCompletion":8228,"completion":8229,"start":8230,"enrollment":8231,"conditions":21225,"interventions":21226},[94],[8233,8234,8235,8236],[8238,8239,8240,8174,8241],{"intervention":6081,"totalTrials":184,"cells":21228},{"EARLY_PHASE1":21229,"PHASE1":21231,"PHASE2":21233,"PHASE3":21235,"PHASE4":21237,"NA":21239},{"trials":21230,"activeCount":102},[],{"trials":21232,"activeCount":102},[],{"trials":21234,"activeCount":102},[],{"trials":21236,"activeCount":102},[],{"trials":21238,"activeCount":102},[],{"trials":21240,"activeCount":102},[21241],{"nctId":6074,"briefTitle":6075,"status":108,"phases":21242,"primaryCompletion":1604,"completion":1604,"start":1863,"enrollment":1818,"conditions":21243,"interventions":21244},[94],[6078,954,6079],[6081,5595],{"intervention":21246,"totalTrials":184,"cells":21247},"Betadine 5%",{"EARLY_PHASE1":21248,"PHASE1":21250,"PHASE2":21252,"PHASE3":21254,"PHASE4":21256,"NA":21258},{"trials":21249,"activeCount":102},[],{"trials":21251,"activeCount":102},[],{"trials":21253,"activeCount":102},[],{"trials":21255,"activeCount":102},[],{"trials":21257,"activeCount":102},[],{"trials":21259,"activeCount":102},[21260],{"nctId":21261,"briefTitle":21262,"status":108,"phases":21263,"primaryCompletion":2889,"completion":2889,"start":21264,"enrollment":3305,"conditions":21265,"interventions":21268},"NCT02472223","Reducing Adenoviral Patient Infected Days",[94],"2015-03-23",[21266,21267],"Conjunctivitis","Adenoviral Conjunctivitis",[21246,21269],"Artificial Tears",{"intervention":21269,"totalTrials":184,"cells":21271},{"EARLY_PHASE1":21272,"PHASE1":21274,"PHASE2":21276,"PHASE3":21278,"PHASE4":21280,"NA":21282},{"trials":21273,"activeCount":102},[],{"trials":21275,"activeCount":102},[],{"trials":21277,"activeCount":102},[],{"trials":21279,"activeCount":102},[],{"trials":21281,"activeCount":102},[],{"trials":21283,"activeCount":102},[21284],{"nctId":21261,"briefTitle":21262,"status":108,"phases":21285,"primaryCompletion":2889,"completion":2889,"start":21264,"enrollment":3305,"conditions":21286,"interventions":21287},[94],[21266,21267],[21246,21269],{"intervention":21289,"totalTrials":184,"cells":21290},"L-NAME",{"EARLY_PHASE1":21291,"PHASE1":21293,"PHASE2":21295,"PHASE3":21297,"PHASE4":21299,"NA":21301},{"trials":21292,"activeCount":102},[],{"trials":21294,"activeCount":102},[],{"trials":21296,"activeCount":102},[],{"trials":21298,"activeCount":102},[],{"trials":21300,"activeCount":102},[],{"trials":21302,"activeCount":102},[21303],{"nctId":21304,"briefTitle":21305,"status":108,"phases":21306,"primaryCompletion":382,"completion":382,"start":10670,"enrollment":5325,"conditions":21307,"interventions":21308},"NCT00603720","Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling",[94],[8705],[21289,21309,21310],"L-Arginine","Phenylephrine",{"intervention":21309,"totalTrials":184,"cells":21312},{"EARLY_PHASE1":21313,"PHASE1":21315,"PHASE2":21317,"PHASE3":21319,"PHASE4":21321,"NA":21323},{"trials":21314,"activeCount":102},[],{"trials":21316,"activeCount":102},[],{"trials":21318,"activeCount":102},[],{"trials":21320,"activeCount":102},[],{"trials":21322,"activeCount":102},[],{"trials":21324,"activeCount":102},[21325],{"nctId":21304,"briefTitle":21305,"status":108,"phases":21326,"primaryCompletion":382,"completion":382,"start":10670,"enrollment":5325,"conditions":21327,"interventions":21328},[94],[8705],[21289,21309,21310],{"intervention":21310,"totalTrials":184,"cells":21330},{"EARLY_PHASE1":21331,"PHASE1":21333,"PHASE2":21335,"PHASE3":21337,"PHASE4":21339,"NA":21341},{"trials":21332,"activeCount":102},[],{"trials":21334,"activeCount":102},[],{"trials":21336,"activeCount":102},[],{"trials":21338,"activeCount":102},[],{"trials":21340,"activeCount":102},[],{"trials":21342,"activeCount":102},[21343],{"nctId":21304,"briefTitle":21305,"status":108,"phases":21344,"primaryCompletion":382,"completion":382,"start":10670,"enrollment":5325,"conditions":21345,"interventions":21346},[94],[8705],[21289,21309,21310],{"intervention":21348,"totalTrials":184,"cells":21349},"C-11 Choline PET Imaging",{"EARLY_PHASE1":21350,"PHASE1":21352,"PHASE2":21354,"PHASE3":21356,"PHASE4":21358,"NA":21360},{"trials":21351,"activeCount":102},[],{"trials":21353,"activeCount":102},[],{"trials":21355,"activeCount":102},[],{"trials":21357,"activeCount":102},[],{"trials":21359,"activeCount":102},[],{"trials":21361,"activeCount":102},[21362],{"nctId":21363,"briefTitle":21364,"status":21365,"phases":21366,"conditions":21367,"interventions":21368},"NCT02355054","Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study","APPROVED_FOR_MARKETING",[],[8521],[21348],{"intervention":21370,"totalTrials":184,"cells":21371},"low-dose leptin",{"EARLY_PHASE1":21372,"PHASE1":21374,"PHASE2":21376,"PHASE3":21378,"PHASE4":21380,"NA":21382},{"trials":21373,"activeCount":102},[],{"trials":21375,"activeCount":102},[],{"trials":21377,"activeCount":102},[],{"trials":21379,"activeCount":102},[],{"trials":21381,"activeCount":102},[],{"trials":21383,"activeCount":102},[21384],{"nctId":21385,"briefTitle":21386,"status":108,"phases":21387,"primaryCompletion":19597,"completion":19597,"start":21388,"enrollment":1056,"conditions":21389,"interventions":21391},"NCT01207934","Recombinant Human Leptin Therapy Effects on Insulin Action",[94],"1998-08",[21390],"Type Two Diabetes Mellitus",[21370,21392],"high-dose leptin",{"intervention":21392,"totalTrials":184,"cells":21394},{"EARLY_PHASE1":21395,"PHASE1":21397,"PHASE2":21399,"PHASE3":21401,"PHASE4":21403,"NA":21405},{"trials":21396,"activeCount":102},[],{"trials":21398,"activeCount":102},[],{"trials":21400,"activeCount":102},[],{"trials":21402,"activeCount":102},[],{"trials":21404,"activeCount":102},[],{"trials":21406,"activeCount":102},[21407],{"nctId":21385,"briefTitle":21386,"status":108,"phases":21408,"primaryCompletion":19597,"completion":19597,"start":21388,"enrollment":1056,"conditions":21409,"interventions":21410},[94],[21390],[21370,21392],{"intervention":19835,"totalTrials":184,"cells":21412},{"EARLY_PHASE1":21413,"PHASE1":21415,"PHASE2":21417,"PHASE3":21419,"PHASE4":21421,"NA":21423},{"trials":21414,"activeCount":102},[],{"trials":21416,"activeCount":102},[],{"trials":21418,"activeCount":102},[],{"trials":21420,"activeCount":102},[],{"trials":21422,"activeCount":102},[],{"trials":21424,"activeCount":102},[21425],{"nctId":19830,"briefTitle":19831,"status":108,"phases":21426,"primaryCompletion":3021,"completion":490,"start":8044,"enrollment":1181,"conditions":21427,"interventions":21428},[94],[3865],[19835,10890],{"intervention":21430,"totalTrials":184,"cells":21431},"lansoprazole",{"EARLY_PHASE1":21432,"PHASE1":21434,"PHASE2":21436,"PHASE3":21438,"PHASE4":21440,"NA":21442},{"trials":21433,"activeCount":102},[],{"trials":21435,"activeCount":102},[],{"trials":21437,"activeCount":102},[],{"trials":21439,"activeCount":102},[],{"trials":21441,"activeCount":102},[],{"trials":21443,"activeCount":102},[21444],{"nctId":21445,"briefTitle":21446,"status":108,"phases":21447,"primaryCompletion":364,"completion":364,"start":19427,"enrollment":960,"conditions":21448,"interventions":21450},"NCT00546117","A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion",[94],[21449],"Otitis Media With Effusion",[21430],{"intervention":8366,"totalTrials":184,"cells":21452},{"EARLY_PHASE1":21453,"PHASE1":21455,"PHASE2":21457,"PHASE3":21459,"PHASE4":21461,"NA":21463},{"trials":21454,"activeCount":102},[],{"trials":21456,"activeCount":102},[],{"trials":21458,"activeCount":102},[],{"trials":21460,"activeCount":102},[],{"trials":21462,"activeCount":102},[],{"trials":21464,"activeCount":102},[21465],{"nctId":8358,"briefTitle":8359,"status":108,"phases":21466,"primaryCompletion":1441,"completion":1873,"start":8361,"enrollment":8362,"conditions":21467,"interventions":21468},[94],[8364],[8324,8366,8367],{"intervention":8367,"totalTrials":184,"cells":21470},{"EARLY_PHASE1":21471,"PHASE1":21473,"PHASE2":21475,"PHASE3":21477,"PHASE4":21479,"NA":21481},{"trials":21472,"activeCount":102},[],{"trials":21474,"activeCount":102},[],{"trials":21476,"activeCount":102},[],{"trials":21478,"activeCount":102},[],{"trials":21480,"activeCount":102},[],{"trials":21482,"activeCount":102},[21483],{"nctId":8358,"briefTitle":8359,"status":108,"phases":21484,"primaryCompletion":1441,"completion":1873,"start":8361,"enrollment":8362,"conditions":21485,"interventions":21486},[94],[8364],[8324,8366,8367],{"intervention":21488,"totalTrials":184,"cells":21489},"sodium thiosulfate",{"EARLY_PHASE1":21490,"PHASE1":21492,"PHASE2":21494,"PHASE3":21496,"PHASE4":21498,"NA":21500},{"trials":21491,"activeCount":102},[],{"trials":21493,"activeCount":102},[],{"trials":21495,"activeCount":102},[],{"trials":21497,"activeCount":102},[],{"trials":21499,"activeCount":102},[],{"trials":21501,"activeCount":102},[21502],{"nctId":21503,"briefTitle":21504,"status":108,"phases":21505,"primaryCompletion":1646,"completion":1646,"start":1400,"enrollment":565,"conditions":21506,"interventions":21508},"NCT00568399","Sodium Thiosulfate Treatment of Vascular Calcification in ESRD",[94],[21507,8705],"Complication of Hemodialysis",[21488],{"intervention":21510,"totalTrials":184,"cells":21511},"Desipramine",{"EARLY_PHASE1":21512,"PHASE1":21514,"PHASE2":21516,"PHASE3":21518,"PHASE4":21520,"NA":21522},{"trials":21513,"activeCount":102},[],{"trials":21515,"activeCount":102},[],{"trials":21517,"activeCount":102},[],{"trials":21519,"activeCount":102},[],{"trials":21521,"activeCount":102},[],{"trials":21523,"activeCount":102},[21524],{"nctId":21525,"briefTitle":21526,"status":137,"phases":21527,"primaryCompletion":21528,"completion":21528,"start":1431,"enrollment":1056,"conditions":21529,"interventions":21531},"NCT00880594","Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine",[94],"2014-11-11",[21530],"Irritable Bowel Syndrome",[21510],{"intervention":21533,"totalTrials":184,"cells":21534},"B12-Folic Acid, nitrous oxide",{"EARLY_PHASE1":21535,"PHASE1":21537,"PHASE2":21539,"PHASE3":21541,"PHASE4":21543,"NA":21545},{"trials":21536,"activeCount":102},[],{"trials":21538,"activeCount":102},[],{"trials":21540,"activeCount":102},[],{"trials":21542,"activeCount":102},[],{"trials":21544,"activeCount":102},[],{"trials":21546,"activeCount":102},[21547],{"nctId":21548,"briefTitle":21549,"status":108,"phases":21550,"primaryCompletion":6399,"completion":6399,"start":11781,"enrollment":1380,"conditions":21551,"interventions":21553},"NCT00901394","Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia",[94],[21552],"Cardiovascular Abnormalities",[21533,21554],"Nitrous oxide (NO) and placebo",{"intervention":21554,"totalTrials":184,"cells":21556},{"EARLY_PHASE1":21557,"PHASE1":21559,"PHASE2":21561,"PHASE3":21563,"PHASE4":21565,"NA":21567},{"trials":21558,"activeCount":102},[],{"trials":21560,"activeCount":102},[],{"trials":21562,"activeCount":102},[],{"trials":21564,"activeCount":102},[],{"trials":21566,"activeCount":102},[],{"trials":21568,"activeCount":102},[21569],{"nctId":21548,"briefTitle":21549,"status":108,"phases":21570,"primaryCompletion":6399,"completion":6399,"start":11781,"enrollment":1380,"conditions":21571,"interventions":21572},[94],[21552],[21533,21554],{"intervention":6092,"totalTrials":184,"cells":21574},{"EARLY_PHASE1":21575,"PHASE1":21577,"PHASE2":21579,"PHASE3":21581,"PHASE4":21583,"NA":21585},{"trials":21576,"activeCount":102},[],{"trials":21578,"activeCount":102},[],{"trials":21580,"activeCount":102},[],{"trials":21582,"activeCount":102},[],{"trials":21584,"activeCount":102},[],{"trials":21586,"activeCount":102},[21587],{"nctId":6083,"briefTitle":6084,"status":108,"phases":21588,"primaryCompletion":365,"completion":365,"start":3250,"enrollment":353,"conditions":21589,"interventions":21590},[94],[6087,6088,6089,6090],[5595,6092],{"intervention":21592,"totalTrials":184,"cells":21593},"Kuvan",{"EARLY_PHASE1":21594,"PHASE1":21596,"PHASE2":21598,"PHASE3":21600,"PHASE4":21602,"NA":21604},{"trials":21595,"activeCount":102},[],{"trials":21597,"activeCount":102},[],{"trials":21599,"activeCount":102},[],{"trials":21601,"activeCount":102},[],{"trials":21603,"activeCount":102},[],{"trials":21605,"activeCount":102},[21606],{"nctId":21607,"briefTitle":21608,"status":137,"phases":21609,"primaryCompletion":6399,"completion":6399,"start":12030,"enrollment":456,"conditions":21610,"interventions":21611},"NCT00827762","Behavioral Effects of Kuvan in Children With Mild Phenylketonuria",[],[20543],[21592],{"intervention":21613,"totalTrials":184,"cells":21614},"Risperidone, Olanzapine",{"EARLY_PHASE1":21615,"PHASE1":21617,"PHASE2":21619,"PHASE3":21621,"PHASE4":21623,"NA":21625},{"trials":21616,"activeCount":102},[],{"trials":21618,"activeCount":102},[],{"trials":21620,"activeCount":102},[],{"trials":21622,"activeCount":102},[],{"trials":21624,"activeCount":102},[],{"trials":21626,"activeCount":102},[21627],{"nctId":21628,"briefTitle":21629,"status":108,"phases":21630,"primaryCompletion":1648,"completion":1648,"start":19597,"enrollment":3556,"conditions":21631,"interventions":21632},"NCT00205738","Janssen - Glucose Regulation\u002FRisp\u002FOlanz",[94],[3999,6121],[21613],{"intervention":21634,"totalTrials":184,"cells":21635},"Rifaximin",{"EARLY_PHASE1":21636,"PHASE1":21638,"PHASE2":21640,"PHASE3":21642,"PHASE4":21644,"NA":21646},{"trials":21637,"activeCount":102},[],{"trials":21639,"activeCount":102},[],{"trials":21641,"activeCount":102},[],{"trials":21643,"activeCount":102},[],{"trials":21645,"activeCount":102},[],{"trials":21647,"activeCount":102},[21648],{"nctId":21649,"briefTitle":21650,"status":108,"phases":21651,"primaryCompletion":19427,"completion":19427,"start":8340,"enrollment":21652,"conditions":21653,"interventions":21655},"NCT00858988","Trial of Rifaximin in the Treatment of Tropical Enteropathy",[94],147,[21654],"Tropical Enteropathy",[21634],{"intervention":20316,"totalTrials":184,"cells":21657},{"EARLY_PHASE1":21658,"PHASE1":21660,"PHASE2":21662,"PHASE3":21664,"PHASE4":21666,"NA":21668},{"trials":21659,"activeCount":102},[],{"trials":21661,"activeCount":102},[],{"trials":21663,"activeCount":102},[],{"trials":21665,"activeCount":102},[],{"trials":21667,"activeCount":102},[],{"trials":21669,"activeCount":102},[21670],{"nctId":20306,"briefTitle":20307,"status":122,"phases":21671,"primaryCompletion":20309,"completion":20309,"start":20310,"enrollment":102,"conditions":21672,"interventions":21673},[94],[20312,20313,20314],[8944,20316],{"intervention":19459,"totalTrials":184,"cells":21675},{"EARLY_PHASE1":21676,"PHASE1":21678,"PHASE2":21680,"PHASE3":21682,"PHASE4":21684,"NA":21686},{"trials":21677,"activeCount":102},[],{"trials":21679,"activeCount":102},[],{"trials":21681,"activeCount":102},[],{"trials":21683,"activeCount":102},[],{"trials":21685,"activeCount":102},[],{"trials":21687,"activeCount":102},[21688],{"nctId":19452,"briefTitle":19453,"status":108,"phases":21689,"primaryCompletion":19455,"completion":19456,"start":3281,"enrollment":1299,"conditions":21690,"interventions":21691},[94],[6247],[558,19459],{"intervention":21693,"totalTrials":184,"cells":21694},"Self-Help Plus (SH+) and cash transfer",{"EARLY_PHASE1":21695,"PHASE1":21697,"PHASE2":21699,"PHASE3":21701,"PHASE4":21703,"NA":21705},{"trials":21696,"activeCount":102},[],{"trials":21698,"activeCount":102},[],{"trials":21700,"activeCount":102},[],{"trials":21702,"activeCount":102},[],{"trials":21704,"activeCount":102},[],{"trials":21706,"activeCount":102},[21707],{"nctId":21708,"briefTitle":21709,"status":108,"phases":21710,"primaryCompletion":5774,"completion":21711,"start":21712,"enrollment":506,"conditions":21713,"interventions":21716},"NCT07016646","SH+ and Cash Assistance",[94],"2025-09-20","2025-06-20",[21714,21715],"Stress","Depression Symptoms",[21693],{"intervention":21718,"totalTrials":184,"cells":21719},"fesoterodine",{"EARLY_PHASE1":21720,"PHASE1":21722,"PHASE2":21724,"PHASE3":21726,"PHASE4":21728,"NA":21730},{"trials":21721,"activeCount":102},[],{"trials":21723,"activeCount":102},[],{"trials":21725,"activeCount":102},[],{"trials":21727,"activeCount":102},[],{"trials":21729,"activeCount":102},[],{"trials":21731,"activeCount":102},[21732],{"nctId":21733,"briefTitle":21734,"status":108,"phases":21735,"primaryCompletion":2288,"completion":2288,"start":1965,"enrollment":36,"conditions":21736,"interventions":21738},"NCT01367886","Comparative Urine Proteomic Studies of Overactive Bladder in Humans",[94],[21737],"Overactive Bladder",[21718],{"intervention":21740,"totalTrials":184,"cells":21741},"Nutrient",{"EARLY_PHASE1":21742,"PHASE1":21744,"PHASE2":21746,"PHASE3":21748,"PHASE4":21750,"NA":21752},{"trials":21743,"activeCount":102},[],{"trials":21745,"activeCount":102},[],{"trials":21747,"activeCount":102},[],{"trials":21749,"activeCount":102},[],{"trials":21751,"activeCount":102},[],{"trials":21753,"activeCount":102},[21754],{"nctId":21755,"briefTitle":21756,"status":108,"phases":21757,"primaryCompletion":17443,"completion":17443,"start":3208,"enrollment":21758,"conditions":21759,"interventions":21761},"NCT00828243","Genetic Regulation of Surfactant Deficiency",[],525,[21760],"Respiratory Distress Syndrome, Newborn",[21740],{"intervention":21763,"totalTrials":184,"cells":21764},"[18F]FDG",{"EARLY_PHASE1":21765,"PHASE1":21767,"PHASE2":21769,"PHASE3":21771,"PHASE4":21773,"NA":21775},{"trials":21766,"activeCount":102},[],{"trials":21768,"activeCount":102},[],{"trials":21770,"activeCount":102},[],{"trials":21772,"activeCount":102},[],{"trials":21774,"activeCount":102},[],{"trials":21776,"activeCount":102},[21777],{"nctId":21778,"briefTitle":21779,"status":137,"phases":21780,"primaryCompletion":21781,"completion":21781,"start":3020,"enrollment":3305,"conditions":21782,"interventions":21784},"NCT02204202","PET Assessment of Acute Lung Transplant Rejection",[],"2017-02-04",[21783],"Lung Disease",[21763,21785],"[18F]ISO-1",{"intervention":21785,"totalTrials":184,"cells":21787},{"EARLY_PHASE1":21788,"PHASE1":21790,"PHASE2":21792,"PHASE3":21794,"PHASE4":21796,"NA":21798},{"trials":21789,"activeCount":102},[],{"trials":21791,"activeCount":102},[],{"trials":21793,"activeCount":102},[],{"trials":21795,"activeCount":102},[],{"trials":21797,"activeCount":102},[],{"trials":21799,"activeCount":102},[21800],{"nctId":21778,"briefTitle":21779,"status":137,"phases":21801,"primaryCompletion":21781,"completion":21781,"start":3020,"enrollment":3305,"conditions":21802,"interventions":21803},[],[21783],[21763,21785],{"intervention":21805,"totalTrials":184,"cells":21806},"Rasburicase",{"EARLY_PHASE1":21807,"PHASE1":21809,"PHASE2":21811,"PHASE3":21813,"PHASE4":21815,"NA":21817},{"trials":21808,"activeCount":102},[],{"trials":21810,"activeCount":102},[],{"trials":21812,"activeCount":102},[],{"trials":21814,"activeCount":102},[],{"trials":21816,"activeCount":102},[],{"trials":21818,"activeCount":102},[21819],{"nctId":21820,"briefTitle":21821,"status":108,"phases":21822,"primaryCompletion":382,"completion":3217,"start":12126,"enrollment":1938,"conditions":21823,"interventions":21826},"NCT01931527","Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status",[94],[15,21824,21825],"Metabolic Syndrome","Hyperuricemia",[21805],{"intervention":21828,"totalTrials":184,"cells":21829},"64Cu-ATSM PET",{"EARLY_PHASE1":21830,"PHASE1":21832,"PHASE2":21834,"PHASE3":21836,"PHASE4":21838,"NA":21840},{"trials":21831,"activeCount":102},[],{"trials":21833,"activeCount":102},[],{"trials":21835,"activeCount":102},[],{"trials":21837,"activeCount":102},[],{"trials":21839,"activeCount":102},[],{"trials":21841,"activeCount":102},[21842],{"nctId":21843,"briefTitle":21844,"status":122,"phases":21845,"enrollment":102,"conditions":21846,"interventions":21847},"NCT01006226","64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab",[94],[1553],[21828],{"intervention":20147,"totalTrials":184,"cells":21849},{"EARLY_PHASE1":21850,"PHASE1":21852,"PHASE2":21854,"PHASE3":21856,"PHASE4":21858,"NA":21860},{"trials":21851,"activeCount":102},[],{"trials":21853,"activeCount":102},[],{"trials":21855,"activeCount":102},[],{"trials":21857,"activeCount":102},[],{"trials":21859,"activeCount":102},[],{"trials":21861,"activeCount":102},[21862],{"nctId":20140,"briefTitle":20141,"status":108,"phases":21863,"primaryCompletion":3032,"completion":3032,"start":20143,"enrollment":2434,"conditions":21864,"interventions":21865},[94],[20145],[20147,20148],{"intervention":21867,"totalTrials":184,"cells":21868},"Micronized progesterone suppository",{"EARLY_PHASE1":21869,"PHASE1":21871,"PHASE2":21873,"PHASE3":21875,"PHASE4":21877,"NA":21879},{"trials":21870,"activeCount":102},[],{"trials":21872,"activeCount":102},[],{"trials":21874,"activeCount":102},[],{"trials":21876,"activeCount":102},[],{"trials":21878,"activeCount":102},[],{"trials":21880,"activeCount":102},[21881],{"nctId":21882,"briefTitle":21883,"status":137,"phases":21884,"primaryCompletion":21885,"completion":21885,"start":2287,"enrollment":6505,"conditions":21886,"interventions":21889},"NCT01840228","Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor",[94],"2018-05-07",[21887,21888],"Premature Birth","Obstetric Labor, Premature",[21867],{"intervention":21891,"totalTrials":184,"cells":21892},"Alvimopan",{"EARLY_PHASE1":21893,"PHASE1":21895,"PHASE2":21897,"PHASE3":21899,"PHASE4":21901,"NA":21903},{"trials":21894,"activeCount":102},[],{"trials":21896,"activeCount":102},[],{"trials":21898,"activeCount":102},[],{"trials":21900,"activeCount":102},[],{"trials":21902,"activeCount":102},[],{"trials":21904,"activeCount":102},[21905],{"nctId":21906,"briefTitle":21907,"status":108,"phases":21908,"primaryCompletion":20711,"completion":16630,"start":1736,"enrollment":1938,"conditions":21909,"interventions":21912},"NCT02218190","Alvimopan and Ileus in PSF",[94],[21910,21911],"Ileus","Spinal Fusion",[21891],{"intervention":21914,"totalTrials":184,"cells":21915},"Marcaine",{"EARLY_PHASE1":21916,"PHASE1":21918,"PHASE2":21920,"PHASE3":21922,"PHASE4":21924,"NA":21926},{"trials":21917,"activeCount":102},[],{"trials":21919,"activeCount":102},[],{"trials":21921,"activeCount":102},[],{"trials":21923,"activeCount":102},[],{"trials":21925,"activeCount":102},[],{"trials":21927,"activeCount":102},[21928],{"nctId":21929,"briefTitle":21930,"status":137,"phases":21931,"primaryCompletion":21932,"completion":21933,"start":1443,"enrollment":456,"conditions":21934,"interventions":21936},"NCT01294098","Efficacy Study of Femoral Nerve Block in Children With a Femur Fracture",[94],"2013-10-08","2014-10-08",[21935,9702],"Femoral Fractures",[21914],{"intervention":21938,"totalTrials":184,"cells":21939},"locally harvested autograft, demineralized bone matrix, and cadaveric allograft",{"EARLY_PHASE1":21940,"PHASE1":21942,"PHASE2":21944,"PHASE3":21946,"PHASE4":21948,"NA":21950},{"trials":21941,"activeCount":102},[],{"trials":21943,"activeCount":102},[],{"trials":21945,"activeCount":102},[],{"trials":21947,"activeCount":102},[],{"trials":21949,"activeCount":102},[],{"trials":21951,"activeCount":102},[21952],{"nctId":21953,"briefTitle":21954,"status":137,"phases":21955,"primaryCompletion":21956,"completion":21956,"start":3020,"enrollment":2289,"conditions":21957,"interventions":21960},"NCT02068547","Bone Marrow Aspirate Concentration in Posterior Cervical Fusion",[94],"2017-04-05",[21958,21959],"Cervical Myelopathy","Radiculopathy",[21938,21961],"Bone Marrow Aspirate",{"intervention":21961,"totalTrials":184,"cells":21963},{"EARLY_PHASE1":21964,"PHASE1":21966,"PHASE2":21968,"PHASE3":21970,"PHASE4":21972,"NA":21974},{"trials":21965,"activeCount":102},[],{"trials":21967,"activeCount":102},[],{"trials":21969,"activeCount":102},[],{"trials":21971,"activeCount":102},[],{"trials":21973,"activeCount":102},[],{"trials":21975,"activeCount":102},[21976],{"nctId":21953,"briefTitle":21954,"status":137,"phases":21977,"primaryCompletion":21956,"completion":21956,"start":3020,"enrollment":2289,"conditions":21978,"interventions":21979},[94],[21958,21959],[21938,21961],{"intervention":21981,"totalTrials":184,"cells":21982},"Iodine-alcohol",{"EARLY_PHASE1":21983,"PHASE1":21985,"PHASE2":21987,"PHASE3":21989,"PHASE4":21991,"NA":21993},{"trials":21984,"activeCount":102},[],{"trials":21986,"activeCount":102},[],{"trials":21988,"activeCount":102},[],{"trials":21990,"activeCount":102},[],{"trials":21992,"activeCount":102},[],{"trials":21994,"activeCount":102},[21995],{"nctId":21996,"briefTitle":21997,"status":108,"phases":21998,"primaryCompletion":1734,"completion":1734,"start":2288,"enrollment":21999,"conditions":22000,"interventions":22002},"NCT01472549","The Skin Prep Study",[94],1147,[22001],"Surgical Site Infections",[21981,22003],"Chlorhexidine-alcohol",{"intervention":22003,"totalTrials":184,"cells":22005},{"EARLY_PHASE1":22006,"PHASE1":22008,"PHASE2":22010,"PHASE3":22012,"PHASE4":22014,"NA":22016},{"trials":22007,"activeCount":102},[],{"trials":22009,"activeCount":102},[],{"trials":22011,"activeCount":102},[],{"trials":22013,"activeCount":102},[],{"trials":22015,"activeCount":102},[],{"trials":22017,"activeCount":102},[22018],{"nctId":21996,"briefTitle":21997,"status":108,"phases":22019,"primaryCompletion":1734,"completion":1734,"start":2288,"enrollment":21999,"conditions":22020,"interventions":22021},[94],[22001],[21981,22003],{"intervention":22023,"totalTrials":184,"cells":22024},"Gadofosveset Triodium",{"EARLY_PHASE1":22025,"PHASE1":22027,"PHASE2":22029,"PHASE3":22031,"PHASE4":22033,"NA":22035},{"trials":22026,"activeCount":102},[],{"trials":22028,"activeCount":102},[],{"trials":22030,"activeCount":102},[],{"trials":22032,"activeCount":102},[],{"trials":22034,"activeCount":102},[],{"trials":22036,"activeCount":102},[22037],{"nctId":22038,"briefTitle":22039,"status":108,"phases":22040,"primaryCompletion":2646,"completion":2646,"start":365,"enrollment":1080,"conditions":22041,"interventions":22043},"NCT01165892","Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)",[],[22042],"Pulmonary Embolism",[22023],{"intervention":22045,"totalTrials":184,"cells":22046},"Extended-release Epidural morphine (EREM) 80",{"EARLY_PHASE1":22047,"PHASE1":22049,"PHASE2":22051,"PHASE3":22053,"PHASE4":22055,"NA":22057},{"trials":22048,"activeCount":102},[],{"trials":22050,"activeCount":102},[],{"trials":22052,"activeCount":102},[],{"trials":22054,"activeCount":102},[],{"trials":22056,"activeCount":102},[],{"trials":22058,"activeCount":102},[22059],{"nctId":22060,"briefTitle":22061,"status":137,"phases":22062,"primaryCompletion":882,"completion":882,"start":1604,"enrollment":1249,"conditions":22063,"interventions":22065},"NCT00955877","Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children",[94],[22064],"Spastic Cerebral Palsy",[22045,22066,22067],"Extended-release Epidural Morphine (EREM) 120","Control: Saline",{"intervention":22066,"totalTrials":184,"cells":22069},{"EARLY_PHASE1":22070,"PHASE1":22072,"PHASE2":22074,"PHASE3":22076,"PHASE4":22078,"NA":22080},{"trials":22071,"activeCount":102},[],{"trials":22073,"activeCount":102},[],{"trials":22075,"activeCount":102},[],{"trials":22077,"activeCount":102},[],{"trials":22079,"activeCount":102},[],{"trials":22081,"activeCount":102},[22082],{"nctId":22060,"briefTitle":22061,"status":137,"phases":22083,"primaryCompletion":882,"completion":882,"start":1604,"enrollment":1249,"conditions":22084,"interventions":22085},[94],[22064],[22045,22066,22067],{"intervention":22067,"totalTrials":184,"cells":22087},{"EARLY_PHASE1":22088,"PHASE1":22090,"PHASE2":22092,"PHASE3":22094,"PHASE4":22096,"NA":22098},{"trials":22089,"activeCount":102},[],{"trials":22091,"activeCount":102},[],{"trials":22093,"activeCount":102},[],{"trials":22095,"activeCount":102},[],{"trials":22097,"activeCount":102},[],{"trials":22099,"activeCount":102},[22100],{"nctId":22060,"briefTitle":22061,"status":137,"phases":22101,"primaryCompletion":882,"completion":882,"start":1604,"enrollment":1249,"conditions":22102,"interventions":22103},[94],[22064],[22045,22066,22067],{"intervention":8086,"totalTrials":184,"cells":22105},{"EARLY_PHASE1":22106,"PHASE1":22108,"PHASE2":22110,"PHASE3":22112,"PHASE4":22114,"NA":22116},{"trials":22107,"activeCount":102},[],{"trials":22109,"activeCount":102},[],{"trials":22111,"activeCount":102},[],{"trials":22113,"activeCount":102},[],{"trials":22115,"activeCount":102},[],{"trials":22117,"activeCount":102},[22118],{"nctId":8079,"briefTitle":8080,"status":108,"phases":22119,"primaryCompletion":3555,"completion":3555,"start":364,"enrollment":8082,"conditions":22120,"interventions":22121},[94],[8066,8084],[8028,8086],{"intervention":22123,"totalTrials":184,"cells":22124},"Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration",{"EARLY_PHASE1":22125,"PHASE1":22127,"PHASE2":22129,"PHASE3":22131,"PHASE4":22133,"NA":22135},{"trials":22126,"activeCount":102},[],{"trials":22128,"activeCount":102},[],{"trials":22130,"activeCount":102},[],{"trials":22132,"activeCount":102},[],{"trials":22134,"activeCount":102},[],{"trials":22136,"activeCount":102},[22137],{"nctId":22138,"briefTitle":22139,"status":108,"phases":22140,"primaryCompletion":22141,"completion":22142,"start":3116,"enrollment":22143,"conditions":22144,"interventions":22146},"NCT01905436","Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia",[],"2017-04","2021-07",21862,[8191,5143,22145],"Soil Transmitted Helminth (STH) Infections",[22123],{"intervention":22148,"totalTrials":184,"cells":22149},"dexmedetomidine sedation protocol",{"EARLY_PHASE1":22150,"PHASE1":22152,"PHASE2":22154,"PHASE3":22156,"PHASE4":22158,"NA":22160},{"trials":22151,"activeCount":102},[],{"trials":22153,"activeCount":102},[],{"trials":22155,"activeCount":102},[],{"trials":22157,"activeCount":102},[],{"trials":22159,"activeCount":102},[],{"trials":22161,"activeCount":102},[22162],{"nctId":22163,"briefTitle":22164,"status":122,"phases":22165,"primaryCompletion":1647,"completion":1647,"start":1646,"enrollment":102,"conditions":22166,"interventions":22168},"NCT00878345","Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation",[94],[22167],"Sedation",[22148,22169],"pentobarbital sedation protocol",{"intervention":22169,"totalTrials":184,"cells":22171},{"EARLY_PHASE1":22172,"PHASE1":22174,"PHASE2":22176,"PHASE3":22178,"PHASE4":22180,"NA":22182},{"trials":22173,"activeCount":102},[],{"trials":22175,"activeCount":102},[],{"trials":22177,"activeCount":102},[],{"trials":22179,"activeCount":102},[],{"trials":22181,"activeCount":102},[],{"trials":22183,"activeCount":102},[22184],{"nctId":22163,"briefTitle":22164,"status":122,"phases":22185,"primaryCompletion":1647,"completion":1647,"start":1646,"enrollment":102,"conditions":22186,"interventions":22187},[94],[22167],[22148,22169],{"intervention":22189,"totalTrials":184,"cells":22190},"Mupirocin ointment",{"EARLY_PHASE1":22191,"PHASE1":22193,"PHASE2":22195,"PHASE3":22197,"PHASE4":22199,"NA":22201},{"trials":22192,"activeCount":102},[],{"trials":22194,"activeCount":102},[],{"trials":22196,"activeCount":102},[],{"trials":22198,"activeCount":102},[],{"trials":22200,"activeCount":102},[],{"trials":22202,"activeCount":102},[22203],{"nctId":22204,"briefTitle":22205,"status":108,"phases":22206,"primaryCompletion":9191,"completion":1963,"start":11731,"enrollment":5140,"conditions":22207,"interventions":22208},"NCT00513799","The Natural History of Community-Associated MRSA Infections and Decolonization Strategies",[94],[20172,20173,10409,20171],[22189,22209],"Chlorhexidine showers",{"intervention":22209,"totalTrials":184,"cells":22211},{"EARLY_PHASE1":22212,"PHASE1":22214,"PHASE2":22216,"PHASE3":22218,"PHASE4":22220,"NA":22222},{"trials":22213,"activeCount":102},[],{"trials":22215,"activeCount":102},[],{"trials":22217,"activeCount":102},[],{"trials":22219,"activeCount":102},[],{"trials":22221,"activeCount":102},[],{"trials":22223,"activeCount":102},[22224],{"nctId":22204,"briefTitle":22205,"status":108,"phases":22225,"primaryCompletion":9191,"completion":1963,"start":11731,"enrollment":5140,"conditions":22226,"interventions":22227},[94],[20172,20173,10409,20171],[22189,22209],{"intervention":22229,"totalTrials":184,"cells":22230},"Propofol Alone",{"EARLY_PHASE1":22231,"PHASE1":22233,"PHASE2":22235,"PHASE3":22237,"PHASE4":22239,"NA":22241},{"trials":22232,"activeCount":102},[],{"trials":22234,"activeCount":102},[],{"trials":22236,"activeCount":102},[],{"trials":22238,"activeCount":102},[],{"trials":22240,"activeCount":102},[],{"trials":22242,"activeCount":102},[22243],{"nctId":22244,"briefTitle":22245,"status":137,"phases":22246,"primaryCompletion":3302,"completion":3302,"start":8918,"enrollment":22,"conditions":22247,"interventions":22249},"NCT01315158","Propofol vs Propofol + Benzo\u002FOpiates in High Risk Group",[94],[22248,15],"Sleep Apnea, Obstructive",[22229,22250],"Propofol+Benzo\u002FOpioids",{"intervention":22250,"totalTrials":184,"cells":22252},{"EARLY_PHASE1":22253,"PHASE1":22255,"PHASE2":22257,"PHASE3":22259,"PHASE4":22261,"NA":22263},{"trials":22254,"activeCount":102},[],{"trials":22256,"activeCount":102},[],{"trials":22258,"activeCount":102},[],{"trials":22260,"activeCount":102},[],{"trials":22262,"activeCount":102},[],{"trials":22264,"activeCount":102},[22265],{"nctId":22244,"briefTitle":22245,"status":137,"phases":22266,"primaryCompletion":3302,"completion":3302,"start":8918,"enrollment":22,"conditions":22267,"interventions":22268},[94],[22248,15],[22229,22250],{"intervention":22270,"totalTrials":184,"cells":22271},"Ziprasidone, Olanzapine",{"EARLY_PHASE1":22272,"PHASE1":22274,"PHASE2":22276,"PHASE3":22278,"PHASE4":22280,"NA":22282},{"trials":22273,"activeCount":102},[],{"trials":22275,"activeCount":102},[],{"trials":22277,"activeCount":102},[],{"trials":22279,"activeCount":102},[],{"trials":22281,"activeCount":102},[],{"trials":22283,"activeCount":102},[22284],{"nctId":22285,"briefTitle":22286,"status":108,"phases":22287,"primaryCompletion":1648,"completion":1648,"start":12227,"enrollment":3556,"conditions":22288,"interventions":22289},"NCT00205725","Pfizer\u002FIVGTT\u002FZiprasidone\u002FOlanzapine",[94],[3999,6121],[22270],{"intervention":22291,"totalTrials":184,"cells":22292},"Lexapro",{"EARLY_PHASE1":22293,"PHASE1":22295,"PHASE2":22297,"PHASE3":22299,"PHASE4":22301,"NA":22303},{"trials":22294,"activeCount":102},[],{"trials":22296,"activeCount":102},[],{"trials":22298,"activeCount":102},[],{"trials":22300,"activeCount":102},[],{"trials":22302,"activeCount":102},[],{"trials":22304,"activeCount":102},[22305],{"nctId":22306,"briefTitle":22307,"status":108,"phases":22308,"primaryCompletion":4008,"completion":382,"start":22309,"enrollment":2827,"conditions":22310,"interventions":22311},"NCT00749125","fMRI Studies of Emotional Brain Circuitry in People With Major Depression",[94],"2001-07",[21],[22291],{"intervention":22313,"totalTrials":184,"cells":22314},"Hydroxychloroquine",{"EARLY_PHASE1":22315,"PHASE1":22317,"PHASE2":22319,"PHASE3":22321,"PHASE4":22323,"NA":22325},{"trials":22316,"activeCount":102},[],{"trials":22318,"activeCount":102},[],{"trials":22320,"activeCount":102},[],{"trials":22322,"activeCount":102},[],{"trials":22324,"activeCount":102},[],{"trials":22326,"activeCount":102},[22327],{"nctId":22328,"briefTitle":22329,"status":137,"phases":22330,"primaryCompletion":6976,"completion":6976,"start":3116,"enrollment":36,"conditions":22331,"interventions":22332},"NCT02026232","Metabolic Effects of Hydroxychloroquine",[94],[6121],[22313],{"intervention":22334,"totalTrials":184,"cells":22335},"IV racemic methadone HCl",{"EARLY_PHASE1":22336,"PHASE1":22338,"PHASE2":22340,"PHASE3":22342,"PHASE4":22344,"NA":22346},{"trials":22337,"activeCount":102},[],{"trials":22339,"activeCount":102},[],{"trials":22341,"activeCount":102},[],{"trials":22343,"activeCount":102},[],{"trials":22345,"activeCount":102},[],{"trials":22347,"activeCount":102},[22348],{"nctId":22349,"briefTitle":22350,"status":108,"phases":22351,"primaryCompletion":8246,"completion":1734,"start":3217,"enrollment":8362,"conditions":22352,"interventions":22353},"NCT01648283","CYP2B6 Polymorphisms in Methadone Disposition",[94],[10673],[22334,22354],"Oral racemic methadone HCl",{"intervention":22354,"totalTrials":184,"cells":22356},{"EARLY_PHASE1":22357,"PHASE1":22359,"PHASE2":22361,"PHASE3":22363,"PHASE4":22365,"NA":22367},{"trials":22358,"activeCount":102},[],{"trials":22360,"activeCount":102},[],{"trials":22362,"activeCount":102},[],{"trials":22364,"activeCount":102},[],{"trials":22366,"activeCount":102},[],{"trials":22368,"activeCount":102},[22369],{"nctId":22349,"briefTitle":22350,"status":108,"phases":22370,"primaryCompletion":8246,"completion":1734,"start":3217,"enrollment":8362,"conditions":22371,"interventions":22372},[94],[10673],[22334,22354],{"intervention":22374,"totalTrials":184,"cells":22375},"Fluorescein injection, USP 10%",{"EARLY_PHASE1":22376,"PHASE1":22378,"PHASE2":22380,"PHASE3":22382,"PHASE4":22384,"NA":22386},{"trials":22377,"activeCount":102},[],{"trials":22379,"activeCount":102},[],{"trials":22381,"activeCount":102},[],{"trials":22383,"activeCount":102},[],{"trials":22385,"activeCount":102},[],{"trials":22387,"activeCount":102},[22388],{"nctId":22389,"briefTitle":22390,"status":122,"phases":22391,"primaryCompletion":1996,"completion":1996,"start":6255,"enrollment":102,"conditions":22392,"interventions":22395},"NCT02628496","Confocal Laser Microlaryngoscopy (CLMx)",[94],[22393,22394],"Laryngeal Dysplasia","Laryngeal Neoplasm",[22374],{"intervention":22397,"totalTrials":184,"cells":22398},"Pregabalin",{"EARLY_PHASE1":22399,"PHASE1":22401,"PHASE2":22403,"PHASE3":22405,"PHASE4":22407,"NA":22409},{"trials":22400,"activeCount":102},[],{"trials":22402,"activeCount":102},[],{"trials":22404,"activeCount":102},[],{"trials":22406,"activeCount":102},[],{"trials":22408,"activeCount":102},[],{"trials":22410,"activeCount":102},[22411],{"nctId":22412,"briefTitle":22413,"status":108,"phases":22414,"primaryCompletion":22415,"completion":22415,"start":6255,"enrollment":442,"conditions":22416,"interventions":22417},"NCT02394951","Pregabalin in CIPN",[94],"2018-04-02",[12937,955],[22397],{"intervention":22419,"totalTrials":184,"cells":22420},"Vitamin B12 and folic acid",{"EARLY_PHASE1":22421,"PHASE1":22423,"PHASE2":22425,"PHASE3":22427,"PHASE4":22429,"NA":22431},{"trials":22422,"activeCount":102},[],{"trials":22424,"activeCount":102},[],{"trials":22426,"activeCount":102},[],{"trials":22428,"activeCount":102},[],{"trials":22430,"activeCount":102},[],{"trials":22432,"activeCount":102},[22433],{"nctId":22434,"briefTitle":22435,"status":108,"phases":22436,"primaryCompletion":14504,"completion":14504,"start":20049,"enrollment":22437,"conditions":22438,"interventions":22440},"NCT00655980","Vitamins in Nitrous Oxide Study",[94],687,[22439,18295],"Major Surgery",[22419,22441],"Nitrous oxide and placebo",{"intervention":22441,"totalTrials":184,"cells":22443},{"EARLY_PHASE1":22444,"PHASE1":22446,"PHASE2":22448,"PHASE3":22450,"PHASE4":22452,"NA":22454},{"trials":22445,"activeCount":102},[],{"trials":22447,"activeCount":102},[],{"trials":22449,"activeCount":102},[],{"trials":22451,"activeCount":102},[],{"trials":22453,"activeCount":102},[],{"trials":22455,"activeCount":102},[22456],{"nctId":22434,"briefTitle":22435,"status":108,"phases":22457,"primaryCompletion":14504,"completion":14504,"start":20049,"enrollment":22437,"conditions":22458,"interventions":22459},[94],[22439,18295],[22419,22441],{"intervention":22461,"totalTrials":184,"cells":22462},"Alfentanil",{"EARLY_PHASE1":22463,"PHASE1":22465,"PHASE2":22467,"PHASE3":22469,"PHASE4":22471,"NA":22473},{"trials":22464,"activeCount":102},[],{"trials":22466,"activeCount":102},[],{"trials":22468,"activeCount":102},[],{"trials":22470,"activeCount":102},[],{"trials":22472,"activeCount":102},[],{"trials":22474,"activeCount":102},[22475],{"nctId":22476,"briefTitle":22477,"status":108,"phases":22478,"primaryCompletion":1442,"completion":1442,"start":3103,"enrollment":1131,"conditions":22479,"interventions":22481},"NCT01008059","Alfentanil: Simultaneous Testing Pilot",[94],[22480],"Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A",[22461],{"intervention":22483,"totalTrials":184,"cells":22484},"Annual versus Semiannual Albendazole plus Ivermectin MDA",{"EARLY_PHASE1":22485,"PHASE1":22487,"PHASE2":22489,"PHASE3":22491,"PHASE4":22493,"NA":22495},{"trials":22486,"activeCount":102},[],{"trials":22488,"activeCount":102},[],{"trials":22490,"activeCount":102},[],{"trials":22492,"activeCount":102},[],{"trials":22494,"activeCount":102},[],{"trials":22496,"activeCount":102},[22497],{"nctId":22498,"briefTitle":22499,"status":108,"phases":22500,"primaryCompletion":22501,"completion":22501,"start":3020,"enrollment":22502,"conditions":22503,"interventions":22504},"NCT02032043","Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)",[],"2017-12-04",14457,[8191,5143,22145],[22483],{"intervention":8321,"totalTrials":184,"cells":22506},{"EARLY_PHASE1":22507,"PHASE1":22509,"PHASE2":22511,"PHASE3":22513,"PHASE4":22515,"NA":22517},{"trials":22508,"activeCount":102},[],{"trials":22510,"activeCount":102},[],{"trials":22512,"activeCount":102},[],{"trials":22514,"activeCount":102},[],{"trials":22516,"activeCount":102},[],{"trials":22518,"activeCount":102},[22519],{"nctId":8313,"briefTitle":8314,"status":108,"phases":22520,"primaryCompletion":8316,"completion":8316,"start":1996,"enrollment":1299,"conditions":22521,"interventions":22522},[94],[8318,8319],[8321,8240,8322],{"intervention":8322,"totalTrials":184,"cells":22524},{"EARLY_PHASE1":22525,"PHASE1":22527,"PHASE2":22529,"PHASE3":22531,"PHASE4":22533,"NA":22535},{"trials":22526,"activeCount":102},[],{"trials":22528,"activeCount":102},[],{"trials":22530,"activeCount":102},[],{"trials":22532,"activeCount":102},[],{"trials":22534,"activeCount":102},[],{"trials":22536,"activeCount":102},[22537],{"nctId":8313,"briefTitle":8314,"status":108,"phases":22538,"primaryCompletion":8316,"completion":8316,"start":1996,"enrollment":1299,"conditions":22539,"interventions":22540},[94],[8318,8319],[8321,8240,8322],{"intervention":20370,"totalTrials":184,"cells":22542},{"EARLY_PHASE1":22543,"PHASE1":22545,"PHASE2":22547,"PHASE3":22549,"PHASE4":22551,"NA":22553},{"trials":22544,"activeCount":102},[],{"trials":22546,"activeCount":102},[],{"trials":22548,"activeCount":102},[],{"trials":22550,"activeCount":102},[],{"trials":22552,"activeCount":102},[],{"trials":22554,"activeCount":102},[22555],{"nctId":20362,"briefTitle":20363,"status":108,"phases":22556,"primaryCompletion":20365,"completion":20366,"start":14965,"enrollment":1380,"conditions":22557,"interventions":22558},[94],[20368],[15670,20370],{"intervention":22560,"totalTrials":184,"cells":22561},"Armodafinil",{"EARLY_PHASE1":22562,"PHASE1":22564,"PHASE2":22566,"PHASE3":22568,"PHASE4":22570,"NA":22572},{"trials":22563,"activeCount":102},[],{"trials":22565,"activeCount":102},[],{"trials":22567,"activeCount":102},[],{"trials":22569,"activeCount":102},[],{"trials":22571,"activeCount":102},[],{"trials":22573,"activeCount":102},[22574],{"nctId":22575,"briefTitle":22576,"status":122,"phases":22577,"primaryCompletion":3021,"completion":3021,"start":1604,"enrollment":102,"conditions":22578,"interventions":22581},"NCT01044004","Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue",[94],[22579,22580],"B-cell Lymphoma","Fatigue",[22560,22560],{"intervention":22583,"totalTrials":184,"cells":22584},"Depakote",{"EARLY_PHASE1":22585,"PHASE1":22587,"PHASE2":22589,"PHASE3":22591,"PHASE4":22593,"NA":22595},{"trials":22586,"activeCount":102},[],{"trials":22588,"activeCount":102},[],{"trials":22590,"activeCount":102},[],{"trials":22592,"activeCount":102},[],{"trials":22594,"activeCount":102},[],{"trials":22596,"activeCount":102},[22597],{"nctId":22598,"briefTitle":22599,"status":108,"phases":22600,"primaryCompletion":22601,"completion":22601,"start":10772,"enrollment":3556,"conditions":22602,"interventions":22604},"NCT00552500","Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia",[94],"2005-12",[6120,22603],"Body Composition",[22583],{"intervention":22606,"totalTrials":184,"cells":22607},"zidovudine, lamivudine, nevirapine",{"EARLY_PHASE1":22608,"PHASE1":22610,"PHASE2":22612,"PHASE3":22614,"PHASE4":22616,"NA":22618},{"trials":22609,"activeCount":102},[],{"trials":22611,"activeCount":102},[],{"trials":22613,"activeCount":102},[],{"trials":22615,"activeCount":102},[],{"trials":22617,"activeCount":102},[],{"trials":22619,"activeCount":102},[22620],{"nctId":22621,"briefTitle":22622,"status":108,"phases":22623,"primaryCompletion":1873,"completion":1873,"start":365,"enrollment":383,"conditions":22624,"interventions":22625},"NCT01529125","Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV",[],[8066,8084,8064,9768],[22606],{"intervention":22627,"totalTrials":184,"cells":22628},"BCNU",{"EARLY_PHASE1":22629,"PHASE1":22631,"PHASE2":22633,"PHASE3":22635,"PHASE4":22637,"NA":22639},{"trials":22630,"activeCount":102},[],{"trials":22632,"activeCount":102},[],{"trials":22634,"activeCount":102},[],{"trials":22636,"activeCount":102},[],{"trials":22638,"activeCount":102},[],{"trials":22640,"activeCount":102},[22641],{"nctId":22642,"briefTitle":22643,"status":137,"phases":22644,"primaryCompletion":22645,"completion":22645,"start":22646,"enrollment":456,"conditions":22647,"interventions":22648},"NCT03591861","Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis",[94],"2022-11-01","2019-05-01",[2222],[22627],{"intervention":22650,"totalTrials":184,"cells":22651},"Room air",{"EARLY_PHASE1":22652,"PHASE1":22654,"PHASE2":22656,"PHASE3":22658,"PHASE4":22660,"NA":22662},{"trials":22653,"activeCount":102},[],{"trials":22655,"activeCount":102},[],{"trials":22657,"activeCount":102},[],{"trials":22659,"activeCount":102},[],{"trials":22661,"activeCount":102},[],{"trials":22663,"activeCount":102},[22664],{"nctId":22665,"briefTitle":22666,"status":108,"phases":22667,"primaryCompletion":6423,"completion":22668,"start":2370,"enrollment":6441,"conditions":22669,"interventions":22673},"NCT02741284","Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings",[94],"2020-12",[22670,22671,22672],"Electronic Fetal Monitoring","Fetal Hypoxia","Fetal-Placental Circulation",[22650,22674],"10L Oxygen by nonrebreather mask",{"intervention":22674,"totalTrials":184,"cells":22676},{"EARLY_PHASE1":22677,"PHASE1":22679,"PHASE2":22681,"PHASE3":22683,"PHASE4":22685,"NA":22687},{"trials":22678,"activeCount":102},[],{"trials":22680,"activeCount":102},[],{"trials":22682,"activeCount":102},[],{"trials":22684,"activeCount":102},[],{"trials":22686,"activeCount":102},[],{"trials":22688,"activeCount":102},[22689],{"nctId":22665,"briefTitle":22666,"status":108,"phases":22690,"primaryCompletion":6423,"completion":22668,"start":2370,"enrollment":6441,"conditions":22691,"interventions":22692},[94],[22670,22671,22672],[22650,22674],{"intervention":22694,"totalTrials":184,"cells":22695},"Diagnostic Imaging",{"EARLY_PHASE1":22696,"PHASE1":22698,"PHASE2":22700,"PHASE3":22702,"PHASE4":22704,"NA":22706},{"trials":22697,"activeCount":102},[],{"trials":22699,"activeCount":102},[],{"trials":22701,"activeCount":102},[],{"trials":22703,"activeCount":102},[],{"trials":22705,"activeCount":102},[],{"trials":22707,"activeCount":102},[22708],{"nctId":22709,"briefTitle":22710,"status":122,"phases":22711,"primaryCompletion":882,"completion":1351,"start":22712,"enrollment":102,"conditions":22713,"interventions":22714},"NCT01714128","FES-PET for Patients Treated on NCI Protocol 8762",[94],"2013-06",[18],[22694]]